fluorouracil has been researched along with Neoplasms in 1793 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The granisetron transdermal system (GTS) showed non-inferior efficacy to oral granisetron to control chemotherapy-induced nausea and vomiting (CINV) during multiday chemotherapy." | 9.20 | A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients. ( Ahn, JS; Hong, YS; Kim, JE; Kim, KP; Kim, TW; Lee, J; Lee, JL; Park, SJ; Park, YS; Shin, DB; Sym, SJ, 2015) |
| "Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated." | 9.14 | Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. ( Berenberg, JL; Christian, D; Delaune, R; Loprinzi, CL; Menon, SP; Pajon, ER; Qin, R; Rowland, KM; Satele, DV; Thomas, S; Wolf, SL, 2010) |
| " Oral glutamine supplements (OGS) may have a role in the prevention of chemotherapy-induced mucositis/stomatitis." | 9.12 | The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test. ( Choi, K; Jeon, WK; Kim, JW; Lee, SS; Lim, SY; Oh, SJ; Oh, TY, 2007) |
| "Nedaplatin (NDP)/5-fluorouracil (5-FU) combination therapy frequently causes severe neutropenia and febrile neutropenia (FN)." | 8.31 | Poor Renal Function and a High Modified Glasgow Prognostic Score Are Predictive Factors for Nedaplatin/5-Fluorouracil Combination Therapy-induced Febrile Neutropenia. ( Harasawa, H; Hashizume, J; Kodama, Y; Nakagawa, H; Nambu, M, 2023) |
| "Coronary vasospasm is a known side effect of 5-FU (fluorouracil) therapy." | 8.12 | The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm. ( Blaszkowsky, LS; Clark, JR; Clark, JW; Drobni, ZD; Gilman, HK; Gongora, CA; Hartmann, S; Jones-O'Connor, M; Lei, M; Lou, UY; Mahmood, A; Mosarla, R; Murphy, SP; Neilan, TG; Nipp, R; Quinaglia, T; Tavares, E; Weekes, CD; Zafar, A, 2022) |
| "To determine the incidence of cardiotoxicity in patients treated with different chemotherapy regimens containing 5-fluorouracil (5-FU) in Zanjan, Iran." | 8.12 | EVALUATION OF 5-FLUOROURACIL-INDUCED CARDIOTOXICITY: ROLE OF CARDIAC BIOMARKERS. ( Abadi, H; Amirmoghaddami, H; Karamitanha, F; Moghaddam, Z; Rostami, M; Zeraatchi, A, 2022) |
| "Capecitabine- or 5-fluorouracil (5-FU)-based chemotherapy is widely used in many solid tumours, but is associated with cardiotoxicity." | 8.12 | Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study. ( Ålgars, A; Bärlund, M; Flygare, P; Frödin, JE; Glimelius, B; Hagman, H; Halonen, P; Heervä, E; Kallio, R; Kinos, S; Kwakman, JJM; Liposits, G; McDermott, R; O'Reilly, M; Osterlund, P; Pfeiffer, P; Punt, CJA; Ristamäki, R; Röckert, R; Salminen, T; Shah, CH; Sorbye, H; Soveri, LM; Teske, AJ; van Werkhoven, E, 2022) |
| "Cholinergic syndrome is an acute adverse reaction associated with irinotecan." | 7.88 | Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis. ( Hosokawa, T; Ishikawa, T; Kanazawa, M; Kanbayashi, Y; Kawano, R; Nakajima, Y; Tabuchi, Y; Taguchi, T; Takayama, K; Yoshida, N; Yoshioka, T, 2018) |
| "The efficacy of primary prophylactic granulocyte colony-stimulating factor (G-CSF) in preventing febrile neutropenia (FN) in patients treated with docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy remains controversial." | 7.88 | Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy. ( Fukutomi, A; Hamauchi, S; Kawahira, M; Kawai, S; Machida, N; Onozawa, Y; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T; Yoshida, Y, 2018) |
| "5-Fluorouracil (5-FU) is widely used as an anti cancer drug and is known to cause severe diarrhea." | 7.85 | Active Ingredients of Hange-shashin-to, Baicalelin and 6-Gingerol, Inhibit 5-Fluorouracil-Induced Upregulation of CXCL1 in the Colon to Attenuate Diarrhea Development. ( Isa, Y; Kai, Y; Kimura, M; Miyano, K; Narita, M; Sakai, H; Sato, F; Tabata, S; Uezono, Y; Yabe, S; Yumoto, T, 2017) |
| "Hand-foot syndrome( HFS) has been reported to be the most common adverse effect of capecitabine, with an incidence of more than 50%." | 7.79 | [Efficacy of AboundTM for hand-foot syndrome caused by capecitabine]. ( Fujii, C; Fujino, M; Fukunaga, M; Hachino, Y; Hamaguchi, Y; Imamura, H; Iseki, C; Ishizaka, T; Kamigaki, S; Kawabata, R; Kawase, T; Kimura, Y; Yamamoto, E, 2013) |
| " Body weight loss results, diarrhea scores, and villi measurements showed that minocycline attenuated the severity of intestinal mucositis induced by 5-fluorouracil (5-FU)." | 7.75 | Minocycline attenuates 5-fluorouracil-induced small intestinal mucositis in mouse model. ( Chao, YC; Chu, HC; Ho, WH; Hou, HS; Huang, TY; Liao, CL; Lin, YL, 2009) |
| "To characterize diarrhea events in patients with cancer treated with lapatinib as monotherapy or in combination with capecitabine or taxanes." | 7.74 | Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. ( Boyle, F; Burris, HA; Byrne, J; Chan, S; Crown, JP; Jones, S; Koehler, M; Newstat, BO; Oliva, C; Parikh, R; Preston, A, 2008) |
| " This report describes a Phase Ib clinical trial investigating PG-11047 in combination with cytotoxic and anti-angiogenic chemotherapeutic agents in patients with advanced refractory metastatic solid tumors or lymphoma." | 7.01 | A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma. ( Becerra, CHR; Boyd, TE; Casero, RA; Conkling, PR; Fitzgerald, M; Garbo, LE; Jotte, RM; Marton, LJ; Murray Stewart, T; Richards, DA; Smith, DA; Stephenson, JJ; Vogelzang, NJ; Von Hoff, D; Wu, HH, 2021) |
| "Patients with previously treated solid tumors received axitinib (starting dose 5 mg twice daily) combined with FOLFOX plus bevacizumab (1, 2, or 5 mg/kg, cohorts 1-3, respectively), FOLFIRI (cohort 4), or FOLFOX (cohort 5)." | 6.75 | A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. ( Abhyankar, V; Burgess, RE; Chen, Y; Infante, J; Kim, S; Robles, RL; Sharma, S; Tarazi, J; Tortorici, M; Trowbridge, RC, 2010) |
| "In intermediate-risk breast cancer, complete hormonal blockade and chemotherapy provided similar outcomes." | 6.72 | Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. ( Bonneterre, J; Chollet, P; Clavère, P; Fargeot, P; Fumoleau, P; Goudier, MJ; Guastalla, JP; Kerbrat, P; Monnier, A; Roché, H; Serin, D, 2006) |
| "Mucositis is a common toxicity of cancer chemotherapy." | 6.68 | Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. ( Anderson, PM; Skubitz, KM, 1996) |
| "Unfortunately, complexity in treating cachexia is amplified by both the underlying malignancy and the anti-cancer therapy which can independently promote cachexia." | 5.72 | Quercetin Improved Muscle Mass and Mitochondrial Content in a Murine Model of Cancer and Chemotherapy-Induced Cachexia. ( Bullard, BM; Cardaci, TD; Cunningham, P; Fan, D; McDonald, SJ; Murphy, EA; VanderVeen, BN; Velázquez, KT, 2022) |
| "Capecitabine is an oral fluoropyrimidine which is transformed to 5-Fluorouracil inside tumor cells, where it achieves high drug concentrations." | 5.36 | Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect? ( Emiliani, A; Losanno, T; Manna, G; Seminara, P, 2010) |
| "Capecitabine is a chemotherapeutic drug for use in cancers." | 5.35 | Topical henna for capecitabine induced hand-foot syndrome. ( Guzin, G; Yucel, I, 2008) |
| "Between July 1999 and August 2001, 95 cancer patients were evaluated." | 5.32 | Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? ( Carnaghi, C; Castagna, L; Fallini, M; Magagnoli, M; Masci, G; Pedicini, V; Santoro, A; Sarina, B; Zucali, PA, 2003) |
| "Azotemia, body fluid insufficiency and bacterial infections were frequently found in these patients." | 5.30 | Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. ( Chang, HK; Chen, JS; Liaw, CC; Liaw, SJ; Lin, YC; Wang, CH; Wang, HM; Yang, TS; Yeh, CT, 1999) |
| "The granisetron transdermal system (GTS) showed non-inferior efficacy to oral granisetron to control chemotherapy-induced nausea and vomiting (CINV) during multiday chemotherapy." | 5.20 | A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients. ( Ahn, JS; Hong, YS; Kim, JE; Kim, KP; Kim, TW; Lee, J; Lee, JL; Park, SJ; Park, YS; Shin, DB; Sym, SJ, 2015) |
| " Three of six patients in cohort 2B-1 experienced grade 3 mucositis, and further study of the combination of everolimus, mFOLFOX6 and panitumumab was aborted." | 5.19 | A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors. ( Bernard, S; Davies, JM; Dees, EC; Goldberg, RM; Ivanova, A; Keller, K; McRee, AJ; O'Neil, BH; Sanoff, HG, 2014) |
| "To observe the effect of the Traditional Chinese Medicine, modified Taohongsiwu decoction, versus pyridoxine on patients with hand-foot syndrome (HFS) from capecitabine, sorafenib, and gefitinib chemotherapy for gastric, lung, breast, colon, or rectal cancer." | 5.19 | Effect of modified taohongsiwu decoction on patients with chemotherapy-induced hand-foot syndrome. ( Chen, J; Chen, X; Dai, C; Wu, X; Yu, B; Zhao, C; Zhou, C, 2014) |
| "Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated." | 5.14 | Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. ( Berenberg, JL; Christian, D; Delaune, R; Loprinzi, CL; Menon, SP; Pajon, ER; Qin, R; Rowland, KM; Satele, DV; Thomas, S; Wolf, SL, 2010) |
| "Cancer patients experienced an increased risk of cardiotoxicity during fluoropyrimidine-based chemotherapy (5-fluorouracil or capecitabine)." | 5.12 | Risk Factors of Fluoropyrimidine Induced Cardiotoxicity among Cancer Patients: A Systematic Review and Meta-analysis. ( Chen, L; Chou, C; Li, C; Ngorsuraches, S; Qian, J, 2021) |
| " Oral glutamine supplements (OGS) may have a role in the prevention of chemotherapy-induced mucositis/stomatitis." | 5.12 | The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test. ( Choi, K; Jeon, WK; Kim, JW; Lee, SS; Lim, SY; Oh, SJ; Oh, TY, 2007) |
| " Infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) is a standard therapy for colorectal cancer." | 5.12 | Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors. ( Bolling, C; Brennscheidt, U; Cassidy, J; Díaz-Rubio, E; Fettner, S; Feyereislova, A; Hanauske, AR; Jones, RJ; Rakhit, A; Sastre, J, 2007) |
| " Other toxicities included hand-foot syndrome, diarrhea, hyperbilirubinemia, skin rash, myalgia, and arthralgia." | 5.09 | Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. ( Burger, HU; Burris, HA; Drengler, RL; Eckhardt, SG; Griffin, T; Kraynak, M; Moczygemba, J; Reigner, B; Rodrigues, G; Rowinsky, EK; Villalona-Calero, MA; Von Hoff, DD; Weiss, GR, 1999) |
| "Diarrhea is dose-limiting with weekly 5-fluorouracil (5-FU) plus high-dose leucovorin (LV)." | 5.09 | Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant. ( Blumenson, LE; Creaven, PJ; Frank, C; Meropol, NJ; Rustum, YM, 1999) |
| "We have recently evaluated the combination of raltitrexed, levofolinic acid (LFA) and 5-fluorouracil (5-FU) in advanced head and neck and colorectal cancer, and we have shown that this combination is well tolerated and has clinical activity." | 5.09 | Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours. ( Avallone, A; Caponigro, F; Comella, G; Comella, P; De Rosa, V; Ionna, F; Rivellini, F, 2001) |
| "5-Fluorouracil (5-FU) activity for various carcinomas of adults has been enhanced through the synergistic effect of leucovorin." | 5.07 | Phase II study of 5-fluorouracil/leucovorin for pediatric patients with malignant solid tumors. ( Bowman, LC; Douglass, EC; Houghton, JA; Howlett, N; Kun, LE; Meyer, WH; Mounce, K; Poe, D; Pratt, CB, 1994) |
| "Because of biochemical and tissue culture evidence casting doubt on the physiologic relevance of reported synergy afforded by sequential administration of methotrexate (MTX) followed by 5-fluorouracil (5-FU), a randomized controlled clinical trial was conducted in 108 patients with advanced cancer, including 70 with squamous cell carcinoma (SCC) of the head and neck, nine with SCC of other primary sites, 24 with colorectal, and five with gastric adenocarcinomas." | 5.05 | Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration. ( Coates, AS; Fox, RM; Hedley, D; Raghavan, D; Swanson, C; Tattersall, MH, 1984) |
| " In this article, the current knowledge on the prevention, monitoring and treatment of cardiotoxicity induced by medical anti-cancer treatment with focus on anthracyclines, trastuzumab and 5-fluorouracil is described." | 4.98 | [Management of cardiovascular complications secondary to medical treatment of cancer]. ( Banke, A; Fosbøl, EL; Nielsen, D; Nielsen, KM; Overgaard, U; Polk, A; Schou, M; Vaage-Nielsen, M; Videbæk, L, 2018) |
| "Hand-foot syndrome is a highly unpleasant adverse reaction caused by treatment protocols containing capecitabine (an orally administered drug), docetaxel, liposomal doxorubicin infusions or continuously infused 5-fluorouracil." | 4.87 | [Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy]. ( Bartal, A; Liszkay, G; Mátrai, Z; Szûcs, A, 2011) |
| "Pulmonary fibrosis is a rare complication of oxaliplatin and capecitabine/5-fluorouracil." | 4.87 | Pulmonary toxicity with oxaliplatin and capecitabine/5-Fluorouracil chemotherapy: a case report and review of the literature. ( Chan, AK; Choo, BA; Glaholm, J, 2011) |
| "We reviewed published studies reporting phase II and III clinical trials of dose-dense regimens for breast cancer and NHL, TAC (docetaxel, adriamycin, cyclophosphamide) chemotherapy for breast cancer, and infusional 5-fluorouracil-based regimens for colorectal cancer." | 4.83 | Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. ( Avritscher, EB; Bekele, BN; Cooksley, CD; Elting, LS; Jones, JA; Michelet, M, 2006) |
| "Fluorouracil (FU) is an antimetabolite with activity against numerous types of neoplasms, including those of the breast, esophagus, larynx, and gastrointestinal and genitourinary tracts." | 4.82 | Capecitabine: a review. ( Lindley, C; Walko, CM, 2005) |
| "For over four decades, 5-fluorouracil (5-FU) has been the mainstay of therapy for colorectal cancer and a major cytotoxic agent for treating gastrointestinal tumors and a variety of others, including breast and head and neck cancers." | 4.80 | Potential of Xeloda in colorectal cancer and other solid tumors. ( Cassidy, J, 1999) |
| "At this juncture in the development of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), knowledge about the agent's pharmacologic behavior and clinical antitumor activity in less common neoplasms is being elucidated." | 4.79 | Paclitaxel pharmacology and other tumor types. ( Rowinsky, EK, 1997) |
| "Nedaplatin (NDP)/5-fluorouracil (5-FU) combination therapy frequently causes severe neutropenia and febrile neutropenia (FN)." | 4.31 | Poor Renal Function and a High Modified Glasgow Prognostic Score Are Predictive Factors for Nedaplatin/5-Fluorouracil Combination Therapy-induced Febrile Neutropenia. ( Harasawa, H; Hashizume, J; Kodama, Y; Nakagawa, H; Nambu, M, 2023) |
| "Coronary vasospasm is a known side effect of 5-FU (fluorouracil) therapy." | 4.12 | The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm. ( Blaszkowsky, LS; Clark, JR; Clark, JW; Drobni, ZD; Gilman, HK; Gongora, CA; Hartmann, S; Jones-O'Connor, M; Lei, M; Lou, UY; Mahmood, A; Mosarla, R; Murphy, SP; Neilan, TG; Nipp, R; Quinaglia, T; Tavares, E; Weekes, CD; Zafar, A, 2022) |
| "To determine the incidence of cardiotoxicity in patients treated with different chemotherapy regimens containing 5-fluorouracil (5-FU) in Zanjan, Iran." | 4.12 | EVALUATION OF 5-FLUOROURACIL-INDUCED CARDIOTOXICITY: ROLE OF CARDIAC BIOMARKERS. ( Abadi, H; Amirmoghaddami, H; Karamitanha, F; Moghaddam, Z; Rostami, M; Zeraatchi, A, 2022) |
| "Capecitabine- or 5-fluorouracil (5-FU)-based chemotherapy is widely used in many solid tumours, but is associated with cardiotoxicity." | 4.12 | Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study. ( Ålgars, A; Bärlund, M; Flygare, P; Frödin, JE; Glimelius, B; Hagman, H; Halonen, P; Heervä, E; Kallio, R; Kinos, S; Kwakman, JJM; Liposits, G; McDermott, R; O'Reilly, M; Osterlund, P; Pfeiffer, P; Punt, CJA; Ristamäki, R; Röckert, R; Salminen, T; Shah, CH; Sorbye, H; Soveri, LM; Teske, AJ; van Werkhoven, E, 2022) |
| "5-Fluorouracil (5-FU) is a key component of chemotherapy for colorectal cancer (CRC)." | 4.12 | SHMT2-mediated mitochondrial serine metabolism drives 5-FU resistance by fueling nucleotide biosynthesis. ( Arcangeli, A; Caselli, A; Chiarugi, P; Cirri, P; Colantuoni, V; Leo, A; Lottini, T; Maddocks, ODK; Muccillo, L; Nesi, I; Paoli, P; Pardella, E; Parri, M; Pranzini, E; Raugei, G; Sabatino, L; Santi, A; Taddei, ML; Uribe, AH; Zhang, T, 2022) |
| "Although first-line chemotherapy drugs, including 5-fluorouracil (5-FU), remain one of the major choice for cancer treatment, the clinical use is also accompanied with dose-depending toxicities, such as intestinal mucositis (IM), in cancer patients undergoing treatment." | 4.02 | RNA-seq and ( Cai, BY; Lu, Y; Wang, XY; Wang, YJ; Xu, L; Yao, QH; Zhang, B, 2021) |
| "Cholinergic syndrome is an acute adverse reaction associated with irinotecan." | 3.88 | Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis. ( Hosokawa, T; Ishikawa, T; Kanazawa, M; Kanbayashi, Y; Kawano, R; Nakajima, Y; Tabuchi, Y; Taguchi, T; Takayama, K; Yoshida, N; Yoshioka, T, 2018) |
| " Possible risk factors are duration of treatment, capecitabine-based chemotherapy, pre-existing cardiac diseases and hypertension." | 3.88 | Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study. ( Chen, G; Dong, C; Li, W; Peng, J; Qiu, M; Wang, C; Wang, F; Wu, Q; Yu, H; Yuan, Y; Zhang, J; Zhang, M; Zhao, Q; Zhou, W; Zhu, B, 2018) |
| "The efficacy of primary prophylactic granulocyte colony-stimulating factor (G-CSF) in preventing febrile neutropenia (FN) in patients treated with docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy remains controversial." | 3.88 | Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy. ( Fukutomi, A; Hamauchi, S; Kawahira, M; Kawai, S; Machida, N; Onozawa, Y; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T; Yoshida, Y, 2018) |
| "5-Fluorouracil (5-FU) is widely used as an anti cancer drug and is known to cause severe diarrhea." | 3.85 | Active Ingredients of Hange-shashin-to, Baicalelin and 6-Gingerol, Inhibit 5-Fluorouracil-Induced Upregulation of CXCL1 in the Colon to Attenuate Diarrhea Development. ( Isa, Y; Kai, Y; Kimura, M; Miyano, K; Narita, M; Sakai, H; Sato, F; Tabata, S; Uezono, Y; Yabe, S; Yumoto, T, 2017) |
| " We silenced UBXN2A in the human osteosarcoma U2OS cell line, an enriched mortalin cancer cell, followed by a clinical dosage of the chemotherapeutic agent 5-fluorouracil (5-FU)." | 3.83 | Structural studies of UBXN2A and mortalin interaction and the putative role of silenced UBXN2A in preventing response to chemotherapy. ( Abdullah, A; Chauhan, SC; Nelson, ME; Newton, SS; Rezvani, K; Sane, S; Wang, H, 2016) |
| "As all the anticancer agents, 5-FU leads to several toxicities." | 3.80 | Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. ( Malet-Martino, M; Martino, R, 2002) |
| "Hand-foot syndrome( HFS) has been reported to be the most common adverse effect of capecitabine, with an incidence of more than 50%." | 3.79 | [Efficacy of AboundTM for hand-foot syndrome caused by capecitabine]. ( Fujii, C; Fujino, M; Fukunaga, M; Hachino, Y; Hamaguchi, Y; Imamura, H; Iseki, C; Ishizaka, T; Kamigaki, S; Kawabata, R; Kawase, T; Kimura, Y; Yamamoto, E, 2013) |
| " Body weight loss results, diarrhea scores, and villi measurements showed that minocycline attenuated the severity of intestinal mucositis induced by 5-fluorouracil (5-FU)." | 3.75 | Minocycline attenuates 5-fluorouracil-induced small intestinal mucositis in mouse model. ( Chao, YC; Chu, HC; Ho, WH; Hou, HS; Huang, TY; Liao, CL; Lin, YL, 2009) |
| "To characterize diarrhea events in patients with cancer treated with lapatinib as monotherapy or in combination with capecitabine or taxanes." | 3.74 | Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. ( Boyle, F; Burris, HA; Byrne, J; Chan, S; Crown, JP; Jones, S; Koehler, M; Newstat, BO; Oliva, C; Parikh, R; Preston, A, 2008) |
| "Chemotherapy-induced diarrhea (CID) became first apparent during clinical studies on the combination of 5-FU with leucovorin and, furthermore, with irinotecan in the treatment of metastatic colorectal carcinoma." | 3.72 | [Management of chemotherapy induced diarrhea]. ( Kullmann, F; Schölmerich, J; Schultz, M, 2004) |
| "To retrospectively analyze a clinical experience with a fixed-unit daily dose of capecitabine employed continuously (open ended without cycling) as a single agent, in combination with other agents, or combined with radiation to determine the drug tolerability with regard to stomatitis, diarrhea, and hand/foot syndrome, compared with the "standard" dose schedule." | 3.72 | Capecitabine: fixed daily dose and continuous (noncyclic) dosing schedule. ( Lokich, J, 2004) |
| " It is the first drug since fluorouracil to possess consistent antitumour activity against metastatic colorectal cancer." | 3.70 | A risk-benefit assessment of irinotecan in solid tumours. ( Rowinsky, EK; Siu, LL, 1998) |
| "A toxicokinetic study was performed using rats to investigate the possible mechanism of 18 acute deaths in Japanese patients with cancer and herpes zoster by interactions of the new oral antiviral drug, sorivudine (SRV), with one of the oral 5-fluorouracil (5-FU) prodrugs within 40 days after approval of the use of SRV." | 3.70 | A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. ( Kato, A; Ogura, K; Okuda, H; Takubo, H; Watabe, T, 1998) |
| "The aim of this study was to demonstrate the value of the level of platinum in lymphocytes, plasma and saliva, in order to predict neutropenia during the same cycle after cisplatin chemotherapy." | 3.70 | [Pharmacologic markers predictive of neutropenia chemically induced by cisplatin (CDDP)]. ( Brès, J; Constans, B; Cupissol, D; Gau, F; Gory-Delabaere, G; Nouguier-Soulé, J, 1999) |
| "The purpose of this study was the evaluation of the effectiveness of intrapericardial administration of tetracycline, 5-fluorouracil and cisplatin in patients with recurrent malignant pericardial effusion." | 3.69 | New approaches to the management and treatment of malignant pericardial effusion. ( Burakowski, J; Fijałkowska, A; Filipecki, S; Szturmowicz, M; Tomkowski, W, 1997) |
| "In a previous trial in which methotrexate and N-phosphonacetyl-L-aspartate (PALA) were used to modulate 5-fluorouracil (5-FU), four of six patients could not tolerate treatment at the 600 mg/m2 5-FU dose level because of mucositis, diarrhea, and a decrease in performance status." | 3.68 | Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin. ( Colofiore, J; Kemeny, N; Martin, D; Sawyer, R; Schneider, A; Seiter, K; Williams, L, 1993) |
| "5-FU-induced leukopenia was reversed for several weeks after the administration of oral uridine." | 3.68 | Reversal of 5-fluorouracil-induced toxicity by oral administration of uridine. ( Peters, GJ; Pinedo, HM; van Groeningen, CJ, 1993) |
| "Because of conflicting reports of clinical synergy, we used the tetrazolium-based colorimetric (MTT) assay to test in vitro combination effects of methotrexate (MTX) plus 5-fluorouracil (FUra) in 4 schedules on 2 human non-small-cell lung cancer cell lines (adenocarcinoma, NC1-H23; bronchio-alveolar-cell carcinoma, NC1-H358), and 1 human colorectal adenocarcinoma cell line (SNU-C1)." | 3.68 | Schedule-dependent in vitro combination effects of methotrexate and 5-fluorouracil in human tumor cell lines. ( Gazdar, AF; Kramer, BS; Perng, RP; Tsai, CM, 1991) |
| "A total of 65 patients with advanced colorectal or breast cancer were given oral tegafur in the phase I study." | 3.66 | Phase I-II studies of oral tegafur (ftorafur). ( Ansfield, FJ; Kallas, GJ; Singson, JP, 1983) |
| " Results of treatment of B16 melanoma and Lewis lung carcinoma with 3,4-dihydroxybenzohydroxamic acid are used to demonstrate this definition." | 3.66 | Drug activity and therapeutic synergism in cancer treatment. ( Campbell, ED; Carter, WH; Stablein, DM; Wampler, GL, 1982) |
| "The penetration of [3H]thymidine, [3H]D-leucine, [125I]albumin, and the drugs [3H]5-fluorouracil and [3H]vinblastine into human glioma spheroids (in vitro tumor models) was studied by a method based on rapid freezing, freeze drying, vapor fixation, wax embedding, dry sectioning, and contact autoradiography." | 3.66 | Penetration of substances into tumor tissue--a methodological study on cellular spheroids. ( Carlsson, J; Malmqvist, M; Nederman, T, 1981) |
| " 5-Fluorouracil (5 FU) is the first chemotherapeutic agent found to have a significant effect on gastrointestinal adenocarcinoma." | 3.64 | PALLIATIVE MANAGEMENT OF GASTROINTESTINAL CANCER. ( HART, GD, 1964) |
| " This report describes a Phase Ib clinical trial investigating PG-11047 in combination with cytotoxic and anti-angiogenic chemotherapeutic agents in patients with advanced refractory metastatic solid tumors or lymphoma." | 3.01 | A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma. ( Becerra, CHR; Boyd, TE; Casero, RA; Conkling, PR; Fitzgerald, M; Garbo, LE; Jotte, RM; Marton, LJ; Murray Stewart, T; Richards, DA; Smith, DA; Stephenson, JJ; Vogelzang, NJ; Von Hoff, D; Wu, HH, 2021) |
| "Capecitabine is an oral pre-pro-drug of the anti-cancer drug 5-fluorouracil (5-FU)." | 2.94 | Phase I pharmacological study of continuous chronomodulated capecitabine treatment. ( Beijnen, JH; de Vries, N; Huitema, ADR; Jacobs, BAW; Marchetti, S; Nuijen, B; Pluim, D; Roosendaal, J; Rosing, H; Schellens, JHM; van Werkhoven, E, 2020) |
| "Patients with advanced solid malignancy received Deflexifol as weekly bolus (375-575 mg/m²) or two-weekly 46 h infusion (1200-3600 mg/m²) for six cycles in a 3+3 dose escalation design." | 2.90 | First-in-human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment. ( Ackland, SP; Aghmesheh, M; Brungs, D; Clingan, PR; de Souza, P; Garg, MB; Jokela, R; Parker, S; Ranson, M; Ranson, RD, 2019) |
| "vomiting, anorexia and infection) were recorded, and short-term effect of chemotherapy was evaluated regularly." | 2.84 | Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms. ( Deng, B; Jia, L; Li, X; Li, Y; Lou, Y; Tan, H; Yu, L, 2017) |
| "Acriflavine (ACF) has been known for years as an antibacterial drug." | 2.82 | Acriflavine, an Acridine Derivative for Biomedical Application: Current State of the Art. ( Kurjata, J; Piorecka, K; Stanczyk, WA, 2022) |
| "5-Fluorouracil (5-FU) has been widely used as a chemotherapeutic agent in the clinical treatment of various cancers, but several studies showed its adverse effects on reproduction." | 2.82 | Reproductive and developmental toxicities of 5-fluorouracil in model organisms and humans. ( Bai, Q; Fan, N; Guo, J; Naren, G; Nashun, B, 2022) |
| "In many cancers TP is expressed at high levels and promotes thymidine catabolism, ultimately generating 2-deoxyribose (2dDR) that can support multiple procancer processes, including glycation of proteins, alternative metabolism, extracellular matrix remodeling, and angiogenesis." | 2.82 | Multifunctional role of thymidine phosphorylase in cancer. ( Reigan, P; Warfield, BM, 2022) |
| " 2006-001177-25) investigated aflibercept, a vascular endothelial growth factor decoy receptor protein (VEGF Trap), in combination with docetaxel, cisplatin, and 5-fluorouracil in patients with advanced solid tumors." | 2.82 | Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies. ( Ajani, JA; Assadourian, S; Bahleda, R; Baker, J; Boelle, E; Deutsch, E; Gadgeel, SM; Garris, JL; Izzedine, H; Khan, A; Massard, C; Rogers, JE; Soria, JC, 2016) |
| "Lenalidomide was given orally on days 1-14, oxaliplatin and leucovorin were given intravenously on day 1, and 5-fluorouracil was given as a continuous infusion on days 1-2." | 2.82 | Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. ( Falchook, G; Fu, S; Hong, DS; Naing, A; Piha-Paul, S; Said, R; Tsimberidou, AM; Wheler, JJ; Ye, Y, 2016) |
| "Capecitabine was administered for 14 days and the RO49029097 once daily, 3 days per week, both for a 21 day cycle." | 2.80 | A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. ( Carmichael, L; Deming, DA; Eickhoff, J; Holen, KD; Ivy, P; Kolesar, J; Leverence, R; Liu, G; LoConte, NK; Lubner, SJ; Mulkerin, DL; Razak, AR; Schelman, WR; Siu, L; Tevaarwerk, A, 2015) |
| "Capecitabine (Cape) is a prodrug that is metabolized into 5'-deoxy-5-fluorocytidine (DFCR), 5'-deoxy-5-fluorouridine (DFUR), and 5-fluorouracil (5-FU) after oral administration." | 2.80 | Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry. ( Chen, X; Dai, X; Deng, P; Ding, L; Ji, C; Zhong, D, 2015) |
| "Patients with advanced solid tumors received oral BKM120 daily combined with standard doses of mFOLFOX6 every 2 weeks of a 28 day cycle." | 2.80 | A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. ( Carlson, C; Ivanova, A; McRee, AJ; O'Neil, BH; Sanoff, HK, 2015) |
| "This was a prospective single-centre, phase I study to document the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and the recommended phase II dose for future study of capecitabine in combination with radioembolization." | 2.79 | Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer. ( Astsaturov, I; Ball, DS; Cade, DN; Cohen, SJ; Dickens, A; Konski, AA; Marlow, C; Meropol, NJ; Meyer, JE; Putnam, S; Yu, JQ, 2014) |
| "UGT1A1 genotype affects the dose and pharmacokinetics of the CAPIRINOX regimen and UGT1A1 genotype-guided dosing of CAPIRINOX is ongoing in a phase II study of small bowel cancer (NCT00433550)." | 2.78 | UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. ( Ames, MM; Erlichman, C; Goetz, MP; Goldberg, RM; Grothey, AA; Kuffel, MA; Mandrekar, SJ; McGovern, RM; McKean, HA; McWilliams, R; Reid, JM; Safgren, SL; Tan, AD, 2013) |
| "The maximum planned dose of oxaliplatin at 100 mg/m(2) per dose in combination with 5-FU and leucovorin was safe and well tolerated and in this patient population." | 2.78 | A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors. ( Arceci, RJ; Bagatell, R; Boklan, J; Christians, U; Duncan, T; Gore, L; Herzog, C; Hunger, SP; Ivy, SP; Macy, ME; Narendren, A; Rolla, K; Trippett, T; Whitlock, J, 2013) |
| " Most frequent adverse events (AEs, any grade) were diarrhea and nausea." | 2.78 | A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. ( Ehrnrooth, E; Lahogue, A; Machiels, JP; Pelling, K; Rottey, S; Vermorken, JB; Wind, S, 2013) |
| " Pharmacokinetic parameters, including Cmax, Tmax, t1/2, AUC0-t, and AUC0-∞ were determined using non-compartmental models with DAS2." | 2.78 | Pharmacokinetic evaluation of novel oral fluorouracil antitumor drug S-1 in Chinese cancer patients. ( Bian, HH; Chen, L; Pu, WY; Wang, H; Wang, J; Zhang, H; Zhu, H; Zhu, MG; Zhuang, ZX, 2013) |
| " Cohort C explored an alternate schedule of 7-day on/7-day off flat dose capecitabine 1,000 mg BID with continuous dosing of sorafenib 400 mg BID." | 2.77 | A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine. ( Bendell, JC; Burris, HA; Greco, FA; Hainsworth, JD; Infante, JR; Jones, SF; Lane, CM; Spigel, DR; Yardley, DA, 2012) |
| "Everolimus is an oral mTOR-inhibitor." | 2.77 | Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies. ( Beijnen, JH; Deenen, MJ; Klümpen, HJ; Richel, DJ; Schellens, JH; Sparidans, RW; Weterman, MJ; Wilmink, JW, 2012) |
| "Sorafenib plus 5-FU/LCV was generally well tolerated with encouraging antitumor activity and no clinically relevant drug-drug interactions in patients with advanced solid tumors." | 2.77 | Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors. ( Atsmon, J; Brendel, E; Bulocinic, S; Figer, A; Geva, R; Nalbandyan, K; Shacham-Shmueli, E; Shpigel, S, 2012) |
| "This phase I study assessed the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, and preliminary antitumor effects of sunitinib combined with modified FOLFOX6 (mFOLFOX6)." | 2.77 | A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors. ( Camidge, DR; Chan, E; Chow Maneval, E; Diab, S; Eckhardt, SG; Khosravan, R; Leong, S; Lin, X; Lockhart, AC; Messersmith, WA; Spratlin, J, 2012) |
| " This phase I study investigated the safety, tolerability, pharmacokinetics and antitumour activity of axitinib combined with chemotherapy." | 2.77 | Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. ( Chen, Y; Cohen, RB; Herbst, RS; Kim, S; Kozloff, MF; Martin, LP; Olszanski, AJ; Rado, T; Rosbrook, B; Samuel, TA; Starr, A; Tarazi, J; Tortorici, M, 2012) |
| "Response to anticancer therapy is believed to be directly related to the concentration of the anticancer drug in the tumor itself." | 2.76 | Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study. ( de Bruijn, P; Ghobadi Moghaddam-Helmantel, IM; Konings, IR; Loos, WJ; Mathijssen, RH; Sleijfer, S; van Dam, LM; Verweij, J; Wiemer, EA, 2011) |
| " Most frequent drug-related adverse events were hand-foot skin reaction (HFSR, 89%), diarrhea (71%), and fatigue (69%)." | 2.76 | Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial. ( Awada, A; Besse-Hammer, T; Brendel, E; Delesen, H; Gil, T; Hendlisz, A; Joosten, MC; Lathia, CD; Loembé, BA; Piccart-Ghebart, M; Van Hamme, J; Whenham, N, 2011) |
| "The purpose of this study was to investigate the effect of gimeracil (CDHP), a reversible dihydropyrimidine dehydrogenase (DPD) inhibitor, on the pharmacokinetics of 5-fluorouracil (5-FU) and other related metabolites by comparing the pharmacokinetic (PK) profile of S-1 (tegafur [FT] + CDHP + oteracil potassium [Oxo]) to that of FT alone." | 2.76 | A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil. ( Mendelson, DS; Ravage-Mass, L; Rosen, LS; Saif, MW; Saito, K; Zergebel, C, 2011) |
| "This phase I study was conducted primarily to determine the maximum tolerated dose (MTD) of tesetaxel, a novel, orally active, semisynthetic microtubule inhibitor of the taxane class, administered with oral capecitabine to patients with advanced solid tumors." | 2.76 | Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors. ( Beeram, M; Patnaik, A; Saif, MW; Sarantopoulos, J; Takimoto, C; Tolcher, AW, 2011) |
| "Patients with previously treated solid tumors received axitinib (starting dose 5 mg twice daily) combined with FOLFOX plus bevacizumab (1, 2, or 5 mg/kg, cohorts 1-3, respectively), FOLFIRI (cohort 4), or FOLFOX (cohort 5)." | 2.75 | A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. ( Abhyankar, V; Burgess, RE; Chen, Y; Infante, J; Kim, S; Robles, RL; Sharma, S; Tarazi, J; Tortorici, M; Trowbridge, RC, 2010) |
| "We studied the safety and tolerability of telatinib, an orally available, small-molecule tyrosine kinase inhibitor of the vascular endothelial growth factor receptor (VEGFR-2/VEGFR-3), platelet-derived growth factor receptor beta, and c-Kit in combination with capecitabine and irinotecan." | 2.75 | Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. ( Brendel, E; Laferriere, N; Langenberg, MH; Mergui-Roelvink, M; Roodhart, JM; Schellens, JH; van der Sar, J; Verheul, HM; Voest, EE; Witteveen, PO, 2010) |
| "Edotecarin (J-107088), a novel inhibitor of topoisomerase I has an additive effect on colon cell lines (HCT-116) when combined with 5-fluorouracil (5-FU)." | 2.75 | A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors. ( Diasio, RB; Douillard, JY; Saif, MW; Sellers, S, 2010) |
| "We developed a population pharmacokinetic (PPK) model of S-1 including the cytochrome P450 (CYP) 2A6 genotype and then used this PPK model to assess the influence of the CYP2A6 genotype on PK parameters of S-1 and the relationship between toxicity and the individual maximum concentrations (Cmax) or the area under the concentration-time curve (AUC) of 5-fluorouracil (5-FU) in Japanese patients with advanced cancer." | 2.75 | Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer. ( Adachi, M; Fujita, K; Hirose, T; Ishida, H; Miwa, K; Mizuno, K; Nagashima, F; Nishimura, K; Sasaki, Y; Sunakawa, Y; Tanigawara, Y; Yamashita, K, 2010) |
| "5, or 50 mg) was administered orally once daily on three dosing schedules: 4 weeks on treatment, 2 weeks off treatment (Schedule 4/2); 2 weeks on treatment, 1 week off treatment (Schedule 2/1); and continuous daily dosing (CDD schedule)." | 2.75 | A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. ( Bello, A; Burris, HA; Chao, R; Chiorean, EG; Jones, S; Lee, FC; Liau, KF; Royce, M; Sweeney, CJ; Tye, L; Verschraegen, CF, 2010) |
| "Of 25 patients with colorectal cancer, 11 had as best response SD for >3 m (median 6 m, range 4." | 2.75 | A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. ( Cane, LM; Carvajal, RD; Dials, HJ; Dickson, MA; Gonen, M; Lefkowitz, RA; Rathkopf, D; Schwartz, GK; Shah, MA; Tse, A; Wu, N, 2010) |
| " We conducted this study to investigate its efficacy and safety when combined with chemotherapy in patients with advanced solid tumors." | 2.75 | Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors. ( Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW, 2010) |
| "Patients with refractory solid tumors who had not failed 5-fluorouracil (5-FU) analogs or topoisomerase I inhibitors were eligible." | 2.74 | Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies. ( Eberhardt, S; Lee, F; Lee, SJ; Lu, H; Maestas, A; Rabinowitz, I; Royce, M; Sayar, H; Shen, Z; Smith, H; Verschraegen, C, 2009) |
| "Capecitabine was administered orally every 8 h x 6 doses, days 1 and 15." | 2.74 | A phase I study of an oral simulated FOLFOX with high dose capecitabine. ( Alberti, D; Eickhoff, J; Feierabend, C; Holen, KD; Kolesar, J; LoConte, NK; Marnocha, R; Mulkerin, D; Oliver, K; Thomas, JP; Wilding, G, 2009) |
| "Valproic acid is a clinically relevant HDAC inhibitor, and PBMCs may serve as a surrogate for tumor histone acetylation in solid tumor malignancies." | 2.74 | Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. ( Bicaku, E; Centeno, B; Daud, A; Kim, J; Lacevic, M; Marchion, D; Minton, S; Munster, P; Neuger, A; Sullivan, D, 2009) |
| " Pharmacokinetic assessments were conducted in cycles 1 and 3." | 2.74 | Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. ( Berg, DJ; Bernaards, C; Blanchard, R; Denlinger, CS; Dorr, A; Hambleton, J; Holden, S; Kearns, A; Kenkare-Mitra, S; Litwin, S; Lum, B; McLaughlin, S; Meropol, NJ; O'Dwyer, PJ; Redlinger, M; Spittle, C; Xu, L, 2009) |
| "To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of the combination of weekly oxaliplatin x 4, weekly irinotecan x 4 and capecitabine Monday through Friday for 4 weeks of every 6 week cycle in patients with solid tumors; to determine the pharmacokinetic profile of these agents in this combination; to observe patients for clinical anti-tumor response." | 2.74 | Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. ( Brell, JM; Cooney, MM; Dowlati, A; Egorin, MJ; Gibbons, J; Hoppel, CL; Ingalls, ST; Ivy, SP; Krishnamurthi, SS; Li, X; Overmoyer, BA; Remick, SC; Schluchter, MD; Weaver, KC; Zuhowski, EG, 2009) |
| "Celecoxib was eliminated due to concerns of increased risk for cardiovascular toxicity, although no patients in this study had cardiac events." | 2.73 | A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors. ( Baron, A; Basche, M; Dancey, J; Eckhardt, SG; Gore, L; Gustafson, DL; Holden, SN; Lam, ET; O'Bryant, CL; Serkova, N, 2008) |
| "Gemcitabine was administered at FDR of 10 mg/m(2) per min in escalating durations of infusion on days 1 and 8." | 2.73 | A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients. ( Leoni, V; Rocci, L; Santini, D; Tonini, G; Vincenzi, B; Virzí, V, 2007) |
| "Irinotecan was given as a 30 min infusion on days 1 and 8, and capecitabine on days 1-14 of a 21-day cycle." | 2.73 | Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. ( Baker, S; Bulgaru, A; Camacho, F; Chaudhary, I; Desai, K; Einstein, M; Goel, S; Goldberg, G; Gollamudi, R; Karri, S; Kaubisch, A; Mani, S, 2007) |
| "Oral capecitabine was administered twice daily continuously with weekend breaks, in patients with advanced solid tumours refractory to standard therapy." | 2.73 | Weekday on-weekend off oral capecitabine: a phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy. ( Boumba, VA; Fountzilas, G; Golfinopoulos, V; Marselos, M; Nikiforidis, L; Nikolaidou, M; Pappas, P; Pavlidis, N; Pentheroudakis, G; Siarabi, O; Tzamakou, E; Vougiouklakis, T, 2007) |
| "Thalidomide 100 mg was kept stable for all cohorts." | 2.73 | A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer. ( Khan, MI; Kloecker, GH; Laber, DA; Salvador, C; Schonard, C; Taft, BS, 2007) |
| "Irofulven was given i." | 2.73 | A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors. ( Alexandre, J; Bertheault-Cvitkovic, F; Cvitkovic, E; Faivre, S; Goldwasser, F; Hilgers, W; Kahatt, C; Lokiec, F; MacDonald, JR; Raymond, E; Shah, A; Shibata, S; Weems, G, 2007) |
| "Lapatinib was administered once daily for the entire duration of the study." | 2.73 | Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. ( Beijnen, JH; Boot, H; Keessen, M; Koch, KM; Pandite, L; Richel, DJ; Schellens, JH; Siegel-Lakhai, WS; Smith, DA; Versola, M; Vervenne, WL, 2007) |
| " Additional patients were treated at the OTR dose level to further evaluate safety and for pharmacokinetic analyses." | 2.73 | Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies. ( Arya, N; Chu, QS; Curtright, J; de Bono, J; Fleming, RA; Ho, PT; Koch, KM; Pandite, L; Rowinsky, EK; Schwartz, G; Smith, DA; Versola, MJ, 2007) |
| " Co-administration of lapatinib increased the area under the plasma concentration-time curve of SN-38, the active metabolite of irinotecan, by an average of 41%; no other pharmacokinetic interactions were observed." | 2.73 | A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. ( Flaherty, KT; Fleming, RA; Kerr, DJ; Koch, KM; Middleton, MR; Midgley, RS; O'Dwyer, PJ; Pratap, SE; Smith, DA; Stevenson, JP; Versola, M; Ward, C, 2007) |
| " In conclusion, capecitabine can safely be combined with docetaxel (40 mg m(-2)) and mitomycin C (4 mg m(-2))." | 2.73 | Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial. ( Ernst, T; Gnad-Vogt, U; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Merx, K; Schultheis, B, 2007) |
| " Although a traditional toxicity-based maximum tolerated dose was not achieved, the highest dosing cohort represented a biologically relevant dose of enzastaurin, on the basis of preclinical data and correlative pharmacodynamic biomarker assays of protein kinase Cbeta inhibition in peripheral blood mononucleocytes, in combination with a standard dose of capecitabine." | 2.73 | A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors. ( Baldwin, J; Basche, M; Britten, CD; Camidge, DR; Darstein, C; Finn, RS; Gail Eckhardt, S; Gore, L; Holden, SN; Leong, S; Musib, L; O'Bryant, CL; Thornton, D, 2008) |
| "Continuous dosing of the combination of capecitabine and celecoxib was well tolerated, produced antiangiogenic effects, and has antitumor activity." | 2.73 | Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study. ( Arends, J; Drevs, J; Frost, A; Häring, B; Hennig, J; Medinger, M; Mross, K; Steinbild, S; Strecker, R; Unger, C, 2007) |
| " No dose-limiting toxicities were noted at all bortezomib dose levels when administered with full dose capecitabine and oxaliplatin." | 2.73 | Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors. ( Beard, M; Cohen, SJ; Engstrom, PF; Langer, CJ; Lewis, NL; McLaughlin, S; Meropol, NJ; Weiner, LM, 2008) |
| " Thus, we prospectively analyzed the effects of the CYP2A6 genotype, plasma level of CDHP, and patient characteristics on the pharmacokinetic (PK) variability of FT and 5-FU." | 2.73 | CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. ( Akiyama, Y; Ando, Y; Araki, K; Endo, H; Endo, S; Fujita, K; Ichikawa, W; Kamataki, T; Kawara, K; Kodama, K; Miwa, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W, 2008) |
| " The most frequent adverse event was asthenia, which was grade 3 in two patients." | 2.73 | A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors. ( Albanell, J; Beech, J; Brewster, M; Gascon, P; Jones, ET; Mellado, B; Montagut, C; Pronk, L; Saunders, MP; Valle, JW; Zugmaier, G, 2008) |
| " Historically, dosing of these drugs has been based on body surface area." | 2.72 | Overcoming barriers to implementing precision dosing with 5-fluorouracil and capecitabine. ( Galettis, P; Martin, JH; Schneider, JJ, 2021) |
| "5-Fluorouracil (5-FU) has been an important anti-cancer drug to date." | 2.72 | 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. ( Kundu, CN; Sethy, C, 2021) |
| "Considering that cancer continues to be an important cause of death worldwide, several conventional anticancer treatments are widely used." | 2.72 | Chemistry and Anticancer Activity of Hybrid Molecules and Derivatives based on 5-Fluorouracil. ( Cardona-G, W; Castrillón-L, W; Herrera-R, A; Ramírez-Malule, H, 2021) |
| " The key player in fluoropyrimidine toxicity is DPD activity, and patients with deficits are more likely to develop significant adverse events." | 2.72 | Role of microRNAs in fluoropyrimidine-related toxicity: what we know. ( Achimaș-Cadariu, P; Bocșan, IC; Burz, CC; Buzoianu, AD; Deac, AL; Militaru, C; Pop, RM, 2021) |
| "Capecitabine was administered orally according to following schedule: 1/4 of dose at 8:00 a." | 2.72 | Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer. ( Gasparro, S; La Cesa, A; Santini, D; Schiavon, G; Tonini, G; Vincenzi, A; Vincenzi, B, 2006) |
| "The purpose of this study was to look at the pharmacokinetics of docetaxel, cisplatin-derived platinum and 5-fluorouracil (5-FU), when used in combination, to exclude potential clinically relevant pharmacokinetic interactions." | 2.72 | A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors. ( Cirillo, I; de Bruijn, P; de Jonge, MJ; Felici, A; Loos, WJ; Mathijssen, RH; Nooter, K; Verweij, J, 2006) |
| "Bacterial infections are major life-threatening complications in patients receiving cytotoxic drugs." | 2.72 | Granulocyte function is stimulated by a novel hexapeptide, WKYMVm, in chemotherapy-treated cancer patients. ( Heo, SK; Kim, BS; Kim, H; Kim, MJ; Lee, EH; Min, YJ; Park, JH; Park, SK, 2006) |
| "In intermediate-risk breast cancer, complete hormonal blockade and chemotherapy provided similar outcomes." | 2.72 | Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. ( Bonneterre, J; Chollet, P; Clavère, P; Fargeot, P; Fumoleau, P; Goudier, MJ; Guastalla, JP; Kerbrat, P; Monnier, A; Roché, H; Serin, D, 2006) |
| " doses of tipifarnib, without a dose-response relationship." | 2.72 | A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors. ( Cohen, RB; Eckhardt, SG; Gore, L; Gustafson, D; Holden, SN; Mikule, C; Morrow, M; O'Bryant, CL; Palmer, PA; Persky, M; Pierson, AS; Zhang, S, 2006) |
| "Capecitabine is a prodrug of 5-fluorouracil that is approved for use in patients with metastatic breast carcinoma and colorectal carcinoma, and it offers the convenience of oral administration." | 2.71 | A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors. ( Clark, JW; Fuchs, CS; Garcia-Carbonero, R; Michaelson, MD; Paul Eder, J; Ryan, DP; Supko, JG, 2003) |
| "Capecitabine is a novel fluoropyrimidine carbamate which is selectively activated after oral administration to 5-fluorouracil (5-FU) by a sequential triple enzyme pathway in liver and tumor cells." | 2.71 | Capecitabine treatment results in increased mean corpuscular volume of red blood cells in patients with advanced solid malignancies. ( Kornek, GV; Locker, GJ; Mader, RM; Pluschnig, U; Scheithauer, W; Steger, GG; Wenzel, C, 2003) |
| "To determine the toxicities and pharmacokinetic effects of eniluracil (EU) given on two weekly dosing schedules with 5-fluorouracil (5-FU) and leucovorin (LV)." | 2.71 | Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. ( Cliatt, J; Grem, JL; Grollman, F; Guo, XD; Hamilton, JM; Harold, N; McQuigan, EA; Monahan, BP; Nguyen, D; Quinn, MG; Saif, MW; Schuler, B; Szabo, E; Takimoto, CH; Thomas, RR; Wilson, R, 2003) |
| " One cohort of five patients received ONYX-015 once a week for 6 weeks at a dose of 2 x 10(12) particles per infusion in combination with weekly infusions of irinotecan (CPT11, 125 mg per week) and 5-fluorouracil (5FU, 500 mg per week)." | 2.71 | Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. ( Blackburn, A; Cunningham, C; Freeman, S; Gibson, B; Nemunaitis, J; Netto, G; Paulson, AS; Post, L; Randlev, B; Rich, D; Sands, B; Tong, A, 2003) |
| " No pharmacokinetic interaction between CCI-779 and 5-FU was observed." | 2.71 | Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. ( Boni, J; Bruntsch, U; Peters, M; Punt, CJ; Thielert, C, 2003) |
| " Leucovorin (LV) dosage was fixed at 500 mg/m(2)." | 2.71 | Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. ( Fleming, GF; Hong, AM; Meyerson, A; Ratain, MJ; Schilsky, RL; Schumm, LP; Vogelzang, NJ, 2003) |
| " Pharmacokinetic and neurotoxicity assessments were performed at the cohort 2 MTD." | 2.71 | Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. ( Adjei, AA; Ames, MM; Atherton, P; Erlichman, C; Galanis, E; Goetz, MP; Goldberg, RM; Pitot, H; Reid, JM; Rubin, J; Sloan, JA; Windebank, AJ, 2003) |
| "5-Fluorouracil was administered intravenously at 200 mg/m(2)/day for 14 days and repeated every 21 days (one cycle)." | 2.71 | Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors. ( Bulgaru, A; Egorin, M; Goel, S; Harvey, E; Hochster, H; Ivy, P; Leibes, L; Lockwood, G; Mani, S; Muggia, F; Renshaw, G; Wadler, S; Zamboni, W, 2003) |
| " A phase I, open-label dose-escalating study was performed to determine the maximum tolerated dose (MTD) of BBR 3464 administered in combination with protracted venous infusional (PVI) 5-fluorouracil (5-FU) for up to six courses in patients with locally advanced and/or metastatic cancer." | 2.71 | A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer. ( Bisset, D; Boyle, D; Camboni, G; Cassidy, J; Edwards, C; Gourley, C; Jodrell, D; Samuel, L; Young, A, 2004) |
| "The recommended phase II dose of PKC412 is 150 mg/day when combined with a continuous infusion of 200 mg/m2/day 5-FU." | 2.71 | A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies. ( Campbell, A; Clark, JW; Deluca, P; Eder, JP; Garcia-Carbonero, R; LoRusso, P; Puchalski, TA; Rothermel, J; Ryan, DP; Supko, JG; Wozniak, A, 2004) |
| "From 2% to 10% of cancer patients treated with 5-fluorouracil (5-FU) will develop symptomatic cardiotoxicity." | 2.71 | 5-Fluorouracil induces arterial vasocontractions. ( Enderle, MD; Graeven, U; Pahlke, M; Petz, C; Schmiegel, W; Südhoff, T; Teschendorf, C, 2004) |
| " Fasting decreased Tmax of FT, 5FU, CDHP, and oxonic acid significantly (P < 0." | 2.71 | The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. ( Beijnen, JH; Fumoleau, P; Giaccone, G; Holwerda, U; Noordhuis, P; Peters, GJ; Schellens, JH; Schornagel, JH; Schrijvers, A; Van Groeningen, CJ; Voorn, D, 2004) |
| "Grade 2/3 neutropenia was observed in 4 (3%) treatment cycles." | 2.71 | Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors. ( Agelaki, S; Amarantidis, K; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Xenidis, N, 2004) |
| "Capecitabine was administered in twice daily divided doses, and CI-994 was given as a single daily dose." | 2.71 | A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. ( Janisch, L; Kimmel, KA; Kindler, HL; Macek, TA; Olson, SC; Ratain, MJ; Schilsky, RL; Undevia, SD; Vogelzang, NJ, 2004) |
| " Pharmacokinetic analysis showed that there was no interaction between oral irinotecan and capecitabine, and that body-surface area was not significantly contributing to the observed pharmacokinetic variability." | 2.71 | Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors. ( Assadourian, S; deJonge, MJ; Dumez, H; Eskens, FA; Sanderink, GJ; Selleslach, J; Semiond, D; Soepenberg, O; Sparreboom, A; ter Steeg, J; van Oosterom, AT; Verweij, J, 2005) |
| " We designed a phase I clinical trial of FU in combination with UCN-01." | 2.71 | Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. ( Gonen, M; Ilson, DI; Kaubisch, A; Kelsen, DP; Kemeny, N; Kortmansky, J; Maki, RG; O'reilly, E; Saltz, LB; Schwartz, GK; Shah, MA; Sowers, R; Tong, W; Weyerbacher, A; Yi, S, 2005) |
| "Capecitabine in combination with docetaxel given every 3 weeks has shown a high degree of activity in a number of tumor types, but at the expense of significant toxicity." | 2.71 | Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. ( Belani, CP; Chatta, GS; Egorin, MJ; Fakih, M; Friedland, DM; Jacobs, SA; Jung, LL; Potter, DM; Ramalingam, S; Ramanathan, RK; Shin, DM; Strychor, S; Tutchko, S; Zamboni, WC, 2005) |
| "Sixteen patients with malignant solid tumors (seven breast, seven colorectal, and two gastric) were enrolled, all of whom were evaluable." | 2.71 | A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors. ( Fukuyama, Y; Koizumi, W; Nomura, N; Ohno, S; Osaki, A; Saeki, T; Satoh, A; Taguchi, T; Takashima, S; Terashima, M; Toge, T; Toi, M, 2005) |
| "Tezacitabine at a dose of 200 mg/m(2) in combination with CI 5-FU at a dose of 200 mg/m(2) per day was relatively well tolerated and had clinical activity in patients with advanced solid tumors, particularly in patients with esophageal and other gastrointestinal carcinomas." | 2.71 | Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors. ( Bendell, JC; Clark, JW; Eder, JP; Fidias, P; Lynch, TJ; Ryan, DP; Seiden, MV, 2005) |
| " This phase I pharmacokinetic and clinical study evaluated escalating CPT-11 doses administered every 3 weeks combined with a fixed dose of 5-FU CI over 14 days to find the maximum tolerated dose (MTD) of this combined chemotherapy." | 2.71 | A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours. ( Alfonso, R; Carcas, A; Cortés-Funes, H; Díaz-Rubio, E; Frías, J; Grávalos, C; Guerra, P; Paz-Ares, L; Pronk, L; Sastre, J, 2005) |
| " This study is a preliminary clinical investigation to determine if HA could be safely used in combination with 5-fluorouracil (5-FU) and doxorubicin (DOX)." | 2.71 | Phase I and pharmacokinetic evaluation of intravenous hyaluronic acid in combination with doxorubicin or 5-fluorouracil. ( Brown, TJ; Ellis, A; Fox, RM; Gibbs, P; Heldin, P; Li, L; Rosenthal, MA; Uren, S; Wong, S, 2005) |
| "Four of 22 patients with colorectal cancer had partial responses, two of which had prior bolus CPT-11/5-FU." | 2.71 | A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors. ( Fioravanti, S; Grem, JL; Guo, X; Harold, N; Hopkins, JL; Leguizamo, JP; Leonard, GD; Lin, P; Monahan, BP; Morrison, G; Nguyen, D; Pang, J; Quinn, MG; Saif, MW; Schuler, B; Szabo, E; Wright, MA, 2005) |
| "Topotecan was administered once a day for 5 consecutive days followed by 2 days of rest and was administered again for 5 consecutive days." | 2.71 | Phase I trial of an all-oral combination chemotherapy regimen: topotecan and capecitabine in solid tumor patients. ( Adams, N; Barrera, D; Cunningham, C; Graham, S; Nemunaitis, J; Nugent, J; Senzer, N; Stewart, C, 2005) |
| "Forty patients and 75 pharmacokinetic time-courses were available for analysis." | 2.71 | Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer. ( Lokiec, F; Rezaí, K; Urien, S, 2005) |
| "5-Fluorouracil (5FU) is an antimetabolite that interferes with DNA synthesis." | 2.70 | Phase I study of sequential administration of topotecan and 5-fluorouracil in patients with advanced malignancies. ( Devereux, L; Goldberg, J; Grana, G; Hageboutros, A; Khatri, J; Rodman, WD; Sbar, EI; Tritschler, L, 2002) |
| "Nine patients with colorectal cancer and one with gastric cancer had partial or minor responses." | 2.70 | A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin. ( Adjei, AA; Alberts, SR; Atherton, P; Erlichman, C; Goldberg, RM; Kaufmann, SH; Miller, LL; Pitot, HC; Rubin, J; Sloan, JA, 2002) |
| " The treatment plan consisted of weekly gemcitabine for three weeks with twice daily dosing of 5-FU and eniluracil for 21 days beginning on day one of gemcitabine." | 2.70 | Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy. ( Alberti, D; Arzoomanian, RZ; Bailey, H; Berlin, JD; Binger, K; Feierabend, C; Marrocha, R; Morgan-Meadows, S; Mulkerin, D; Thomas, JP; Volkman, J; Wilding, G, 2002) |
| " The same dosage of combine drugs were used in the two groups." | 2.70 | [Phase III clinical study of a new anticancer drug atofluding]. ( Feng, FY; Han, J; Li, L; Li, Q; Sui, GJ; Wang, PH; Zhang, Y; Zhang, YC; Zhang, ZH; Zhou, MZ; Zhu, YG, 2002) |
| "rhuMAbVEGF can be safely combined with chemotherapy at doses associated with VEGF blockade and without apparent synergistic toxicity." | 2.70 | Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. ( Adelman, D; Breed, J; Fyfe, G; Gaudreault, J; Gordon, MS; Holmgren, E; Margolin, K; Novotny, W; Stalter, S, 2001) |
| " Schedule 1 maximum tolerated dose of gemcitabine was 600 mg/m(2)/week when combined with 5-fluorouracil (5-FU) at 200 mg/m(2)/day (Days 1-21) repeated every 4 weeks." | 2.70 | Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. ( Bertucci, D; Mani, S; Ratain, MJ; Schilsky, RL; Stadler, WM; Vogelzang, NJ, 2001) |
| "Gemcitabine was administered as a 30-minute intravenous infusion weekly for 3 weeks followed by a 1-week break." | 2.70 | Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. ( Bertucci, D; Kindler, HL; Ratain, MJ; Schilsky, RL; Vogelzang, NJ, 2002) |
| " Pharmacokinetic parameters of capecitabine and its metabolites (5'-deoxy-5-fluorouridine, 5-fluorouracil and alpha-fluoro-beta-alanine) were similar to those reported by other authors." | 2.70 | Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics. ( Budd, GT; Bukowski, R; Chang, DZ; Ganapathi, R; Olencki, T; Osterwalder, B; Peereboom, D, 2001) |
| "Capecitabine (Xeloda) is an orally administered precursor of 5'-deoxy-5-fluorouridine (5'-DFUR), which is preferentially activated to 5-fluorouracil (5-FU) in tumors." | 2.70 | Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. ( Banken, L; Cassidy, J; Gardiner, J; Harper, P; Johnston, P; Monkhouse, J; Poole, C; Reigner, B; Twelves, C; Weidekamm, E, 2002) |
| ", Carlsbad, CA) when administered in combination with 5-fluorouracil (5-FU) and leucovorin (LV)." | 2.70 | Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. ( Dorr, FA; Geary, RS; Holmlund, JT; Kindler, HL; Kunkel, K; Mani, S; Ratain, MJ; Rudin, CM, 2002) |
| "When eniluracil is given with 5-FU/LV, DPD inhibition appears to be influenced by schedule, and the time to recovery is much longer than has been observed with eniluracil given alone." | 2.70 | Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition. ( Grem, JL; Guo, XD; Harold, N; Keith, B; Quinn, M; Schuler, B; Shapiro, J; Zentko, S, 2002) |
| "This phase I, dose-escalation study was conducted to determine the recommended dose of intermittent oral capecitabine in combination with a fixed dose of i." | 2.70 | Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. ( Baselga, J; Bisset, D; Cassidy, J; Díaz-Rubio, E; Eatock, M; Evans, TR; Regueiro, P; Sastre, J; Tabemero, J, 2002) |
| "Patients with advanced solid tumors refractory to standard therapy were enrolled at two institutions." | 2.69 | Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. ( Burris, HA; Diasio, R; Hohneker, J; Janisch, L; Khor, SP; Lucas, VS; Ratain, MJ; Schilsky, RL; Smetzer, L; Von Hoff, DD, 1998) |
| "Levamisole was administered to 38 patients orally three times a day for 5 days concurrently with a course of 5-FU administered daily by rapid intravenous injection for 5 days." | 2.69 | Clinical and pharmacokinetic studies of high-dose levamisole in combination with 5-fluorouracil in patients with advanced cancer. ( Bagniewski, PG; Kovach, JS; Moertel, CG; O'Connell, MJ; Reid, JM, 1998) |
| "The suggested phase II dose on a continuous 42-day dosing schedule is 1,331 mg/m2/d." | 2.69 | Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. ( Behr, J; Berghorn, E; Budman, DR; Creaven, PJ; Gordon, RJ; Griffin, T; Lichtman, SM; Meropol, NJ; Osterwalder, B; Reigner, B, 1998) |
| "Capecitabine is an orally administered fluoropyrimidine carbamate selectively activated to fluorouracil (5-FU) in tumors." | 2.69 | Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. ( Allman, D; Griffin, T; Kaye, S; Mackean, M; Osterwalder, B; Planting, A; Reigner, B; Schellens, J; Twelves, C; Verweij, J, 1998) |
| "Capecitabine (Xeloda) is a novel rationally designed fluoropyrimidine carbamate." | 2.69 | A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. ( Allman, D; Bissett, D; Cassidy, J; Dirix, L; Griffin, T; Osterwalder, B; Reigner, B; Van Oosterom, AT, 1998) |
| " Unexpectedly, moderate increases in the Cmax and AUC0-infinity values obtained for capecitabine and 5'-deoxy-5-fluorocytidine were observed when Maalox was given together with capecitabine." | 2.69 | Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. ( Banken, L; Cassidy, J; Clive, S; Goggin, T; Jodrell, D; Mulligan, T; Reigner, B; Roos, B; Schulz, R; Utoh, M; Weidekamm, E, 1999) |
| "Two patients with metastatic breast cancer experienced complete responses and a partial response occurred in a patient with metastatic non-small-cell lung cancer." | 2.69 | A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies. ( Aylesworth, C; Bellet, R; Burris, H; Peacock, N; Petit, T; Ravdin, P; Rodriguez, G; Rowinsky, EK; Smetzer, L; Smith, L; Von Hoff, DD, 1999) |
| "The paclitaxel dose was escalated from 100-135-170-200-225 to 250 mg/m2, whereas i." | 2.69 | Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors. ( Arbuck, SG; Bhalla, KN; Ibrado, AM; Javed, T; Kumar, GN; Reed, C; Stuart, RK; Walle, T; Walle, UK, 1999) |
| "Based on the primary pharmacokinetic parameter, AUC(0-infinity) of 5'-DFUR, equivalence was concluded for the two formulations, since the 90% confidence interval of the estimate of formulation B relative to formulation A of 97% to 107% was within the acceptance region 80% to 125%." | 2.69 | Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. ( Banken, L; Bush, E; Cameron, D; Cassidy, J; Goggin, T; Jodrell, D; Jones, D; O'Byrne, K; Reigner, B; Roos, B; Steward, W; Twelves, C; Weidekamm, E, 1999) |
| "Gemcitabine is a chemotherapy agent with efficacy in the treatment of lung, pancreas, bladder and breast cancer." | 2.69 | Leucovorin, 5-fluorouracil, and gemcitabine: a phase I study. ( Grant, S; Poplin, E; Roberts, J; Rubin, E; Tombs, M, 1999) |
| " infusion of 5FU in patients with advanced solid tumors to determine the maximum tolerated dose, the recommended dose for Phase II studies, and the safety and pharmacokinetic profiles of this combination." | 2.69 | A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. ( Bartholomeus, S; Bleiberg, H; Brassinne, C; Cazenave, I; de Valeriola, D; Hennebert, P; Kerger, J; Kusenda, Z; Lefresne-Soulas, F; Piccart, M; Selleslags, J; Van Den Neste, E; Wythouck, H, 2000) |
| "One patient with metastatic gastric cancer achieved a near-complete response of his gastric mass and adrenal metastasis." | 2.69 | A phase I trial of gemcitabine and infusional 5-fluorouracil (5-FU) in patients with refractory solid tumors: Louisiana Oncology Associates protocol no. 1 (LOA-1). ( Brierre, JE; Buller, EJ; Cole, JL; Fontenot, MF; Lormand, NA; Rainey, JM; Rinaldi, DA; Stagg, MP, 2000) |
| " This phase I study was performed to determine the maximum tolerated dose (MTD) and side-effects of the combination, and to establish whether there is any pharmacokinetic interaction between the two compounds." | 2.69 | A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. ( Gordon, RJ; Osterwalder, B; Planting, AS; Pronk, LC; Reigner, B; Sparreboom, A; Twelves, C; Vasey, P; Verweij, J, 2000) |
| "39 adult cancer patients were enrolled with advanced/refractory disease not amenable to established treatments, PS | 2.69 | A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours. ( Barbet, N; Buuren, IV; Capdeville, R; Choi, L; de Vries, EG; Dumez, H; Groen, HJ; Muskiet, F; Oosterom, AT; Paridaens, R; Seeghers, M; Uges, DR; van der Graaf, WT, 2000) |
| "To determine the toxicities, dose-limiting toxicities (DLT), maximum-tolerated dose, and pharmacokinetic profile of emitefur (BOF-A2) in patients with advanced solid tumors." | 2.69 | Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors. ( Corey, A; Eager, R; Hoff, PM; Nemunaitis, J; Pazdur, R; Sekar, K; Thompson, J; Tkaczuk, K; Twaddell, T, 2000) |
| "Patients received a single 24-hour infusion of 5-FU (2,300 mg/m(2) on day 2) with leucovorin (15 mg orally [PO] bid on days 1 through 3) to provide reference pharmacokinetic data." | 2.69 | Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors. ( Bi, DQ; Donavan, S; Grem, JL; Grollman, F; Hamilton, JM; Harold, N; Keith, B; Monahan, BP; Morrison, G; Quinn, MG; Shapiro, J; Takimoto, CH; Zentko, S, 2000) |
| " To determine the bioequivalence of the combined eniluracil/5-FU dosing forms compared to the separate tablets, an analysis of variance on pharmacokinetic parameters reflecting eniluracil and 5-FU exposure was performed." | 2.69 | Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. ( Cohen, D; Drengler, R; Ertel, VP; Hoffman, C; Hsieh, A; Hurwitz, HI; Magnum, S; Monroe, P; Ochoa, L; Petros, WP; Rowinsky, EK; Schwartz, G; Thomas, JP; Wilding, G, 2000) |
| "54 patients with advanced malignancy refractory to chemotherapy were studied to evaluate efficacy and toxicity of continuous infusion of 5-fluorouracil (5FU) given for 3 weeks." | 2.69 | [Dose-intensive chemotherapy with continuous infusion 5-fluorouracil]. ( Berger, R; Brenner, H; Ghodsizade, E; Katz, A; Rath, P; Tichler, T, 1999) |
| "courses in 15 patients with cancer of different origins." | 2.68 | Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies. ( Gabizon, AA; Gorodetsky, R; Mou, X; Vexler, AM, 1995) |
| "Thirteen patients with metastatic cancer received 30 cycles of therapy." | 2.68 | Phase I trial of high-dose infused zidovudine combined with leucovorin plus fluorouracil. ( Beitz, JG; Bigley, JW; Browne, MJ; Clark, JW; Cummings, FJ; Damowski, JW; Weitberg, AB, 1995) |
| " As a result, the extent of toxicity of cancer chemotherapy varies by 50% or more according to dosing time in mice or rats." | 2.68 | [Chrono-chemotherapy and dose intensity]. ( Lévi, F, 1995) |
| "Brequinar was administered over 1 h and 5-FU over 2 h starting 18-20 h after the initiation of infusion of brequinar." | 2.68 | Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I study. ( Buzaid, AC; Hait, WN; Marsh, JC; Murren, JR; Pizzorno, G; Poo, WJ; Ravikumar, TS; Strair, RK; Todd, M, 1995) |
| "Diarrhea was dose-limiting; 6/13 patients had grade II or worse diarrhea at 2,600 mg/m2." | 2.68 | Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer. ( Brennan, J; Hageboutros, A; Hudes, GR; LaCreta, FP; McAleer, C; Newman, EM; O'Dwyer, PJ; Ozols, RF; Rogatko, A, 1995) |
| "Mucositis is a common toxicity of cancer chemotherapy." | 2.68 | Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. ( Anderson, PM; Skubitz, KM, 1996) |
| " Prior FU exposure appeared to protect tissues normally susceptible to MTX toxicity, and allowed safe administration of high dose MTX without leucovorin rescue." | 2.68 | 5-fluorouracil modulates the toxicity of high dose methotrexate. ( White, RM, 1995) |
| " On day 1 of treatment, CPT-11 alone was given by 90-minute infusion, and pharmacokinetic sampling was performed over 24 hours." | 2.68 | Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. ( Berkery, R; Dietz, A; Eng, M; Kanowitz, J; Kelsen, DP; Kemeny, NE; Locker, P; Saltz, LB; Schaaf, L; Spriggs, D; Staton, BA; Steger, C, 1996) |
| "Twelve patients completed the bioavailability and pharmacokinetic studies." | 2.68 | Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. ( Adjei, AA; Baker, SD; Donehower, RC; Doucette, M; Grochow, LB; Hohneker, JA; Khor, SP; Noe, DA; Rowinsky, EK; Sartorius, SE; Spector, T, 1996) |
| "6 g of PN401 as an oral suspension or 6 g given in tablet form resulted in high bioavailability of URD, with sustained plasma concentrations greater than 50 mumol/L." | 2.68 | Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. ( Bertino, J; Kelsen, DP; Martin, D; O'Neil, J; Saltz, L; Schwartz, G; Sung, MT; von Borstel, R, 1997) |
| " Pharmacokinetic evaluation showed that single-dose UFT results in maximum plasma levels and an area under the concentration-time curve that increased with escalating UFT doses." | 2.68 | Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin. ( Pazdur, R, 1997) |
| "The response rate was 56." | 2.68 | [Current status of low-dose CDDP. 5-FU therapy for solid malignant tumors--nationwide questionnaire survey]. ( Aiba, K; Araki, H; Chung, Y; Hirata, K; Saji, S; Sasaki, K; Shirasaka, T; Sowa, M; Tanaka, M; Toge, T; Wada, H; Yamamitsu, S; Yasumoto, K, 1997) |
| " 5-FU can be combined with IFN using 24- and 48-h high-dose and long-term low-dose CI schedules, with large differences in dose intensity at maximum tolerated dose." | 2.68 | Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha. ( Elias, L; Ferguson, J; Greenblatt, MS; Mangalik, A, 1995) |
| "Eighty-eight patients with advanced cancer were entered into this Phase I trial." | 2.68 | Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer. ( Capizzi, RL; Case, L; Fernandes, DJ; Fleming, RA; Homesley, H; Loggie, BW; Morris, R; Muss, HB; Richards, F; Russell, GB; Smith, S, 1996) |
| " Absolute bioavailability after the oral dosing on day 1 was 87." | 2.67 | Oral ondansetron pharmacokinetics: the effect of chemotherapy. ( Bjurstrom, T; Bozigian, HP; Gooding, AE; Griffin, RH; Hansen, LA; Hsyu, PH; Huang, AT; Mitchell, R; Panella, TL; Pritchard, JF, 1994) |
| " The pharmacokinetic advantage of 5-FU-ip was confirmed in our study (ratio AUC peritoneum/plasma between 160 and 328)." | 2.67 | [Continuous double administration of 5 fluorouracil (intravenous and intraperitoneal) modulated by folinic acid: phase I clinical study and pharmacokinetics in patients with intra-abdominal developing cancers]. ( Bugat, R; Canal, P; Chevreau, C; de Forni, M; Gualano, V; Izar-Soum, F; Martel, P; Roché, H; Soulié, P, 1993) |
| "We assessed N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine-HCl (DPPE) potentiation of chemotherapy in vitro and performed a pharmacokinetic study and phase I/II trial of DPPE, combined with various single agents, in patients with advanced refractory cancer." | 2.67 | Results of a clinical trial in humans with refractory cancer of the intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine-HCl, in combination with various single antineoplastic agents. ( Bracken, SP; Brandes, LJ; Simons, KJ; Warrington, RC, 1994) |
| " Our findings suggest that under certain conditions, mechanisms other than altered 5-FU pharmacokinetics may be responsible for the ability of IFN-alpha to enhance the toxic effects of 5-FU." | 2.67 | Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation. ( Diasio, RB; Einzig, A; Lu, Z; Schwartz, EL; Sparano, JA; Wadler, S; Wiernik, PH; Zhang, R, 1993) |
| " Therefore, a phase I and pharmacokinetic study of FUra with escalating doses of rIFN-a was initiated." | 2.67 | Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. ( Danhauser, LL; Freimann, JH; Gilchrist, TL; Gutterman, JU; Hunter, CY; Markowitz, AB; Yeomans, AC, 1993) |
| " If the combination is to be given on a protracted basis, 5-FU must be administered at a much smaller dosage than has been traditionally utilized." | 2.67 | A phase I trial of protracted 5-fluorouracil infusion and oral calcium leucovorin. ( Anderson, T; Beatty, PA; Hansen, RM; Quebbeman, EJ, 1993) |
| "One patient with metastatic colon cancer who received 5-FU at 540 mg/m2 achieved a partial response." | 2.67 | Phase I study of 5-fluorouracil with folinic acid combined with recombinant human granulocyte-macrophage colony-stimulating factor. ( Moore, DF; Pazdur, R, 1992) |
| "Twenty-nine patients with advanced cancer (75% colon or pancreatic cancer) were treated." | 2.67 | A phase I trial of fluorouracil, leucovorin, and recombinant interferon alpha-2b in patients with advanced malignancy. ( Alberts, DS; Hersh, EM; Marcus, SG; Modiano, MR; Taylor, CW; Woodson, ME, 1992) |
| "Twenty-seven patients with advanced cancer were entered in a phase I study of bolus i." | 2.67 | Pharmacokinetics and toxicity of continuous infusion (6S)-folinic acid and bolus 5-fluorouracil in patients with advanced cancer. ( Ahn, CW; Akman, SA; Doroshow, JH; Harrison, JS; Leong, LA; Margolin, KA; Morgan, RJ; Newman, EM; Raschko, JW; Somlo, G, 1992) |
| "Stomatitis was observed in 44/78 (56%) courses." | 2.67 | A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions. ( Alberti, D; Arzoomanian, RZ; Bailey, H; Grem, JL; Spriggs, DR; Tombes, MB; Tutsch, KD; Wilding, G, 1992) |
| "Oral hydroxyurea (HU) was added to a regimen of 5-fluorouracil (5-FU) plus leucovorin (LCV) administered as a continuous 24-hour infusion for 14 days." | 2.67 | Dual modulation of 5-fluorouracil using leucovorin and hydroxyurea. A phase I trial. ( Anderson, N; Bern, M; Coco, F; Gonsalves, L; Lokich, J; Moore, C; Zipoli, T, 1991) |
| "Four of ten patients with colorectal cancer responded to the treatment (four partial responses), of whom three had been treated previously." | 2.67 | A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. ( Ardalan, B; Benedetto, P; Feun, L; Fodor, M; Livingstone, A; Morrell, L; Richman, S; Savaraj, N; Sridhar, KS; Waldman, S, 1991) |
| "5-Fluorouracil was given daily on days 2 to 6 as an i." | 2.67 | Pharmacology and phase I trial of high-dose oral leucovorin plus 5-fluorouracil in children with refractory cancer: a report from the Children's Cancer Study Group. ( Finklestein, JZ; Hammond, GD; Holcenberg, JS; Krailo, MD; Newman, EM; Patel, R; Reaman, GH; Sato, JK; Villacorte, DG, 1991) |
| "route, in various types of cancer disease such as non-small cell lung cancer and advanced breast cancer." | 2.67 | Experimental studies and preliminary clinical trial of vinorelbine-loaded polymeric bioresorbable implants for the local treatment of solid tumors. ( Bouffard, P; Caty, A; Fournier, C; Hecquet, B; Krikorian, A; Lefebvre, JL; Merle, S; Vanseymortier, L; Vert, M; Vilain, MO, 1991) |
| "Many trials of anticancer agents have been conducted, excluding patients with heart diseases." | 2.66 | Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines. ( Hiraide, M; Shiga, T, 2020) |
| " Attempts to improve the dosing regimen of gemcitabine were aimed at maximising the intracellular gemcitabine triphosphate concentrations." | 2.66 | Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action. ( Beijnen, JH; Derissen, EJB, 2020) |
| "1 with small-cell lung cancer, 3 with squamous cell lung cancer and 1 with metastases of low-differentiated cancer from an undetected focus to supraclavicular lymph nodes the effect was partial." | 2.66 | [Elaboration of the combination of antitumor preparations bleomycetin + 5-fluorouracil + cisplatin]. ( Batov, SV; Zharkov, SA, 1988) |
| "Pretreatment with allopurinol did not reduce the toxicity of 5-FU administered as an intravenous bolus." | 2.65 | Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection. ( Howell, SB; Pfeifle, CE; Wung, WE, 1983) |
| " On closer examination, the agents that appear to be responsible for these especially adverse effects are methotrexate and methyl-CCNU." | 2.65 | Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. ( Begg, CB; Carbone, PP, 1983) |
| "Patients with advanced cancer who had documented disease progression while receiving chemotherapy alone were subsequently treated with the same drug, by the same dose and route, combined with localized hyperthermia." | 2.65 | Clinical thermochemotherapy. A controlled trial in advanced cancer patients. ( Elliott, RS; Harrison, WH; Haskell, CM; Kaiser, LR; Morton, DL; Ramming, KR; Sarna, G; Silberman, AW; Storm, FK, 1984) |
| "Progress in the treatment of cancer with drugs has radically altered the clinical approach to patients with malignancy." | 2.65 | Cancer chemotherapy. Progress and expectations, 1984. ( Allegra, CJ; Chabner, BA; Curt, GA; Fine, RL; Yeh, GW, 1984) |
| "This finding was clinically applied to cancer chemotherapy for enhancing drug delivery to tumor tissue selectively." | 2.65 | [Clinical studies on induced hypertension chemotherapy based on functional characteristics of microcirculation of tumor vessels]. ( Sato, H; Wakui, A, 1984) |
| " The optimal dosage was considered to be between 17 mg/kg and 24 mg/kg." | 2.65 | [Joint clinical Phase II study of SF-SP]. ( Hanatani, Y; Sato, H; Sato, T, 1984) |
| "Adjuvant trials in cancer treatment present special problems in statistical analysis." | 2.64 | Special problems in the evaluation of results in adjuvant trials of cancer treatment. ( Higgins, GA, 1978) |
| "Matrine is an alkaloid isolated from Sophora flavescens Ait." | 2.61 | Research advances on anticancer activities of matrine and its derivatives: An updated overview. ( Jiang, J; Muhammad, Y; Rashid, HU; Wang, L; Xu, Y, 2019) |
| "The global pandemic of drug-sensitive cancers and the increasing threat from drug-resistant cancers make an urgent need to develop more effective anti-cancer candidates." | 2.61 | Quinolone hybrids and their anti-cancer activities: An overview. ( Gao, F; Wang, T; Xiao, J; Zhang, X, 2019) |
| "Currently, cancer and its progression to metastasis result in a large number of deaths." | 2.61 | Multi-target compounds acting in cancer progression: Focus on thiosemicarbazone, thiazole and thiazolidinone analogues. ( de Lima Ferreira, LP; de Melo Rêgo, MJB; de Moraes Gomes, PAT; de Siqueira, LRP; Leite, ACL, 2019) |
| "The anticancer agents play an intriguing role in the treatment of cancers, while the severe anticancer scenario and the emergence of drug-resistant especially multidrug-resistant cancers create a huge demand for novel anticancer drugs with different mechanisms of action." | 2.61 | Coumarin-containing hybrids and their anticancer activities. ( Xu, Z; Zhang, L, 2019) |
| "Anticancer agents are critical for the cancer treatment, but side effects and the drug resistance associated with the currently used anticancer agents create an urgent need to explore novel drugs with low side effects and high efficacy." | 2.61 | 1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships. ( Liu, Y; Xu, Z; Zhao, SJ, 2019) |
| "5-Fluorouracil (5-FU) is an anticancer drug widely used to treat many cancers in the human body." | 2.61 | Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs. ( Gupta, SK; Sharma, V; Verma, M, 2019) |
| " Study description, pharmacokinetic parameter values and influential covariates are reported." | 2.61 | Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters. ( Barbolosi, D; Deyme, L; Gattacceca, F, 2019) |
| "Severe gastrointestinal (GI) toxicity is a common adverse effect following 5-fluorouracil (5-FU)-based chemotherapy treatment." | 2.61 | Toll-like receptor/interleukin-1 domain innate immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal toxicity risk following 5-fluorouracil-based chemotherapy. ( Bowen, JM; Coller, JK; Gibson, RJ; Korver, SK, 2019) |
| "We discuss how conventional cancer therapies can be properly selected to set up combinatorial approaches with ICI leading to treatment improvement." | 2.61 | Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors? ( Apetoh, L; Rivera Vargas, T, 2019) |
| "A large number of anticancer drugs currently in use include drugs based on platinum complexes such as cisplatin, base analogues such as 5-florouracil and some ruthenium drugs." | 2.58 | Chemotherapeutic Drugs and Plasma Proteins: Exploring New Dimensions. ( Ahsan, H; Ali, SS; Khan, FH; Rehman, AA; Siddiqui, T; Zia, MK, 2018) |
| "Curcumin has been found to be able to negatively regulate these processes." | 2.58 | The combination of curcumin and 5-fluorouracil in cancer therapy. ( Cao, S; Wei, Y; Yang, P; Zhao, L, 2018) |
| " This review summarizes the current state of knowledge of FIC with special regard to proposed pathogenetic models (coronary vasospasm, endothelium and cardiomyocytes damage, toxic metabolites, dihydropyrimidine dehydrogenase deficiency); risk and predictive factors; efficacy and usefulness in detection of laboratory markers, electrocardiographic changes and cardiac imaging; and specific treatment, including a novel agent, uridine triacetate." | 2.58 | Fluoropyrimidine-induced cardiotoxicity. ( Aglietta, M; Bonzano, A; Cagnazzo, C; Depetris, I; Filippi, R; Leone, F; Marino, D, 2018) |
| " However, despite dosage adaptation based on DPD status, some patients may still experience under- or over-exposure, leading to inefficacy or major toxicity." | 2.58 | [5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer]. ( Boyer, JC; Chatelut, E; Ciccolini, J; Evrard, A; Goirand, F; Guilhaumou, R; Launay, M; Lemaitre, F; Paludetto, MN; Schmitt, A, 2018) |
| " 5-FU dosing is traditionally based on body surface area (BSA), but this strategy is usually associated with severe toxicities." | 2.58 | How can we best monitor 5-FU administration to maximize benefit to risk ratio? ( Bardou, M; Boyer, JC; Chatelut, E; Goirand, F; Launay, M; Lemaitre, F; Schmitt, A; Tron, C, 2018) |
| "Uridine triacetate treatment within 96 hours of administration is associated with survival." | 2.58 | 5-Fluorouracil and Capecitabine: Assessment and Treatment of Uncommon Early-Onset Severe Toxicities Associated With Administration. ( Brutcher, E; Christensen, D; Hennessey Smith, M; Koutlas, JB; Sellers, JB; Thompson, J; Timmons, T, 2018) |
| "Among them, the anticancer and anti-inflammatory activities are the most studied." | 2.55 | Oleanane-, ursane-, and quinone methide friedelane-type triterpenoid derivatives: Recent advances in cancer treatment. ( Alho, DPS; Figueiredo, SAC; Gonçalves, BMF; Leal, AS; Mendes, VIS; Salvador, JAR; Silvestre, SM; Valdeira, AS, 2017) |
| "Treatment of MLH1-methylated colon cancer cell lines with the demethylating agent 5'-aza-2'-deoxycytidine induces the expression of MLH1 and sensitizes cancer cells to 5-fluorouracil." | 2.53 | The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer. ( Gao, D; Guo, M; Herman, JG, 2016) |
| "5-FU dosing has been typically determined by using body surface area (BSA)." | 2.53 | Therapeutic drug monitoring of 5-fluorouracil. ( Beumer, JH; Chu, E; Lee, JJ, 2016) |
| " However, the practice of precision dosing is hampered by a lack of smart dosing algorithms." | 2.53 | Pharmacokinetically guided algorithm of 5-fluorouracil dosing, a reliable strategy of precision chemotherapy for solid tumors: a meta-analysis. ( Ding, H; Fang, L; Huang, P; Li, J; Luo, H; Xin, W; Yang, Y; Zhang, Y; Zhong, L, 2016) |
| "Clin Cancer Res; 22(18); 4545-49." | 2.53 | FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs. ( Bai, G; Beaver, JA; Charlab, R; Chen, XH; Cheng, J; Dinin, J; Dorff, SE; Ibrahim, A; Ison, G; Jin, R; Kim, G; Liu, Q; Marathe, A; McGuinn, WD; McKee, AE; Palmby, TR; Pazdur, R; Pierce, W; Sridhara, R; Stephens, O; Tang, S; Wang, Y; Ysern, X, 2016) |
| "5-fluorouracil(5-FU)therapy has advanced greatly over the past 50 years, achieving enhanced therapeutic effects and reduced adverse effects." | 2.53 | [Evolving 5-Fluorouracil Therapy to Achieve Enhanced Efficacy-Past and Current Efforts of Researchers]. ( Baba, H; Emi, Y; Iimori, M; Kakeji, Y; Kataoka, Y; Kitao, H; Maehara, Y; Niimi, S; Oki, E; Saeki, H; Shirasaka, T; Tokunaga, E, 2016) |
| "In the treatment of cancer with 5-fluorouracil, the administration of folates mechanistically leads to the formation of [6R]-5,10-methylene-tetrahydrofolate, and the increased concentration of this molecule leads to stabilization of the ternary complex comprising thymidylate synthase, 2'-deoxy-uridine-5'-monophosphate, and [6R]-5,10-methylene-tetrahydrofolate." | 2.53 | Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action. ( Danenberg, PV; Gustavsson, B; Johnston, P; Lindberg, P; Moser, R; Odin, E; Peters, GJ; Petrelli, N, 2016) |
| " Myriad chemotherapeutic drugs produce adverse cardiovascular effects such as arterial hypertension, heart failure, and thromboembolic events." | 2.53 | Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy. ( Cadeddu, C; Deidda, M; Demurtas, L; Madeddu, C; Mercuro, G; Piras, A; Piscopo, G; Puzzoni, M; Scartozzi, M, 2016) |
| "Literature search for metallic taste and chemotherapy was performed in PubMed up to September 2014, resulting in 184 articles of which 13 articles fulfilled the inclusion criteria: English publications addressing metallic taste in cancer patients treated with FDA-approved chemotherapy." | 2.52 | Metallic taste in cancer patients treated with chemotherapy. ( IJpma, I; Renken, RJ; Reyners, AK; Ter Horst, GJ, 2015) |
| " Because the oral bioavailability of 5-FU is unpredictable and highly variable, 5-FU is commonly administered intravenously." | 2.52 | Role of ABC transporters in fluoropyrimidine-based chemotherapy response. ( Magdy, T; Nies, AT; Schwab, M; Zanger, UM, 2015) |
| "Sex-dependent differences, ethnicity, cancer types and 5-FU-based chemotherapy regimens might affect the heterogeneity of genetic variants for predictive 5-FU-related toxicity." | 2.52 | Pharmacogenomics of fluorouracil -based chemotherapy toxicity. ( Lenz, HJ; Matsusaka, S, 2015) |
| "Ulcerative oral mucositis can be costly to healthcare systems, yet there are few preventive interventions proven to be beneficial." | 2.52 | Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy. ( Clarkson, JE; Glenny, AM; Littlewood, A; McCabe, MG; Riley, P; Worthington, HV, 2015) |
| "Variability in body composition of cancer patients may be a source of disparities in the metabolism of cytotoxic agents." | 2.49 | Assessment of nutritional status in cancer--the relationship between body composition and pharmacokinetics. ( Baracos, VE; Maia, YL; Ormsbee, M; Prado, CM; Sawyer, MB, 2013) |
| "Many types of cancer are now curable or, if not cured, becoming a chronic illness." | 2.49 | Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management. ( Carver, JR; Liu, J; Manrique, C; Steingart, RM; Yadav, N, 2013) |
| "DPD-deficient cancer patients may be at risk of severe and sometimes lethal toxicity after the administration of 5-FU." | 2.48 | [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil]. ( Dołegowska, B; Ostapowicz, A, 2012) |
| "As an anticancer agent, because of its low efficacy and high toxicity, numerous modifications of 5-FU structure have been performed." | 2.47 | Development of 5-Fluorouracil derivatives as anticancer agents. ( Hu, Z; Li, P; Pan, X; Shan, Y; Wang, C; Wang, F; Zhang, J, 2011) |
| "Capecitabine is an oral prodrug of 5-FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile." | 2.46 | Safety of capecitabine: a review. ( Marshall, JL; Mikhail, SE; Sun, JF, 2010) |
| "Lapatinib was administered at doses ranging from 1000 to 1500 mg/day as monotherapy (n=928) or in combination with paclitaxel or capecitabine (n=491)." | 2.45 | Analysis of dermatologic events in patients with cancer treated with lapatinib. ( Blackwell, KL; Byrne, JA; Di Leo, A; Gomez, HL; Koch, KM; Koehler, M; Laabs, SM; Lacouture, ME; Preston, AJ; Salazar, VM; Sweetman, RW, 2009) |
| "The most commonly treated tumors were gastrointestinal (60%), head and neck (22%) and breast (4%)." | 2.45 | Fluoropyrimidine-associated cardiotoxicity: revisited. ( Saif, MW; Shah, AR; Shah, MM, 2009) |
| " While clinical efficacy was limited with the viral mutants alone, outcomes were improved in combination with chemotherapeutics." | 2.45 | Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics. ( Halldén, G, 2009) |
| "The CTS plays a role in cancer processes and their treatments through the downregulation of malignant growth and the generation of large and predictable 24 hour changes in toxicity and efficacy of anti-cancer drugs." | 2.44 | Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. ( Altinok, A; Clairambault, J; Goldbeter, A; Lévi, F, 2008) |
| " Patients are now surviving long enough for the adverse cardiovascular effects of some cancer therapies to become apparent." | 2.44 | Chemotherapy and cardiotoxicity. ( Broder, H; Gottlieb, RA; Lepor, NE, 2008) |
| "Capecitabine (Xeloda) was developed as a pro-drug of fluorouracil (FU), with the aim of improving tolerability and intratumor drug concentrations through its tumorspecific conversion to the active drug." | 2.44 | Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review. ( Koukourakis, GV; Koukourakis, MJ; Kouloulias, V; Kouvaris, J; Zabatis, H; Zacharias, GA, 2008) |
| "Differently from target-based anticancer drugs, molecular mechanisms of actions are not well-known in many of the classical antineoplastic agents." | 2.44 | [DNA repair as a determinant of tumour chemosensitivity]. ( Kuraoka, I; Maehara, Y; Oda, S, 2007) |
| " We present a concise review of cancer chemotherapy dosing in the setting of liver dysfunction." | 2.43 | Chemotherapy dosing in the setting of liver dysfunction. ( Eklund, JW; Mulcahy, MF; Trifilio, S, 2005) |
| "High-dose cancer treatment protocols can induce a state of acute folate depletion which may lead to significant treatment-related toxicity." | 2.43 | Pharmacogenetics of folate-related drug targets in cancer treatment. ( Boynton, A; Robien, K; Ulrich, CM, 2005) |
| " It is experientially clear that inter-individual differences exist in the degree of efficacy and occurrence of adverse effects." | 2.43 | [SNPs associated with adverse effects]. ( Isomura, M; Miki, Y, 2005) |
| "The treatment of cancer patients with 5-fluorouracil (5FU)-based chemotherapy can be accompanied by severe and sometimes lethal toxicity." | 2.43 | Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question. ( van Kuilenburg, AB, 2006) |
| "As the treatment for metastatic colorectal cancer, capecitabine showed at least comparable efficacy with a favorable safety profile to bolus 5-FU/LV." | 2.43 | [Capecitabine]. ( Shimamura, T; Tada, M; Yamaguchi, K, 2006) |
| "However, genotyping of cancer patients with reduced or normal DPD activity showed that only 17% of those patients had a molecular basis for their deficient phenotype, which emphasized the complex nature of the molecular mechanisms controlling polymorphic DPD activity in vivo,suggesting that it is difficult to identify DPD deficiency by genotyping." | 2.43 | [Dihydropyrimidine dehydrogenase activity and its genetic aberrations]. ( Ogura, K, 2006) |
| "Thus, loss of the S-phase checkpoint in cancer cells may provide the molecular basis for selective killing of tumors compared with normal tissues." | 2.42 | The mechanism of action of radiosensitization of conventional chemotherapeutic agents. ( Blackstock, AW; Lawrence, TS; McGinn, C, 2003) |
| " Pharmacogenomics is the study of inherited differences in interindividual drug disposition and effects, with the goal of selecting the optimal drug therapy and dosage for each patient." | 2.42 | Cancer pharmacogenomics: current and future applications. ( McLeod, HL; Watters, JW, 2003) |
| "In 5-FU-based cancer chemotherapy, severe toxicities were observed at higher rates in patients who were heterozygous for a mutant DPYD allele, compared with toxicities in patients who were homozygous for the wild DPYD allele." | 2.42 | Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. ( Omura, K, 2003) |
| "Capecitabine is an orally administered pro-drug of 5-fluorouracil (5-FU), designed to exploit tissue-specific differences in metabolic enzyme activities in order to enhance efficacy and safety." | 2.42 | Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience. ( Blesch, KS; Burger, HU; Gieschke, R; Reigner, BG; Steimer, JL; Tsukamoto, Y, 2003) |
| "For colorectal cancer patients with unresectable liver metastases, chronotherapy with l-OHP + 5-FU + FA (folinic acid) has been reported to allow complete surgical resection of liver metastases, resulting in 39-50% 5-year survival." | 2.42 | Chronotherapy for cancer. ( Eriguchi, M; Hisa, T; Levi, F; Nonaka, Y; Takeda, Y; Yanagie, H, 2003) |
| "The efficacy of cancer therapy is compromised by the fact that there are currently no good ways to predict which patients will benefit from treatment." | 2.42 | Potential for predicting toxicity and response of fluoropyrimidines in patients. ( Eliason, JF; Megyeri, A, 2004) |
| " Fluorouracil (FU) chemoradiotherapy has demonstrated success in several organ sites with multiple dosing schedules that now guide the selection of oral analogs of FU to provide new chemoradiotherapy options." | 2.42 | Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. ( Mosley, ST; Rich, TA; Shepard, RC, 2004) |
| "The main purpose of the present review article was to shed light on the different 5-fluorouracil (5-FU) prodrugs by underlining their respective pharmacological features in terms of metabolic activation, dihydropyrimidine dehydrogenase inhibition, pharmacokinetic profile and biomodulation ability." | 2.42 | Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation. ( Ferrero, JM; François, E; Milano, G, 2004) |
| "To address its potential in cancer treatment, we will also discuss the regulatory mechanisms of UPase gene expression and its induction in tumor tissues." | 2.42 | Uridine phosophorylase: an important enzyme in pyrimidine metabolism and fluoropyrimidine activation. ( Cao, D; Pizzorno, G, 2004) |
| "The most recent attempts at improving cancer treatment have taken the pharmacogenetic approach of identifying biochemical response determinants for response, so that patients with suboptimal determinants who unlikely to respond can be identified prior to treatment." | 2.42 | Pharmacogenomics of thymidylate synthase in cancer treatment. ( Danenberg, PV, 2004) |
| " Each chemotherapeutic drug has the potential to induce various adverse events in the patients receiving chemotherapy." | 2.41 | [Prevention and treatment for adverse events induced by chemotherapy]. ( Tsukuda, M, 2002) |
| "As all the anticancer agents, FU leads to several toxicities." | 2.41 | The prodrugs of 5-fluorouracil. ( Jolimaitre, P; Malet-Martino, M; Martino, R, 2002) |
| "Trapping of 5-FU in tumors is a necessary, albeit not a sufficient condition, for response." | 2.41 | 19F-MRS studies of fluorinated drugs in humans. ( Presant, CA; Waluch, V; Wolf, W, 2000) |
| "TS has been used as a target for cancer chemotherapy in the development of fluoropyrimidines such as 5-fluorouracil (5-FU) and 5-fluorodeoxyuridine and of novel folate-based TS inhibitors such as ZD1694 (Tomudex, Raltitrexed), ZD9331, LY231514 (ALIMTA, Pemetrexed), AG337 (Thymitaq, Nolatrexed) and AG331." | 2.41 | Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. ( Giaccone, G; Peters, GJ; Pinedo, HM; Van Triest, B, 2000) |
| "Eniluracil is a promising drug, which permits reliable and safe administration of oral 5-FU and has the potential to overcome 5-FU resistance mediated by overexpression of DPD." | 2.41 | Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. ( Kindler, HL; Schilsky, RL, 2000) |
| "Eniluracil/5-FU has demonstrated efficacy as monotherapy in patients with a variety of solid tumors when given on a 5 or 28-day dosing schedule." | 2.41 | Clinical development of eniluracil/fluorouracil: an oral treatment for patients with solid tumors. ( Hohneker, J; Levin, J, 2000) |
| "The development of anticancer drugs has conventionally focused on intravenous rather than oral regimens." | 2.41 | Novel oral chemotherapy agents. ( Hoff, PM; Pazdur, R; Royce, ME, 2000) |
| "To briefly review the biotransformation and bioavailability of fluorouracil (5-FU); discuss the effects of dihydropyrimidine dehydrogenase (DpD) on the efficacy and toxicity profiles of 5-FU; and review a new class of drugs known collectively as the oral fluorinated pyrimidines, which inhibit or circumvent DpD activity and, when administered with 5-FU, alter its pharmacokinetic and pharmacodynamic properties." | 2.41 | Fluorouracil and the new oral fluorinated pyrimidines. ( Kuhn, JG, 2001) |
| " This includes variable 5-FU levels over 24 hours during a continuous infusion; the widely reported variability in the pharmacokinetics of 5-FU; the observed variable bioavailability that led to the recommendation that 5-FU not be administered as an oral agent; and lastly, the observed variability in both toxicity and drug response (resistance) after identical 5-FU doses." | 2.41 | Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology. ( Diasio, RB, 2001) |
| " The unpredictable and low oral bioavailability of 5FU initially discouraged this form of treatment." | 2.41 | The oral fluorinated pyrimidines. ( de Bono, JS; Twelves, CJ, 2001) |
| "Patients with malignancy may present with acute circulatory compromise requiring ICU monitoring and care." | 2.41 | Circulatory shock. ( Bogolioubov, A; Groeger, JS; Keefe, DL, 2001) |
| "Gemcitabine has been well studied in the laboratory, with respect to mechanisms of radiosensitization and strategies that may increase the therapeutic index." | 2.41 | Recent advances in the use of radiosensitizing nucleosides. ( Lawrence, TS; McGinn, CJ, 2001) |
| "Some non-cytotoxic drugs in cancer treatment, for example angiogenesis inhibitors, may be able to induce and maintain tumor dormancy." | 2.41 | [Tumor dormancy therapy--what do you think of this therapy?]. ( Sasaki, T, 2001) |
| "Fluorouracil is a pro-drug that requires intracellular activation to exert its effects." | 2.41 | Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. ( Chamorey, AL; Milano, G, 2002) |
| "The administration of anti-cancer agents is currently associated with significant toxicity and lack of tumour specificity." | 2.41 | The role of pro-drug therapy in the treatment of cancer. ( Ahmed, FY; Cassidy, J; Ferguson, MJ, 2001) |
| "Capecitabine is a synthetic oral fluoropyrimidine carbamate that is sequentially activated in a three-step process, which results in the preferential production of 5-fluorouracil in tumours, rather than in the normal surrounding tissue." | 2.41 | Capecitabine: fulfilling the promise of oral chemotherapy. ( Hwang, JJ; Marshall, JL, 2002) |
| "Studies thus far involving colorectal tumors obtained from patients have focused predominantly on the predictive value of levels of TS expression and p53 mutations in determining response to 5-FU." | 2.41 | Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. ( Banerjee, D; Bertino, JR; Budak-Alpdogan, T; Capiaux, G; Gorlick, R; Mayer-Kuckuk, P, 2002) |
| "In a panel of 17 colon cancer cells, including several variants with acquired resistance to 5FU, sensitivity was related to TS levels, but exclusion of the resistant variants abolished this relation." | 2.41 | Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. ( Backus, HH; Bloemena, E; Calvert, AH; Codacci-Pisanelli, G; Freemantle, S; Jansen, G; Lunec, J; Marsh, S; McLeod, HL; Meijer, S; Peters, GJ; Pinedo, HM; Smid, K; van der Wilt, CL; van Groeningen, CJ; van Triest, B, 2002) |
| "Antimetabolic anticancer agents possess their own target enzymes: that of methotrexate is dihydrofolate reductase; 5-fluorouracil and ZD1604, thymidylate synthase; hydroxyurea, ribonucleotide reductase; 2'-deoxycoformycin, adenosine deaminase; N-(phosphonacetyl)-L-aspartate, aspartate transcarbamylase." | 2.40 | [Acquisition of resistance to anticancer agents by overproduction of target enzymes]. ( Inaba, M, 1997) |
| " Combining a dihydropyrimidine dehydrogenase inhibitor with 5-FU offers the potential to minimize pharmacokinetic variability and, in that way, to improve oral bioavailability, facilitate dosage adjustment to achieve desired concentrations, and increase the likelihood of tumor response while minimizing the risk of severe toxicity to individual patients." | 2.40 | Biochemical and clinical pharmacology of 5-fluorouracil. ( Schilsky, RL, 1998) |
| " Variability in DPD activity in the normal population accounts for observed differences in the pharmacokinetics and oral bioavailability of 5-FU with an additional smaller percentage (< 5%) of the population having a relatively profound deficiency in DPD activity." | 2.40 | The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. ( Diasio, RB, 1998) |
| "Irinotecan (CPT11) is a synthetic camptothecin-derived DNA topoisomerase I inhibitor." | 2.40 | [Irinotecan: various administration schedules, study of drug combinations, phase I experience]. ( Armand, JP; Boige, V; Raymond, E, 1998) |
| "It was modestly active on pancreatic cancer and was not active on acute leukemias." | 2.40 | Novel anticancer drugs in Japan. ( Ogawa, M, 1999) |
| "Capecitabine recently was approved to treat metastatic breast cancer refractory to paclitaxel and anthracycline-containing regimens." | 2.40 | Capecitabine: nursing implications of a new oral chemotherapeutic agent. ( Frye, DK; Mrozek-Orlowski, ME; Sanborn, HM, 1999) |
| " Dose nomograms and pharmacokinetic models based on limited sampling strategies have been developed, as have empirical dose escalation schedules based on multivariate analysis of the determinants of toxicity, The utility of these approaches should be tested in properly powered, prospective, randomised trials." | 2.40 | Can pharmacokinetic monitoring improve clinical use of fluorouracil? ( Daryanani, S; Kerr, DJ; Young, AM, 1999) |
| "Fluorouracil (5-FU) is a relatively unique drug in oncology because administration in different doses and schedules results in dramatically different patterns of qualitative toxicity." | 2.40 | Toxicity of 5-fluorouracil. ( Macdonald, JS, 1999) |
| "Capecitabine has additional characteristics not found with 5-FU, such as potent antimetastatic and anticachectic actions in mouse tumor models." | 2.40 | [Discovery and development of novel anticancer drug capecitabine]. ( Horii, I; Ishitsuka, H; Shimma, N, 1999) |
| "Paclitaxel also has been reported to cause arrhythmias and possibly ischemia." | 2.39 | Cardiotoxicity and cardioprotection during chemotherapy. ( Hochster, H; Speyer, J; Wasserheit, C, 1995) |
| " Pharmacodynamic studies of TS inhibition after fluoropyrimidines clearly can predict for tumor sensitivity and response to fluoropyrimidine-based therapy or identify factors related to resistance, and ara-dCTP levels in leukemic cells can be useful for refined dosing of araC." | 2.39 | Clinical resistance to antimetabolites. ( Spears, CP, 1995) |
| " Dose and duration of infusion of a drug may govern its activity; the drugs exhibiting a short half-life in plasma and a marked phase-dependence in their mechanism of action have to be administered as continuous infusions." | 2.39 | [Pharmacokinetic mechanisms of resistance to anticancer medications]. ( Robert, J, 1994) |
| "Pursuant to this, the North Central Cancer Treatment Group has developed a series of clinical trials designed to study antidotes for these pathologic processes." | 2.39 | Alleviation of cytotoxic therapy-induced normal tissue damage. ( Foote, RL; Loprinzi, CL; Michalak, J, 1995) |
| "This is illustrated by the anticancer agents, etoposide and 5-fluorouracil, both of which are still not used optimally, despite more than 20 years of clinical investigation." | 2.39 | Chemotherapy administration: doses, infusions and choice of schedule. ( Cassidy, J, 1994) |
| "Experimental studies on human cancer cell lines have demonstrated the wide variability among cell lines, ranging from 0." | 2.39 | Critical factors for optimizing the 5-fluorouracil-folinic acid association in cancer chemotherapy. ( Etienne, MC; Guillot, T; Milano, G, 1996) |
| " 1H and 13C are likely to be useful as non-perturbing NMR probes for future pharmacokinetic studies." | 2.38 | New techniques in the pharmacokinetic analysis of cancer drugs. III. Nuclear magnetic resonance. ( Maxwell, RJ, 1993) |
| "Justification for use of infusions in cancer chemotherapy has been slow in appearing with few studies proceeding to the comparative stage." | 2.38 | Protracted drug infusions in cancer treatment: an appraisal of 5-fluorouracil, doxorubicin, and platinums. ( DelaFlor-Weiss, E; Muggia, FM; Uziely, B, 1993) |
| " The pharmacokinetic rationales were based on the theories of "first pass effect" and "increased local concentration without first pass effect" advocated by Dr." | 2.38 | [Pharmacokinetics in arterial infusion chemotherapy]. ( Arai, Y; Ariyoshi, Y; Kido, C, 1993) |
| " Recent clinical trials suggest that oral mesna has adequate bioavailability (roughly 50% by urinary thiol measurements) to prevent urotoxicity in high-dose ifosfamide regimens." | 2.38 | Chemoprotectants for cancer chemotherapy. ( Dorr, RT, 1991) |
| "5FU itself has only modest anticancer activity but has been shown to be a very attractive target for biochemical modulation." | 2.38 | Clinical relevance of biochemical modulation of 5-fluorouracil. ( Peters, GJ; van Groeningen, CJ, 1991) |
| "5-Fluorouracil (FUra) has emerged as the most promising clinical radiosensitizer now available." | 2.38 | 5-Fluorouracil radiation sensitization--a brief review. ( Byfield, JE, 1989) |
| "The toxic effects of 5-fluorouracil - an antimitotic drug widely used in the treatment of cancer - mainly affect the digestive tract and the blood." | 2.37 | [Cardiac toxicity of 5-fluorouracil. Review of the literature, 5 new cases]. ( Clavel, M; Grivet, B; Siméone, P, 1988) |
| "Patients with cancer commonly suffer neurologic disabilities." | 2.37 | Neurologic complications of systemic cancer. ( Patchell, RA; Posner, JB, 1985) |
| "Thymidine has been demonstrated to alter the pharmacokinetic parameters of 5-FU in man and in mice, but a selective modification of the antitumor activity of 5-FU has not yet been unequivocally demonstrated." | 2.36 | Determinants of response to antimetabolites and their modulation by normal purine and pyrimidine metabolites. ( Au, JL; Danhauser, L; Luccioni, C; Rustum, YM, 1981) |
| "The potential impact on cancer mortality from these treatment results is obvious." | 2.36 | Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects. ( DeVita, VT; Weiss, RB, 1979) |
| "This paper presents an overview of studies of therapy of head and neck squamous cell carcinoma in which chemotherapy was combined with other modalities." | 2.35 | Current concepts of chemotherapy combined with other modalities for head and neck cancer. ( DeWys, WD, 1975) |
| "Cancer cachexia is common in many cancers and the loss of skeletal muscle mass compromises the response to therapies and quality of life." | 1.91 | Sulforaphane attenuates cancer cell-induced atrophy of C2C12 myotubes. ( Blazev, R; Li, W; Lynch, GS; Murphy, KT; Parker, BL; Swiderski, K; Trieu, J, 2023) |
| "We also report a potential anticancer drug delivery system targeting the folate receptor." | 1.91 | Design of novel polyurethane-based ionene nanocarriers for cancer therapy: Synthesis, in-vitro, and in-vivo studies. ( Mahdieh, A; Nyström, B; Sande, SA; Yeganeh, H, 2023) |
| "Blood samples from 8054 patients with cancer from 40 different hospitals were used to determine the prevalence of the 4 variants located in the DPYD gene." | 1.91 | Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study. ( Gutiérrez Nicolás, F; Manzaneque Gordón, A; Miarons, M; Riera, P, 2023) |
| "Using human colorectal cancer organoids prepared from surgical specimens, we looked at changes in CSCs, the emergence and changes in the original population, which single-cell analysis identified." | 1.91 | Cancer Stem Cells Persist Despite Cellular Damage, Emergence of the Refractory Cell Population. ( Doki, Y; Eguchi, H; Fujino, S; Hamabe, A; Hata, T; Horie, M; Miyoshi, N; Nagae, A; Ogino, T; Sasaki, M; Sekido, Y; Takahashi, H; Uemura, M; Yachida, S; Yamamoto, H, 2023) |
| " We aimed to establish physiologically based pharmacokinetic (PBPK) models of capecitabine-metabolites and 5-FU-metabolites to describe their pharmacokinetics in tumor and plasma of cancer patients with liver impairment." | 1.91 | Physiologically Based Pharmacokinetic Modeling for Prediction of 5-FU Pharmacokinetics in Cancer Patients with Hepatic Impairment After 5-FU and Capecitabine Administration. ( Hu, H; Wang, Y; Yu, L; Zeng, S, 2023) |
| "This work demonstrated that the rare mutational burden of DPYS, a gene strictly cooperating with DPYD in the catabolic pathway of fluoropyrimidines, is a promising pharmacogenetic marker for precision dosing of fluoropyrimidines." | 1.91 | The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity. ( Calza, S; Cecchin, E; De Mattia, E; Polesel, J; Puglisi, F; Roncato, R; Scarabel, L; Silvestri, M; Spina, M; Toffoli, G, 2023) |
| "Breast cancer (BC) is one of the leading fatal diseases affecting females worldwide." | 1.91 | In-vitro and in-vivo assessment of pH-responsive core-shell nanocarrier system for sequential delivery of methotrexate and 5-fluorouracil for the treatment of breast cancer. ( Ahmed, OM; El-Sherbiny, IM; Fytory, M; Mansour, A; Rahman, FESA, 2023) |
| " Guidelines recommend FP dosing adjusted to genotype-predicted DPD activity based on four DPYD variants (rs3918290, rs55886062, rs67376798 and rs56038477)." | 1.72 | DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols. ( Bilić, I; Božina, N; Ganoci, L; Lešnjaković, L; Pleština, S; Šimičević, L; Trkulja, V, 2022) |
| "Unfortunately, in some cancers, 5-fluorouracil has low effectiveness because of its drug resistance." | 1.72 | Signaling Pathways Involved in 5-FU Drug Resistance in Cancer. ( Danesh Pouya, F; Nemati, M; Rasmi, Y, 2022) |
| "According to WHO, cancer is the second leading cause of global deaths and accounted for approximately 9." | 1.72 | Heterocyclic Compounds: Importance in Anticancer Drug Discovery. ( Goel, N; Kumar, N, 2022) |
| "Carmofur is an antineoplastic agent that inhibits ceramidase, a key enzyme in the sphingolipid pathway." | 1.72 | The reproductive effects of the cancer chemotherapy agent, Carmofur, on Daphnia magna are mediated by its metabolite, 5-Fluorouracil. ( Baldwin, WS; Gessner, EE; Ghent, BN; Shah, MH; van den Hurk, P; Westbrook, NE, 2022) |
| "The presenting symptoms of 5-FU-induced leukoencephalopathy are often confusing and pose a diagnostic dilemma in routine clinical practice." | 1.72 | Diagnosis and management of 5-fluorouracil (5-FU)-induced acute leukoencephalopathy: lessons learnt from a single-Centre case series. ( Georgy, JT; Joel, A; John, AO; Jose, N; Ram, TS; Ramireddy, J; Selvakumar, RJ; Singh, A, 2022) |
| "In this study, we evaluated the anticancer properties of prodigiosins in a murine model "Ehrlich tumor" and tested whether it can be added to 5-FU to potentiate its effects." | 1.72 | Evaluation of the antineoplastic property of prodigiosins and 5-fluorouracil in restraining the growth of Ehrlich solid tumors in mice. ( Abdel Moneim, AE; Abdelfattah, MS; Al-Megrin, WA; Bakkar, AA; El-Khadragy, MF; Essawy, E; Faraag, AHI; Hassan, ESE; Shafaa, MW, 2022) |
| " Tolerance was good and 5-FU dosing was next shifted to 25% reduction, then further shifted to normal dosing at the 5th course, with still no sign for drug-related toxicities." | 1.72 | Renal impairment and DPD testing: Watch out for false-positive results! ( Carriat, L; Ciccolini, J; Quaranta, S; Rony, M; Solas, C, 2022) |
| "Today, cancer treatment is an important issue in the medical world due to the challenges and side effects of ongoing treatment procedures." | 1.72 | Chitosan/Gamma-Alumina/Fe ( Ajalli, N; Díez-Pascual, AM; Navaei-Nigjeh, M; Pourmadadi, M; Rashedi, H; Yazdian, F, 2022) |
| "Unfortunately, complexity in treating cachexia is amplified by both the underlying malignancy and the anti-cancer therapy which can independently promote cachexia." | 1.72 | Quercetin Improved Muscle Mass and Mitochondrial Content in a Murine Model of Cancer and Chemotherapy-Induced Cachexia. ( Bullard, BM; Cardaci, TD; Cunningham, P; Fan, D; McDonald, SJ; Murphy, EA; VanderVeen, BN; Velázquez, KT, 2022) |
| "Capecitabine can cause severe hypersensitivity reactions which can be dangerous and life-threatening." | 1.72 | Capecitabine induced Steven-Johnson syndrome: A rare case report. ( Karthikeyan, K; Madhu, CS; Sameera, KV; Shaji, S; Swetha, MAC, 2022) |
| "The optimal use of many cancer drugs is hampered by a lack of detailed understanding of their mechanism of action (MoA)." | 1.72 | CETSA interaction proteomics define specific RNA-modification pathways as key components of fluorouracil-based cancer drug cytotoxicity. ( Bacanu, S; Cao, Y; Cinatl, J; Coffill, CR; Dai, L; Lane, DP; Liang, YY; Michaelis, M; Nordlund, P; Prabhu, N; Ramos, AD; Seki, T; Sreekumar, L, 2022) |
| " Some patients starting standard dosed 5-FU will experience severe adverse events (SAEs)." | 1.62 | [New recommendation on pharmacogenetic screening prior to 5-fluorouracil based cancer treatment - Swedish experience indicates less adverse effects and healthcare cost savings]. ( Kohnke, H; Nygren, P; Schultz, A; Wadelius, M, 2021) |
| "Due to the worsening of oral mucositis, the patient may progress to a worse clinical condition and interrupt antineoplastic treatment." | 1.62 | Laser Therapy as a Preventive Approach for Oral Mucositis in Cancer Patients Undergoing Chemotherapy: The Potential Role of Superoxide Dismutase. ( Bissoli, NS; Bonela, LAS; Gonçalves, WL; Gouvea, SA; Menezes, BC; Oliveira, KG; Sartorio, CL; Thebit, MM, 2021) |
| "We found that cancer cells stably transduced with yCD::UPRT gene by retrovirus infection released exosomes acting similarly like yCD::UPRT-MSC exosomes." | 1.62 | Intracellular prodrug gene therapy for cancer mediated by tumor cell suicide gene exosomes. ( Altaner, C; Altanerova, U; Babelova, A; Benejova, K; Jakubechova, J; Priscakova, P; Repiska, V; Smolkova, B, 2021) |
| "In continuation of our previous work on cancer and inflammation, 15 novel pyrazole-pyrazoline hybrids (WSPP1-15) were synthesized and fully characterized." | 1.62 | Design and synthesis of pyrazole-pyrazoline hybrids as cancer-associated selective COX-2 inhibitors. ( Akhtar, M; Akhtar, W; Alam, MM; Anwer, T; Azam, F; Khan, F; Khan, MF; Marella, A; Naematullah, M; Rizvi, MA; Shaquiquzzaman, M, 2021) |
| " The metabolism-dependent toxic effect of Tegafur, an oral prodrug of 5-fluorouracil, combined with uracil was examined in each cell type." | 1.62 | Pumpless, unidirectional microphysiological system for testing metabolism-dependent chemotherapeutic toxicity. ( LaValley, DJ; Miller, PG; Shuler, ML, 2021) |
| "A study of in vivo anticancer activity in A549 tumor-bearing nude mice shows that the tumor inhibition rate (TIR) of 5-FU@AICRM is up to ≈86." | 1.62 | Deep Drug Penetration of Nanodrug Aggregates at Tumor Tissues by Fast Extracellular Drug Release. ( Chen, Y; Dai, X; Liao, C; Tan, Y; Yang, T; Yao, Y; Yu, Y; Zhang, S, 2021) |
| " Given regional differences in treatment practices and rates of adverse events (AEs), we investigated the impact of pretreatment DPYD genotyping on AEs in a Canadian context." | 1.62 | Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events. ( Choi, YH; Keller, D; Kim, RB; Legan, RM; Lenehan, J; Mailloux, J; Medwid, S; Nevison, S; Panuganty, V; Povitz, BL; Sarma, S; Schwarz, UI; Siebring, V; Teft, WA; Welch, S; Wigle, TJ; Winquist, E, 2021) |
| " Therefore, the previously identified increased toxicity and shorter survival in patients with a low SMM, could not be explained by changes in pharmacokinetic characteristics of capecitabine and metabolites." | 1.62 | Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics. ( Beijnen, JH; Dorlo, TPC; Huitema, ADR; Jacobs, BAW; Kurk, SA; May, AM; Molenaar-Kuijsten, L; Steeghs, N, 2021) |
| " In complex diseases like cancer, single-agent approaches are often insufficient for an effective treatment, and drug combination therapies can be implemented." | 1.62 | New In Vitro-In Silico Approach for the Prediction of In Vivo Performance of Drug Combinations. ( Correia, C; Ferreira, A; Lapa, R; Santos, J; Urtti, A; Vale, N; Yliperttula, M, 2021) |
| "The 5Fu in CS-GCNCs retained high cancer cell killing bioactivity by enhancing the caspase-3 expression level." | 1.56 | Biocompatible chitosan-carbon nanocage hybrids for sustained drug release and highly efficient laser and microwave co-irradiation induced cancer therapy. ( Chen, Y; Chu, M; Fu, K; Guo, Y; Han, P; Li, W; Liu, Y; Zhu, F, 2020) |
| "5-FU-induced hyperammonaemic encephalopathy started 2 [1-4] days after 5-FU infusion onset." | 1.56 | 5-Fluorouracil-induced hyperammonaemic encephalopathy: A French national survey. ( Boige, V; Boilève, A; Chouchana, L; Ducreux, M; Gaboriau, L; Hillaire-Buys, D; Hollebecque, A; Jozwiak, M; Lillo-Le Louët, A; Malka, D; Thomas, L, 2020) |
| "To improve the efficiency of cancer treatment, the multifunctional nanocomposites MGO/FU-MI (MGO/FU-MI NCs) were used for combination chemotherapy and radiotherapy to verify its effectiveness in treating tumors." | 1.56 | Multifunctional nanocomposites MGO/FU-MI inhibit the proliferation of tumor cells and enhance the effect of chemoradiotherapy in vivo and in vitro. ( Dai, W; Kong, X; Peng, X; Quan, H; Xiang, Y; Yang, C, 2020) |
| "A model animal of oral mucositis was prepared by injecting an acetic acid aqueous solution into the buccal mucosa of rats to which a 5-FU solution had been previously administered." | 1.56 | A Rat Model of Oral Mucositis Induced by Cancer Chemotherapy for Quantitative Experiments. ( Kawamata, R; Makino, K; Takeuchi, I, 2020) |
| "All models were stratified on the three cancer locations." | 1.56 | DPD status and fluoropyrimidines-based treatment: high activity matters too. ( Barranger, E; Bozec, A; Cassuto, O; Chamorey, E; Etienne, MC; Ferrero, JM; Francois, E; Largillier, R; Milano, G; Peyrade, F; Schiappa, R; Viotti, J, 2020) |
| "In a xenografted mouse model of cancer, HEP with 5-Fu significantly suppressed tumor growth, inhibited inflammatory markers such as interferon (IFN)-γ, interleukin (IL)-1β, IL-2, IL-6, tumor necrosis factor (TNF)-α, and lipopolysaccharide (LPS), and regulated the expression of Akt, CCDN1, CKD4, FOXM1, MMP7, MYC, PPAR-α, and PPAR-γ." | 1.56 | Auxiliary antitumor effects of fungal proteins from Hericium erinaceus by target on the gut microbiota. ( Chen, D; Li, H; Tang, X; Wang, D; Yizhen, X; Zhu, X, 2020) |
| "The anticancer agent 5-fluorouracil (5-FU) is cytotoxic and often used to treat various cancers." | 1.56 | Inhibition of the ATR kinase enhances 5-FU sensitivity independently of nonhomologous end-joining and homologous recombination repair pathways. ( Hasegawa, M; Ito, SS; Kajihara, A; Kashino, G; Kikuchi, S; Kirita, T; Kitayoshi, F; Kobashigawa, S; Matsubayashi, M; Matsui, TK; Mori, E; Nakagawa, Y; Nakanishi, M; Nanaura, H; Sakaguchi, YM; Sugie, K; Takahashi, A; Tamaki, S, 2020) |
| "Chemotherapy is widely used in cancer treatments." | 1.56 | Targeted delivery of 5-fluorouracil-1-acetic acid (5-FA) to cancer cells overexpressing epithelial growth factor receptor (EGFR) using virus-like nanoparticles. ( Alitheen, NB; Gan, BK; Ho, KL; Omar, AR; Rullah, K; Tan, WS; Yong, CY, 2020) |
| "Meanwhile, AlbA-DCA selectively kills cancer cells and exhibits an excellent synergistic effect." | 1.51 | Natural Product Albiziabioside A Conjugated with Pyruvate Dehydrogenase Kinase Inhibitor Dichloroacetate To Induce Apoptosis-Ferroptosis-M2-TAMs Polarization for Combined Cancer Therapy. ( Cheng, M; Cui, S; Hou, Z; Liu, Y; Luan, W; Sun, J; Wang, S; Wei, G, 2019) |
| "5-Fluorouracil (5-FU) is a chemotherapeutic drug commonly used for the treatment of solid cancers." | 1.51 | 5-Fluorouracil treatment induces characteristic T>G mutations in human cancer. ( Besselink, N; Boymans, S; Christensen, S; Cuppen, E; Janssen, R; Kuijk, E; Martens, JWM; Priestley, P; Van der Roest, B; Van Hoeck, A; Yaspo, ML, 2019) |
| "As chemotherapy does not target the cancer stem cells, we conclude that the tumor cells recover due to the presence of cancer stem cells." | 1.51 | Modeling the stem cell hypothesis: Investigating the effects of cancer stem cells and TGF-β on tumor growth. ( Elliott, SL; Kose, E; Lewis, AL; Steinfeld, AE; Zollinger, EA, 2019) |
| "It is acknowledged that cancer cells are able to undergo senescence in response to clinically used chemotherapeutics." | 1.51 | Diversity of the Senescence Phenotype of Cancer Cells Treated with Chemotherapeutic Agents. ( Bojko, A; Charzynska, A; Czarnecka-Herok, J; Dabrowski, M; Sikora, E, 2019) |
| " To avoid drawbacks of the 5-Fu, GP11 in combination with 5-Fu was investigated in this study." | 1.51 | Effect of Grifola frondosa polysaccharide on anti-tumor activity in combination with 5-Fu in Heps-bearing mice. ( Ali, SS; Chen, H; Ding, YY; Fei, F; Feng, WW; Mao, GH; Wu, XY; Yang, LQ; Zhang, WJ; Zhang, ZH; Zhao, T, 2019) |
| " Cardiotoxic adverse events (AEs) such as angina, ischemia, arrhythmias, and cardiomyopathy associated with 5-fluorouracil (5-FU) and capecitabine (CAPE) have been sparingly described in studies, primarily through case reports." | 1.51 | Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal. ( Brell, JM; Carver, JR; Denlinger, CS; Dimond, EP; Kircher, SM; Ky, B; O'Neill, A; Upshaw, JN; Wagner, LI, 2019) |
| " Our study is the first to show that DPYD*2A genotype-guided dosing appears to have no negative effect on effectiveness of fluoropyrimidine-based chemotherapy, while resulting in significantly improved patient safety." | 1.51 | Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis. ( Beijnen, JH; Cats, A; de Boer, A; Deenen, MJ; Henricks, LM; Meulendijks, D; Schellens, JHM; van Merendonk, LN, 2019) |
| "Oral mucositis (OM) induced by cancer chemotherapy has a high incidence and serious symptoms, which often force chemotherapy to be stopped." | 1.51 | Therapeutic Effect of GGsTop, Selective Gamma-glutamyl Transpeptidase Inhibitor, on a Mouse Model of 5-Fluorouracil-induced Oral Mucositis. ( Makino, K; Shimamura, Y; Takeuchi, I; Terada, H, 2019) |
| "Cancer cachexia is a metabolic disorder involving perturbed energy balance and altered mitochondrial function." | 1.51 | Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. ( Barreto, R; Bonetto, A; Couch, ME; O'Connell, TM; Pin, F, 2019) |
| " The pharmacological effect of 5-FU is influenced by genetic polymorphisms as well as differently dosed regimens." | 1.51 | Therapeutic drug monitoring (TDM) of 5-fluorouracil (5-FU): new preanalytic aspects. ( Aida, S; Gutting, T; Hedtke, M; Hofheinz, RD; Merx, K; Mindt, S; Müller, A; Neumaier, M, 2019) |
| "Nephrotoxicity is a well-known side effect of cisplatin for cancer treatment." | 1.51 | Evaluating dose of cisplatin responsible for causing nephrotoxicity. ( Higuchi, K; Yanagawa, T, 2019) |
| "Juglone has been showed to exert a direct cytotoxic effect on tumor cells." | 1.51 | Juglone eliminates MDSCs accumulation and enhances antitumor immunity. ( Cui, Y; E, F; Gao, X; Qiu, Z; Wang, H; Yu, Y; Zhang, H; Zhao, W; Zou, C, 2019) |
| "5-fluorouracil (5FU) was found to be released in a controlled manner from the nanoparticles at pH = 4." | 1.51 | The Impact of Magnesium-Aluminum-Layered Double Hydroxide-Based Polyvinyl Alcohol Coated on Magnetite on the Preparation of Core-Shell Nanoparticles as a Drug Delivery Agent. ( Buskaran, K; Ebadi, M; Fakurazi, S; Hussein, MZ; Saifullah, B, 2019) |
| " Associations of serious fluoropyrimidine adverse effects have focused on inherited deficiency of the catabolic enzyme, dihydropyrimidine dehydrogenase." | 1.48 | Preliminary Evidence for Enhanced Thymine Absorption: A Putative New Phenotype Associated With Fluoropyrimidine Toxicity in Cancer Patients. ( Charles, BG; Cowley, D; Duley, JA; George, R; Harris, M; Helsby, N; Ni, M; Norris, RL; Shannon, C; Sheffield, L; van Kuilenburg, ABP, 2018) |
| "Using data from The Cancer Genome Atlas (TCGA), we analysed the expression levels of xanthine dehydrogenase (XDH) and adenine phosphoribosyltransferase (APRT), two key enzymes in UA production and the purine salvage pathway, respectively." | 1.48 | A pan-cancer study of the transcriptional regulation of uricogenesis in human tumours: pathological and pharmacological correlates. ( Ceballos-Picot, I; Chatelain, D; Chauffert, B; Dahmani, S; Galmiche, A; Guedda, S; Louandre, C; Saidak, Z; Sauzay, C, 2018) |
| " The primary endpoint of the study was the frequency of severe (National Cancer Institute Common Terminology Criteria for Adverse Events version 4." | 1.48 | DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. ( Baars, A; Beijnen, JH; Cats, A; Creemers, GJ; de Man, FM; Dezentjé, VO; Droogendijk, HJ; Frederix, GWJ; Gelderblom, H; Guchelaar, HJ; Hamberg, P; Henricks, LM; Imholz, ALT; Jansen, RLH; Jeurissen, FJF; Kienhuis, E; Koopman, M; Lunenburg, CATC; Mandigers, CMPW; Mathijssen, RHJ; Meulendijks, D; Nieboer, P; Portielje, JEA; Rosing, H; Schellens, JHM; Swen, JJ; Ten Tije, AJ; van de Poel, MHW; van Kuilenburg, ABP; van Schaik, RHN; Werkhoven, EV, 2018) |
| " Severe (grade ≥III) toxicity in DPYD variant allele carriers receiving upfront FP dose reductions according to pharmacogenetic dosing guidelines and DPYD variant allele carriers not receiving FP dose reductions was compared with DPYD wild-type patients receiving standard dose of FPs in CRT." | 1.48 | Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. ( Cecchin, E; Dreussi, E; Fiocco, M; Gelderblom, H; Guchelaar, HJ; Henricks, LM; Lunenburg, CATC; Meulendijks, D; Peters, FP; Schellens, JHM; Swen, JJ; Toffoli, G, 2018) |
| "Precision or personalized cancer medicine is a clinical approach that strives to customize therapies based upon the genomic profiles of individual patient tumors." | 1.48 | Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy. ( Benigno, BB; Clayton, EA; Huang, C; Matyunina, LV; McDonald, JF; McDonald, LD; Vannberg, F, 2018) |
| "In all, 3,890 cancer patients were included in this study." | 1.48 | Hepatitis B Reactivation Rate Is Higher Undergoing Some Cytotoxic Chemotherapy in Patients with Solid Tumors: A Large Retrospective Study. ( Akar, E; Bayrak, S; Çil, İ; Hocaoglu, E; Karaca, M; Ozet, A; Ozet, G; Tural, D; Yucel, OK, 2018) |
| "Uracil was superior to the dihydrouracil/uracil ratio as a predictor of severe toxicity." | 1.46 | Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. ( Aliev, A; Beijnen, JH; Cats, A; de Boer, A; de Vries, N; Deenen, MJ; Henricks, LM; Jacobs, BAW; Mandigers, CMPW; Meulendijks, D; Rosing, H; Schellens, JHM; Soesan, M; van Werkhoven, E, 2017) |
| "Drug-tolerant cancer cell subpopulations are responsible for relapse after chemotherapy." | 1.46 | Inhibition of PI3K suppresses propagation of drug-tolerant cancer cell subpopulations enriched by 5-fluorouracil. ( Ishida, K; Ito, C; Iwaya, T; Kobunai, T; Koizumi, Y; Konta, A; Kume, K; Nishizuka, SS; Nukatsuka, M; Ohmori, Y; Sato, KA; Takechi, T, 2017) |
| " Uridine triacetate delivers high concentrations of uridine, which competes with toxic 5-FU metabolites." | 1.46 | Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. ( Bamat, MK; Cartwright, TH; El-Rayes, BF; Fakih, MG; King, TR; Ma, WW; Posey, JA; Saif, MW; von Borstel, RW, 2017) |
| " At the moment, there is a lack of using cost-effective CE tool combined with novel miniaturized sample clean-up techniques for analysis of these important anti-cancer agents in plasma samples." | 1.46 | Capillary electrophoresis with online stacking in combination with AgNPs@MCM-41 reinforced hollow fiber solid-liquid phase microextraction for quantitative analysis of Capecitabine and its main metabolite 5-Fluorouracil in plasma samples isolated from can ( Farhadi, K; Forough, M; Khalili, H; Matin, AA; Molaei, R; Shakeri, R; Zamani, A, 2017) |
| " A lethal toxicity in two DPD patients suggests that fluoropyrimidines combined with other therapies such as radiotherapy might be particularly toxic for DPD deficient patients." | 1.46 | Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing. ( Dezentjé, V; Dobritzsch, D; Hennekam, RC; Hertz, JM; Jansen, RL; Knegt, LC; Los, M; Maurer, D; Meijer, J; Meinsma, R; van Huis-Tanja, LH; van Kampen, RJ; van Kuilenburg, AB; Zoetekouw, L, 2017) |
| "5-Fluorouracil (5-FU) is an antimetabolite widely used in the treatment of a variety of solid tumors." | 1.46 | A rapid albumin-binding 5-fluorouracil prodrug with a prolonged circulation time and enhanced antitumor activity. ( He, Z; Sun, J; Tao, W; Wei, W; Zhang, H; Zhao, D, 2017) |
| "Resistance to anticancer medications often leads to poor outcomes." | 1.46 | Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity. ( Kasamatsu, A; Minakawa, Y; Okamoto, A; Sakamoto, Y; Shiiba, M; Takiguchi, Y; Tanzawa, H; Uzawa, K; Yamagami, H; Yamamoto, A, 2017) |
| "An anticancer drug, 5-fluorouracil (5FU), was chosen as a model drug to be loaded in RGO/AuNR/HA." | 1.46 | RGO/AuNR/HA-5FU nanocomposite with multi-stage release behavior and efficient antitumor activity for synergistic therapy. ( Chen, Y; Shen, Y; Wang, Y; Xiao, Y; Xie, A; Yang, Y; Zhu, M, 2017) |
| " We observed >50% infection within 25 days in all lines and 5-fluorocytosine LD50 values between 0." | 1.43 | Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types. ( Burrascano, C; Diago, OR; Hogan, DJ; Ibanez, CE; Jolly, DJ; Ostertag, D; Twitty, CG, 2016) |
| "Spheroids generated from 100 different cancer cell lines were classified into four distinct groups based on morphology." | 1.43 | Novel Morphologic and Genetic Analysis of Cancer Cells in a 3D Microenvironment Identifies STAT3 as a Regulator of Tumor Permeability Barrier Function. ( Goughnour, PC; Han, D; Hwang, D; Jeong, H; Kang, T; Kim, S; Kim, Y; Kwon, NH; Moon, HE; Nam, DH; Paek, SH; Park, MC; Seol, HJ; Son, SH, 2016) |
| " Pharmacokinetic parameters were estimated using non-compartmental analysis." | 1.43 | Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment. ( Beijnen, JH; Derissen, EJ; Huitema, AD; Jacobs, BA; Rosing, H; Schellens, JH, 2016) |
| "Using four different human cancer cell lines, HeLa, HCT116, CNE-2Z and MCF7, we find that SMFs increase the antitumor efficacy of 5-FU or 5-FU/Taxol, but not Cisplatin, which indicates that the SMF-induced combinational effects with chemodrugs are drug-specific." | 1.43 | Moderate intensity static magnetic fields affect mitotic spindles and increase the antitumor efficacy of 5-FU and Taxol. ( Chen, W; Ji, X; Li, Z; Liu, J; Liu, Q; Luo, Y; Wang, J; Wang, W; Zhang, X, 2016) |
| "Three-dimensional (3D) cancer cell culture models mimic the complex 3D organization and microenvironment of human solid tumor tissue and are thus considered as highly predictive models representing avascular tumor regions." | 1.43 | Mini-pillar array for hydrogel-supported 3D culture and high-content histologic analysis of human tumor spheroids. ( Hwang, HJ; Kang, J; Kuh, HJ; Lee, DW; Lee, MY; Yeon, SE, 2016) |
| "Here we report that exposure of tumors to focused ultrasound after intravenous coinjection of cups and oncolytic vaccinia virus , leads to substantial and significant increases in activity." | 1.43 | Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus. ( Balloul, JM; Carlisle, R; Coussios, C; Coviello, C; Crake, C; Erbs, P; Finn, S; Foloppe, J; Jackson, E; Kwan, J; Myers, R; Rowe, C; Story, C, 2016) |
| "The objective of this phase II study was to evaluate the potential of pharmacokinetic (PK) drug-drug interactions between ramucirumab and irinotecan or its metabolite, SN-38, when administered with folinic acid and 5-fluorouracil (FOLFIRI)." | 1.43 | Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors. ( Asakiewicz, C; Braiteh, F; Chaudhary, A; Denlinger, CS; Gao, L; Lee, JJ; Lin, Y; LoRusso, P; Nasroulah, F; Shepard, DR; Wang, D, 2016) |
| "Molecular profiling (MP) of tumors to identify biomarkers that predict potential outcomes with individual therapies is an emerging strategy to guide treatment decisions." | 1.43 | Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling. ( Byrne, A; Dean, A; Hayden, I; Marinova, M, 2016) |
| " Dosing recommendations to individualize treatment have been provided for three DPYD variants (DPYD*2A, c." | 1.43 | Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines. ( Aliev, A; Beijnen, JH; Cats, A; de Graaf, H; Henricks, LM; Jacobs, BA; Meijer, J; Meulendijks, D; Rozeman, L; Schellens, JH; van Kuilenburg, AB, 2016) |
| "Mucositis is a common side effect of cancer therapies that causes painful, erythematous lesions to develop in the gastrointestinal tract." | 1.43 | Potential Benefits of Oral Cryotherapy for Chemotherapy-Induced Mucositis. ( Wodzinski, A, 2016) |
| "8h also induced cancer cell apoptosis in an Annexin V-FITC/propidium iodide flow cytometry assay, and triggered the mitochondrial/caspase apoptosis by decreasing mitochondrial membrane potential which was associated with up-regulation of Bax, down-regulation of Bcl-2 and activation levels of the caspase cascade in a concentration-dependent manner." | 1.43 | Design, synthesis and biological evaluation of hybrids of β-carboline and salicylic acid as potential anticancer and apoptosis inducing agents. ( Cai, JY; Chen, XF; Feng, J; Huang, C; Ling, Y; Liu, FT; Liu, J; Miao, JF; Niu, BX; Xu, QB; Zhang, Y, 2016) |
| " In order to obtain an improvement of the bioavailability and solubility of 5-fluorouracil, a pyrimidine analogue used as chemotherapeutic agent in the treatment of the colon, liver, and stomac cancers, the drug was complexed with alpha- and beta-cyclodextrin." | 1.43 | Alpha- and Beta-Cyclodextrin Inclusion Complexes with 5-Fluorouracil: Characterization and Cytotoxic Activity Evaluation. ( Di Donato, C; Fattorusso, R; Iacovino, R; Isernia, C; Isidori, M; Lavorgna, M; Malgieri, G; Piscitelli, C; Russo, C; Russo, L, 2016) |
| "With the loss of mitochondrial citrate, cancer cells rely on the 'conditionally essential' amino acid glutamine (Q) as an anaplerotic carbon source for TCA cycle intermediates." | 1.42 | Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs. ( Alhamed, A; Chatterjee, A; Foster, DA; Hosny, C; Mukhopadhyay, S; Saqcena, M, 2015) |
| " In view of the observed pharmacokinetic parameters, including maximum concentration, time to maximum concentration, area under the concentration-time curve (AUC), mean residence time, elimination half-life and clearance, our results showed no significant differences in all of the pharmacokinetic parameters between the ginseng co-treated group and 5-FU alone group." | 1.42 | Effects of American ginseng on pharmacokinetics of 5-fluorouracil in rats. ( He, YS; Li, P; Qi, LW; Sun, W; Wang, CZ; Wen, XD; Yang, J; Yuan, CS, 2015) |
| "Acute kidney injury is an important issue in chemotherapy receiving patients an neutrophil gelatinase-associated lipocalin has been proposed as a novel marker." | 1.42 | Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury. ( Babacan, NA; Deveci, K; Kacan, T; Sancakdar, E; Seker, A; Seker, MM; Turesin, AK; Yilmaz, A, 2015) |
| "Multidrug resistance (MDR) in cancer cells is a substantial limitation to the success of chemotherapy." | 1.42 | Implantable hydrogel embedded dark-gold nanoswitch as a theranostic probe to sense and overcome cancer multidrug resistance. ( Artzi, N; Conde, J; Oliva, N, 2015) |
| "An insight into the complex cancer pathophysiology reveals that a dependable amelioration of the disease could only be envisaged with a multipronged treatment approach." | 1.42 | Nanopotentiated combination cancer therapy: Chemotherapeutic and chemosensitizer (2C approach). ( Iqbal, Z; Khuroo, T; Talegaonkar, S; Verma, D, 2015) |
| " There was no significant difference in T1/2, Cmax and Vss in plasma between both groups." | 1.42 | Local pelvic irradiation modulates Pharmacokinetics of 5-Fluorouracil in the plasma but not in the Lymphatic System. ( Chen, YJ; Hou, ML; Hsieh, CH; Tai, HC; Tsai, TH; Wang, LY, 2015) |
| "Six hundred three cancer patients, treated with FL, have been retrospectively tested for eight DPYD polymorphisms (DPYD-rs3918290, DPYD-rs55886062, DPYD-rs67376798, DPYD-rs2297595, DPYD-rs1801160, DPYD-rs1801158, DPYD-rs1801159, DPYD-rs17376848) for association with Grade ≥3 toxicity, developed within the first three cycles of therapy." | 1.42 | Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. ( Berretta, M; Buonadonna, A; Cecchin, E; De Paoli, A; Dreussi, E; Gagno, S; Giodini, L; Lo Re, G; Lonardi, S; Mini, E; Miolo, G; Montico, M; Nobili, S; Pella, N; Roncato, R; Scalone, S; Toffoli, G, 2015) |
| "The recurrence of colorectal cancer after chemotherapy is the leading cause of its high mortality." | 1.42 | CXCL4 mediates tumor regrowth after chemotherapy by suppression of antitumor immunity. ( Deng, S; Gao, J; Guan, W; Han, W; Wang, X; Wu, M; Ye, H; Yu, Y; Zhang, Y; Zhu, S, 2015) |
| "We found that culturing cancer cells at 39°C mildly inhibited cell growth by arresting the cells at the G1 phase of the cell cycle." | 1.42 | Culture at a Higher Temperature Mildly Inhibits Cancer Cell Growth but Enhances Chemotherapeutic Effects by Inhibiting Cell-Cell Collaboration. ( Liao, DJ; Lin, X; Luo, Z; Wang, J; Xie, B; Zhu, S, 2015) |
| "These data suggest that low doses of 5-FU have no adverse effects on DC maturation and function, and the efficacy of DC-based cancer immunotherapy may be greatly enhanced by combining it with suboptimal doses of 5-FU." | 1.42 | Low Noncytotoxic Concentrations of 5-Fluorouracil Have No Adverse Effects on Maturation and Function of Bone Marrow-Derived Dendritic Cells in vitro: A Potentially Safe Adjuvant for Dendritic Cell-Based Cancer Therapy. ( Hadjati, J; Hafezi, M; Kheshtchin, N; Khosravianfar, N; Mirzaei, HR; Mirzaei, R; Namdar, A; Rezaei, A, 2015) |
| "Many promising anticancer molecules are abandoned during the course from bench to bedside due to lack of clear-cut efficiency and/or severe side effects." | 1.42 | PRX1 knockdown potentiates vitamin K3 toxicity in cancer cells: a potential new therapeutic perspective for an old drug. ( Hatem, E; He, T; Huang, ME; Lei, M; Vernis, L, 2015) |
| "3-40 mg/kg) resulted in no dose-limiting toxicities (DLTs); adverse events (AEs) included fatigue, hypotension, abdominal pain, dyspnea, and nausea." | 1.40 | Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. ( Bilic, S; Burris, HA; de Vries, EG; Gietema, JA; Goldbrunner, M; Infante, JR; Oldenhuis, CN; Parker, K; Scott, JW; Sharma, S; Yang, L, 2014) |
| "These data suggest that tumors displaying MET aberrations achieve plateau responses by MET monotherapy and do not receive further benefit by addition of cytotoxic treatments." | 1.40 | An 'in-cell trial' to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics. ( Arnesano, A; Benvenuti, S; Comoglio, PM; Gentile, A; Lazzari, L; Trusolino, L, 2014) |
| "3%); alteration and complete recovery (31%) or sustained deterioration (45%), possibly due to inadequate chronotherapy dosing and/or timing." | 1.40 | The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy. ( Beau, J; Innominato, PF; Iurisci, I; Karaboue, A; Lévi, F; Madrid, JA; Moreau, T; Ortiz-Tudela, E; Rol, MA, 2014) |
| "In vivo anti-cancer evaluation was performed using 5-fluorouracil-cholesterol conjugate in a mouse model." | 1.40 | Design and synthesis of new cholesterol-conjugated 5-Fluorouracil: a novel potential delivery system for cancer treatment. ( Alanazi, FK; Radwan, AA, 2014) |
| "5-fluorouracil (5-FU) is a fluorinated pyrimidine analog, which is commonly used in combination chemotherapy for treating solid tumors." | 1.40 | 5-Fluorouracil toxicity and dihydropyrimidine dehydrogenase enzyme: implications for practice. ( Guastella, A; Latchman, J; Tofthagen, C, 2014) |
| "Capecitabine is a complex chemotherapeutic agent with many side effects that might affect patient adherence to treatment." | 1.40 | Adherence to capecitabine treatment and contributing factors among cancer patients in Malaysia. ( Hassan, NB; Norazwany, Y; Norhayati, I; Norsa'adah, B; Roslan, MH; Wan Nazuha, WR; Zahrina, AK, 2014) |
| "However, in cancer cell lines expressing Haps59 the 5FC sensitivity difference between the presence and absence of HIF-1α was not as large as desired." | 1.40 | Advancements in the development of HIF-1α-activated protein switches for use in enzyme prodrug therapy. ( Eshleman, JR; Khakhar, A; Ostermeier, M; Wright, RC, 2014) |
| "Oral mucositis was induced in male hamsters by two intraperitoneal administrations of 5-FU on the first and second days of the experiment (60 and 40 mg/kg, respectively) followed by mechanical trauma on the fourth day." | 1.40 | S-nitrosoglutathione accelerates recovery from 5-fluorouracil-induced oral mucositis. ( Baldim, V; Braga, CM; Brito, GA; Cavalcante, MM; Colombo, AP; de Oliveira, MG; Holanda-Afonso, RC; Leitão, RF; Moura-Neto, V; Ribeiro, RA; Silva-Boghossian, CM; Skeff, MA, 2014) |
| "In the cancer microenvironment, CICs/CSCs may localize in a specific area, the so-called stem cell niche, and isolation of this niche is important to elucidate the molecular mechanism of how CICs/CSCs acquire malignancy." | 1.39 | Possible role of mural cell-covered mature blood vessels in inducing drug resistance in cancer-initiating cells. ( Kanakura, Y; Kinugasa, Y; Matsui, T; Tahara, H; Takakura, N, 2013) |
| " The effects of extracts from Panax ginseng (PGS) and Salvia miltiorrhiza Bunge (SMB) on the pharmacokinetics of 5-fluorouracil (5-FU) were performed in vivo and detected by high performance liquid chromatography (HPLC), while, an ATP assay was used to study the pharmacodynamic interactions in vitro." | 1.39 | Preliminary evaluation of the interactions of Panax ginseng and Salvia miltiorrhiza Bunge with 5-fluorouracil on pharmacokinetics in rats and pharmacodynamics in human cells. ( Du, J; Gu, C; Han, M; Lu, W; Qiao, J; Shang, W; Wang, W; Yin, W; Zhu, M, 2013) |
| "A better anticancer efficiency was obtained over the nanovehicles than the free drug which can be attributed to their positively charged surfaces for favorable interaction with the negatively charged cell membranes." | 1.39 | A facile synthesis of strong near infrared fluorescent layered double hydroxide nanovehicles with an anticancer drug for tumor optical imaging and therapy. ( Chen, C; Gong, H; Xu, R; Yee, LK; Zhang, Y, 2013) |
| " However, adverse drug reactions are a major clinical problem, often necessitating treatment discontinuation." | 1.39 | Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. ( Arenas Hernandez, M; Corrigan, A; Fairbanks, L; Harper, P; Lewis, CM; Loganayagam, A; Maisey, N; Marinaki, AM; Ross, P; Sanderson, JD, 2013) |
| "In phase II cancer trials, tumour response is either the primary or an important secondary endpoint." | 1.39 | Using continuous data on tumour measurements to improve inference in phase II cancer studies. ( Seaman, SR; Wason, JM, 2013) |
| "Genomic DNA from 672 cancer patients treated with 5-FU monotherapy and with documented toxicity according to WHO criteria was genotyped for 12 ABCC11 tag SNPs." | 1.39 | ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression. ( Arlanov, R; Ishikawa, T; Klein, K; Lang, T; Magdy, T; Schwab, M; Toyoda, Y; Winter, S; Zanger, UM, 2013) |
| "To explore in vitro anticancer potential of Aerva lanata L." | 1.39 | In vitro anti cancer activity of ethanol extract fractions of Aerva lanata L. ( Bhanot, A; Noolvi, MN; Sharma, R; Singh, S, 2013) |
| " Detection of reduced DPD activity in patients with planned chemotherapy will allow a lower dosage of 5-FU or alternative treatment without exposing them to adverse reactions." | 1.39 | [Dihydropirymidine dehydrogenase (DPD)--a toxicity marker for 5-fluorouracil?]. ( Dołegowska, B; Jedrzychowska, A, 2013) |
| "Patients with cancer often receive chemotherapeutic agents concurrently with other medications to treat comorbidity." | 1.39 | Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer. ( Fujita, K; Ishida, H; Kato, Y; Miwa, K; Saji, S; Sasaki, T; Sasaki, Y; Sunakawa, Y; Yamashita, K, 2013) |
| "In cancer tumors, growth, invasion, and formation of metastasis at a secondary site play a pivotal role, participating in diverse processes in the development of the pathology, such as degradation of extracellular matrix." | 1.39 | Blocking the proliferation of human tumor cell lines by peptidase inhibitors from Bauhinia seeds. ( Hansen, D; Mayer, B; Nakahata, AM; Neth, P; Oliva, ML; Sampaio, MU, 2013) |
| "Compounds were subjected to National Cancer Institute (NCI) in vitro assessment for their antitumor activity, at a single dose of 10 μM." | 1.38 | Substituted thiazoles VII. Synthesis and antitumor activity of certain 2-(substituted amino)-4-phenyl-1,3-thiazole analogs. ( Al-Omary, FA; El-Messery, SM; El-Subbagh, HI; Hassan, GS, 2012) |
| "Current study we purified a polysaccharide (BRP) from Boschniakia rossica and the antitumor effects of BRP alone or combined with 5-Fluorouracil (5-FU) was examined in S180 tumor bearing mice by intragastric administration." | 1.38 | Purification of a polysaccharide from Boschniakia rossica and its synergistic antitumor effect combined with 5-Fluorouracil. ( Chang, H; Lu, X; Ren, X; Wang, Z; Wu, B; Xu, M; Zhang, X, 2012) |
| "In recent years, the number of oral anticancer agents has increased substantially." | 1.38 | Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008. ( Beckeringh, JJ; Boven, E; Hugtenburg, JG; Timmers, L; van Herk-Sukel, MP, 2012) |
| " So far, only very limited information is available regarding the pharmacokinetics of 5FU in patients with a (partial) DPD deficiency and no limited sampling models have been developed taking into account the non-linear pharmacokinetic behaviour of 5FU." | 1.38 | Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy. ( Behnke, D; Häusler, P; Jabschinsky, K; Maring, JG; Proost, JH; Schalhorn, A; Schwabe, W; Tanck, MW; Terborg, C; van Kuilenburg, AB, 2012) |
| "Capecitabine (Xeloda) is an orally administered precursor of 5'deoxy-5-fluorouridine, which is a preferentially activated to 5-fluorouracil in tumors." | 1.38 | A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL/min) and end stage renal disease on hemodialysis. ( Flombaum, C; Jhaveri, KD; Latcha, S; Shah, M, 2012) |
| " These results collectively suggest that 5-FU-NPs prepared using SEDS have potential anti-tumor applications as a controlled drug release dosage form without harmful drug toxicity." | 1.38 | Preparation and characterization of 5-fluorouracil-loaded PLLA-PEG/PEG nanoparticles by a novel supercritical CO2 technique. ( Cui, F; Huang, Q; Li, G; Wang, Y; Zhang, C; Zhang, J, 2012) |
| "5-Fluorouracil (5FU) was successfully entrapped within poly(lactide-co-glycolide) (PLGA) and hydroyapatite (HA) composite microspheres using the emulsification/solvent extraction technique." | 1.38 | 5-Fluorouracil encapsulated HA/PLGA composite microspheres for cancer therapy. ( Li, Y; Lin, Y; Ooi, CP, 2012) |
| "The extracts which gave the highest anticancer activity were selected to prepare the semipurified extracts and analysis for the constituents by gas chromatography-mass spectrometry (GC/MS)." | 1.38 | Anticancer activities of the extract from Longkong (Lansium domesticum) young fruits. ( Jantrawut, P; Manosroi, A; Manosroi, J; Manosroi, W; Sainakham, M, 2012) |
| "Forty-three patients with gastric cancer treated with neoadjuvant chemotherapy followed by curative resection between September 2011 and February 2012 were analyzed." | 1.38 | Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy. ( Ang, J; Cao, CH; Chen, L; Hu, L; Huang, LN; Huang, PT; Wu, JX; Zheng, YX, 2012) |
| "Also, in vivo anticancer activity of the positional isomers 5p, 6c further showed that 6-isomers of 5, 8-O-dimethyl acylshikonin derivatives were more active than their corresponding 2-isomers." | 1.37 | Semi-synthesis and antitumor activity of 6-isomers of 5, 8-O-dimethyl acylshikonin derivatives. ( Ding, J; Li, SS; Liu, QH; Xiao, L; Zhang, X; Zhou, W, 2011) |
| "5-Fluorouracil (5-FU) is a small, very membrane permeable drug that is poorly retained within the aqueous compartment of liposomal nanoparticles (LNP)." | 1.37 | Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy. ( Bally, MB; Edwards, K; Hare, JI; Kapanen, AI; Karlsson, G; Ramsay, E; Thomas, AM, 2011) |
| " The pharmacokinetic experiment indicated that there was an approximately 151% increase in the maximum plasma concentration (C(max)) and an approximately 425% increase in the area under the plasma concentration curve (AUC) of 5-FU in the green tea-treated group compared with the control group." | 1.37 | Effect of green tea on pharmacokinetics of 5-fluorouracil in rats and pharmacodynamics in human cell lines in vitro. ( Du, J; Gu, C; Han, M; Lu, W; Qiao, J; Shang, W; Wang, W; Yin, W; Zhu, M, 2011) |
| "5-Fluorouracil (5-FU) is a mainstay for treating various solid tumours in adults, including digestive and head and neck cancers." | 1.37 | 5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases. ( Ciccolini, J; Cordier, PY; Lacarelle, B; Mercier, C; Nau, A; Oliver, M; Peytel, E, 2011) |
| "Among the panel of cancer cell lines, all studied polymeric FdU-conjugates demonstrated an up to 50× increased cytotoxicity in human prostate cancer PC-3, breast cancer MCF-7, and MDA-MB-231 cells, and more than 100× higher efficacy against cytarabine-resistant human T-lymphoma (CEM/araC/8) and gemcitabine-resistant follicular lymphoma (RL7/G) cells as compared to free drugs." | 1.37 | Novel anticancer polymeric conjugates of activated nucleoside analogues. ( Senanayake, TH; Vinogradov, SV; Warren, G, 2011) |
| "Capecitabine treatment resulted in a 70% decrease in blood cell counts of WT animals, with only a marginal effect in UPase(-/-) mice." | 1.37 | Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity. ( Cao, D; Flynn, S; Gach, M; Kim, B; McCabe, J; Pizzorno, G; Wan, L; Yan, R; Ziemba, A, 2011) |
| "TC extract inhibited cancer cell growth by inducing apoptosis and G(2)/M cell cycle arrest." | 1.37 | Anticancer activity of an extract from needles and twigs of Taxus cuspidata and its synergistic effect as a cocktail with 5-fluorouracil. ( Du, J; Gu, C; Han, M; Lu, W; Qiao, J; Shang, W; Wang, W; Yin, W; Zhu, M, 2011) |
| " In the present study, we show that GA induces actin disruption and has tumor cell-selective toxic properties, and that its selectivity is superior to those of all the clinically available antitumor agents tested." | 1.36 | Novel effects of glycyrrhetinic acid on the central nervous system tumorigenic progenitor cells: induction of actin disruption and tumor cell-selective toxicity. ( Kamiie, K; Kidachi, Y; Noshita, T; Ryoyama, K; Umetsu, H; Yamaguchi, H; Yu, T, 2010) |
| "Capecitabine is an oral fluoropyrimidine which is transformed to 5-Fluorouracil inside tumor cells, where it achieves high drug concentrations." | 1.36 | Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect? ( Emiliani, A; Losanno, T; Manna, G; Seminara, P, 2010) |
| "More precisely, the French Plan cancer and the December 2004 << arrêté >> aim at << facilitating home-based chemotherapy by injection >> only << within the framework of a network of health in oncology >>, this in order to improve the quality of care and quality of life of patients." | 1.35 | [Outpatient chemotherapy and oncology network : Onco Pays-de-la-Loire experiment]. ( Barbarot, V; Courant-Menanteau, M; Lewden-Bernadac, B; Perrocheau, G; Thomare, P, 2008) |
| "Thus, a DPD deficiency could be predicted from 5FU blood concentrations measured after the administration of a test dose of 5FU." | 1.35 | Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene. ( Behnke, D; Hausler, P; Jabschinsky, K; Maring, JG; Schalhorn, A; Schmalenberg, H; Schwabe, W; Terborg, C; van Kuilenburg, AB, 2008) |
| "The activity of dihydropyrimidine dehydrogenase (DPD), the key enzyme of pyrimidine catabolism, is thought to be an important determinant for the occurrence of severe toxic reactions to 5-fluorouracil (5-FU), which is one of the most commonly prescribed chemotherapeutic agents for the treatment of solid cancers." | 1.35 | Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy. ( Aebi, S; Amstutz, U; Farese, S; Largiadèr, CR, 2008) |
| "Approximately 60% of the gastric cancers exhibited elevated mRNA and protein expression levels of DPD, while >65% of the colorectal cancers showed low levels of DPD expression." | 1.35 | Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. ( Danenberg, KD; Danenberg, PV; Fukui, Y; Fukushima, M; Nagayama, S; Oka, T, 2008) |
| " Furthermore, 'alternate-day S-1 regimen' may improve the dosing schedule for 5-FU by utilizing its strongly time-dependent mode of action; the former is characterized by the low incidences of myelotoxicity and non-hematologic toxicities (e." | 1.35 | Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. ( Shirasaka, T, 2009) |
| "Our results show compelling evidence that, at least in distinct tumor types, a common DPYD polymorphism strongly contributes to the occurrence of fluoropyrimidine-related drug adverse effects." | 1.35 | Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. ( Busse, B; Gross, E; Kiechle, M; Klein, HG; Lordick, F; Meindl, A; Neubauer, S; Riemenschneider, M; Seck, K, 2008) |
| "Mucositis is a common side-effect of high-dose chemotherapy regimens." | 1.35 | Grape seed extract protects IEC-6 cells from chemotherapy-induced cytotoxicity and improves parameters of small intestinal mucositis in rats with experimentally-induced mucositis. ( Bastian, SE; Butler, RN; Cheah, KY; Howarth, GS; Payne, C; Whitford, EJ; Wright, TH; Yazbeck, R, 2009) |
| "Conventional chemotherapy for cancer has limited specificity for cancer cells." | 1.35 | The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells. ( Huq, A; Mascarenhas, D; Meeker, T; Singh, B, 2009) |
| "S-1 is an oral anticancer agent that combines tegafur, a prodrug of 5-fluorouracil (5-FU), and 5-chloro-2,4-dihydroxypyridine (CDHP), an inhibitor of dihydropyrimidine dehydrogenase." | 1.35 | Pharmacokinetics of 5-fluorouracil in elderly Japanese patients with cancer treated with S-1 (a combination of tegafur and dihydropyrimidine dehydrogenase inhibitor 5-chloro-2,4-dihydroxypyridine). ( Akiyama, Y; Ando, Y; Araki, K; Endo, H; Fujita, K; Hirose, T; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Miya, T; Mizuno, K; Nagashima, F; Nakayama, H; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W; Yamashita, K, 2009) |
| "The status of TDG expression in a cancer is therefore likely to determine its response to 5-FU-based chemotherapy." | 1.35 | Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil. ( Focke, F; Kunz, C; Lettieri, T; Saito, Y; Schär, P; Schuermann, D; Selfridge, J, 2009) |
| "Steven Burakoff, director of the NYU Cancer Institute (2000 to 2008), followed with welcoming remarks." | 1.35 | XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center. ( Landolph, JR; Muggia, FM; Peters, GJ, 2009) |
| "1236G>A), which was observed five- out of eight-times in patients with severe adverse effects." | 1.35 | Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. ( Aebi, S; Amstutz, U; Farese, S; Largiadèr, CR, 2009) |
| "The ideal anticancer regimen is one that is specific for cancer cells with limited toxicity to normal tissues." | 1.35 | Tumor-targeted Salmonella typhimurium overexpressing cytosine deaminase: a novel, tumor-selective therapy. ( Bermudes, D; Itterson, M; King, I, 2009) |
| "In this study, we generated a dual cancer-specific targeting vector system by using PEGylation and the telomere reverse transcriptase (TERT) promoter and attempted to treat experimental metastases through systemic administration of the vectors." | 1.35 | Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis. ( Eto, Y; Mizuguchi, H; Morishige, T; Mukai, Y; Nakagawa, S; Okada, N; Okada, Y; Watanabe, H; Yao, X; Yoshioka, Y, 2009) |
| " Our results show that IL-21 therapy can be successfully combined with agents from different chemotherapeutic drug classes, i." | 1.35 | In vivo antitumor efficacy of interleukin-21 in combination with chemotherapeutics. ( Ehrnrooth, E; Frederiksen, KS; Skak, K; Søndergaard, H, 2009) |
| "Patients with cerebrovascular accidents were excluded." | 1.35 | Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients. ( Baehring, JM; Fulbright, RK, 2008) |
| "Capecitabine is a chemotherapeutic drug for use in cancers." | 1.35 | Topical henna for capecitabine induced hand-foot syndrome. ( Guzin, G; Yucel, I, 2008) |
| "Samples from 142 cancer patients were investigated in this study." | 1.35 | Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients. ( He, YF; Hu, B; Huang, HQ; Jiang, WQ; Li, S; Li, YH; Li, ZM; Lin, XB; Wang, FH; Wei, W; Zhang, DS; Zhang, X, 2008) |
| "Fourteen human cancer cell lines with and without DNA MMR derived from carcinomas of the colon, bladder, ovary and prostate were treated with CAI, vehicle or control drugs (nifedipine and 5-flurouracil)." | 1.35 | Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency. ( Friedlander, ML; Kohn, EC; Qu, XJ; Yang, JL; Yu, Y, 2008) |
| "The history of cancer chemotherapy and of the discipline of medical oncology has been that of drug discovery." | 1.34 | The contribution of Gianni Bonadonna to the history of chemotherapy. ( Ribatti, D, 2007) |
| "Loss of ATR function in knock-in cancer cells strikingly enhanced the effects of several of the most commonly used therapeutic compounds, impeding the progression of the cell cycle and reducing long-term cancer cell survival." | 1.34 | Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival. ( Bunz, F; Wilsker, D, 2007) |
| "One important feature of human solid tumors is the presence of a hypoxic microenvironment." | 1.33 | Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy. ( Deen, DF; Hu, L; Kong, EL; Lamborn, KR; Rehemtulla, A; Ruan, H; Wang, D, 2005) |
| " However, this is typically impossible due to pharmacokinetic constraints." | 1.33 | The mathematical modelling of adjuvant chemotherapy scheduling: incorporating the effects of protocol rest phases and pharmacokinetics. ( Gaffney, EA, 2005) |
| "However, in certain instances, tumors previously known to be resistant to specific single chemotherapeutic agents were shown to respond by the addition of NHS76/PEP(2) pretreatment." | 1.33 | NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy. ( Epstein, AL; Hu, P; Khawli, LA, 2005) |
| "The incidence of 5-fluorouracil (5-FU)-related cardiotoxicity seems to be dosage and schedule dependent." | 1.33 | Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up. ( Alakavuklar, MN; Barutca, S; Kundak, I; Meydan, N; Oztop, I; Yavuzsen, T; Yilmaz, U, 2005) |
| " In conclusion, the LC-MS method developed is simple, highly selective and sensitive and permits pharmacodynamic studies of TS inhibitors in several species." | 1.33 | Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. ( Clarke, SJ; Li, KM; Rivory, LP, 2005) |
| "We examine a large class of prior distributions to model the dose-response relationship in cancer phase I clinical trials." | 1.33 | Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control. ( Babb, JS; Rogatko, A; Tighiouart, M, 2005) |
| "The results suggest that adenovirus-mediated IL-12 gene transfer combined with Ad." | 1.33 | Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice. ( Cho, WK; Hwang, KS; Im, DS; Kim, S; Yoo, J; Yun, HJ, 2005) |
| "With these fluorescent tools, tumors and metastasis in host organs can be externally imaged down to the single-cell level." | 1.33 | Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. ( Hoffman, RM, 2005) |
| "Studies of human tumors show that cells adapt to chemotherapy, but it has been largely assumed that clonal selection leads to the resistance of recurrent tumors." | 1.33 | Cancer cell adaptation to chemotherapy. ( Cree, IA; Di Nicolantonio, F; Di Palma, S; Fernando, A; Gabriel, FG; Glaysher, S; Gulliford, T; Higgins, B; Hurren, J; Johnson, P; Knight, LA; Lamont, A; Mercer, SJ; Sharma, S; Somers, SS; Toh, S; Whitehouse, PA; Yiangou, C, 2005) |
| "During capecitabine treatment, the area under the plasma concentration time curve from 0 to infinity (AUC(0-infinity)) of S-warfarin increased by 57% (90% CI, 32% to 88%) with a 51% prolongation of the elimination half-life (t(1/2); 90% CI, 32% to 74%)." | 1.33 | Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. ( Abt, M; Camidge, R; Cassidy, J; Grange, S; Jodrell, D; Reigner, B; Weidekamm, E, 2005) |
| "Anaphylactic shock, is rare but serious, and must be considered in the event of any severe blood pressure decrease." | 1.33 | Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. ( André, T; De Gramont, A; Louvet, C; Maindrault-Goebel, F; Perez-Staub, N; Tournigand, C; Zeghib, N, 2005) |
| "The anticancer effects primarily depend on intratumoral levels of enzymes metabolizing the drugs, such as dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyltransferase (OPRT), thymidine phosphorylase (TP), and thymidylate synthase (TS)." | 1.33 | Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer. ( Inada, K; Kamoshida, S; Maeda, K; Matuoka, H; Ochiai, M; Sakurai, Y; Shimomura, R; Shiogama, K; Tsutsumi, Y, 2005) |
| "Furthermore, the doubling time of tumors with a variant C allele (AC or CC) in MTHFR-A1298C was significantly longer than that of tumors with a normal allele (AA) (P=0." | 1.33 | Effect of cystathionine beta-synthase variant 844ins68bp and methylenetetrahydrofolate reductase A1298C polymorphisms in xenografts on 5-FU efficacy and doubling time. ( Kobunai, T; Nagawa, H; Sasaki, S; Watanabe, T, 2006) |
| "DPD deficiency was identified phenotypically by both enzyme assay and uracil breath test, and genotypically by denaturing high-performance liquid chromatography." | 1.33 | Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. ( Diasio, RB; Ezzeldin, HH; Lee, AM; Mattison, LK, 2005) |
| " Twelve were on an average warfarin dosage of 19." | 1.33 | A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin. ( Diasio, R; Ledbetter, L; Saif, MW; Shah, HR, 2006) |
| "The efficacy of all anticancer drugs was assayed using human tumor xenografts in nude mice." | 1.33 | Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs. ( Fukushima, M; Kitazato, K; Nagase, H; Oka, T; Okayama, Y; Ooyama, A; Sugimoto, Y; Takechi, T; Toda, E, 2006) |
| "To evaluate the effects of the novel protein kinase C (PKC) inhibitor enzastaurin on intracellular phosphoprotein signaling using flow cytometry and to use this approach to measure enzastaurin effects on surrogate target cells taken from cancer patients that were orally dosed with this agent." | 1.33 | Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor. ( Basche, M; Britten, CD; Carducci, M; Cook, CA; Eckhardt, SG; Green, LJ; Herbst, RS; Jaken, S; Marder, P; Musib, LC; Ray, C; Thornton, D, 2006) |
| "In metastatic colorectal cancer, a combination of Leucovorin (LV) and fluorouraci (l FU) with oxaliplatin (FOLFOX) is a standard first-line regimen." | 1.33 | [FOLFOX]. ( Fujitani, K; Hirao, M; Ikenaga, M; Kashiwazaki, M; Mishima, H; Miyazaki, M; Nakamori, S; Tsujinaka, T; Yasui, M, 2006) |
| "cerevisiae and cancer cells in vitro and in murine tumors in vivo treated with 5-fluorouracil." | 1.33 | A proposed clinical test for monitoring fluoropyrimidine therapy: detection and stability of thymidylate synthase ternary complexes. ( Brody, JR; Canto, MI; Gallmeier, E; Hruban, RH; Hucl, T; Kern, SE; Kulesza, P; Schulick, RD; Yoshimura, K, 2006) |
| " As a single agent, S-1 showed higher antitumor activity with its low intestinal toxicity compared to continuous venous infusion 5-FU, the most effective dosing method of 5-FU, and/or to clinically available oral fluoropyrimidines such as UFT, doxyfluridine and capecitabine on various murine tumors and human tumor xenografts." | 1.33 | [Antitumor activity and function of S-1, a new oral tegafur-based formulation]. ( Fukushima, M, 2006) |
| "We show that, despite this fact, cancers maintain high amplitude, circadian rhythms in their growth, DNA synthesis, and mitosis." | 1.33 | Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. ( Du-Quiton, J; Hrushesky, WJ; Wood, PA; You, S, 2006) |
| " Comparison of the U/UH2 ratios with a reference, non-toxic population, showed abnormal values suggesting impaired DPD activity in 57 out of the 80 toxic patients (71%) included in this study, and in 4 out of 5 patients (80%) with a fatal outcome." | 1.33 | A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. ( Blanquicett, C; Blesius, A; Boyer, JC; Ciccolini, J; Dahan, L; Duffaud, F; Durand, A; Evrard, A; Favre, R; Lacarelle, B; Mercier, C; Milano, G; Richard, K; Seitz, JF, 2006) |
| "Recently, mass media reported cancer patients who were eager to receive the standard chemotherapy and requesting the regulatory authorities its quick approval." | 1.33 | [What happened during these 12 years since CPT-11 was launched in Japan ?]. ( Sekine, N; Terada, K, 2006) |
| "Cotreatment with trichostatin A and cycloheximide restored TS mRNA expression, suggesting that TS mRNA is repressed through new protein synthesis." | 1.33 | Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. ( Bang, YJ; Jong, HS; Jung, Y; Kim, JH; Kim, TY; Lee, JH; Park, JH, 2006) |
| "Eniluracil is an inactivator of dihydropyrimidine dehydrogenase, the first enzyme in the catabolic pathway of 5-fluorouracil (5-FU)." | 1.32 | A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005). ( Beale, P; Ertel, P; Judson, I; O'Donnell, A; Punt, CJ; Suttle, AB; Van Maanen, L, 2003) |
| "Between July 1999 and August 2001, 95 cancer patients were evaluated." | 1.32 | Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? ( Carnaghi, C; Castagna, L; Fallini, M; Magagnoli, M; Masci, G; Pedicini, V; Santoro, A; Sarina, B; Zucali, PA, 2003) |
| "Other than phosphorylation in tumors, [(18)F]FLT was found to be metabolically stable in vivo." | 1.32 | 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. ( Aboagye, EO; Barthel, H; Brady, F; Cleij, MC; Collingridge, DR; He, Q; Hutchinson, OC; Luthra, SK; Osman, S; Price, PM, 2003) |
| "Our results indicate that disseminated breast cancer cells in BM can survive first-line adjuvant chemotherapy." | 1.32 | Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. ( Braun, S; Coith, C; Ebel, S; Hemsen, A; Jänicke, F; Kentenich, C; Oberhoff, C; Pantel, K; Riethdorf, S; Thurm, H; Wallwiener, D, 2003) |
| "Chemotherapy is 1 method for the treatment of cancer, but serious side effects can sometimes limit the dosage given." | 1.32 | Simultaneous onset of acute inflammatory response, sepsis-like symptoms and intestinal mucosal injury after cancer chemotherapy. ( Fukushima, R; Hiki, N; Kaminishi, M; Kojima, J; Mafune, K; Mimura, Y; Nomura, S; Ogawa, T; Tsuji, E, 2003) |
| "The LD50 of pentamidine on cancer cells maintained in vitro is correlated with the endo-exonuclease enzyme activity." | 1.32 | The DNA double-stranded break repair protein endo-exonuclease as a therapeutic target for cancer. ( Alaoui-Jamali, MA; Chow, TY; Griller, D; Yeh, C; Yuen, L, 2004) |
| "In contrast, CD-UPRT-expressing tumors had increased CD gene activity with a threefold higher intratumoral accumulation of 5FU and significant generation of F-nucs." | 1.32 | The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. ( Chen, M; Chenevert, TL; Dornfeld, KJ; Gelovani, JT; Hamstra, DA; Lawrence, TS; Lee, KC; Moffat, BA; Rehemtulla, A; Ross, BD; Schepkin, VD; Tychewicz, JM, 2004) |
| "In the United States, tumors of the central nervous system remain the third leading cancer-related cause of death in young adults with a median survival time of < 1 year." | 1.31 | Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. ( Bharara, S; Blanquicett, C; Buchsbaum, DJ; Diasio, RB; Gillespie, GY; Johnson, MR; Miller, CR; Nabors, LB, 2002) |
| "longum accumulated in hypoxic solid tumors." | 1.31 | Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors. ( Amano, J; Fujimori, M; Kano, Y; Nakamura, T; Sasaki, T; Taniguchi, S; Yazawa, K, 2002) |
| "A nationwide questionnaire survey was carried out on low-dose cisplatin-5-FU therapy for solid malignant tumors (mostly stomach and colon cancer) regarding its antitumor as well as adverse effects." | 1.31 | [Current status of "low-dose cisplatin-5-FU therapy" for solid tumors (2nd report)--from a nationwide questionnaire on its adverse effects]. ( Hirata, K; Nakazato, H; Nishiyama, M; Saji, S; Sowa, M; Toge, T; Yamamitsu, S, 2000) |
| " combined with HT (43 degrees C for 1 h) and 5-FU (30 mg / kg / day i." | 1.31 | Enhanced efficacy of radioimmunotherapy combined with systemic chemotherapy and local hyperthermia in xenograft model. ( Aburano, T; Hiramatsu, T; Kinuya, S; Konishi, S; Michigishi, T; Shuke, N; Takayama, T; Tonami, N; Watanabe, N; Yokoyama, K, 2000) |
| "The susceptibility of tumors to fluoropyrimidines is reported to correlate with tumor levels of these enzymes." | 1.31 | Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. ( Aoyagi, S; Fujii, H; Fukuda, M; Hasegawa, M; Hirakawa-YS Chung, K; Ikeda, T; Imamoto, H; Kameyama, M; Kinoshita, H; Kitamura, M; Kubota, T; Makuuchi, H; Manabe, T; Mizutani, K; Mori, K; Murai, M; Nagasue, N; Nakao, A; Nakashima, Y; Nishida, M; Ogawa, M; Oka, M; Onishi, Y; Ozono, S; Sasaki, H; Shimada, Y; Takasaki, K; Toi, M; Toma, H; Tono, T; Yamana, H, 2000) |
| "In the present study we adapted 4 colon cancer (C26-A, C26-10, C26-G and WiDr) and 3 squamous cell carcinoma of the head and neck (HNSCC) cell lines (11B, 14C and 22B) to culture medium with low folate (LF) levels (2." | 1.31 | Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates. ( Backus, HH; Jansen, G; Molders, N; Padrón, JM; Peters, GJ; Pinedo, HM; van Der Wilt, CL; van Groeningen, CJ; Wouters, D, 2000) |
| "A survey of cancer treatment in a sample of hospitals > 100 beds conducted in 1998 compared with experience in the US showed that good progress has been achieved in Japan in the screening and early treatment of gastric cancer, and that the prognosis for breast cancer is better than in the West." | 1.31 | [Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development]. ( Aiba, K; Akaza, H; Blackledge, G; Hinotsu, S; Isonishi, S; Kono, S; Mikami, O; Noguchi, S; Ogawa, O; Shibuya, M; Sone, S; Stribling, D; Tsuruo, T; Vose, B, 2000) |
| "In other two groups (gastric and colorectal cancer patients) side effects of chemotherapy caused relatively less QL deterioration." | 1.31 | Quality of life in cancer patients treated by chemotherapy. ( Herman, ZS; Machalski, M; Scieszka, M; Zielinski, M, 2000) |
| " We also studied the association between toxic response to 5FU and heterozygous frame shift or missense mutation of the DPYD gene among eight cancer patients who had received 5FU-based chemotherapy." | 1.31 | Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil. ( Akagi, K; Arai, Y; Kanda, Y; Yamaguchi, K, 2001) |
| "The enzyme kinetic parameters for each of the four enzymes involved in the activation of capecitabine to 5-FU and its elimination were measured experimentally in vitro to construct a physiologically based pharmacokinetic model." | 1.31 | A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. ( Horii, I; Ishitsuka, H; Kato, Y; Kusuhara, H; Sugiyama, Y; Tsukamoto, Y; Ura, M, 2001) |
| " The aim of this study was to assess the systemic bioavailability of this rationally designed drug in 16 patients with advanced solid cancers." | 1.31 | Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver. ( Brown, G; Carmichael, J; Clayton, KT; Eatock, MM; McLelland, HR; Moyses, C; O'Byrne, KJ; Sharma, RA; Steward, WP; Twelves, CJ, 2001) |
| " However, the area under the curve from zero to infinity [AUC(INF)] and the terminal elimination half-life (T-HALF) values for R-FT were about 4." | 1.31 | Stereoselective metabolism and pharmacokinetics of tegafur. ( Damle, BD; Kaul, S; Narasimhan, NI, 2001) |
| "Hypoxia in tumors is associated with malignant progression, metastatic spread, and increased resistance to radiotherapy and chemotherapy." | 1.31 | Nitric oxide-mediated regulation of chemosensitivity in cancer cells. ( Adams, MA; Gofton, TE; Graham, CH; Matthews, NE; Maxwell, LR, 2001) |
| "Recruitment is complete." | 1.31 | Future treatment options with capecitabine in solid tumours. ( Wilke, H, 2002) |
| "Fluorouracil has been reported to induce severe side-effects in particular subjects who have deficiency in dehydropyrimidine dehyrogenase activity, the major enzyme in the catabolism of fluorouracil." | 1.31 | Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients. ( Celik, I; Guc, D; Kars, A; Ruacan, S; Tekuzman, G, 2002) |
| "The present study supports the toxic effect of 5-FU on myocardium, which is largely schedule-dependent." | 1.31 | Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy -- a survey of 427 patients. ( Beldecos, D; Efremidis, M; Kosmas, C; Koufos, C; Sakelariou, D; Stamatelos, G; Tsavaris, N; Vadiaka, M; Zinelis, A, 2002) |
| "This is further complicated by cancer being a highly heterogeneous group of diseases, each of which may have a unique concentration-effect relationship for any given drug or drug combination." | 1.30 | Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. ( Evans, WE; Hon, YY, 1998) |
| " These high 5-FU levels disappeared with an apparent elimination half-life (tl/2,beta) of 5." | 1.30 | Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. ( Brown, N; Covington, W; Ho, DH; Huo, YY; Kuritani, J; Lassere, Y; Pazdur, R, 1998) |
| "In cultures of human cancer cell lines, the highest level of cytotoxicity was shown by 5-FU itself, followed by 5'-dFUrd." | 1.30 | Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. ( Ishikawa, T; Ishitsuka, H; Miwa, M; Mori, K; Nishida, M; Sawada, N; Shimma, N; Umeda, I; Ura, M, 1998) |
| " Details are presented here on the methodology of NMRS data acquisition and on their pharmacokinetic analysis." | 1.30 | Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies. ( Presant, CA; Waluch, V; Wolf, W, 1998) |
| "We have experienced cancer home chemotherapy in 90 cases of terminal cancer from August 1990 to May 1998." | 1.30 | [Experience of cancer home chemotherapy with cooperation between hospital and clinic]. ( Nakamura, M; Sawada, K; Sawada, M; Suzuki, Y, 1998) |
| "Azotemia, body fluid insufficiency and bacterial infections were frequently found in these patients." | 1.30 | Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. ( Chang, HK; Chen, JS; Liaw, CC; Liaw, SJ; Lin, YC; Wang, CH; Wang, HM; Yang, TS; Yeh, CT, 1999) |
| "Twenty-one paired pharmacokinetic studies were completed on patients with colorectal, gastric, and hepatocellular cancer, utilizing positron emission tomography (PET), which allowed the acquisition of tumor, normal tissue, and plasma pharmacokinetic data and tumor blood flow (TBF) measurements." | 1.30 | Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. ( Brady, F; Brown, G; Harte, RJ; Jones, T; Luthra, SJ; Matthews, JC; O'Reilly, SM; Osman, S; Price, PM; Tilsley, DW, 1999) |
| "An excretion balance and pharmacokinetic study was conducted in cancer patients with solid tumors who received a single oral dose of capecitabine of 2000 mg including 50 microCi of 14C-radiolabelled capecitabine." | 1.30 | A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. ( Aherne, W; Beale, PJ; Bush, E; Crompton, T; Jones, D; Judson, IR; Reigner, B; Trigo, JM, 1999) |
| "This is not an exception in cancer therapy; the conversion from hospital treatment to ambulatory and domiciliary treatment is promoted." | 1.30 | [Ambulatory and domiciliary cancer chemotherapy with forearm implant catheter system and low-dose CDDP + 5-FU therapy]. ( Horimi, T; Morita, S; Shirasaka, T; Takahashi, I; Takasaki, M; Tsuji, A, 1999) |
| "The recurrent tumors are suggested to be sensitive to the agents as follows: locally recurrent solid tumors, 5-FU; distantly recurrent solid tumors, 5-FU and CDDP; locally recurrent effusion, CDDP; distantly recurrent effusion, ADR." | 1.29 | Anticancer chemosensitivity changes between the original and recurrent tumors after successful chemotherapy selected according to the sensitivity assay. ( Araya, S; Hayashi, H; Imamura, M; Ishigami, S; Kawabata, K; Masai, Y; Nio, Y; Tamura, K; Tsubono, M, 1995) |
| "5-Fluorouracil is widely known to be toxic to the hematopoietic and gastrointestinal systems." | 1.29 | Clinical cardiotoxicity of 5-fluorouracil. ( Keefe, DL; Pierri, MK; Roistacher, N, 1993) |
| " To assess feasibility and bioavailability of s." | 1.29 | Bioavailability and feasibility of subcutaneous 5-fluorouracil. ( Borner, MM; Brunner, KW; Cerny, T; Crevoisier, C; Kneer, J, 1993) |
| "The sample consisted of 127 adults with cancer who were to receive their first dose of chemotherapy (e." | 1.29 | Predictors of self-care: a test of Orem's model. ( Dibble, SL; Dodd, MJ, 1993) |
| "Pharmacokinetic study of anticancer drug is essential for clinical application of cancer chemotherapy." | 1.29 | [Clinical application of drug delivery system of anti-cancer drugs--the pharmacokinetics and clinical results]. ( Hagiwara, A; Takahashi, T; Taniguchi, H; Yamaguchi, T, 1993) |
| "Two patients (breast and colorectal cancer) achieved a partial remission; two additional cases showed a > 50% decrease in tumor marker levels." | 1.29 | 5-fluorouracil by protracted subcutaneous infusion. A pilot study. ( Alghisi, A; Marini, G; Meriggi, F; Zaniboni, A, 1995) |
| "PKC activity was reduced in tumors derived from mice treated with either DXR or CGP 41251, but not from those derived from mice treated with the combination." | 1.29 | The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251. ( Beltran, P; Fan, D; Fidler, IJ; Killion, JJ; O'Brian, CA; Wilson, MR; Yoon, SS, 1995) |
| "Flank tumors measuring approximately 1." | 1.29 | Tumor retention of 5-fluorouracil following irradiation observed using 19F nuclear magnetic resonance spectroscopy. ( Blackstock, AW; Branch, C; Kwock, L; Tepper, JE; Zeman, EM, 1996) |
| "Twenty-four patients with advanced cancer were treated with 5-Fluorouracil 600 mg/m2 intravenously and interferon-alfa-2b 3 MU subcutaneously both given weekly for 6 weeks followed by a 2-week hiatus." | 1.29 | Weekly 5-fluorouracil and interferon-alfa-2b in metastatic cancer. ( Casal, R; Quan, WD, 1996) |
| " The hypothesis of a toxic cardiomyopathic process requires further confirmation." | 1.28 | Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. ( Bachaud, JM; Canal, P; Carrié, D; Chevreau, C; de Forni, M; Jaillais, P; Lemaire, L; Malet-Martino, MC; Shubinski, RE; Soulié, P, 1992) |
| " Ambulatory continuous-infusion pumps were used to administer 5-FU in a dosage of 300 mg/m2/24 h." | 1.28 | [Ambulatory continuous intravenous infusion of fluorouracil: a feasible palliative form of chemotherapy]. ( de Graeff, A; Neijt, JP; Tjia, P; van Hoef, ME; van Milligen de Wit, AW; Zonnenberg, BA, 1991) |
| "Those tumors with the lowest thymidylate synthase expression had the best response to both the 5-fluorouracil-leucovorin and 5-fluorouracil-cisplatin combinations." | 1.28 | Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. ( Aigner, K; Danenberg, KD; Frösing, R; Gustavsson, B; Horikoshi, T; Leichman, L; Ray, M; Shea, LC; Stadlbauer, TH; Volkenandt, M, 1992) |
| "A care system for cancer bearing patients at a highly advanced stage should be informed by a better quality of life based on a life style of the patients and their families." | 1.28 | [Nutritional support for cancer bearing patients]. ( Yamada, S, 1991) |
| " These findings suggested that arterial infusion chemotherapy in combination with biochemical modulation was a safe and effective method for treating cancer patients." | 1.28 | [Arterial infusion chemotherapy combined with biochemical modulation in cancer patients]. ( Mai, M; Ogino, T; Suga, T; Takahashi, Y, 1991) |
| "In the cancerous tissues, both the UR kinase and TdR kinase activities were low, but the UR Prylase and TdR Prylase activities were markedly high." | 1.28 | [Activities of enzymes converting 5-fluorouracil to 5-fluorouridine-5' monophosphate and 5-fluorodeoxyuridine-5' monophosphate in subcultured cell lines and solid tumor tissues]. ( Ho, DH; Kamiya, K; Nakamura, T; Sasaki, K; Tsutani, H; Uchida, M; Yoshimura, T, 1990) |
| " The half-life (T1/2) of this tumor pool of "trapped" 5FU was 0." | 1.28 | Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics. ( Albright, MJ; Atkinson, D; Blayney, D; King, M; Ong, RL; Presant, CA; Ring, R; Servis, KL; Wiseman, C; Wolf, W, 1990) |
| "Dipyridamole was administered in a fixed dose of 7." | 1.28 | Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion. ( Alberti, DB; Bruggink, J; Fischer, PH; Grem, JL; Nieting, LM; Remick, SC; Tombes, MB; Trump, DL; Tutsch, KD; Willson, JK, 1990) |
| "To determine the maximum tolerated dose of 5-fluorouracil administered as a 120-hour continuous intravenous infusion to pediatric patients, we performed a phase I study using a starting dosage of 900 mg/m2/day." | 1.28 | Phase I study of a 120-hour continuous intravenous infusion of 5-fluorouracil in pediatric patients with recurrent solid tumors: a Pediatric Oncology Group study. ( Bell, B; Brecher, ML; Cushing, B; Green, DM; Krischer, JP; Whitehead, VM, 1990) |
| " Thus, TMTX can be given with 5-FU (400 mg/m2) on a daily x 5-day bolus schedule at the 12 mg/m2 per day dose level, which was the recommended dose of TMTX as a single agent for phase II studies using the 5-day bolus schedule." | 1.28 | Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil. ( Catalano, R; Comis, RL; DeLap, RJ; Grillo-Lopez, AJ; Hudes, GR; LaCreta, F, 1989) |
| "Fifty-two non-resectable and recurrent cancer patients with prior treatment, were entered in this study; 1 esophageal, 33 gastric, 1 duodenal, 4 colorectal, 2 pancreatic, 2 bile duct, and 9 breast cancer." | 1.28 | [Combination chemotherapy of CPM-MTX-5-FU in non-resectable and recurrent cancer patients]. ( Hattori, T; Jinushi, K; Kim, R; Niimoto, M; Saeki, K; Saeki, T; Toi, M; Yanagawa, E; Yoshinaka, K, 1989) |
| "Leukopenia was reversed for several weeks but thrombocytopenia was not." | 1.28 | Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine. ( Laurensse, E; Leyva, A; Peters, GJ; Pinedo, HM; van Groeningen, CJ, 1989) |
| "Dissociated cancer cells are exposed to antineoplastic drugs (5 X 10(4) viable cells/drug for 1 hr or continuously) and cultured for 4 to 6 days in liquid medium." | 1.27 | A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. ( Dill, PL; Macaluso, CK; Marsden, JA; Weisenthal, LM, 1983) |
| " At this time the ITC therapy is used in combination with induced-hypertension-chemotherapy (IHC therapy)." | 1.27 | [The clinical effect of hyperthermia combined with induced hypertension chemotherapy]. ( Hayashida, S; Kobayashi, T; Sugimoto, K, 1984) |
| "Of 17 anticancer drugs, the cytotoxic effects of six drugs, namely, peplomycin, bleomycin, aclacinomycin, cisplatin, 5-fluorouracil (5-FU), and Adriamycin (doxorubicin) were potentiated by concomitant application of interferon." | 1.27 | In vitro and in vivo studies on potentiation of cytotoxic effects of anticancer drugs or cobalt 60 gamma ray by interferon on human neoplastic cells. ( Kanamori, T; Kimoto, T; Namba, M; Nobuhara, M; Tanaka, H; Yamamoto, S, 1984) |
| " With use of these studies, a therapeutic ratio (concentration that prevented 25% clonal growth compared to untreated control of bone marrow divided by LD50 of tumor) was calculated for each drug in each tumor." | 1.27 | 5'-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow. ( Armstrong, RD; Cadman, E, 1983) |
| "The expanding use of cytotoxic drugs in cancer therapy has resulted in a confusing and increasingly frequent array of severe renal complications." | 1.27 | Renal complications of cytotoxic therapy. ( Clarkson, AR; Healy, HG, 1983) |
| "We found that this conversion in human tumors was catalyzed not by uridine phosphorylase but by thymidine phosphorylase." | 1.27 | [5'-Deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues]. ( Hara, Y, 1984) |
| "This finding could be applied to cancer chemotherapy for enhancing drug delivery to tumor tissue selectively." | 1.27 | [Cancer chemotherapy in combination with angiotensin-induced hypertension]. ( Suzuki, M; Wakui, A, 1983) |
| "FT and 5-FU fractions in cancer tissues were found to be higher than those of the patients receiving only 800 mg of Tegafur fine granules as previously reported." | 1.27 | [UFT concentration in various tissues from cancer patients]. ( Bekki, E; Hashimoto, I; Kasai, Y; Mikami, J; Nakamura, T; Nakanishi, Y; Nishi, H; Nishindai, H; Sawada, Y; Yoshimoto, M, 1983) |
| " Pharmacokinetic study after single oral administration of 300 to 1200 mg of UFT-E was carried out in cancer patients measuring tagafur, uracil and 5-FU levels in serum, normal tissue and tumor tissue using HPLC and GC-mass." | 1.27 | [Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients]. ( Fujii, S; Hoshino, A; Kamiya, O; Kimura, K; Kojima, T; Nagata, K; Ohara, K; Sugihara, T; Suzuki, M; Yamada, M, 1983) |
| "CR was observed in one case of breast cancer, and PR in 29 cases." | 1.27 | [Cooperative phase II study of spansule tegafur (SF-SP)]. ( Taguchi, T, 1984) |
| "Exponentially growing cells of human cancer lines have been utilized to investigate the cytotoxic activity of antineoplastic agents." | 1.27 | The use of human cancer cell lines as a primary screening system for antineoplastic compounds. ( Baguley, BC; Finlay, GJ, 1984) |
| "Fifteen patients with advanced solid tumors participated in a phase I study of a biochemically designed combination chemotherapy program which employed PALA and thymidine (TdR) with 5-FU." | 1.27 | Phase I evaluation of a biochemically designed combination: PALA, thymidine, and 5-FU. ( Casper, ES; Kemeny, N; Martin, DS; Michaelson, RA; Young, CW, 1984) |
| "Nineteen patients had cancer of gastrointestinal origin, 13 of these colorectal, and 2 patients had breast adenocarcinoma." | 1.27 | Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. ( Berne, M; Bernstein, L; Danenberg, PV; Gustavsson, BG; Mitchell, MS; Spears, CP; Spicer, D, 1984) |
| "However, against colo-rectal and stomach cancer, the response rate was only 25% (2/8) and 28." | 1.27 | [Chemotherapy and total body hyperthermia]. ( Kato, N; Yamanaka, N, 1985) |
| "43 metastatic cancer patients received 190 portable infusors over 24 hours or more." | 1.27 | [Chemotherapy by ambulatory continuous infusion using a portable pump: a feasibility trial]. ( Benahmed, M; Carde, P; Laplanche, A; Renaux, J; Rouesse, J; Sancho-Garnier, H; Spielmann, M, 1985) |
| " Cisplatin (100 mg/m2) was administered with mannitol, or at a twofold larger total dosage (50 mg/m2 per day for 4 days) in a 3% saline infusion." | 1.27 | Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity. ( Dodge, RK; Forastiere, AA; Goren, MP; Horowitz, ME; Kamen, BA; Pratt, CB; Viar, MJ; Wright, RK, 1987) |
| "Melatonin was enhanced after CDDP and CMF, and cortisol decreased after CMF and FEC, but their variations were not statistically significant with respect to those seen during saline infusion." | 1.27 | Acute effects of various chemotherapeutic combinations on hypophyseal and pineal hormone secretions in cancer patients. ( Barni, S; Crispino, S; Esposti, D; Esposti, G; Ferri, L; Fumagalli, G; Lissoni, P; Paolorossi, F; Rovelli, F; Tancini, G, 1987) |
| " From these results, it was suggested that the release speed of anti-cancer agents can be controlled by modifying the drug dosage and form." | 1.27 | [Basic study of anti-cancer agents suspended in lipiodol]. ( Takahashi, T; Taniguchi, H; Yamaguchi, T, 1986) |
| "It is desirable for multidisciplinary cancer treatments to be concentrated as selectively as possible onto the cancer-bearing organs in order to augment the anticancer effects and minimize the untoward effects." | 1.27 | [Combination of selective intra-arterial infusion of an anticancer agent via the vascular access port with RF local hyperthermia]. ( Agishi, T; Fuchinoue, S; Honda, H; Nakazawa, H; Okumura, T; Teraoka, S, 1986) |
| "Tissues used included 27 gastric cancers, 10 breast cancers, 7 colorectal cancers, 4 gallbladder cancers, 4 sarcomas, 3 lymphomas, and 5 other tumors." | 1.27 | Comparative studies on in vitro human tumor clonogenic assay (HTCA) and in vivo nude mouse-isotope assay (NM-IA). ( Hattori, T; Hirabayashi, N; Niimi, K; Niimoto, M; Nishiyama, M; Noso, Y; Toge, T; Yamaguchi, M, 1987) |
| "To determine the optimal condition of the clonogenic assay, the antitumor activities of 5-fluorouracil (5-FU) in vitro and in vivo were investigated from a pharmacodynamic viewpoint using 8 human carcinoma xenografts." | 1.27 | [Pharmacodynamic study of the in vitro clonogenic assay--with reference to dose levels]. ( Isobe, Y, 1988) |
| "In analysing the anticancer effects of TBHT according to cancer site, a high efficacy was observed in patients with their main tumor in the lung, liver and lymph nodes." | 1.27 | [Clinical results and problems of total-body thermochemotherapy]. ( Hamazoe, R; Inoue, Y; Ishiguro, M; Koga, S; Maeta, M; Murakami, A; Sawata, T; Shimizu, N; Shimizu, T, 1988) |
| " Dosage adjustment according to body surface area would seem indicated by the toxicity data, with a 5-FU dose of 1200 mg/m2 body surface area and citrovorum factor 50 mg/m2 being recommended for Phase II trials of this combination of drugs given according to this weekly schedule." | 1.27 | Phase I trial of intraperitoneal chemotherapy with 5-fluorouracil and citrovorum factor. ( Budd, GT; Bukowski, RM; Schreiber, MJ; Steiger, E; Weick, JK, 1986) |
| "Thirty cancer patients, who were diagnosed to be beyond the operable stage, were treated by intra-arterial anticancer agent infusion via an implantable vascular access device (VAD) combined with local hyperthermia and/or charcoal hemoperfusion." | 1.27 | [Implantation of a vascular access device in cancer treatment: operation or angiographic technic?]. ( Agishi, T; Honda, H; Huchinoue, S; Kihara, K; Nakagawa, Y; Nakazawa, H; Oba, S; Ota, K; Teraoka, S, 1987) |
| "Eleven non-resectable cancer patients have been successfully treated by means of a one-shot and continuous intra-arterial infusion chemotherapy, utilizing an implantable vascular access device (Catheter Access) connected to a continuous infusion pump (Nipro portable syringe infusion pump) via a non-corning needle (Nipro coreless needle set)." | 1.27 | [Continuous intra-arterial infusion chemotherapy by implantable catheter access connected with a continuous infusion pump]. ( Agishi, T; Fuchinoue, S; Honda, H; Nakagawa, Y; Nakazawa, H; Ohta, K; Takahashi, K; Teraoka, S, 1987) |
| "A clinical and pharmacokinetic investigation of prolonged administration of high-dose uridine was performed in seven patients with advanced-stage cancer." | 1.27 | Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity. ( Kraal, I; Leyva, A; Peters, GJ; Pinedo, HM; van Groeningen, CJ, 1986) |
| "Since these results hold for both tumors and hosts, the effects of combined drugs should be considered in terms of therapeutic index." | 1.27 | [Drug administration in combination for management of cancer]. ( Wakui, A, 1985) |
| "Some of these solid tumors contain greater amounts of activity than do their normal equivalents, which encourages the use of inhibitors of this enzyme in conjunction with treatment of these tumors by 5-fluorouracil." | 1.27 | Enzymes of uracil catabolism in normal and neoplastic human tissues. ( Cha, S; el Kouni, MH; Naguib, FN, 1985) |
| " Minor variations in 5-FU clearance therefore probably contribute to the natural range found in the dose-response relationship for infused 5-FU toxicities." | 1.27 | Phase I and pharmacologic study of 72-hour infused 5-fluorouracil and hyperfractionated cyclical radiation. ( Byfield, JE; Callipari, FB; Frankel, SS; Hornbeck, CL; Sharp, TR, 1985) |
| " In three patients, the duration of FUra infusion was prolonged up to 72 h to determine the toxic limits of therapy." | 1.27 | Sequential infusions of methotrexate and 5-fluorouracil in advanced cancer: pharmacology, toxicity, and response. ( Benz, C; Cadman, E; DeGregorio, M; Holleran, W; Ignoffo, R; Lewis, B; Saks, S; Sambol, N, 1985) |
| " The therapy is to be used effectfully only then, when indication, dosage and control of the patients are performed critically and exactly." | 1.26 | [Chemotherapy of malignant solid tumors]. ( Knöll, P; Siering, H, 1980) |
| "Phosphorylating activity in squamous cell carcinoma of the lung was similar to that in adenocarcinomas." | 1.26 | Metabolism of 5-fluorouracil in various human normal and tumor tissues. ( Fujii, S; Maehara, Y; Nagayama, S; Nakamura, H; Okazaki, H; Shirasaka, T, 1981) |
| "5-Fluorouracil (5-FU) is an effective anti-tumor drug, which has been used both as a single agent and in combination with other chemotherapeutic agents for the treatment of tumors such as breast and colorectal carcinoma." | 1.26 | Metabolic and distribution studies with radiolabeled 5-fluorouracil. ( Ghanbarpour, A; Shani, J; Siemsen, JK; Vine, E; Wolf, W; Young, D, 1982) |
| "Stomatitis was the predominant dose-limiting toxicity (22% grade 1, 19% grade 2, and 27% grade 3 toxicity)." | 1.26 | Allopurinol modulation of fluorouracil toxicity. ( Fox, RM; Piper, AA; Sampson, D; Tattersall, MH; Woods, RL, 1981) |
| " The recommended dosage for daily oral administration of FD-1 is 6-12 mg/kg/day." | 1.26 | Review of a new antimetabolic agent, 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione (FD-1). ( Taguchi, T, 1980) |
| "These xenografts were 1 line of rectal cancer (H-26), two lines of gastric cancer (H-08 and H-22), and 1 line of breast cancer (H-62)." | 1.26 | Relationship of chemotherapy on human cancer xenografts in nude mice to clinical response in donor patient. ( Fujita, M; Hayata, S; Taguchi, T, 1980) |
| "Fifteen cases with advanced cancer were treated with UFD-1 (mixture of FD-1 and uracil under molar ratio of 1: 20) in a daily dose of 300 mg of FD-1." | 1.26 | [Clinical experiences with UFD-1]. ( Furue, H, 1982) |
| "The levels of anticancer drugs in tissue were measured by bioassay method in 28 patients with gastrointestinal cancer, who were treated with intravenous administration of 500 mg of 5-FU combined with ANG-II during surgery." | 1.26 | [Clinical studies of cancer chemotherapy combined with angiotensin-II (ANG-II)]. ( Kanno, H; Kikuchi, K; Kunii, Y; Takahashi, N, 1982) |
| "Constant infusion cancer chemotherapy is feasible, reliable, and safe." | 1.26 | The delivery of cancer chemotherapy by constant venous infusion. Ambulatory management of venous access and portable pump. ( Bothe, A; Fine, N; Lokich, J; Perri, J, 1982) |
| " Two other non-T-/non-B-cells showed unique ara-C dose-response curves." | 1.26 | Differences in chemotherapeutic susceptibility of human T-, B-, and non-T-/non-B-lymphocytes in culture. ( Arkin, H; Holland, JF; Ohnuma, T, 1980) |
| "An unique combination treatment for cancer patients has been attempted in our department." | 1.26 | [Protective effect of CoQ 10 administration on cardial toxicity in FAC therapy]. ( Enomoto, K; Kodama, K; Okada, N; Sakurai, T; Suzuki, Y; Takimoto, M; Yokoi, H, 1982) |
| "Stomach cancer and colorectal cancer showed partial responses in 10." | 1.26 | [Phase II study of a new fluorinated pyrimidine, ethyl (+/-)-t-6-butoxy-5-fluoro-2, 4-dioxohexahydropyrimidine-r-5-carboxylate (TAC-278)]. ( , 1982) |
| " Twelve (33%) of the 36 patients reported adverse effects: gastrointestinal symptoms in 8, CNS symptoms in 3, and others in 1." | 1.26 | [TAC-278. A new 5-FU derivative, by the oral route for its efficacy and safety in 36 patients with advanced cancers]. ( Arimori, S; Furue, H; Ikenaga, M; Iketa, T; Komita, T; Nagao, T; Ohki, S; Satoh, H; Watanabe, K; Yamamoto, S, 1982) |
| "Twenty-three cases of cancer patients were treated with FT-207 alone orally more than 52 weeks up to 199 weeks continuously with daily dose of 600-800mg with capsules, and 600-1200mg with enteric coated capsules, except one case with markedly light body weight (28kg)." | 1.26 | [Toxic effects of prolonged oral administration of tegafur (FT-207)]. ( Majima, H; Nishimura, A, 1982) |
| "Further subclassification of the tumors based on elements suggestive of tumor differentiation detected on light and electron microscopic examination was possible in 22 of the 35 patients." | 1.26 | Anaplastic malignant neoplasms: diagnosis and treatment. ( Bedikian, AY; Luna, M; Mackay, B; Valdivieso, M, 1981) |
| " For this reason a comparative pharmacokinetic study of intravenous versus oral application was performed on six patients, as well as a pilot study on 13 patients with adenocarcinomas of different origins." | 1.26 | 5-Fluorouracil: a comparative pharmacokinetic study and preliminary results of a clinical phase I study. ( Alberto, P; Cano, JP; Crevoisier, C; Forgo, I; Germano, GH; Heintz, R; Obrecht, JP; Weber, W, 1981) |
| "The serum half-life of 5-fluorouracil (5-FUra) in humans is best described as a biexponential decay function, with t1/2 alpha = 7." | 1.26 | Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a Phase I trial. ( Ensminger, W; Frei, E; Kirkwood, JM; Papathanasopoulos, N; Rosowsky, A, 1980) |
| " This route-dependent pharmacokinetic profile is consistent with the reported absence of myelosuppression in prolonged infusion and may be related to the resultant lower levels of 5-FUra achieved in bone marrow." | 1.26 | Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. ( Baker, LH; Buroker, TR; Fraile, RJ; Horwitz, J; Vaitkevicius, VK, 1980) |
| "Thymine was the major metabolite of TdR." | 1.26 | Clinical pharmacologic effects of thymidine plus 5-FU. ( Holland, JF; Mandel, E; Martin, DS; Ohnuma, T; Roboz, J; Waxman, S, 1980) |
| "A pleural effusion is a frequent complication of malignant disease." | 1.26 | Management of malignant pleural effusion. ( Bennett, JM; Greenwald, DW; Phillips, C, 1978) |
| " Consequently, they are either excluded from antitumor therapy or receive only reduced dosage regimens." | 1.26 | [Parenteral feeding during aggressive chemotherapy of various neoplasms]. ( Jehn, U; Kohlschütter, B, 1978) |
| "Cell free supernatants from human breast tumors produce less total phosphorylation than murine tumors and some specimens produce only monophosphates whereas others produce mono-, di and triphosphates." | 1.26 | Studies on mechanisms of 5-fluorouracil resistance in murine and human tumors. ( Ardalan, B; Cooney, D; Macdonald, JS; Schein, PS, 1979) |
| "A recently developed model of the human granulpoietic system had been used to analyze the toxic effects of 5-fluorouracil administered to cancer patients." | 1.26 | Assessment of myelotoxic effects of chemotherapy from early leukopenic response: application of a mathematical model for granulopoiesis. ( Blumenson, LE; Bross, ID, 1979) |
| "0 g intravenous and oral doses nine weeks apart, an increase in the bioavailability of the drug coincided with a marked clinical regression in palpable intra-abdominal metastases." | 1.26 | Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients. ( Bending, MR; Finch, RE; Lant, AF, 1979) |
| " The mean half-life was 11." | 1.26 | Pharmacokinetics of fluorouracil in humans. ( MacMillan, WE; Welling, PG; Wolberg, WH, 1978) |
| "In 137 patients with different kinds of cancer and different cancer stage, cell-mediated immunity was investigated by DNCB (dinitrochlorobenzene) and tuberculin test." | 1.26 | Tuberculin and dinitrochlorobenzene (DNCB) tests in cancer patients before and after cytostatic drug therapy. ( Mazloumi, B; Missmahl, HP; Weber, W, 1978) |
| "2 5-fluorouracil was extracted from plasma by a novel procedure which removed plasma components interferring with the sensitivity of the assay." | 1.26 | A sensitive assay of 5-fluorouracil in plasma by gas chromatography-mass spectrometry. ( Hillcoat, BL; Kawai, M; McCulloch, PB; Rosenfeld, J; Williams, CK, 1976) |
| "The treatment of breast and ovarian cancer brought the best results, improved by a synchronisation therapy." | 1.26 | [Five years treatment of advanced solid malignomas with a combination of four cytostatic drugs (author's transl)]. ( Siebner, H; Weber, W, 1976) |
| "Seventeen patients with primary liver cancer were also treated with adriamycin." | 1.26 | Adriamycin in the treatment of cancer. ( Falkson, G; Falkson, HC; van der Merwe, AM; van Dyk, JJ, 1976) |
| "The topography of the neoplasm had no influence on the I." | 1.25 | Immunological overshoot phenomenon following cancer chemotherapy: significance in prognosis evaluation of solid tumors. ( Dubois, JB; Serrou, B, 1975) |
| "Generally, metastases responded better than the advanced primaries from which they were derived, except for those from breast tumours." | 1.25 | The influence of site of metastasis on tumour growth and response to chemotherapy. ( Bross, ID; Slack, NH, 1975) |
| "All 14 patients with breast carcinoma underwent remission and in 6 this was complete." | 1.25 | Seventy-five cases of solid tumours treated by a modified quadruple chemotherapy regime. ( Hanham, IW; Newton, KA; Westbury, G, 1971) |
| " The 5-fluoro-uracil was given intravenously at a relatively nontoxic dosage level." | 1.24 | The potentiation of radiation effects with 5-fluoro-uracil. ( FOYE, LV; HALL, B; ROTH, M; WILLETT, FM, 1960) |
| " Timing and dosage are also considered." | 1.24 | SOME PROBLEMS IN THE CHEMOTHERAPY OF SOLID TUMOURS. ( ARONOVITCH, M; GROSZMAN, M; KAHANA, LM, 1964) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 675 (37.65) | 18.7374 |
| 1990's | 245 (13.66) | 18.2507 |
| 2000's | 363 (20.25) | 29.6817 |
| 2010's | 386 (21.53) | 24.3611 |
| 2020's | 124 (6.92) | 2.80 |
| Authors | Studies |
|---|---|
| Matsuda, A | 1 |
| Takenuki, K | 1 |
| Sasaki, T | 7 |
| Ueda, T | 1 |
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Li, F | 1 |
| Awale, S | 1 |
| Tezuka, Y | 1 |
| Kadota, S | 1 |
| Wang, Y | 14 |
| Jiang, J | 3 |
| Jiang, X | 1 |
| Cai, S | 1 |
| Han, H | 1 |
| Li, L | 5 |
| Tian, Z | 1 |
| Jiang, W | 1 |
| Zhang, Z | 4 |
| Xiao, Y | 3 |
| Wright, SC | 1 |
| Larrick, JW | 1 |
| Al-Obaid, AM | 1 |
| Abdel-Hamide, SG | 1 |
| El-Kashef, HA | 1 |
| Abdel-Aziz, AA | 1 |
| El-Azab, AS | 1 |
| Al-Khamees, HA | 1 |
| El-Subbagh, HI | 2 |
| Liu, W | 2 |
| Liu, C | 2 |
| Gong, C | 1 |
| Lin, W | 1 |
| Guo, C | 1 |
| León, LG | 1 |
| Donadel, OJ | 1 |
| Tonn, CE | 1 |
| Padrón, JM | 2 |
| Yamaguchi, H | 2 |
| Noshita, T | 1 |
| Yu, T | 1 |
| Kidachi, Y | 1 |
| Kamiie, K | 1 |
| Umetsu, H | 1 |
| Ryoyama, K | 1 |
| Kamal, A | 1 |
| Kumar, BA | 1 |
| Suresh, P | 1 |
| Juvekar, A | 1 |
| Zingde, S | 1 |
| Zhou, W | 3 |
| Zhang, X | 9 |
| Xiao, L | 1 |
| Ding, J | 1 |
| Liu, QH | 1 |
| Li, SS | 1 |
| Mo, WY | 1 |
| Liang, YJ | 1 |
| Gu, YC | 1 |
| Fu, LW | 1 |
| He, HW | 1 |
| Zhang, D | 3 |
| Wang, G | 1 |
| Zhao, G | 1 |
| Xu, W | 2 |
| Huo, L | 2 |
| Huang, WT | 1 |
| Liu, J | 7 |
| Liu, JF | 1 |
| Hui, L | 1 |
| Ding, YL | 1 |
| Chen, SW | 1 |
| Majeed, R | 1 |
| Reddy, MV | 1 |
| Chinthakindi, PK | 1 |
| Sangwan, PL | 1 |
| Hamid, A | 1 |
| Chashoo, G | 1 |
| Saxena, AK | 1 |
| Koul, S | 1 |
| Rathish, IG | 1 |
| Javed, K | 1 |
| Ahmad, S | 1 |
| Bano, S | 1 |
| Alam, MS | 1 |
| Akhter, M | 1 |
| Pillai, KK | 1 |
| Ovais, S | 1 |
| Samim, M | 1 |
| Onen-Bayram, FE | 1 |
| Durmaz, I | 1 |
| Scherman, D | 1 |
| Herscovici, J | 1 |
| Cetin-Atalay, R | 1 |
| Hassan, GS | 1 |
| El-Messery, SM | 1 |
| Al-Omary, FA | 1 |
| Kashyap, M | 1 |
| Kandekar, S | 1 |
| Baviskar, AT | 1 |
| Das, D | 1 |
| Preet, R | 1 |
| Mohapatra, P | 1 |
| Satapathy, SR | 1 |
| Siddharth, S | 1 |
| Guchhait, SK | 1 |
| Kundu, CN | 2 |
| Banerjee, UC | 1 |
| Chavva, K | 1 |
| Pillalamarri, S | 1 |
| Banda, V | 1 |
| Gautham, S | 1 |
| Gaddamedi, J | 1 |
| Yedla, P | 1 |
| Kumar, CG | 1 |
| Banda, N | 1 |
| Lee, HY | 1 |
| Pan, SL | 1 |
| Su, MC | 1 |
| Liu, YM | 2 |
| Kuo, CC | 1 |
| Chang, YT | 1 |
| Wu, JS | 1 |
| Nien, CY | 1 |
| Mehndiratta, S | 1 |
| Chang, CY | 1 |
| Wu, SY | 1 |
| Lai, MJ | 1 |
| Chang, JY | 1 |
| Liou, JP | 1 |
| Zhang, H | 7 |
| Zhu, P | 1 |
| Yang, X | 3 |
| Xu, S | 1 |
| Yao, H | 1 |
| Ye, W | 1 |
| Wu, X | 4 |
| Xu, J | 3 |
| Qu, FZ | 1 |
| Liu, YF | 1 |
| Cao, JQ | 1 |
| Wang, XD | 1 |
| Zhang, XS | 1 |
| Zhao, C | 3 |
| Zhao, YQ | 1 |
| Ma, LY | 2 |
| Wang, B | 2 |
| Pang, LP | 1 |
| Zhang, M | 3 |
| Wang, SQ | 1 |
| Zheng, YC | 1 |
| Shao, KP | 1 |
| Xue, DQ | 1 |
| Liu, HM | 2 |
| Tang, WJ | 1 |
| Wang, J | 6 |
| Tong, X | 1 |
| Shi, JB | 1 |
| Liu, XH | 1 |
| Li, J | 6 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 2 |
| Hitosugi, T | 1 |
| Zhang, L | 5 |
| Zhang, S | 4 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 2 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 2 |
| Li, Y | 4 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 7 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 3 |
| Kang, S | 1 |
| Fan, J | 2 |
| Chen, J | 4 |
| Lewandowska, M | 1 |
| Ruszkowski, P | 1 |
| Chojnacka, K | 1 |
| Kleczewska, N | 1 |
| Hoffmann, M | 1 |
| Kacprzak, K | 1 |
| Celewicz, L | 1 |
| Sharma, P | 1 |
| Srinivasa Reddy, T | 1 |
| Thummuri, D | 1 |
| Senwar, KR | 1 |
| Praveen Kumar, N | 1 |
| Naidu, VGM | 1 |
| Bhargava, SK | 1 |
| Shankaraiah, N | 1 |
| Gregorić, T | 1 |
| Sedić, M | 1 |
| Grbčić, P | 1 |
| Tomljenović Paravić, A | 1 |
| Kraljević Pavelić, S | 1 |
| Cetina, M | 1 |
| Vianello, R | 1 |
| Raić-Malić, S | 1 |
| Wang, M | 4 |
| Yang, J | 3 |
| Yuan, M | 2 |
| Xue, L | 1 |
| Li, H | 2 |
| Tian, C | 2 |
| Wang, X | 3 |
| Abouzid, KAM | 1 |
| Al-Ansary, GH | 1 |
| El-Naggar, AM | 1 |
| Huang, CY | 1 |
| Ahmed, AF | 1 |
| Su, JH | 1 |
| Sung, PJ | 1 |
| Hwang, TL | 1 |
| Chiang, PL | 1 |
| Dai, CF | 1 |
| Liaw, CC | 3 |
| Sheu, JH | 1 |
| Salvador, JAR | 1 |
| Leal, AS | 1 |
| Valdeira, AS | 1 |
| Gonçalves, BMF | 1 |
| Alho, DPS | 1 |
| Figueiredo, SAC | 1 |
| Silvestre, SM | 1 |
| Mendes, VIS | 1 |
| Raffa, D | 1 |
| Maggio, B | 1 |
| Raimondi, MV | 1 |
| Plescia, F | 1 |
| Daidone, G | 1 |
| Khwaja, S | 1 |
| Fatima, K | 1 |
| Hasanain, M | 1 |
| Behera, C | 1 |
| Kour, A | 1 |
| Singh, A | 2 |
| Luqman, S | 1 |
| Sarkar, J | 1 |
| Chanda, D | 1 |
| Shanker, K | 1 |
| Gupta, AK | 1 |
| Mondhe, DM | 1 |
| Negi, AS | 1 |
| Zhao, TQ | 1 |
| Zhao, YD | 1 |
| Liu, XY | 1 |
| Li, ZH | 1 |
| He, ZX | 1 |
| Zhang, XH | 1 |
| Liang, JJ | 1 |
| Mostafa, AS | 1 |
| Selim, KB | 1 |
| Han, T | 1 |
| Li, X | 4 |
| Cheng, K | 1 |
| Gao, X | 2 |
| Li, Z | 4 |
| Bai, J | 1 |
| Hua, H | 1 |
| Li, D | 2 |
| Wang, N | 1 |
| Li, CW | 1 |
| Cui, CB | 1 |
| Cai, B | 1 |
| Xu, LL | 1 |
| Zhu, HJ | 1 |
| Mahdjour, S | 1 |
| Guardia, JJ | 1 |
| Rodríguez-Serrano, F | 1 |
| Garrido, JM | 1 |
| López-Barajas, IB | 1 |
| Mut-Salud, N | 1 |
| Chahboun, R | 1 |
| Alvarez-Manzaneda, E | 1 |
| Rashid, HU | 1 |
| Xu, Y | 1 |
| Muhammad, Y | 1 |
| Wang, L | 7 |
| Gao, F | 1 |
| Wang, T | 3 |
| Xiao, J | 1 |
| Cao, J | 1 |
| Zang, J | 1 |
| Kong, X | 3 |
| Chen, T | 1 |
| Ran, Y | 1 |
| Dong, H | 1 |
| Zhang, Y | 8 |
| de Siqueira, LRP | 1 |
| de Moraes Gomes, PAT | 1 |
| de Lima Ferreira, LP | 1 |
| de Melo Rêgo, MJB | 1 |
| Leite, ACL | 1 |
| Xu, Z | 3 |
| Wei, G | 1 |
| Sun, J | 2 |
| Luan, W | 1 |
| Hou, Z | 1 |
| Wang, S | 3 |
| Cui, S | 1 |
| Cheng, M | 1 |
| Liu, Y | 8 |
| Zhao, SJ | 1 |
| Liang, GB | 1 |
| Wei, JH | 1 |
| Jiang, H | 1 |
| Huang, RZ | 1 |
| Qin, JT | 1 |
| Wang, HL | 1 |
| Wang, HS | 1 |
| Hao, EJ | 1 |
| Li, GX | 1 |
| Liang, YR | 1 |
| Xie, MS | 1 |
| Wang, DC | 1 |
| Jiang, XH | 1 |
| Cheng, JY | 1 |
| Shi, ZX | 1 |
| Guo, HM | 1 |
| Zhou, S | 1 |
| Huang, G | 1 |
| Chen, G | 3 |
| Valipour, M | 1 |
| Guo, K | 1 |
| Ma, X | 1 |
| Zhang, C | 2 |
| Wu, L | 1 |
| Piorecka, K | 1 |
| Kurjata, J | 1 |
| Stanczyk, WA | 1 |
| Schultz, A | 1 |
| Kohnke, H | 1 |
| Wadelius, M | 1 |
| Nygren, P | 2 |
| Menezes, BC | 1 |
| Thebit, MM | 1 |
| Bonela, LAS | 1 |
| Oliveira, KG | 1 |
| Gonçalves, WL | 1 |
| Bissoli, NS | 1 |
| Sartorio, CL | 1 |
| Gouvea, SA | 1 |
| García-Alfonso, P | 2 |
| Saiz-Rodríguez, M | 1 |
| Mondéjar, R | 1 |
| Salazar, J | 1 |
| Páez, D | 1 |
| Borobia, AM | 1 |
| Safont, MJ | 1 |
| García-García, I | 1 |
| Colomer, R | 1 |
| García-González, X | 3 |
| Herrero, MJ | 1 |
| López-Fernández, LA | 3 |
| Abad-Santos, F | 1 |
| Božina, N | 1 |
| Bilić, I | 1 |
| Ganoci, L | 1 |
| Šimičević, L | 1 |
| Pleština, S | 1 |
| Lešnjaković, L | 1 |
| Trkulja, V | 1 |
| Padya, BS | 1 |
| Hegde, AR | 1 |
| Mutalik, SP | 1 |
| Biswas, S | 1 |
| Mutalik, S | 1 |
| Naren, G | 1 |
| Guo, J | 1 |
| Bai, Q | 1 |
| Fan, N | 1 |
| Nashun, B | 1 |
| Warfield, BM | 1 |
| Reigan, P | 1 |
| Ioannou, C | 1 |
| Ragia, G | 1 |
| Balgkouranidou, I | 1 |
| Xenidis, N | 3 |
| Amarantidis, K | 5 |
| Koukaki, T | 1 |
| Biziota, E | 1 |
| Kakolyris, S | 6 |
| Manolopoulos, VG | 1 |
| Danesh Pouya, F | 1 |
| Rasmi, Y | 1 |
| Nemati, M | 1 |
| Vater, LB | 1 |
| Lefebvre, B | 1 |
| Turk, A | 1 |
| Clasen, SC | 1 |
| Parsaei, M | 1 |
| Akhbari, K | 1 |
| Kumar, N | 1 |
| Goel, N | 1 |
| Zafar, A | 1 |
| Drobni, ZD | 1 |
| Lei, M | 2 |
| Gongora, CA | 1 |
| Quinaglia, T | 1 |
| Lou, UY | 1 |
| Mosarla, R | 1 |
| Murphy, SP | 1 |
| Jones-O'Connor, M | 1 |
| Mahmood, A | 1 |
| Hartmann, S | 1 |
| Gilman, HK | 1 |
| Weekes, CD | 1 |
| Nipp, R | 1 |
| Clark, JR | 1 |
| Clark, JW | 5 |
| Blaszkowsky, LS | 1 |
| Tavares, E | 1 |
| Neilan, TG | 1 |
| Launay, M | 3 |
| Guitton, J | 1 |
| Balluet, R | 1 |
| Moreau, A | 1 |
| Phelip, JM | 1 |
| Tholance, Y | 1 |
| Gonzalo, P | 1 |
| Mteremko, D | 1 |
| Shadrack, DM | 1 |
| Ntie-Kang, F | 1 |
| Chilongola, J | 1 |
| Chacha, M | 1 |
| Moghaddam, Z | 1 |
| Rostami, M | 1 |
| Zeraatchi, A | 1 |
| Abadi, H | 1 |
| Karamitanha, F | 1 |
| Amirmoghaddami, H | 1 |
| Gessner, EE | 1 |
| Shah, MH | 1 |
| Ghent, BN | 1 |
| Westbrook, NE | 1 |
| van den Hurk, P | 1 |
| Baldwin, WS | 1 |
| Jose, N | 1 |
| Joel, A | 1 |
| Selvakumar, RJ | 1 |
| Ramireddy, J | 1 |
| John, AO | 1 |
| Georgy, JT | 1 |
| Ram, TS | 1 |
| Principe, N | 1 |
| Aston, WJ | 1 |
| Hope, DE | 1 |
| Tilsed, CM | 1 |
| Fisher, SA | 1 |
| Boon, L | 1 |
| Dick, IM | 1 |
| Chin, WL | 1 |
| McDonnell, AM | 1 |
| Nowak, AK | 1 |
| Lake, RA | 1 |
| Chee, J | 1 |
| Lesterhuis, WJ | 1 |
| Noel, K | 1 |
| Bokhari, A' | 1 |
| Bertrand, R | 1 |
| Renaud, F | 1 |
| Bourgoin, P | 1 |
| Cohen, R | 1 |
| Svrcek, M | 1 |
| Joly, AC | 1 |
| Duval, A | 1 |
| Collura, A | 1 |
| Dawood, KM | 1 |
| Raslan, MA | 1 |
| Abbas, AA | 1 |
| Mohamed, BE | 1 |
| Nafie, MS | 1 |
| Hassan, ESE | 1 |
| Shafaa, MW | 1 |
| Faraag, AHI | 1 |
| Essawy, E | 1 |
| Bakkar, AA | 1 |
| Al-Megrin, WA | 1 |
| El-Khadragy, MF | 1 |
| Abdelfattah, MS | 1 |
| Abdel Moneim, AE | 1 |
| Osterlund, P | 1 |
| Kinos, S | 1 |
| Pfeiffer, P | 2 |
| Salminen, T | 1 |
| Kwakman, JJM | 1 |
| Frödin, JE | 1 |
| Shah, CH | 1 |
| Sorbye, H | 1 |
| Ristamäki, R | 1 |
| Halonen, P | 1 |
| Soveri, LM | 1 |
| Heervä, E | 1 |
| Ålgars, A | 1 |
| Bärlund, M | 1 |
| Hagman, H | 1 |
| McDermott, R | 1 |
| O'Reilly, M | 1 |
| Röckert, R | 1 |
| Liposits, G | 1 |
| Kallio, R | 1 |
| Flygare, P | 1 |
| Teske, AJ | 1 |
| van Werkhoven, E | 4 |
| Punt, CJA | 1 |
| Glimelius, B | 1 |
| Boddu, A | 1 |
| Obireddy, SR | 1 |
| Rao, KSVK | 1 |
| Lai, WF | 1 |
| Carriat, L | 1 |
| Quaranta, S | 3 |
| Solas, C | 2 |
| Rony, M | 1 |
| Ciccolini, J | 9 |
| VanderVeen, BN | 2 |
| Cardaci, TD | 2 |
| McDonald, SJ | 2 |
| Madero, SS | 1 |
| Unger, CA | 1 |
| Bullard, BM | 2 |
| Enos, RT | 1 |
| Velázquez, KT | 2 |
| Kubinak, JL | 1 |
| Fan, D | 3 |
| Murphy, EA | 2 |
| Shimolina, L | 1 |
| Gulin, A | 1 |
| Khlynova, A | 1 |
| Ignatova, N | 1 |
| Druzhkova, I | 1 |
| Gubina, M | 1 |
| Zagaynova, E | 1 |
| Kuimova, MK | 1 |
| Shirmanova, M | 1 |
| Pranzini, E | 1 |
| Pardella, E | 1 |
| Muccillo, L | 1 |
| Leo, A | 1 |
| Nesi, I | 1 |
| Santi, A | 1 |
| Parri, M | 1 |
| Zhang, T | 1 |
| Uribe, AH | 1 |
| Lottini, T | 1 |
| Sabatino, L | 1 |
| Caselli, A | 1 |
| Arcangeli, A | 1 |
| Raugei, G | 1 |
| Colantuoni, V | 1 |
| Cirri, P | 1 |
| Chiarugi, P | 1 |
| Maddocks, ODK | 1 |
| Paoli, P | 1 |
| Taddei, ML | 1 |
| Bourzikat, O | 1 |
| El Abbouchi, A | 1 |
| Ghammaz, H | 1 |
| El Brahmi, N | 1 |
| El Fahime, E | 1 |
| Paris, A | 1 |
| Daniellou, R | 1 |
| Suzenet, F | 1 |
| Guillaumet, G | 1 |
| El Kazzouli, S | 1 |
| Ajalli, N | 1 |
| Pourmadadi, M | 3 |
| Yazdian, F | 1 |
| Rashedi, H | 1 |
| Navaei-Nigjeh, M | 1 |
| Díez-Pascual, AM | 3 |
| Wu, Y | 2 |
| Tang, X | 2 |
| Hu, F | 1 |
| Zhu, T | 1 |
| Liu, H | 1 |
| Xiong, Y | 1 |
| Zuo, X | 1 |
| Xu, A | 1 |
| Zhuang, X | 1 |
| Paulsen, NH | 1 |
| Qvortrup, C | 1 |
| Vojdeman, FJ | 1 |
| Plomgaard, P | 1 |
| Andersen, SE | 1 |
| Ramlov, A | 1 |
| Bertelsen, B | 1 |
| Rossing, M | 1 |
| Nielsen, CG | 1 |
| Hoffmann-Lücke, E | 1 |
| Greibe, E | 1 |
| Spangsberg Holm, H | 1 |
| Nielsen, HH | 1 |
| Lolas, IBY | 1 |
| Madsen, JS | 1 |
| Bergmann, ML | 1 |
| Mørk, M | 1 |
| Fruekilde, PBN | 1 |
| Bøttger, P | 1 |
| Petersen, PC | 1 |
| Nissen, PH | 1 |
| Feddersen, S | 1 |
| Bergmann, TK | 1 |
| Damkier, P | 1 |
| Valencia-Lazcano, AA | 2 |
| Hassan, D | 2 |
| Shamsabadipour, A | 2 |
| Behzadmehr, R | 2 |
| Rahdar, A | 2 |
| Medina, DI | 2 |
| Li, W | 4 |
| Trieu, J | 1 |
| Blazev, R | 1 |
| Parker, BL | 1 |
| Murphy, KT | 1 |
| Swiderski, K | 1 |
| Lynch, GS | 1 |
| Boroushaki, T | 1 |
| Dekamin, MG | 1 |
| Liu, X | 4 |
| Jaiswal, Y | 1 |
| Xu, H | 1 |
| Chen, R | 2 |
| Lu, R | 1 |
| Nong, Y | 1 |
| Williams, L | 2 |
| Liang, Y | 1 |
| Jia, Z | 1 |
| Cunningham, P | 1 |
| Rubin, R | 1 |
| Hanna, DH | 1 |
| El-Mazaly, MH | 1 |
| Mohamed, RR | 1 |
| Zheng, L | 1 |
| Zhang, W | 1 |
| Jin, X | 1 |
| Yu, X | 1 |
| Chen, H | 2 |
| Abolhassani, H | 1 |
| Zaer, M | 1 |
| Shojaosadati, SA | 1 |
| Hashemi-Najafabadi, S | 1 |
| Miyazaki, K | 1 |
| Kishimoto, H | 1 |
| Kobayashi, H | 1 |
| Suzuki, A | 1 |
| Higuchi, K | 2 |
| Shirasaka, Y | 1 |
| Inoue, K | 1 |
| Monirujjaman, M | 1 |
| Renani, LB | 1 |
| Isesele, P | 1 |
| Dunichand-Hoedl, AR | 1 |
| Mazurak, VC | 1 |
| Mahdieh, A | 1 |
| Yeganeh, H | 1 |
| Sande, SA | 1 |
| Nyström, B | 1 |
| Miarons, M | 1 |
| Manzaneque Gordón, A | 1 |
| Riera, P | 1 |
| Gutiérrez Nicolás, F | 1 |
| Hao, H | 1 |
| Hu, X | 1 |
| Guo, W | 1 |
| Yang, C | 2 |
| Heibloem, RE | 1 |
| Komen, MMC | 1 |
| Ilozumba, OUC | 1 |
| van den Hurk, CJG | 1 |
| Hashizume, J | 1 |
| Nambu, M | 1 |
| Nakagawa, H | 1 |
| Harasawa, H | 1 |
| Kodama, Y | 1 |
| Morris, SA | 1 |
| Moore, DC | 1 |
| Musselwhite, LW | 1 |
| Lopes, KE | 1 |
| Hamilton, A | 1 |
| Steuerwald, N | 1 |
| Hanson, SL | 1 |
| Larck, C | 1 |
| Swift, K | 1 |
| Smith, M | 1 |
| Kadakia, KC | 1 |
| Chai, S | 1 |
| Hwang, JJ | 2 |
| Patel, JN | 1 |
| Gul, SK | 1 |
| Tepetam, H | 1 |
| Yildiz, F | 1 |
| Er, I | 1 |
| Oksuz, DC | 1 |
| Parvizi, M | 1 |
| Ozden, AS | 1 |
| Alicikus, ZA | 1 |
| Sari, SY | 1 |
| Alomari, O | 1 |
| Gorken, IB | 1 |
| Cetin, AE | 1 |
| Topkaya, SN | 1 |
| Yazici, ZA | 1 |
| Yalcin-Ozuysal, O | 1 |
| Feng, YS | 1 |
| Qin, YT | 1 |
| Zhuang, J | 1 |
| Ma, YJ | 1 |
| He, XW | 1 |
| Li, WY | 1 |
| Zhang, YK | 1 |
| Oliveira, JV | 1 |
| Almeida, GC | 1 |
| Nogueira, MCBL | 1 |
| Aguiar Júnior, FCA | 1 |
| Melo, AO | 1 |
| Silva, TDS | 1 |
| Santos, NPS | 1 |
| Magalhães, NSS | 1 |
| Melo, SJ | 1 |
| Falcão, EPS | 1 |
| Puzderova, B | 1 |
| Belvoncikova, P | 1 |
| Grossmannova, K | 1 |
| Csaderova, L | 1 |
| Labudova, M | 1 |
| Fecikova, S | 1 |
| Pastorek, J | 1 |
| Barathova, M | 1 |
| Nagae, A | 1 |
| Miyoshi, N | 1 |
| Fujino, S | 1 |
| Horie, M | 1 |
| Yachida, S | 1 |
| Sasaki, M | 1 |
| Sekido, Y | 1 |
| Hata, T | 1 |
| Hamabe, A | 1 |
| Ogino, T | 2 |
| Takahashi, H | 4 |
| Uemura, M | 1 |
| Yamamoto, H | 2 |
| Doki, Y | 1 |
| Eguchi, H | 1 |
| Meng, J | 2 |
| Xin, L | 1 |
| Zou, B | 1 |
| Zhao, X | 1 |
| Gao, J | 2 |
| Zhang, R | 4 |
| Takai, M | 1 |
| Takamoto, M | 1 |
| Amano, Y | 1 |
| Yamamoto, M | 1 |
| Hara, K | 1 |
| Yashiro, N | 1 |
| Tsujiuchi, T | 1 |
| Hu, H | 1 |
| Yu, L | 3 |
| Zeng, S | 1 |
| Knikman, JE | 1 |
| Wilting, TA | 1 |
| Lopez-Yurda, M | 1 |
| Henricks, LM | 8 |
| Lunenburg, CATC | 4 |
| de Man, FM | 3 |
| Meulendijks, D | 10 |
| Nieboer, P | 3 |
| Droogendijk, HJ | 3 |
| Creemers, GJ | 3 |
| Mandigers, CMPW | 4 |
| Imholz, ALT | 3 |
| Mathijssen, RHJ | 3 |
| Portielje, JEA | 3 |
| Valkenburg-van Iersel, L | 1 |
| Vulink, A | 1 |
| van der Poel, MHW | 1 |
| Baars, A | 3 |
| Swen, JJ | 5 |
| Gelderblom, H | 5 |
| Schellens, JHM | 9 |
| Beijnen, JH | 16 |
| Guchelaar, HJ | 7 |
| Cats, A | 9 |
| Hu, J | 1 |
| Li, A | 1 |
| Guo, Y | 2 |
| Ma, T | 1 |
| Feng, S | 1 |
| De Mattia, E | 2 |
| Polesel, J | 1 |
| Silvestri, M | 1 |
| Roncato, R | 2 |
| Scarabel, L | 1 |
| Calza, S | 1 |
| Spina, M | 1 |
| Puglisi, F | 1 |
| Toffoli, G | 5 |
| Cecchin, E | 4 |
| Mansour, A | 1 |
| Fytory, M | 1 |
| Ahmed, OM | 1 |
| Rahman, FESA | 1 |
| El-Sherbiny, IM | 1 |
| Hennequin, C | 2 |
| Guillerm, S | 1 |
| Quero, L | 2 |
| Levêque, D | 1 |
| Becker, G | 1 |
| Sharma, V | 1 |
| Gupta, SK | 1 |
| Verma, M | 1 |
| Kanduri, J | 1 |
| More, LA | 1 |
| Godishala, A | 1 |
| Asnani, A | 1 |
| Christensen, S | 1 |
| Van der Roest, B | 1 |
| Besselink, N | 1 |
| Janssen, R | 1 |
| Boymans, S | 1 |
| Martens, JWM | 1 |
| Yaspo, ML | 1 |
| Priestley, P | 1 |
| Kuijk, E | 1 |
| Cuppen, E | 1 |
| Van Hoeck, A | 1 |
| Cunha-Junior, GF | 1 |
| Bastos-Rodrigues, L | 1 |
| Azevedo, PG | 1 |
| Bicalho, MA | 1 |
| Magno, LAV | 1 |
| De Marco, L | 1 |
| Coelho, LG | 1 |
| Johnson, J | 1 |
| Sharick, JT | 1 |
| Skala, MC | 1 |
| Elliott, SL | 1 |
| Kose, E | 1 |
| Lewis, AL | 1 |
| Steinfeld, AE | 1 |
| Zollinger, EA | 1 |
| Kumar, B | 1 |
| Priyadarshi, R | 1 |
| Deeba, F | 1 |
| Kulshreshtha, A | 1 |
| Kumar, A | 1 |
| Agrawal, G | 1 |
| Gopinath, P | 1 |
| Negi, YS | 1 |
| Bojko, A | 1 |
| Czarnecka-Herok, J | 1 |
| Charzynska, A | 1 |
| Dabrowski, M | 1 |
| Sikora, E | 1 |
| Perez, RP | 1 |
| Chen, E | 1 |
| Thaddeus Beck, J | 1 |
| Shirai, K | 1 |
| Neil Hayes, D | 1 |
| Shen, T | 1 |
| Baldwin, JR | 1 |
| Bryant, KB | 1 |
| He, S | 1 |
| Chin, S | 1 |
| Hamzic, S | 1 |
| Kummer, D | 1 |
| Froehlich, TK | 2 |
| Joerger, M | 2 |
| Aebi, S | 3 |
| Palles, C | 2 |
| Thomlinson, I | 1 |
| Amstutz, U | 5 |
| Largiadèr, CR | 6 |
| Chen, Y | 9 |
| Han, P | 1 |
| Zhu, F | 1 |
| Fu, K | 1 |
| Chu, M | 1 |
| Marin, C | 1 |
| Krache, A | 1 |
| Palmaro, C | 1 |
| Lucas, M | 1 |
| Hilaire, V | 1 |
| Ugdonne, R | 1 |
| De Victor, B | 1 |
| Lacarelle, B | 3 |
| Maytin, EV | 1 |
| Hasan, T | 1 |
| Boilève, A | 1 |
| Thomas, L | 1 |
| Lillo-Le Louët, A | 1 |
| Gaboriau, L | 1 |
| Chouchana, L | 1 |
| Ducreux, M | 1 |
| Malka, D | 1 |
| Boige, V | 2 |
| Hollebecque, A | 1 |
| Hillaire-Buys, D | 1 |
| Jozwiak, M | 1 |
| Peng, X | 1 |
| Xiang, Y | 1 |
| Dai, W | 1 |
| Quan, H | 1 |
| Shiga, T | 1 |
| Hiraide, M | 1 |
| Valero, M | 1 |
| Courand, PY | 1 |
| Gilbert, T | 1 |
| Bonnin, N | 1 |
| Bonnefoy, M | 1 |
| Lantelme, P | 1 |
| Falandry, C | 1 |
| Hussain, S | 1 |
| Takeuchi, I | 2 |
| Kawamata, R | 1 |
| Makino, K | 2 |
| Roosendaal, J | 1 |
| Jacobs, BAW | 3 |
| Pluim, D | 1 |
| Rosing, H | 5 |
| de Vries, N | 2 |
| Nuijen, B | 1 |
| Huitema, ADR | 2 |
| Marchetti, S | 1 |
| Chamorey, E | 1 |
| Francois, E | 4 |
| Etienne, MC | 8 |
| Ferrero, JM | 2 |
| Peyrade, F | 1 |
| Barranger, E | 1 |
| Bozec, A | 1 |
| Largillier, R | 1 |
| Cassuto, O | 1 |
| Viotti, J | 1 |
| Schiappa, R | 1 |
| Milano, G | 19 |
| Zhu, X | 2 |
| Yizhen, X | 1 |
| Chen, D | 3 |
| Ayyanaar, S | 1 |
| Balachandran, C | 1 |
| Bhaskar, RC | 1 |
| Kesavan, MP | 1 |
| Aoki, S | 1 |
| Raja, RP | 1 |
| Rajesh, J | 1 |
| Webster, TJ | 1 |
| Rajagopal, G | 1 |
| Altanerova, U | 1 |
| Jakubechova, J | 1 |
| Benejova, K | 1 |
| Priscakova, P | 1 |
| Repiska, V | 1 |
| Babelova, A | 1 |
| Smolkova, B | 1 |
| Altaner, C | 1 |
| Chavani, O | 1 |
| Ito, SS | 1 |
| Nakagawa, Y | 3 |
| Matsubayashi, M | 1 |
| Sakaguchi, YM | 1 |
| Kobashigawa, S | 1 |
| Matsui, TK | 1 |
| Nanaura, H | 1 |
| Nakanishi, M | 1 |
| Kitayoshi, F | 1 |
| Kikuchi, S | 1 |
| Kajihara, A | 1 |
| Tamaki, S | 1 |
| Sugie, K | 1 |
| Kashino, G | 1 |
| Takahashi, A | 1 |
| Hasegawa, M | 2 |
| Mori, E | 1 |
| Kirita, T | 1 |
| Hashimoto, Y | 1 |
| Yoshida, Y | 3 |
| Yamada, T | 1 |
| Aisu, N | 1 |
| Yoshimatsu, G | 1 |
| Yoshimura, F | 1 |
| Hasegawa, S | 1 |
| Giuliani, J | 1 |
| Bonetti, A | 1 |
| Clayton, EA | 2 |
| Pujol, TA | 1 |
| McDonald, JF | 2 |
| Qiu, P | 1 |
| Akhtar, W | 1 |
| Marella, A | 1 |
| Alam, MM | 1 |
| Khan, MF | 1 |
| Akhtar, M | 1 |
| Anwer, T | 1 |
| Khan, F | 1 |
| Naematullah, M | 1 |
| Azam, F | 1 |
| Rizvi, MA | 1 |
| Shaquiquzzaman, M | 1 |
| Gan, BK | 1 |
| Rullah, K | 1 |
| Yong, CY | 1 |
| Ho, KL | 1 |
| Omar, AR | 1 |
| Alitheen, NB | 1 |
| Tan, WS | 1 |
| Derissen, EJB | 1 |
| Wörmann, B | 1 |
| Bokemeyer, C | 1 |
| Burmeister, T | 1 |
| Köhne, CH | 1 |
| Schwab, M | 4 |
| Arnold, D | 1 |
| Blohmer, JU | 1 |
| Borner, M | 1 |
| Brucker, S | 1 |
| Cascorbi, I | 1 |
| Decker, T | 1 |
| de Wit, M | 2 |
| Dietz, A | 2 |
| Einsele, H | 1 |
| Eisterer, W | 1 |
| Folprecht, G | 1 |
| Hilbe, W | 1 |
| Hoffmann, J | 1 |
| Knauf, W | 1 |
| Kunzmann, V | 1 |
| Lorenzen, S | 1 |
| Lüftner, D | 1 |
| Moehler, M | 1 |
| Nöthen, MM | 1 |
| Pox, C | 1 |
| Reinacher-Schick, A | 1 |
| Scharl, A | 1 |
| Schlegelberger, B | 1 |
| Seufferlein, T | 1 |
| Sinn, M | 1 |
| Stroth, M | 1 |
| Tamm, I | 1 |
| Trümper, L | 1 |
| Wilhelm, M | 1 |
| Wöll, E | 1 |
| Hofheinz, RD | 3 |
| Luo, Y | 2 |
| Pei, S | 1 |
| Murray Stewart, T | 1 |
| Von Hoff, D | 2 |
| Fitzgerald, M | 1 |
| Marton, LJ | 1 |
| Becerra, CHR | 1 |
| Boyd, TE | 1 |
| Conkling, PR | 1 |
| Garbo, LE | 1 |
| Jotte, RM | 1 |
| Richards, DA | 1 |
| Smith, DA | 5 |
| Stephenson, JJ | 1 |
| Vogelzang, NJ | 6 |
| Wu, HH | 1 |
| Casero, RA | 1 |
| LaValley, DJ | 1 |
| Miller, PG | 1 |
| Shuler, ML | 1 |
| Yao, Y | 2 |
| Dai, X | 2 |
| Tan, Y | 1 |
| Liao, C | 1 |
| Yang, T | 1 |
| Yu, Y | 4 |
| Takeuchi, M | 1 |
| Imamura, CK | 1 |
| Booka, E | 1 |
| Takeuchi, H | 1 |
| Mizukami, T | 1 |
| Kawakami, T | 1 |
| Funakoshi, T | 1 |
| Wakuda, K | 1 |
| Aoki, Y | 2 |
| Hamamoto, Y | 1 |
| Kitago, M | 1 |
| Kawakubo, H | 1 |
| Boku, N | 1 |
| Tanigawara, Y | 2 |
| Kitagawa, Y | 1 |
| Koutsilieri, S | 1 |
| Patrinos, GP | 1 |
| Periyasamy, M | 1 |
| Singh, AK | 1 |
| Gemma, C | 1 |
| Farzan, R | 1 |
| Allsopp, RC | 1 |
| Shaw, JA | 1 |
| Charmsaz, S | 1 |
| Young, LS | 1 |
| Cunnea, P | 1 |
| Coombes, RC | 1 |
| Győrffy, B | 1 |
| Buluwela, L | 1 |
| Ali, S | 1 |
| Schneider, JJ | 1 |
| Galettis, P | 1 |
| Martin, JH | 1 |
| Shakeel, F | 1 |
| Fang, F | 1 |
| Kwon, JW | 1 |
| Koo, K | 1 |
| Pasternak, AL | 1 |
| Henry, NL | 1 |
| Sahai, V | 1 |
| Kidwell, KM | 1 |
| Hertz, DL | 1 |
| Houzong, R | 1 |
| Fu, J | 1 |
| Shao, K | 1 |
| Ma, Y | 2 |
| Shi, J | 1 |
| Sethy, C | 1 |
| Cardona-G, W | 1 |
| Herrera-R, A | 1 |
| Castrillón-L, W | 1 |
| Ramírez-Malule, H | 1 |
| Wigle, TJ | 1 |
| Povitz, BL | 1 |
| Medwid, S | 1 |
| Teft, WA | 1 |
| Legan, RM | 1 |
| Lenehan, J | 1 |
| Nevison, S | 1 |
| Panuganty, V | 1 |
| Keller, D | 1 |
| Mailloux, J | 1 |
| Siebring, V | 1 |
| Sarma, S | 1 |
| Choi, YH | 1 |
| Welch, S | 1 |
| Winquist, E | 2 |
| Schwarz, UI | 1 |
| Kim, RB | 2 |
| Kalinina, A | 1 |
| Golubeva, I | 1 |
| Kudryavtsev, I | 1 |
| Khromova, N | 1 |
| Antoshina, E | 1 |
| Trukhanova, L | 1 |
| Gorkova, T | 1 |
| Kazansky, D | 1 |
| Khromykh, L | 1 |
| Winquist, LE | 1 |
| Sanatani, M | 1 |
| Eisenberg, S | 1 |
| Ito, K | 1 |
| Rodriguez, A | 1 |
| King, DA | 1 |
| Diasio, RB | 19 |
| Saif, MW | 9 |
| Clua, A | 1 |
| Fàbrega, C | 1 |
| García-Chica, J | 1 |
| Grijalvo, S | 1 |
| Eritja, R | 1 |
| Deac, AL | 1 |
| Burz, CC | 1 |
| Militaru, C | 1 |
| Bocșan, IC | 1 |
| Pop, RM | 1 |
| Achimaș-Cadariu, P | 1 |
| Buzoianu, AD | 1 |
| Li, C | 2 |
| Ngorsuraches, S | 1 |
| Chou, C | 1 |
| Chen, L | 5 |
| Qian, J | 1 |
| Leung, M | 1 |
| Rogers, JE | 2 |
| Shureiqi, I | 1 |
| Meyer, FB | 1 |
| Goebel, S | 1 |
| Spangel, SB | 1 |
| Leovsky, C | 1 |
| Hoelzer, D | 1 |
| Thierbach, R | 1 |
| Insuasty, D | 1 |
| García, S | 1 |
| Abonia, R | 1 |
| Insuasty, B | 1 |
| Quiroga, J | 1 |
| Nogueras, M | 1 |
| Cobo, J | 1 |
| Borosky, GL | 1 |
| Laali, KK | 1 |
| Tendwa, MB | 1 |
| Chebon-Bore, L | 1 |
| Lobb, K | 1 |
| Musyoka, TM | 1 |
| Tastan Bishop, Ö | 1 |
| Molenaar-Kuijsten, L | 1 |
| Kurk, SA | 1 |
| May, AM | 1 |
| Dorlo, TPC | 1 |
| Steeghs, N | 1 |
| Karthikeyan, K | 1 |
| Sameera, KV | 1 |
| Shaji, S | 1 |
| Swetha, MAC | 1 |
| Madhu, CS | 1 |
| Liang, YY | 1 |
| Bacanu, S | 1 |
| Sreekumar, L | 1 |
| Ramos, AD | 1 |
| Dai, L | 1 |
| Michaelis, M | 1 |
| Cinatl, J | 1 |
| Seki, T | 1 |
| Cao, Y | 1 |
| Coffill, CR | 1 |
| Lane, DP | 1 |
| Prabhu, N | 1 |
| Nordlund, P | 1 |
| Correia, C | 1 |
| Ferreira, A | 1 |
| Santos, J | 1 |
| Lapa, R | 1 |
| Yliperttula, M | 1 |
| Urtti, A | 1 |
| Vale, N | 1 |
| Wang, XY | 1 |
| Zhang, B | 1 |
| Lu, Y | 1 |
| Xu, L | 2 |
| Wang, YJ | 1 |
| Cai, BY | 1 |
| Yao, QH | 1 |
| Ciaffaglione, V | 1 |
| Modica, MN | 1 |
| Pittalà, V | 1 |
| Romeo, G | 1 |
| Salerno, L | 1 |
| Intagliata, S | 1 |
| Miura, K | 1 |
| Shima, H | 1 |
| Takebe, N | 1 |
| Rhie, J | 1 |
| Satoh, K | 1 |
| Kakugawa, Y | 1 |
| Satoh, M | 1 |
| Kinouchi, M | 1 |
| Yamamoto, K | 1 |
| Hasegawa, Y | 1 |
| Kawai, M | 2 |
| Kanazawa, K | 1 |
| Fujiya, T | 1 |
| Unno, M | 1 |
| Katakura, R | 1 |
| Hagenkort, A | 1 |
| Paulin, CBJ | 1 |
| Desroses, M | 1 |
| Sarno, A | 1 |
| Wiita, E | 1 |
| Mortusewicz, O | 1 |
| Koolmeister, T | 1 |
| Loseva, O | 1 |
| Jemth, AS | 1 |
| Almlöf, I | 1 |
| Homan, E | 1 |
| Lundbäck, T | 1 |
| Gustavsson, AL | 1 |
| Scobie, M | 1 |
| Helleday, T | 1 |
| Aliev, A | 2 |
| Deenen, MJ | 5 |
| de Boer, A | 2 |
| Soesan, M | 2 |
| Ishida, K | 1 |
| Ito, C | 1 |
| Ohmori, Y | 1 |
| Kume, K | 1 |
| Sato, KA | 1 |
| Koizumi, Y | 1 |
| Konta, A | 1 |
| Iwaya, T | 1 |
| Nukatsuka, M | 1 |
| Kobunai, T | 4 |
| Takechi, T | 3 |
| Nishizuka, SS | 1 |
| Fallon, JK | 1 |
| Liu, F | 2 |
| Hazrati, MK | 1 |
| Javanshir, Z | 1 |
| Bagheri, Z | 1 |
| Yan, JK | 1 |
| Qiu, WY | 1 |
| Wang, YY | 1 |
| Wu, LX | 1 |
| Cheung, PCK | 1 |
| Cavaliere, A | 1 |
| Probst, KC | 1 |
| Westwell, AD | 1 |
| Slusarczyk, M | 1 |
| Zhao, H | 1 |
| Yin, R | 1 |
| Lee, YH | 1 |
| Luo, T | 1 |
| Zhang, J | 4 |
| Qiu, H | 1 |
| Ambrose, S | 1 |
| Ren, J | 1 |
| Yao, J | 1 |
| Liang, Z | 2 |
| Zhen, J | 1 |
| Ye, Z | 1 |
| Zeng, J | 1 |
| Huang, N | 1 |
| Gu, Y | 1 |
| Zia, MK | 1 |
| Siddiqui, T | 1 |
| Ali, SS | 2 |
| Rehman, AA | 1 |
| Ahsan, H | 1 |
| Khan, FH | 1 |
| Thysiadis, S | 1 |
| Katsamakas, S | 1 |
| Dalezis, P | 1 |
| Chatzisideri, T | 1 |
| Trafalis, D | 1 |
| Sarli, V | 1 |
| Sakai, H | 1 |
| Tabata, S | 1 |
| Kimura, M | 1 |
| Yabe, S | 1 |
| Isa, Y | 1 |
| Kai, Y | 1 |
| Sato, F | 1 |
| Yumoto, T | 1 |
| Miyano, K | 1 |
| Narita, M | 1 |
| Uezono, Y | 1 |
| Wei, Y | 2 |
| Yang, P | 1 |
| Cao, S | 1 |
| Zhao, L | 1 |
| Moghimipour, E | 1 |
| Rezaei, M | 1 |
| Ramezani, Z | 1 |
| Kouchak, M | 1 |
| Amini, M | 1 |
| Angali, KA | 1 |
| Dorkoosh, FA | 1 |
| Handali, S | 1 |
| Chen, YJ | 2 |
| Tsai, TH | 2 |
| Wang, LY | 2 |
| Hsieh, CH | 2 |
| Shariatpanahi, SP | 2 |
| Madjidzadeh, K | 1 |
| Hassan, M | 1 |
| Abedi-Valugerdi, M | 1 |
| Leilabadi-Asl, A | 1 |
| Divsalar, A | 1 |
| Saboury, AA | 1 |
| Parivar, K | 1 |
| Banke, A | 1 |
| Polk, A | 1 |
| Nielsen, D | 1 |
| Videbæk, L | 1 |
| Overgaard, U | 1 |
| Fosbøl, EL | 1 |
| Vaage-Nielsen, M | 1 |
| Nielsen, KM | 1 |
| Schou, M | 1 |
| Loriot, MA | 2 |
| Thomas, F | 1 |
| Barin-Le-Guellec, C | 1 |
| Royer, B | 2 |
| Picard, N | 1 |
| Becquemont, L | 1 |
| Verstuyft, C | 1 |
| Narjoz, C | 2 |
| Schmitt, A | 3 |
| Bobin-Dubigeon, C | 1 |
| Harle, A | 1 |
| Paci, A | 1 |
| Poinsignon, V | 1 |
| Evrard, A | 4 |
| Hennart, B | 1 |
| Broly, F | 1 |
| Fonrose, X | 1 |
| Lafay-Chebassier, C | 1 |
| Wozny, AS | 1 |
| Masskouri, F | 1 |
| Boyer, JC | 4 |
| Etienne-Grimaldi, MC | 1 |
| Depetris, I | 1 |
| Marino, D | 1 |
| Bonzano, A | 1 |
| Cagnazzo, C | 1 |
| Filippi, R | 1 |
| Aglietta, M | 1 |
| Leone, F | 1 |
| Saei, AA | 1 |
| Sabatier, P | 1 |
| Tokat, ÜG | 1 |
| Chernobrovkin, A | 1 |
| Pirmoradian, M | 1 |
| Zubarev, RA | 1 |
| Güçlü, H | 1 |
| Doganlar, ZB | 1 |
| Gürlü, VP | 1 |
| Özal, A | 1 |
| Dogan, A | 1 |
| Turhan, MA | 1 |
| Doganlar, O | 1 |
| Wang, H | 6 |
| Miao, W | 1 |
| Wang, F | 3 |
| Cheng, Y | 1 |
| Kanbayashi, Y | 1 |
| Ishikawa, T | 4 |
| Kanazawa, M | 1 |
| Nakajima, Y | 1 |
| Tabuchi, Y | 1 |
| Kawano, R | 1 |
| Yoshioka, T | 1 |
| Yoshida, N | 1 |
| Hosokawa, T | 1 |
| Takayama, K | 1 |
| Taguchi, T | 13 |
| Peng, J | 1 |
| Dong, C | 1 |
| Wang, C | 3 |
| Yu, H | 1 |
| Zhao, Q | 1 |
| Zhu, B | 1 |
| Wu, Q | 1 |
| Yuan, Y | 2 |
| Qiu, M | 2 |
| George, RP | 1 |
| Barker, TH | 1 |
| Lymn, KA | 1 |
| Bigatton, DA | 1 |
| Howarth, GS | 2 |
| Whittaker, AL | 1 |
| Duley, JA | 1 |
| Ni, M | 1 |
| Shannon, C | 1 |
| Norris, RL | 1 |
| Sheffield, L | 1 |
| Cowley, D | 1 |
| Harris, M | 1 |
| van Kuilenburg, ABP | 3 |
| Helsby, N | 1 |
| George, R | 1 |
| Charles, BG | 1 |
| You, Q | 1 |
| Aguilar, LE | 1 |
| Thomas, RG | 1 |
| Moon, MJ | 1 |
| Jeong, YY | 1 |
| Park, CH | 1 |
| Kim, CS | 1 |
| Li, B | 2 |
| Tang, J | 2 |
| Chen, W | 3 |
| Hao, G | 1 |
| Kurniawan, N | 1 |
| Gu, Z | 1 |
| Xu, ZP | 1 |
| Akune, Y | 1 |
| Yamada, M | 2 |
| Shigeyasu, C | 1 |
| Kawahira, M | 1 |
| Yokota, T | 1 |
| Hamauchi, S | 1 |
| Kawai, S | 1 |
| Onozawa, Y | 1 |
| Tsushima, T | 1 |
| Todaka, A | 1 |
| Machida, N | 1 |
| Yamazaki, K | 1 |
| Fukutomi, A | 1 |
| Yasui, H | 1 |
| Deng, B | 1 |
| Jia, L | 1 |
| Tan, H | 1 |
| Lou, Y | 1 |
| Lo Re, G | 2 |
| Lo Re, F | 1 |
| Doretto, P | 1 |
| Del Conte, A | 1 |
| Amadio, M | 1 |
| Cozzi, C | 1 |
| Casarotto, MM | 1 |
| Maruzzi, D | 1 |
| Marus, W | 1 |
| Ubiali, P | 1 |
| Sandri, P | 1 |
| Del Re, M | 2 |
| Danesi, R | 3 |
| Raymond, E | 4 |
| Spyridopoulou, K | 1 |
| Aindelis, G | 1 |
| Lampri, E | 1 |
| Giorgalli, M | 1 |
| Lamprianidou, E | 1 |
| Kotsianidis, I | 1 |
| Tsingotjidou, A | 1 |
| Pappa, A | 1 |
| Kalogirou, O | 1 |
| Chlichlia, K | 1 |
| Wei, Z | 1 |
| Zhang, P | 1 |
| Zhu, L | 1 |
| Chen, K | 1 |
| Lemaitre, F | 2 |
| Goirand, F | 2 |
| Chatelut, E | 3 |
| Paludetto, MN | 1 |
| Guilhaumou, R | 1 |
| Saidak, Z | 1 |
| Louandre, C | 1 |
| Dahmani, S | 1 |
| Sauzay, C | 1 |
| Guedda, S | 1 |
| Chauffert, B | 1 |
| Chatelain, D | 1 |
| Ceballos-Picot, I | 1 |
| Galmiche, A | 1 |
| Seker, M | 1 |
| Isen, HC | 1 |
| Çevirme, N | 1 |
| Aydın, S | 1 |
| Bilici, A | 1 |
| Bulut, H | 1 |
| Yasin, AI | 1 |
| Coban, E | 1 |
| Demir, T | 1 |
| Aliyev, A | 1 |
| Kocyigit, A | 1 |
| Turk, HM | 1 |
| Mao, GH | 1 |
| Zhang, ZH | 2 |
| Fei, F | 1 |
| Ding, YY | 1 |
| Zhang, WJ | 1 |
| Zhao, T | 2 |
| Feng, WW | 1 |
| Wu, XY | 1 |
| Yang, LQ | 1 |
| Frederix, GWJ | 2 |
| Kienhuis, E | 2 |
| Dezentjé, VO | 2 |
| Jeurissen, FJF | 2 |
| Jansen, RLH | 2 |
| Hamberg, P | 2 |
| Ten Tije, AJ | 2 |
| Koopman, M | 3 |
| van de Poel, MHW | 2 |
| Werkhoven, EV | 1 |
| van Schaik, RHN | 2 |
| Upshaw, JN | 1 |
| O'Neill, A | 1 |
| Carver, JR | 2 |
| Dimond, EP | 1 |
| Denlinger, CS | 3 |
| Kircher, SM | 1 |
| Wagner, LI | 1 |
| Ky, B | 1 |
| Brell, JM | 2 |
| Dreussi, E | 2 |
| Peters, FP | 1 |
| Fiocco, M | 1 |
| Huang, C | 3 |
| Matyunina, LV | 1 |
| McDonald, LD | 1 |
| Benigno, BB | 1 |
| Vannberg, F | 1 |
| Karaca, M | 1 |
| Tural, D | 1 |
| Akar, E | 1 |
| Çil, İ | 1 |
| Bayrak, S | 1 |
| Ozet, G | 1 |
| Yucel, OK | 1 |
| Hocaoglu, E | 1 |
| Ozet, A | 1 |
| Deyme, L | 1 |
| Barbolosi, D | 1 |
| Gattacceca, F | 1 |
| Tron, C | 1 |
| Bardou, M | 1 |
| Brutcher, E | 1 |
| Christensen, D | 1 |
| Hennessey Smith, M | 1 |
| Koutlas, JB | 1 |
| Sellers, JB | 1 |
| Timmons, T | 1 |
| Thompson, J | 2 |
| Milczarek, M | 1 |
| Mielczarek, L | 1 |
| Lubelska, K | 1 |
| Dąbrowska, A | 1 |
| Chilmonczyk, Z | 1 |
| Matosiuk, D | 1 |
| Wiktorska, K | 1 |
| Korver, SK | 1 |
| Gibson, RJ | 1 |
| Bowen, JM | 3 |
| Coller, JK | 2 |
| van Merendonk, LN | 1 |
| Sun, CH | 1 |
| Berg, K | 1 |
| Hirschberg, H | 1 |
| Shimamura, Y | 1 |
| Terada, H | 1 |
| Pin, F | 1 |
| Barreto, R | 1 |
| Couch, ME | 1 |
| Bonetto, A | 1 |
| O'Connell, TM | 1 |
| Mindt, S | 1 |
| Aida, S | 1 |
| Merx, K | 2 |
| Müller, A | 1 |
| Gutting, T | 1 |
| Hedtke, M | 1 |
| Neumaier, M | 1 |
| Ghosh, C | 1 |
| Nandi, A | 1 |
| Basu, S | 1 |
| Hoffman, RM | 2 |
| Stern, PH | 1 |
| Yang, Y | 3 |
| Shen, Y | 2 |
| Zhu, M | 5 |
| Robert, J | 3 |
| Clingan, PR | 1 |
| Ackland, SP | 2 |
| Brungs, D | 1 |
| de Souza, P | 1 |
| Aghmesheh, M | 1 |
| Garg, MB | 1 |
| Ranson, RD | 1 |
| Parker, S | 1 |
| Jokela, R | 1 |
| Ranson, M | 1 |
| Nejadshafiee, V | 1 |
| Naeimi, H | 1 |
| Goliaei, B | 1 |
| Bigdeli, B | 1 |
| Sadighi, A | 1 |
| Dehghani, S | 1 |
| Lotfabadi, A | 1 |
| Hosseini, M | 1 |
| Nezamtaheri, MS | 1 |
| Amanlou, M | 1 |
| Sharifzadeh, M | 1 |
| Khoobi, M | 1 |
| Zhu, Y | 2 |
| Hu, SW | 1 |
| Zhang, TT | 1 |
| Li, XL | 1 |
| Chen, HY | 1 |
| Xu, JJ | 1 |
| Yanagawa, T | 1 |
| Zou, C | 2 |
| Zhao, W | 1 |
| Cui, Y | 1 |
| E, F | 1 |
| Qiu, Z | 1 |
| Yin, J | 1 |
| Chen, X | 3 |
| Wang, CC | 1 |
| Zhao, Y | 1 |
| Sun, YZ | 1 |
| Rivera Vargas, T | 1 |
| Apetoh, L | 6 |
| Colomer, C | 1 |
| Margalef, P | 1 |
| Villanueva, A | 1 |
| Vert, A | 1 |
| Pecharroman, I | 1 |
| Solé, L | 1 |
| González-Farré, M | 1 |
| Alonso, J | 1 |
| Montagut, C | 2 |
| Martinez-Iniesta, M | 1 |
| Bertran, J | 1 |
| Borràs, E | 1 |
| Iglesias, M | 1 |
| Sabidó, E | 1 |
| Bigas, A | 1 |
| Boulton, SJ | 1 |
| Espinosa, L | 1 |
| Burns, KE | 1 |
| Allright, D | 1 |
| Porter, D | 1 |
| Findlay, MP | 2 |
| Helsby, NA | 1 |
| Ebadi, M | 1 |
| Buskaran, K | 1 |
| Saifullah, B | 1 |
| Fakurazi, S | 1 |
| Hussein, MZ | 1 |
| Ostapowicz, A | 1 |
| Dołegowska, B | 2 |
| Park, JS | 1 |
| Chang, DY | 1 |
| Kim, JH | 5 |
| Jung, JH | 1 |
| Park, J | 1 |
| Kim, SH | 3 |
| Lee, YD | 1 |
| Kim, SS | 1 |
| Suh-Kim, H | 1 |
| Wu, Z | 1 |
| Yang, H | 1 |
| Guo, S | 1 |
| Cheng, L | 1 |
| Ramishetti, S | 1 |
| Fu, Q | 1 |
| Racette, K | 1 |
| Matsui, T | 1 |
| Kinugasa, Y | 1 |
| Tahara, H | 1 |
| Kanakura, Y | 1 |
| Takakura, N | 1 |
| Gu, C | 3 |
| Qiao, J | 3 |
| Du, J | 3 |
| Shang, W | 3 |
| Yin, W | 3 |
| Wang, W | 5 |
| Han, M | 3 |
| Lu, W | 3 |
| Chen, C | 1 |
| Yee, LK | 1 |
| Gong, H | 1 |
| Xu, R | 1 |
| Ghiringhelli, F | 6 |
| Koch, S | 1 |
| Wein, A | 1 |
| Siebler, J | 1 |
| Boxberger, F | 1 |
| Neurath, MF | 1 |
| Harich, HD | 1 |
| Hohenberger, W | 1 |
| Dörje, F | 1 |
| Kelly, C | 1 |
| Bhuva, N | 1 |
| Harrison, M | 1 |
| Buckley, A | 1 |
| Saunders, M | 1 |
| Offer, SM | 4 |
| Lee, AM | 2 |
| Mattison, LK | 2 |
| Fossum, C | 1 |
| Wegner, NJ | 2 |
| Sharma, S | 4 |
| de Vries, EG | 3 |
| Infante, JR | 2 |
| Oldenhuis, CN | 1 |
| Gietema, JA | 1 |
| Yang, L | 2 |
| Bilic, S | 1 |
| Parker, K | 1 |
| Goldbrunner, M | 1 |
| Scott, JW | 1 |
| Burris, HA | 7 |
| van Kuilenburg, AB | 12 |
| Maring, JG | 4 |
| Ling, WH | 1 |
| Soe, PP | 1 |
| Pang, AS | 1 |
| Lee, SC | 1 |
| Loganayagam, A | 2 |
| Arenas Hernandez, M | 1 |
| Corrigan, A | 1 |
| Fairbanks, L | 2 |
| Lewis, CM | 1 |
| Harper, P | 2 |
| Maisey, N | 1 |
| Ross, P | 2 |
| Sanderson, JD | 3 |
| Marinaki, AM | 3 |
| Wason, JM | 1 |
| Seaman, SR | 1 |
| Elmeshad, AN | 1 |
| Mortazavi, SM | 1 |
| Mozafari, MR | 1 |
| Végran, F | 3 |
| Mary, R | 1 |
| Gibeaud, A | 1 |
| Mirjolet, C | 1 |
| Collin, B | 1 |
| Oudot, A | 1 |
| Charon-Barra, C | 1 |
| Arnould, L | 1 |
| Lizard-Nacol, S | 1 |
| Boidot, R | 1 |
| Li, TJ | 1 |
| Huang, CC | 1 |
| Ruan, PW | 1 |
| Chuang, KY | 1 |
| Huang, KJ | 1 |
| Shieh, DB | 1 |
| Yeh, CS | 1 |
| Bhatta, SS | 1 |
| Wroblewski, KE | 1 |
| Agarwal, KL | 1 |
| Sit, L | 1 |
| Cohen, EE | 1 |
| Seiwert, TY | 1 |
| Karrison, T | 1 |
| Bakris, GL | 1 |
| Ratain, MJ | 9 |
| Vokes, EE | 2 |
| Maitland, ML | 1 |
| Spanakis, M | 1 |
| Bouropoulos, N | 1 |
| Theodoropoulos, D | 1 |
| Sygellou, L | 1 |
| Ewart, S | 1 |
| Moschovi, AM | 1 |
| Siokou, A | 1 |
| Niopas, I | 1 |
| Kachrimanis, K | 1 |
| Nikolakis, V | 1 |
| Cox, PA | 1 |
| Vizirianakis, IS | 1 |
| Fatouros, DG | 1 |
| Prado, CM | 1 |
| Maia, YL | 1 |
| Ormsbee, M | 1 |
| Sawyer, MB | 1 |
| Baracos, VE | 1 |
| Ait-Tihyaty, M | 1 |
| Rachid, Z | 1 |
| Larroque-Lombard, AL | 1 |
| Jean-Claude, BJ | 1 |
| Magdy, T | 2 |
| Arlanov, R | 1 |
| Winter, S | 1 |
| Lang, T | 1 |
| Klein, K | 1 |
| Toyoda, Y | 1 |
| Zanger, UM | 3 |
| Zaanan, A | 1 |
| Dumont, LM | 1 |
| Taieb, J | 1 |
| Goetz, MP | 2 |
| McKean, HA | 1 |
| Reid, JM | 4 |
| Mandrekar, SJ | 1 |
| Tan, AD | 1 |
| Kuffel, MA | 1 |
| Safgren, SL | 1 |
| McGovern, RM | 1 |
| Goldberg, RM | 5 |
| Grothey, AA | 1 |
| McWilliams, R | 1 |
| Erlichman, C | 6 |
| Ames, MM | 3 |
| Burke, CW | 1 |
| Alexander, E | 1 |
| Timbie, K | 1 |
| Kilbanov, AL | 1 |
| Price, RJ | 1 |
| Mao, G | 1 |
| Zou, Y | 1 |
| Feng, W | 1 |
| Gu, X | 1 |
| Mao, R | 1 |
| Steingart, RM | 1 |
| Yadav, N | 1 |
| Manrique, C | 1 |
| Benvenuti, S | 1 |
| Gentile, A | 1 |
| Lazzari, L | 1 |
| Arnesano, A | 1 |
| Trusolino, L | 1 |
| Comoglio, PM | 1 |
| Fujii, C | 1 |
| Imamura, H | 1 |
| Fukunaga, M | 1 |
| Kamigaki, S | 1 |
| Kimura, Y | 1 |
| Kawase, T | 1 |
| Kawabata, R | 1 |
| Fujino, M | 1 |
| Iseki, C | 1 |
| Hamaguchi, Y | 1 |
| Yamamoto, E | 1 |
| Ishizaka, T | 1 |
| Hachino, Y | 1 |
| Butterfield, GL | 1 |
| Jerde, CR | 1 |
| Fossum, CC | 1 |
| Ortiz-Tudela, E | 1 |
| Iurisci, I | 1 |
| Beau, J | 1 |
| Karaboue, A | 1 |
| Moreau, T | 1 |
| Rol, MA | 1 |
| Madrid, JA | 1 |
| Lévi, F | 5 |
| Innominato, PF | 1 |
| Bhanot, A | 1 |
| Sharma, R | 1 |
| Singh, S | 2 |
| Noolvi, MN | 1 |
| Shi, WB | 1 |
| Le, VM | 1 |
| Gu, CH | 1 |
| Zheng, YH | 1 |
| Lang, MD | 1 |
| Lu, YH | 1 |
| Liu, JW | 1 |
| Balasubramanian, S | 1 |
| Girija, AR | 1 |
| Nagaoka, Y | 1 |
| Iwai, S | 1 |
| Suzuki, M | 3 |
| Kizhikkilot, V | 1 |
| Maekawa, T | 1 |
| Nair, SD | 1 |
| Tavano, L | 2 |
| Aiello, R | 1 |
| Ioele, G | 1 |
| Picci, N | 2 |
| Muzzalupo, R | 2 |
| Rangwala, F | 1 |
| Bendell, JC | 3 |
| Kozloff, MF | 2 |
| Arrowood, CC | 1 |
| Dellinger, A | 1 |
| Meadows, J | 1 |
| Tourt-Uhlig, S | 1 |
| Murphy, J | 1 |
| Meadows, KL | 3 |
| Starr, A | 2 |
| Broderick, S | 1 |
| Brady, JC | 1 |
| Cushman, SM | 1 |
| Morse, MA | 2 |
| Uronis, HE | 1 |
| Hsu, SD | 1 |
| Zafar, SY | 1 |
| Wallace, J | 1 |
| Starodub, AN | 1 |
| Strickler, JH | 1 |
| Pang, H | 1 |
| Nixon, AB | 2 |
| Hurwitz, HI | 4 |
| Wang, Z | 3 |
| Wu, B | 1 |
| Xu, M | 1 |
| Chang, H | 1 |
| Lu, X | 1 |
| Ren, X | 1 |
| McRee, AJ | 2 |
| Davies, JM | 1 |
| Sanoff, HG | 1 |
| Bernard, S | 1 |
| Dees, EC | 1 |
| Keller, K | 1 |
| Ivanova, A | 2 |
| O'Neil, BH | 2 |
| Bruchard, M | 2 |
| Cohen, SJ | 2 |
| Konski, AA | 1 |
| Putnam, S | 1 |
| Ball, DS | 1 |
| Meyer, JE | 1 |
| Yu, JQ | 1 |
| Astsaturov, I | 1 |
| Marlow, C | 1 |
| Dickens, A | 1 |
| Cade, DN | 1 |
| Meropol, NJ | 7 |
| Saqcena, M | 1 |
| Mukhopadhyay, S | 1 |
| Hosny, C | 1 |
| Alhamed, A | 1 |
| Chatterjee, A | 1 |
| Foster, DA | 1 |
| Jedrzychowska, A | 1 |
| Xie, N | 2 |
| Mou, L | 1 |
| Yuan, J | 1 |
| Deng, T | 1 |
| Jing, Y | 1 |
| Jin, Y | 1 |
| Hu, Z | 2 |
| Yu, B | 1 |
| Dai, C | 1 |
| Zhou, C | 1 |
| Radwan, AA | 1 |
| Alanazi, FK | 1 |
| Lin, Q | 1 |
| Cai, Y | 1 |
| Ma, L | 1 |
| Su, J | 1 |
| Latchman, J | 1 |
| Guastella, A | 1 |
| Tofthagen, C | 1 |
| Isakoff, SJ | 1 |
| Campone, M | 1 |
| Calles, A | 1 |
| Leip, E | 1 |
| Turnbull, K | 1 |
| Bardy-Bouxin, N | 1 |
| Duvillié, L | 1 |
| Calvo, E | 1 |
| Liu, XQ | 1 |
| Zhuang, M | 1 |
| Huber, RM | 1 |
| LoConte, NK | 2 |
| Razak, AR | 1 |
| Ivy, P | 2 |
| Tevaarwerk, A | 1 |
| Leverence, R | 1 |
| Kolesar, J | 2 |
| Siu, L | 1 |
| Lubner, SJ | 1 |
| Mulkerin, DL | 2 |
| Schelman, WR | 2 |
| Deming, DA | 1 |
| Holen, KD | 3 |
| Carmichael, L | 1 |
| Eickhoff, J | 2 |
| Liu, G | 2 |
| White, IA | 1 |
| Logan, RM | 1 |
| Tuke, J | 1 |
| Richards, AM | 1 |
| Mead, KR | 1 |
| Karapetis, CS | 1 |
| He, YS | 1 |
| Sun, W | 1 |
| Wang, CZ | 1 |
| Qi, LW | 1 |
| Li, P | 2 |
| Wen, XD | 1 |
| Yuan, CS | 1 |
| Turrini, E | 1 |
| Ferruzzi, L | 1 |
| Fimognari, C | 1 |
| Rushing, C | 1 |
| Honeycutt, W | 1 |
| Latta, K | 1 |
| Howard, L | 1 |
| Arrowood, CA | 1 |
| Niedzwiecki, D | 1 |
| Gao, HY | 1 |
| Baba, M | 1 |
| Okada, Y | 2 |
| Okuyama, T | 1 |
| Wu, LJ | 1 |
| Zhan, LB | 1 |
| Li, M | 1 |
| Sun, X | 1 |
| Gong, T | 1 |
| Zahrina, AK | 1 |
| Norsa'adah, B | 1 |
| Hassan, NB | 1 |
| Norazwany, Y | 1 |
| Norhayati, I | 1 |
| Roslan, MH | 1 |
| Wan Nazuha, WR | 1 |
| Wright, RC | 1 |
| Khakhar, A | 1 |
| Eshleman, JR | 1 |
| Ostermeier, M | 1 |
| Jin, S | 1 |
| Rao, W | 1 |
| Song, F | 1 |
| Yin, Q | 1 |
| Xi, Y | 1 |
| Ge, H | 1 |
| Ureña-Tavera, A | 1 |
| Zamora-Verduga, M | 1 |
| Madrigal-Burgaleta, R | 1 |
| Angel-Pereira, D | 1 |
| Berges-Gimeno, MP | 1 |
| Alvarez-Cuesta, E | 1 |
| Kim, JE | 1 |
| Hong, YS | 1 |
| Lee, JL | 1 |
| Kim, KP | 1 |
| Park, SJ | 1 |
| Sym, SJ | 1 |
| Shin, DB | 1 |
| Lee, J | 1 |
| Park, YS | 1 |
| Ahn, JS | 1 |
| Kim, TW | 1 |
| Skeff, MA | 1 |
| Brito, GA | 1 |
| de Oliveira, MG | 1 |
| Braga, CM | 1 |
| Cavalcante, MM | 1 |
| Baldim, V | 1 |
| Holanda-Afonso, RC | 1 |
| Silva-Boghossian, CM | 1 |
| Colombo, AP | 1 |
| Ribeiro, RA | 1 |
| Moura-Neto, V | 1 |
| Leitão, RF | 1 |
| IJpma, I | 1 |
| Renken, RJ | 1 |
| Ter Horst, GJ | 1 |
| Reyners, AK | 1 |
| She, X | 1 |
| Velleman, L | 1 |
| Zhu, H | 2 |
| Shigdar, S | 1 |
| Duan, W | 1 |
| Kong, L | 1 |
| Nies, AT | 1 |
| Sistonen, J | 1 |
| Seker, MM | 1 |
| Deveci, K | 1 |
| Seker, A | 1 |
| Sancakdar, E | 1 |
| Yilmaz, A | 1 |
| Turesin, AK | 1 |
| Kacan, T | 1 |
| Babacan, NA | 1 |
| Zheng, Y | 1 |
| Dou, Y | 1 |
| Duan, L | 1 |
| Cong, C | 1 |
| Gao, A | 1 |
| Lai, Q | 1 |
| Sun, Y | 3 |
| Conde, J | 1 |
| Oliva, N | 1 |
| Artzi, N | 1 |
| Maione, F | 1 |
| Oliaro-Bosso, S | 1 |
| Meda, C | 1 |
| Di Nicolantonio, F | 3 |
| Bussolino, F | 1 |
| Balliano, G | 1 |
| Viola, F | 1 |
| Giraudo, E | 1 |
| Verma, D | 1 |
| Khuroo, T | 1 |
| Talegaonkar, S | 1 |
| Iqbal, Z | 1 |
| Jin, H | 1 |
| Gui, R | 1 |
| Matsusaka, S | 1 |
| Lenz, HJ | 2 |
| Deng, P | 1 |
| Ji, C | 1 |
| Zhong, D | 1 |
| Ding, L | 1 |
| Sullivan, KD | 1 |
| Nakagawa, A | 1 |
| Xue, D | 1 |
| Espinosa, JM | 1 |
| Bartlett, JM | 1 |
| McConkey, CC | 1 |
| Munro, AF | 1 |
| Desmedt, C | 1 |
| Dunn, JA | 1 |
| Larsimont, DP | 1 |
| O'Malley, FP | 1 |
| Cameron, DA | 1 |
| Earl, HM | 1 |
| Poole, CJ | 1 |
| Shepherd, LE | 1 |
| Cardoso, F | 1 |
| Jensen, MB | 1 |
| Caldas, C | 1 |
| Twelves, CJ | 3 |
| Rea, DW | 1 |
| Ejlertsen, B | 1 |
| Di Leo, A | 2 |
| Pritchard, KI | 1 |
| Hou, ML | 1 |
| Tai, HC | 1 |
| Jing, F | 1 |
| Fu, X | 1 |
| Li, S | 2 |
| Zhao, J | 2 |
| Chen, B | 1 |
| Giodini, L | 1 |
| Buonadonna, A | 1 |
| Berretta, M | 2 |
| De Paoli, A | 1 |
| Scalone, S | 1 |
| Miolo, G | 1 |
| Mini, E | 1 |
| Nobili, S | 1 |
| Lonardi, S | 2 |
| Pella, N | 1 |
| Montico, M | 1 |
| Gagno, S | 1 |
| Chi, JY | 1 |
| Hsiao, YW | 1 |
| Li, CF | 1 |
| Lo, YC | 1 |
| Lin, ZY | 1 |
| Hong, JY | 1 |
| Han, X | 1 |
| Wang, SM | 1 |
| Chen, BK | 1 |
| Tsai, KK | 1 |
| Wang, JM | 1 |
| An, N | 1 |
| Zhou, Y | 1 |
| Luo, J | 1 |
| Su, W | 1 |
| Balboa-Beltrán, E | 1 |
| Cruz, R | 1 |
| Carracedo, A | 1 |
| Barros, F | 1 |
| Rossi, CO | 1 |
| Ranieri, GA | 1 |
| Piuhola, J | 1 |
| Tenhunen, O | 1 |
| Kerkelä, R | 1 |
| Kawashima, R | 1 |
| Fujimaki, M | 1 |
| Ikenoue, Y | 1 |
| Danjo, K | 1 |
| Koizumi, W | 2 |
| Ichikawa, T | 1 |
| Twitty, CG | 1 |
| Diago, OR | 1 |
| Hogan, DJ | 1 |
| Burrascano, C | 1 |
| Ibanez, CE | 1 |
| Jolly, DJ | 1 |
| Ostertag, D | 1 |
| Chang, BY | 1 |
| Kim, SB | 1 |
| Lee, MK | 1 |
| Park, H | 1 |
| Kim, SY | 1 |
| Deng, S | 1 |
| Ye, H | 1 |
| Guan, W | 1 |
| Wu, M | 1 |
| Zhu, S | 2 |
| Han, W | 2 |
| Sanoff, HK | 1 |
| Carlson, C | 1 |
| Bahleda, R | 1 |
| Baker, J | 1 |
| Massard, C | 1 |
| Gadgeel, SM | 1 |
| Izzedine, H | 1 |
| Deutsch, E | 1 |
| Garris, JL | 1 |
| Khan, A | 1 |
| Boelle, E | 1 |
| Assadourian, S | 4 |
| Soria, JC | 1 |
| Ajani, JA | 1 |
| Xie, B | 1 |
| Luo, Z | 1 |
| Lin, X | 2 |
| Liao, DJ | 1 |
| Abdel-Rahman, O | 1 |
| ElHalawani, H | 1 |
| Essam-Eldin, S | 1 |
| Sonke, GS | 1 |
| Jennings, BA | 1 |
| Kleibl, Z | 3 |
| Kleiblova, P | 3 |
| Tomlinson, I | 1 |
| Gross, E | 3 |
| Punt, CJ | 4 |
| Schellens, JH | 11 |
| Uboha, N | 1 |
| Hochster, HS | 1 |
| Sane, S | 1 |
| Abdullah, A | 1 |
| Nelson, ME | 1 |
| Chauhan, SC | 1 |
| Newton, SS | 1 |
| Rezvani, K | 1 |
| Cavalcante, GC | 1 |
| Freitas, Ndo S | 1 |
| Ribeiro-Dos-Santos, AM | 1 |
| De Carvalho, DC | 1 |
| Da Silva, EM | 1 |
| De Assumpção, PP | 1 |
| Ribeiro-Dos-Santos, Â | 1 |
| Santos, S | 1 |
| Dos Santos, NP | 1 |
| Park, MC | 1 |
| Jeong, H | 1 |
| Son, SH | 1 |
| Kim, Y | 1 |
| Han, D | 1 |
| Goughnour, PC | 1 |
| Kang, T | 1 |
| Kwon, NH | 1 |
| Moon, HE | 1 |
| Paek, SH | 1 |
| Hwang, D | 1 |
| Seol, HJ | 1 |
| Nam, DH | 1 |
| Kim, S | 5 |
| Namdar, A | 1 |
| Mirzaei, HR | 1 |
| Hafezi, M | 1 |
| Khosravianfar, N | 1 |
| Kheshtchin, N | 1 |
| Mirzaei, R | 1 |
| Hadjati, J | 1 |
| Rezaei, A | 1 |
| He, T | 1 |
| Hatem, E | 1 |
| Vernis, L | 1 |
| Huang, ME | 1 |
| Riley, P | 1 |
| Glenny, AM | 1 |
| Worthington, HV | 1 |
| Littlewood, A | 1 |
| Clarkson, JE | 1 |
| McCabe, MG | 1 |
| Ghasemi, AS | 1 |
| Mashhadban, F | 1 |
| Hoseini-Alfatemi, SM | 1 |
| Sharifi-Rad, J | 1 |
| Derissen, EJ | 1 |
| Jacobs, BA | 2 |
| Huitema, AD | 1 |
| Andrade, LN | 1 |
| Amaral, RG | 1 |
| Dória, GA | 1 |
| Fonseca, CS | 1 |
| da Silva, TK | 1 |
| Albuquerque Júnior, RL | 1 |
| Thomazzi, SM | 1 |
| do Nascimento, LG | 1 |
| Carvalho, AA | 1 |
| de Sousa, DP | 1 |
| Chandel, AK | 1 |
| Kumar, CU | 1 |
| Jewrajka, SK | 1 |
| Ji, X | 1 |
| Liu, Q | 2 |
| Said, R | 1 |
| Ye, Y | 1 |
| Hong, DS | 1 |
| Naing, A | 1 |
| Falchook, G | 1 |
| Fu, S | 1 |
| Wheler, JJ | 1 |
| Piha-Paul, S | 1 |
| Tsimberidou, AM | 1 |
| Kim, DY | 2 |
| Kwon, DY | 2 |
| Kwon, JS | 2 |
| Park, JH | 3 |
| Park, SH | 1 |
| Oh, HJ | 1 |
| Min, BH | 2 |
| Park, K | 1 |
| Kim, MS | 2 |
| Campbell, JM | 1 |
| Bateman, E | 1 |
| Peters, MDj | 1 |
| Keefe, DM | 1 |
| Stephenson, MD | 1 |
| Gao, D | 1 |
| Herman, JG | 1 |
| Guo, M | 1 |
| Kaplan, JA | 1 |
| Shieh, A | 1 |
| Sun, HL | 1 |
| Croce, CM | 1 |
| Grinstaff, MW | 1 |
| Parquette, JR | 1 |
| Taniguchi, K | 1 |
| Sakai, M | 1 |
| Sugito, N | 1 |
| Kuranaga, Y | 1 |
| Kumazaki, M | 1 |
| Shinohara, H | 1 |
| Ueda, H | 1 |
| Futamura, M | 1 |
| Yoshida, K | 1 |
| Uchiyama, K | 1 |
| Akao, Y | 1 |
| Camacho, KM | 1 |
| Menegatti, S | 1 |
| Vogus, DR | 1 |
| Pusuluri, A | 1 |
| Fuchs, Z | 1 |
| Jarvis, M | 1 |
| Zakrewsky, M | 1 |
| Evans, MA | 1 |
| Mitragotri, S | 1 |
| Li, Q | 2 |
| Nice, EC | 1 |
| Lei, Y | 1 |
| Lunenburg, CA | 1 |
| van Staveren, MC | 1 |
| Kang, J | 1 |
| Lee, DW | 1 |
| Hwang, HJ | 1 |
| Yeon, SE | 1 |
| Lee, MY | 1 |
| Kuh, HJ | 1 |
| Lee, JJ | 2 |
| Beumer, JH | 1 |
| Chu, E | 4 |
| Fang, L | 1 |
| Xin, W | 1 |
| Ding, H | 1 |
| Zhong, L | 1 |
| Luo, H | 1 |
| Huang, P | 1 |
| Cortejoso, L | 1 |
| García, MI | 1 |
| Sanjurjo, M | 1 |
| Myers, R | 1 |
| Coviello, C | 1 |
| Erbs, P | 1 |
| Foloppe, J | 1 |
| Rowe, C | 1 |
| Kwan, J | 1 |
| Crake, C | 1 |
| Finn, S | 1 |
| Jackson, E | 1 |
| Balloul, JM | 1 |
| Story, C | 1 |
| Coussios, C | 1 |
| Carlisle, R | 1 |
| Ison, G | 1 |
| Beaver, JA | 1 |
| McGuinn, WD | 1 |
| Palmby, TR | 1 |
| Dinin, J | 1 |
| Charlab, R | 1 |
| Marathe, A | 1 |
| Jin, R | 1 |
| Chen, XH | 1 |
| Ysern, X | 1 |
| Stephens, O | 1 |
| Bai, G | 1 |
| Dorff, SE | 1 |
| Cheng, J | 1 |
| Tang, S | 1 |
| Sridhara, R | 1 |
| Pierce, W | 1 |
| McKee, AE | 1 |
| Ibrahim, A | 1 |
| Kim, G | 1 |
| Pazdur, R | 8 |
| Fong, CW | 1 |
| Maehara, Y | 4 |
| Oki, E | 1 |
| Saeki, H | 1 |
| Tokunaga, E | 1 |
| Kitao, H | 1 |
| Iimori, M | 1 |
| Niimi, S | 1 |
| Kataoka, Y | 1 |
| Emi, Y | 1 |
| Kakeji, Y | 1 |
| Baba, H | 1 |
| Shirasaka, T | 9 |
| Lee, BN | 1 |
| Jung, S | 1 |
| Darvin, ME | 1 |
| Eucker, J | 1 |
| Kühnhardt, D | 1 |
| Sehouli, J | 1 |
| Chekerov, R | 1 |
| Patzelt, A | 1 |
| Fuss, H | 1 |
| Yu, RX | 1 |
| Lademann, J | 1 |
| Braiteh, F | 1 |
| Shepard, DR | 1 |
| Chaudhary, A | 1 |
| Lin, Y | 2 |
| Gao, L | 1 |
| Asakiewicz, C | 1 |
| Nasroulah, F | 1 |
| LoRusso, P | 2 |
| Dean, A | 1 |
| Byrne, A | 1 |
| Marinova, M | 1 |
| Hayden, I | 1 |
| Rozeman, L | 1 |
| Meijer, J | 2 |
| de Graaf, H | 1 |
| Lam, SW | 1 |
| Boven, E | 3 |
| Ma, WW | 1 |
| El-Rayes, BF | 1 |
| Fakih, MG | 2 |
| Cartwright, TH | 1 |
| Posey, JA | 1 |
| King, TR | 1 |
| von Borstel, RW | 1 |
| Bamat, MK | 1 |
| Robinson, SM | 1 |
| Mann, DA | 1 |
| Manas, DM | 1 |
| Oakley, F | 1 |
| Mann, J | 1 |
| White, SA | 1 |
| Lentschener, C | 1 |
| Nicco, C | 1 |
| Terris, B | 1 |
| Samama, CM | 1 |
| Coriat, R | 1 |
| Danenberg, PV | 5 |
| Gustavsson, B | 2 |
| Johnston, P | 2 |
| Lindberg, P | 1 |
| Moser, R | 1 |
| Odin, E | 1 |
| Peters, GJ | 17 |
| Petrelli, N | 1 |
| Turkeli, M | 1 |
| Aldemir, MN | 1 |
| Bingol, F | 1 |
| Dogan, C | 1 |
| Kara, A | 1 |
| Wodzinski, A | 1 |
| Madeddu, C | 1 |
| Deidda, M | 1 |
| Piras, A | 1 |
| Cadeddu, C | 1 |
| Demurtas, L | 1 |
| Puzzoni, M | 1 |
| Piscopo, G | 1 |
| Scartozzi, M | 1 |
| Mercuro, G | 1 |
| Spivakovsky, S | 1 |
| Xu, QB | 1 |
| Chen, XF | 1 |
| Feng, J | 1 |
| Miao, JF | 1 |
| Liu, FT | 1 |
| Niu, BX | 1 |
| Cai, JY | 1 |
| Ling, Y | 1 |
| Chon, J | 1 |
| Stover, PJ | 1 |
| Field, MS | 1 |
| Forough, M | 1 |
| Farhadi, K | 1 |
| Molaei, R | 1 |
| Khalili, H | 1 |
| Shakeri, R | 1 |
| Zamani, A | 1 |
| Matin, AA | 1 |
| Di Donato, C | 1 |
| Lavorgna, M | 1 |
| Fattorusso, R | 1 |
| Isernia, C | 1 |
| Isidori, M | 1 |
| Malgieri, G | 1 |
| Piscitelli, C | 1 |
| Russo, C | 1 |
| Russo, L | 1 |
| Iacovino, R | 1 |
| Maurer, D | 1 |
| Dobritzsch, D | 1 |
| Meinsma, R | 3 |
| Los, M | 1 |
| Knegt, LC | 1 |
| Zoetekouw, L | 5 |
| Jansen, RL | 1 |
| Dezentjé, V | 1 |
| van Huis-Tanja, LH | 1 |
| van Kampen, RJ | 1 |
| Hertz, JM | 1 |
| Hennekam, RC | 1 |
| Zhao, D | 1 |
| Tao, W | 1 |
| Wei, W | 2 |
| He, Z | 1 |
| Restante, G | 1 |
| Di Paolo, A | 2 |
| Crucitta, S | 1 |
| Rofi, E | 1 |
| Peng, M | 1 |
| Darko, KO | 1 |
| Tao, T | 1 |
| Huang, Y | 1 |
| Su, Q | 1 |
| Yin, T | 1 |
| Liu, Z | 1 |
| Shiiba, M | 1 |
| Yamagami, H | 1 |
| Yamamoto, A | 1 |
| Minakawa, Y | 1 |
| Okamoto, A | 1 |
| Kasamatsu, A | 1 |
| Sakamoto, Y | 1 |
| Uzawa, K | 1 |
| Takiguchi, Y | 1 |
| Tanzawa, H | 1 |
| Ke, S | 1 |
| Shi, L | 1 |
| Yang, Z | 2 |
| Xie, A | 1 |
| Lewden-Bernadac, B | 1 |
| Courant-Menanteau, M | 1 |
| Perrocheau, G | 1 |
| Barbarot, V | 1 |
| Thomare, P | 1 |
| Rotolo, S | 1 |
| Ceccarelli, S | 1 |
| Romano, F | 1 |
| Frati, L | 1 |
| Marchese, C | 1 |
| Angeloni, A | 1 |
| Lazar, A | 1 |
| Jetter, A | 2 |
| Lacouture, ME | 1 |
| Laabs, SM | 1 |
| Koehler, M | 2 |
| Sweetman, RW | 1 |
| Preston, AJ | 1 |
| Gomez, HL | 1 |
| Salazar, VM | 1 |
| Byrne, JA | 1 |
| Koch, KM | 4 |
| Blackwell, KL | 1 |
| Schalhorn, A | 2 |
| Terborg, C | 2 |
| Schmalenberg, H | 1 |
| Behnke, D | 2 |
| Schwabe, W | 2 |
| Jabschinsky, K | 2 |
| Hausler, P | 2 |
| Klumpen, HJ | 2 |
| Westermann, AM | 1 |
| Bakker, PJ | 1 |
| Richel, DJ | 4 |
| Jain, SK | 1 |
| Chaurasiya, A | 1 |
| Gupta, Y | 1 |
| Jain, A | 1 |
| Dagur, P | 1 |
| Joshi, B | 1 |
| Katoch, VM | 1 |
| Altinok, A | 1 |
| Clairambault, J | 1 |
| Goldbeter, A | 1 |
| Broder, H | 1 |
| Gottlieb, RA | 1 |
| Lepor, NE | 1 |
| Stebbing, J | 1 |
| Bunz, F | 2 |
| Pérez-Zúñiga, FJ | 1 |
| Günther Sillero, MA | 1 |
| Sillero, A | 1 |
| Sayar, H | 1 |
| Shen, Z | 1 |
| Lee, SJ | 1 |
| Royce, M | 2 |
| Rabinowitz, I | 1 |
| Lee, F | 1 |
| Smith, H | 1 |
| Eberhardt, S | 1 |
| Maestas, A | 1 |
| Lu, H | 2 |
| Verschraegen, C | 1 |
| Koukourakis, GV | 1 |
| Kouloulias, V | 1 |
| Koukourakis, MJ | 1 |
| Zacharias, GA | 1 |
| Zabatis, H | 1 |
| Kouvaris, J | 1 |
| Shen, X | 1 |
| Zhu, HF | 1 |
| He, FR | 1 |
| Xing, W | 1 |
| Pan, XF | 1 |
| Lei, P | 1 |
| Wang, ZH | 1 |
| Shen, GX | 1 |
| Ito, T | 1 |
| Tanabe, K | 1 |
| Yamada, H | 1 |
| Hatta, H | 1 |
| Nishimoto, S | 1 |
| Attia, S | 1 |
| Morgan-Meadows, S | 2 |
| Bailey, HH | 1 |
| Eickhoff, JC | 1 |
| Traynor, AM | 1 |
| Campbell, TC | 1 |
| McFarland, TA | 1 |
| Huie, MS | 1 |
| Cleary, JF | 1 |
| Tevaarwerk, AJ | 1 |
| Alberti, DB | 2 |
| Wilding, G | 5 |
| Midgley, R | 1 |
| Kerr, DJ | 3 |
| Farese, S | 2 |
| Singh, P | 2 |
| Gupta, U | 1 |
| Asthana, A | 1 |
| Jain, NK | 1 |
| Chaigneau, L | 1 |
| Montange, D | 1 |
| Nguyen, T | 1 |
| Maurina, T | 1 |
| Villanueva, C | 1 |
| Demarchi, M | 1 |
| Borg, C | 1 |
| Fagnoni-Legat, C | 1 |
| Kantelip, JP | 1 |
| Pivot, X | 2 |
| Bocci, G | 1 |
| Barbara, C | 1 |
| Masi, G | 2 |
| Fornaro, L | 1 |
| Loupakis, F | 2 |
| Allegrini, G | 1 |
| Falcone, A | 1 |
| Del Tacca, M | 1 |
| Kimura, T | 1 |
| Iwase, K | 1 |
| Aono, T | 1 |
| Nakai, S | 1 |
| Fujii, M | 1 |
| Nishikawa, K | 1 |
| Matsuda, C | 1 |
| Shimada, K | 1 |
| Hirota, M | 1 |
| Nasu, S | 1 |
| Wada, D | 1 |
| Hasegawa, J | 1 |
| Tanaka, Y | 1 |
| Zhang, Q | 1 |
| Huang, XE | 2 |
| Gao, LL | 1 |
| Fukui, Y | 1 |
| Oka, T | 4 |
| Nagayama, S | 2 |
| Danenberg, KD | 2 |
| Fukushima, M | 10 |
| Ota, K | 9 |
| Kurita, S | 1 |
| Nishimura, M | 2 |
| Ogawa, M | 3 |
| Kamei, Y | 1 |
| Imai, K | 1 |
| Ariyoshi, Y | 3 |
| Kataoka, K | 1 |
| Murakami, M | 2 |
| Oyama, A | 1 |
| Hoshino, A | 2 |
| Amo, H | 1 |
| Kato, T | 2 |
| Baki, M | 1 |
| Lam, ET | 1 |
| O'Bryant, CL | 3 |
| Basche, M | 4 |
| Gustafson, DL | 1 |
| Serkova, N | 1 |
| Baron, A | 1 |
| Holden, SN | 3 |
| Dancey, J | 1 |
| Eckhardt, SG | 6 |
| Gore, L | 5 |
| Saleem, A | 1 |
| Price, PM | 3 |
| Busse, B | 1 |
| Riemenschneider, M | 1 |
| Neubauer, S | 1 |
| Seck, K | 2 |
| Klein, HG | 1 |
| Kiechle, M | 2 |
| Lordick, F | 1 |
| Meindl, A | 2 |
| Mulkerin, D | 2 |
| Thomas, JP | 3 |
| Alberti, D | 3 |
| Marnocha, R | 1 |
| Oliver, K | 1 |
| Feierabend, C | 2 |
| Grimberg, H | 1 |
| Levin, G | 1 |
| Shirvan, A | 1 |
| Cohen, A | 1 |
| Yogev-Falach, M | 1 |
| Reshef, A | 1 |
| Ziv, I | 1 |
| Hilton, DJ | 1 |
| Kile, BT | 1 |
| Alexander, WS | 1 |
| Ticha, I | 1 |
| Fidlerova, J | 2 |
| Novotny, J | 2 |
| Pohlreich, P | 1 |
| Cheah, KY | 1 |
| Yazbeck, R | 1 |
| Wright, TH | 1 |
| Whitford, EJ | 1 |
| Payne, C | 1 |
| Butler, RN | 1 |
| Bastian, SE | 1 |
| Shah, MM | 1 |
| Shah, AR | 1 |
| Favaudon, V | 1 |
| Munster, P | 1 |
| Marchion, D | 1 |
| Bicaku, E | 1 |
| Lacevic, M | 1 |
| Kim, J | 1 |
| Centeno, B | 1 |
| Daud, A | 1 |
| Neuger, A | 1 |
| Minton, S | 1 |
| Sullivan, D | 1 |
| Shibata, SI | 1 |
| Doroshow, JH | 2 |
| Frankel, P | 1 |
| Synold, TW | 1 |
| Yen, Y | 1 |
| Gandara, DR | 2 |
| Chow, WA | 1 |
| Leong, LA | 2 |
| Lim, D | 1 |
| Margolin, KA | 2 |
| Morgan, RJ | 2 |
| Somlo, G | 2 |
| Newman, EM | 5 |
| Huq, A | 1 |
| Singh, B | 1 |
| Meeker, T | 1 |
| Mascarenhas, D | 1 |
| Kilickap, S | 1 |
| Arslan, C | 1 |
| Muggia, FM | 5 |
| Fujita, K | 4 |
| Nakayama, H | 1 |
| Ichikawa, W | 2 |
| Yamamoto, W | 2 |
| Endo, H | 2 |
| Nagashima, F | 3 |
| Tanaka, R | 2 |
| Miya, T | 2 |
| Sunakawa, Y | 4 |
| Yamashita, K | 3 |
| Mizuno, K | 2 |
| Ishida, H | 3 |
| Araki, K | 2 |
| Narabayashi, M | 2 |
| Miwa, K | 4 |
| Ando, Y | 2 |
| Akiyama, Y | 2 |
| Kawara, K | 2 |
| Hirose, T | 2 |
| Sasaki, Y | 4 |
| Kunz, C | 1 |
| Focke, F | 1 |
| Saito, Y | 2 |
| Schuermann, D | 1 |
| Lettieri, T | 1 |
| Selfridge, J | 1 |
| Schär, P | 1 |
| Blanchard, R | 1 |
| Bernaards, C | 1 |
| Litwin, S | 1 |
| Spittle, C | 1 |
| Berg, DJ | 1 |
| McLaughlin, S | 2 |
| Redlinger, M | 1 |
| Dorr, A | 1 |
| Hambleton, J | 1 |
| Holden, S | 1 |
| Kearns, A | 1 |
| Kenkare-Mitra, S | 1 |
| Lum, B | 1 |
| O'Dwyer, PJ | 7 |
| Landolph, JR | 1 |
| Kim, YI | 1 |
| McNeill, DR | 1 |
| Lam, W | 1 |
| DeWeese, TL | 1 |
| Cheng, YC | 1 |
| Wilson, DM | 1 |
| Lubin, M | 1 |
| Lubin, A | 1 |
| Valentini, V | 1 |
| Massaccesi, M | 1 |
| Balducci, M | 1 |
| Mantini, G | 1 |
| Micciché, F | 1 |
| Mattiucci, GC | 1 |
| Dinapoli, N | 1 |
| Meduri, B | 1 |
| D'Agostino, GR | 1 |
| Salvi, G | 1 |
| Nardone, L | 1 |
| Ichikawa, Y | 1 |
| Goto, A | 1 |
| Hirokawa, S | 1 |
| Kijima, M | 1 |
| Chishima, T | 1 |
| Suwa, H | 1 |
| Yamagishi, S | 1 |
| Osada, S | 1 |
| Ota, M | 1 |
| Fujii, S | 3 |
| King, I | 1 |
| Itterson, M | 1 |
| Bermudes, D | 1 |
| Yao, X | 1 |
| Yoshioka, Y | 1 |
| Morishige, T | 1 |
| Eto, Y | 1 |
| Watanabe, H | 1 |
| Mizuguchi, H | 1 |
| Mukai, Y | 1 |
| Okada, N | 2 |
| Nakagawa, S | 1 |
| Bilek, M | 1 |
| Kormunda, S | 1 |
| Formankova, Z | 1 |
| Panahi, Y | 1 |
| Ala, S | 1 |
| Saeedi, M | 1 |
| Okhovatian, A | 1 |
| Bazzaz, N | 1 |
| Naghizadeh, MM | 1 |
| Hansson, EK | 1 |
| Wallin, JE | 1 |
| Lindman, H | 1 |
| Sandström, M | 2 |
| Karlsson, MO | 1 |
| Friberg, LE | 1 |
| Skak, K | 1 |
| Søndergaard, H | 1 |
| Frederiksen, KS | 1 |
| Ehrnrooth, E | 2 |
| Dawood, S | 1 |
| Waller, EK | 1 |
| Barlett, N | 1 |
| Chen, CH | 1 |
| Mujic, V | 1 |
| Sussman, H | 1 |
| Toepker, S | 1 |
| Grenier, K | 1 |
| Huang, TY | 1 |
| Chu, HC | 1 |
| Lin, YL | 1 |
| Ho, WH | 1 |
| Hou, HS | 1 |
| Chao, YC | 1 |
| Liao, CL | 1 |
| Li, LS | 1 |
| Morales, JC | 1 |
| Veigl, M | 1 |
| Sedwick, D | 1 |
| Greer, S | 1 |
| Meyers, M | 1 |
| Wagner, M | 1 |
| Fishel, R | 1 |
| Boothman, DA | 1 |
| Halldén, G | 1 |
| Arenas-Hernandez, M | 1 |
| Ofverholm, A | 1 |
| Arkblad, E | 1 |
| Skrtic, S | 1 |
| Albertsson, P | 1 |
| Shubbar, E | 1 |
| Enerbäck, C | 1 |
| Chelis, L | 1 |
| Chiotis, A | 1 |
| Tentes, A | 2 |
| Chatzaki, E | 3 |
| Kortsaris, A | 1 |
| Polychronidis, A | 1 |
| Karakitsos, P | 1 |
| Booth, CM | 1 |
| Ohorodnyk, P | 1 |
| Eisenhauer, EA | 1 |
| Arts, J | 1 |
| King, P | 1 |
| Mariën, A | 1 |
| Floren, W | 1 |
| Beliën, A | 1 |
| Janssen, L | 1 |
| Pilatte, I | 1 |
| Roux, B | 1 |
| Decrane, L | 1 |
| Gilissen, R | 1 |
| Hickson, I | 1 |
| Vreys, V | 1 |
| Cox, E | 1 |
| Bol, K | 1 |
| Talloen, W | 1 |
| Goris, I | 1 |
| Andries, L | 1 |
| Du Jardin, M | 1 |
| Janicot, M | 1 |
| Page, M | 1 |
| van Emelen, K | 1 |
| Angibaud, P | 1 |
| Rathkopf, D | 2 |
| Dickson, MA | 2 |
| Feldman, DR | 1 |
| Carvajal, RD | 2 |
| Shah, MA | 3 |
| Wu, N | 2 |
| Lefkowitz, R | 1 |
| Gonen, M | 3 |
| Cane, LM | 2 |
| Dials, HJ | 2 |
| Winkelmann, JL | 1 |
| Bosl, GJ | 1 |
| Schwartz, GK | 4 |
| Abhyankar, V | 1 |
| Burgess, RE | 1 |
| Infante, J | 1 |
| Trowbridge, RC | 1 |
| Tarazi, J | 2 |
| Tortorici, M | 2 |
| Robles, RL | 1 |
| Arias, JL | 1 |
| López-Viota, M | 1 |
| Delgado, AV | 1 |
| Ruiz, MA | 1 |
| Langenberg, MH | 1 |
| Witteveen, PO | 1 |
| Roodhart, JM | 1 |
| Verheul, HM | 1 |
| Mergui-Roelvink, M | 1 |
| van der Sar, J | 1 |
| Brendel, E | 3 |
| Laferriere, N | 1 |
| Voest, EE | 1 |
| Seminara, P | 1 |
| Losanno, T | 1 |
| Emiliani, A | 1 |
| Manna, G | 1 |
| Cerić, T | 1 |
| Obralić, N | 1 |
| Kapur-Pojskić, L | 1 |
| Macić, D | 1 |
| Beslija, S | 1 |
| Pasić, A | 1 |
| Cerić, S | 1 |
| Dugan, E | 1 |
| Truax, R | 1 |
| Petros, WP | 2 |
| Favaro, J | 1 |
| Fernando, NH | 1 |
| Blobe, GC | 1 |
| Sellers, S | 1 |
| Douillard, JY | 1 |
| Wan, YW | 1 |
| Qian, Y | 1 |
| Rathnagiriswaran, S | 1 |
| Castranova, V | 1 |
| Guo, NL | 1 |
| Nishimura, K | 1 |
| Adachi, M | 1 |
| Konings, IR | 1 |
| Sleijfer, S | 1 |
| Mathijssen, RH | 2 |
| de Bruijn, P | 2 |
| Ghobadi Moghaddam-Helmantel, IM | 1 |
| van Dam, LM | 1 |
| Wiemer, EA | 1 |
| Verweij, J | 6 |
| Loos, WJ | 2 |
| Mikhail, SE | 1 |
| Sun, JF | 1 |
| Marshall, JL | 2 |
| Lee, SY | 2 |
| McLeod, HL | 8 |
| Jung, A | 1 |
| Jaitner, S | 1 |
| Schäffauer, AJ | 1 |
| Kirchner, T | 1 |
| Sweeney, CJ | 1 |
| Chiorean, EG | 1 |
| Verschraegen, CF | 1 |
| Lee, FC | 1 |
| Jones, S | 2 |
| Tye, L | 1 |
| Liau, KF | 1 |
| Bello, A | 1 |
| Chao, R | 1 |
| Disis, ML | 1 |
| Cannistra, SA | 1 |
| Perotti, A | 1 |
| Locatelli, A | 1 |
| Sessa, C | 2 |
| Hess, D | 2 |
| Viganò, L | 1 |
| Capri, G | 1 |
| Maur, M | 1 |
| Cerny, T | 2 |
| Cresta, S | 1 |
| Rojo, F | 1 |
| Albanell, J | 2 |
| Marsoni, S | 2 |
| Corradino, I | 1 |
| Berk, L | 1 |
| Rivera, VM | 1 |
| Haluska, F | 1 |
| Gianni, L | 1 |
| Goff, LW | 1 |
| Benson, AB | 1 |
| LoRusso, PM | 1 |
| Tan, AR | 1 |
| Berlin, JD | 2 |
| Denis, LJ | 1 |
| Benner, RJ | 1 |
| Yin, D | 1 |
| Rothenberg, ML | 1 |
| Sakamoto, K | 2 |
| Sakata, M | 1 |
| Nakagawa, F | 1 |
| Saito, H | 1 |
| Sakata, Y | 1 |
| Tse, A | 1 |
| Lefkowitz, RA | 1 |
| Escorcia, FE | 1 |
| Henke, E | 1 |
| McDevitt, MR | 1 |
| Villa, CH | 1 |
| Smith-Jones, P | 1 |
| Blasberg, RG | 1 |
| Benezra, R | 1 |
| Scheinberg, DA | 1 |
| Simon, N | 1 |
| Décaudin, B | 1 |
| Lannoy, D | 1 |
| Danicourt, F | 1 |
| Barthélémy, C | 1 |
| Odou, P | 1 |
| Wolf, SL | 1 |
| Qin, R | 1 |
| Menon, SP | 1 |
| Rowland, KM | 1 |
| Thomas, S | 1 |
| Delaune, R | 1 |
| Christian, D | 1 |
| Pajon, ER | 1 |
| Satele, DV | 1 |
| Berenberg, JL | 1 |
| Loprinzi, CL | 3 |
| Thomas, AM | 1 |
| Kapanen, AI | 1 |
| Hare, JI | 1 |
| Ramsay, E | 1 |
| Edwards, K | 1 |
| Karlsson, G | 1 |
| Bally, MB | 1 |
| Serdar, MA | 1 |
| Sertoğlu, E | 1 |
| Uyanık, M | 1 |
| Tapan, S | 1 |
| Akın, O | 1 |
| Cihan, M | 1 |
| Yan, PW | 1 |
| Jiang, Y | 1 |
| Xiang, J | 1 |
| Réti, A | 1 |
| Blaschke, M | 1 |
| Cameron, S | 1 |
| Emami, K | 1 |
| Blumberg, J | 1 |
| Wegner, U | 1 |
| Nischwitz, M | 1 |
| Ramadori, G | 1 |
| Gallerani, E | 1 |
| Bauer, J | 1 |
| Boehm, S | 1 |
| Droege, C | 1 |
| Jeckelmann, S | 1 |
| Miani, M | 1 |
| Herrmann, R | 6 |
| Sperka, S | 1 |
| Awada, A | 1 |
| Gil, T | 1 |
| Whenham, N | 1 |
| Van Hamme, J | 1 |
| Besse-Hammer, T | 1 |
| Delesen, H | 1 |
| Joosten, MC | 1 |
| Lathia, CD | 1 |
| Loembé, BA | 1 |
| Piccart-Ghebart, M | 1 |
| Hendlisz, A | 1 |
| Qian, X | 1 |
| Ding, Y | 1 |
| Liu, B | 1 |
| Rosen, LS | 1 |
| Saito, K | 1 |
| Zergebel, C | 1 |
| Ravage-Mass, L | 1 |
| Mendelson, DS | 1 |
| Moldenhauer, A | 1 |
| Futschik, M | 1 |
| Helmig, M | 1 |
| Götze, P | 1 |
| Bal, G | 1 |
| Zenke, M | 1 |
| Salama, A | 1 |
| Soltysova, A | 1 |
| Minarik, G | 1 |
| Dzurenkova, A | 1 |
| Sufliarska, S | 1 |
| Kadasi, L | 1 |
| Turna, J | 1 |
| Mladosievicova, B | 1 |
| Sarantopoulos, J | 1 |
| Patnaik, A | 1 |
| Tolcher, AW | 1 |
| Takimoto, C | 1 |
| Beeram, M | 1 |
| Cordier, PY | 1 |
| Nau, A | 1 |
| Oliver, M | 1 |
| Mercier, C | 3 |
| Peytel, E | 1 |
| Ladoire, S | 1 |
| Jones, SF | 1 |
| Greco, FA | 1 |
| Yardley, DA | 1 |
| Lane, CM | 1 |
| Spigel, DR | 1 |
| Hainsworth, JD | 1 |
| Bartal, A | 1 |
| Mátrai, Z | 1 |
| Szûcs, A | 1 |
| Liszkay, G | 1 |
| Green, E | 1 |
| White, R | 1 |
| Janes, K | 1 |
| Fields, A | 1 |
| Easty, A | 1 |
| Jeanneret, LA | 1 |
| Schneider, MP | 1 |
| Troxler, S | 1 |
| Bugnon, O | 1 |
| Lüthi, F | 1 |
| Rouquette, I | 1 |
| Mazieres, J | 1 |
| Sparidans, RW | 1 |
| Weterman, MJ | 1 |
| Wilmink, JW | 1 |
| Senanayake, TH | 1 |
| Warren, G | 1 |
| Vinogradov, SV | 1 |
| Pan, X | 1 |
| Shan, Y | 1 |
| Li, DW | 1 |
| Tian, FF | 1 |
| Ge, YS | 1 |
| Ding, XL | 1 |
| Li, JH | 1 |
| Xu, ZQ | 1 |
| Zhang, MF | 1 |
| Han, XL | 1 |
| Li, R | 1 |
| Jiang, FL | 1 |
| Katrancı, N | 1 |
| Ovayolu, N | 1 |
| Ovayolu, O | 1 |
| Sevinc, A | 2 |
| Rivera, E | 1 |
| Moulder-Thompson, SL | 1 |
| Eppers, S | 1 |
| Grolnic, S | 1 |
| O'Bryant, C | 1 |
| Cleere, D | 1 |
| Elsayed, YA | 1 |
| Chan, AK | 1 |
| Choo, BA | 1 |
| Glaholm, J | 1 |
| Cao, D | 3 |
| Ziemba, A | 1 |
| McCabe, J | 1 |
| Yan, R | 1 |
| Wan, L | 1 |
| Kim, B | 1 |
| Gach, M | 1 |
| Flynn, S | 1 |
| Pizzorno, G | 4 |
| Timmers, L | 1 |
| Beckeringh, JJ | 1 |
| van Herk-Sukel, MP | 1 |
| Hugtenburg, JG | 1 |
| Koca, D | 1 |
| Salman, T | 1 |
| Unek, IT | 1 |
| Oztop, I | 2 |
| Ellidokuz, H | 1 |
| Eren, M | 1 |
| Yilmaz, U | 2 |
| Mazard, T | 1 |
| Ychou, M | 2 |
| Thezenas, S | 1 |
| Poujol, S | 1 |
| Pinguet, F | 1 |
| Thirion, A | 1 |
| Bleuse, JP | 1 |
| Portales, F | 1 |
| Samalin, E | 1 |
| Assenat, E | 1 |
| Martin, F | 2 |
| Gao, Y | 1 |
| Ma, HM | 1 |
| Xu, HT | 1 |
| Zhang, XN | 1 |
| Pan, WS | 1 |
| Hendrayana, T | 1 |
| Kurth, V | 1 |
| Krolop, L | 1 |
| Kenny, P | 1 |
| Hilger, RA | 1 |
| Schmidt-Wolf, IG | 1 |
| Ko, YD | 1 |
| Jaehde, U | 1 |
| Shacham-Shmueli, E | 1 |
| Geva, R | 1 |
| Figer, A | 1 |
| Bulocinic, S | 1 |
| Nalbandyan, K | 1 |
| Shpigel, S | 1 |
| Atsmon, J | 1 |
| Larsen, ME | 1 |
| Farmer, A | 1 |
| Weaver, A | 1 |
| Young, A | 2 |
| Tarassenko, L | 1 |
| Yu, DC | 1 |
| Lee, JS | 2 |
| Yoo, JY | 1 |
| Shin, H | 1 |
| Deng, H | 1 |
| Yun, CO | 1 |
| Hassan, BA | 1 |
| Yusoff, ZB | 1 |
| Hassali, MA | 1 |
| Othman, SB | 1 |
| Tanck, MW | 1 |
| Proost, JH | 1 |
| Vahdat, LT | 1 |
| Thomas, ES | 1 |
| Roché, HH | 1 |
| Hortobagyi, GN | 1 |
| Sparano, JA | 2 |
| Yelle, L | 1 |
| Fornier, MN | 1 |
| Martín, M | 1 |
| Bunnell, CA | 1 |
| Mukhopadhyay, P | 1 |
| Peck, RA | 1 |
| Perez, EA | 2 |
| Jhaveri, KD | 1 |
| Flombaum, C | 1 |
| Shah, M | 2 |
| Latcha, S | 1 |
| Tomasi, G | 1 |
| Kimberley, S | 1 |
| Rosso, L | 1 |
| Aboagye, E | 1 |
| Turkheimer, F | 1 |
| Chuang, JC | 1 |
| Sheu, GT | 1 |
| Wang, PC | 1 |
| Liao, FT | 1 |
| Liu, WS | 1 |
| Huang, CF | 1 |
| Tseng, MH | 1 |
| Wu, MF | 1 |
| Stathopoulou, A | 1 |
| Roukos, V | 1 |
| Petropoulou, C | 1 |
| Kotsantis, P | 1 |
| Karantzelis, N | 1 |
| Nishitani, H | 1 |
| Lygerou, Z | 1 |
| Taraviras, S | 1 |
| Di Francia, R | 1 |
| Cimino, L | 1 |
| Cai, Z | 1 |
| Yu, F | 1 |
| Sun, B | 1 |
| Leong, S | 2 |
| Chan, E | 1 |
| Messersmith, WA | 1 |
| Spratlin, J | 1 |
| Camidge, DR | 2 |
| Diab, S | 1 |
| Khosravan, R | 1 |
| Chow Maneval, E | 1 |
| Lockhart, AC | 1 |
| Dutta, RK | 1 |
| Sahu, S | 1 |
| Saji, S | 3 |
| Kato, Y | 2 |
| Peng, W | 1 |
| Yin, XG | 1 |
| Xu, JF | 1 |
| Cheng, LZ | 1 |
| Shatz, M | 1 |
| Menendez, D | 1 |
| Resnick, MA | 1 |
| Li, G | 1 |
| Cui, F | 1 |
| Huang, Q | 1 |
| Khan, MA | 1 |
| Masood, N | 1 |
| Husain, N | 1 |
| Ahmad, B | 1 |
| Aziz, T | 1 |
| Naeem, A | 1 |
| Kim, MY | 1 |
| Kang, SY | 1 |
| Yang, MS | 1 |
| Kim, MH | 1 |
| Song, WJ | 1 |
| Kim, YJ | 1 |
| Lee, KW | 1 |
| Cho, SH | 1 |
| Min, KU | 1 |
| Chang, YS | 1 |
| Tang, B | 1 |
| Testa, JR | 1 |
| Kruger, WD | 1 |
| Ooi, CP | 1 |
| Manosroi, A | 1 |
| Jantrawut, P | 1 |
| Sainakham, M | 1 |
| Manosroi, W | 1 |
| Manosroi, J | 1 |
| Manta, S | 1 |
| Parmenopoulou, V | 1 |
| Kiritsis, C | 1 |
| Dimopoulou, A | 1 |
| Kollatos, N | 1 |
| Papasotiriou, I | 1 |
| Balzarini, J | 1 |
| Komiotis, D | 1 |
| Kulcsár, G | 1 |
| Gaál, D | 1 |
| Kulcsár, PI | 1 |
| Schulcz, Á | 1 |
| Czömpöly, T | 1 |
| Ishikawa, ET | 1 |
| Cancelas, JA | 1 |
| Van Cutsem, E | 2 |
| Khayat, D | 2 |
| Verslype, C | 2 |
| Billemont, B | 1 |
| Tejpar, S | 2 |
| Meric, JB | 1 |
| Soussan-Lazard, K | 2 |
| Cartot-Cotton, S | 1 |
| Rixe, O | 1 |
| Ribatti, D | 3 |
| Ranieri, G | 2 |
| Basile, A | 1 |
| Azzariti, A | 1 |
| Paradiso, A | 1 |
| Vacca, A | 2 |
| Martin, LP | 1 |
| Herbst, RS | 2 |
| Samuel, TA | 1 |
| Rosbrook, B | 1 |
| Olszanski, AJ | 1 |
| Rado, T | 1 |
| Cohen, RB | 2 |
| Macy, ME | 1 |
| Duncan, T | 1 |
| Whitlock, J | 1 |
| Hunger, SP | 1 |
| Boklan, J | 1 |
| Narendren, A | 1 |
| Herzog, C | 1 |
| Arceci, RJ | 1 |
| Bagatell, R | 1 |
| Trippett, T | 1 |
| Christians, U | 1 |
| Rolla, K | 1 |
| Ivy, SP | 2 |
| Covell, DG | 1 |
| Yuki, M | 1 |
| Sekine, S | 1 |
| Takase, K | 1 |
| Ishida, T | 1 |
| Sessink, PJ | 1 |
| Hirashima, Y | 1 |
| Shirao, K | 2 |
| Mandigers, CM | 1 |
| Terpstra, WE | 1 |
| Mignot, G | 1 |
| Derangère, V | 1 |
| Chalmin, F | 1 |
| Chevriaux, A | 1 |
| Boireau, W | 1 |
| Simon, B | 1 |
| Ryffel, B | 1 |
| Connat, JL | 1 |
| Kanellopoulos, J | 1 |
| Rébé, C | 1 |
| Yasuno, H | 1 |
| Kurasawa, M | 1 |
| Yanagisawa, M | 1 |
| Sato, Y | 1 |
| Harada, N | 1 |
| Mori, K | 5 |
| Diker-Cohen, T | 1 |
| Uziel, O | 1 |
| Szyper-Kravitz, M | 1 |
| Shapira, H | 1 |
| Natur, A | 1 |
| Lahav, M | 1 |
| Vermorken, JB | 1 |
| Rottey, S | 1 |
| Pelling, K | 1 |
| Lahogue, A | 1 |
| Wind, S | 1 |
| Machiels, JP | 1 |
| Shurin, MR | 1 |
| Realini, N | 1 |
| Solorzano, C | 1 |
| Pagliuca, C | 1 |
| Pizzirani, D | 1 |
| Armirotti, A | 1 |
| Luciani, R | 1 |
| Costi, MP | 1 |
| Bandiera, T | 1 |
| Piomelli, D | 1 |
| Spano, JP | 1 |
| Bloch, J | 1 |
| Vandecaveye, V | 1 |
| Cartot-Coton, S | 1 |
| Ang, J | 1 |
| Hu, L | 2 |
| Huang, PT | 1 |
| Wu, JX | 1 |
| Huang, LN | 1 |
| Cao, CH | 1 |
| Zheng, YX | 1 |
| Seo, HW | 1 |
| Jin, LM | 1 |
| Lee, B | 1 |
| Nakahata, AM | 1 |
| Mayer, B | 1 |
| Neth, P | 1 |
| Hansen, D | 1 |
| Sampaio, MU | 1 |
| Oliva, ML | 1 |
| Basu Baul, TS | 1 |
| Dutta, D | 1 |
| de Vos, D | 1 |
| Höpfl, H | 1 |
| Gupta, A | 1 |
| Nuber, N | 1 |
| Esslinger, C | 1 |
| Wittenbrink, M | 1 |
| Treder, M | 1 |
| Landshammer, A | 1 |
| Noguchi, T | 1 |
| Kelly, M | 1 |
| Gnjatic, S | 1 |
| Ritter, E | 1 |
| von Boehmer, L | 1 |
| Nishikawa, H | 1 |
| Shiku, H | 1 |
| Old, L | 1 |
| Ritter, G | 1 |
| Knuth, A | 1 |
| van den Broek, M | 1 |
| Weng, L | 1 |
| Peng, Y | 1 |
| Huang, RS | 1 |
| Zhuang, ZX | 1 |
| Zhu, MG | 1 |
| Pu, WY | 1 |
| Bian, HH | 1 |
| Gardiner, SJ | 1 |
| Begg, EJ | 1 |
| Robinson, BA | 1 |
| Sugimura, T | 1 |
| Tsukuda, M | 2 |
| Malet-Martino, M | 3 |
| Martino, R | 4 |
| Sbar, EI | 1 |
| Khatri, J | 1 |
| Rodman, WD | 1 |
| Tritschler, L | 1 |
| Goldberg, J | 1 |
| Grana, G | 1 |
| Devereux, L | 1 |
| Hageboutros, A | 3 |
| Van Gennip, AH | 4 |
| Kaufmann, SH | 1 |
| Atherton, P | 3 |
| Sloan, JA | 3 |
| Adjei, AA | 4 |
| Pitot, HC | 2 |
| Alberts, SR | 2 |
| Rubin, J | 3 |
| Miller, LL | 1 |
| Bailey, H | 2 |
| Binger, K | 1 |
| Volkman, J | 1 |
| Marrocha, R | 1 |
| Arzoomanian, RZ | 2 |
| Berrada, M | 1 |
| Lehnert, S | 1 |
| Blanquicett, C | 2 |
| Gillespie, GY | 1 |
| Nabors, LB | 1 |
| Miller, CR | 1 |
| Bharara, S | 1 |
| Buchsbaum, DJ | 1 |
| Johnson, MR | 3 |
| Michaelson, MD | 1 |
| Ryan, DP | 3 |
| Fuchs, CS | 1 |
| Supko, JG | 2 |
| Garcia-Carbonero, R | 2 |
| Paul Eder, J | 1 |
| O'Donnell, A | 1 |
| Judson, I | 1 |
| Van Maanen, L | 1 |
| Suttle, AB | 1 |
| Ertel, P | 1 |
| Beale, P | 2 |
| Schneider, T | 1 |
| Osl, F | 1 |
| Friess, T | 1 |
| Stockinger, H | 1 |
| Scheuer, WV | 1 |
| Nakamura, T | 4 |
| Fujimori, M | 1 |
| Yazawa, K | 1 |
| Kano, Y | 1 |
| Amano, J | 1 |
| Taniguchi, S | 1 |
| Lawrence, TS | 4 |
| Blackstock, AW | 2 |
| McGinn, C | 1 |
| Feng, FY | 1 |
| Han, J | 1 |
| Sui, GJ | 1 |
| Zhu, YG | 1 |
| Wang, PH | 1 |
| Zhou, MZ | 1 |
| Zhang, YC | 1 |
| Wenzel, C | 1 |
| Mader, RM | 2 |
| Steger, GG | 1 |
| Pluschnig, U | 1 |
| Kornek, GV | 1 |
| Scheithauer, W | 1 |
| Locker, GJ | 1 |
| Masci, G | 3 |
| Magagnoli, M | 3 |
| Zucali, PA | 1 |
| Castagna, L | 3 |
| Carnaghi, C | 2 |
| Sarina, B | 1 |
| Pedicini, V | 1 |
| Fallini, M | 1 |
| Santoro, A | 3 |
| Conroy, T | 1 |
| Seitz, JF | 3 |
| Gourgou, S | 1 |
| Hua, A | 1 |
| Mery-Mignard, D | 1 |
| Kramar, A | 1 |
| Watters, JW | 1 |
| Desmoulin, F | 1 |
| Gilard, V | 1 |
| Molina, C | 1 |
| Smith, P | 1 |
| Jolimaitre, P | 1 |
| Berg, RW | 1 |
| Ferguson, PJ | 1 |
| Vincent, MD | 1 |
| Koropatnick, DJ | 1 |
| Clarke, SJ | 2 |
| Guo, XD | 2 |
| Harold, N | 4 |
| Schuler, B | 3 |
| Szabo, E | 2 |
| Hamilton, JM | 3 |
| Monahan, BP | 3 |
| Quinn, MG | 3 |
| Cliatt, J | 1 |
| Nguyen, D | 2 |
| Grollman, F | 2 |
| Thomas, RR | 1 |
| McQuigan, EA | 1 |
| Wilson, R | 1 |
| Takimoto, CH | 2 |
| Grem, JL | 10 |
| Nemunaitis, J | 5 |
| Cunningham, C | 4 |
| Tong, A | 1 |
| Post, L | 1 |
| Netto, G | 1 |
| Paulson, AS | 1 |
| Rich, D | 1 |
| Blackburn, A | 1 |
| Sands, B | 1 |
| Gibson, B | 1 |
| Randlev, B | 1 |
| Freeman, S | 1 |
| Noordhuis, P | 3 |
| Schornagel, JH | 4 |
| Gall, H | 1 |
| Turner, SL | 1 |
| Swart, MS | 1 |
| Voorn, D | 2 |
| Wanders, J | 1 |
| Holwerda, U | 3 |
| Smid, K | 3 |
| Giaccone, G | 3 |
| Fumoleau, P | 3 |
| Van Groeningen, CJ | 8 |
| McSheehy, PM | 1 |
| Troy, H | 1 |
| Kelland, LR | 1 |
| Judson, IR | 2 |
| Leach, MO | 3 |
| Griffiths, JR | 1 |
| Cianci, G | 1 |
| Morelli, MF | 1 |
| Cannita, K | 1 |
| Morese, R | 1 |
| Ricevuto, E | 1 |
| Di Rocco, ZC | 1 |
| Porzio, G | 1 |
| Lanfiuti Baldi, P | 1 |
| Ficorella, C | 1 |
| El Amrani, M | 1 |
| Aidi, S | 1 |
| Amarenco, P | 1 |
| Boni, J | 1 |
| Bruntsch, U | 1 |
| Peters, M | 1 |
| Thielert, C | 1 |
| Barthel, H | 1 |
| Cleij, MC | 1 |
| Collingridge, DR | 1 |
| Hutchinson, OC | 1 |
| Osman, S | 2 |
| He, Q | 1 |
| Luthra, SK | 1 |
| Brady, F | 2 |
| Aboagye, EO | 1 |
| Kubota, T | 5 |
| Omura, K | 1 |
| Fleming, GF | 2 |
| Schilsky, RL | 9 |
| Schumm, LP | 1 |
| Meyerson, A | 1 |
| Hong, AM | 1 |
| Correale, P | 1 |
| Cerretani, D | 1 |
| Marsili, S | 1 |
| Pozzessere, D | 1 |
| Petrioli, R | 1 |
| Messinese, S | 1 |
| Sabatino, M | 1 |
| Roviello, F | 1 |
| Pinto, E | 1 |
| Francini, G | 1 |
| Giorgi, G | 1 |
| Thurm, H | 1 |
| Ebel, S | 1 |
| Kentenich, C | 1 |
| Hemsen, A | 1 |
| Riethdorf, S | 1 |
| Coith, C | 1 |
| Wallwiener, D | 1 |
| Braun, S | 1 |
| Oberhoff, C | 1 |
| Jänicke, F | 1 |
| Pantel, K | 1 |
| Lin, Hs | 1 |
| D'Rosario, T | 1 |
| Blesch, KS | 1 |
| Gieschke, R | 1 |
| Tsukamoto, Y | 2 |
| Reigner, BG | 1 |
| Burger, HU | 2 |
| Steimer, JL | 1 |
| Van Rijnsoever, M | 1 |
| Elsaleh, H | 1 |
| Joseph, D | 1 |
| McCaul, K | 1 |
| Iacopetta, B | 1 |
| Tsuji, E | 1 |
| Hiki, N | 1 |
| Nomura, S | 1 |
| Fukushima, R | 1 |
| Kojima, J | 1 |
| Ogawa, T | 1 |
| Mafune, K | 1 |
| Mimura, Y | 1 |
| Kaminishi, M | 1 |
| Windebank, AJ | 1 |
| Pitot, H | 1 |
| Galanis, E | 1 |
| CHAUDHURI, NK | 1 |
| MONTAG, BJ | 1 |
| HEIDELBERGER, C | 9 |
| CURRERI, AR | 3 |
| ANSFIELD, FJ | 16 |
| McIVER, FA | 1 |
| WAISMAN, HA | 1 |
| SKOLD, O | 2 |
| LINDNER, A | 1 |
| REICHARD, P | 2 |
| KLEIN, G | 1 |
| CORNELL, GN | 1 |
| CAHOW, CE | 1 |
| FREY, C | 1 |
| McSHERRY, C | 1 |
| BEAL, JM | 1 |
| FOYE, LV | 2 |
| WILLETT, FM | 2 |
| HALL, B | 2 |
| ROTH, M | 2 |
| FRANK, W | 3 |
| BRENNAN, JT | 2 |
| LOPRESTI, JM | 1 |
| GOLDE, A | 1 |
| VIGIER, P | 1 |
| GRIFFING, J | 1 |
| SAYLER, C | 1 |
| VANN, P | 1 |
| SENSENBRENNER, L | 1 |
| HALL, BE | 3 |
| GOOD, JW | 3 |
| WEISS, AJ | 2 |
| JACKSON, L | 1 |
| BRENNAN, MJ | 1 |
| VAITKEVICIUS, VK | 3 |
| SULLIVAN, RD | 4 |
| YOUNG, CW | 8 |
| MILLER, E | 4 |
| GLATSTEIN, N | 1 |
| CLARKSON, B | 2 |
| BURCHENAL, JH | 2 |
| ELLISON, RR | 1 |
| LEVICK, SN | 1 |
| KAUFMAN, R | 1 |
| WOLDOW, I | 1 |
| ESCHER, G | 1 |
| LI, MC | 1 |
| KARNOFSKY, DA | 2 |
| ALLAIRE, FJ | 1 |
| THIEME, ET | 1 |
| KORST, DR | 1 |
| BAINES, CJ | 1 |
| LEY, DC | 1 |
| CANTAROW, A | 1 |
| RUPP, JJ | 1 |
| CREWS, QE | 1 |
| EYERLY, RC | 1 |
| NEWCOMER, KL | 2 |
| CIRKSENA, WJ | 2 |
| BAUER, AJ | 1 |
| BLOM, J | 2 |
| HAGGMARK, A | 1 |
| SCHNEIDERMAN, MA | 1 |
| TARR, N | 1 |
| LANE, M | 4 |
| LEUBNER, H | 1 |
| LYTTON, B | 2 |
| MARK, JB | 2 |
| HARVARD, BM | 2 |
| BENSON, JW | 2 |
| KIEHN, CL | 2 |
| HOLDEN, WD | 1 |
| BIRNIE, GD | 1 |
| REEVE, TS | 1 |
| SCANLON, EF | 2 |
| NORA, PF | 1 |
| TARKINGTON, JA | 1 |
| MEYER, NI | 1 |
| WATNE, AL | 4 |
| MOORE, GE | 7 |
| NADLER, S | 2 |
| ROSS, CA | 1 |
| JACKSON, LG | 1 |
| CARABASI, R | 1 |
| WHITE, JE | 1 |
| RICKETTS, WN | 1 |
| STRUDWICK, WJ | 1 |
| WINSTON, JH | 1 |
| MATHIS, PL | 1 |
| EDWARDS, MD | 1 |
| CHOY, DS | 1 |
| STYLIANOU, S | 1 |
| HANGUL, AO | 1 |
| CRANSTON, EM | 1 |
| DEMAREE, EW | 1 |
| SHARP, GS | 1 |
| LEMON, HM | 3 |
| MODZEN, PJ | 1 |
| MIRCHANDANI, R | 1 |
| FARMER, DA | 1 |
| ATHANS, J | 1 |
| LEONE, LA | 1 |
| KNOCK, FE | 6 |
| LATOURETTE, HB | 1 |
| LAWTON, RL | 4 |
| BASHORE, RA | 1 |
| LAGASSE, LD | 1 |
| NADLER, SH | 3 |
| SKOELD, O | 1 |
| WELCH, AD | 1 |
| GROESBECK, HP | 2 |
| CUDMORE, JT | 2 |
| MRAZEK, RG | 2 |
| KASBEKAR, DK | 1 |
| GREENBERG, DM | 1 |
| BRINDLEY, CO | 1 |
| HODNETT, EM | 1 |
| VELASCO, RN | 1 |
| ESTEVEZ, RA | 1 |
| LANGDON, EA | 2 |
| OTTOMAN, RE | 2 |
| ROCHLIN, DB | 5 |
| SMART, CR | 5 |
| VONESSEN, CF | 1 |
| KLIGERMAN, MM | 1 |
| CALABRESI, P | 4 |
| FIELD, JB | 1 |
| GOLDENBERG, DM | 1 |
| RAVINA, A | 1 |
| WATKINS, E | 1 |
| JESSE, RH | 2 |
| VILLARREAL, R | 1 |
| LETAYF, V | 1 |
| RUFINO, C | 1 |
| HICKEY, RC | 1 |
| GOLOMB, FM | 3 |
| SAMMONS, BP | 1 |
| WRIGHT, JC | 2 |
| MALKASIAN, GD | 1 |
| DECKER, DG | 1 |
| MUSSEY, E | 1 |
| JOHNSON, CE | 1 |
| STREHL, FW | 1 |
| SOUTHWICK, HW | 1 |
| REITEMEIER, RJ | 5 |
| MOERTEL, CG | 7 |
| BLACKBURN, CM | 1 |
| ROSSMAN, RE | 1 |
| KNOX, JM | 1 |
| FREEMAN, RG | 1 |
| DALMAUCIRIA, M | 1 |
| ARONOVITCH, M | 2 |
| GROSZMAN, M | 2 |
| KAHANA, LM | 1 |
| KOOP, CE | 1 |
| STROUD, AN | 1 |
| MCDONALD, GO | 1 |
| SVOBODA, BR | 1 |
| BRUES, AM | 1 |
| MARSHALL, SF | 1 |
| KREMENTZ, ET | 1 |
| KOKAME, GM | 1 |
| IGLESIAS, F | 1 |
| DELMON, G | 1 |
| MOORE, JG | 1 |
| VANCAMPENHOUT, JL | 1 |
| BRANDKAMP, WW | 1 |
| SCHELL, HW | 3 |
| EISMAN, SG | 1 |
| RICHARDSON, FM | 1 |
| BROCKMAN, RW | 1 |
| ANDERSON, EP | 1 |
| GOLDIN, A | 3 |
| GLYNN, JP | 1 |
| MOLONEY, JB | 1 |
| HUMPHREYS, SR | 1 |
| CHIRIGOS, MA | 1 |
| FINKEL, AJ | 1 |
| CZAJKA, DM | 1 |
| KATZ, JJ | 1 |
| COBB, JP | 1 |
| WALKER, DG | 2 |
| KABAKOW, B | 1 |
| ALBAUM, H | 1 |
| ANTOPOL, W | 1 |
| BLINICK, G | 1 |
| SUSSMAN, L | 1 |
| GINZBURG, L | 1 |
| HURLEY, JD | 1 |
| HOWE, CD | 1 |
| FLETCHER, GH | 1 |
| SAMUELS, ML | 1 |
| SUIT, HD | 1 |
| AUSMAN, RK | 4 |
| AUST, JB | 2 |
| CHAN, DP | 1 |
| HO, JH | 1 |
| WOO, AW | 1 |
| DOWD, JE | 1 |
| DIPAOLO, JA | 1 |
| FALKSON, G | 6 |
| SNYMAN, HJ | 1 |
| DEJAGER, ME | 1 |
| GOLLIN, FF | 3 |
| VERMUND, H | 3 |
| HART, GD | 1 |
| GOLDGRABER, MB | 1 |
| KIRSNER, JB | 1 |
| BOUCHARD, J | 1 |
| MEAKINSS, JF | 1 |
| HAZEL, J | 1 |
| JALIL, A | 1 |
| MYHRE, K | 1 |
| FJAERLI, J | 1 |
| CENTARO, A | 1 |
| GASPARRI, F | 1 |
| MAIJNELLI, M | 2 |
| PERITI, P | 2 |
| BADER, JP | 1 |
| JOHNSON, RO | 4 |
| CASTRO, R | 1 |
| HENDERSON, IW | 1 |
| HARROLD, MW | 1 |
| EDWARDS, CN | 1 |
| GRAVEY, FK | 1 |
| DONALDSON, SS | 1 |
| FLETCHER, WS | 2 |
| SCHULZ, EJ | 1 |
| GASTPAR, H | 1 |
| SCHREINER, L | 1 |
| RUTMAN, RJ | 1 |
| KINSEY, DL | 1 |
| SCHULTZ, PE | 1 |
| LYONS, MM | 1 |
| GUMPORT, SL | 1 |
| MEDREK, TJ | 1 |
| GREENSPAN, EM | 1 |
| DESPREZ, JD | 2 |
| DAMM, H | 1 |
| BOLTON, CF | 1 |
| SHORTER, RG | 1 |
| HELSPER, JT | 1 |
| DEMOSS, EV | 1 |
| RIEHL, JL | 1 |
| BROWN, WJ | 1 |
| CAMMACK, KV | 1 |
| SPIERS, AS | 2 |
| NEWELL, FW | 1 |
| HOLSTI, LR | 1 |
| SAKURAI, Y | 3 |
| CHILDS, DS | 2 |
| COLBY, MY | 2 |
| HOLBROOK, MA | 2 |
| LINDEBOOM, GA | 1 |
| MARTIN, DS | 14 |
| WHITE, HM | 1 |
| HOBBS, J | 1 |
| KURZWEG, FT | 1 |
| HUDSON, PJ | 1 |
| HAKIM, P | 1 |
| GRADY, ED | 2 |
| SILVA, A | 1 |
| PACE, WG | 1 |
| KNOERNSCHILD, H | 1 |
| CRESSY, NL | 2 |
| HULKA, JF | 1 |
| BISEL, HF | 1 |
| ESQUIVEL, EL | 1 |
| MACKENZIE, AR | 1 |
| WHITMORE, WF | 1 |
| SCHROEDER, JM | 1 |
| KISKEN, WA | 3 |
| MCALISTER, WH | 1 |
| MENGEL, CE | 1 |
| BAKER, RR | 1 |
| GAERTNER, RA | 1 |
| LAGARDE, C | 1 |
| HUGUES, A | 1 |
| CHAUVERGNE, J | 1 |
| LACHAPELE, AP | 1 |
| FLOCH, MH | 1 |
| HELLMAN, L | 1 |
| CAVANAGH, D | 2 |
| FERGUSON, JH | 1 |
| KLEIN, E | 3 |
| STOLL, HL | 2 |
| MILGROM, H | 2 |
| CASE, RW | 1 |
| TRAENKLE, HL | 2 |
| GRAHAM, S | 2 |
| LAOR, Y | 1 |
| HELM, F | 2 |
| BRULE, G | 2 |
| SCHLUMBERGER, JR | 2 |
| GRISCELLI, C | 2 |
| MORSE, PA | 1 |
| POTTER, VR | 1 |
| WILSON, WL | 2 |
| DELAGARZA, JG | 1 |
| BLOKHINA, NG | 4 |
| BYCHKOV, MB | 1 |
| STARICHKOV, MS | 1 |
| RAPP, F | 1 |
| BUTEL, JS | 1 |
| FELDMAN, LA | 1 |
| KITAHARA, T | 1 |
| MELNICK, JL | 1 |
| HERNANDEZ-ROMAN, P | 1 |
| SUHRLAND, LG | 1 |
| WEISBERGER, AS | 1 |
| SILVA, AR | 1 |
| LAMY, P | 1 |
| ANTHOINE, D | 1 |
| DUC, M | 1 |
| VAILLANT, G | 1 |
| CERVONI, P | 1 |
| OLSON, KB | 3 |
| GREENE, JR | 1 |
| JACQUEZ, JA | 1 |
| KENNEDY, BJ | 1 |
| THEOLOGIDES, A | 1 |
| RIEBELING, M | 1 |
| SHINER, J | 1 |
| LANGDON, E | 1 |
| OTTOMAN, R | 1 |
| Senzer, N | 2 |
| Kuhn, J | 1 |
| Cramm, J | 1 |
| Litz, C | 1 |
| Cavagnolo, R | 1 |
| Cahill, A | 1 |
| Clairmont, C | 1 |
| Sznol, M | 1 |
| Lee, S | 1 |
| Lee, YS | 1 |
| Jung, SH | 1 |
| Shin, KH | 1 |
| Kim, BK | 1 |
| Kang, SS | 1 |
| Eriguchi, M | 2 |
| Hisa, T | 1 |
| Yanagie, H | 1 |
| Nonaka, Y | 1 |
| Takeda, Y | 1 |
| Goel, S | 2 |
| Bulgaru, A | 2 |
| Hochster, H | 2 |
| Wadler, S | 7 |
| Zamboni, W | 1 |
| Egorin, M | 1 |
| Leibes, L | 1 |
| Muggia, F | 1 |
| Lockwood, G | 1 |
| Harvey, E | 1 |
| Renshaw, G | 1 |
| Mani, S | 4 |
| Deery, P | 1 |
| Faithfull, S | 1 |
| Akaza, H | 2 |
| Konishi, T | 1 |
| Gourley, C | 1 |
| Cassidy, J | 12 |
| Edwards, C | 1 |
| Samuel, L | 1 |
| Bisset, D | 2 |
| Camboni, G | 1 |
| Boyle, D | 1 |
| Jodrell, D | 4 |
| Ullrich, T | 1 |
| Mueller, V | 1 |
| von Schilling, C | 1 |
| Schmitt, M | 1 |
| Dart, DA | 1 |
| Picksley, SM | 1 |
| Cooper, PA | 1 |
| Double, JA | 1 |
| Bibby, MC | 1 |
| Brown, NL | 1 |
| Lemoine, NR | 3 |
| Orel, NF | 1 |
| Viele, CS | 1 |
| Eder, JP | 2 |
| Puchalski, TA | 1 |
| Deluca, P | 1 |
| Wozniak, A | 1 |
| Campbell, A | 1 |
| Rothermel, J | 1 |
| Jefford, M | 1 |
| Michael, M | 1 |
| Rosenthal, MA | 2 |
| Davis, ID | 1 |
| Green, M | 1 |
| McClure, B | 1 |
| Smith, J | 1 |
| Waite, B | 1 |
| Zalcberg, J | 1 |
| Green, SK | 1 |
| Francia, G | 1 |
| Isidoro, C | 1 |
| Kerbel, RS | 1 |
| Cuq, P | 1 |
| Südhoff, T | 1 |
| Enderle, MD | 1 |
| Pahlke, M | 1 |
| Petz, C | 1 |
| Teschendorf, C | 1 |
| Graeven, U | 1 |
| Schmiegel, W | 1 |
| Eliason, JF | 1 |
| Megyeri, A | 1 |
| Critchley, RJ | 1 |
| Jezzard, S | 1 |
| Radford, KJ | 1 |
| Goussard, S | 1 |
| Grillot-Courvalin, C | 1 |
| Vassaux, G | 1 |
| Rich, TA | 1 |
| Shepard, RC | 1 |
| Mosley, ST | 1 |
| Schultz, M | 1 |
| Schölmerich, J | 1 |
| Kullmann, F | 1 |
| Schrijvers, A | 1 |
| Souglakos, J | 2 |
| Kouroussis, C | 2 |
| Androulakis, N | 2 |
| Samonis, G | 1 |
| Vardakis, N | 3 |
| Agelaki, S | 2 |
| Mavroudis, D | 3 |
| Georgoulias, V | 3 |
| Chow, TY | 1 |
| Alaoui-Jamali, MA | 1 |
| Yeh, C | 1 |
| Yuen, L | 1 |
| Griller, D | 1 |
| Rustum, YM | 4 |
| Mahan, SD | 1 |
| Ireton, GC | 1 |
| Knoeber, C | 1 |
| Stoddard, BL | 1 |
| Black, ME | 1 |
| Hamstra, DA | 1 |
| Lee, KC | 1 |
| Tychewicz, JM | 1 |
| Schepkin, VD | 1 |
| Moffat, BA | 1 |
| Chen, M | 1 |
| Dornfeld, KJ | 1 |
| Chenevert, TL | 1 |
| Ross, BD | 1 |
| Gelovani, JT | 1 |
| Rehemtulla, A | 2 |
| Dertinger, SD | 1 |
| Camphausen, K | 1 |
| Macgregor, JT | 1 |
| Bishop, ME | 1 |
| Torous, DK | 1 |
| Avlasevich, S | 1 |
| Cairns, S | 1 |
| Tometsko, CR | 1 |
| Menard, C | 1 |
| Muanza, T | 1 |
| Miller, RK | 1 |
| Cederbrant, K | 1 |
| Sandelin, K | 1 |
| Pontén, I | 1 |
| Bolcsfoldi, G | 1 |
| Undevia, SD | 1 |
| Kindler, HL | 4 |
| Janisch, L | 2 |
| Olson, SC | 1 |
| Kimmel, KA | 1 |
| Macek, TA | 1 |
| Wolf, W | 7 |
| Presant, CA | 6 |
| Van Laar, JA | 1 |
| Van der Wilt, CL | 5 |
| de Bruin, M | 1 |
| van Capel, T | 1 |
| van der Born, K | 1 |
| Hoekman, K | 1 |
| Pinedo, HM | 11 |
| Lokich, J | 6 |
| Lim, WT | 1 |
| Fei, X | 1 |
| Wang, JQ | 1 |
| Miller, KD | 1 |
| Sledge, GW | 1 |
| Hutchins, GD | 1 |
| Zheng, QH | 1 |
| Fei, P | 1 |
| Burns, TF | 1 |
| Sax, JK | 1 |
| Buzzai, M | 1 |
| Dicker, DT | 1 |
| McKenna, WG | 1 |
| Bernhard, EJ | 1 |
| El-Deiry, WS | 1 |
| Ruan, H | 1 |
| Lamborn, KR | 1 |
| Kong, EL | 1 |
| Deen, DF | 1 |
| Soepenberg, O | 1 |
| Dumez, H | 2 |
| Semiond, D | 1 |
| deJonge, MJ | 1 |
| Eskens, FA | 1 |
| ter Steeg, J | 1 |
| Selleslach, J | 1 |
| Sanderink, GJ | 1 |
| Sparreboom, A | 2 |
| van Oosterom, AT | 2 |
| Kortmansky, J | 1 |
| Kaubisch, A | 2 |
| Weyerbacher, A | 1 |
| Yi, S | 1 |
| Tong, W | 1 |
| Sowers, R | 1 |
| O'reilly, E | 1 |
| Kemeny, N | 3 |
| Ilson, DI | 1 |
| Saltz, LB | 2 |
| Maki, RG | 1 |
| Kelsen, DP | 3 |
| Ramanathan, RK | 1 |
| Ramalingam, S | 1 |
| Egorin, MJ | 2 |
| Belani, CP | 1 |
| Potter, DM | 1 |
| Fakih, M | 1 |
| Jung, LL | 1 |
| Strychor, S | 2 |
| Jacobs, SA | 1 |
| Friedland, DM | 1 |
| Shin, DM | 1 |
| Chatta, GS | 1 |
| Tutchko, S | 1 |
| Zamboni, WC | 2 |
| Saeki, T | 2 |
| Takashima, S | 2 |
| Terashima, M | 1 |
| Satoh, A | 1 |
| Toi, M | 3 |
| Osaki, A | 1 |
| Toge, T | 6 |
| Ohno, S | 1 |
| Nomura, N | 1 |
| Fukuyama, Y | 1 |
| Walko, CM | 1 |
| Lindley, C | 1 |
| Fidias, P | 1 |
| Lynch, TJ | 1 |
| Seiden, MV | 1 |
| Sastre, J | 3 |
| Paz-Ares, L | 1 |
| Carcas, A | 1 |
| Alfonso, R | 1 |
| Grávalos, C | 1 |
| Frías, J | 1 |
| Guerra, P | 1 |
| Pronk, L | 2 |
| Cortés-Funes, H | 1 |
| Díaz-Rubio, E | 3 |
| Gaffney, EA | 1 |
| Khawli, LA | 1 |
| Hu, P | 1 |
| Epstein, AL | 1 |
| Mercer, SJ | 2 |
| Knight, LA | 2 |
| Gabriel, FG | 2 |
| Whitehouse, PA | 2 |
| Fernando, A | 2 |
| Bhandari, P | 1 |
| Somers, SS | 2 |
| Toh, SK | 1 |
| Cree, IA | 2 |
| Meydan, N | 1 |
| Kundak, I | 1 |
| Yavuzsen, T | 1 |
| Barutca, S | 1 |
| Alakavuklar, MN | 1 |
| Li, KM | 1 |
| Rivory, LP | 1 |
| Gibbs, P | 1 |
| Brown, TJ | 1 |
| Wong, S | 1 |
| Uren, S | 1 |
| Ellis, A | 1 |
| Heldin, P | 1 |
| Fox, RM | 3 |
| Tighiouart, M | 1 |
| Rogatko, A | 2 |
| Babb, JS | 1 |
| Hwang, KS | 1 |
| Cho, WK | 1 |
| Yoo, J | 1 |
| Yun, HJ | 1 |
| Im, DS | 1 |
| Bramanti, S | 1 |
| Morenghi, E | 1 |
| Wright, MA | 1 |
| Morrison, G | 2 |
| Lin, P | 1 |
| Leonard, GD | 1 |
| Guo, X | 1 |
| Hopkins, JL | 1 |
| Leguizamo, JP | 1 |
| Fioravanti, S | 1 |
| Pang, J | 2 |
| Altundag, O | 1 |
| Altundag, K | 1 |
| Silay, K | 1 |
| Turen, S | 1 |
| van Laarhoven, HW | 1 |
| Kamm, YJ | 1 |
| Heerschap, A | 1 |
| Glaysher, S | 1 |
| Di Palma, S | 1 |
| Johnson, P | 2 |
| Toh, S | 1 |
| Higgins, B | 1 |
| Lamont, A | 1 |
| Gulliford, T | 1 |
| Hurren, J | 1 |
| Yiangou, C | 1 |
| Camidge, R | 1 |
| Reigner, B | 10 |
| Grange, S | 1 |
| Abt, M | 1 |
| Weidekamm, E | 4 |
| Creaven, PJ | 4 |
| Ramnath, N | 1 |
| Trump, D | 1 |
| Javle, M | 1 |
| Repinski, TV | 1 |
| Zamboni, BA | 1 |
| Schwarz, JK | 1 |
| French, RA | 1 |
| Giunta, G | 1 |
| Eklund, JW | 1 |
| Trifilio, S | 1 |
| Mulcahy, MF | 1 |
| Maindrault-Goebel, F | 1 |
| André, T | 1 |
| Tournigand, C | 1 |
| Louvet, C | 1 |
| Perez-Staub, N | 1 |
| Zeghib, N | 1 |
| De Gramont, A | 1 |
| Adams, N | 1 |
| Barrera, D | 1 |
| Nugent, J | 1 |
| Stewart, C | 1 |
| Gradishar, WJ | 1 |
| Baydar, M | 1 |
| Dikilitas, M | 1 |
| Aydogdu, I | 1 |
| Vamvakas, L | 2 |
| Saridaki, Z | 2 |
| Robien, K | 1 |
| Boynton, A | 1 |
| Ulrich, CM | 1 |
| Kamoshida, S | 1 |
| Shiogama, K | 1 |
| Shimomura, R | 1 |
| Inada, K | 1 |
| Ochiai, M | 1 |
| Matuoka, H | 1 |
| Maeda, K | 1 |
| Tsutsumi, Y | 1 |
| Marsh, S | 2 |
| Jansen, C | 1 |
| Miaskowski, C | 1 |
| Dodd, M | 1 |
| Dowling, G | 1 |
| Kramer, J | 1 |
| Nishiyama, M | 3 |
| Isomura, M | 1 |
| Miki, Y | 1 |
| Urien, S | 1 |
| Rezaí, K | 1 |
| Lokiec, F | 2 |
| Sasaki, S | 2 |
| Watanabe, T | 2 |
| Nagawa, H | 2 |
| Süzen, HS | 1 |
| Yüce, N | 1 |
| Güvenç, G | 1 |
| Duydu, Y | 1 |
| Erke, T | 1 |
| Ezzeldin, HH | 1 |
| Maltezos, E | 1 |
| Trichas, M | 1 |
| Vasiliadis, M | 1 |
| Toromanidou, M | 1 |
| Karayiannakis, A | 1 |
| Tsaroucha, A | 2 |
| Romanidis, K | 1 |
| Lee, GD | 1 |
| Longo, DL | 1 |
| Rifkind, JM | 1 |
| Abdul-Raman, L | 1 |
| Mamczarz, JA | 1 |
| Duffy, KB | 1 |
| Spangler, EL | 1 |
| Taub, DD | 1 |
| Mattson, MP | 1 |
| Ingram, DK | 1 |
| Padmanabhan, P | 1 |
| Otero, J | 1 |
| Ray, P | 1 |
| Paulmurugan, R | 1 |
| Hoffman, AR | 1 |
| Gambhir, SS | 1 |
| Biswal, S | 1 |
| Ulaner, GA | 1 |
| Santini, D | 2 |
| Vincenzi, B | 2 |
| Schiavon, G | 1 |
| La Cesa, A | 1 |
| Gasparro, S | 1 |
| Vincenzi, A | 1 |
| Tonini, G | 2 |
| Hyodo, I | 1 |
| Shah, HR | 1 |
| Ledbetter, L | 1 |
| Diasio, R | 3 |
| Felici, A | 1 |
| Cirillo, I | 1 |
| Nooter, K | 1 |
| de Jonge, MJ | 1 |
| Ellis, LM | 1 |
| Rosen, L | 1 |
| Gordon, MS | 2 |
| Kim, H | 1 |
| Lee, EH | 1 |
| Kim, MJ | 1 |
| Park, SK | 1 |
| Heo, SK | 1 |
| Kim, BS | 1 |
| Min, YJ | 1 |
| Jones, JA | 1 |
| Avritscher, EB | 1 |
| Cooksley, CD | 1 |
| Michelet, M | 1 |
| Bekele, BN | 1 |
| Elting, LS | 1 |
| Kang, HC | 1 |
| Kim, IJ | 1 |
| Park, HW | 1 |
| Jang, SG | 1 |
| Ahn, SA | 1 |
| Yoon, SN | 1 |
| Chang, HJ | 1 |
| Yoo, BC | 1 |
| Park, JG | 1 |
| Ploylearmsaeng, SA | 1 |
| Fuhr, U | 1 |
| Hildebrand, J | 1 |
| Roché, H | 2 |
| Kerbrat, P | 1 |
| Bonneterre, J | 1 |
| Fargeot, P | 1 |
| Monnier, A | 1 |
| Clavère, P | 1 |
| Goudier, MJ | 1 |
| Chollet, P | 3 |
| Guastalla, JP | 2 |
| Serin, D | 1 |
| Ooyama, A | 2 |
| Toda, E | 1 |
| Nagase, H | 2 |
| Okayama, Y | 1 |
| Kitazato, K | 1 |
| Sugimoto, Y | 1 |
| Green, LJ | 1 |
| Marder, P | 1 |
| Ray, C | 1 |
| Cook, CA | 1 |
| Jaken, S | 1 |
| Musib, LC | 1 |
| Carducci, M | 1 |
| Britten, CD | 2 |
| Thornton, D | 2 |
| Oka, M | 2 |
| Yoshino, S | 1 |
| Hazama, S | 1 |
| Abe, T | 2 |
| Okayama, N | 1 |
| Hinoda, Y | 1 |
| Yamaguchi, K | 3 |
| Shimamura, T | 1 |
| Tada, M | 1 |
| Mishima, H | 1 |
| Ikenaga, M | 2 |
| Tsujinaka, T | 1 |
| Yasui, M | 1 |
| Kashiwazaki, M | 1 |
| Miyazaki, M | 1 |
| Hirao, M | 1 |
| Fujitani, K | 1 |
| Nakamori, S | 1 |
| Brody, JR | 2 |
| Gallmeier, E | 1 |
| Yoshimura, K | 1 |
| Hucl, T | 2 |
| Kulesza, P | 1 |
| Canto, MI | 1 |
| Hruban, RH | 1 |
| Schulick, RD | 1 |
| Kern, SE | 2 |
| Hirata, K | 3 |
| Horikoshi, N | 1 |
| Tominaga, K | 1 |
| Sohma, K | 1 |
| Okazaki, M | 1 |
| Furuhata, T | 1 |
| Sasaki, K | 3 |
| Nakano, Y | 1 |
| Ishizuka, H | 1 |
| Yamada, Y | 2 |
| Uno, S | 1 |
| Yamamitsu, S | 3 |
| Tirandaz, H | 1 |
| Salehi-Najafabadi, A | 1 |
| Eslamifar, A | 1 |
| Ogura, K | 2 |
| Xiao, Z | 1 |
| Xue, J | 1 |
| Sowin, TJ | 1 |
| Wood, PA | 1 |
| Du-Quiton, J | 1 |
| You, S | 1 |
| Hrushesky, WJ | 4 |
| Choi, K | 1 |
| Lee, SS | 1 |
| Oh, SJ | 1 |
| Lim, SY | 2 |
| Jeon, WK | 1 |
| Oh, TY | 1 |
| Kim, JW | 1 |
| Morrow, M | 1 |
| Pierson, AS | 1 |
| Persky, M | 1 |
| Gustafson, D | 1 |
| Mikule, C | 1 |
| Palmer, PA | 1 |
| Curtiss, FR | 1 |
| Gelibter, AJ | 1 |
| Di Segni, S | 1 |
| Fontana, A | 1 |
| Cognetti, F | 1 |
| Labianca, R | 2 |
| Dahan, L | 1 |
| Duffaud, F | 1 |
| Richard, K | 1 |
| Blesius, A | 1 |
| Durand, A | 1 |
| Favre, R | 1 |
| Sekine, N | 1 |
| Terada, K | 1 |
| Gilkes, DM | 1 |
| Hauteville, D | 1 |
| Virzí, V | 1 |
| Rocci, L | 1 |
| Leoni, V | 1 |
| Lee, JH | 1 |
| Jung, Y | 1 |
| Jong, HS | 1 |
| Kim, TY | 1 |
| Bang, YJ | 1 |
| Desai, K | 1 |
| Karri, S | 1 |
| Gollamudi, R | 1 |
| Chaudhary, I | 1 |
| Goldberg, G | 1 |
| Einstein, M | 1 |
| Camacho, F | 1 |
| Baker, S | 1 |
| Kim, SR | 1 |
| Ozawa, S | 1 |
| Kurose, K | 1 |
| Kaniwa, N | 1 |
| Kamatani, N | 1 |
| Hamaguchi, T | 1 |
| Muto, M | 1 |
| Ohtsu, A | 1 |
| Yoshida, T | 1 |
| Matsumura, Y | 1 |
| Saijo, N | 3 |
| Sawada, J | 1 |
| Wierzba, K | 1 |
| Hanauske, AR | 2 |
| Bolling, C | 1 |
| Jones, RJ | 1 |
| Rakhit, A | 1 |
| Fettner, S | 1 |
| Brennscheidt, U | 1 |
| Feyereislova, A | 1 |
| Nief, N | 1 |
| Le Morvan, V | 1 |
| Pentheroudakis, G | 1 |
| Pappas, P | 1 |
| Golfinopoulos, V | 1 |
| Fountzilas, G | 1 |
| Nikolaidou, M | 1 |
| Boumba, VA | 1 |
| Vougiouklakis, T | 1 |
| Nikiforidis, L | 1 |
| Tzamakou, E | 1 |
| Siarabi, O | 1 |
| Marselos, M | 1 |
| Pavlidis, N | 1 |
| Yen, JL | 1 |
| Oda, S | 1 |
| Kuraoka, I | 1 |
| Wilsker, D | 1 |
| Midorikawa, Y | 1 |
| Nakachi, T | 1 |
| Kasuga, T | 1 |
| Houhouli, K | 1 |
| Papatheodorou, K | 1 |
| Miloussis, A | 1 |
| Matthaios, D | 1 |
| Lyrantzopoulos, N | 1 |
| Laber, DA | 1 |
| Khan, MI | 1 |
| Kloecker, GH | 1 |
| Schonard, C | 1 |
| Taft, BS | 1 |
| Salvador, C | 1 |
| Alexandre, J | 1 |
| Kahatt, C | 1 |
| Bertheault-Cvitkovic, F | 1 |
| Faivre, S | 1 |
| Shibata, S | 1 |
| Hilgers, W | 1 |
| Goldwasser, F | 1 |
| Weems, G | 1 |
| Shah, A | 1 |
| MacDonald, JR | 1 |
| Cvitkovic, E | 2 |
| Bremberg, ER | 1 |
| Rotstein, S | 1 |
| Eksborg, S | 1 |
| Siegel-Lakhai, WS | 1 |
| Vervenne, WL | 1 |
| Boot, H | 1 |
| Keessen, M | 1 |
| Versola, M | 2 |
| Pandite, L | 2 |
| Baehring, JM | 1 |
| Fulbright, RK | 1 |
| Chu, QS | 1 |
| Schwartz, G | 4 |
| de Bono, J | 1 |
| Versola, MJ | 1 |
| Arya, N | 1 |
| Curtright, J | 1 |
| Fleming, RA | 3 |
| Ho, PT | 1 |
| Rowinsky, EK | 8 |
| Seki, K | 1 |
| Nishijima, K | 1 |
| Kuge, Y | 2 |
| Tamaki, N | 1 |
| Wiebe, LI | 1 |
| Ohkura, K | 1 |
| Ray-Coquard, I | 1 |
| Bachelot, T | 1 |
| Saba, C | 1 |
| Confavreux, C | 1 |
| Brantus, JF | 1 |
| Rustam, F | 1 |
| Ghesquière, H | 1 |
| Sebban, C | 1 |
| Biron, P | 1 |
| Blay, JY | 1 |
| Midgley, RS | 1 |
| Flaherty, KT | 1 |
| Stevenson, JP | 1 |
| Pratap, SE | 1 |
| Ward, C | 1 |
| Middleton, MR | 1 |
| Sakamoto, E | 1 |
| Oie, S | 1 |
| Yucel, I | 1 |
| Guzin, G | 1 |
| Royo, JL | 1 |
| Becker, PD | 1 |
| Camacho, EM | 1 |
| Cebolla, A | 1 |
| Link, C | 1 |
| Santero, E | 1 |
| Guzmán, CA | 1 |
| Gal-Mor, O | 1 |
| Finlay, BB | 1 |
| Bozionelou, V | 1 |
| Kentepozidis, N | 1 |
| Kotsakis, A | 1 |
| Kalykaki, A | 1 |
| Gioulbasanis, I | 1 |
| Karampeazis, A | 1 |
| Karabeazis, A | 1 |
| Ernst, T | 1 |
| Gnad-Vogt, U | 1 |
| Lukan, N | 1 |
| Kripp, M | 1 |
| Schultheis, B | 1 |
| Hochhaus, A | 1 |
| Gail Eckhardt, S | 1 |
| Musib, L | 1 |
| Baldwin, J | 1 |
| Darstein, C | 1 |
| Finn, RS | 1 |
| Steinbild, S | 1 |
| Arends, J | 1 |
| Medinger, M | 1 |
| Häring, B | 1 |
| Frost, A | 1 |
| Drevs, J | 1 |
| Unger, C | 1 |
| Strecker, R | 1 |
| Hennig, J | 1 |
| Mross, K | 1 |
| Crown, JP | 1 |
| Boyle, F | 1 |
| Newstat, BO | 1 |
| Parikh, R | 1 |
| Oliva, C | 1 |
| Preston, A | 1 |
| Byrne, J | 1 |
| Chan, S | 1 |
| Roccaro, AM | 1 |
| Durando, X | 1 |
| Thivat, E | 1 |
| Gimbergues, P | 1 |
| Cellarier, E | 1 |
| Abrial, C | 1 |
| Dib, M | 1 |
| Tacca, O | 1 |
| Robey, RW | 1 |
| Shukla, S | 1 |
| Finley, EM | 1 |
| Oldham, RK | 1 |
| Barnett, D | 1 |
| Ambudkar, SV | 1 |
| Fojo, T | 1 |
| Bates, SE | 1 |
| Chu, L | 1 |
| Gu, J | 1 |
| Sun, L | 1 |
| Qian, Q | 1 |
| Qian, C | 1 |
| Shim, J | 1 |
| Matsumura, N | 1 |
| Tazumi, K | 1 |
| Kouji, K | 1 |
| Kondo, M | 1 |
| Mizuki, M | 1 |
| Engstrom, PF | 1 |
| Lewis, NL | 2 |
| Langer, CJ | 1 |
| Beard, M | 1 |
| Weiner, LM | 1 |
| Endo, S | 1 |
| Kodama, K | 2 |
| Kamataki, T | 1 |
| Krishnamurthi, SS | 1 |
| Hoppel, CL | 1 |
| Weaver, KC | 1 |
| Ingalls, ST | 1 |
| Zuhowski, EG | 1 |
| Schluchter, MD | 1 |
| Dowlati, A | 1 |
| Cooney, MM | 1 |
| Gibbons, J | 1 |
| Overmoyer, BA | 1 |
| Remick, SC | 2 |
| Showalter, SL | 1 |
| Showalter, TN | 1 |
| Witkiewicz, A | 1 |
| Havens, R | 1 |
| Kennedy, EP | 1 |
| Yeo, CJ | 1 |
| Jones, ET | 1 |
| Mellado, B | 1 |
| Beech, J | 1 |
| Gascon, P | 1 |
| Zugmaier, G | 1 |
| Brewster, M | 1 |
| Saunders, MP | 1 |
| Valle, JW | 1 |
| He, YF | 1 |
| Li, YH | 1 |
| Wang, FH | 1 |
| Lin, XB | 1 |
| Li, ZM | 1 |
| Zhang, DS | 1 |
| Huang, HQ | 1 |
| Hu, B | 1 |
| Jiang, WQ | 1 |
| Yang, JL | 1 |
| Qu, XJ | 1 |
| Kohn, EC | 1 |
| Friedlander, ML | 1 |
| Lehman, JA | 1 |
| Shinn, GL | 1 |
| Ishiyama, S | 1 |
| Sakabe, T | 1 |
| Ushio, S | 1 |
| Yamagata, S | 1 |
| Funabashi, W | 1 |
| Kasimis, BS | 1 |
| Janis, MG | 1 |
| Bidet, JM | 1 |
| Ferriere, JP | 1 |
| Besse, G | 1 |
| Gaillard, G | 1 |
| Plagne, R | 1 |
| Siering, H | 2 |
| Knöll, P | 1 |
| Okazaki, H | 1 |
| Nakamura, H | 1 |
| Schlag, P | 2 |
| Wolfrum, J | 1 |
| Vergani, G | 1 |
| Schreml, W | 1 |
| Herfarth, C | 1 |
| Weisenthal, LM | 1 |
| Marsden, JA | 1 |
| Dill, PL | 1 |
| Macaluso, CK | 1 |
| Ellims, PH | 1 |
| Miyoshi, T | 3 |
| Ogawa, S | 3 |
| Kanamori, T | 4 |
| Nobuhara, M | 4 |
| Namba, M | 4 |
| Kimoto, T | 3 |
| Moran, RG | 2 |
| Basu, TK | 4 |
| Curt, GA | 2 |
| Clendeninn, NJ | 1 |
| Chabner, BA | 7 |
| Browman, GP | 1 |
| Tanigawa, N | 1 |
| Mizuno, Y | 1 |
| Hashimura, T | 1 |
| Honda, K | 1 |
| Satomura, K | 1 |
| Hikasa, Y | 2 |
| Niwa, O | 1 |
| Sugahara, T | 1 |
| Yoshida, O | 1 |
| Kern, DH | 1 |
| Hayashida, S | 1 |
| Sugimoto, K | 1 |
| Kobayashi, T | 1 |
| Markman, M | 3 |
| Peters, WP | 1 |
| Weiss, G | 1 |
| Kufe, DW | 2 |
| Yamamoto, S | 2 |
| Tanaka, H | 1 |
| Frei, E | 4 |
| Garnick, MB | 1 |
| Ensminger, WD | 2 |
| Israel, M | 1 |
| Steele, GD | 1 |
| Kaplan, WD | 1 |
| Come, SE | 1 |
| Armstrong, RD | 1 |
| Cadman, E | 3 |
| Kimura, K | 4 |
| Suga, S | 3 |
| Healy, HG | 1 |
| Clarkson, AR | 1 |
| Ardalan, B | 5 |
| Jamin, D | 1 |
| Jayaram, HN | 1 |
| Hara, Y | 3 |
| Singer, Z | 2 |
| Kozaczka, A | 1 |
| Wilk, J | 1 |
| Janas, J | 1 |
| Young, D | 2 |
| Vine, E | 1 |
| Ghanbarpour, A | 1 |
| Shani, J | 1 |
| Siemsen, JK | 1 |
| Irie, T | 1 |
| Fukushi, K | 1 |
| Ido, T | 1 |
| Howell, SB | 1 |
| Pfeifle, CE | 1 |
| Wung, WE | 1 |
| Begg, CB | 1 |
| Carbone, PP | 1 |
| Storm, FK | 1 |
| Silberman, AW | 1 |
| Ramming, KR | 1 |
| Kaiser, LR | 1 |
| Harrison, WH | 1 |
| Elliott, RS | 1 |
| Haskell, CM | 2 |
| Sarna, G | 1 |
| Morton, DL | 1 |
| Coates, AS | 1 |
| Tattersall, MH | 2 |
| Swanson, C | 1 |
| Hedley, D | 1 |
| Raghavan, D | 1 |
| Fine, RL | 1 |
| Allegra, CJ | 6 |
| Yeh, GW | 1 |
| Nederman, T | 3 |
| Twentyman, P | 1 |
| Lokich, JJ | 3 |
| Perri, J | 2 |
| Bothe, A | 2 |
| Zipoli, T | 2 |
| Philips, D | 1 |
| Sonneborn, H | 2 |
| Paul, S | 2 |
| Green, R | 2 |
| Wakui, A | 9 |
| Koga, S | 2 |
| Izumi, A | 1 |
| Maeta, M | 2 |
| Shimizu, N | 2 |
| Osaki, Y | 1 |
| Kanayama, H | 1 |
| Kasai, Y | 1 |
| Nakanishi, Y | 1 |
| Nishi, H | 1 |
| Nishindai, H | 1 |
| Yoshimoto, M | 1 |
| Hashimoto, I | 1 |
| Sawada, Y | 1 |
| Mikami, J | 1 |
| Bekki, E | 1 |
| Kamiya, O | 1 |
| Ohara, K | 1 |
| Nagata, K | 1 |
| Kojima, T | 2 |
| Sugihara, T | 1 |
| Kallas, GJ | 1 |
| Singson, JP | 1 |
| Sato, H | 3 |
| Sato, T | 3 |
| Hanatani, Y | 1 |
| Le, J | 1 |
| Yip, YK | 1 |
| Vilcek, J | 1 |
| Fujita, H | 3 |
| Furue, H | 7 |
| Tanneberger, S | 4 |
| Müller, U | 1 |
| Hill, DL | 1 |
| Montgomery, JA | 1 |
| Braun, DP | 1 |
| Harris, JE | 2 |
| Woods, RL | 1 |
| Piper, AA | 1 |
| Sampson, D | 1 |
| Carlsson, J | 2 |
| Kubo, K | 1 |
| Aoyama, H | 1 |
| Inukai, N | 1 |
| Kato, K | 1 |
| Horiuchi, T | 1 |
| Sawada, H | 1 |
| Yokoyama, Y | 1 |
| Finlay, GJ | 1 |
| Baguley, BC | 1 |
| Spreafico, F | 1 |
| Stolfi, RL | 3 |
| Sawyer, RC | 3 |
| Spiegelman, S | 2 |
| Petricciani, JC | 1 |
| Levenbook, I | 1 |
| Locke, R | 1 |
| Gyves, JW | 1 |
| Stetson, P | 1 |
| Niederhuber, JE | 1 |
| Meyer, M | 1 |
| Walker, S | 1 |
| Janis, MA | 1 |
| Gilbertson, S | 1 |
| Casper, ES | 1 |
| Michaelson, RA | 1 |
| Washtien, WL | 1 |
| Cadman, EC | 2 |
| Spears, CP | 4 |
| Gustavsson, BG | 2 |
| Mitchell, MS | 2 |
| Spicer, D | 1 |
| Berne, M | 1 |
| Bernstein, L | 1 |
| Leyva, A | 4 |
| Marunaka, T | 1 |
| Umeno, Y | 1 |
| Minami, Y | 1 |
| Walker, EH | 1 |
| Fujita, M | 1 |
| Hayata, S | 1 |
| Friedman, MA | 1 |
| Ignoffo, RJ | 1 |
| Au, JL | 3 |
| Sadée, W | 2 |
| Shamberger, RC | 1 |
| Devereux, DF | 1 |
| Brennan, MF | 1 |
| Matsuoka, S | 1 |
| Maezawa, S | 1 |
| Sakuma, M | 1 |
| Ohira, S | 2 |
| Saito, T | 7 |
| Carter, WH | 1 |
| Wampler, GL | 1 |
| Stablein, DM | 1 |
| Campbell, ED | 1 |
| Lawson, DH | 1 |
| Nixon, DW | 1 |
| Kutner, MH | 1 |
| Heymsfield, SB | 1 |
| Rudman, D | 1 |
| Moffitt, S | 1 |
| Ansley, J | 1 |
| Chawla, R | 1 |
| Tschiersch, B | 1 |
| Kikuchi, K | 3 |
| Majima, S | 1 |
| Takahashi, N | 1 |
| Kunii, Y | 1 |
| Kanno, H | 1 |
| Benz, C | 3 |
| Silverberg, M | 1 |
| Ciubra-Niczewska, E | 1 |
| Fine, N | 1 |
| Donehower, RC | 2 |
| Speyer, JL | 1 |
| Klecker, R | 1 |
| Ohnuma, T | 2 |
| Arkin, H | 1 |
| Holland, JF | 2 |
| Wiemann, MC | 1 |
| Cummings, FJ | 4 |
| Kaplan, HG | 1 |
| Spremulli, EN | 1 |
| Doolittle, CH | 1 |
| Nayak, R | 1 |
| Woodcock, T | 1 |
| Wasternack, C | 1 |
| Cooney, D | 2 |
| Macdonald, JS | 3 |
| Veronesi, A | 1 |
| Talamini, R | 1 |
| Mauro Trovò, G | 1 |
| Tirelli, U | 1 |
| Galligioni, E | 1 |
| Tumolo, S | 1 |
| Grigoletto, E | 1 |
| Danhauser, L | 1 |
| Luccioni, C | 1 |
| Gammelli, RL | 1 |
| Costanza, MC | 1 |
| Foster, RS | 1 |
| Chlebowski, RT | 1 |
| Heber, D | 1 |
| Weiss, GR | 3 |
| Ervin, TJ | 1 |
| Meshad, MW | 1 |
| Schade, D | 1 |
| Branfman, AR | 1 |
| Bruni, RJ | 1 |
| Chadwick, M | 1 |
| Beretta, G | 1 |
| Clerici, M | 1 |
| Fraschini, P | 1 |
| Luporini, G | 1 |
| Demicheli, R | 1 |
| Jirillo, A | 1 |
| Bonciarelli, G | 1 |
| Bellini, A | 1 |
| Petrosino, L | 1 |
| Bigi, L | 1 |
| Garusi, GF | 1 |
| Takimoto, M | 1 |
| Sakurai, T | 1 |
| Yokoi, H | 1 |
| Suzuki, Y | 2 |
| Enomoto, K | 1 |
| Koyama, Y | 2 |
| Watanabe, K | 1 |
| Satoh, H | 1 |
| Ohki, S | 1 |
| Komita, T | 1 |
| Iketa, T | 1 |
| Arimori, S | 1 |
| Nagao, T | 1 |
| Majima, H | 1 |
| Nishimura, A | 1 |
| Bedikian, AY | 1 |
| Mackay, B | 1 |
| Luna, M | 1 |
| Valdivieso, M | 3 |
| Malmqvist, M | 1 |
| Obrecht, JP | 1 |
| Weber, W | 3 |
| Cano, JP | 2 |
| Crevoisier, C | 2 |
| Alberto, P | 3 |
| Forgo, I | 1 |
| Heintz, R | 1 |
| Germano, GH | 1 |
| Aubert, C | 1 |
| Rigault, JP | 1 |
| Carcassonne, Y | 1 |
| Garelli, S | 1 |
| Valbonesi, M | 1 |
| Schieppati, G | 1 |
| Banfi, L | 1 |
| Woodcock, TM | 2 |
| Kirkwood, JM | 1 |
| Ensminger, W | 1 |
| Rosowsky, A | 1 |
| Papathanasopoulos, N | 1 |
| Damin, LA | 1 |
| Kemeny, NE | 3 |
| Fraile, RJ | 1 |
| Baker, LH | 1 |
| Buroker, TR | 1 |
| Horwitz, J | 1 |
| Lieberman, LM | 1 |
| Wessels, BW | 1 |
| Wiley, AL | 1 |
| Gatley, SJ | 1 |
| Nickles, RJ | 1 |
| Wolberg, WH | 6 |
| Bogden, AE | 1 |
| Blair, WF | 1 |
| Kilpatrick, WC | 1 |
| Saiki, JH | 2 |
| Atler, EJ | 1 |
| Aksoy, M | 1 |
| Brient, J | 1 |
| Dickerson, JW | 2 |
| Bernstein, IL | 1 |
| Webster, MM | 1 |
| Marzecki, Z | 1 |
| Krygier-Stojalowska, A | 1 |
| Zaborek, B | 1 |
| Mietkiewski, J | 1 |
| Meyer, A | 1 |
| Mazuryk, R | 1 |
| Torbé, Z | 1 |
| Roboz, J | 1 |
| Waxman, S | 1 |
| Mandel, E | 1 |
| Elias, AD | 1 |
| Ayash, L | 1 |
| Tepler, I | 1 |
| Wheeler, C | 1 |
| Mazanet, R | 1 |
| Schnipper, L | 1 |
| Antman, K | 1 |
| Vexler, AM | 1 |
| Mou, X | 1 |
| Gabizon, AA | 1 |
| Gorodetsky, R | 1 |
| Rinck, G | 1 |
| Kleijnen, J | 1 |
| Van den Bos, TG | 1 |
| de Haes, HJ | 1 |
| Schadé, E | 1 |
| Veenhof, CH | 1 |
| Dercksen, MW | 1 |
| Gerritsen, WR | 1 |
| Rodenhuis, S | 1 |
| Dirkson, MK | 1 |
| Slaper-Cortenbach, IC | 1 |
| Schaasberg, WP | 1 |
| von dem Borne, AE | 1 |
| van der Schoot, CE | 1 |
| Emerson, SS | 1 |
| Beitz, JG | 1 |
| Damowski, JW | 1 |
| Browne, MJ | 2 |
| Bigley, JW | 1 |
| Weitberg, AB | 2 |
| Johnston, PG | 2 |
| Behan, KA | 1 |
| Drake, JC | 1 |
| Greenhouse, JB | 1 |
| Wasserman, L | 1 |
| Wasserheit, C | 1 |
| Speyer, J | 1 |
| Harris, JD | 1 |
| Gutierrez, AA | 1 |
| Hurst, HC | 1 |
| Sikora, K | 1 |
| Bjarnason, GA | 1 |
| Buzaid, AC | 1 |
| Marsh, JC | 1 |
| Ravikumar, TS | 1 |
| Murren, JR | 1 |
| Todd, M | 1 |
| Strair, RK | 1 |
| Poo, WJ | 1 |
| Hait, WN | 1 |
| Healy, JB | 1 |
| Machover, D | 1 |
| Foote, RL | 1 |
| Michalak, J | 1 |
| de Forni, M | 4 |
| Armand, JP | 2 |
| McAleer, C | 1 |
| Brennan, J | 2 |
| LaCreta, FP | 3 |
| Hudes, GR | 5 |
| Ozols, RF | 3 |
| Nio, Y | 1 |
| Tamura, K | 1 |
| Tsubono, M | 1 |
| Kawabata, K | 1 |
| Masai, Y | 1 |
| Hayashi, H | 1 |
| Ishigami, S | 1 |
| Araya, S | 1 |
| Imamura, M | 1 |
| Trudeau, M | 1 |
| Zukiwski, A | 1 |
| Langleben, A | 1 |
| Boos, G | 1 |
| Batist, G | 1 |
| Price, P | 1 |
| Griffiths, J | 1 |
| Waluch, V | 3 |
| Wiseman, C | 2 |
| Kennedy, P | 1 |
| Blayney, D | 2 |
| Brechner, RR | 1 |
| Pratt, CB | 2 |
| Meyer, WH | 1 |
| Howlett, N | 1 |
| Douglass, EC | 1 |
| Bowman, LC | 1 |
| Poe, D | 1 |
| Mounce, K | 1 |
| Kun, LE | 1 |
| Houghton, JA | 1 |
| Hsyu, PH | 1 |
| Pritchard, JF | 1 |
| Bozigian, HP | 1 |
| Gooding, AE | 1 |
| Griffin, RH | 1 |
| Mitchell, R | 1 |
| Bjurstrom, T | 1 |
| Panella, TL | 1 |
| Huang, AT | 1 |
| Hansen, LA | 1 |
| Lu, Z | 3 |
| Van Hoef, ME | 2 |
| Baumann, I | 1 |
| Lange, C | 1 |
| De Wynter, EA | 1 |
| Testa, NG | 1 |
| Howell, A | 1 |
| Keizer, HJ | 1 |
| De Bruijn, EA | 1 |
| Tjaden, UR | 1 |
| De Clercq, E | 1 |
| Fleming, TR | 1 |
| Prentice, RL | 1 |
| Pepe, MS | 1 |
| Glidden, D | 1 |
| Milano, GA | 1 |
| Maxwell, RJ | 1 |
| Gualano, V | 1 |
| Canal, P | 3 |
| Martel, P | 1 |
| Izar-Soum, F | 1 |
| Chevreau, C | 2 |
| Soulié, P | 3 |
| Bugat, R | 1 |
| Brandes, LJ | 1 |
| Simons, KJ | 1 |
| Bracken, SP | 1 |
| Warrington, RC | 1 |
| DelaFlor-Weiss, E | 1 |
| Uziely, B | 1 |
| Keefe, DL | 2 |
| Roistacher, N | 1 |
| Pierri, MK | 1 |
| Elsässer-Beile, U | 1 |
| von Kleist, S | 1 |
| Lindenthal, A | 1 |
| Birken, R | 1 |
| Gallati, H | 1 |
| Mönting, JS | 1 |
| Schwartz, EL | 3 |
| Einzig, A | 1 |
| Wiernik, PH | 2 |
| Borner, MM | 1 |
| Kneer, J | 1 |
| Brunner, KW | 1 |
| Liaw, SJ | 2 |
| Wang, CH | 2 |
| Chiu, MC | 1 |
| Huang, JS | 1 |
| Dodd, MJ | 1 |
| Dibble, SL | 1 |
| Arai, Y | 2 |
| Kido, C | 1 |
| Yamaguchi, T | 3 |
| Hagiwara, A | 1 |
| Taniguchi, H | 2 |
| Takahashi, T | 3 |
| Grogan, L | 1 |
| Sotos, GA | 1 |
| Rice, A | 1 |
| Barbot, C | 1 |
| Lacombe, F | 1 |
| Dubosc-Marchenay, N | 1 |
| Marit, G | 1 |
| Hau, F | 1 |
| Boiron, JM | 1 |
| Reiffers, J | 1 |
| Seiter, K | 1 |
| Martin, D | 2 |
| Schneider, A | 2 |
| Colofiore, J | 4 |
| Sawyer, R | 1 |
| Danhauser, LL | 1 |
| Freimann, JH | 1 |
| Gilchrist, TL | 1 |
| Gutterman, JU | 1 |
| Hunter, CY | 1 |
| Yeomans, AC | 1 |
| Markowitz, AB | 1 |
| Stewart, FM | 2 |
| Temeles, D | 1 |
| Lowry, P | 1 |
| Thraves, T | 1 |
| Grosh, WW | 1 |
| Quesenberry, PJ | 2 |
| Hansen, RM | 3 |
| Beatty, PA | 1 |
| Quebbeman, EJ | 2 |
| Anderson, T | 2 |
| Zaniboni, A | 2 |
| Meriggi, F | 1 |
| Alghisi, A | 1 |
| Marini, G | 2 |
| Green, F | 1 |
| Hoffman, J | 2 |
| Horowitz, R | 1 |
| Carlsson, G | 1 |
| Jaresko, G | 1 |
| Shahinian, HS | 1 |
| Depenbrock, H | 1 |
| Wenger, M | 1 |
| Peter, R | 1 |
| Fellbaum, C | 1 |
| Block, T | 1 |
| Rastetter, J | 1 |
| Skubitz, KM | 1 |
| Anderson, PM | 1 |
| Vaughn, DJ | 1 |
| Armstead, B | 1 |
| Haller, DG | 1 |
| Nomura, H | 1 |
| Murakami, Y | 1 |
| Aiba, K | 4 |
| Jansen, WJ | 1 |
| Feller, N | 1 |
| Bamberger, U | 1 |
| Lagrange, JL | 1 |
| Renée, N | 2 |
| Bajard, F | 1 |
| Guillot, T | 2 |
| White, RM | 2 |
| Muc, M | 1 |
| Baranowski, M | 1 |
| Braczkowski, R | 1 |
| Zubelewicz, B | 1 |
| Kozowicz, A | 1 |
| Parmar, MK | 2 |
| Stewart, LA | 1 |
| Altman, DG | 1 |
| Eckardt, J | 1 |
| Eckhardt, G | 1 |
| Villalona-Calero, M | 1 |
| Drengler, R | 2 |
| Manziuk, LV | 1 |
| Donenko, FV | 1 |
| Sitdikova, SM | 1 |
| Moroz, LV | 1 |
| Haynes, H | 2 |
| Schechner, R | 1 |
| Rozenblit, A | 1 |
| Killion, JJ | 1 |
| Beltran, P | 1 |
| O'Brian, CA | 1 |
| Yoon, SS | 1 |
| Wilson, MR | 1 |
| Fidler, IJ | 1 |
| Judde, JG | 1 |
| Spangler, G | 1 |
| Magrath, I | 1 |
| Bhatia, K | 1 |
| Knudsen, LM | 1 |
| Gaarsdal, E | 1 |
| Jensen, L | 1 |
| Nielsen, KJ | 1 |
| Nikolaisen, K | 1 |
| Johnsen, HE | 1 |
| Christman, K | 1 |
| Saltz, L | 2 |
| Casper, E | 1 |
| Quan, V | 1 |
| Bertino, J | 2 |
| Kelsen, D | 1 |
| Kanowitz, J | 1 |
| Schaaf, L | 1 |
| Spriggs, D | 1 |
| Staton, BA | 1 |
| Berkery, R | 1 |
| Steger, C | 1 |
| Eng, M | 1 |
| Locker, P | 1 |
| Ungerleider, RS | 1 |
| Simon, R | 1 |
| Kwock, L | 1 |
| Branch, C | 1 |
| Zeman, EM | 1 |
| Tepper, JE | 1 |
| Nishida, M | 3 |
| Hino, A | 1 |
| Matsumoto, T | 1 |
| Yoshikubo, T | 1 |
| Ishitsuka, H | 5 |
| Baker, SD | 1 |
| Khor, SP | 2 |
| Doucette, M | 1 |
| Spector, T | 1 |
| Grochow, LB | 1 |
| Sartorius, SE | 1 |
| Noe, DA | 1 |
| Hohneker, JA | 1 |
| O'Brien, SM | 1 |
| Hoffman, PC | 1 |
| Waggoner, SE | 1 |
| Tomkowski, W | 1 |
| Szturmowicz, M | 1 |
| Fijałkowska, A | 1 |
| Burakowski, J | 1 |
| Filipecki, S | 1 |
| Yeh, KH | 1 |
| Cheng, AL | 1 |
| Comte, L | 1 |
| Lorgeot, V | 1 |
| Volkov, L | 1 |
| Roullet, B | 1 |
| Tubiana, N | 1 |
| Praloran, V | 1 |
| Okabe, H | 1 |
| Tsujimoto, H | 1 |
| Fragu, P | 1 |
| Kahn, E | 1 |
| Inaba, M | 1 |
| O'Neil, J | 1 |
| Sung, MT | 1 |
| von Borstel, R | 1 |
| Chéradame, S | 1 |
| Chazal, M | 1 |
| Fischel, JL | 1 |
| Formento, P | 1 |
| Brienza, S | 2 |
| Baxevanis, CN | 1 |
| Tsavaris, NB | 1 |
| Papadhimitriou, SI | 1 |
| Zarkadis, IK | 1 |
| Papadopoulos, NG | 1 |
| Bastounis, EA | 1 |
| Papamichail, M | 1 |
| Griffiths, L | 1 |
| Stratford, IJ | 1 |
| Araki, H | 1 |
| Sowa, M | 2 |
| Tanaka, M | 2 |
| Chung, Y | 1 |
| Yasumoto, K | 1 |
| Wada, H | 3 |
| Inuyama, Y | 1 |
| Kanamaru, R | 2 |
| Hasegawa, K | 2 |
| Akazawa, S | 2 |
| Niitani, H | 1 |
| Kurihara, M | 2 |
| Takai, S | 1 |
| Shimoyama, T | 1 |
| Sugimachi, K | 2 |
| Tsukagoshi, S | 1 |
| Nakao, I | 4 |
| Jung, M | 1 |
| Berger, G | 1 |
| Pohlen, U | 1 |
| Päuser, S | 1 |
| Reszka, R | 1 |
| Buhr, HJ | 1 |
| Hon, YY | 1 |
| Evans, WE | 1 |
| Hohneker, J | 2 |
| Smetzer, L | 2 |
| Lucas, VS | 1 |
| Von Hoff, DD | 5 |
| Kovach, JS | 1 |
| O'Connell, MJ | 1 |
| Bagniewski, PG | 1 |
| Kinsella, AR | 1 |
| Smith, D | 1 |
| Anderson, KM | 1 |
| Bonomi, P | 1 |
| Budman, DR | 1 |
| Lichtman, SM | 1 |
| Berghorn, E | 1 |
| Behr, J | 1 |
| Gordon, RJ | 2 |
| Osterwalder, B | 5 |
| Griffin, T | 4 |
| John, WJ | 1 |
| Foon, KA | 1 |
| Lavit, M | 1 |
| Pujol, A | 1 |
| Siu, LL | 1 |
| Krasnopol'skiĭ, IuM | 1 |
| Dranov, AL | 1 |
| Stepanov, AE | 1 |
| Shvets, VI | 1 |
| Teicher, BA | 2 |
| Ara, G | 1 |
| Chen, YN | 1 |
| Recht, A | 1 |
| Coleman, CN | 2 |
| Mackean, M | 1 |
| Planting, A | 1 |
| Twelves, C | 4 |
| Schellens, J | 1 |
| Allman, D | 2 |
| Kaye, S | 1 |
| Ho, DH | 2 |
| Covington, W | 1 |
| Brown, N | 1 |
| Huo, YY | 1 |
| Lassere, Y | 1 |
| Kuritani, J | 1 |
| Sekine, I | 1 |
| Fukuda, H | 1 |
| Kunitoh, H | 1 |
| Okuda, H | 1 |
| Kato, A | 1 |
| Takubo, H | 1 |
| Watabe, T | 1 |
| Makower, D | 1 |
| McAtee, N | 1 |
| Murphy, RF | 1 |
| Balis, FM | 1 |
| Cullen, E | 1 |
| Chen, AP | 2 |
| Steinberg, SM | 1 |
| Quinn, M | 2 |
| Sorensen, JM | 1 |
| Arbuck, SG | 3 |
| Lawrence, D | 1 |
| Greenblatt, MS | 1 |
| Mangalik, A | 1 |
| Ferguson, J | 1 |
| Elias, L | 1 |
| Capizzi, RL | 1 |
| Muss, HB | 1 |
| Smith, S | 1 |
| Fernandes, DJ | 1 |
| Homesley, H | 1 |
| Loggie, BW | 1 |
| Case, L | 1 |
| Morris, R | 1 |
| Russell, GB | 1 |
| Richards, F | 1 |
| Dirix, L | 1 |
| Bissett, D | 1 |
| Miwa, M | 2 |
| Ura, M | 2 |
| Sawada, N | 1 |
| Shimma, N | 2 |
| Umeda, I | 1 |
| Sadoff, L | 1 |
| Sawada, K | 1 |
| Sawada, M | 1 |
| Nakamura, M | 1 |
| Pierrefite, V | 1 |
| Barberi-Heyob, M | 1 |
| Deporte-Fety, R | 1 |
| Clive, S | 1 |
| Schulz, R | 1 |
| Goggin, T | 2 |
| Banken, L | 3 |
| Roos, B | 2 |
| Utoh, M | 1 |
| Mulligan, T | 1 |
| Petit, T | 1 |
| Aylesworth, C | 1 |
| Burris, H | 1 |
| Ravdin, P | 1 |
| Rodriguez, G | 1 |
| Smith, L | 1 |
| Peacock, N | 1 |
| Bellet, R | 1 |
| Lennard, L | 2 |
| Bondar', GV | 1 |
| Kaĭriak, OV | 1 |
| Lisovskaia, NIu | 1 |
| Kanibolotskiĭ, AL | 1 |
| González Barón, M | 1 |
| Wang, HM | 1 |
| Yang, TS | 1 |
| Chen, JS | 1 |
| Chang, HK | 1 |
| Lin, YC | 1 |
| Yeh, CT | 1 |
| Harte, RJ | 1 |
| Matthews, JC | 1 |
| O'Reilly, SM | 1 |
| Tilsley, DW | 1 |
| Brown, G | 2 |
| Luthra, SJ | 1 |
| Jones, T | 1 |
| Mrozek-Orlowski, ME | 1 |
| Frye, DK | 1 |
| Sanborn, HM | 1 |
| Young, AM | 1 |
| Daryanani, S | 1 |
| Bhalla, KN | 1 |
| Kumar, GN | 1 |
| Walle, UK | 1 |
| Ibrado, AM | 1 |
| Javed, T | 1 |
| Stuart, RK | 1 |
| Reed, C | 1 |
| Walle, T | 1 |
| Kvinnsland, S | 1 |
| Cameron, D | 1 |
| Steward, W | 1 |
| O'Byrne, K | 1 |
| Jones, D | 2 |
| Bush, E | 2 |
| Blanke, CD | 2 |
| Teng, M | 1 |
| Choy, H | 1 |
| Beale, PJ | 1 |
| Trigo, JM | 1 |
| Aherne, W | 1 |
| Crompton, T | 1 |
| Poplin, E | 1 |
| Roberts, J | 1 |
| Tombs, M | 1 |
| Grant, S | 1 |
| Rubin, E | 1 |
| Villalona-Calero, MA | 2 |
| Kraynak, M | 1 |
| Rodrigues, G | 1 |
| Drengler, RL | 1 |
| Moczygemba, J | 1 |
| Hughes, A | 1 |
| Calvert, H | 1 |
| Joseph, CD | 1 |
| Praveenkumar, V | 1 |
| Kuttan, G | 1 |
| Kuttan, R | 1 |
| Horii, I | 2 |
| Muto, Y | 1 |
| Takebuchi, K | 1 |
| Watanabe, M | 1 |
| Sakonji, M | 1 |
| Matsukawa, M | 1 |
| Tsuji, A | 1 |
| Morita, S | 1 |
| Horimi, T | 1 |
| Takasaki, M | 1 |
| Takahashi, I | 1 |
| Van Den Neste, E | 1 |
| de Valeriola, D | 1 |
| Kerger, J | 1 |
| Bleiberg, H | 1 |
| Kusenda, Z | 1 |
| Brassinne, C | 1 |
| Bartholomeus, S | 1 |
| Selleslags, J | 1 |
| Hennebert, P | 1 |
| Wythouck, H | 1 |
| Cazenave, I | 1 |
| Lefresne-Soulas, F | 1 |
| Piccart, M | 1 |
| Rinaldi, DA | 1 |
| Lormand, NA | 1 |
| Brierre, JE | 1 |
| Cole, JL | 1 |
| Stagg, MP | 1 |
| Fontenot, MF | 1 |
| Buller, EJ | 1 |
| Rainey, JM | 1 |
| Hoyer, KA | 1 |
| Lambin, P | 1 |
| Nuyts, S | 1 |
| Landuyt, W | 1 |
| Theys, J | 1 |
| De Bruijn, E | 1 |
| Anné, J | 1 |
| Van Mellaert, L | 1 |
| Fowler, J | 1 |
| Nakazato, H | 1 |
| Collie-Duguid, ES | 2 |
| Kinuya, S | 1 |
| Yokoyama, K | 1 |
| Konishi, S | 1 |
| Hiramatsu, T | 1 |
| Watanabe, N | 1 |
| Shuke, N | 1 |
| Aburano, T | 1 |
| Takayama, T | 1 |
| Michigishi, T | 1 |
| Tonami, N | 1 |
| Van Triest, B | 2 |
| Quan, WD | 1 |
| Casal, R | 1 |
| Gory-Delabaere, G | 1 |
| Cupissol, D | 1 |
| Brès, J | 1 |
| Gau, F | 1 |
| Constans, B | 1 |
| Nouguier-Soulé, J | 1 |
| Toma, H | 2 |
| Fukuda, M | 1 |
| Nagasue, N | 1 |
| Yamana, H | 1 |
| Hirakawa-YS Chung, K | 1 |
| Ikeda, T | 1 |
| Takasaki, K | 1 |
| Kameyama, M | 1 |
| Fujii, H | 1 |
| Kitamura, M | 1 |
| Murai, M | 1 |
| Sasaki, H | 1 |
| Ozono, S | 1 |
| Makuuchi, H | 1 |
| Shimada, Y | 1 |
| Onishi, Y | 1 |
| Aoyagi, S | 1 |
| Mizutani, K | 1 |
| Nakao, A | 1 |
| Kinoshita, H | 1 |
| Tono, T | 1 |
| Imamoto, H | 1 |
| Nakashima, Y | 1 |
| Manabe, T | 1 |
| Pronk, LC | 1 |
| Vasey, P | 1 |
| Planting, AS | 1 |
| Li, BS | 1 |
| Payne, GS | 1 |
| Collins, DJ | 1 |
| Canaparo, R | 1 |
| Casale, F | 1 |
| Muntoni, E | 1 |
| Zara, GP | 1 |
| Della Pepa, C | 1 |
| Berno, E | 1 |
| Pons, N | 1 |
| Fornari, G | 1 |
| Eandi, M | 1 |
| Paridaens, R | 1 |
| Uges, DR | 1 |
| Barbet, N | 1 |
| Choi, L | 1 |
| Seeghers, M | 1 |
| van der Graaf, WT | 1 |
| Groen, HJ | 1 |
| Buuren, IV | 1 |
| Muskiet, F | 1 |
| Capdeville, R | 1 |
| Oosterom, AT | 1 |
| Backus, HH | 2 |
| Wouters, D | 1 |
| Molders, N | 1 |
| Jansen, G | 2 |
| Blumenson, LE | 2 |
| Frank, C | 1 |
| Eager, R | 1 |
| Twaddell, T | 1 |
| Corey, A | 1 |
| Sekar, K | 1 |
| Tkaczuk, K | 1 |
| Hoff, PM | 3 |
| Madajewicz, S | 1 |
| Hentschel, P | 1 |
| Burns, P | 1 |
| Caruso, R | 1 |
| Fiore, J | 1 |
| Fried, M | 1 |
| Malhotra, H | 1 |
| Ostrow, S | 1 |
| Sugarman, S | 1 |
| Viola, M | 1 |
| Isonishi, S | 1 |
| Ogawa, O | 1 |
| Shibuya, M | 1 |
| Sone, S | 1 |
| Tsuruo, T | 1 |
| Noguchi, S | 1 |
| Hinotsu, S | 1 |
| Kono, S | 1 |
| Mikami, O | 1 |
| Blackledge, G | 1 |
| Vose, B | 1 |
| Stribling, D | 1 |
| Levin, J | 1 |
| Shapiro, J | 3 |
| Bi, DQ | 1 |
| Zentko, S | 2 |
| Keith, B | 2 |
| Donavan, S | 1 |
| von Heideman, A | 1 |
| Csoka, K | 1 |
| Tholander, B | 1 |
| Larsson, R | 1 |
| Bergh, J | 1 |
| Ochoa, L | 1 |
| Cohen, D | 1 |
| Monroe, P | 1 |
| Ertel, VP | 1 |
| Hsieh, A | 1 |
| Hoffman, C | 1 |
| Magnum, S | 1 |
| Royce, ME | 1 |
| Haasjes, J | 1 |
| Van Lenthe, H | 1 |
| De Abreu, RA | 1 |
| Vreken, P | 1 |
| Heise, C | 1 |
| Lemmon, M | 1 |
| Kirn, D | 1 |
| Margolin, K | 1 |
| Holmgren, E | 1 |
| Gaudreault, J | 1 |
| Novotny, W | 1 |
| Fyfe, G | 1 |
| Adelman, D | 1 |
| Stalter, S | 1 |
| Breed, J | 1 |
| Boushey, RP | 1 |
| Yusta, B | 1 |
| Drucker, DJ | 1 |
| Kuhn, JG | 1 |
| Saad, ED | 1 |
| Lee, KH | 1 |
| Rudolph, KL | 1 |
| Ju, YJ | 1 |
| Greenberg, RA | 1 |
| Cannizzaro, L | 1 |
| Chin, L | 1 |
| Weiler, SR | 1 |
| DePinho, RA | 1 |
| Scieszka, M | 1 |
| Zielinski, M | 1 |
| Machalski, M | 1 |
| Herman, ZS | 1 |
| Kanda, Y | 1 |
| Akagi, K | 1 |
| Caponigro, F | 2 |
| Avallone, A | 2 |
| Rivellini, F | 1 |
| Comella, P | 2 |
| Ionna, F | 1 |
| De Rosa, V | 1 |
| Comella, G | 2 |
| Stipanov, M | 1 |
| Morrow, J | 1 |
| Rothenberg, M | 1 |
| Chinery, R | 1 |
| Shyr, Y | 1 |
| Coffey, R | 1 |
| Johnson, DH | 1 |
| Leach, SD | 1 |
| Beauchamp, RD | 1 |
| de Bono, JS | 1 |
| Moiseenko, VM | 1 |
| Semenova, AI | 1 |
| Orlova, RV | 1 |
| Sulkes, A | 1 |
| Khang, G | 1 |
| Kim, SW | 1 |
| Cho, JC | 1 |
| Rhee, JM | 1 |
| Yoon, SC | 1 |
| Lee, HB | 1 |
| Tichler, T | 1 |
| Ghodsizade, E | 1 |
| Katz, A | 1 |
| Rath, P | 1 |
| Berger, R | 1 |
| Brenner, H | 1 |
| Becker, P | 1 |
| D'Hondt, L | 1 |
| Frimberger, A | 1 |
| Lambert, JF | 1 |
| Colvin, GA | 1 |
| Miller, C | 1 |
| Heyes, C | 1 |
| Abedi, M | 1 |
| Dooner, M | 1 |
| Carlson, J | 1 |
| Reilly, J | 1 |
| McAuliffe, C | 1 |
| Stencel, K | 1 |
| Ballen, K | 1 |
| Emmons, R | 1 |
| Doyle, P | 1 |
| Zhong, S | 1 |
| Habibian, H | 1 |
| Budillon, A | 1 |
| Tanaka, F | 1 |
| Fukuse, T | 1 |
| Kuhara, T | 1 |
| Ohdoi, C | 1 |
| Ohse, M | 1 |
| Bogolioubov, A | 1 |
| Groeger, JS | 1 |
| Kusuhara, H | 1 |
| Sugiyama, Y | 1 |
| Sharma, RA | 1 |
| Eatock, MM | 1 |
| McLelland, HR | 1 |
| Clayton, KT | 1 |
| O'Byrne, KJ | 1 |
| Moyses, C | 1 |
| Carmichael, J | 1 |
| Steward, WP | 1 |
| McGinn, CJ | 2 |
| Longley, DB | 1 |
| Ferguson, PR | 1 |
| Boyer, J | 1 |
| Latif, T | 1 |
| Lynch, M | 1 |
| Maxwell, P | 1 |
| Harkin, DP | 1 |
| Niculescu-Duvaz, I | 1 |
| Cooper, RG | 1 |
| Stribbling, SM | 1 |
| Heyes, JA | 1 |
| Metcalfe, JA | 1 |
| Springer, CJ | 1 |
| Bertucci, D | 2 |
| Stadler, WM | 1 |
| Damle, BD | 1 |
| Narasimhan, NI | 1 |
| Kaul, S | 1 |
| Matthews, NE | 1 |
| Adams, MA | 1 |
| Maxwell, LR | 1 |
| Gofton, TE | 1 |
| Graham, CH | 1 |
| Chang, DZ | 1 |
| Olencki, T | 1 |
| Budd, GT | 2 |
| Peereboom, D | 1 |
| Ganapathi, R | 1 |
| Bukowski, R | 1 |
| Bartelink, H | 1 |
| Verheij, M | 1 |
| Wilke, H | 1 |
| Hanson, LJ | 1 |
| Poole, C | 1 |
| Gardiner, J | 1 |
| Monkhouse, J | 1 |
| Rudin, CM | 1 |
| Kunkel, K | 1 |
| Holmlund, JT | 1 |
| Geary, RS | 1 |
| Dorr, FA | 1 |
| Chamorey, AL | 1 |
| Ferguson, MJ | 1 |
| Ahmed, FY | 1 |
| Innocenti, F | 1 |
| Celik, I | 1 |
| Kars, A | 1 |
| Guc, D | 1 |
| Tekuzman, G | 1 |
| Ruacan, S | 1 |
| Nadella, P | 1 |
| Shapiro, C | 1 |
| Otterson, GA | 1 |
| Hauger, M | 1 |
| Erdal, S | 1 |
| Kraut, E | 1 |
| Clinton, S | 1 |
| Stanek, M | 1 |
| Monk, P | 1 |
| Evans, TR | 1 |
| Tabemero, J | 1 |
| Eatock, M | 1 |
| Regueiro, P | 1 |
| Baselga, J | 1 |
| Tsavaris, N | 2 |
| Kosmas, C | 1 |
| Vadiaka, M | 1 |
| Efremidis, M | 1 |
| Zinelis, A | 1 |
| Beldecos, D | 1 |
| Sakelariou, D | 1 |
| Koufos, C | 1 |
| Stamatelos, G | 1 |
| Leffert, JJ | 1 |
| Russell, RL | 1 |
| Handschumacher, RE | 2 |
| Banerjee, D | 1 |
| Mayer-Kuckuk, P | 1 |
| Capiaux, G | 1 |
| Budak-Alpdogan, T | 1 |
| Gorlick, R | 1 |
| Bertino, JR | 3 |
| Freemantle, S | 1 |
| Codacci-Pisanelli, G | 1 |
| Lunec, J | 1 |
| Calvert, AH | 2 |
| Bloemena, E | 1 |
| Meijer, S | 1 |
| Price, LA | 2 |
| Hill, BT | 1 |
| Shaw, HJ | 2 |
| Hughes, KB | 1 |
| DeWys, WD | 1 |
| Vider, M | 1 |
| Kashmin, R | 1 |
| Meeker, WR | 1 |
| Moses, B | 1 |
| Maruyama, Y | 2 |
| Schumann, J | 1 |
| Ehring, F | 1 |
| Gohde, W | 1 |
| Myers, CE | 3 |
| Oliverio, VT | 1 |
| Greenwald, DW | 1 |
| Phillips, C | 1 |
| Bennett, JM | 1 |
| Kohlschütter, B | 1 |
| Jehn, U | 1 |
| Dorr, RT | 2 |
| Trinca, CE | 1 |
| Griffith, K | 1 |
| Dombrowsky, PL | 1 |
| Salmon, SE | 1 |
| Athlin, L | 2 |
| Domellöf, L | 2 |
| Björkstén, B | 1 |
| Le Pecq, JB | 1 |
| Soejima, S | 1 |
| Chawla, PL | 1 |
| Johns, DG | 1 |
| Mattern, J | 3 |
| Kaufmann, M | 2 |
| Hinderer, H | 1 |
| Wayss, K | 3 |
| Volm, M | 3 |
| Oberfield, RA | 3 |
| Livingston, RB | 1 |
| Boggust, WA | 1 |
| McGauley, H | 1 |
| Chavaudra, N | 1 |
| Malaise, EP | 1 |
| Rozencweig, M | 1 |
| Louie, AC | 1 |
| Ezdinli, EZ | 1 |
| Simonson, KL | 1 |
| Smith, RA | 1 |
| Golubeva, VA | 1 |
| Osipov, NE | 1 |
| Bukharova, IK | 1 |
| Smolianskaia, AZ | 3 |
| Aledseev, VM | 1 |
| Sokolova, VD | 1 |
| Sawai, K | 2 |
| Sonoda, Y | 1 |
| Ohkuma, S | 1 |
| Misawa, S | 2 |
| Takino, T | 2 |
| Hall, SW | 1 |
| Benjamin, RS | 1 |
| Shioda, R | 1 |
| Nomura, Y | 1 |
| Hall, TC | 4 |
| Schotz, W | 1 |
| Shnider, BI | 1 |
| Taylor, S | 1 |
| Sokova, OI | 1 |
| Volgareva, GM | 1 |
| Weiss, RB | 2 |
| DeVita, VT | 1 |
| Kaplan, HS | 1 |
| Schein, PS | 2 |
| Jones, KD | 1 |
| Hughes, LE | 1 |
| Bross, ID | 5 |
| Danjoux, CE | 1 |
| Finch, RE | 1 |
| Bending, MR | 1 |
| Lant, AF | 1 |
| Masuda, M | 1 |
| Kawai, K | 1 |
| Musilová, J | 1 |
| Michalová, K | 1 |
| Urban, J | 1 |
| De Leenheer, AP | 1 |
| Cosyns-Duyck, MC | 1 |
| Ikeda, H | 1 |
| Niimoto, M | 3 |
| Hattori, T | 5 |
| Kurokawa, T | 1 |
| Furukawa, K | 2 |
| Kanko, T | 2 |
| Yokoyama, T | 1 |
| Ohashi, Y | 1 |
| Kono, A | 1 |
| Eguchi, S | 1 |
| Matsushima, Y | 1 |
| Streffer, C | 1 |
| Warren, RD | 1 |
| Bender, RA | 1 |
| Bishun, NP | 1 |
| Reed, J | 1 |
| Williams, D | 4 |
| Nordman, E | 2 |
| Saarimaa, H | 1 |
| Toivanen, A | 1 |
| Pottage, A | 1 |
| Holt, S | 1 |
| Ludgate, S | 1 |
| Langlands, AO | 1 |
| Berghem, L | 1 |
| MacMillan, WE | 1 |
| Welling, PG | 1 |
| Higgins, GA | 1 |
| Missmahl, HP | 1 |
| Mazloumi, B | 1 |
| Hobara, N | 1 |
| Watanabe, A | 1 |
| Slavik, M | 1 |
| Heppner, GH | 1 |
| Minnich, V | 1 |
| Smith, ME | 1 |
| Thompson, D | 1 |
| Kornfeld, S | 1 |
| Blokhin, NN | 1 |
| Copeland, EM | 4 |
| MacFadyen, BV | 1 |
| Lanzotti, VJ | 1 |
| Dudrick, SJ | 4 |
| Souchon, EA | 1 |
| Watson, P | 1 |
| Berry, RJ | 1 |
| Laing, AH | 1 |
| Wells, J | 1 |
| Serrou, B | 1 |
| Dubois, JB | 1 |
| Hill, GJ | 3 |
| Metter, G | 1 |
| Davis, HL | 3 |
| Grage, T | 1 |
| Cruz, AB | 2 |
| Bearden, JD | 1 |
| Coltman, CA | 2 |
| Moon, TE | 1 |
| Costanzi, JJ | 2 |
| Balcerzak, SP | 1 |
| Rivkin, SE | 1 |
| Morrison, FS | 1 |
| Spigel, SC | 1 |
| Jamieson, GG | 1 |
| Carter, DC | 1 |
| Smolyanskaya, AZ | 1 |
| Felsch, G | 1 |
| Barthel, E | 1 |
| Eliot, HM | 1 |
| Hillcoat, BL | 2 |
| McCulloch, PB | 1 |
| Rosenfeld, J | 1 |
| Williams, CK | 1 |
| Baumgartner, G | 1 |
| Siebner, H | 2 |
| Focan, C | 1 |
| Dowell, KE | 1 |
| Armstrong, DM | 1 |
| Slack, NH | 3 |
| Townsend, LB | 1 |
| Rusho, WJ | 1 |
| Eyre, HJ | 1 |
| Quagliana, JM | 1 |
| Wilson, ML | 1 |
| Edwards, CB | 1 |
| Manning, SJ | 1 |
| Rieche, K | 6 |
| Matthes, ML | 1 |
| Old, LJ | 1 |
| Krakoff, IH | 1 |
| van Dyk, JJ | 3 |
| van der Merwe, AM | 3 |
| Falkson, HC | 3 |
| Bodey, GP | 1 |
| Gottlieb, JA | 1 |
| Freireich, EJ | 1 |
| Tugarinov, OA | 1 |
| Schmoll, HJ | 1 |
| Malet-Martino, MC | 2 |
| Jaillais, P | 1 |
| Shubinski, RE | 1 |
| Bachaud, JM | 1 |
| Lemaire, L | 2 |
| Carrié, D | 1 |
| Moore, DF | 1 |
| Posner, MR | 2 |
| Darnowski, JW | 2 |
| Dudley, MN | 1 |
| Corvese, D | 2 |
| Clark, J | 2 |
| Murray, C | 1 |
| Clendennin, N | 1 |
| Bigley, J | 1 |
| Visini, R | 1 |
| Aceto, L | 1 |
| Rapani, C | 1 |
| Sica, G | 1 |
| Trulli, R | 1 |
| Zakaria, M | 1 |
| Gaspari, AL | 1 |
| Tinari, N | 1 |
| Natoli, C | 1 |
| Graczyk, J | 1 |
| Kinsella, TJ | 1 |
| Narasimha, K | 1 |
| Sandovsky-Losica, H | 1 |
| Barr-Nea, L | 1 |
| Segal, E | 1 |
| Abe, M | 2 |
| Nakajima, I | 1 |
| Koike, T | 1 |
| Hayashi, T | 1 |
| Honda, H | 5 |
| Fuchinoue, S | 4 |
| Teraoka, S | 5 |
| Agishi, T | 5 |
| Otaka, T | 1 |
| Taylor, CW | 1 |
| Modiano, MR | 1 |
| Woodson, ME | 1 |
| Marcus, SG | 1 |
| Alberts, DS | 1 |
| Hersh, EM | 1 |
| Akman, SA | 1 |
| Harrison, JS | 1 |
| Raschko, JW | 1 |
| Ahn, CW | 1 |
| Thyss, A | 3 |
| Gaspard, MH | 1 |
| Marsault, R | 1 |
| Frelin, C | 1 |
| Schneider, M | 4 |
| Seitz, DE | 1 |
| Lasserre, B | 1 |
| Tutsch, KD | 2 |
| Tombes, MB | 2 |
| Spriggs, DR | 1 |
| Brown, TD | 1 |
| Itri, LM | 1 |
| Alley, MC | 1 |
| Pacula-Cox, CM | 1 |
| Hursey, ML | 1 |
| Rubinstein, LR | 1 |
| Boyd, MR | 1 |
| Zonnenberg, BA | 1 |
| de Graeff, A | 1 |
| van Milligen de Wit, AW | 1 |
| Tjia, P | 1 |
| Neijt, JP | 1 |
| Walczak, J | 1 |
| Comis, RL | 3 |
| Neefe, JR | 1 |
| John, W | 1 |
| Weckbecker, G | 1 |
| Horikoshi, T | 1 |
| Stadlbauer, TH | 1 |
| Volkenandt, M | 1 |
| Shea, LC | 1 |
| Aigner, K | 1 |
| Leichman, L | 1 |
| Frösing, R | 1 |
| Ray, M | 1 |
| Stridhar, K | 1 |
| Reddy, R | 1 |
| Benedetto, P | 2 |
| Richman, S | 2 |
| Waldman, S | 2 |
| Morrell, L | 2 |
| Feun, L | 2 |
| Savaraj, N | 2 |
| Livingstone, A | 2 |
| Pourreau-Schneider, N | 1 |
| Soudry, M | 1 |
| Franquin, JC | 1 |
| Zattara, H | 1 |
| Martin, PM | 1 |
| Ciais, G | 1 |
| Namer, M | 1 |
| Chauvel, P | 1 |
| Demard, F | 2 |
| Yamada, S | 1 |
| Nanninga, AG | 1 |
| Willemse, PH | 1 |
| Oosterhuis, BE | 1 |
| Sleijfer, DT | 1 |
| Hoekstra, HJ | 1 |
| Mulder, NH | 1 |
| Yeh, GC | 1 |
| Tsai, CM | 1 |
| Gazdar, AF | 1 |
| Perng, RP | 1 |
| Kramer, BS | 1 |
| Anderson, N | 4 |
| Bern, M | 4 |
| Coco, F | 1 |
| Moore, C | 4 |
| Gonsalves, L | 1 |
| Sridhar, KS | 1 |
| Fodor, M | 1 |
| Port, RE | 3 |
| Daniel, B | 1 |
| Ding, RW | 1 |
| Patel, R | 1 |
| Villacorte, DG | 1 |
| Sato, JK | 1 |
| Reaman, GH | 1 |
| Finklestein, JZ | 1 |
| Krailo, MD | 1 |
| Hammond, GD | 1 |
| Holcenberg, JS | 1 |
| Suga, T | 1 |
| Takahashi, Y | 1 |
| Mai, M | 1 |
| Fournier, C | 1 |
| Hecquet, B | 1 |
| Bouffard, P | 1 |
| Vert, M | 1 |
| Caty, A | 1 |
| Vilain, MO | 1 |
| Vanseymortier, L | 1 |
| Merle, S | 1 |
| Krikorian, A | 1 |
| Lefebvre, JL | 1 |
| Saphner, T | 1 |
| Tormey, DC | 2 |
| Albertini, M | 1 |
| Furukawa, T | 1 |
| Suto, A | 1 |
| Takahara, T | 1 |
| Takeuchi, T | 1 |
| Kase, S | 1 |
| Kodaira, S | 1 |
| Ishibiki, K | 1 |
| Kitajima, M | 1 |
| Meadows, LM | 1 |
| Walther, P | 1 |
| Ozer, H | 1 |
| Ritch, PS | 1 |
| Libnoch, JA | 1 |
| Edler, L | 1 |
| Feldmann, U | 1 |
| Rotman, M | 1 |
| Aziz, H | 1 |
| Yamaue, H | 1 |
| Tanimura, H | 1 |
| Terashita, S | 1 |
| Iwahashi, M | 1 |
| Tani, M | 1 |
| Tsunoda, T | 1 |
| Tamai, M | 1 |
| Reece, PA | 1 |
| Olver, IN | 1 |
| Morris, RG | 1 |
| Bishop, JF | 1 |
| Guentert, TW | 1 |
| Hill, HS | 1 |
| Romanini, A | 1 |
| Uchida, M | 1 |
| Kamiya, K | 1 |
| Yoshimura, T | 1 |
| Tsutani, H | 1 |
| Uwajima, T | 1 |
| Oshiro, T | 1 |
| Eguchi, T | 1 |
| Horiguchi, A | 1 |
| Igarashi, A | 1 |
| Mochida, K | 1 |
| Iwakura, M | 1 |
| Albright, MJ | 2 |
| Servis, KL | 1 |
| Ring, R | 1 |
| Atkinson, D | 1 |
| Ong, RL | 1 |
| King, M | 1 |
| Brunetti, I | 1 |
| Curt, G | 2 |
| Beitz, J | 1 |
| Karagiaouris, P | 1 |
| Vonorta, K | 1 |
| Bacogianis, H | 1 |
| Milonakis, N | 1 |
| Karvounis, N | 1 |
| Kakoliris, S | 1 |
| Zepou, E | 1 |
| Karabelis, A | 1 |
| Papazahariou, M | 1 |
| Fischer, PH | 2 |
| Nieting, LM | 1 |
| Bruggink, J | 1 |
| Willson, JK | 1 |
| Trump, DL | 1 |
| Green, DM | 1 |
| Krischer, JP | 1 |
| Bell, B | 1 |
| Brecher, ML | 1 |
| Cushing, B | 1 |
| Whitehead, VM | 1 |
| Abbruzzese, JL | 1 |
| Amato, R | 1 |
| Schmidt, S | 1 |
| Raber, MN | 1 |
| Frost, P | 1 |
| Yamanaka, N | 1 |
| Kato, N | 1 |
| Ganem, G | 1 |
| Carde, P | 2 |
| Gouyette, A | 1 |
| Kakuta, H | 1 |
| Ishioka, C | 1 |
| Konishi, Y | 1 |
| Ishikawa, A | 1 |
| Asamura, M | 1 |
| McIntosh-Lowe, NL | 1 |
| Rose, CM | 1 |
| Zharkov, SA | 1 |
| Batov, SV | 1 |
| Strauss, LG | 2 |
| Semmler, W | 1 |
| Wallach, S | 3 |
| Umprayn, V | 1 |
| Morgan, RG | 1 |
| LaCreta, F | 1 |
| DeLap, RJ | 1 |
| Grillo-Lopez, AJ | 1 |
| Catalano, R | 1 |
| Benahmed, M | 1 |
| Laplanche, A | 1 |
| Renaux, J | 1 |
| Rouesse, J | 1 |
| Spielmann, M | 1 |
| Sancho-Garnier, H | 1 |
| Laurensse, E | 2 |
| Wang, QL | 1 |
| Bleyer, WA | 1 |
| Klubes, P | 1 |
| Leyland-Jones, B | 2 |
| Miser, AW | 1 |
| Kardinal, C | 1 |
| Everson, LK | 1 |
| Ahlquist, DA | 1 |
| Dose, AM | 1 |
| Byfield, JE | 3 |
| Mathé, G | 1 |
| Kidani, Y | 1 |
| Segiguchi, M | 1 |
| Fredj, G | 1 |
| Peytavin, G | 1 |
| Misset, JL | 1 |
| de Vassals, F | 1 |
| Chenu, E | 1 |
| Jinushi, K | 1 |
| Kim, R | 1 |
| Saeki, K | 1 |
| Yoshinaka, K | 1 |
| Yanagawa, E | 1 |
| Santini, J | 1 |
| Frenay, M | 1 |
| Ohya, K | 1 |
| Soh, M | 1 |
| Kaneko, H | 1 |
| Kawai, T | 1 |
| Yamazaki, S | 1 |
| Iwasaki, M | 1 |
| Kameya, S | 1 |
| Denham, A | 1 |
| Wiebe, VJ | 1 |
| DeGregorio, MW | 1 |
| Goren, MP | 1 |
| Forastiere, AA | 1 |
| Wright, RK | 1 |
| Horowitz, ME | 1 |
| Dodge, RK | 1 |
| Kamen, BA | 1 |
| Viar, MJ | 1 |
| Beauchamp, K | 1 |
| Lönn, U | 1 |
| Lönn, S | 1 |
| Barni, S | 1 |
| Lissoni, P | 1 |
| Tancini, G | 1 |
| Crispino, S | 1 |
| Paolorossi, F | 1 |
| Rovelli, F | 1 |
| Fumagalli, G | 1 |
| Ferri, L | 1 |
| Esposti, D | 1 |
| Esposti, G | 1 |
| Nishimura, J | 1 |
| Kamiyama, T | 1 |
| Clavel, M | 1 |
| Siméone, P | 1 |
| Grivet, B | 1 |
| Huennekens, FM | 1 |
| Montejano, YD | 1 |
| Vitols, KS | 1 |
| Becher, R | 1 |
| Kurschel, E | 1 |
| Wandl, U | 1 |
| Kloke, O | 1 |
| Scheulen, M | 1 |
| Weinhardt, O | 1 |
| Höffken, K | 1 |
| Niederle, N | 1 |
| Khan, H | 1 |
| Bergner, S | 1 |
| Nakazawa, H | 4 |
| Okumura, T | 1 |
| Goto, T | 1 |
| Urata, A | 1 |
| Sugiura, T | 1 |
| Hirabayashi, N | 1 |
| Noso, Y | 1 |
| Niimi, K | 1 |
| Yamaguchi, M | 1 |
| Hull, WE | 1 |
| Britsch, B | 1 |
| Kunz, W | 1 |
| Yamamoto, Y | 1 |
| Amano, T | 1 |
| Imada, T | 1 |
| Tamura, S | 1 |
| Matsumoto, A | 1 |
| Caballero, GA | 1 |
| Giai, M | 1 |
| De Fabiani, E | 1 |
| Lamberto, A | 1 |
| Cortese, P | 1 |
| Giardina, G | 1 |
| Konovalova, NP | 1 |
| D'iachkovskaia, RF | 1 |
| Ganieva, LKh | 1 |
| Volkova, LM | 1 |
| Lapshin, IM | 1 |
| Sugiyama, S | 1 |
| Kuwahara, K | 1 |
| Kitahara, M | 1 |
| Mashiyama, S | 1 |
| Takahashi, K | 4 |
| Kanno, S | 1 |
| Isobe, Y | 1 |
| Robinson, PJ | 1 |
| Bass, L | 1 |
| Pond, SM | 1 |
| Roberts, MS | 1 |
| Wagner, JG | 1 |
| Pályi, I | 1 |
| Straw, JA | 1 |
| King, SA | 1 |
| Hoth, DF | 1 |
| Shiu, W | 1 |
| Tsang, V | 1 |
| Lam, YM | 1 |
| Zacharia, A | 1 |
| Martin, WM | 1 |
| Petit, E | 1 |
| Bailleul, F | 1 |
| Hamazoe, R | 1 |
| Murakami, A | 1 |
| Inoue, Y | 1 |
| Ishiguro, M | 1 |
| Sawata, T | 1 |
| Shimizu, T | 1 |
| D'Atri, S | 1 |
| Fuggetta, MP | 1 |
| Giganti, G | 1 |
| Tentori, L | 1 |
| Roselli, M | 1 |
| Nunziata, C | 1 |
| Pastore, S | 1 |
| Bonmassar, E | 1 |
| De Vecchis, L | 1 |
| Keniry, M | 1 |
| Shafer, RH | 1 |
| James, TL | 1 |
| Schreiber, MJ | 1 |
| Steiger, E | 1 |
| Bukowski, RM | 1 |
| Weick, JK | 1 |
| Gorni, F | 1 |
| Marpicati, P | 1 |
| Montini, E | 1 |
| Simoncini, E | 1 |
| Satou, H | 1 |
| Kamano, T | 1 |
| Izumi, T | 1 |
| Yoshida, M | 1 |
| Ito, M | 1 |
| Taki, T | 1 |
| Reshad, K | 1 |
| Ninomiya, K | 1 |
| Ikeda, S | 1 |
| Oba, S | 1 |
| Kihara, K | 1 |
| Huchinoue, S | 1 |
| Silver, MS | 1 |
| Weber, H | 1 |
| Reichardt, U | 1 |
| Sauer, R | 1 |
| Kusumoto, H | 1 |
| Anai, H | 1 |
| Kusumoto, T | 1 |
| Hiramoto, Y | 1 |
| Ohta, K | 1 |
| Akimoto, M | 1 |
| Nishihira, T | 1 |
| Kasai, M | 1 |
| Kraal, I | 1 |
| Patchell, RA | 1 |
| Posner, JB | 1 |
| Naguib, FN | 1 |
| el Kouni, MH | 1 |
| Cha, S | 1 |
| Woolley, PV | 1 |
| Ayoob, MJ | 1 |
| Smith, FP | 1 |
| Lokey, JL | 1 |
| DeGreen, P | 1 |
| Marantz, A | 1 |
| Schwartz, PM | 1 |
| Turek, PJ | 1 |
| Hyde, CM | 1 |
| Frankel, SS | 2 |
| Sharp, TR | 2 |
| Hornbeck, CL | 2 |
| Callipari, FB | 2 |
| Kawasaki, H | 1 |
| Nobori, T | 1 |
| Kamiya, H | 1 |
| Sakurai, M | 1 |
| Garin, AM | 2 |
| Mamedov, FF | 1 |
| DeGregorio, M | 1 |
| Saks, S | 1 |
| Sambol, N | 1 |
| Holleran, W | 1 |
| Ignoffo, R | 1 |
| Lewis, B | 1 |
| Beaupain, R | 1 |
| Dionet, C | 1 |
| Phillips, D | 1 |
| Zipoli, TE | 1 |
| Byar, DP | 1 |
| Piantadosi, S | 1 |
| Floyd, RA | 1 |
| Bounous, G | 1 |
| Gentile, JM | 1 |
| Hugon, J | 1 |
| Cappelaere, P | 1 |
| Wada, T | 1 |
| Oara, H | 1 |
| Mayer, M | 1 |
| Colon, J | 1 |
| Donegan, WL | 1 |
| Harris, HS | 1 |
| Gary-Bobo, J | 1 |
| Franke, HD | 1 |
| Bergevin, PR | 1 |
| Greenwald, ES | 1 |
| Galt, RM | 4 |
| Oester, YT | 4 |
| Sylvester, R | 3 |
| Ikawa, Y | 1 |
| Brescia, T | 1 |
| Johnson, RK | 1 |
| Goerttler, K | 1 |
| Snow, GB | 2 |
| Sindram, PJ | 1 |
| Simmonds, WP | 1 |
| Wand, H | 2 |
| Siering, VH | 1 |
| Abendroth, K | 1 |
| Goffinet, DR | 1 |
| Bagshaw, MA | 1 |
| Allen, BL | 1 |
| Frenster, JH | 1 |
| Navashin, SM | 1 |
| Fomina, IP | 1 |
| Osokina, LI | 1 |
| Zharikov, AA | 1 |
| Liebman, IM | 1 |
| Maguire, HC | 1 |
| Muller, CJ | 1 |
| Wüst, GP | 1 |
| Zimmermann, G | 1 |
| Boeckl, O | 1 |
| Nervi, C | 1 |
| Casale, C | 1 |
| Cortese, M | 1 |
| Ammon, J | 1 |
| Giesen, M | 1 |
| Schwab, W | 1 |
| Palme, G | 1 |
| Macfayden, BV | 1 |
| Andreesu, M | 1 |
| Matefsu, C | 1 |
| Mogos, I | 1 |
| Mudric, V | 1 |
| Caspersson, T | 1 |
| Farber, S | 1 |
| Foley, GE | 1 |
| Killander, D | 1 |
| Zetterberg, A | 1 |
| Blomgren, SE | 1 |
| Dendy, PP | 1 |
| Fennelly, JJ | 1 |
| Fitzgerald, MX | 1 |
| Windheuser, JJ | 2 |
| Jato, J | 1 |
| Cady, B | 1 |
| Booth, JC | 1 |
| Ti, TK | 1 |
| Yong, NK | 1 |
| Tashima, CK | 1 |
| Arndt, A | 1 |
| Watt, J | 1 |
| Bergsagel, DE | 1 |
| Kenis, Y | 1 |
| Nitze, HR | 6 |
| Ganzer, U | 4 |
| Vosteen, KH | 2 |
| Israel, L | 2 |
| Depierre, A | 2 |
| Moskalik, KG | 1 |
| Kozlov, AP | 1 |
| Akimov, AA | 1 |
| Moertel, C | 1 |
| Kirsch, WM | 1 |
| Schulz, D | 1 |
| Van Buskirk, JJ | 1 |
| Young, HE | 1 |
| Sparwald, E | 1 |
| Müllensiefen, C | 1 |
| Lange, G | 1 |
| Slanina, I | 1 |
| The, KK | 1 |
| Pettigrew, RT | 1 |
| Galt, JM | 1 |
| Ludgate, CM | 1 |
| Smith, AN | 1 |
| Hecker, D | 1 |
| Klug, H | 1 |
| Rose, H | 1 |
| Lychev, VA | 1 |
| Yokoyama, M | 3 |
| Padilla, H | 1 |
| Mackman, S | 1 |
| Ramirez, G | 3 |
| Freckman, HA | 1 |
| Kühböck, J | 2 |
| Shigematsu, Y | 1 |
| Waddell, WR | 1 |
| Grover, FL | 1 |
| Glenn, EH | 1 |
| Cole, D | 1 |
| Wunderlich, HO | 1 |
| Klaassen, DJ | 1 |
| Friedkin, M | 1 |
| Ellerby, RA | 1 |
| Hackethal, L | 1 |
| Larsen, RR | 1 |
| Bridge, MF | 1 |
| Melamed, MR | 1 |
| Kummer, F | 1 |
| Berenbaum, MC | 1 |
| Imaizumi, M | 1 |
| Tanaka, N | 1 |
| Takahashi, M | 2 |
| Foley, JF | 1 |
| Miller, DM | 1 |
| Tisman, G | 1 |
| Herbert, V | 1 |
| Edlis, H | 1 |
| Omura, GA | 1 |
| Roberts, GA | 1 |
| Priestman, TJ | 1 |
| Van Eden, EB | 2 |
| Hamersley, J | 1 |
| Luce, JK | 2 |
| Florentz, TR | 1 |
| Burkholder, MM | 1 |
| Pepper, JJ | 1 |
| Gerner, RE | 1 |
| Karjalainen, J | 1 |
| Wasastjerna, C | 1 |
| Mil'man, MSh | 1 |
| Litvin, AI | 1 |
| Karimova, SB | 1 |
| Shek, BA | 1 |
| Lee, TC | 1 |
| Sullivan, S | 1 |
| Fritsch, H | 1 |
| Castor, H | 1 |
| Drings, P | 1 |
| Moskwa, G | 1 |
| Di Pietro, S | 1 |
| De Palo, GM | 1 |
| Gennari, L | 1 |
| Molinari, R | 1 |
| Damascelli, B | 1 |
| Ogaki, K | 1 |
| Inoue, A | 1 |
| Osaragi, M | 1 |
| Koyama, T | 1 |
| Himori, T | 1 |
| Mohr, A | 1 |
| Bruckner, HW | 1 |
| Creasey, WA | 1 |
| Raven, RW | 1 |
| Williams, DC | 1 |
| Berndt, H | 1 |
| Kuśnierczykówna, J | 1 |
| Iwanicka, B | 1 |
| Egawa, J | 1 |
| Lüscher, EF | 1 |
| Astrakhan, VI | 1 |
| Ausmans, R | 1 |
| Jones, R | 3 |
| Slack, N | 1 |
| Rimm, AA | 3 |
| Burdette, WJ | 1 |
| Chahinian, P | 1 |
| Shetty, PA | 1 |
| Wilmanns, W | 1 |
| Tsuya, A | 1 |
| Kaneda, K | 1 |
| Okano, S | 1 |
| Goto, H | 1 |
| Clément, F | 1 |
| Nolan, TR | 1 |
| Crumbley, AJ | 1 |
| Grady, CK | 1 |
| Horton, J | 2 |
| Cunningham, T | 1 |
| Sullivan, J | 1 |
| Schwartz, GF | 1 |
| Green, HL | 1 |
| Bendon, ML | 1 |
| Graham, WP | 1 |
| Blakemore, WS | 1 |
| Couture, J | 1 |
| Deschênes, L | 1 |
| Izsak, FC | 1 |
| Eylan, E | 1 |
| Naharin, A | 1 |
| Schmähl, D | 1 |
| Magarey, CJ | 2 |
| Grage, TB | 1 |
| Wilson, W | 1 |
| Jewell, WR | 1 |
| Gulesserian, HP | 2 |
| Sharzer, LA | 1 |
| Lleander, VC | 1 |
| Goldstein, G | 1 |
| Horsley, JS | 1 |
| O'Brien, PH | 1 |
| Artz, CP | 1 |
| al-Sarraf, M | 2 |
| Vaughn, CB | 1 |
| Reed, ML | 1 |
| Vaitkevicious, VK | 1 |
| Vozny, EK | 1 |
| Sutter, JL | 1 |
| Auen, E | 1 |
| Harashima, S | 1 |
| Berstad, T | 1 |
| Liavåg, I | 1 |
| Tamsfoss, S | 1 |
| Jacobs, EM | 2 |
| Reeves, WJ | 1 |
| Wood, DA | 2 |
| Pugh, R | 1 |
| Braunwald, J | 1 |
| Bateman, JR | 1 |
| White, RS | 1 |
| Fuqua, WB | 1 |
| Barrett, O | 1 |
| Kolár, V | 1 |
| Mechl, Z | 1 |
| Goldie, JH | 1 |
| Nathanson, L | 1 |
| Hanham, IW | 1 |
| Newton, KA | 1 |
| Westbury, G | 1 |
| Trott, KR | 1 |
| Miura, T | 1 |
| Ishida, M | 1 |
| Hatano, S | 1 |
| Tynni, K | 1 |
| Calnan, J | 1 |
| Davies, A | 1 |
| Barkin, M | 1 |
| Cowan, CR | 1 |
| MacDonald, JA | 1 |
| Mahoney, LJ | 1 |
| Yonemoto, RH | 1 |
| Byron, RL | 1 |
| Riihimaki, DU | 1 |
| Keating, JL | 1 |
| Hosley, HF | 1 |
| Gorgun, B | 1 |
| Evseenko, LS | 1 |
| Disvetova, VV | 1 |
| Korman, DB | 1 |
| Levitin, EI | 1 |
| Shiiataia, OK | 1 |
| Rowe-Jones, DC | 1 |
| Toriyama, K | 1 |
| Maeda, H | 1 |
| Kikuchi, M | 1 |
| Kumagai, K | 1 |
| Rosemann, G | 1 |
| Ringleb, D | 1 |
| Bosnar, M | 1 |
| Krieg, R | 1 |
| Sauer, D | 1 |
| Steckenmesser, R | 1 |
| Rall, DP | 1 |
| Glintzer, W | 1 |
| Korbitz, BC | 1 |
| Suzuki, T | 1 |
| Nishimura, G | 1 |
| Imamura, K | 1 |
| Sugahara, K | 1 |
| Fujii, Y | 1 |
| Maisin, H | 1 |
| Salamon, E | 1 |
| Deckers, C | 1 |
| Longueville, J | 1 |
| Wambersie, A | 1 |
| Wong, P | 1 |
| Sardesai, S | 1 |
| Voznyĭ, EK | 1 |
| Bollag, W | 1 |
| Baum, M | 1 |
| Yamana, T | 1 |
| Kubo, A | 1 |
| Renaud, OV | 1 |
| Dudley, GM | 1 |
| Haut, A | 1 |
| Gehan, EA | 1 |
| Brincker, H | 2 |
| Milonov, BV | 1 |
| Kosarev, VA | 1 |
| Nikiforov, AM | 1 |
| Dederick, MM | 2 |
| Taft, PD | 1 |
| Ogston, D | 1 |
| Dawson, AA | 1 |
| Philip, JF | 1 |
| Gualdi, G | 1 |
| Anaveri, G | 1 |
| Tucker, WG | 1 |
| Talley, RW | 1 |
| Brownlee, RW | 1 |
| Burrows, JH | 1 |
| Stott, PB | 1 |
| Moorhead, EL | 1 |
| San Diego, EL | 1 |
| Hamaguchi, E | 1 |
| Utsunomiya, J | 1 |
| Hishigi, S | 1 |
| Zwaveling, A | 1 |
| Stubbé, LT | 1 |
| Lagaaij, MB | 1 |
| Goepfert, H | 1 |
| Lindberg, RD | 1 |
| Johnson, RH | 1 |
| Eridani, S | 1 |
| Esposito, R | 1 |
| Ponti, GB | 1 |
| Giangrande, A | 1 |
| Valentini, R | 1 |
| Ohkita, T | 1 |
| O'Connor, A | 1 |
| Engell, HC | 1 |
| Ulrich, K | 1 |
| Priore, RL | 1 |
| Cavins, JA | 1 |
| Khung, CL | 1 |
| Griffiths, CT | 1 |
| Yount, WJ | 1 |
| Huys, J | 1 |
| Van Vaerenbergh, PM | 1 |
| Dewulf, L | 1 |
| Galletti, PM | 1 |
| Pasqualino, A | 1 |
| Geering, RG | 1 |
| Foti, E | 1 |
| Rasá, G | 1 |
| Mancuso, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity in Patients With Solid Tumors: A Retrospective, International and Non-interventional Study[NCT04260269] | 200 participants (Anticipated) | Observational | 2018-06-01 | Enrolling by invitation | |||
| Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines[NCT02324452] | 1,103 participants (Actual) | Interventional | 2015-03-31 | Completed | |||
| Improving the Safety of Fluoropyrimidine-based Chemotherapy by Combined DPYD Genotype-guided and DPD Phenotype-guided Dose Individualization: The ALPE2U Study[NCT04194957] | 1,440 participants (Anticipated) | Interventional | 2020-01-15 | Recruiting | |||
| A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma[NCT00433550] | Phase 2 | 33 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| A Sequential Phase I Study Of The Combination Of Everolimus (Rad001) With 5-Fu/Lv (De Gramont), Folfox6, And Folfox6/Panitumumab In Patients With Refractory Solid Malignancies[NCT00610948] | Phase 1 | 74 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2 Neuroendocrine Tumors[NCT04339036] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-10-07 | Recruiting | ||
| A Phase 1/2, Open-Label Study Of Bosutinib Administered In Combination With Capecitabine In Subjects With Solid Tumor And ErbB2 Negative Locally Advanced Or Metastatic Breast Cancer[NCT00959946] | Phase 1/Phase 2 | 32 participants (Actual) | Interventional | 2009-09-30 | Terminated | ||
| An Open Label, Pilot Study Evaluating the Effect of Topical Sildenafil as Pre-Treatment for Hand-Foot Skin Reaction[NCT03229512] | Early Phase 1 | 2 participants (Actual) | Interventional | 2017-04-11 | Completed | ||
| Randomized Study of the Efficacy and Safety of Transdermal Granisetron Compared With Intravenous and Oral Agent in the Control of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy[NCT01662687] | Phase 4 | 276 participants (Anticipated) | Interventional | 2012-02-29 | Recruiting | ||
| Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer[NCT02163291] | Phase 2 | 30 participants (Anticipated) | Interventional | 2013-12-31 | Not yet recruiting | ||
| Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced Non-squamous Non-small Cell Lung Cancer[NCT03700333] | Phase 3 | 120 participants (Anticipated) | Interventional | 2018-10-20 | Not yet recruiting | ||
| A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062] | Phase 1 | 120 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| Low-dose Radiotherapy as a Chemo-potentiator of a Induction Chemotherapy Regimen With Gem-based Doublets and Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer[NCT02416609] | 44 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | |||
| Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies[NCT02648711] | Phase 1 | 41 participants (Actual) | Interventional | 2015-10-31 | Terminated (stopped due to Company decision) | ||
| A Phase I Dose Escalation Study of Imatinib Mesylate (Gleevec/STI571) Plus Capecitabine (Xeloda) in Advanced Solid Tumor Malignancies[NCT00253565] | Phase 1 | 25 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| A Phase II, Randomised Controlled Trial to Evaluate the Efficacy and Safety of Moisturising Creams With or Without Palm-oil-derived Vitamin E Concentrate in Addition to Urea-based Cream or Urea-based Cream Alone in Capecitabine-associated Palmar-Plantar E[NCT05939726] | 90 participants (Anticipated) | Interventional | 2023-05-16 | Recruiting | |||
| A Phase III Randomized, Placebo-controlled, Double-blind Trial to Determine the Effectiveness of a Urea/Lactic Acid-Based Topical Keratolytic Agent and Vitamin B-6 for Prevention of Capecitabine-Induced Hand and Foot Syndrome[NCT00296036] | Phase 3 | 137 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Phase I Study Of The Combination Of Oral DJ-927 And Capecitabine In Patients With Advanced Solid Tumors[NCT00077077] | Phase 1 | 0 participants | Interventional | 2004-02-29 | Completed | ||
| Andrographolides With or Without Capecitabine for Elderly Patients With Locally Advanced or Recurrent or Metastasis Inoperable Colorectal Cancer: a Randomized, Open-label Trial.[NCT01993472] | Phase 2 | 308 participants (Anticipated) | Interventional | 2013-11-30 | Terminated (stopped due to low accrual rate) | ||
| Candidate Gene Polymorphisms and Response to Rituximab-CHOP in Patients With Diffuse Large Cell Lymphoma[NCT00590941] | 52 participants (Actual) | Interventional | 2005-02-28 | Completed | |||
| A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia[NCT01822015] | Early Phase 1 | 55 participants (Actual) | Interventional | 2013-03-15 | Completed | ||
| Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies[NCT00703625] | Phase 1 | 26 participants (Actual) | Interventional | 2008-03-08 | Completed | ||
| A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy[NCT01869114] | Phase 2 | 57 participants (Actual) | Interventional | 2013-07-08 | Active, not recruiting | ||
| A Phase-II Clinical Trial to Evaluate the Accuracy of FDG-/FLT-PET for Early Prediction of Non-progression in Patients With Advanced NSCLC Treated With Erlotinib and to Associate PET Findings With Molecular Markers[NCT00568841] | Phase 2 | 40 participants (Anticipated) | Interventional | 2007-10-31 | Active, not recruiting | ||
| A Phase I Study of Oxaliplatin, CPT-11, 5-FU and Leucovorin in Patients With Solid Tumors[NCT00005068] | Phase 1 | 0 participants | Interventional | 2000-01-31 | Completed | ||
| Microvascular Function in Patients Undergoing 5-Fluorouracil Chemotherapy[NCT04042298] | 106 participants (Anticipated) | Observational | 2019-06-25 | Recruiting | |||
| Stereotactic Body Radiation Therapy With Sequential S-1 for Patients With Locally Advanced Pancreatic Cancer and Poor Medical Conditions --a Phase II Clinical Trial[NCT02704143] | 63 participants (Actual) | Interventional | 2016-02-29 | Completed | |||
| 09.017 - A Phase I Study of Tolfenamic Acid With Gemcitabine and Radiation in Patients With Locally Advanced or Metastatic Pancreatic Cancer Requiring Definitive or Palliative Radiation Therapy[NCT02159248] | Phase 1 | 0 participants (Actual) | Interventional | 2014-03-31 | Withdrawn (stopped due to The study closed prior to enrolling any participants.) | ||
| Aromatase Inhibitors Plus Metronomic Capecitabine in Treatment of Patients With Recurrent or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer[NCT04942899] | Phase 2 | 70 participants (Anticipated) | Interventional | 2023-08-30 | Not yet recruiting | ||
| Efficacy and Safety of Supplement Adjuvant Capecitabine in Postoperative Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative High-risk Breast Cancer Patients: a Multicenter, Single-arm Clinical Trial[NCT05212454] | Phase 3 | 400 participants (Anticipated) | Interventional | 2023-03-15 | Recruiting | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| The Effect of Topical Chamomile in the Prevention of Chemotherapy-induced Oral Mucositis (a Randomized Controlled Clinical Trial)[NCT04317183] | Phase 2 | 45 participants (Anticipated) | Interventional | 2019-05-15 | Recruiting | ||
| A Randomized Study of a New Medical Device for Oral Mucositis (MDOM Trial)[NCT05104268] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2021-11-30 | Not yet recruiting | ||
| A Phase 1/Phase 2 Study for the Prevention of Oral Mucositis (SPOM)[NCT05338398] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2022-04-15 | Enrolling by invitation | ||
| Phase I Study of Multiple Ascending Dose, to Investigate the Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy[NCT05308732] | Phase 1 | 36 participants (Anticipated) | Interventional | 2021-05-11 | Recruiting | ||
| Impacts of Oral Supplement With L-Glutamine on the Radiation-induced Toxicity and Nutritional Status of Head and Neck Cancer Patients Under Radiotherapy[NCT03015077] | 59 participants (Actual) | Interventional | 2014-07-31 | Completed | |||
| Phase I Study of Oxaliplatin (NSC# 266046), Irinotecan, and Capecitabine in Patients With Solid Tumors[NCT00006465] | Phase 1 | 22 participants (Actual) | Interventional | 2000-12-31 | Completed | ||
| A Phase II Study of 5-Fluorouracil Administered as a One Hour Infusion in Combination With Calcium Leucovorin and Interferon Alpha-2A in Advanced Colorectal Cancer[NCT00001428] | Phase 2 | 65 participants | Interventional | 1995-02-28 | Completed | ||
| trūFreeze® Spray Cryotherapy Patient Registry[NCT01802203] | 275 participants (Actual) | Observational [Patient Registry] | 2013-04-30 | Completed | |||
| A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer[NCT01291407] | Phase 1 | 27 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Bre[NCT01367028] | Phase 2 | 100 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer[NCT01045538] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Marginally Resectable Carcinoma of the Pancreas[NCT00763516] | 8 participants (Actual) | Interventional | 2009-02-28 | Completed | |||
| A Study Using Photon/Proton Beam Radiation Therapy and Chemotherapy for Unresectable Carcinoma of the Pancreas[NCT00685763] | 13 participants (Actual) | Interventional | 2008-03-31 | Completed | |||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer[NCT01396707] | Phase 2 | 55 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas[NCT00447330] | Phase 2 | 60 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Analysis of the Effect of Teduglutide Treatment on Intestinal Malabsorption and Paneth Cell Numbers in Patients With Steroid-refractory Gastrointestinal Graft Versus Host Disease (SR-GI-GVHD).[NCT04290429] | Early Phase 1 | 6 participants (Actual) | Interventional | 2017-12-06 | Completed | ||
| Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.[NCT05049473] | Phase 2 | 100 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Evaluated using RECIST version 1.0. Confirmed tumor response rate was defined as achieving partial response (PR) or complete response (CR) in two consecutive assessments at least 6 weeks apart. CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. The confirmed response rate is reported as the number of participants with confirmed responses divided by the number of evaluated participants. (NCT00433550)
Timeframe: 36 weeks
| Intervention | proportion of patients (Number) |
|---|---|
| All Patients (6/6, 6/7, 7/7 UGT1A1 Genotype) | .38 |
Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented. Duration of response will be analyzed using Kaplan-Meier methods. (NCT00433550)
Timeframe: Up to 2 years
| Intervention | months (Median) |
|---|---|
| All Patients (6/6, 6/7, 7/7 UGT1A1 Genotype) | 9.0 |
Overall survival will be defined as the time from registration to death. Patients lost to follow-up for this endpoint will be censored at the date of last contact (i.e., last known alive). The distribution of overall survival will be estimated using Kaplan-Meier methodology. (NCT00433550)
Timeframe: Up to 2 years
| Intervention | months (Median) |
|---|---|
| All Patients (6/6, 6/7, 7/7 UGT1A1 Genotype) | 13.4 |
Time to disease progression is defined as the time from registration to the earlier of documentation of disease progression or death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The distribution of time to progression will be estimated using Kaplan-Meier methodology. (NCT00433550)
Timeframe: Up to 2 years
| Intervention | months (Median) |
|---|---|
| All Patients (6/6, 6/7, 7/7 UGT1A1 Genotype) | 8.9 |
Time to treatment failure is defined to be the time from the date of registration to the date at which the patient is removed from treatment due to progression, toxicity, or refusal. If the patient is considered to have had a major treatment violation or is taken off study as a non-protocol failure, the patient will be censored on the date they are removed from treatment. Time to treatment failure will be analyzed using Kaplan-Meier methods. (NCT00433550)
Timeframe: Up to 2 years
| Intervention | months (Median) |
|---|---|
| All Patients (6/6, 6/7, 7/7 UGT1A1 Genotype) | 6.7 |
The MTD contour is defined as the dose combinations that achieve a toxicity rate (dose-limiting toxicity [DLT] rate) of less than (<) 1/3. The observed toxicity rates for all the reporting groups (to which at least 1 cohort of participants was allocated) was estimated by calculating the proportion of DLTs observed in the first 21 days of treatment at those reporting groups. DLT includes grade (Gr) 3/4 nausea, vomiting, diarrhea, or asthenia more than 3 days, Gr 4 hematologic toxicities, delayed study treatment administration due to dose toxicities by more than 3 weeks. Pre-defined criterion for MTD: if a higher dose level of capecitabine existed such that the same dose level of bosutinib had a DLT rate of <1/3, no MTD was recommended for that capecitabine dose and if even the lowest dose of bosutinib achieved a toxicity rate of greater than (>) 1/3, no MTD was recommended for that capecitabine dose level. (NCT00959946)
Timeframe: Part 1 Baseline up to Day 21
| Intervention | mg (Number) |
|---|---|
| Bosutinib + Capecitabine 625 mg/m^2 | NA |
| Bosutinib + Capecitabine 750 mg/m^2 | NA |
| Bosutinib + Capecitabine 1000 mg/m^2 | 300 |
Best overall response based on investigator's disease status assessment. CR: disappearance of all lesions. PR: at least 30% decrease in sum of LDs of target lesions taking as reference baseline sum LDs. Progressive disease (PD): at least 20% increase in sum of LD of target lesions taking as a reference smallest sum of the recorded LDs since treatment start, or the appearance of 1 or more new lesions. Stable disease (SD): neither sufficient shrinkage for PR nor sufficient increase for PD taking as reference smallest sum of LD since treatment started. (NCT00959946)
Timeframe: Part 1 Baseline, every 6 weeks up to 6 months
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | Progressive Disease | Indeterminate | |
| Bosutinib 200 mg + Capecitabine 1000 mg/m^2 (Part 1) | 0 | 0 | 2 | 2 | 0 |
| Bosutinib 200 mg + Capecitabine 625 mg/m^2 (Part 1) | 0 | 0 | 0 | 1 | 0 |
| Bosutinib 200 mg + Capecitabine 750 mg/m^2 (Part 1) | 0 | 0 | 1 | 3 | 0 |
| Bosutinib 300 mg + Capecitabine 1000 mg/m^2 (Part 1) | 0 | 0 | 6 | 2 | 1 |
| Bosutinib 300 mg + Capecitabine 625 mg/m^2 (Part 1) | 0 | 0 | 0 | 5 | 0 |
| Bosutinib 300 mg + Capecitabine 750 mg/m^2 (Part 1) | 0 | 2 | 1 | 1 | 0 |
| Bosutinib 400 mg + Capecitabine 1000 mg/m^2 (Part 1) | 0 | 0 | 1 | 0 | 0 |
| Bosutinib 400 mg + Capecitabine 750 mg/m^2 (Part 1) | 0 | 0 | 1 | 1 | 0 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. (NCT00959946)
Timeframe: Part 1 Baseline up to 28 days after last dose of study treatment
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| AEs | SAEs | |
| Bosutinib 200 mg + Capecitabine 1000 mg/m^2 (Part 1) | 100.0 | 50.0 |
| Bosutinib 200 mg + Capecitabine 625 mg/m^2 (Part 1) | 100.0 | 0.0 |
| Bosutinib 200 mg + Capecitabine 750 mg/m^2 (Part 1) | 100.0 | 50.0 |
| Bosutinib 300 mg + Capecitabine 1000 mg/m^2 (Part 1) | 100.0 | 33.3 |
| Bosutinib 300 mg + Capecitabine 625 mg/m^2 (Part 1) | 100.0 | 40.0 |
| Bosutinib 300 mg + Capecitabine 750 mg/m^2 (Part 1) | 100.0 | 0.0 |
| Bosutinib 400 mg + Capecitabine 1000 mg/m^2 (Part 1) | 100.0 | 50.0 |
| Bosutinib 400 mg + Capecitabine 750 mg/m^2 (Part 1) | 100.0 | 0.0 |
A patient self-reported hand-foot syndrome (HFSD), also known as palmar-plantar erythrodysesthesia, was completed daily while applying the cream. Patients rated skin severity symptoms individually in their hands and in their feet. Definitions of symptoms, which were based on Common Terminology Criteria for Adverse Events (CTCAE) v3.0, were provided to patients. The number of patients reporting moderate to severe symptoms in either hands or feet were tabulated and percentages are reported. (NCT00296036)
Timeframe: First 3 weeks of treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Urea/Lactic Acid Cream | 13.6 |
| Placebo Cream | 10.2 |
Frequency and severity of adverse events reported by patients in weekly diary and evaluated through clinical assessment by NCI CTCAE v3.0. The number of patients reporting grade 3 or higher events are reported in this outcome measure. For a full list of all events, please refer to the Adverse Events section of this report. (NCT00296036)
Timeframe: Up to 4, 21-day cycles
| Intervention | participants (Number) | |
|---|---|---|
| Grade 3+ Adverse Event | Grade 4+ Adverse Event | |
| Placebo Cream | 18 | 3 |
| Urea/Lactic Acid Cream | 21 | 3 |
Median overall survival is calculated by Kaplan-Meier method. (NCT02704143)
Timeframe: 3 years
| Intervention | months (Median) |
|---|---|
| Combination of Cyberknife With S-1 | 14.4 |
The acute toxicities are determined by RTOG Acute Radiation Morbidity Scoring Criteria. (NCT02704143)
Timeframe: Within 90 days after completion of SBRT
| Intervention | Participants (Count of Participants) |
|---|---|
| Combination of Cyberknife With S-1 | 9 |
The late toxicities are determined by RTOG/EORTC Late Radiation Morbidity Scoring Criteria. (NCT02704143)
Timeframe: 90 days after SBRT
| Intervention | Participants (Count of Participants) |
|---|---|
| Combination of Cyberknife With S-1 | 5 |
One-year overall survival rate is calculated by the ratio of number of patients surviving more than 1 year to the total number of patients enrolled. (NCT02704143)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Combination of Cyberknife With S-1 | 46 |
Progression-free survival is the time from the date of enrollment to the confirmation of disease progression at any sites, including local progression or metastasis, or death from any causes, if this occurred before disease progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT02704143)
Timeframe: 3 years
| Intervention | months (Median) |
|---|---|
| Combination of Cyberknife With S-1 | 10.1 |
The analysis of quality of life is based on The European Organization for Reasearch and Treatment of Cancer (EORTC): Quality of Life Questionnare-Core 30 (QLQ-C30). Higher scores in function domains and global health status indicate better quality of life, while higher scores in symptom domains imply worse quality of life. The scale range of all domains of QLQ-C30 is 0-100 (the minimum and maximum score is 0 and 100 points, respectively). (NCT02704143)
Timeframe: 1 years
| Intervention | units on a scale (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global health status | Physical functioning | Role functioning | Emotional functioning | Cognitive functioning | Social functioning | Fatigue | Nausea and vomiting | Pain | Dyspnea | Insomnia | Appetite loss | Constipation | Diarrhea | Financial difficulties | |
| Combination of Cyberknife With S-1 | 50.0 | 64.2 | 54.8 | 68.5 | 73.8 | 74.6 | 46.7 | 55.3 | 48.7 | 9.5 | 19.0 | 59.2 | 13.2 | 13.7 | 31.2 |
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
(NCT00685763)
Timeframe: 1 year following the completion of radiation therapy
| Intervention | participants (Number) |
|---|---|
| Proton Radiation and Chemotherapy | 0 |
Time in months from the start of study treatment to the date of first progression (PD) according to the RECIST criteria, or death due to any cause. PER RECIST, a PD is indicated when there is at least a 20% increase in the sum of the longest diameters from target lesions relative to the smallest sum recorded since treatment is initiated. Median PFS was estimated using a Kaplan-Meier curve, and is the time at which 50% of patients remain alive without disease progression. (NCT00447330)
Timeframe: 5 years from study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1- Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin | 6.97 |
Time in months from the start of study treatment to date of death due to any cause. Median survival was estimated using a Kaplan-Meier curve and is the time point at which 50% of patients remain alive. (NCT00447330)
Timeframe: 5 years after study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 10.51 |
The proportion of patients for whom the best overall response is complete response (CR) or partial response (PR). A CR occurs when all lesions disappear; whereas, a PR is indicated when there is at least a 30% decrease in the sum of the longest diameters (LD) of the target lesion. A PD (progressive disese) occurs when there is at least a 20% increase in the sum of the LD relative to the smallest sum LD recorded since treatment is initiated. Disease is considered stable if there is no response and no PD. All patients were assigned a best response for inclusion in this calculation in accordance with the protocol. (NCT00447330)
Timeframe: Every 9 weeks for up to 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 41.7 |
Number of subjects who experienced an adverse event (NCT00447330)
Timeframe: Every 21 days
| Intervention | participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 56 |
330 reviews available for fluorouracil and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Oleanane-, ursane-, and quinone methide friedelane-type triterpenoid derivatives: Recent advances in cancer treatment.
Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Indolequinones; Neoplasms; | 2017 |
Oleanane-, ursane-, and quinone methide friedelane-type triterpenoid derivatives: Recent advances in cancer treatment.
Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Indolequinones; Neoplasms; | 2017 |
Recent discoveries of anticancer flavonoids.
Topics: Animals; Antineoplastic Agents, Phytogenic; Benzopyrans; Drug Discovery; Flavonoids; Humans; Neoplas | 2017 |
Recent discoveries of anticancer flavonoids.
Topics: Animals; Antineoplastic Agents, Phytogenic; Benzopyrans; Drug Discovery; Flavonoids; Humans; Neoplas | 2017 |
Research advances on anticancer activities of matrine and its derivatives: An updated overview.
Topics: Alkaloids; Antineoplastic Agents; Biomedical Research; Cell Proliferation; Dose-Response Relationshi | 2019 |
Research advances on anticancer activities of matrine and its derivatives: An updated overview.
Topics: Alkaloids; Antineoplastic Agents; Biomedical Research; Cell Proliferation; Dose-Response Relationshi | 2019 |
Quinolone hybrids and their anti-cancer activities: An overview.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Quinolones; Structure-Activity Relationship | 2019 |
Quinolone hybrids and their anti-cancer activities: An overview.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Quinolones; Structure-Activity Relationship | 2019 |
Multi-target compounds acting in cancer progression: Focus on thiosemicarbazone, thiazole and thiazolidinone analogues.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Disease Progression; Drug Delivery Systems; Dru | 2019 |
Multi-target compounds acting in cancer progression: Focus on thiosemicarbazone, thiazole and thiazolidinone analogues.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Disease Progression; Drug Delivery Systems; Dru | 2019 |
Coumarin-containing hybrids and their anticancer activities.
Topics: Animals; Antineoplastic Agents; Coumarins; Drug Design; Drug Discovery; Humans; Neoplasms; Structure | 2019 |
Coumarin-containing hybrids and their anticancer activities.
Topics: Animals; Antineoplastic Agents; Coumarins; Drug Design; Drug Discovery; Humans; Neoplasms; Structure | 2019 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Tria | 2019 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Tria | 2019 |
Synthesis and anti-tumor activity of marine alkaloids.
Topics: Alkaloids; Antineoplastic Agents; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Mole | 2021 |
Synthesis and anti-tumor activity of marine alkaloids.
Topics: Alkaloids; Antineoplastic Agents; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Mole | 2021 |
Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
Topics: Antineoplastic Agents; Apoptosis; Humans; Naphthoquinones; Neoplasms | 2022 |
Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
Topics: Antineoplastic Agents; Apoptosis; Humans; Naphthoquinones; Neoplasms | 2022 |
Recent advances in combretastatin A-4 codrugs for cancer therapy.
Topics: Antineoplastic Agents, Phytogenic; Drug Design; Humans; Neoplasms; Organophosphates; Stilbenes; Wate | 2022 |
Recent advances in combretastatin A-4 codrugs for cancer therapy.
Topics: Antineoplastic Agents, Phytogenic; Drug Design; Humans; Neoplasms; Organophosphates; Stilbenes; Wate | 2022 |
Acriflavine, an Acridine Derivative for Biomedical Application: Current State of the Art.
Topics: Acridines; Acriflavine; Anti-Bacterial Agents; COVID-19 Drug Treatment; Humans; Intercalating Agents | 2022 |
Acriflavine, an Acridine Derivative for Biomedical Application: Current State of the Art.
Topics: Acridines; Acriflavine; Anti-Bacterial Agents; COVID-19 Drug Treatment; Humans; Intercalating Agents | 2022 |
Reproductive and developmental toxicities of 5-fluorouracil in model organisms and humans.
Topics: Antineoplastic Agents; Female; Fluorouracil; Humans; Male; Neoplasms; Reproduction | 2022 |
Reproductive and developmental toxicities of 5-fluorouracil in model organisms and humans.
Topics: Antineoplastic Agents; Female; Fluorouracil; Humans; Male; Neoplasms; Reproduction | 2022 |
Multifunctional role of thymidine phosphorylase in cancer.
Topics: Fluorouracil; Humans; Neoplasms; Neovascularization, Pathologic; Thymidine; Thymidine Phosphorylase | 2022 |
Multifunctional role of thymidine phosphorylase in cancer.
Topics: Fluorouracil; Humans; Neoplasms; Neovascularization, Pathologic; Thymidine; Thymidine Phosphorylase | 2022 |
Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cardiotoxicity; Fluorouracil; Humans; Incidence; Neop | 2022 |
Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cardiotoxicity; Fluorouracil; Humans; Incidence; Neop | 2022 |
5-Fluorouracil nano-delivery systems as a cutting-edge for cancer therapy.
Topics: Antineoplastic Agents; Drug Carriers; Drug Delivery Systems; Fluorouracil; Nanoparticle Drug Deliver | 2023 |
5-Fluorouracil nano-delivery systems as a cutting-edge for cancer therapy.
Topics: Antineoplastic Agents; Drug Carriers; Drug Delivery Systems; Fluorouracil; Nanoparticle Drug Deliver | 2023 |
5-Fluorouracil nano-delivery systems as a cutting-edge for cancer therapy.
Topics: Antineoplastic Agents; Drug Carriers; Drug Delivery Systems; Fluorouracil; Nanoparticle Drug Deliver | 2023 |
5-Fluorouracil nano-delivery systems as a cutting-edge for cancer therapy.
Topics: Antineoplastic Agents; Drug Carriers; Drug Delivery Systems; Fluorouracil; Nanoparticle Drug Deliver | 2023 |
5-Fluorouracil nano-delivery systems as a cutting-edge for cancer therapy.
Topics: Antineoplastic Agents; Drug Carriers; Drug Delivery Systems; Fluorouracil; Nanoparticle Drug Deliver | 2023 |
5-Fluorouracil nano-delivery systems as a cutting-edge for cancer therapy.
Topics: Antineoplastic Agents; Drug Carriers; Drug Delivery Systems; Fluorouracil; Nanoparticle Drug Deliver | 2023 |
5-Fluorouracil nano-delivery systems as a cutting-edge for cancer therapy.
Topics: Antineoplastic Agents; Drug Carriers; Drug Delivery Systems; Fluorouracil; Nanoparticle Drug Deliver | 2023 |
5-Fluorouracil nano-delivery systems as a cutting-edge for cancer therapy.
Topics: Antineoplastic Agents; Drug Carriers; Drug Delivery Systems; Fluorouracil; Nanoparticle Drug Deliver | 2023 |
The relationship between tumor metabolism and 5-fluorouracil resistance.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Humans; | 2023 |
The relationship between tumor metabolism and 5-fluorouracil resistance.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Humans; | 2023 |
Combination of chemotherapy and radiotherapy: A thirty years evolution.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherapy; | 2019 |
Combination of chemotherapy and radiotherapy: A thirty years evolution.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherapy; | 2019 |
The role of therapeutic drug monitoring in the management of safety of anticancer agents: a focus on 3 cytotoxics.
Topics: Antineoplastic Agents; Busulfan; Dose-Response Relationship, Drug; Drug Monitoring; Fluorouracil; Hu | 2019 |
The role of therapeutic drug monitoring in the management of safety of anticancer agents: a focus on 3 cytotoxics.
Topics: Antineoplastic Agents; Busulfan; Dose-Response Relationship, Drug; Drug Monitoring; Fluorouracil; Hu | 2019 |
Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); Disease | 2019 |
Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); Disease | 2019 |
Fluoropyrimidine-Associated Cardiotoxicity.
Topics: Antimetabolites, Antineoplastic; Cardiotoxicity; Fluorouracil; Global Health; Heart Diseases; Humans | 2019 |
Fluoropyrimidine-Associated Cardiotoxicity.
Topics: Antimetabolites, Antineoplastic; Cardiotoxicity; Fluorouracil; Global Health; Heart Diseases; Humans | 2019 |
Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Fluorouracil; Hand-Foot Syndrome; Humans; Hydro-Lyase | 2020 |
Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Fluorouracil; Hand-Foot Syndrome; Humans; Hydro-Lyase | 2020 |
Vitamin D and Other Differentiation-promoting Agents as Neoadjuvants for Photodynamic Therapy of Cancer.
Topics: Administration, Oral; Aminolevulinic Acid; Cell Differentiation; Fluorouracil; Humans; Methotrexate; | 2020 |
Vitamin D and Other Differentiation-promoting Agents as Neoadjuvants for Photodynamic Therapy of Cancer.
Topics: Administration, Oral; Aminolevulinic Acid; Cell Differentiation; Fluorouracil; Humans; Methotrexate; | 2020 |
Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Cardiovascula | 2020 |
Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Cardiovascula | 2020 |
5-Fluorouracil Response Prediction and Blood Level-Guided Therapy in Oncology: Existing Evidence Fundamentally Supports Instigation.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Drug Monitoring; Fluorouracil; | 2020 |
5-Fluorouracil Response Prediction and Blood Level-Guided Therapy in Oncology: Existing Evidence Fundamentally Supports Instigation.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Drug Monitoring; Fluorouracil; | 2020 |
Current Status of Therapeutic Drug Monitoring of 5-Fluorouracil Prodrugs.
Topics: Drug Monitoring; Fluorouracil; Humans; Neoplasms; Prodrugs | 2020 |
Current Status of Therapeutic Drug Monitoring of 5-Fluorouracil Prodrugs.
Topics: Drug Monitoring; Fluorouracil; Humans; Neoplasms; Prodrugs | 2020 |
Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action.
Topics: Cytarabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoplasms; Phosphorylation; Prodrugs; | 2020 |
Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action.
Topics: Cytarabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoplasms; Phosphorylation; Prodrugs; | 2020 |
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper.
Topics: Antimetabolites, Antineoplastic; Austria; Capecitabine; Consensus; Dihydrouracil Dehydrogenase (NADP | 2020 |
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper.
Topics: Antimetabolites, Antineoplastic; Austria; Capecitabine; Consensus; Dihydrouracil Dehydrogenase (NADP | 2020 |
Overcoming barriers to implementing precision dosing with 5-fluorouracil and capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Fluorouracil; Humans; Neoplasms | 2021 |
Overcoming barriers to implementing precision dosing with 5-fluorouracil and capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Fluorouracil; Humans; Neoplasms | 2021 |
5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; DNA Damage | 2021 |
5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; DNA Damage | 2021 |
Chemistry and Anticancer Activity of Hybrid Molecules and Derivatives based on 5-Fluorouracil.
Topics: Antineoplastic Agents; Drug Discovery; Fluorouracil; Humans; Neoplasms; Structure-Activity Relations | 2021 |
Chemistry and Anticancer Activity of Hybrid Molecules and Derivatives based on 5-Fluorouracil.
Topics: Antineoplastic Agents; Drug Discovery; Fluorouracil; Humans; Neoplasms; Structure-Activity Relations | 2021 |
Role of microRNAs in fluoropyrimidine-related toxicity: what we know.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Humans; MicroRNAs; Neoplasms | 2021 |
Role of microRNAs in fluoropyrimidine-related toxicity: what we know.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Humans; MicroRNAs; Neoplasms | 2021 |
Risk Factors of Fluoropyrimidine Induced Cardiotoxicity among Cancer Patients: A Systematic Review and Meta-analysis.
Topics: Capecitabine; Cardiotoxicity; Fluorouracil; Humans; Neoplasms; Risk Factors | 2021 |
Risk Factors of Fluoropyrimidine Induced Cardiotoxicity among Cancer Patients: A Systematic Review and Meta-analysis.
Topics: Capecitabine; Cardiotoxicity; Fluorouracil; Humans; Neoplasms; Risk Factors | 2021 |
Mutual Prodrugs of 5-Fluorouracil: From a Classic Chemotherapeutic Agent to Novel Potential Anticancer Drugs.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Fluor | 2021 |
Mutual Prodrugs of 5-Fluorouracil: From a Classic Chemotherapeutic Agent to Novel Potential Anticancer Drugs.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Fluor | 2021 |
Drug delivery of oral anti-cancer fluoropyrimidine agents.
Topics: Administration, Intravenous; Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic A | 2017 |
Drug delivery of oral anti-cancer fluoropyrimidine agents.
Topics: Administration, Intravenous; Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic A | 2017 |
Fluorinated nucleosides as an important class of anticancer and antiviral agents.
Topics: Antineoplastic Agents; Antiviral Agents; Deoxycytidine; Fluorine; Fluorouracil; Gemcitabine; HIV; Ne | 2017 |
Fluorinated nucleosides as an important class of anticancer and antiviral agents.
Topics: Antineoplastic Agents; Antiviral Agents; Deoxycytidine; Fluorine; Fluorouracil; Gemcitabine; HIV; Ne | 2017 |
Chemotherapeutic Drugs and Plasma Proteins: Exploring New Dimensions.
Topics: Antineoplastic Agents; Blood Proteins; Cell Survival; Cisplatin; Coordination Complexes; Fluorouraci | 2018 |
Chemotherapeutic Drugs and Plasma Proteins: Exploring New Dimensions.
Topics: Antineoplastic Agents; Blood Proteins; Cell Survival; Cisplatin; Coordination Complexes; Fluorouraci | 2018 |
The combination of curcumin and 5-fluorouracil in cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Curcumin; Fluorouracil; Humans; Neoplasms | 2018 |
The combination of curcumin and 5-fluorouracil in cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Curcumin; Fluorouracil; Humans; Neoplasms | 2018 |
Local Radiotherapy Affects Drug Pharmacokinetics-Exploration of a Neglected but Significant Uncertainty of Cancer Therapy.
Topics: Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Drug-Related Side Ef | 2017 |
Local Radiotherapy Affects Drug Pharmacokinetics-Exploration of a Neglected but Significant Uncertainty of Cancer Therapy.
Topics: Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Drug-Related Side Ef | 2017 |
[Management of cardiovascular complications secondary to medical treatment of cancer].
Topics: Anthracyclines; Antineoplastic Agents; Biomarkers; Cardiotoxicity; Echocardiography; Electrocardiogr | 2018 |
[Management of cardiovascular complications secondary to medical treatment of cancer].
Topics: Anthracyclines; Antineoplastic Agents; Biomarkers; Cardiotoxicity; Echocardiography; Electrocardiogr | 2018 |
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrour | 2018 |
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrour | 2018 |
Fluoropyrimidine-induced cardiotoxicity.
Topics: Acetates; Capecitabine; Cardiotoxicity; Cardiovascular Diseases; Drug Combinations; Fluorouracil; Hu | 2018 |
Fluoropyrimidine-induced cardiotoxicity.
Topics: Acetates; Capecitabine; Cardiotoxicity; Cardiovascular Diseases; Drug Combinations; Fluorouracil; Hu | 2018 |
[5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer].
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2018 |
[5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer].
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2018 |
Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Flu | 2019 |
Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Flu | 2019 |
How can we best monitor 5-FU administration to maximize benefit to risk ratio?
Topics: Algorithms; Antimetabolites, Antineoplastic; Area Under Curve; Body Surface Area; Dose-Response Rela | 2018 |
How can we best monitor 5-FU administration to maximize benefit to risk ratio?
Topics: Algorithms; Antimetabolites, Antineoplastic; Area Under Curve; Body Surface Area; Dose-Response Rela | 2018 |
5-Fluorouracil and Capecitabine: Assessment and Treatment of Uncommon Early-Onset Severe Toxicities Associated With Administration.
Topics: Acetates; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Drug-Related Side Effects and | 2018 |
5-Fluorouracil and Capecitabine: Assessment and Treatment of Uncommon Early-Onset Severe Toxicities Associated With Administration.
Topics: Acetates; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Drug-Related Side Effects and | 2018 |
Toll-like receptor/interleukin-1 domain innate immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal toxicity risk following 5-fluorouracil-based chemotherapy.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Gastrointestinal Diseases; Genetic Markers; Humans; I | 2019 |
Toll-like receptor/interleukin-1 domain innate immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal toxicity risk following 5-fluorouracil-based chemotherapy.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Gastrointestinal Diseases; Genetic Markers; Humans; I | 2019 |
Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
Topics: Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 | 2019 |
Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
Topics: Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 | 2019 |
[Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
Topics: Antineoplastic Agents; Biomarkers; Breath Tests; Capecitabine; Comorbidity; Deoxycytidine; Dihydropy | 2012 |
[Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
Topics: Antineoplastic Agents; Biomarkers; Breath Tests; Capecitabine; Comorbidity; Deoxycytidine; Dihydropy | 2012 |
Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxy | 2013 |
Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxy | 2013 |
Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients.
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as T | 2013 |
Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients.
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as T | 2013 |
Assessment of nutritional status in cancer--the relationship between body composition and pharmacokinetics.
Topics: Antineoplastic Agents; Body Composition; Body Mass Index; Capecitabine; Deoxycytidine; Fluorouracil; | 2013 |
Assessment of nutritional status in cancer--the relationship between body composition and pharmacokinetics.
Topics: Antineoplastic Agents; Body Composition; Body Mass Index; Capecitabine; Deoxycytidine; Fluorouracil; | 2013 |
The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Gemcitabin | 2014 |
The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Gemcitabin | 2014 |
Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Cardiovascula | 2013 |
Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Cardiovascula | 2013 |
[Impact of chemotherapies on immunosuppression and discovery of new therapeutic targets].
Topics: Animals; Carrier Proteins; CD4-Positive T-Lymphocytes; Deoxycytidine; Epoxy Compounds; Fluorouracil; | 2014 |
[Impact of chemotherapies on immunosuppression and discovery of new therapeutic targets].
Topics: Animals; Carrier Proteins; CD4-Positive T-Lymphocytes; Deoxycytidine; Epoxy Compounds; Fluorouracil; | 2014 |
Correlation between dihydropyrimidine dehydrogenase and efficacy and toxicity of fluoropyrimidine drugs.
Topics: Animals; Antimetabolites; Dihydrouracil Dehydrogenase (NADP); Enzyme Activation; Fluorouracil; Human | 2014 |
Correlation between dihydropyrimidine dehydrogenase and efficacy and toxicity of fluoropyrimidine drugs.
Topics: Animals; Antimetabolites; Dihydrouracil Dehydrogenase (NADP); Enzyme Activation; Fluorouracil; Human | 2014 |
Natural compounds to overcome cancer chemoresistance: toxicological and clinical issues.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Curcumin; Drug Resista | 2014 |
Natural compounds to overcome cancer chemoresistance: toxicological and clinical issues.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Curcumin; Drug Resista | 2014 |
Metallic taste in cancer patients treated with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fluorouracil; Humans; | 2015 |
Metallic taste in cancer patients treated with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fluorouracil; Humans; | 2015 |
Role of ABC transporters in fluoropyrimidine-based chemotherapy response.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassett | 2015 |
Role of ABC transporters in fluoropyrimidine-based chemotherapy response.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassett | 2015 |
Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogeni | 2015 |
Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogeni | 2015 |
Pharmacogenomics of fluorouracil -based chemotherapy toxicity.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Genetic Variation; Humans; Mutation; Neoplasms; Pharm | 2015 |
Pharmacogenomics of fluorouracil -based chemotherapy toxicity.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Genetic Variation; Humans; Mutation; Neoplasms; Pharm | 2015 |
Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.
Topics: Anthracyclines; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot | 2015 |
Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.
Topics: Anthracyclines; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot | 2015 |
[Adverse cardiac effects associated with anticancer drugs].
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug-Related Side Effects | 2015 |
[Adverse cardiac effects associated with anticancer drugs].
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug-Related Side Effects | 2015 |
S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Combinations; Fluorouracil; Humans; I | 2016 |
S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Combinations; Fluorouracil; Humans; I | 2016 |
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gas | 2015 |
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gas | 2015 |
TAS-102: a novel antimetabolite for the 21st century.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2016 |
TAS-102: a novel antimetabolite for the 21st century.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2016 |
Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy.
Topics: Adult; Antineoplastic Agents; Cryotherapy; Fluorouracil; Hematopoietic Stem Cell Transplantation; Hu | 2015 |
Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy.
Topics: Adult; Antineoplastic Agents; Cryotherapy; Fluorouracil; Hematopoietic Stem Cell Transplantation; Hu | 2015 |
Conformational stability, spectroscopic and computational studies, hikes' occupied molecular orbital, lowest unoccupied molecular orbital, natural bond orbital analysis and thermodynamic parameters of anticancer drug on nanotube-A review.
Topics: Antineoplastic Agents; Drug Carriers; Fluorouracil; Humans; Molecular Conformation; Molecular Dynami | 2015 |
Conformational stability, spectroscopic and computational studies, hikes' occupied molecular orbital, lowest unoccupied molecular orbital, natural bond orbital analysis and thermodynamic parameters of anticancer drug on nanotube-A review.
Topics: Antineoplastic Agents; Drug Carriers; Fluorouracil; Humans; Molecular Conformation; Molecular Dynami | 2015 |
Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Fluorouracil; Humans; Meta-Analysis as Topic; Neoplas | 2016 |
Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Fluorouracil; Humans; Meta-Analysis as Topic; Neoplas | 2016 |
The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Carcinogenesis; CpG Islands; Decita | 2016 |
The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Carcinogenesis; CpG Islands; Decita | 2016 |
Cancer drug resistance: redox resetting renders a way.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP B | 2016 |
Cancer drug resistance: redox resetting renders a way.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP B | 2016 |
Therapeutic drug monitoring of 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Monitoring; Fluorouracil; Hu | 2016 |
Therapeutic drug monitoring of 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Monitoring; Fluorouracil; Hu | 2016 |
Pharmacokinetically guided algorithm of 5-fluorouracil dosing, a reliable strategy of precision chemotherapy for solid tumors: a meta-analysis.
Topics: Algorithms; Antimetabolites, Antineoplastic; Body Surface Area; Clinical Trials as Topic; Drug Dosag | 2016 |
Pharmacokinetically guided algorithm of 5-fluorouracil dosing, a reliable strategy of precision chemotherapy for solid tumors: a meta-analysis.
Topics: Algorithms; Antimetabolites, Antineoplastic; Body Surface Area; Clinical Trials as Topic; Drug Dosag | 2016 |
FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs.
Topics: Acetates; Animals; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Drug Approval; Dru | 2016 |
FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs.
Topics: Acetates; Animals; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Drug Approval; Dru | 2016 |
[Evolving 5-Fluorouracil Therapy to Achieve Enhanced Efficacy-Past and Current Efforts of Researchers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Design; Fluoro | 2016 |
[Evolving 5-Fluorouracil Therapy to Achieve Enhanced Efficacy-Past and Current Efforts of Researchers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Design; Fluoro | 2016 |
The role of pharmacogenetics in capecitabine efficacy and toxicity.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carboxylesterase; Cytidine Deaminase; Dihydrouracil D | 2016 |
The role of pharmacogenetics in capecitabine efficacy and toxicity.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carboxylesterase; Cytidine Deaminase; Dihydrouracil D | 2016 |
Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and A | 2016 |
Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and A | 2016 |
Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Folic Acid; Humans; Neoplasms | 2016 |
Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Folic Acid; Humans; Neoplasms | 2016 |
Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy.
Topics: Anthracyclines; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Cardiotoxicity; Fluorourac | 2016 |
Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy.
Topics: Anthracyclines; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Cardiotoxicity; Fluorourac | 2016 |
Targeting nuclear thymidylate biosynthesis.
Topics: Animals; Cell Nucleus; Drug Resistance, Neoplasm; Fluorouracil; Humans; Neoplasms; Sumoylation; Thym | 2017 |
Targeting nuclear thymidylate biosynthesis.
Topics: Animals; Cell Nucleus; Drug Resistance, Neoplasm; Fluorouracil; Humans; Neoplasms; Sumoylation; Thym | 2017 |
Pharmacogenetics and Metabolism from Science to Implementation in Clinical Practice: The Example of Dihydropyrimidine Dehydrogenase.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Neoplasms | 2017 |
Pharmacogenetics and Metabolism from Science to Implementation in Clinical Practice: The Example of Dihydropyrimidine Dehydrogenase.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Neoplasms | 2017 |
Combination of metformin with chemotherapeutic drugs via different molecular mechanisms.
Topics: Androgen Antagonists; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic C | 2017 |
Combination of metformin with chemotherapeutic drugs via different molecular mechanisms.
Topics: Androgen Antagonists; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic C | 2017 |
[Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase].
Topics: Amino Acid Substitution; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency | 2008 |
[Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase].
Topics: Amino Acid Substitution; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency | 2008 |
Analysis of dermatologic events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinic | 2009 |
Analysis of dermatologic events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinic | 2009 |
Implications of circadian clocks for the rhythmic delivery of cancer therapeutics.
Topics: Animals; Antineoplastic Agents; Biological Clocks; Cell Cycle; Circadian Rhythm; Colorectal Neoplasm | 2008 |
Implications of circadian clocks for the rhythmic delivery of cancer therapeutics.
Topics: Animals; Antineoplastic Agents; Biological Clocks; Cell Cycle; Circadian Rhythm; Colorectal Neoplasm | 2008 |
Chemotherapy and cardiotoxicity.
Topics: Age of Onset; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplas | 2008 |
Chemotherapy and cardiotoxicity.
Topics: Age of Onset; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplas | 2008 |
Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; N | 2008 |
Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; N | 2008 |
Radiation- and photo-induced activation of 5-fluorouracil prodrugs as a strategy for the selective treatment of solid tumors.
Topics: Drug Delivery Systems; Fluorouracil; Humans; Neoplasms; Prodrugs; Radiation, Ionizing; Ultraviolet R | 2008 |
Radiation- and photo-induced activation of 5-fluorouracil prodrugs as a strategy for the selective treatment of solid tumors.
Topics: Drug Delivery Systems; Fluorouracil; Humans; Neoplasms; Prodrugs; Radiation, Ionizing; Ultraviolet R | 2008 |
Capecitabine: have we got the dose right?
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diet; Dose-Response Relationship, Drug | 2009 |
Capecitabine: have we got the dose right?
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diet; Dose-Response Relationship, Drug | 2009 |
C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Resistance, Neoplasm; Fluorouracil; Folic Acid Antago | 2009 |
C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Resistance, Neoplasm; Fluorouracil; Folic Acid Antago | 2009 |
Fluoropyrimidine-associated cardiotoxicity: revisited.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blo | 2009 |
Fluoropyrimidine-associated cardiotoxicity: revisited.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blo | 2009 |
[Biological basis of chemo-radiotherapy associations].
Topics: Cell Proliferation; Cisplatin; Combined Modality Therapy; Dacarbazine; Deoxycytidine; DNA Damage; DN | 2009 |
[Biological basis of chemo-radiotherapy associations].
Topics: Cell Proliferation; Cisplatin; Combined Modality Therapy; Dacarbazine; Deoxycytidine; DNA Damage; DN | 2009 |
Role of the MTHFR polymorphisms in cancer risk modification and treatment.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Fluorouracil; Folic Acid; Genetic Predisposition t | 2009 |
Role of the MTHFR polymorphisms in cancer risk modification and treatment.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Fluorouracil; Folic Acid; Genetic Predisposition t | 2009 |
DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; DNA Mismatch Repair; Fluorouracil; Humans; Models | 2009 |
DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; DNA Mismatch Repair; Fluorouracil; Humans; Models | 2009 |
Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycy | 2009 |
Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycy | 2009 |
Safety of capecitabine: a review.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 2010 |
Safety of capecitabine: a review.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 2010 |
Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application.
Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP2D6; ErbB Receptors; Fluorouracil; Glucuron | 2011 |
Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application.
Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP2D6; ErbB Receptors; Fluorouracil; Glucuron | 2011 |
Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Fluorouracil; Humans; Immune Tolerance; Immunosuppression | 2011 |
Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Fluorouracil; Humans; Immune Tolerance; Immunosuppression | 2011 |
[Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy].
Topics: Antineoplastic Agents; Capecitabine; Cytarabine; Deoxycytidine; Docetaxel; Doxorubicin; Fluorouracil | 2011 |
[Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy].
Topics: Antineoplastic Agents; Capecitabine; Cytarabine; Deoxycytidine; Docetaxel; Doxorubicin; Fluorouracil | 2011 |
[A brief overview of a lung cancer biomarker: thymidylate synthase].
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small | 2011 |
[A brief overview of a lung cancer biomarker: thymidylate synthase].
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small | 2011 |
Development of 5-Fluorouracil derivatives as anticancer agents.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Discovery; Fluorouracil; Humans; Neoplasms | 2011 |
Development of 5-Fluorouracil derivatives as anticancer agents.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Discovery; Fluorouracil; Humans; Neoplasms | 2011 |
Pulmonary toxicity with oxaliplatin and capecitabine/5-Fluorouracil chemotherapy: a case report and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectom | 2011 |
Pulmonary toxicity with oxaliplatin and capecitabine/5-Fluorouracil chemotherapy: a case report and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectom | 2011 |
Role of myeloid-derived suppressor cells in tumor immunotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Ge | 2012 |
Role of myeloid-derived suppressor cells in tumor immunotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Ge | 2012 |
Genetic variants influencing fluoropyrimidine based-therapy and available methods to detect them.
Topics: Animals; Antimetabolites, Antineoplastic; Fluorouracil; Genetic Variation; Genotype; Humans; Neoplas | 2012 |
Genetic variants influencing fluoropyrimidine based-therapy and available methods to detect them.
Topics: Animals; Antimetabolites, Antineoplastic; Fluorouracil; Genetic Variation; Genotype; Humans; Neoplas | 2012 |
Tumor endothelial markers as a target in cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Cell Adhesion Molecules; | 2012 |
Tumor endothelial markers as a target in cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Cell Adhesion Molecules; | 2012 |
Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.
Topics: Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Discovery; Fluorouracil; Genetic Variation; | 2013 |
Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.
Topics: Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Discovery; Fluorouracil; Genetic Variation; | 2013 |
The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotype | 2002 |
The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotype | 2002 |
[The principles of cancer treatment--changes in chemotherapy].
Topics: ADP Ribose Transferases; Animals; Antineoplastic Agents; Benzamides; Cisplatin; Drug Combinations; F | 2002 |
[The principles of cancer treatment--changes in chemotherapy].
Topics: ADP Ribose Transferases; Animals; Antineoplastic Agents; Benzamides; Cisplatin; Drug Combinations; F | 2002 |
[Prevention and treatment for adverse events induced by chemotherapy].
Topics: Anaphylaxis; Antineoplastic Agents; Brain Diseases; Cisplatin; Docetaxel; Fluorouracil; Humans; Neop | 2002 |
[Prevention and treatment for adverse events induced by chemotherapy].
Topics: Anaphylaxis; Antineoplastic Agents; Brain Diseases; Cisplatin; Docetaxel; Fluorouracil; Humans; Neop | 2002 |
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neop | 2002 |
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neop | 2002 |
The mechanism of action of radiosensitization of conventional chemotherapeutic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Floxuridine; Fluorouracil; Gemcitabin | 2003 |
The mechanism of action of radiosensitization of conventional chemotherapeutic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Floxuridine; Fluorouracil; Gemcitabin | 2003 |
Cancer pharmacogenomics: current and future applications.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Dihydrour | 2003 |
Cancer pharmacogenomics: current and future applications.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Dihydrour | 2003 |
The prodrugs of 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Biotransformation; Fluorouracil; Humans; Neoplasms; Prodru | 2002 |
The prodrugs of 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Biotransformation; Fluorouracil; Humans; Neoplasms; Prodru | 2002 |
Thymidylate synthase inhibitors.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Fluorouracil; Folic Aci | 2002 |
Thymidylate synthase inhibitors.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Fluorouracil; Folic Aci | 2002 |
[Cerebral ischemic events and anti-cancer therapy].
Topics: Adolescent; Adult; Antineoplastic Agents; Asparaginase; Brain Ischemia; Cerebral Hemorrhage; Child; | 2003 |
[Cerebral ischemic events and anti-cancer therapy].
Topics: Adolescent; Adult; Antineoplastic Agents; Asparaginase; Brain Ischemia; Cerebral Hemorrhage; Child; | 2003 |
5-fluorouracil and dihydropyrimidine dehydrogenase.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Neoplasms | 2003 |
5-fluorouracil and dihydropyrimidine dehydrogenase.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Neoplasms | 2003 |
Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 2003 |
Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 2003 |
Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience.
Topics: Animals; Area Under Curve; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Huma | 2003 |
Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience.
Topics: Animals; Area Under Curve; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Huma | 2003 |
BIOCHEMICAL MECHANISMS OF ACTION OF FLUORINATED PYRIMIDINES.
Topics: DNA; DNA, Neoplasm; Floxuridine; Fluorouracil; Ligases; Neoplasms; Pharmacology; Pyrimidines; Resear | 1963 |
BIOCHEMICAL MECHANISMS OF ACTION OF FLUORINATED PYRIMIDINES.
Topics: DNA; DNA, Neoplasm; Floxuridine; Fluorouracil; Ligases; Neoplasms; Pharmacology; Pyrimidines; Resear | 1963 |
EXPERIMENTAL AND CLINICAL USE OF FLUORINATED PYRIMIDINES IN CANCER CHEMOTHERAPY.
Topics: Breast Neoplasms; Carbon Isotopes; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Me | 1963 |
EXPERIMENTAL AND CLINICAL USE OF FLUORINATED PYRIMIDINES IN CANCER CHEMOTHERAPY.
Topics: Breast Neoplasms; Carbon Isotopes; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Me | 1963 |
DRUGS USED WITH RADIATION IN THE TREATMENT OF CANCER.
Topics: Antineoplastic Agents; Chlortetracycline; Dactinomycin; DNA; DNA, Neoplasm; Fluorouracil; Humans; Me | 1963 |
DRUGS USED WITH RADIATION IN THE TREATMENT OF CANCER.
Topics: Antineoplastic Agents; Chlortetracycline; Dactinomycin; DNA; DNA, Neoplasm; Fluorouracil; Humans; Me | 1963 |
BIOCHEMISTRY OF CANCER (METABOLIC ASPECTS).
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Azaguanine; Azaserine; Carcinoma, Ehrlich Tum | 1963 |
BIOCHEMISTRY OF CANCER (METABOLIC ASPECTS).
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Azaguanine; Azaserine; Carcinoma, Ehrlich Tum | 1963 |
NEWER ANTICANCER AGENTS.
Topics: Alkylating Agents; Antineoplastic Agents; Arsenicals; Cyclophosphamide; Dactinomycin; Fluorouracil; | 1964 |
NEWER ANTICANCER AGENTS.
Topics: Alkylating Agents; Antineoplastic Agents; Arsenicals; Cyclophosphamide; Dactinomycin; Fluorouracil; | 1964 |
[CHEMOTHERAPY OF UTERINE CERVIX CARCINOMA].
Topics: Antineoplastic Agents; Azaguanine; Aziridines; Chemotherapy, Cancer, Regional Perfusion; Cyclophosph | 1964 |
[CHEMOTHERAPY OF UTERINE CERVIX CARCINOMA].
Topics: Antineoplastic Agents; Azaguanine; Aziridines; Chemotherapy, Cancer, Regional Perfusion; Cyclophosph | 1964 |
THERAPY OF THE MALIGNANT CARCINOID SYNDROME.
Topics: Anti-Allergic Agents; Antihypertensive Agents; Cyclophosphamide; Fluorouracil; Histamine H1 Antagoni | 1965 |
THERAPY OF THE MALIGNANT CARCINOID SYNDROME.
Topics: Anti-Allergic Agents; Antihypertensive Agents; Cyclophosphamide; Fluorouracil; Histamine H1 Antagoni | 1965 |
Chronotherapy for cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Fluorouracil; Humans; Leucovorin; Neo | 2003 |
Chronotherapy for cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Fluorouracil; Humans; Leucovorin; Neo | 2003 |
[Use of xeloda (capecitabine) in the treatment of cancer patients (review)].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free | 2003 |
[Use of xeloda (capecitabine) in the treatment of cancer patients (review)].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free | 2003 |
Overview of chemotherapy-induced diarrhea.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Fluorouracil; Humans; Irinot | 2003 |
Overview of chemotherapy-induced diarrhea.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Fluorouracil; Humans; Irinot | 2003 |
Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Fluorouracil; Hum | 2004 |
Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Fluorouracil; Hum | 2004 |
Potential for predicting toxicity and response of fluoropyrimidines in patients.
Topics: Fluorouracil; Humans; Neoplasms; Predictive Value of Tests; Pyrimidines | 2004 |
Potential for predicting toxicity and response of fluoropyrimidines in patients.
Topics: Fluorouracil; Humans; Neoplasms; Predictive Value of Tests; Pyrimidines | 2004 |
Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Admini | 2004 |
Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Admini | 2004 |
Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Admini | 2004 |
Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Admini | 2004 |
Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Admini | 2004 |
Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Admini | 2004 |
Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Admini | 2004 |
Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Admini | 2004 |
Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2004 |
Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2004 |
Uridine phosophorylase: an important enzyme in pyrimidine metabolism and fluoropyrimidine activation.
Topics: Animals; Antimetabolites, Antineoplastic; Floxuridine; Fluorouracil; Gene Expression Regulation, Enz | 2004 |
Uridine phosophorylase: an important enzyme in pyrimidine metabolism and fluoropyrimidine activation.
Topics: Animals; Antimetabolites, Antineoplastic; Floxuridine; Fluorouracil; Gene Expression Regulation, Enz | 2004 |
Thymidylate synthase: a critical target in cancer therapy?
Topics: Animals; Antineoplastic Agents; Apoptosis; Capecitabine; Cell Cycle; Cell Proliferation; Clinical Tr | 2004 |
Thymidylate synthase: a critical target in cancer therapy?
Topics: Animals; Antineoplastic Agents; Apoptosis; Capecitabine; Cell Cycle; Cell Proliferation; Clinical Tr | 2004 |
Pharmacogenomics of thymidylate synthase in cancer treatment.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Folic Acid; Gene Expression Regulation, Neoplastic; Hu | 2004 |
Pharmacogenomics of thymidylate synthase in cancer treatment.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Folic Acid; Gene Expression Regulation, Neoplastic; Hu | 2004 |
Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Glucuronosyltran | 2004 |
Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Glucuronosyltran | 2004 |
Capecitabine: a review.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Flu | 2005 |
Capecitabine: a review.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Flu | 2005 |
Capecitabine: a review.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Flu | 2005 |
Capecitabine: a review.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Flu | 2005 |
Capecitabine: a review.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Flu | 2005 |
Capecitabine: a review.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Flu | 2005 |
Capecitabine: a review.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Flu | 2005 |
Capecitabine: a review.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Flu | 2005 |
Monitoring fluoropyrimidine metabolism in solid tumors with in vivo (19)F magnetic resonance spectroscopy.
Topics: Animals; Antimetabolites, Antineoplastic; Fluorine; Fluorouracil; Humans; Magnetic Resonance Spectro | 2005 |
Monitoring fluoropyrimidine metabolism in solid tumors with in vivo (19)F magnetic resonance spectroscopy.
Topics: Animals; Antimetabolites, Antineoplastic; Fluorine; Fluorouracil; Humans; Magnetic Resonance Spectro | 2005 |
Chemotherapy dosing in the setting of liver dysfunction.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Dos | 2005 |
Chemotherapy dosing in the setting of liver dysfunction.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Dos | 2005 |
Pharmacogenetics of folate-related drug targets in cancer treatment.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Folic Acid; Folic Acid Antagonists; Humans; Methotrexa | 2005 |
Pharmacogenetics of folate-related drug targets in cancer treatment.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Folic Acid; Folic Acid Antagonists; Humans; Methotrexa | 2005 |
Thymidylate synthase pharmacogenetics.
Topics: Antimetabolites, Antineoplastic; Enhancer Elements, Genetic; Fluorouracil; Humans; Neoplasms; Pharma | 2005 |
Thymidylate synthase pharmacogenetics.
Topics: Antimetabolites, Antineoplastic; Enhancer Elements, Genetic; Fluorouracil; Humans; Neoplasms; Pharma | 2005 |
Potential mechanisms for chemotherapy-induced impairments in cognitive function.
Topics: Anemia; Animals; Antineoplastic Agents; Attention; Blood-Brain Barrier; Cognition Disorders; Cycloph | 2005 |
Potential mechanisms for chemotherapy-induced impairments in cognitive function.
Topics: Anemia; Animals; Antineoplastic Agents; Attention; Blood-Brain Barrier; Cognition Disorders; Cycloph | 2005 |
[Polygenetic pharmacogenomic strategies to identify drug sensitivity biomarkers].
Topics: Antineoplastic Agents; Dihydrouracil Dehydrogenase (NADP); Drug Screening Assays, Antitumor; Fluorou | 2005 |
[Polygenetic pharmacogenomic strategies to identify drug sensitivity biomarkers].
Topics: Antineoplastic Agents; Dihydrouracil Dehydrogenase (NADP); Drug Screening Assays, Antitumor; Fluorou | 2005 |
[SNPs associated with adverse effects].
Topics: Antineoplastic Agents; Camptothecin; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Meth | 2005 |
[SNPs associated with adverse effects].
Topics: Antineoplastic Agents; Camptothecin; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Meth | 2005 |
Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question.
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Humans; M | 2006 |
Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question.
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Humans; M | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
How may anticancer chemotherapy with fluorouracil be individualised?
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Dihydrouracil Dehydrogenase (NADP); Fluor | 2006 |
How may anticancer chemotherapy with fluorouracil be individualised?
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Dihydrouracil Dehydrogenase (NADP); Fluor | 2006 |
Neurological complications of cancer chemotherapy.
Topics: Antineoplastic Agents; Capecitabine; Central Nervous System; Deoxycytidine; Fluorouracil; Humans; Ma | 2006 |
Neurological complications of cancer chemotherapy.
Topics: Antineoplastic Agents; Capecitabine; Central Nervous System; Deoxycytidine; Fluorouracil; Humans; Ma | 2006 |
[Capecitabine].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clini | 2006 |
[Capecitabine].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clini | 2006 |
[Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinatio | 2006 |
[Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinatio | 2006 |
[Pharmacokinetics of S-1].
Topics: Administration, Oral; Adult; Aged; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined | 2006 |
[Pharmacokinetics of S-1].
Topics: Administration, Oral; Adult; Aged; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined | 2006 |
[Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; Dihydrouracil Dehydrogenase | 2006 |
[Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; Dihydrouracil Dehydrogenase | 2006 |
Gender specific tumour pharmacology--from kinetics to genetics.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cytochrome P-450 Enzyme System; Cytochrome R | 2006 |
Gender specific tumour pharmacology--from kinetics to genetics.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cytochrome P-450 Enzyme System; Cytochrome R | 2006 |
[Request for a compassionate use of biotherapies in oncology].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
[Request for a compassionate use of biotherapies in oncology].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehyd | 2006 |
Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehyd | 2006 |
Capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil | 2007 |
Capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil | 2007 |
Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gene Expression R | 2007 |
Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gene Expression R | 2007 |
Should DPD analysis be required prior to prescribing fluoropyrimidines?
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Dihydropyrimidine Dehydrogena | 2007 |
Should DPD analysis be required prior to prescribing fluoropyrimidines?
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Dihydropyrimidine Dehydrogena | 2007 |
[DNA repair as a determinant of tumour chemosensitivity].
Topics: Adenomatous Polyposis Coli; Antineoplastic Agents; Cisplatin; DNA; DNA Mismatch Repair; DNA Repair; | 2007 |
[DNA repair as a determinant of tumour chemosensitivity].
Topics: Adenomatous Polyposis Coli; Antineoplastic Agents; Cisplatin; DNA; DNA Mismatch Repair; DNA Repair; | 2007 |
Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Immunoassay; Med | 2007 |
Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Immunoassay; Med | 2007 |
[Are antiangiogenic antibodies universal for solid tumor?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
[Are antiangiogenic antibodies universal for solid tumor?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
Thymidine phosphorylase (platelet-derived endothelial cell growth factor) as a target for capecitabine: from biology to the bedside.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as | 2006 |
Thymidine phosphorylase (platelet-derived endothelial cell growth factor) as a target for capecitabine: from biology to the bedside.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as | 2006 |
[Methionine dependency of cancer cells: a new therapeutic approach?].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carbon-Sulfur Lyases; Fluorouraci | 2008 |
[Methionine dependency of cancer cells: a new therapeutic approach?].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carbon-Sulfur Lyases; Fluorouraci | 2008 |
Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Drug Resistance, Neoplasm; Fluorouracil; | 2008 |
Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Drug Resistance, Neoplasm; Fluorouracil; | 2008 |
Thymidine as an anticancer agent, alone or in combination. A biochemical appraisal.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Drug Therapy, Combination; Fluo | 1982 |
Thymidine as an anticancer agent, alone or in combination. A biochemical appraisal.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Drug Therapy, Combination; Fluo | 1982 |
Fluorinated pyrimidines and their nucleosides.
Topics: Animals; Enzyme Activation; Fluorouracil; Humans; Neoplasms; Pyrimidines; RNA; Thymidylate Synthase; | 1983 |
Fluorinated pyrimidines and their nucleosides.
Topics: Animals; Enzyme Activation; Fluorouracil; Humans; Neoplasms; Pyrimidines; RNA; Thymidylate Synthase; | 1983 |
Spheroids for studies of drug effects.
Topics: Animals; Antineoplastic Agents; Cell Aggregation; Cell Division; Cell Survival; Cells, Cultured; Cyt | 1984 |
Spheroids for studies of drug effects.
Topics: Animals; Antineoplastic Agents; Cell Aggregation; Cell Division; Cell Survival; Cells, Cultured; Cyt | 1984 |
Selective uptake and retention of anticancer agents by sensitive cells.
Topics: Animals; Antineoplastic Agents; Cytarabine; Doxorubicin; Floxuridine; Fluorouracil; Humans; Melphala | 1980 |
Selective uptake and retention of anticancer agents by sensitive cells.
Topics: Animals; Antineoplastic Agents; Cytarabine; Doxorubicin; Floxuridine; Fluorouracil; Humans; Melphala | 1980 |
Is there a role for thymidine in cancer chemotherapy?
Topics: Cytarabine; Drug Therapy, Combination; Fluorouracil; Humans; Kinetics; Leukemia; Methotrexate; Neopl | 1982 |
Is there a role for thymidine in cancer chemotherapy?
Topics: Cytarabine; Drug Therapy, Combination; Fluorouracil; Humans; Kinetics; Leukemia; Methotrexate; Neopl | 1982 |
The pharmacology of ftorafur (R, S-1-(tetrahydro-2-furanyl)-5-fluorouracil.
Topics: Animals; Biotransformation; Fluorouracil; Humans; Kinetics; Neoplasms; Tegafur | 1981 |
The pharmacology of ftorafur (R, S-1-(tetrahydro-2-furanyl)-5-fluorouracil.
Topics: Animals; Biotransformation; Fluorouracil; Humans; Kinetics; Neoplasms; Tegafur | 1981 |
Studies of analogs of fluorinated pyrimidine in Japan.
Topics: Animals; Antineoplastic Agents; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fluorouraci | 1981 |
Studies of analogs of fluorinated pyrimidine in Japan.
Topics: Animals; Antineoplastic Agents; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fluorouraci | 1981 |
The effect of chemotherapeutic agents on wound healing.
Topics: Adrenal Cortex Hormones; Anemia; Animals; Antineoplastic Agents; Azathioprine; Collagen; Cyclophosph | 1981 |
The effect of chemotherapeutic agents on wound healing.
Topics: Adrenal Cortex Hormones; Anemia; Animals; Antineoplastic Agents; Azathioprine; Collagen; Cyclophosph | 1981 |
[Metabolic modulation as a method in tumor chemotherapy].
Topics: Antineoplastic Agents; Cytarabine; Fluorouracil; Humans; Methotrexate; Neoplasms; Tegafur; Thymidine | 1982 |
[Metabolic modulation as a method in tumor chemotherapy].
Topics: Antineoplastic Agents; Cytarabine; Fluorouracil; Humans; Methotrexate; Neoplasms; Tegafur; Thymidine | 1982 |
An overview of thymidine.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Cytarabine; DNA, Neoplasm; Dr | 1980 |
An overview of thymidine.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Cytarabine; DNA, Neoplasm; Dr | 1980 |
Degradation of pyrimidines and pyrimidine analogs--pathways and mutual influences.
Topics: Aminoisobutyric Acids; Animals; Antimetabolites; Antimetabolites, Antineoplastic; Aza Compounds; Bar | 1980 |
Degradation of pyrimidines and pyrimidine analogs--pathways and mutual influences.
Topics: Aminoisobutyric Acids; Animals; Antimetabolites; Antimetabolites, Antineoplastic; Aza Compounds; Bar | 1980 |
Physiological and pharmacological determinants of sensitivity and resistance to 5-fluorouracil in lower animals and man.
Topics: Animals; Drug Interactions; Drug Resistance; Enzymes; Fluorouracil; Humans; Neoplasms | 1980 |
Physiological and pharmacological determinants of sensitivity and resistance to 5-fluorouracil in lower animals and man.
Topics: Animals; Drug Interactions; Drug Resistance; Enzymes; Fluorouracil; Humans; Neoplasms | 1980 |
Determinants of response to antimetabolites and their modulation by normal purine and pyrimidine metabolites.
Topics: Animals; Antimetabolites, Antineoplastic; Cytarabine; DNA, Neoplasm; Fluorodeoxyuridylate; Fluoroura | 1981 |
Determinants of response to antimetabolites and their modulation by normal purine and pyrimidine metabolites.
Topics: Animals; Antimetabolites, Antineoplastic; Cytarabine; DNA, Neoplasm; Fluorodeoxyuridylate; Fluoroura | 1981 |
New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.
Topics: Animals; Antimetabolites, Antineoplastic; Fluorouracil; Folic Acid Antagonists; Humans; Interferons; | 1994 |
New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.
Topics: Animals; Antimetabolites, Antineoplastic; Fluorouracil; Folic Acid Antagonists; Humans; Interferons; | 1994 |
Cardiotoxicity and cardioprotection during chemotherapy.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Child; Clinical Trials as Topic | 1995 |
Cardiotoxicity and cardioprotection during chemotherapy.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Child; Clinical Trials as Topic | 1995 |
Clinical cancer chronotherapy trials: a review.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Circadian Rhythm; Clinical Trials as Topic; Drug | 1995 |
Clinical cancer chronotherapy trials: a review.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Circadian Rhythm; Clinical Trials as Topic; Drug | 1995 |
Cancer chronotherapy: is there a right time in the day to treat?
Topics: Animals; Antineoplastic Agents; Circadian Rhythm; Floxuridine; Fluorouracil; Humans; Neoplasms; Neop | 1995 |
Cancer chronotherapy: is there a right time in the day to treat?
Topics: Animals; Antineoplastic Agents; Circadian Rhythm; Floxuridine; Fluorouracil; Humans; Neoplasms; Neop | 1995 |
Clinical resistance to antimetabolites.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; DNA Damage; DNA Replication; DNA, Neopla | 1995 |
Clinical resistance to antimetabolites.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; DNA Damage; DNA Replication; DNA, Neopla | 1995 |
Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy.
Topics: Antineoplastic Agents; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Genetics, Populatio | 1994 |
Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy.
Topics: Antineoplastic Agents; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Genetics, Populatio | 1994 |
The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data.
Topics: Aspartic Acid; Drug Interactions; Fluorouracil; Humans; Leucovorin; Methotrexate; Neoplasms; Phospho | 1994 |
The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data.
Topics: Aspartic Acid; Drug Interactions; Fluorouracil; Humans; Leucovorin; Methotrexate; Neoplasms; Phospho | 1994 |
[Pharmacokinetic mechanisms of resistance to anticancer medications].
Topics: Antineoplastic Agents; Blood-Brain Barrier; Dose-Response Relationship, Drug; Drug Resistance; Epiru | 1994 |
[Pharmacokinetic mechanisms of resistance to anticancer medications].
Topics: Antineoplastic Agents; Blood-Brain Barrier; Dose-Response Relationship, Drug; Drug Resistance; Epiru | 1994 |
Alleviation of cytotoxic therapy-induced normal tissue damage.
Topics: Chlorhexidine; Clinical Trials as Topic; Cryotherapy; Dermatitis; Esophagitis; Eye Diseases; Fluorou | 1995 |
Alleviation of cytotoxic therapy-induced normal tissue damage.
Topics: Chlorhexidine; Clinical Trials as Topic; Cryotherapy; Dermatitis; Esophagitis; Eye Diseases; Fluorou | 1995 |
Cardiotoxicity of chemotherapy.
Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combi | 1994 |
Cardiotoxicity of chemotherapy.
Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combi | 1994 |
In vivo monitoring of fluoropyrimidine metabolites: magnetic resonance spectroscopy in the evaluation of 5-fluorouracil.
Topics: Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Fluorine; Fluorouracil; Humans; Mag | 1994 |
In vivo monitoring of fluoropyrimidine metabolites: magnetic resonance spectroscopy in the evaluation of 5-fluorouracil.
Topics: Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Fluorine; Fluorouracil; Humans; Mag | 1994 |
Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy.
Topics: Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Male; Neoplasms; Oxidoreductases | 1994 |
Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy.
Topics: Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Male; Neoplasms; Oxidoreductases | 1994 |
Chemotherapy administration: doses, infusions and choice of schedule.
Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Etoposide; Fluorouracil; Humans; | 1994 |
Chemotherapy administration: doses, infusions and choice of schedule.
Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Etoposide; Fluorouracil; Humans; | 1994 |
Clinical pharmacokinetics of anti-metabolites.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcyt | 1993 |
Clinical pharmacokinetics of anti-metabolites.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcyt | 1993 |
New techniques in the pharmacokinetic analysis of cancer drugs. III. Nuclear magnetic resonance.
Topics: Antineoplastic Agents; Fluorouracil; Folic Acid; Humans; Magnetic Resonance Spectroscopy; Misonidazo | 1993 |
New techniques in the pharmacokinetic analysis of cancer drugs. III. Nuclear magnetic resonance.
Topics: Antineoplastic Agents; Fluorouracil; Folic Acid; Humans; Magnetic Resonance Spectroscopy; Misonidazo | 1993 |
Protracted drug infusions in cancer treatment: an appraisal of 5-fluorouracil, doxorubicin, and platinums.
Topics: Animals; Cisplatin; Doxorubicin; Fluorouracil; Humans; Infusions, Intravenous; Neoplasms | 1993 |
Protracted drug infusions in cancer treatment: an appraisal of 5-fluorouracil, doxorubicin, and platinums.
Topics: Animals; Cisplatin; Doxorubicin; Fluorouracil; Humans; Infusions, Intravenous; Neoplasms | 1993 |
[Pharmacokinetics in arterial infusion chemotherapy].
Topics: Drug Administration Schedule; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver | 1993 |
[Pharmacokinetics in arterial infusion chemotherapy].
Topics: Drug Administration Schedule; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver | 1993 |
Leucovorin modulation of fluorouracil.
Topics: Drug Synergism; Fluorouracil; Humans; Leucovorin; Neoplasms | 1993 |
Leucovorin modulation of fluorouracil.
Topics: Drug Synergism; Fluorouracil; Humans; Leucovorin; Neoplasms | 1993 |
[Development of fluorinated pyrimidines in Japan].
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorode | 1993 |
[Development of fluorinated pyrimidines in Japan].
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorode | 1993 |
Modulation of 5-fluorouracil by interferon: a review of potential cellular targets.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Combined Modality Therapy; Fluorouracil; Humans; Interfe | 1995 |
Modulation of 5-fluorouracil by interferon: a review of potential cellular targets.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Combined Modality Therapy; Fluorouracil; Humans; Interfe | 1995 |
Aspects of one-carbon folate cycling related to fluoropyrimidine and antifolate therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Fluorodeoxyuridylate; Fluorouracil; Folic Acid; Folic Acid | 1995 |
Aspects of one-carbon folate cycling related to fluoropyrimidine and antifolate therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Fluorodeoxyuridylate; Fluorouracil; Folic Acid; Folic Acid | 1995 |
Fluoropyrimidine catabolism.
Topics: Animals; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Floxuridine; Fluoroura | 1995 |
Fluoropyrimidine catabolism.
Topics: Animals; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Floxuridine; Fluoroura | 1995 |
Critical factors for optimizing the 5-fluorouracil-folinic acid association in cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administration Schedu | 1996 |
Critical factors for optimizing the 5-fluorouracil-folinic acid association in cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administration Schedu | 1996 |
New anticancer agents in clinical development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1995 |
New anticancer agents in clinical development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1995 |
[Factors of the therapeutic effectiveness of 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Drug Resistance, Neoplasm; Fluorouracil; Humans; Neoplasms; Thymidy | 1996 |
[Factors of the therapeutic effectiveness of 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Drug Resistance, Neoplasm; Fluorouracil; Humans; Neoplasms; Thymidy | 1996 |
Methotrexate: an effective agent for treating cancer and building careers. The polyglutamate era.
Topics: Animals; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Leucovorin; Methotrexate; Mice; Neop | 1996 |
Methotrexate: an effective agent for treating cancer and building careers. The polyglutamate era.
Topics: Animals; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Leucovorin; Methotrexate; Mice; Neop | 1996 |
The suitability of selected new anticancer agents for infusional therapy and the effects of others on infusional therapy practices.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoc | 1995 |
The suitability of selected new anticancer agents for infusional therapy and the effects of others on infusional therapy practices.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoc | 1995 |
[Acquisition of resistance to anticancer agents by overproduction of target enzymes].
Topics: Animals; Antimetabolites, Antineoplastic; Drug Resistance, Neoplasm; Enzymes; Fluorouracil; Gene Amp | 1997 |
[Acquisition of resistance to anticancer agents by overproduction of target enzymes].
Topics: Animals; Antimetabolites, Antineoplastic; Drug Resistance, Neoplasm; Enzymes; Fluorouracil; Gene Amp | 1997 |
Modulation of 5-FU and its related compounds.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; | 1997 |
Modulation of 5-FU and its related compounds.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; | 1997 |
[Oxaliplatin: the first DACH platinum in clinical practice].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; | 1997 |
[Oxaliplatin: the first DACH platinum in clinical practice].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; | 1997 |
Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy.
Topics: Antineoplastic Agents; Endothelial Growth Factors; Fluorouracil; Genes; Humans; Neoplasm Proteins; N | 1997 |
Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy.
Topics: Antineoplastic Agents; Endothelial Growth Factors; Fluorouracil; Genes; Humans; Neoplasm Proteins; N | 1997 |
Docetaxel in combination with fluorouracil for advanced solid tumors.
Topics: Adult; Aged; Animals; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplas | 1997 |
Docetaxel in combination with fluorouracil for advanced solid tumors.
Topics: Adult; Aged; Animals; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplas | 1997 |
Paclitaxel pharmacology and other tumor types.
Topics: Alkylating Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols | 1997 |
Paclitaxel pharmacology and other tumor types.
Topics: Alkylating Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols | 1997 |
Tumor resistance to antimetabolites.
Topics: Antimetabolites, Antineoplastic; Cell Cycle Proteins; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug | 1998 |
Tumor resistance to antimetabolites.
Topics: Antimetabolites, Antineoplastic; Cell Cycle Proteins; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug | 1998 |
Interferon use in solid tumors.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Smal | 1998 |
Interferon use in solid tumors.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Smal | 1998 |
UFT: biochemical modulation for 5-fluorouracil (5-FU).
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as | 1997 |
UFT: biochemical modulation for 5-fluorouracil (5-FU).
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as | 1997 |
Cancer chemotherapy in the elderly.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Anthraquinones; Antineoplastic Agents; Breast Neo | 1998 |
Cancer chemotherapy in the elderly.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Anthraquinones; Antineoplastic Agents; Breast Neo | 1998 |
Biochemical and clinical pharmacology of 5-fluorouracil.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Biological Availability; Dihydrouracil Dehydr | 1998 |
Biochemical and clinical pharmacology of 5-fluorouracil.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Biological Availability; Dihydrouracil Dehydr | 1998 |
The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Neoplasms | 1998 |
The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Neoplasms | 1998 |
[Irinotecan: various administration schedules, study of drug combinations, phase I experience].
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoc | 1998 |
[Irinotecan: various administration schedules, study of drug combinations, phase I experience].
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoc | 1998 |
Therapeutic drug monitoring of antimetabolic cytotoxic drugs.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Drug Monitoring; Fluorouracil; Humans; Mercaptopurine; | 1999 |
Therapeutic drug monitoring of antimetabolic cytotoxic drugs.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Drug Monitoring; Fluorouracil; Humans; Mercaptopurine; | 1999 |
[Oral fluoropyrimidines in oncology].
Topics: Administration, Oral; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplas | 1998 |
[Oral fluoropyrimidines in oncology].
Topics: Administration, Oral; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplas | 1998 |
[Combination chemotherapy--present status and problems].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclopho | 1999 |
[Combination chemotherapy--present status and problems].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclopho | 1999 |
Novel anticancer drugs in Japan.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 1999 |
Novel anticancer drugs in Japan.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 1999 |
Capecitabine: nursing implications of a new oral chemotherapeutic agent.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neop | 1999 |
Capecitabine: nursing implications of a new oral chemotherapeutic agent.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neop | 1999 |
Can pharmacokinetic monitoring improve clinical use of fluorouracil?
Topics: Age Factors; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Monitoring; Fem | 1999 |
Can pharmacokinetic monitoring improve clinical use of fluorouracil?
Topics: Age Factors; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Monitoring; Fem | 1999 |
Potential of Xeloda in colorectal cancer and other solid tumors.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1999 |
Potential of Xeloda in colorectal cancer and other solid tumors.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1999 |
Introduction. Beyond 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; Neopla | 1999 |
Introduction. Beyond 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; Neopla | 1999 |
Clinical implications of dihydropyrimidine dehydrogenase inhibition.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biological Availabi | 1999 |
Clinical implications of dihydropyrimidine dehydrogenase inhibition.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biological Availabi | 1999 |
Toxicity of 5-fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Bone Marrow; Digestive System; Dihydrouracil Dehydrogenase (N | 1999 |
Toxicity of 5-fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Bone Marrow; Digestive System; Dihydrouracil Dehydrogenase (N | 1999 |
The role of UFT in combined-modality therapy.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as To | 1999 |
The role of UFT in combined-modality therapy.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as To | 1999 |
[Theoretical basis for low-dose CDDP/5-FU therapy].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colonic Neopla | 1999 |
[Theoretical basis for low-dose CDDP/5-FU therapy].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colonic Neopla | 1999 |
[Discovery and development of novel anticancer drug capecitabine].
Topics: Animals; Antineoplastic Agents; Biological Availability; Bridged-Ring Compounds; Capecitabine; Cyclo | 1999 |
[Discovery and development of novel anticancer drug capecitabine].
Topics: Animals; Antineoplastic Agents; Biological Availability; Bridged-Ring Compounds; Capecitabine; Cyclo | 1999 |
19F-MRS studies of fluorinated drugs in humans.
Topics: Fluorine; Fluorouracil; Humans; Magnetic Resonance Spectroscopy; Models, Biological; Neoplasms; Prod | 2000 |
19F-MRS studies of fluorinated drugs in humans.
Topics: Fluorine; Fluorouracil; Humans; Magnetic Resonance Spectroscopy; Models, Biological; Neoplasms; Prod | 2000 |
[Combination of levofolinate calcium and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Drug Administrat | 2000 |
[Combination of levofolinate calcium and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Drug Administrat | 2000 |
Fluorouracil.
Topics: Antimetabolites, Antineoplastic; Drug Interactions; Drug Monitoring; Fluorouracil; Humans; Neoplasms | 1999 |
Fluorouracil.
Topics: Antimetabolites, Antineoplastic; Drug Interactions; Drug Monitoring; Fluorouracil; Humans; Neoplasms | 1999 |
Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?
Topics: Antimetabolites, Antineoplastic; Circadian Rhythm; Dihydrouracil Dehydrogenase (NADP); Drug Interact | 2000 |
Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?
Topics: Antimetabolites, Antineoplastic; Circadian Rhythm; Dihydrouracil Dehydrogenase (NADP); Drug Interact | 2000 |
The potential therapeutic gain of radiation-associated gene therapy with the suicide gene cytosine deaminase.
Topics: Animals; Antimetabolites; Cytosine Deaminase; Dose-Response Relationship, Drug; Flucytosine; Fluorou | 2000 |
The potential therapeutic gain of radiation-associated gene therapy with the suicide gene cytosine deaminase.
Topics: Animals; Antimetabolites; Cytosine Deaminase; Dose-Response Relationship, Drug; Flucytosine; Fluorou | 2000 |
Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.
Topics: Antimetabolites, Antineoplastic; DNA Repair; Drug Design; Fluorouracil; Folic Acid Antagonists; Gene | 2000 |
Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.
Topics: Antimetabolites, Antineoplastic; DNA Repair; Drug Design; Fluorouracil; Folic Acid Antagonists; Gene | 2000 |
Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU from bench to clinic.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2000 |
Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU from bench to clinic.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2000 |
The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Neoplasms; Pharmacogenetics | 2000 |
The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Neoplasms; Pharmacogenetics | 2000 |
Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
Topics: Animals; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Dihydrouracil Dehydrogenase (NAD | 2000 |
Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
Topics: Animals; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Dihydrouracil Dehydrogenase (NAD | 2000 |
Clinical development of eniluracil/fluorouracil: an oral treatment for patients with solid tumors.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2000 |
Clinical development of eniluracil/fluorouracil: an oral treatment for patients with solid tumors.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2000 |
Oral fluoropyrimidines in cancer treatment.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colo | 2000 |
Oral fluoropyrimidines in cancer treatment.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colo | 2000 |
Novel oral chemotherapy agents.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 2000 |
Novel oral chemotherapy agents.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 2000 |
Fluorouracil and the new oral fluorinated pyrimidines.
Topics: Animals; Antimetabolites, Antineoplastic; Biological Availability; Biotransformation; Fluorouracil; | 2001 |
Fluorouracil and the new oral fluorinated pyrimidines.
Topics: Animals; Antimetabolites, Antineoplastic; Biological Availability; Biotransformation; Fluorouracil; | 2001 |
Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology.
Topics: Antimetabolites, Antineoplastic; Biological Availability; Dihydrouracil Dehydrogenase (NADP); Fluoro | 2001 |
Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology.
Topics: Antimetabolites, Antineoplastic; Biological Availability; Dihydrouracil Dehydrogenase (NADP); Fluoro | 2001 |
Other fluorinated pyrimidines in the treatment of solid tumors.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Drug Combinations; Fluorouracil; Humans; | 2001 |
Other fluorinated pyrimidines in the treatment of solid tumors.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Drug Combinations; Fluorouracil; Humans; | 2001 |
The oral fluorinated pyrimidines.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Biological Availability; Biotransfor | 2001 |
The oral fluorinated pyrimidines.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Biological Availability; Biotransfor | 2001 |
[5-fluorouracil and dihydropyrimidine dehydrogenase].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehyd | 2001 |
[5-fluorouracil and dihydropyrimidine dehydrogenase].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehyd | 2001 |
From 5 fluorouracil to the new oral fluoropyrimidines: a brief overview of four decades of clinical investigations.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Drug Admin | 2001 |
From 5 fluorouracil to the new oral fluoropyrimidines: a brief overview of four decades of clinical investigations.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Drug Admin | 2001 |
Stem cell engraftment strategies.
Topics: Adolescent; Adult; Aged; Animals; Antibodies, Monoclonal; Antigens, Ly; Apoptosis; CD40 Antigens; CD | 2001 |
Stem cell engraftment strategies.
Topics: Adolescent; Adult; Aged; Animals; Antibodies, Monoclonal; Antigens, Ly; Apoptosis; CD40 Antigens; CD | 2001 |
Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 2001 |
Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 2001 |
The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents.
Topics: Animals; Antimetabolites, Antineoplastic; Fluorouracil; History, 20th Century; Humans; Neoplasms | 2000 |
The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents.
Topics: Animals; Antimetabolites, Antineoplastic; Fluorouracil; History, 20th Century; Humans; Neoplasms | 2000 |
Circulatory shock.
Topics: Adrenal Gland Diseases; Adrenal Gland Neoplasms; Anthracyclines; Antineoplastic Agents; Carcinoid Tu | 2001 |
Circulatory shock.
Topics: Adrenal Gland Diseases; Adrenal Gland Neoplasms; Anthracyclines; Antineoplastic Agents; Carcinoid Tu | 2001 |
Therapeutic drug monitoring of cytotoxic drugs.
Topics: Antimetabolites, Antineoplastic; Drug Interactions; Drug Monitoring; Fluorouracil; Humans; Mercaptop | 2001 |
Therapeutic drug monitoring of cytotoxic drugs.
Topics: Antimetabolites, Antineoplastic; Drug Interactions; Drug Monitoring; Fluorouracil; Humans; Mercaptop | 2001 |
Recent advances in the use of radiosensitizing nucleosides.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dis | 2001 |
Recent advances in the use of radiosensitizing nucleosides.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dis | 2001 |
Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Biotransformation; Bystander Effect; Clinical Trials a | 1999 |
Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Biotransformation; Bystander Effect; Clinical Trials a | 1999 |
[Tumor dormancy therapy--what do you think of this therapy?].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Division; Ci | 2001 |
[Tumor dormancy therapy--what do you think of this therapy?].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Division; Ci | 2001 |
The combined use of radiotherapy and chemotherapy in the treatment of solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modali | 2002 |
The combined use of radiotherapy and chemotherapy in the treatment of solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modali | 2002 |
Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics.
Topics: Antimetabolites, Antineoplastic; Biological Availability; Chronotherapy; Circadian Rhythm; Dihydrour | 2002 |
Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics.
Topics: Antimetabolites, Antineoplastic; Biological Availability; Chronotherapy; Circadian Rhythm; Dihydrour | 2002 |
The role of pro-drug therapy in the treatment of cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Drug Delivery Systems; Fluorouracil; Hu | 2001 |
The role of pro-drug therapy in the treatment of cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Drug Delivery Systems; Fluorouracil; Hu | 2001 |
Capecitabine: fulfilling the promise of oral chemotherapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Capecitabine: fulfilling the promise of oral chemotherapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Homeostatic control of uridine and the role of uridine phosphorylase: a biological and clinical update.
Topics: Animals; Antineoplastic Agents; Biological Transport, Active; Fluorouracil; Gene Expression Regulati | 2002 |
Homeostatic control of uridine and the role of uridine phosphorylase: a biological and clinical update.
Topics: Animals; Antineoplastic Agents; Biological Transport, Active; Fluorouracil; Gene Expression Regulati | 2002 |
Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Cell Cycle Proteins; Dihydrouracil Dehydrogenase (NADP) | 2002 |
Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Cell Cycle Proteins; Dihydrouracil Dehydrogenase (NADP) | 2002 |
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Resistance, Neoplasm; Enzyme Induction; Fluorouracil; | 2002 |
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Resistance, Neoplasm; Enzyme Induction; Fluorouracil; | 2002 |
Current concepts of chemotherapy combined with other modalities for head and neck cancer.
Topics: Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Head; Head and Neck Neoplasms; | 1975 |
Current concepts of chemotherapy combined with other modalities for head and neck cancer.
Topics: Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Head; Head and Neck Neoplasms; | 1975 |
The clinical pharmacology of antineoplastic agents (first of two parts).
Topics: Animals; Antineoplastic Agents; Asparaginase; Binding Sites; Biological Transport; Chemical and Drug | 1975 |
The clinical pharmacology of antineoplastic agents (first of two parts).
Topics: Animals; Antineoplastic Agents; Asparaginase; Binding Sites; Biological Transport; Chemical and Drug | 1975 |
Chemotherapy of solid tumors. Recent advances.
Topics: Adult; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Bronchogenic; Carcinom | 1976 |
Chemotherapy of solid tumors. Recent advances.
Topics: Adult; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Bronchogenic; Carcinom | 1976 |
Immunologic aspects of cancer chemotherapy.
Topics: Animals; BCG Vaccine; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combina | 1977 |
Immunologic aspects of cancer chemotherapy.
Topics: Animals; BCG Vaccine; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combina | 1977 |
Individual cell biology: basis and prospects for a rational cancer chemotherapy.
Topics: Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Cell Cycle; Chromosome Aberrations; Cyclophospham | 1977 |
Individual cell biology: basis and prospects for a rational cancer chemotherapy.
Topics: Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Cell Cycle; Chromosome Aberrations; Cyclophospham | 1977 |
Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Colonic Neoplasms; Evaluation Stud | 1979 |
Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Colonic Neoplasms; Evaluation Stud | 1979 |
1977 Henry H. Janeway lecture: fundamental mechanisms in combined modality therapy of cancer.
Topics: Animals; Antineoplastic Agents; Bromodeoxyuridine; Dactinomycin; DNA Repair; DNA, Neoplasm; Electron | 1977 |
1977 Henry H. Janeway lecture: fundamental mechanisms in combined modality therapy of cancer.
Topics: Animals; Antineoplastic Agents; Bromodeoxyuridine; Dactinomycin; DNA Repair; DNA, Neoplasm; Electron | 1977 |
Selective suppression of humoral immunity by antineoplastic drugs.
Topics: Animals; Antineoplastic Agents; Binding Sites; Chickens; Cyclophosphamide; Cytarabine; Fluorouracil; | 1976 |
Selective suppression of humoral immunity by antineoplastic drugs.
Topics: Animals; Antineoplastic Agents; Binding Sites; Chickens; Cyclophosphamide; Cytarabine; Fluorouracil; | 1976 |
Hypersensitivity reactions.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Aziridines; Benzoquinones; Bleomyc | 1992 |
Hypersensitivity reactions.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Aziridines; Benzoquinones; Bleomyc | 1992 |
Antimetabolites.
Topics: Animals; Cytarabine; Drug Interactions; Drug Resistance; Fluorouracil; Humans; Methotrexate; Neoplas | 1992 |
Antimetabolites.
Topics: Animals; Cytarabine; Drug Interactions; Drug Resistance; Fluorouracil; Humans; Methotrexate; Neoplas | 1992 |
[Totally implantable systems for long-term chemotherapeutic treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Evaluation Studies as Topic; Fluorouracil; Folic Aci | 1992 |
[Totally implantable systems for long-term chemotherapeutic treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Evaluation Studies as Topic; Fluorouracil; Folic Aci | 1992 |
[Effect of antifolates and folates on the antineoplastic action of fluoropyrimidines].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Inte | 1992 |
[Effect of antifolates and folates on the antineoplastic action of fluoropyrimidines].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Inte | 1992 |
The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation.
Topics: Animals; Cell Division; Fluorouracil; Humans; Hydroxyurea; Neoplasm Recurrence, Local; Neoplasms; Ra | 1992 |
The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation.
Topics: Animals; Cell Division; Fluorouracil; Humans; Hydroxyurea; Neoplasm Recurrence, Local; Neoplasms; Ra | 1992 |
Mechanisms of interaction of interferon and 5-fluorouracil in solid tumors.
Topics: Clinical Trials as Topic; Drug Interactions; Fluorouracil; Humans; Interferons; Neoplasms; Tumor Cel | 1991 |
Mechanisms of interaction of interferon and 5-fluorouracil in solid tumors.
Topics: Clinical Trials as Topic; Drug Interactions; Fluorouracil; Humans; Interferons; Neoplasms; Tumor Cel | 1991 |
Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators.
Topics: Animals; Fluorodeoxyuridylate; Fluorouracil; Humans; Neoplasms; Neoplasms, Experimental; Pyrimidines | 1991 |
Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators.
Topics: Animals; Fluorodeoxyuridylate; Fluorouracil; Humans; Neoplasms; Neoplasms, Experimental; Pyrimidines | 1991 |
Antimetabolites.
Topics: Animals; Antimetabolites; Antineoplastic Agents; Cytarabine; Cytidine; Drug Interactions; Drug Resis | 1991 |
Antimetabolites.
Topics: Animals; Antimetabolites; Antineoplastic Agents; Cytarabine; Cytidine; Drug Interactions; Drug Resis | 1991 |
Chemoprotectants for cancer chemotherapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Cisplatin; Cyclophosphamide; Fluor | 1991 |
Chemoprotectants for cancer chemotherapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Cisplatin; Cyclophosphamide; Fluor | 1991 |
Clinical relevance of biochemical modulation of 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance; Drug | 1991 |
Clinical relevance of biochemical modulation of 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance; Drug | 1991 |
alpha-Interferon and 5-fluorouracil: possible mechanisms of antitumor action.
Topics: Clinical Trials as Topic; Drug Synergism; Fluorouracil; Humans; Interferon alpha-2; Interferon-alpha | 1991 |
alpha-Interferon and 5-fluorouracil: possible mechanisms of antitumor action.
Topics: Clinical Trials as Topic; Drug Synergism; Fluorouracil; Humans; Interferon alpha-2; Interferon-alpha | 1991 |
Protracted intravenous infusion of 5-fluorouracil in combination treatments. A review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Fluorouracil; H | 1991 |
Protracted intravenous infusion of 5-fluorouracil in combination treatments. A review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Fluorouracil; H | 1991 |
The role of low-dose PALA in biochemical modulation.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Clinical Trials as Topic; Dose-Response Relationship, | 1990 |
The role of low-dose PALA in biochemical modulation.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Clinical Trials as Topic; Dose-Response Relationship, | 1990 |
Concomitant continuous infusion chemotherapy and radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modali | 1990 |
Concomitant continuous infusion chemotherapy and radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modali | 1990 |
More evidence for circadian rhythm effects in cancer chemotherapy: the fluoropyrimidine story.
Topics: Circadian Rhythm; DNA; Floxuridine; Fluorouracil; Humans; Neoplasms | 1990 |
More evidence for circadian rhythm effects in cancer chemotherapy: the fluoropyrimidine story.
Topics: Circadian Rhythm; DNA; Floxuridine; Fluorouracil; Humans; Neoplasms | 1990 |
Modulation of 5-fluorouracil efficacy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Fluorouracil; | 1990 |
Modulation of 5-fluorouracil efficacy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Fluorouracil; | 1990 |
Intracavitary chemotherapy.
Topics: Absorption; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascitic | 1985 |
Intracavitary chemotherapy.
Topics: Absorption; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascitic | 1985 |
[Prolonged intravenous infusion chemotherapy. General review of theoretical bases and results].
Topics: Antineoplastic Agents; Bleomycin; Cell Cycle; Cisplatin; Clinical Trials as Topic; Cytarabine; Doxor | 1985 |
[Prolonged intravenous infusion chemotherapy. General review of theoretical bases and results].
Topics: Antineoplastic Agents; Bleomycin; Cell Cycle; Cisplatin; Clinical Trials as Topic; Cytarabine; Doxor | 1985 |
Emulsion and activated carbon in cancer chemotherapy.
Topics: Administration, Oral; Adult; Aged; Animals; Bleomycin; Breast Neoplasms; Carbon; Clinical Trials as | 1986 |
Emulsion and activated carbon in cancer chemotherapy.
Topics: Administration, Oral; Adult; Aged; Animals; Bleomycin; Breast Neoplasms; Carbon; Clinical Trials as | 1986 |
Sequential chemotherapy with methotrexate and 5-fluorouracil: mechanism of synergistic effect.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Methotrexate; Neoplas | 1986 |
Sequential chemotherapy with methotrexate and 5-fluorouracil: mechanism of synergistic effect.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Methotrexate; Neoplas | 1986 |
Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Floxuridine; Fluorodeoxyuri | 1989 |
Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Floxuridine; Fluorodeoxyuri | 1989 |
New vistas for leucovorin in cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemical Phenomena; Chemistry; Fluorouracil; Humans; | 1989 |
New vistas for leucovorin in cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemical Phenomena; Chemistry; Fluorouracil; Humans; | 1989 |
Enhancement of 5-fluorouracil's anticancer activity by dipyridamole.
Topics: Animals; Biological Transport; Cell Line, Transformed; Dipyridamole; Drug Screening Assays, Antitumo | 1989 |
Enhancement of 5-fluorouracil's anticancer activity by dipyridamole.
Topics: Animals; Biological Transport; Cell Line, Transformed; Dipyridamole; Drug Screening Assays, Antitumo | 1989 |
Enhancement of the antitumor activity of 5-fluorouracil by uridine rescue.
Topics: Animals; Drug Therapy, Combination; Fluorouracil; Humans; Neoplasms; Uridine | 1989 |
Enhancement of the antitumor activity of 5-fluorouracil by uridine rescue.
Topics: Animals; Drug Therapy, Combination; Fluorouracil; Humans; Neoplasms; Uridine | 1989 |
5-Fluorouracil radiation sensitization--a brief review.
Topics: Combined Modality Therapy; Fluorouracil; Humans; Neoplasms; Radiation-Sensitizing Agents | 1989 |
5-Fluorouracil radiation sensitization--a brief review.
Topics: Combined Modality Therapy; Fluorouracil; Humans; Neoplasms; Radiation-Sensitizing Agents | 1989 |
[Positron emitters for the study of tumor metabolism].
Topics: Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Humans; Neoplasms; Tomog | 1989 |
[Positron emitters for the study of tumor metabolism].
Topics: Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Humans; Neoplasms; Tomog | 1989 |
[Cardiac toxicity of 5-fluorouracil. Review of the literature, 5 new cases].
Topics: Arrhythmias, Cardiac; Female; Fluorouracil; Heart Diseases; Humans; Male; Middle Aged; Neoplasms; Ri | 1988 |
[Cardiac toxicity of 5-fluorouracil. Review of the literature, 5 new cases].
Topics: Arrhythmias, Cardiac; Female; Fluorouracil; Heart Diseases; Humans; Male; Middle Aged; Neoplasms; Ri | 1988 |
Overview: rational basis for development of fluoropyrimidine/5-formyltetrahydrofolate combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Design; Fluorouracil; Formyltetrahydrofolates; | 1988 |
Overview: rational basis for development of fluoropyrimidine/5-formyltetrahydrofolate combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Design; Fluorouracil; Formyltetrahydrofolates; | 1988 |
5-FU/leucovorin: biochemical modulation that works?
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoplasms; Randomi | 1987 |
5-FU/leucovorin: biochemical modulation that works?
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoplasms; Randomi | 1987 |
[Biochemical modulation of 5-fluorouracil by high-dose leucovorin].
Topics: Chemical Phenomena; Chemistry; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Humans; Leu | 1988 |
[Biochemical modulation of 5-fluorouracil by high-dose leucovorin].
Topics: Chemical Phenomena; Chemistry; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Humans; Leu | 1988 |
Role of thymidine in biochemical modulation: a review.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic A | 1987 |
Role of thymidine in biochemical modulation: a review.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic A | 1987 |
Application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy.
Topics: Animals; Aspartic Acid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Co | 1985 |
Application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy.
Topics: Animals; Aspartic Acid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Co | 1985 |
Neurologic complications of systemic cancer.
Topics: Arachnoid; Bacterial Infections; Brain; Brain Neoplasms; Cerebrovascular Disorders; Cisplatin; Disse | 1985 |
Neurologic complications of systemic cancer.
Topics: Arachnoid; Bacterial Infections; Brain; Brain Neoplasms; Cerebrovascular Disorders; Cisplatin; Disse | 1985 |
[Tumors].
Topics: Antigens; Bleomycin; Daunorubicin; Fetal Proteins; Fluorouracil; Glycolipids; Glycoproteins; Humans; | 1972 |
[Tumors].
Topics: Antigens; Bleomycin; Daunorubicin; Fetal Proteins; Fluorouracil; Glycolipids; Glycoproteins; Humans; | 1972 |
Guide to the use of cancer chemotherapeutic agents.
Topics: Alkylating Agents; Allopurinol; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; | 1972 |
Guide to the use of cancer chemotherapeutic agents.
Topics: Alkylating Agents; Allopurinol; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; | 1972 |
Cancer chemotherapy. II.
Topics: Animals; Antineoplastic Agents; Asparaginase; Azathioprine; Bleomycin; Cytarabine; Dactinomycin; Dau | 1972 |
Cancer chemotherapy. II.
Topics: Animals; Antineoplastic Agents; Asparaginase; Azathioprine; Bleomycin; Cytarabine; Dactinomycin; Dau | 1972 |
[Principles of the effect of cytostatics].
Topics: Antineoplastic Agents; Asparaginase; Cell Division; Chlorambucil; Cyclophosphamide; Cytarabine; Drug | 1974 |
[Principles of the effect of cytostatics].
Topics: Antineoplastic Agents; Asparaginase; Cell Division; Chlorambucil; Cyclophosphamide; Cytarabine; Drug | 1974 |
Clinical use of radiation sensitizing agents.
Topics: Animals; Antimetabolites, Antineoplastic; Bleomycin; Bromodeoxycytidine; Bromodeoxyuridine; Bromoura | 1974 |
Clinical use of radiation sensitizing agents.
Topics: Animals; Antimetabolites, Antineoplastic; Bleomycin; Bromodeoxycytidine; Bromodeoxyuridine; Bromoura | 1974 |
Solid tumor chemotherapy: What have we to offer.
Topics: Adult; Antineoplastic Agents; Child; Cyclophosphamide; Dactinomycin; Floxuridine; Fluorouracil; Huma | 1970 |
Solid tumor chemotherapy: What have we to offer.
Topics: Adult; Antineoplastic Agents; Child; Cyclophosphamide; Dactinomycin; Floxuridine; Fluorouracil; Huma | 1970 |
The use of cytotoxic drugs in the surgery of malignant disease.
Topics: Abdominal Neoplasms; Alkylating Agents; Animals; Antimetabolites; Antineoplastic Agents; Carcinoma, | 1968 |
The use of cytotoxic drugs in the surgery of malignant disease.
Topics: Abdominal Neoplasms; Alkylating Agents; Animals; Antimetabolites; Antineoplastic Agents; Carcinoma, | 1968 |
An assessment of massive-dose chemotherapy of malignant disease.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cell Division; Cyclo | 1971 |
An assessment of massive-dose chemotherapy of malignant disease.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cell Division; Cyclo | 1971 |
Chemotherapy of residual disease in solid tumours.
Topics: Colonic Neoplasms; Cyclophosphamide; Floxuridine; Fluorouracil; Head and Neck Neoplasms; Humans; Lun | 1971 |
Chemotherapy of residual disease in solid tumours.
Topics: Colonic Neoplasms; Cyclophosphamide; Floxuridine; Fluorouracil; Head and Neck Neoplasms; Humans; Lun | 1971 |
[Use of optical quantum generators (lasers) in oncology].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Basal Cell; Carcinom | 1972 |
[Use of optical quantum generators (lasers) in oncology].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Basal Cell; Carcinom | 1972 |
[Cytostatics for improvement of clinical tumor surgery].
Topics: Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Female; Fluorouracil; Gastrointestinal | 1973 |
[Cytostatics for improvement of clinical tumor surgery].
Topics: Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Female; Fluorouracil; Gastrointestinal | 1973 |
Newer concepts in chemotherapy of cancer.
Topics: Breast Neoplasms; Colonic Neoplasms; Dysgerminoma; Female; Fluorouracil; Humans; Injections, Intra-A | 1972 |
Newer concepts in chemotherapy of cancer.
Topics: Breast Neoplasms; Colonic Neoplasms; Dysgerminoma; Female; Fluorouracil; Humans; Injections, Intra-A | 1972 |
Thymidylate synthetase.
Topics: Animals; Binding Sites; Deoxyuridine; Drug Stability; Escherichia coli; Fluorouracil; Folic Acid Def | 1973 |
Thymidylate synthetase.
Topics: Animals; Binding Sites; Deoxyuridine; Drug Stability; Escherichia coli; Fluorouracil; Folic Acid Def | 1973 |
Predictive tests in cancer. Tuesday 9 April 1974.
Topics: Age Factors; Breast Neoplasms; Cell Movement; Clinical Enzyme Tests; Colonic Neoplasms; Cytarabine; | 1974 |
Predictive tests in cancer. Tuesday 9 April 1974.
Topics: Age Factors; Breast Neoplasms; Cell Movement; Clinical Enzyme Tests; Colonic Neoplasms; Cytarabine; | 1974 |
[A review of clinical tumor immunology. An approach to immunochemotherapy].
Topics: Animals; Antibiotics, Antineoplastic; BCG Vaccine; Cytarabine; Drug Therapy, Combination; Fluorourac | 1974 |
[A review of clinical tumor immunology. An approach to immunochemotherapy].
Topics: Animals; Antibiotics, Antineoplastic; BCG Vaccine; Cytarabine; Drug Therapy, Combination; Fluorourac | 1974 |
[5-fluorouracil as a radiosensitizer].
Topics: Fluorouracil; Humans; Neoplasms; Radiation-Sensitizing Agents | 1967 |
[5-fluorouracil as a radiosensitizer].
Topics: Fluorouracil; Humans; Neoplasms; Radiation-Sensitizing Agents | 1967 |
[Biochemical aspects of the therapy of advanced malignant tumors].
Topics: Adrenal Cortex Hormones; Alkaloids; Androgens; Anti-Bacterial Agents; Cyclophosphamide; DNA; DNA, Ne | 1966 |
[Biochemical aspects of the therapy of advanced malignant tumors].
Topics: Adrenal Cortex Hormones; Alkaloids; Androgens; Anti-Bacterial Agents; Cyclophosphamide; DNA; DNA, Ne | 1966 |
Local cytostatic chemotherapy and immunotherapy.
Topics: Antineoplastic Agents; Carcinoma, Basal Cell; Drug Hypersensitivity; Fluorouracil; Humans; Neoplasms | 1968 |
Local cytostatic chemotherapy and immunotherapy.
Topics: Antineoplastic Agents; Carcinoma, Basal Cell; Drug Hypersensitivity; Fluorouracil; Humans; Neoplasms | 1968 |
Current progress in the management of cancer. A collective review.
Topics: Adenocarcinoma; Angiography; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Chem | 1969 |
Current progress in the management of cancer. A collective review.
Topics: Adenocarcinoma; Angiography; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Chem | 1969 |
Chemical carcinogenesis, chemotherapy: cancer's continuing core challenges--G. H. A. Clowes Memorial Lecture.
Topics: Animals; Antineoplastic Agents; Arginase; Benz(a)Anthracenes; Benzopyrenes; Carcinogens; Cell Divisi | 1970 |
Chemical carcinogenesis, chemotherapy: cancer's continuing core challenges--G. H. A. Clowes Memorial Lecture.
Topics: Animals; Antineoplastic Agents; Arginase; Benz(a)Anthracenes; Benzopyrenes; Carcinogens; Cell Divisi | 1970 |
Cancer chemotherapy today and tomorrow. (A review).
Topics: Antineoplastic Agents; Child; Fluorouracil; Forecasting; Humans; Leukemia; Mercaptopurine; Methotrex | 1971 |
Cancer chemotherapy today and tomorrow. (A review).
Topics: Antineoplastic Agents; Child; Fluorouracil; Forecasting; Humans; Leukemia; Mercaptopurine; Methotrex | 1971 |
The metabolism and pharmacology of 5-fluorouracil.
Topics: Adenocarcinoma; Alopecia; Animals; Breast Neoplasms; Carbon Isotopes; Cell Division; Chromosome Aber | 1971 |
The metabolism and pharmacology of 5-fluorouracil.
Topics: Adenocarcinoma; Alopecia; Animals; Breast Neoplasms; Carbon Isotopes; Cell Division; Chromosome Aber | 1971 |
[Antimetabolites].
Topics: Allopurinol; Animals; Antimetabolites; Azathioprine; Cell Division; Chemical Phenomena; Chemistry; C | 1971 |
[Antimetabolites].
Topics: Allopurinol; Animals; Antimetabolites; Azathioprine; Cell Division; Chemical Phenomena; Chemistry; C | 1971 |
Multiple combination therapy in cancer chemotherapy in Japan.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Chloroquine; Cyclophosphamide; Cytarabine; Drug | 1969 |
Multiple combination therapy in cancer chemotherapy in Japan.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Chloroquine; Cyclophosphamide; Cytarabine; Drug | 1969 |
[Side-effects of cytostatic therapy with special reference to potential carcinogenic effects].
Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Bus | 1971 |
[Side-effects of cytostatic therapy with special reference to potential carcinogenic effects].
Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Bus | 1971 |
[5-fluorouracil in the chemotherapy of malignant neoplasms].
Topics: Animals; Fluorouracil; Humans; Mice; Neoplasms | 1966 |
[5-fluorouracil in the chemotherapy of malignant neoplasms].
Topics: Animals; Fluorouracil; Humans; Mice; Neoplasms | 1966 |
258 trials available for fluorouracil and Neoplasms
| Article | Year |
|---|---|
Minimal added value of wetting hair before scalp cooling to prevent chemotherapy-induced alopecia in cancer patients - results from the Dutch Scalp Cooling Registry.
Topics: Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2023 |
Minimal added value of wetting hair before scalp cooling to prevent chemotherapy-induced alopecia in cancer patients - results from the Dutch Scalp Cooling Registry.
Topics: Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2023 |
Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cetuximab; Cisp | 2019 |
Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cetuximab; Cisp | 2019 |
Phase I pharmacological study of continuous chronomodulated capecitabine treatment.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Circadian Rhythm; Dihydrouracil Dehydrogenase (NAD | 2020 |
Phase I pharmacological study of continuous chronomodulated capecitabine treatment.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Circadian Rhythm; Dihydrouracil Dehydrogenase (NAD | 2020 |
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplat | 2021 |
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplat | 2021 |
Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application.
Topics: Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Combinations; Female; | 2021 |
Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application.
Topics: Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Combinations; Female; | 2021 |
Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Drugs, Chinese Herbal; Femal | 2017 |
Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Drugs, Chinese Herbal; Femal | 2017 |
Role of Urotensin-2 in 5-Fluorouracil-Related Arterial Vasoconstriction in Cancer Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachial Artery; Cardiotoxicity; Electr | 2018 |
Role of Urotensin-2 in 5-Fluorouracil-Related Arterial Vasoconstriction in Cancer Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachial Artery; Cardiotoxicity; Electr | 2018 |
First-in-human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovori | 2019 |
First-in-human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovori | 2019 |
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidi | 2013 |
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidi | 2013 |
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineo | 2014 |
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineo | 2014 |
A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohor | 2014 |
A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohor | 2014 |
Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Cohort Studies; Deoxycytidin | 2014 |
Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Cohort Studies; Deoxycytidin | 2014 |
Effect of modified taohongsiwu decoction on patients with chemotherapy-induced hand-foot syndrome.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dr | 2014 |
Effect of modified taohongsiwu decoction on patients with chemotherapy-induced hand-foot syndrome.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dr | 2014 |
Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; C | 2014 |
Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; C | 2014 |
A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.
Topics: Aged; Amyloid Precursor Protein Secretases; Antineoplastic Combined Chemotherapy Protocols; Benzazep | 2015 |
A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.
Topics: Aged; Amyloid Precursor Protein Secretases; Antineoplastic Combined Chemotherapy Protocols; Benzazep | 2015 |
Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Double-Blind Method; Female; Fluoro | 2015 |
Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Double-Blind Method; Female; Fluoro | 2015 |
A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients.
Topics: Administration, Cutaneous; Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined | 2015 |
A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients.
Topics: Administration, Cutaneous; Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined | 2015 |
Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; | 2015 |
Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; | 2015 |
A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; D | 2015 |
A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; D | 2015 |
Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administrati | 2016 |
Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administrati | 2016 |
Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Re | 2016 |
Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Re | 2016 |
Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2009 |
Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2009 |
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort | 2009 |
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort | 2009 |
Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence study.
Topics: Absorption; Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluo | 2008 |
Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence study.
Topics: Absorption; Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluo | 2008 |
A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antiemetics; Antineoplastic Agents, Phytogenic; A | 2009 |
A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antiemetics; Antineoplastic Agents, Phytogenic; A | 2009 |
Combination therapy with mitomycin C (NSC-26980), 5-fluorouracil (NSC-19893), and cytosine arabinoside (NSC-63878) for advanced cancer in man.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Colorectal | 1972 |
Combination therapy with mitomycin C (NSC-26980), 5-fluorouracil (NSC-19893), and cytosine arabinoside (NSC-63878) for advanced cancer in man.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Colorectal | 1972 |
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2008 |
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2008 |
A phase I study of an oral simulated FOLFOX with high dose capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2009 |
A phase I study of an oral simulated FOLFOX with high dose capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2009 |
Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Cyclophosphamide; Enzy | 2009 |
Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Cyclophosphamide; Enzy | 2009 |
Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Female; | 2009 |
Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Female; | 2009 |
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Allopurinol mouth rinse for prophylaxis of fluorouracil-induced mucositis.
Topics: Adult; Allopurinol; Antimetabolites, Antineoplastic; Double-Blind Method; Female; Fluorouracil; Huma | 2010 |
Allopurinol mouth rinse for prophylaxis of fluorouracil-induced mucositis.
Topics: Adult; Allopurinol; Antimetabolites, Antineoplastic; Double-Blind Method; Female; Fluorouracil; Huma | 2010 |
A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; | 2010 |
A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; | 2010 |
Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cyclin-Dependent Kinases; Fe | 2009 |
Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cyclin-Dependent Kinases; Fe | 2009 |
A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Ant | 2010 |
A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Ant | 2010 |
Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cap | 2010 |
Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cap | 2010 |
A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Benzamides; Capecitabine; | 2010 |
A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Benzamides; Capecitabine; | 2010 |
A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Dose-Response Relationship, | 2010 |
A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Dose-Response Relationship, | 2010 |
Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Cu | 2010 |
Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Cu | 2010 |
Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Es | 2011 |
Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Es | 2011 |
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2010 |
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2010 |
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineo | 2010 |
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineo | 2010 |
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2012 |
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2012 |
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-R | 2010 |
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-R | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbop | 2010 |
Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbop | 2010 |
A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dia | 2011 |
A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dia | 2011 |
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve | 2011 |
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve | 2011 |
A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Dihydrouracil Dehyd | 2011 |
A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Dihydrouracil Dehyd | 2011 |
Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deo | 2011 |
Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deo | 2011 |
A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Be | 2012 |
A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Be | 2012 |
Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2012 |
Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2012 |
Evaluation of the effect of cryotherapy in preventing oral mucositis associated with chemotherapy - a randomized controlled trial.
Topics: Antineoplastic Agents; Cryotherapy; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasms; Stoma | 2012 |
Evaluation of the effect of cryotherapy in preventing oral mucositis associated with chemotherapy - a randomized controlled trial.
Topics: Antineoplastic Agents; Cryotherapy; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasms; Stoma | 2012 |
Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine | 2012 |
Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine | 2012 |
Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chromatogra | 2012 |
Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chromatogra | 2012 |
Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplasti | 2012 |
Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplasti | 2012 |
A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Do | 2012 |
A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Do | 2012 |
Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationshi | 2013 |
Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationshi | 2013 |
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Capecitabi | 2012 |
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Capecitabi | 2012 |
A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dose-Response R | 2013 |
A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dose-Response R | 2013 |
A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2013 |
A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2013 |
Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Dose-Resp | 2013 |
Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Dose-Resp | 2013 |
Pharmacokinetic evaluation of novel oral fluorouracil antitumor drug S-1 in Chinese cancer patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cross-Ov | 2013 |
Pharmacokinetic evaluation of novel oral fluorouracil antitumor drug S-1 in Chinese cancer patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cross-Ov | 2013 |
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neop | 2002 |
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neop | 2002 |
Phase I study of sequential administration of topotecan and 5-fluorouracil in patients with advanced malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dose-Response Rel | 2002 |
Phase I study of sequential administration of topotecan and 5-fluorouracil in patients with advanced malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dose-Response Rel | 2002 |
A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrh | 2002 |
A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrh | 2002 |
Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorou | 2002 |
Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorou | 2002 |
A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cap | 2003 |
A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cap | 2003 |
[Phase III clinical study of a new anticancer drug atofluding].
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Female; Fluorouracil; Humans; Leukopenia; Male; Middle A | 2002 |
[Phase III clinical study of a new anticancer drug atofluding].
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Female; Fluorouracil; Humans; Leukopenia; Male; Middle A | 2002 |
Capecitabine treatment results in increased mean corpuscular volume of red blood cells in patients with advanced solid malignancies.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Erythrocyte Indices; Erythrocytes; Fem | 2003 |
Capecitabine treatment results in increased mean corpuscular volume of red blood cells in patients with advanced solid malignancies.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Erythrocyte Indices; Erythrocytes; Fem | 2003 |
An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationshi | 2003 |
An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationshi | 2003 |
Metabolism of a novel nucleoside analogue, OGT 719, in the isolated perfused rat liver model, in rats, in tumour models and in patients.
Topics: alpha-Fetoproteins; Animals; Asialoglycoproteins; Biotransformation; Fetuins; Fluorine Radioisotopes | 2003 |
Metabolism of a novel nucleoside analogue, OGT 719, in the isolated perfused rat liver model, in rats, in tumour models and in patients.
Topics: alpha-Fetoproteins; Animals; Asialoglycoproteins; Biotransformation; Fetuins; Fluorine Radioisotopes | 2003 |
Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Enzyme Inhibit | 2003 |
Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Enzyme Inhibit | 2003 |
Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients.
Topics: Adenoviridae; Adenovirus E1B Proteins; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemo | 2003 |
Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients.
Topics: Adenoviridae; Adenovirus E1B Proteins; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemo | 2003 |
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Biological Availability; Dose-Respon | 2003 |
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Biological Availability; Dose-Respon | 2003 |
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Female; Fluorouracil; Human | 2003 |
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Female; Fluorouracil; Human | 2003 |
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Female; Fluorouracil; Human | 2003 |
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Female; Fluorouracil; Human | 2003 |
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Female; Fluorouracil; Human | 2003 |
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Female; Fluorouracil; Human | 2003 |
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Female; Fluorouracil; Human | 2003 |
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Female; Fluorouracil; Human | 2003 |
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Female; Fluorouracil; Human | 2003 |
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Female; Fluorouracil; Human | 2003 |
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Female; Fluorouracil; Human | 2003 |
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Female; Fluorouracil; Human | 2003 |
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Female; Fluorouracil; Human | 2003 |
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Female; Fluorouracil; Human | 2003 |
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Female; Fluorouracil; Human | 2003 |
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Female; Fluorouracil; Human | 2003 |
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Female; Fluorouracil; Human | 2003 |
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Female; Fluorouracil; Human | 2003 |
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bilirubin; Creatinine; Dose-Response Relationship, Dru | 2003 |
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bilirubin; Creatinine; Dose-Response Relationship, Dru | 2003 |
Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2003 |
Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2003 |
Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Sched | 2003 |
Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Sched | 2003 |
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients.
Topics: Aged; Aged, 80 and over; Cytosine Deaminase; Escherichia coli; Female; Flucytosine; Fluorouracil; Ge | 2003 |
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients.
Topics: Aged; Aged, 80 and over; Cytosine Deaminase; Escherichia coli; Female; Flucytosine; Fluorouracil; Ge | 2003 |
Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationsh | 2003 |
Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationsh | 2003 |
A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Fatigu | 2004 |
A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Fatigu | 2004 |
A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2004 |
A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2004 |
A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; | 2004 |
A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; | 2004 |
5-Fluorouracil induces arterial vasocontractions.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Brachial Artery; Endothelins; Fluor | 2004 |
5-Fluorouracil induces arterial vasocontractions.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Brachial Artery; Endothelins; Fluor | 2004 |
The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2004 |
The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2004 |
Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Cap | 2004 |
Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Cap | 2004 |
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2004 |
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2004 |
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cap | 2005 |
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cap | 2005 |
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Female; Fluorouracil; | 2005 |
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Female; Fluorouracil; | 2005 |
Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Deoxycytidine; Docetax | 2005 |
Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Deoxycytidine; Docetax | 2005 |
A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dru | 2005 |
A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dru | 2005 |
Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Dru | 2005 |
Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Dru | 2005 |
A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2005 |
A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2005 |
Phase I and pharmacokinetic evaluation of intravenous hyaluronic acid in combination with doxorubicin or 5-fluorouracil.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Doxoru | 2005 |
Phase I and pharmacokinetic evaluation of intravenous hyaluronic acid in combination with doxorubicin or 5-fluorouracil.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Doxoru | 2005 |
A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Respo | 2005 |
A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Respo | 2005 |
Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Cisplat | 2005 |
Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Cisplat | 2005 |
Phase I trial of an all-oral combination chemotherapy regimen: topotecan and capecitabine in solid tumor patients.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Stu | 2005 |
Phase I trial of an all-oral combination chemotherapy regimen: topotecan and capecitabine in solid tumor patients.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Stu | 2005 |
A dose escalating study of oxaliplatin and high dose weekly leucovorin and 5-Fluorouracil in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration | 2005 |
A dose escalating study of oxaliplatin and high dose weekly leucovorin and 5-Fluorouracil in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration | 2005 |
Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothe | 2005 |
Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothe | 2005 |
Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemot | 2006 |
Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemot | 2006 |
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Docetaxel; Dose- | 2006 |
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Docetaxel; Dose- | 2006 |
Granulocyte function is stimulated by a novel hexapeptide, WKYMVm, in chemotherapy-treated cancer patients.
Topics: Adult; Aged; Bacterial Infections; Blood Bactericidal Activity; Cells, Cultured; Cisplatin; Dose-Res | 2006 |
Granulocyte function is stimulated by a novel hexapeptide, WKYMVm, in chemotherapy-treated cancer patients.
Topics: Adult; Aged; Bacterial Infections; Blood Bactericidal Activity; Cells, Cultured; Cisplatin; Dose-Res | 2006 |
Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, A | 2006 |
Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, A | 2006 |
The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromi | 2007 |
The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromi | 2007 |
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2006 |
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2006 |
A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Admin | 2007 |
A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Admin | 2007 |
Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2007 |
Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2007 |
Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorec | 2007 |
Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorec | 2007 |
Weekday on-weekend off oral capecitabine: a phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Administ | 2007 |
Weekday on-weekend off oral capecitabine: a phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Administ | 2007 |
A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopla | 2006 |
A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopla | 2006 |
A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy | 2007 |
A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy | 2007 |
A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2007 |
A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2007 |
Treatment modifications of antineoplastic drugs in an oncology day-care unit.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Pro | 2007 |
Treatment modifications of antineoplastic drugs in an oncology day-care unit.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Pro | 2007 |
Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Femal | 2007 |
Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Femal | 2007 |
Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Child; Child, | 2007 |
Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Child; Child, | 2007 |
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Hum | 2007 |
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Hum | 2007 |
A dose escalation study of the biweekly administration of paclitaxel, oxaliplatin and capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dose-Respo | 2007 |
A dose escalation study of the biweekly administration of paclitaxel, oxaliplatin and capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dose-Respo | 2007 |
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Di | 2007 |
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Di | 2007 |
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under | 2008 |
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under | 2008 |
Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study.
Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Capec | 2007 |
Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study.
Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Capec | 2007 |
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).
Topics: Adenosine Triphosphatases; Alkaloids; Animals; Antineoplastic Agents; ATP Binding Cassette Transport | 2008 |
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).
Topics: Adenosine Triphosphatases; Alkaloids; Animals; Antineoplastic Agents; ATP Binding Cassette Transport | 2008 |
[Trial of "Huber Plus" in outpatients with chemotherapy by blood port system].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusion Pumps, Implantable; L | 2008 |
[Trial of "Huber Plus" in outpatients with chemotherapy by blood port system].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusion Pumps, Implantable; L | 2008 |
Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2008 |
Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2008 |
CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Aryl Hydrocarbon Hydroxylases; Asia | 2008 |
CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Aryl Hydrocarbon Hydroxylases; Asia | 2008 |
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecit | 2009 |
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecit | 2009 |
A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2008 |
A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2008 |
High-dose intravenous infusions of 5-fluorouracil for refractory solid tumours-the HI-FU regimen.
Topics: Adult; Aged; Blood Platelets; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluorourac | 1980 |
High-dose intravenous infusions of 5-fluorouracil for refractory solid tumours-the HI-FU regimen.
Topics: Adult; Aged; Blood Platelets; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluorourac | 1980 |
Clinical application of the concept of methotrexate plus 5-FU sequence-dependent "synergy": how good is the evidence?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; DNA; Drug Synergi | 1984 |
Clinical application of the concept of methotrexate plus 5-FU sequence-dependent "synergy": how good is the evidence?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; DNA; Drug Synergi | 1984 |
Newer techniques in cancer chemotherapy.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bleomycin; Bone Marrow Transplantation; Carcinoma; Ce | 1984 |
Newer techniques in cancer chemotherapy.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bleomycin; Bone Marrow Transplantation; Carcinoma; Ce | 1984 |
Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection.
Topics: Allopurinol; Clinical Trials as Topic; Drug Evaluation; Fluorouracil; Humans; Inflammation; Leukocyt | 1983 |
Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection.
Topics: Allopurinol; Clinical Trials as Topic; Drug Evaluation; Fluorouracil; Humans; Inflammation; Leukocyt | 1983 |
Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cycloph | 1983 |
Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cycloph | 1983 |
Clinical thermochemotherapy. A controlled trial in advanced cancer patients.
Topics: Adult; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Fema | 1984 |
Clinical thermochemotherapy. A controlled trial in advanced cancer patients.
Topics: Adult; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Fema | 1984 |
Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical T | 1984 |
Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical T | 1984 |
Cancer chemotherapy. Progress and expectations, 1984.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cytarabine; Drug Resistance; Fluorouracil; Humans; | 1984 |
Cancer chemotherapy. Progress and expectations, 1984.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cytarabine; Drug Resistance; Fluorouracil; Humans; | 1984 |
[Clinical studies on induced hypertension chemotherapy based on functional characteristics of microcirculation of tumor vessels].
Topics: Angiotensin II; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Doxorubicin | 1984 |
[Clinical studies on induced hypertension chemotherapy based on functional characteristics of microcirculation of tumor vessels].
Topics: Angiotensin II; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Doxorubicin | 1984 |
[Joint clinical Phase II study of SF-SP].
Topics: Clinical Trials as Topic; Colonic Neoplasms; Delayed-Action Preparations; Drug Evaluation; Female; F | 1984 |
[Joint clinical Phase II study of SF-SP].
Topics: Clinical Trials as Topic; Colonic Neoplasms; Delayed-Action Preparations; Drug Evaluation; Female; F | 1984 |
Continuation of phase II study of 1-(4-amino-2-methylpyrimidine-5-yl)-methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU).
Topics: Adult; Bone Marrow; Clinical Trials as Topic; Doxorubicin; Drug Administration Schedule; Drug Evalua | 1980 |
Continuation of phase II study of 1-(4-amino-2-methylpyrimidine-5-yl)-methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU).
Topics: Adult; Bone Marrow; Clinical Trials as Topic; Doxorubicin; Drug Administration Schedule; Drug Evalua | 1980 |
An overview of thymidine.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Cytarabine; DNA, Neoplasm; Dr | 1980 |
An overview of thymidine.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Cytarabine; DNA, Neoplasm; Dr | 1980 |
[Treatment with 5-fluorouracil: randomized study comparing an oral preparation with intravenous administration].
Topics: Administration, Oral; Aged; Clinical Trials as Topic; Female; Fluorouracil; Humans; Injections, Intr | 1981 |
[Treatment with 5-fluorouracil: randomized study comparing an oral preparation with intravenous administration].
Topics: Administration, Oral; Aged; Clinical Trials as Topic; Female; Fluorouracil; Humans; Injections, Intr | 1981 |
The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow Transplantation; Bre | 1993 |
The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow Transplantation; Bre | 1993 |
Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin; | 1995 |
Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin; | 1995 |
Trials in palliative care.
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasms; Palliative Care; Randomized Contr | 1995 |
Trials in palliative care.
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasms; Palliative Care; Randomized Contr | 1995 |
Phase I trial of high-dose infused zidovudine combined with leucovorin plus fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovori | 1995 |
Phase I trial of high-dose infused zidovudine combined with leucovorin plus fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovori | 1995 |
Robust Bayesian methods for monitoring clinical trials.
Topics: Bayes Theorem; Clinical Trials as Topic; Data Collection; Data Interpretation, Statistical; Extracor | 1995 |
Robust Bayesian methods for monitoring clinical trials.
Topics: Bayes Theorem; Clinical Trials as Topic; Data Collection; Data Interpretation, Statistical; Extracor | 1995 |
[Chrono-chemotherapy and dose intensity].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chronobiology | 1995 |
[Chrono-chemotherapy and dose intensity].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chronobiology | 1995 |
Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; | 1995 |
Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; | 1995 |
The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data.
Topics: Aspartic Acid; Drug Interactions; Fluorouracil; Humans; Leucovorin; Methotrexate; Neoplasms; Phospho | 1994 |
The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data.
Topics: Aspartic Acid; Drug Interactions; Fluorouracil; Humans; Leucovorin; Methotrexate; Neoplasms; Phospho | 1994 |
Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspart | 1995 |
Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspart | 1995 |
A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergism; Female; Fluo | 1995 |
A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergism; Female; Fluo | 1995 |
Phase II study of 5-fluorouracil/leucovorin for pediatric patients with malignant solid tumors.
Topics: Adolescent; Carcinoma; Child; Child, Preschool; Colorectal Neoplasms; Drug Administration Schedule; | 1994 |
Phase II study of 5-fluorouracil/leucovorin for pediatric patients with malignant solid tumors.
Topics: Adolescent; Carcinoma; Child; Child, Preschool; Colorectal Neoplasms; Drug Administration Schedule; | 1994 |
Oral ondansetron pharmacokinetics: the effect of chemotherapy.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Cisplatin; Female; Fluorouracil; H | 1994 |
Oral ondansetron pharmacokinetics: the effect of chemotherapy.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Cisplatin; Female; Fluorouracil; H | 1994 |
Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research.
Topics: Acquired Immunodeficiency Syndrome; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad | 1994 |
Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research.
Topics: Acquired Immunodeficiency Syndrome; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad | 1994 |
[Continuous double administration of 5 fluorouracil (intravenous and intraperitoneal) modulated by folinic acid: phase I clinical study and pharmacokinetics in patients with intra-abdominal developing cancers].
Topics: Abdominal Neoplasms; Drug Synergism; Female; Fluorouracil; Humans; Infusions, Intravenous; Injection | 1993 |
[Continuous double administration of 5 fluorouracil (intravenous and intraperitoneal) modulated by folinic acid: phase I clinical study and pharmacokinetics in patients with intra-abdominal developing cancers].
Topics: Abdominal Neoplasms; Drug Synergism; Female; Fluorouracil; Humans; Infusions, Intravenous; Injection | 1993 |
Results of a clinical trial in humans with refractory cancer of the intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine-HCl, in combination with various single antineoplastic agents.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Screening Assays, Antitumor; Drug Synergi | 1994 |
Results of a clinical trial in humans with refractory cancer of the intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine-HCl, in combination with various single antineoplastic agents.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Screening Assays, Antitumor; Drug Synergi | 1994 |
Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Interactions; Female; Fluorouracil | 1993 |
Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Interactions; Female; Fluorouracil | 1993 |
Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer.
Topics: Adult; Aged; Female; Fluorouracil; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-al | 1993 |
Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer.
Topics: Adult; Aged; Female; Fluorouracil; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-al | 1993 |
Post-5-fluorouracil human marrow: stem cell characteristics and renewal properties after autologous marrow transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carmustine | 1993 |
Post-5-fluorouracil human marrow: stem cell characteristics and renewal properties after autologous marrow transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carmustine | 1993 |
A phase I trial of protracted 5-fluorouracil infusion and oral calcium leucovorin.
Topics: Aged; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin | 1993 |
A phase I trial of protracted 5-fluorouracil infusion and oral calcium leucovorin.
Topics: Aged; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin | 1993 |
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aspartic Aci | 1996 |
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aspartic Aci | 1996 |
Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Antineoplastic Combined Chemotherapy Proto | 1996 |
Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Antineoplastic Combined Chemotherapy Proto | 1996 |
A pilot trial of 5-FU, leucovorin, and cisplatin with or without adriamycin in advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Fluorou | 1996 |
A pilot trial of 5-FU, leucovorin, and cisplatin with or without adriamycin in advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Fluorou | 1996 |
5-fluorouracil modulates the toxicity of high dose methotrexate.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Female | 1995 |
5-fluorouracil modulates the toxicity of high dose methotrexate.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Female | 1995 |
A phase I study of methotrexate administration following 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug A | 1996 |
A phase I study of methotrexate administration following 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug A | 1996 |
Phase I trial of high-dose infusional hydroxyurea, high-dose infusional 5-fluorouracil and recombinant interferon-alpha-2a in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Femal | 1996 |
Phase I trial of high-dose infusional hydroxyurea, high-dose infusional 5-fluorouracil and recombinant interferon-alpha-2a in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Femal | 1996 |
A phase I trial of a modified, dose intensive FAMTX regimen (high dose 5-fluorouracil+doxorubicin+high dose methotrexate+leucovorin) with oral uridine rescue.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Doxoru | 1996 |
A phase I trial of a modified, dose intensive FAMTX regimen (high dose 5-fluorouracil+doxorubicin+high dose methotrexate+leucovorin) with oral uridine rescue.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Doxoru | 1996 |
Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antidotes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Prot | 1996 |
Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antidotes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Prot | 1996 |
Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.
Topics: Absorption; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biolo | 1996 |
Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.
Topics: Absorption; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biolo | 1996 |
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Cispla | 1997 |
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Cispla | 1997 |
Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer.
Topics: Acetates; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; | 1997 |
Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer.
Topics: Acetates; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; | 1997 |
Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy: correlation with clinical responses.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytokines; Cytotoxicity, I | 1997 |
Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy: correlation with clinical responses.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytokines; Cytotoxicity, I | 1997 |
Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin.
Topics: Administration, Oral; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Ph | 1997 |
Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin.
Topics: Administration, Oral; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Ph | 1997 |
[Current status of low-dose CDDP. 5-FU therapy for solid malignant tumors--nationwide questionnaire survey].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administration | 1997 |
[Current status of low-dose CDDP. 5-FU therapy for solid malignant tumors--nationwide questionnaire survey].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administration | 1997 |
[Phase I study of S-1. S-1 Study Group].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 1997 |
[Phase I study of S-1. S-1 Study Group].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 1997 |
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dihydrouracil Dehydro | 1998 |
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dihydrouracil Dehydro | 1998 |
Clinical and pharmacokinetic studies of high-dose levamisole in combination with 5-fluorouracil in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Confusion; Drug Synergism; Drug The | 1998 |
Clinical and pharmacokinetic studies of high-dose levamisole in combination with 5-fluorouracil in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Confusion; Drug Synergism; Drug The | 1998 |
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Administ | 1998 |
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Administ | 1998 |
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Administ | 1998 |
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Administ | 1998 |
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Administ | 1998 |
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Administ | 1998 |
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Administ | 1998 |
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Administ | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response | 1998 |
A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Protocols; Combined Modality Therapy; Drug Administrati | 1997 |
A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Protocols; Combined Modality Therapy; Drug Administrati | 1997 |
Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Ad | 1995 |
Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Ad | 1995 |
Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoylt | 1996 |
Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoylt | 1996 |
A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deo | 1998 |
A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deo | 1998 |
Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients.
Topics: Administration, Oral; Adult; Aged; Aluminum Hydroxide; Antacids; Antineoplastic Agents; Biotransform | 1999 |
Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients.
Topics: Administration, Oral; Adult; Aged; Aluminum Hydroxide; Antacids; Antineoplastic Agents; Biotransform | 1999 |
A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; F | 1999 |
A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; F | 1999 |
Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Follow | 1999 |
Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Follow | 1999 |
Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.
Topics: Analysis of Variance; Antineoplastic Agents; Area Under Curve; Biotransformation; Body Surface Area; | 1999 |
Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.
Topics: Analysis of Variance; Antineoplastic Agents; Area Under Curve; Biotransformation; Body Surface Area; | 1999 |
Leucovorin, 5-fluorouracil, and gemcitabine: a phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxyc | 1999 |
Leucovorin, 5-fluorouracil, and gemcitabine: a phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxyc | 1999 |
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biliru | 1999 |
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biliru | 1999 |
Myeloprotective effect of a non-toxic indigenous preparation Rasayana in cancer patients receiving chemotherapy and radiation therapy. A pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bone Marrow; Chemotherapy, Adjuvant; C | 1999 |
Myeloprotective effect of a non-toxic indigenous preparation Rasayana in cancer patients receiving chemotherapy and radiation therapy. A pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bone Marrow; Chemotherapy, Adjuvant; C | 1999 |
A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Diar | 2000 |
A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Diar | 2000 |
A phase I trial of gemcitabine and infusional 5-fluorouracil (5-FU) in patients with refractory solid tumors: Louisiana Oncology Associates protocol no. 1 (LOA-1).
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidin | 2000 |
A phase I trial of gemcitabine and infusional 5-fluorouracil (5-FU) in patients with refractory solid tumors: Louisiana Oncology Associates protocol no. 1 (LOA-1).
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidin | 2000 |
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biotransformation; | 2000 |
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biotransformation; | 2000 |
A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours.
Topics: Adenosylmethionine Decarboxylase; Adult; Aged; Agranulocytosis; Amidines; Antimetabolites, Antineopl | 2000 |
A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours.
Topics: Adenosylmethionine Decarboxylase; Adult; Aged; Agranulocytosis; Amidines; Antimetabolites, Antineopl | 2000 |
Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Cohort Studies; Diarr | 1999 |
Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Cohort Studies; Diarr | 1999 |
Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; | 2000 |
Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; | 2000 |
Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycyti | 2000 |
Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycyti | 2000 |
Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2000 |
Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2000 |
Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studie | 2000 |
Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studie | 2000 |
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Co | 2001 |
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Co | 2001 |
Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2001 |
Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2001 |
A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies.
Topics: Abdominal Pain; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dinoprost; Do | 2001 |
A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies.
Topics: Abdominal Pain; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dinoprost; Do | 2001 |
[Dose-intensive chemotherapy with continuous infusion 5-fluorouracil].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined | 1999 |
[Dose-intensive chemotherapy with continuous infusion 5-fluorouracil].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined | 1999 |
A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-
Topics: Acyltransferases; Antimetabolites; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytos | 2001 |
A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-
Topics: Acyltransferases; Antimetabolites; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytos | 2001 |
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2001 |
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2001 |
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplasti | 2002 |
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplasti | 2002 |
Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chr | 2001 |
Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chr | 2001 |
Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2002 |
Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2002 |
Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Capecitabine; Deoxycytidine; Fluorouracil; Half-L | 2002 |
Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Capecitabine; Deoxycytidine; Fluorouracil; Half-L | 2002 |
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Diarrhea; DNA, Antise | 2002 |
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Diarrhea; DNA, Antise | 2002 |
Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; | 2002 |
Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; | 2002 |
Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deo | 2002 |
Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deo | 2002 |
1.3 Bis-(2 chloroethyl)-1-nitrosourea and streptozotocin chemotherapy.
Topics: Adolescent; Adult; Aged; Bone Marrow; Carmustine; Child; Child, Preschool; Clinical Trials as Topic; | 1975 |
1.3 Bis-(2 chloroethyl)-1-nitrosourea and streptozotocin chemotherapy.
Topics: Adolescent; Adult; Aged; Bone Marrow; Carmustine; Child; Child, Preschool; Clinical Trials as Topic; | 1975 |
EST 1668--effect of high-dose glucose on therapy with 5-fluorouracil.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Evaluation Studies as Topic; Female; Flu | 1978 |
EST 1668--effect of high-dose glucose on therapy with 5-fluorouracil.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Evaluation Studies as Topic; Female; Flu | 1978 |
Special problems in the evaluation of results in adjuvant trials of cancer treatment.
Topics: Colonic Neoplasms; Evaluation Studies as Topic; Fluorouracil; Humans; Neoplasms; Prognosis; Statisti | 1978 |
Special problems in the evaluation of results in adjuvant trials of cancer treatment.
Topics: Colonic Neoplasms; Evaluation Studies as Topic; Fluorouracil; Humans; Neoplasms; Prognosis; Statisti | 1978 |
Clinical studies with DTIC (NSC-45388) in various malignancies.
Topics: Adult; Carmustine; Child; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Comb | 1976 |
Clinical studies with DTIC (NSC-45388) in various malignancies.
Topics: Adult; Carmustine; Child; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Comb | 1976 |
[Sequential chemotherapy based on the hypothesis of a circadian rhythm of tumor proliferation].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Circadian R | 1975 |
[Sequential chemotherapy based on the hypothesis of a circadian rhythm of tumor proliferation].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Circadian R | 1975 |
Quality of life measurements in anti-emetic trials: a discussion of Professor Selby's paper.
Topics: Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide | 1992 |
Quality of life measurements in anti-emetic trials: a discussion of Professor Selby's paper.
Topics: Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide | 1992 |
Phase I study of 5-fluorouracil with folinic acid combined with recombinant human granulocyte-macrophage colony-stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1992 |
Phase I study of 5-fluorouracil with folinic acid combined with recombinant human granulocyte-macrophage colony-stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1992 |
High-dose intravenous zidovudine with 5-fluorouracil and leucovorin. A phase I trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; DNA Damage; DNA, Neoplasm; Dose-Respons | 1992 |
High-dose intravenous zidovudine with 5-fluorouracil and leucovorin. A phase I trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; DNA Damage; DNA, Neoplasm; Dose-Respons | 1992 |
A phase I trial of fluorouracil, leucovorin, and recombinant interferon alpha-2b in patients with advanced malignancy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1992 |
A phase I trial of fluorouracil, leucovorin, and recombinant interferon alpha-2b in patients with advanced malignancy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1992 |
Pharmacokinetics and toxicity of continuous infusion (6S)-folinic acid and bolus 5-fluorouracil in patients with advanced cancer.
Topics: Adult; Aged; Drug Administration Schedule; Drug Evaluation; Drug Synergism; Female; Fluorouracil; Hu | 1992 |
Pharmacokinetics and toxicity of continuous infusion (6S)-folinic acid and bolus 5-fluorouracil in patients with advanced cancer.
Topics: Adult; Aged; Drug Administration Schedule; Drug Evaluation; Drug Synergism; Female; Fluorouracil; Hu | 1992 |
A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dipyridamole; Dose-Response Relationshi | 1992 |
A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dipyridamole; Dose-Response Relationshi | 1992 |
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Biops | 1991 |
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Biops | 1991 |
Dual modulation of 5-fluorouracil using leucovorin and hydroxyurea. A phase I trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 1991 |
Dual modulation of 5-fluorouracil using leucovorin and hydroxyurea. A phase I trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 1991 |
A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; B | 1991 |
A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; B | 1991 |
Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area; Breast | 1991 |
Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area; Breast | 1991 |
Pharmacology and phase I trial of high-dose oral leucovorin plus 5-fluorouracil in children with refractory cancer: a report from the Children's Cancer Study Group.
Topics: Administration, Oral; Adolescent; Adult; Child; Child, Preschool; Drug Administration Schedule; Drug | 1991 |
Pharmacology and phase I trial of high-dose oral leucovorin plus 5-fluorouracil in children with refractory cancer: a report from the Children's Cancer Study Group.
Topics: Administration, Oral; Adolescent; Adult; Child; Child, Preschool; Drug Administration Schedule; Drug | 1991 |
Experimental studies and preliminary clinical trial of vinorelbine-loaded polymeric bioresorbable implants for the local treatment of solid tumors.
Topics: Adult; Animals; Antineoplastic Agents; Delayed-Action Preparations; Dogs; Dose-Response Relationship | 1991 |
Experimental studies and preliminary clinical trial of vinorelbine-loaded polymeric bioresorbable implants for the local treatment of solid tumors.
Topics: Adult; Animals; Antineoplastic Agents; Delayed-Action Preparations; Dogs; Dose-Response Relationship | 1991 |
Continuous infusion 5-fluorouracil with escalating doses of intermittent cisplatin and etoposide. A phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Dose-Respo | 1991 |
Continuous infusion 5-fluorouracil with escalating doses of intermittent cisplatin and etoposide. A phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Dose-Respo | 1991 |
Continuous 5-fluorouracil infusion and alpha interferon in advanced cancers: a report of initial treatment results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Fluorouracil; | 1991 |
Continuous 5-fluorouracil infusion and alpha interferon in advanced cancers: a report of initial treatment results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Fluorouracil; | 1991 |
Concomitant continuous infusion chemotherapy and radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modali | 1990 |
Concomitant continuous infusion chemotherapy and radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modali | 1990 |
Cancer chronotherapy: a drug delivery challenge.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Circadian Rhythm; Colorectal Neoplasms; Drug | 1990 |
Cancer chronotherapy: a drug delivery challenge.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Circadian Rhythm; Colorectal Neoplasms; Drug | 1990 |
Oral zidovudine, continuous-infusion fluorouracil, and oral leucovorin calcium: a phase I study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; DNA; DNA Damage; | 1990 |
Oral zidovudine, continuous-infusion fluorouracil, and oral leucovorin calcium: a phase I study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; DNA; DNA Damage; | 1990 |
[Prolonged intravenous infusion chemotherapy. General review of theoretical bases and results].
Topics: Antineoplastic Agents; Bleomycin; Cell Cycle; Cisplatin; Clinical Trials as Topic; Cytarabine; Doxor | 1985 |
[Prolonged intravenous infusion chemotherapy. General review of theoretical bases and results].
Topics: Antineoplastic Agents; Bleomycin; Cell Cycle; Cisplatin; Clinical Trials as Topic; Cytarabine; Doxor | 1985 |
Emulsion and activated carbon in cancer chemotherapy.
Topics: Administration, Oral; Adult; Aged; Animals; Bleomycin; Breast Neoplasms; Carbon; Clinical Trials as | 1986 |
Emulsion and activated carbon in cancer chemotherapy.
Topics: Administration, Oral; Adult; Aged; Animals; Bleomycin; Breast Neoplasms; Carbon; Clinical Trials as | 1986 |
Intracavitary chemotherapy.
Topics: Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Ca | 1986 |
Intracavitary chemotherapy.
Topics: Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Ca | 1986 |
[Elaboration of the combination of antitumor preparations bleomycetin + 5-fluorouracil + cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Drug Evaluation; Fluorouracil; | 1988 |
[Elaboration of the combination of antitumor preparations bleomycetin + 5-fluorouracil + cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Drug Evaluation; Fluorouracil; | 1988 |
Cancer control research in the North Central Cancer Treatment Group (NCCTG).
Topics: Allopurinol; Anorexia; Antineoplastic Agents; Cachexia; Clinical Trials as Topic; Colorectal Neoplas | 1989 |
Cancer control research in the North Central Cancer Treatment Group (NCCTG).
Topics: Allopurinol; Anorexia; Antineoplastic Agents; Cachexia; Clinical Trials as Topic; Colorectal Neoplas | 1989 |
5-Fluorouracil and 5-formyltetrahydrofolate in advanced malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Colorect | 1988 |
5-Fluorouracil and 5-formyltetrahydrofolate in advanced malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Colorect | 1988 |
5-FU/leucovorin: biochemical modulation that works?
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoplasms; Randomi | 1987 |
5-FU/leucovorin: biochemical modulation that works?
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoplasms; Randomi | 1987 |
A randomised cross-over trial comparing low-dose metoclopramide and chlorpromazine with high-dose metoclopramide in Chinese patients with advanced cancer receiving cisplatinum and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorpromazine; Cisplatin; Clinical Tri | 1987 |
A randomised cross-over trial comparing low-dose metoclopramide and chlorpromazine with high-dose metoclopramide in Chinese patients with advanced cancer receiving cisplatinum and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorpromazine; Cisplatin; Clinical Tri | 1987 |
[Comparative clinical study of MF(mitomycin and 5-fluorouracil) and MF.BH-AC therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1986 |
[Comparative clinical study of MF(mitomycin and 5-fluorouracil) and MF.BH-AC therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1986 |
[Modulation of the anti-tumor effect of BRM under various nutritional or endocrine conditions].
Topics: Animals; Combined Modality Therapy; Endocrine Glands; Female; Fluorouracil; Humans; Lentinan; Mammar | 1986 |
[Modulation of the anti-tumor effect of BRM under various nutritional or endocrine conditions].
Topics: Animals; Combined Modality Therapy; Endocrine Glands; Female; Fluorouracil; Humans; Lentinan; Mammar | 1986 |
Application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy.
Topics: Animals; Aspartic Acid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Co | 1985 |
Application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy.
Topics: Animals; Aspartic Acid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Co | 1985 |
Clinical effects of whole-body hyperthermia in adnanced malignancy.
Topics: Adult; Body Temperature; Breast Neoplasms; Child; Colonic Neoplasms; Cyclophosphamide; Female; Fluor | 1974 |
Clinical effects of whole-body hyperthermia in adnanced malignancy.
Topics: Adult; Body Temperature; Breast Neoplasms; Child; Colonic Neoplasms; Cyclophosphamide; Female; Fluor | 1974 |
[Polychemotherapy of malignant neoplasms].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Female; | 1972 |
[Polychemotherapy of malignant neoplasms].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Female; | 1972 |
[Trial and results of improved radiotherapy for cancer. 5. Radiotherapy with simultaneous administration of radio-sensitizing agents. Controlled trial at the Osaka University].
Topics: Clinical Trials as Topic; Cycloheptanes; Cyclohexanols; Ethylamines; Fluorouracil; Humans; Imidazole | 1972 |
[Trial and results of improved radiotherapy for cancer. 5. Radiotherapy with simultaneous administration of radio-sensitizing agents. Controlled trial at the Osaka University].
Topics: Clinical Trials as Topic; Cycloheptanes; Cyclohexanols; Ethylamines; Fluorouracil; Humans; Imidazole | 1972 |
Controlled studies of metopimazine for the treatment of nausea and vomiting.
Topics: Antiemetics; Clinical Trials as Topic; Fluorouracil; Humans; Isonipecotic Acids; Nausea; Neoplasms; | 1973 |
Controlled studies of metopimazine for the treatment of nausea and vomiting.
Topics: Antiemetics; Clinical Trials as Topic; Fluorouracil; Humans; Isonipecotic Acids; Nausea; Neoplasms; | 1973 |
Combined radiotherapy and chemotherapy for treatment of unresectable and or metastatic cancer.
Topics: Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Humans; Lu | 1974 |
Combined radiotherapy and chemotherapy for treatment of unresectable and or metastatic cancer.
Topics: Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Humans; Lu | 1974 |
Combination chemotherapy in disseminated solid tumours.
Topics: Clinical Trials as Topic; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Therapy, Combinat | 1974 |
Combination chemotherapy in disseminated solid tumours.
Topics: Clinical Trials as Topic; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Therapy, Combinat | 1974 |
Phase I clinical trial of combined therapy with 5-FU (NSC 19893) and CIS-platinum (II) diaminedichloride (NSC 119875).
Topics: Audiometry; Cisplatin; Clinical Trials as Topic; Deafness; Digestive System; Drug Evaluation; Drug T | 1974 |
Phase I clinical trial of combined therapy with 5-FU (NSC 19893) and CIS-platinum (II) diaminedichloride (NSC 119875).
Topics: Audiometry; Cisplatin; Clinical Trials as Topic; Deafness; Digestive System; Drug Evaluation; Drug T | 1974 |
[Intermittent cytostatic intensive therapy of solid tumors with a combination of four drugs].
Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; | 1973 |
[Intermittent cytostatic intensive therapy of solid tumors with a combination of four drugs].
Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; | 1973 |
A clinical study of fluorouracil.
Topics: Adult; Aged; Clinical Trials as Topic; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Humans; Le | 1968 |
A clinical study of fluorouracil.
Topics: Adult; Aged; Clinical Trials as Topic; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Humans; Le | 1968 |
[Main problems of the method of clinical study of new antineoplastic agents].
Topics: Antineoplastic Agents; Biopsy; Clinical Trials as Topic; Female; Fluorouracil; Humans; Intestinal Po | 1966 |
[Main problems of the method of clinical study of new antineoplastic agents].
Topics: Antineoplastic Agents; Biopsy; Clinical Trials as Topic; Female; Fluorouracil; Humans; Intestinal Po | 1966 |
Effects of 5-fluorouracil (NSC-19893) in 389 patients with cancer. Eastern Clinical Drug Evaluation Program.
Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans | 1968 |
Effects of 5-fluorouracil (NSC-19893) in 389 patients with cancer. Eastern Clinical Drug Evaluation Program.
Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans | 1968 |
Combination chemotherapy for 418 cases of advanced cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Squamous Cel | 1971 |
Combination chemotherapy for 418 cases of advanced cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Squamous Cel | 1971 |
Corticosteroids and fluorouracil toxicity.
Topics: Bone Marrow; Clinical Trials as Topic; Diarrhea; Digestive System; Fluorouracil; Humans; Injections, | 1966 |
Corticosteroids and fluorouracil toxicity.
Topics: Bone Marrow; Clinical Trials as Topic; Diarrhea; Digestive System; Fluorouracil; Humans; Injections, | 1966 |
1213 other studies available for fluorouracil and Neoplasms
| Article | Year |
|---|---|
Nucleosides and nucleotides. 94. Radical deoxygenation of tert-alcohols in 1-(2-C-alkylpentofuranosyl) pyrimidines: synthesis of (2'S)-2'-deoxy-2'-C-methylcytidine, an antileukemic nucleoside.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Screening Assays, Antitumor; Humans; I | 1991 |
Nucleosides and nucleotides. 94. Radical deoxygenation of tert-alcohols in 1-(2-C-alkylpentofuranosyl) pyrimidines: synthesis of (2'S)-2'-deoxy-2'-C-methylcytidine, an antileukemic nucleoside.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Screening Assays, Antitumor; Humans; I | 1991 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Cytotoxic constituents from Brazilian red propolis and their structure-activity relationship.
Topics: Animals; Brazil; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Dr | 2008 |
Cytotoxic constituents from Brazilian red propolis and their structure-activity relationship.
Topics: Animals; Brazil; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Dr | 2008 |
Synthesis and antitumor activity evaluations of albumin-binding prodrugs of CC-1065 analog.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Disease Models, Animal; Duocarmycins; | 2008 |
Synthesis and antitumor activity evaluations of albumin-binding prodrugs of CC-1065 analog.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Disease Models, Animal; Duocarmycins; | 2008 |
Substituted quinazolines, part 3. Synthesis, in vitro antitumor activity and molecular modeling study of certain 2-thieno-4(3H)-quinazolinone analogs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Drug Screening Ass | 2009 |
Substituted quinazolines, part 3. Synthesis, in vitro antitumor activity and molecular modeling study of certain 2-thieno-4(3H)-quinazolinone analogs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Drug Screening Ass | 2009 |
Porphyrins containing nitric oxide donors: Synthesis and cancer cell-oriented NO release.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Fluorouracil | 2009 |
Porphyrins containing nitric oxide donors: Synthesis and cancer cell-oriented NO release.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Fluorouracil | 2009 |
Tessaric acid derivatives induce G2/M cell cycle arrest in human solid tumor cell lines.
Topics: Antineoplastic Agents; Cell Division; Cell Line, Tumor; Drug Screening Assays, Antitumor; G2 Phase; | 2009 |
Tessaric acid derivatives induce G2/M cell cycle arrest in human solid tumor cell lines.
Topics: Antineoplastic Agents; Cell Division; Cell Line, Tumor; Drug Screening Assays, Antitumor; G2 Phase; | 2009 |
Novel effects of glycyrrhetinic acid on the central nervous system tumorigenic progenitor cells: induction of actin disruption and tumor cell-selective toxicity.
Topics: Actins; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Central Nervous System | 2010 |
Novel effects of glycyrrhetinic acid on the central nervous system tumorigenic progenitor cells: induction of actin disruption and tumor cell-selective toxicity.
Topics: Actins; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Central Nervous System | 2010 |
Synthesis of 4β-carbamoyl epipodophyllotoxins as potential antitumour agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; DNA Topoisomerases, Type II; Drug Screening Assays, Antitum | 2011 |
Synthesis of 4β-carbamoyl epipodophyllotoxins as potential antitumour agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; DNA Topoisomerases, Type II; Drug Screening Assays, Antitum | 2011 |
Semi-synthesis and antitumor activity of 6-isomers of 5, 8-O-dimethyl acylshikonin derivatives.
Topics: Acylation; Animals; Antineoplastic Agents; Cell Survival; Drug Screening Assays, Antitumor; Female; | 2011 |
Semi-synthesis and antitumor activity of 6-isomers of 5, 8-O-dimethyl acylshikonin derivatives.
Topics: Acylation; Animals; Antineoplastic Agents; Cell Survival; Drug Screening Assays, Antitumor; Female; | 2011 |
Synthesis and cytotoxicity of 8-cyano-3-substitutedalkyl-5-methyl-4-methylene-7-methoxy-3,4-dihydropyrido[4,3-d]pyrimidines.
Topics: Antimetabolites, Antineoplastic; Drug Design; Drug Screening Assays, Antitumor; Fluorouracil; Humans | 2011 |
Synthesis and cytotoxicity of 8-cyano-3-substitutedalkyl-5-methyl-4-methylene-7-methoxy-3,4-dihydropyrido[4,3-d]pyrimidines.
Topics: Antimetabolites, Antineoplastic; Drug Design; Drug Screening Assays, Antitumor; Fluorouracil; Humans | 2011 |
Synthesis and cytotoxic activity of novel 3-(1H-indol-3-yl)-1H-pyrazole-5-carbohydrazide derivatives.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Hum | 2011 |
Synthesis and cytotoxic activity of novel 3-(1H-indol-3-yl)-1H-pyrazole-5-carbohydrazide derivatives.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Hum | 2011 |
Synthesis and biological evaluation of conjugates of deoxypodophyllotoxin and 5-FU as inducer of caspase-3 and -7.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Drugs, Chinese Herbal; Enz | 2012 |
Synthesis and biological evaluation of conjugates of deoxypodophyllotoxin and 5-FU as inducer of caspase-3 and -7.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Drugs, Chinese Herbal; Enz | 2012 |
Bakuchiol derivatives as novel and potent cytotoxic agents: a report.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; DNA | 2012 |
Bakuchiol derivatives as novel and potent cytotoxic agents: a report.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; DNA | 2012 |
Synthesis and evaluation of anticancer activity of some novel 6-aryl-2-(p-sulfamylphenyl)-pyridazin-3(2H)-ones.
Topics: Animals; Antineoplastic Agents; Benzenesulfonamides; Cell Line, Tumor; Cell Proliferation; Drug Scre | 2012 |
Synthesis and evaluation of anticancer activity of some novel 6-aryl-2-(p-sulfamylphenyl)-pyridazin-3(2H)-ones.
Topics: Animals; Antineoplastic Agents; Benzenesulfonamides; Cell Line, Tumor; Cell Proliferation; Drug Scre | 2012 |
A novel thiazolidine compound induces caspase-9 dependent apoptosis in cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Caspase 9; Cell Line, Tumor; Dose-Response Relationship, Drug; Dru | 2012 |
A novel thiazolidine compound induces caspase-9 dependent apoptosis in cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Caspase 9; Cell Line, Tumor; Dose-Response Relationship, Drug; Dru | 2012 |
Substituted thiazoles VII. Synthesis and antitumor activity of certain 2-(substituted amino)-4-phenyl-1,3-thiazole analogs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Neoplasms; Structure-Activity R | 2012 |
Substituted thiazoles VII. Synthesis and antitumor activity of certain 2-(substituted amino)-4-phenyl-1,3-thiazole analogs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Neoplasms; Structure-Activity R | 2012 |
Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents.
Topics: Antineoplastic Agents; DNA Topoisomerases, Type II; Humans; Indoles; Models, Molecular; Neoplasms; T | 2013 |
Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents.
Topics: Antineoplastic Agents; DNA Topoisomerases, Type II; Humans; Indoles; Models, Molecular; Neoplasms; T | 2013 |
Synthesis and biological evaluation of novel alkyl amide functionalized trifluoromethyl substituted pyrazolo[3,4-b]pyridine derivatives as potential anticancer agents.
Topics: Alkylation; Amides; Antineoplastic Agents; Cell Line, Tumor; Halogenation; Humans; Neoplasms; Pyrazo | 2013 |
Synthesis and biological evaluation of novel alkyl amide functionalized trifluoromethyl substituted pyrazolo[3,4-b]pyridine derivatives as potential anticancer agents.
Topics: Alkylation; Amides; Antineoplastic Agents; Cell Line, Tumor; Halogenation; Humans; Neoplasms; Pyrazo | 2013 |
Furanylazaindoles: potent anticancer agents in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell S | 2013 |
Furanylazaindoles: potent anticancer agents in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell S | 2013 |
Synthesis and antitumor activity of novel 3-oxo-23-hydroxybetulinic acid derivatives.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Humans; Liver Neoplas | 2014 |
Synthesis and antitumor activity of novel 3-oxo-23-hydroxybetulinic acid derivatives.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Humans; Liver Neoplas | 2014 |
Novel 25-hydroxyprotopanaxadiol derivatives incorporating chloroacetyl chloride and their anti-tumor evaluation.
Topics: Acetates; Antineoplastic Agents; Biological Products; Cell Line, Tumor; Cell Proliferation; Ginsenos | 2014 |
Novel 25-hydroxyprotopanaxadiol derivatives incorporating chloroacetyl chloride and their anti-tumor evaluation.
Topics: Acetates; Antineoplastic Agents; Biological Products; Cell Line, Tumor; Cell Proliferation; Ginsenos | 2014 |
Design and synthesis of novel 1,2,3-triazole-pyrimidine-urea hybrids as potential anticancer agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; H | 2015 |
Design and synthesis of novel 1,2,3-triazole-pyrimidine-urea hybrids as potential anticancer agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; H | 2015 |
Design and synthesis of celastrol derivatives as anticancer agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; | 2015 |
Design and synthesis of celastrol derivatives as anticancer agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; | 2015 |
Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
Topics: Amides; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxy | 2016 |
Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
Topics: Amides; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxy | 2016 |
Synthesis and biological evaluation of new benzimidazole-thiazolidinedione hybrids as potential cytotoxic and apoptosis inducing agents.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Cycle; Cell Line, Tumor; Cell Sur | 2016 |
Synthesis and biological evaluation of new benzimidazole-thiazolidinedione hybrids as potential cytotoxic and apoptosis inducing agents.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Cycle; Cell Line, Tumor; Cell Sur | 2016 |
Novel pyrimidine-2,4-dione-1,2,3-triazole and furo[2,3-d]pyrimidine-2-one-1,2,3-triazole hybrids as potential anti-cancer agents: Synthesis, computational and X-ray analysis and biological evaluation.
Topics: Antineoplastic Agents; Catalysis; Cell Cycle Proteins; Crystallography, X-Ray; Cyclization; Drug Scr | 2017 |
Novel pyrimidine-2,4-dione-1,2,3-triazole and furo[2,3-d]pyrimidine-2-one-1,2,3-triazole hybrids as potential anti-cancer agents: Synthesis, computational and X-ray analysis and biological evaluation.
Topics: Antineoplastic Agents; Catalysis; Cell Cycle Proteins; Crystallography, X-Ray; Cyclization; Drug Scr | 2017 |
Synthesis and antiproliferative activity of a series of novel 6-substituted pyrido[3,2-d]pyrimidines as potential nonclassical lipophilic antifolates targeting dihydrofolate reductase.
Topics: Antineoplastic Agents; Cell Cycle; Diamines; Drug Screening Assays, Antitumor; Folic Acid Antagonist | 2017 |
Synthesis and antiproliferative activity of a series of novel 6-substituted pyrido[3,2-d]pyrimidines as potential nonclassical lipophilic antifolates targeting dihydrofolate reductase.
Topics: Antineoplastic Agents; Cell Cycle; Diamines; Drug Screening Assays, Antitumor; Folic Acid Antagonist | 2017 |
Eco-friendly synthesis of novel cyanopyridine derivatives and their anticancer and PIM-1 kinase inhibitory activities.
Topics: Antineoplastic Agents; Apoptosis; Drug Design; Drug Screening Assays, Antitumor; Green Chemistry Tec | 2017 |
Eco-friendly synthesis of novel cyanopyridine derivatives and their anticancer and PIM-1 kinase inhibitory activities.
Topics: Antineoplastic Agents; Apoptosis; Drug Design; Drug Screening Assays, Antitumor; Green Chemistry Tec | 2017 |
Bioactive new withanolides from the cultured soft coral Sinularia brassica.
Topics: Animals; Anthozoa; Anti-Inflammatory Agents; Antineoplastic Agents; Cell Line, Tumor; Cytochalasin B | 2017 |
Bioactive new withanolides from the cultured soft coral Sinularia brassica.
Topics: Animals; Anthozoa; Anti-Inflammatory Agents; Antineoplastic Agents; Cell Line, Tumor; Cytochalasin B | 2017 |
Antiproliferative efficacy of curcumin mimics through microtubule destabilization.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cell Cycle; Cell Line, Tumor; Cell Prolife | 2018 |
Antiproliferative efficacy of curcumin mimics through microtubule destabilization.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cell Cycle; Cell Line, Tumor; Cell Prolife | 2018 |
Discovery of 6-chloro-2-(propylthio)-8,9-dihydro-7H-purines containing a carboxamide moiety as potential selective anti-lung cancer agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Discover | 2018 |
Discovery of 6-chloro-2-(propylthio)-8,9-dihydro-7H-purines containing a carboxamide moiety as potential selective anti-lung cancer agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Discover | 2018 |
Synthesis and anticancer activity of new dihydropyrimidinone derivatives.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Prolife | 2018 |
Synthesis and anticancer activity of new dihydropyrimidinone derivatives.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Prolife | 2018 |
Synthesis of scutellarein derivatives with antiproliferative activity and selectivity through the intrinsic pathway.
Topics: Antineoplastic Agents; Apigenin; Apoptosis; Apoptosis Regulatory Proteins; Benzoic Acid; Cell Line, | 2018 |
Synthesis of scutellarein derivatives with antiproliferative activity and selectivity through the intrinsic pathway.
Topics: Antineoplastic Agents; Apigenin; Apoptosis; Apoptosis Regulatory Proteins; Benzoic Acid; Cell Line, | 2018 |
Four new antitumor metabolites isolated from a mutant 3-f-31 strain derived from Penicillium purpurogenum G59.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biological Products; Cell Line, Tumor; HCT116 Cells; Huma | 2018 |
Four new antitumor metabolites isolated from a mutant 3-f-31 strain derived from Penicillium purpurogenum G59.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biological Products; Cell Line, Tumor; HCT116 Cells; Huma | 2018 |
Synthesis and antiproliferative activity of podocarpane and totarane derivatives.
Topics: Abietanes; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Di | 2018 |
Synthesis and antiproliferative activity of podocarpane and totarane derivatives.
Topics: Abietanes; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Di | 2018 |
Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II.
Topics: Antineoplastic Agents; CD13 Antigens; Cell Line, Tumor; Cell Proliferation; Click Chemistry; Drug De | 2019 |
Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II.
Topics: Antineoplastic Agents; CD13 Antigens; Cell Line, Tumor; Cell Proliferation; Click Chemistry; Drug De | 2019 |
Natural Product Albiziabioside A Conjugated with Pyruvate Dehydrogenase Kinase Inhibitor Dichloroacetate To Induce Apoptosis-Ferroptosis-M2-TAMs Polarization for Combined Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biological Products; Cell Line, Tumor; Dichloroacetic Aci | 2019 |
Natural Product Albiziabioside A Conjugated with Pyruvate Dehydrogenase Kinase Inhibitor Dichloroacetate To Induce Apoptosis-Ferroptosis-M2-TAMs Polarization for Combined Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biological Products; Cell Line, Tumor; Dichloroacetic Aci | 2019 |
Design, synthesis and antitumor evaluation of new 1,8-naphthalimide derivatives targeting nuclear DNA.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleus; C | 2021 |
Design, synthesis and antitumor evaluation of new 1,8-naphthalimide derivatives targeting nuclear DNA.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleus; C | 2021 |
Design, Synthesis, and Activity Evaluation of Novel Acyclic Nucleosides as Potential Anticancer Agents
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug S | 2021 |
Design, Synthesis, and Activity Evaluation of Novel Acyclic Nucleosides as Potential Anticancer Agents
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug S | 2021 |
[New recommendation on pharmacogenetic screening prior to 5-fluorouracil based cancer treatment - Swedish experience indicates less adverse effects and healthcare cost savings].
Topics: Antimetabolites, Antineoplastic; Cost Savings; Delivery of Health Care; Dihydrouracil Dehydrogenase | 2021 |
[New recommendation on pharmacogenetic screening prior to 5-fluorouracil based cancer treatment - Swedish experience indicates less adverse effects and healthcare cost savings].
Topics: Antimetabolites, Antineoplastic; Cost Savings; Delivery of Health Care; Dihydrouracil Dehydrogenase | 2021 |
Laser Therapy as a Preventive Approach for Oral Mucositis in Cancer Patients Undergoing Chemotherapy: The Potential Role of Superoxide Dismutase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2021 |
Laser Therapy as a Preventive Approach for Oral Mucositis in Cancer Patients Undergoing Chemotherapy: The Potential Role of Superoxide Dismutase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2021 |
Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines.
Topics: Capecitabine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotyping Techniques; Humans; Neopl | 2022 |
Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines.
Topics: Capecitabine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotyping Techniques; Humans; Neopl | 2022 |
DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols.
Topics: Adult; Antimetabolites; Bayes Theorem; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects | 2022 |
DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols.
Topics: Adult; Antimetabolites; Bayes Theorem; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects | 2022 |
Analytical and bioanalytical HPLC method for simultaneous estimation of 5-fluorouracil and sonidegib.
Topics: Animals; Biphenyl Compounds; Chromatography, High Pressure Liquid; Fluorouracil; Male; Neoplasms; Py | 2022 |
Analytical and bioanalytical HPLC method for simultaneous estimation of 5-fluorouracil and sonidegib.
Topics: Animals; Biphenyl Compounds; Chromatography, High Pressure Liquid; Fluorouracil; Male; Neoplasms; Py | 2022 |
Topics: Antimetabolites, Antineoplastic; Capecitabine; Female; Fluorouracil; Humans; Male; Methylenetetrahyd | 2022 |
Topics: Antimetabolites, Antineoplastic; Capecitabine; Female; Fluorouracil; Humans; Male; Methylenetetrahyd | 2022 |
Signaling Pathways Involved in 5-FU Drug Resistance in Cancer.
Topics: Apoptosis; Cell Line, Tumor; Drug Resistance; Drug Resistance, Neoplasm; Fluorouracil; Humans; Neopl | 2022 |
Signaling Pathways Involved in 5-FU Drug Resistance in Cancer.
Topics: Apoptosis; Cell Line, Tumor; Drug Resistance; Drug Resistance, Neoplasm; Fluorouracil; Humans; Neopl | 2022 |
MOF-801 as a Nanoporous Water-Based Carrier System for In Situ Encapsulation and Sustained Release of 5-FU for Effective Cancer Therapy.
Topics: Delayed-Action Preparations; Drug Carriers; Fluorouracil; Humans; Metal-Organic Frameworks; Nanopore | 2022 |
MOF-801 as a Nanoporous Water-Based Carrier System for In Situ Encapsulation and Sustained Release of 5-FU for Effective Cancer Therapy.
Topics: Delayed-Action Preparations; Drug Carriers; Fluorouracil; Humans; Metal-Organic Frameworks; Nanopore | 2022 |
Heterocyclic Compounds: Importance in Anticancer Drug Discovery.
Topics: Antineoplastic Agents; Daunorubicin; Doxorubicin; Fluorouracil; Heterocyclic Compounds; Humans; Meth | 2022 |
Heterocyclic Compounds: Importance in Anticancer Drug Discovery.
Topics: Antineoplastic Agents; Daunorubicin; Doxorubicin; Fluorouracil; Heterocyclic Compounds; Humans; Meth | 2022 |
The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm.
Topics: Calcium Channel Blockers; Coronary Vasospasm; Fluorouracil; Humans; Neoplasms; Nitrates; Retrospecti | 2022 |
The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm.
Topics: Calcium Channel Blockers; Coronary Vasospasm; Fluorouracil; Humans; Neoplasms; Nitrates; Retrospecti | 2022 |
Clinical considerations for DPD deficiency testing in advanced cancer patients: tumor lysis syndrome should be considered as a major interference.
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2022 |
Clinical considerations for DPD deficiency testing in advanced cancer patients: tumor lysis syndrome should be considered as a major interference.
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2022 |
Finding alternatives to 5-fluorouracil: application of ensemble-based virtual screening for drug repositioning against human thymidylate synthase.
Topics: Drug Repositioning; Ergotamines; Fluorouracil; Humans; Neoplasms; Thymidylate Synthase | 2023 |
Finding alternatives to 5-fluorouracil: application of ensemble-based virtual screening for drug repositioning against human thymidylate synthase.
Topics: Drug Repositioning; Ergotamines; Fluorouracil; Humans; Neoplasms; Thymidylate Synthase | 2023 |
EVALUATION OF 5-FLUOROURACIL-INDUCED CARDIOTOXICITY: ROLE OF CARDIAC BIOMARKERS.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cardiotoxicity; Female; Fluorourac | 2022 |
EVALUATION OF 5-FLUOROURACIL-INDUCED CARDIOTOXICITY: ROLE OF CARDIAC BIOMARKERS.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cardiotoxicity; Female; Fluorourac | 2022 |
The reproductive effects of the cancer chemotherapy agent, Carmofur, on Daphnia magna are mediated by its metabolite, 5-Fluorouracil.
Topics: Animals; Antineoplastic Agents; Daphnia; Fluorouracil; Neoplasms; Reproduction | 2022 |
The reproductive effects of the cancer chemotherapy agent, Carmofur, on Daphnia magna are mediated by its metabolite, 5-Fluorouracil.
Topics: Animals; Antineoplastic Agents; Daphnia; Fluorouracil; Neoplasms; Reproduction | 2022 |
Diagnosis and management of 5-fluorouracil (5-FU)-induced acute leukoencephalopathy: lessons learnt from a single-Centre case series.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Humans; Leukoencephalopathies; Neoplasms | 2022 |
Diagnosis and management of 5-fluorouracil (5-FU)-induced acute leukoencephalopathy: lessons learnt from a single-Centre case series.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Humans; Leukoencephalopathies; Neoplasms | 2022 |
Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations.
Topics: Animals; CD8-Positive T-Lymphocytes; Fluorouracil; Humans; Immune Checkpoint Inhibitors; Mice; Neopl | 2022 |
Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations.
Topics: Animals; CD8-Positive T-Lymphocytes; Fluorouracil; Humans; Immune Checkpoint Inhibitors; Mice; Neopl | 2022 |
Consequences of the Hsp110DE9 mutation in tumorigenesis and the 5-fluorouracil-based chemotherapy response in Msh2-deficient mice.
Topics: Animals; Carcinogenesis; Fluorouracil; HSP110 Heat-Shock Proteins; Mice; Microsatellite Instability; | 2022 |
Consequences of the Hsp110DE9 mutation in tumorigenesis and the 5-fluorouracil-based chemotherapy response in Msh2-deficient mice.
Topics: Animals; Carcinogenesis; Fluorouracil; HSP110 Heat-Shock Proteins; Mice; Microsatellite Instability; | 2022 |
Novel
Topics: Amides; Antineoplastic Agents; Fluorouracil; Humans; Neoplasms; Thiadiazoles; Thiazoles | 2023 |
Novel
Topics: Amides; Antineoplastic Agents; Fluorouracil; Humans; Neoplasms; Thiadiazoles; Thiazoles | 2023 |
Evaluation of the antineoplastic property of prodigiosins and 5-fluorouracil in restraining the growth of Ehrlich solid tumors in mice.
Topics: Animals; Antineoplastic Agents; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumo | 2022 |
Evaluation of the antineoplastic property of prodigiosins and 5-fluorouracil in restraining the growth of Ehrlich solid tumors in mice.
Topics: Animals; Antineoplastic Agents; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumo | 2022 |
Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Cardiotoxicity; Female; Fluorouracil; Humans; Male; Mi | 2022 |
Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Cardiotoxicity; Female; Fluorouracil; Humans; Male; Mi | 2022 |
ROS-generating, pH-responsive and highly tunable reduced graphene oxide-embedded microbeads showing intrinsic anticancer properties and multi-drug co-delivery capacity for combination cancer therapy.
Topics: Alginates; Chitosan; Curcumin; Drug Carriers; Drug Liberation; Fluorouracil; Graphite; Humans; Hydro | 2022 |
ROS-generating, pH-responsive and highly tunable reduced graphene oxide-embedded microbeads showing intrinsic anticancer properties and multi-drug co-delivery capacity for combination cancer therapy.
Topics: Alginates; Chitosan; Curcumin; Drug Carriers; Drug Liberation; Fluorouracil; Graphite; Humans; Hydro | 2022 |
Renal impairment and DPD testing: Watch out for false-positive results!
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrour | 2022 |
Renal impairment and DPD testing: Watch out for false-positive results!
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrour | 2022 |
Obesity reduced survival with 5-fluorouracil and did not protect against chemotherapy-induced cachexia or immune cell cytotoxicity in mice.
Topics: Animals; Antineoplastic Agents; Cachexia; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Mice; Ne | 2022 |
Obesity reduced survival with 5-fluorouracil and did not protect against chemotherapy-induced cachexia or immune cell cytotoxicity in mice.
Topics: Animals; Antineoplastic Agents; Cachexia; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Mice; Ne | 2022 |
Development of resistance to 5-fluorouracil affects membrane viscosity and lipid composition of cancer cells.
Topics: Cell Membrane; Fluorouracil; Microscopy, Fluorescence; Neoplasms; Phosphatidylcholines; Viscosity | 2022 |
Development of resistance to 5-fluorouracil affects membrane viscosity and lipid composition of cancer cells.
Topics: Cell Membrane; Fluorouracil; Microscopy, Fluorescence; Neoplasms; Phosphatidylcholines; Viscosity | 2022 |
SHMT2-mediated mitochondrial serine metabolism drives 5-FU resistance by fueling nucleotide biosynthesis.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Mitochondri | 2022 |
SHMT2-mediated mitochondrial serine metabolism drives 5-FU resistance by fueling nucleotide biosynthesis.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Mitochondri | 2022 |
Synthesis, Anticancer Activities and Molecular Docking Studies of a Novel Class of 2-Phenyl-5,6,7,8-tetrahydroimidazo [1,2-
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Etopo | 2022 |
Synthesis, Anticancer Activities and Molecular Docking Studies of a Novel Class of 2-Phenyl-5,6,7,8-tetrahydroimidazo [1,2-
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Etopo | 2022 |
Chitosan/Gamma-Alumina/Fe
Topics: Aluminum Oxide; Chitosan; Drug Carriers; Fluorouracil; Humans; Nanoparticles; Neoplasms; Spectroscop | 2022 |
Chitosan/Gamma-Alumina/Fe
Topics: Aluminum Oxide; Chitosan; Drug Carriers; Fluorouracil; Humans; Nanoparticles; Neoplasms; Spectroscop | 2022 |
Long-term use of broad-spectrum antibiotics affects Ly6C
Topics: Animals; Anti-Bacterial Agents; Fluorouracil; Gastrointestinal Microbiome; Interleukin-17; Interleuk | 2022 |
Long-term use of broad-spectrum antibiotics affects Ly6C
Topics: Animals; Anti-Bacterial Agents; Fluorouracil; Gastrointestinal Microbiome; Interleukin-17; Interleuk | 2022 |
Dihydropyrimidine dehydrogenase (DPD) genotype and phenotype among Danish cancer patients: prevalence and correlation between
Topics: Denmark; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotype; Humans; Neoplasms; Phenotype; P | 2022 |
Dihydropyrimidine dehydrogenase (DPD) genotype and phenotype among Danish cancer patients: prevalence and correlation between
Topics: Denmark; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotype; Humans; Neoplasms; Phenotype; P | 2022 |
Sulforaphane attenuates cancer cell-induced atrophy of C2C12 myotubes.
Topics: Antioxidants; Dimethyl Sulfoxide; Fluorouracil; Humans; Muscle Fibers, Skeletal; Muscular Atrophy; N | 2023 |
Sulforaphane attenuates cancer cell-induced atrophy of C2C12 myotubes.
Topics: Antioxidants; Dimethyl Sulfoxide; Fluorouracil; Humans; Muscle Fibers, Skeletal; Muscular Atrophy; N | 2023 |
Interactions between β-cyclodextrin as a carrier for anti-cancer drug delivery: a molecular dynamics simulation study.
Topics: Antineoplastic Agents; beta-Cyclodextrins; Drug Delivery Systems; Fluorouracil; Humans; Molecular Dy | 2023 |
Interactions between β-cyclodextrin as a carrier for anti-cancer drug delivery: a molecular dynamics simulation study.
Topics: Antineoplastic Agents; beta-Cyclodextrins; Drug Delivery Systems; Fluorouracil; Humans; Molecular Dy | 2023 |
Design and Synthesis of Acridine-Triazole and Acridine-Thiadiazole Derivatives and Their Inhibitory Effect against Cancer Cells.
Topics: Acridines; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dermatol | 2022 |
Design and Synthesis of Acridine-Triazole and Acridine-Thiadiazole Derivatives and Their Inhibitory Effect against Cancer Cells.
Topics: Acridines; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dermatol | 2022 |
Quercetin Improved Muscle Mass and Mitochondrial Content in a Murine Model of Cancer and Chemotherapy-Induced Cachexia.
Topics: Animals; Antineoplastic Agents; Cachexia; Disease Models, Animal; Fluorouracil; Mice; Mitochondria; | 2022 |
Quercetin Improved Muscle Mass and Mitochondrial Content in a Murine Model of Cancer and Chemotherapy-Induced Cachexia.
Topics: Animals; Antineoplastic Agents; Cachexia; Disease Models, Animal; Fluorouracil; Mice; Mitochondria; | 2022 |
Updated Labeling for Capecitabine, a 25-Year-Old Cancer Drug.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2023 |
Updated Labeling for Capecitabine, a 25-Year-Old Cancer Drug.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2023 |
Synthesis of biodegradable antimicrobial pH-sensitive silver nanocomposites reliant on chitosan and carrageenan derivatives for 5-fluorouracil drug delivery toward HCT116 cancer cells.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Carrageenan; Chitosan; Fluorouracil; HCT116 Cells; Hum | 2023 |
Synthesis of biodegradable antimicrobial pH-sensitive silver nanocomposites reliant on chitosan and carrageenan derivatives for 5-fluorouracil drug delivery toward HCT116 cancer cells.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Carrageenan; Chitosan; Fluorouracil; HCT116 Cells; Hum | 2023 |
Enhancing the Management of Metastatic Tumors by Robust Co-Delivery of 5-Fluorouracil/MicroRNA-10b Inhibitor Using EGFR-Targeted Nanovehicles.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Fluorouracil; Humans; MicroRNAs; Neopla | 2023 |
Enhancing the Management of Metastatic Tumors by Robust Co-Delivery of 5-Fluorouracil/MicroRNA-10b Inhibitor Using EGFR-Targeted Nanovehicles.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Fluorouracil; Humans; MicroRNAs; Neopla | 2023 |
Rapid generation of homogenous tumor spheroid microtissues in a scaffold-free platform for high-throughput screening of a novel combination nanomedicine.
Topics: Animals; Cell Line, Tumor; Curcumin; Drug Carriers; Drug Delivery Systems; Fluorouracil; High-Throug | 2023 |
Rapid generation of homogenous tumor spheroid microtissues in a scaffold-free platform for high-throughput screening of a novel combination nanomedicine.
Topics: Animals; Cell Line, Tumor; Curcumin; Drug Carriers; Drug Delivery Systems; Fluorouracil; High-Throug | 2023 |
The Glycosylated
Topics: Antineoplastic Agents; Cell Membrane; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Fluorouraci | 2023 |
The Glycosylated
Topics: Antineoplastic Agents; Cell Membrane; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Fluorouraci | 2023 |
Increased Expression of Hepatic Stearoyl-CoA Desaturase (SCD)-1 and Depletion of Eicosapentaenoic Acid (EPA) Content following Cytotoxic Cancer Therapy Are Reversed by Dietary Fish Oil.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Docosahexaenoic Acids; Eicosapentaenoic Aci | 2023 |
Increased Expression of Hepatic Stearoyl-CoA Desaturase (SCD)-1 and Depletion of Eicosapentaenoic Acid (EPA) Content following Cytotoxic Cancer Therapy Are Reversed by Dietary Fish Oil.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Docosahexaenoic Acids; Eicosapentaenoic Aci | 2023 |
Design of novel polyurethane-based ionene nanocarriers for cancer therapy: Synthesis, in-vitro, and in-vivo studies.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Fluorouracil | 2023 |
Design of novel polyurethane-based ionene nanocarriers for cancer therapy: Synthesis, in-vitro, and in-vivo studies.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Fluorouracil | 2023 |
Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study.
Topics: Cross-Sectional Studies; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotype; Humans; Neoplas | 2023 |
Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study.
Topics: Cross-Sectional Studies; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotype; Humans; Neoplas | 2023 |
Cocrystallization of 5-fluorouracil with gallic acid: A novel 5-fluorouracil cocrystal displaying synergistic anti-tumor activity both in oral and intraperitoneal injection administration.
Topics: Animals; Antineoplastic Agents; Calorimetry, Differential Scanning; Fluorouracil; Injections, Intrap | 2023 |
Cocrystallization of 5-fluorouracil with gallic acid: A novel 5-fluorouracil cocrystal displaying synergistic anti-tumor activity both in oral and intraperitoneal injection administration.
Topics: Animals; Antineoplastic Agents; Calorimetry, Differential Scanning; Fluorouracil; Injections, Intrap | 2023 |
Poor Renal Function and a High Modified Glasgow Prognostic Score Are Predictive Factors for Nedaplatin/5-Fluorouracil Combination Therapy-induced Febrile Neutropenia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Febrile Neutropenia; Fluorouracil | 2023 |
Poor Renal Function and a High Modified Glasgow Prognostic Score Are Predictive Factors for Nedaplatin/5-Fluorouracil Combination Therapy-induced Febrile Neutropenia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Febrile Neutropenia; Fluorouracil | 2023 |
Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gen | 2023 |
Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gen | 2023 |
Revisiting the Radical Radiotherapy-Radiochemotherapy Results in Anal Canal Cancers: (TROD Gastrointestinal Group Study 02-005).
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Disea | 2023 |
Revisiting the Radical Radiotherapy-Radiochemotherapy Results in Anal Canal Cancers: (TROD Gastrointestinal Group Study 02-005).
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Disea | 2023 |
Plasmonic Functional Assay Platform Determines the Therapeutic Profile of Cancer Cells.
Topics: Antineoplastic Agents; Doxorubicin; Fluorouracil; Humans; MCF-7 Cells; Neoplasms; Paclitaxel | 2023 |
Plasmonic Functional Assay Platform Determines the Therapeutic Profile of Cancer Cells.
Topics: Antineoplastic Agents; Doxorubicin; Fluorouracil; Humans; MCF-7 Cells; Neoplasms; Paclitaxel | 2023 |
Mitochondria-Targeted Thymidylate Synthase Inhibitor Based on Fluorescent Molecularly Imprinted Polymers for Tumor Antimetabolic Therapy.
Topics: Enzyme Inhibitors; Fluorouracil; Humans; Molecular Imprinting; Molecularly Imprinted Polymers; Neopl | 2023 |
Mitochondria-Targeted Thymidylate Synthase Inhibitor Based on Fluorescent Molecularly Imprinted Polymers for Tumor Antimetabolic Therapy.
Topics: Enzyme Inhibitors; Fluorouracil; Humans; Molecular Imprinting; Molecularly Imprinted Polymers; Neopl | 2023 |
4-amino-2-phenyl-6-(p-fluorophenyl)-5-carbonitrile-pyrimidine-bis-substituted-loaded liposomes as promising system for cancer treatment.
Topics: Animals; Antineoplastic Agents; Fluorouracil; HeLa Cells; Humans; Liposomes; Mice; Mitosis; Neoplasm | 2023 |
4-amino-2-phenyl-6-(p-fluorophenyl)-5-carbonitrile-pyrimidine-bis-substituted-loaded liposomes as promising system for cancer treatment.
Topics: Animals; Antineoplastic Agents; Fluorouracil; HeLa Cells; Humans; Liposomes; Mice; Mitosis; Neoplasm | 2023 |
Propranolol, Promising Chemosensitizer and Candidate for the Combined Therapy through Disruption of Tumor Microenvironment Homeostasis by Decreasing the Level of Carbonic Anhydrase IX.
Topics: Animals; Antigens, Neoplasm; Carbonic Anhydrase IX; Cell Line, Tumor; Fluorouracil; Humans; Mice; Ne | 2023 |
Propranolol, Promising Chemosensitizer and Candidate for the Combined Therapy through Disruption of Tumor Microenvironment Homeostasis by Decreasing the Level of Carbonic Anhydrase IX.
Topics: Animals; Antigens, Neoplasm; Carbonic Anhydrase IX; Cell Line, Tumor; Fluorouracil; Humans; Mice; Ne | 2023 |
Cancer Stem Cells Persist Despite Cellular Damage, Emergence of the Refractory Cell Population.
Topics: Cell Line, Tumor; Fluorouracil; Humans; Hyaluronan Receptors; Neoplasms; Neoplastic Stem Cells | 2023 |
Cancer Stem Cells Persist Despite Cellular Damage, Emergence of the Refractory Cell Population.
Topics: Cell Line, Tumor; Fluorouracil; Humans; Hyaluronan Receptors; Neoplasms; Neoplastic Stem Cells | 2023 |
A manual controlled theranostic nanoplatform with real-time photoacoustic quantification of drug release for chemophotothermal therapy.
Topics: Cell Line, Tumor; Drug Liberation; Ferric Compounds; Fluorouracil; Humans; Nanoparticles; Neoplasms; | 2023 |
A manual controlled theranostic nanoplatform with real-time photoacoustic quantification of drug release for chemophotothermal therapy.
Topics: Cell Line, Tumor; Drug Liberation; Ferric Compounds; Fluorouracil; Humans; Nanoparticles; Neoplasms; | 2023 |
Induction of lysophosphatidic acid (LPA) receptor-mediated signaling regulates cell motility and survival to anticancer drugs in cancer cells treated with hydrogen peroxide.
Topics: Antineoplastic Agents; Cell Movement; Fluorouracil; Humans; Hydrogen Peroxide; Neoplasms; Receptors, | 2023 |
Induction of lysophosphatidic acid (LPA) receptor-mediated signaling regulates cell motility and survival to anticancer drugs in cancer cells treated with hydrogen peroxide.
Topics: Antineoplastic Agents; Cell Movement; Fluorouracil; Humans; Hydrogen Peroxide; Neoplasms; Receptors, | 2023 |
Physiologically Based Pharmacokinetic Modeling for Prediction of 5-FU Pharmacokinetics in Cancer Patients with Hepatic Impairment After 5-FU and Capecitabine Administration.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms | 2023 |
Physiologically Based Pharmacokinetic Modeling for Prediction of 5-FU Pharmacokinetics in Cancer Patients with Hepatic Impairment After 5-FU and Capecitabine Administration.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms | 2023 |
Survival of Patients With Cancer With
Topics: Alleles; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotype; Humans; Matched-P | 2023 |
Survival of Patients With Cancer With
Topics: Alleles; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotype; Humans; Matched-P | 2023 |
The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gene Frequency; H | 2023 |
The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gene Frequency; H | 2023 |
In-vitro and in-vivo assessment of pH-responsive core-shell nanocarrier system for sequential delivery of methotrexate and 5-fluorouracil for the treatment of breast cancer.
Topics: Animals; Drug Carriers; Female; Fluorouracil; Hydrogen-Ion Concentration; Methotrexate; Nanoparticle | 2023 |
In-vitro and in-vivo assessment of pH-responsive core-shell nanocarrier system for sequential delivery of methotrexate and 5-fluorouracil for the treatment of breast cancer.
Topics: Animals; Drug Carriers; Female; Fluorouracil; Hydrogen-Ion Concentration; Methotrexate; Nanoparticle | 2023 |
5-Fluorouracil treatment induces characteristic T>G mutations in human cancer.
Topics: Adult; Age of Onset; Aged; Biopsy; Carcinogenesis; Cell Culture Techniques; Cell Line; Clinical Tria | 2019 |
5-Fluorouracil treatment induces characteristic T>G mutations in human cancer.
Topics: Adult; Age of Onset; Aged; Biopsy; Carcinogenesis; Cell Culture Techniques; Cell Line; Clinical Tria | 2019 |
Prevalence of the DPYD variant (Y186C) in Brazilian individuals of African ancestry.
Topics: Antimetabolites, Antineoplastic; Black People; Brazil; Capecitabine; Dihydropyrimidine Dehydrogenase | 2019 |
Prevalence of the DPYD variant (Y186C) in Brazilian individuals of African ancestry.
Topics: Antimetabolites, Antineoplastic; Black People; Brazil; Capecitabine; Dihydropyrimidine Dehydrogenase | 2019 |
Sample preparation strategies for high-throughput mass spectrometry imaging of primary tumor organoids.
Topics: Centrifugation; Collagen; Deoxycytidine; Drug Combinations; Extracellular Matrix; Fluorouracil; Gemc | 2020 |
Sample preparation strategies for high-throughput mass spectrometry imaging of primary tumor organoids.
Topics: Centrifugation; Collagen; Deoxycytidine; Drug Combinations; Extracellular Matrix; Fluorouracil; Gemc | 2020 |
Modeling the stem cell hypothesis: Investigating the effects of cancer stem cells and TGF-β on tumor growth.
Topics: Animals; Antineoplastic Agents; Calibration; CD8-Positive T-Lymphocytes; Drug Administration Schedul | 2019 |
Modeling the stem cell hypothesis: Investigating the effects of cancer stem cells and TGF-β on tumor growth.
Topics: Animals; Antineoplastic Agents; Calibration; CD8-Positive T-Lymphocytes; Drug Administration Schedul | 2019 |
Redox responsive xylan-SS-curcumin prodrug nanoparticles for dual drug delivery in cancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Curcumin; Disulfides; Drug Delivery Systems; Drug Li | 2020 |
Redox responsive xylan-SS-curcumin prodrug nanoparticles for dual drug delivery in cancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Curcumin; Disulfides; Drug Delivery Systems; Drug Li | 2020 |
Diversity of the Senescence Phenotype of Cancer Cells Treated with Chemotherapeutic Agents.
Topics: Antineoplastic Agents; Cell Proliferation; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p2 | 2019 |
Diversity of the Senescence Phenotype of Cancer Cells Treated with Chemotherapeutic Agents.
Topics: Antineoplastic Agents; Cell Proliferation; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p2 | 2019 |
Biocompatible chitosan-carbon nanocage hybrids for sustained drug release and highly efficient laser and microwave co-irradiation induced cancer therapy.
Topics: Animals; Biocompatible Materials; Carbon; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; C | 2020 |
Biocompatible chitosan-carbon nanocage hybrids for sustained drug release and highly efficient laser and microwave co-irradiation induced cancer therapy.
Topics: Animals; Biocompatible Materials; Carbon; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; C | 2020 |
A Simple and Rapid UPLC-UV Method for Detecting DPD Deficiency in Patients With Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; Chromatog | 2020 |
A Simple and Rapid UPLC-UV Method for Detecting DPD Deficiency in Patients With Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; Chromatog | 2020 |
5-Fluorouracil-induced hyperammonaemic encephalopathy: A French national survey.
Topics: Aged; Ammonia; Antimetabolites, Antineoplastic; Brain Diseases; Citric Acid Cycle; Dose-Response Rel | 2020 |
5-Fluorouracil-induced hyperammonaemic encephalopathy: A French national survey.
Topics: Aged; Ammonia; Antimetabolites, Antineoplastic; Brain Diseases; Citric Acid Cycle; Dose-Response Rel | 2020 |
Multifunctional nanocomposites MGO/FU-MI inhibit the proliferation of tumor cells and enhance the effect of chemoradiotherapy in vivo and in vitro.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; Fluorouracil; Humans; M | 2020 |
Multifunctional nanocomposites MGO/FU-MI inhibit the proliferation of tumor cells and enhance the effect of chemoradiotherapy in vivo and in vitro.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; Fluorouracil; Humans; M | 2020 |
Geriatric oncologists should be aware of cardio-oncology: Impact of age and gender on 5-FU-mediated TakoTsubo cardiomyopathy.
Topics: Aged; Fluorouracil; Humans; Medical Oncology; Neoplasms; Oncologists; Takotsubo Cardiomyopathy | 2020 |
Geriatric oncologists should be aware of cardio-oncology: Impact of age and gender on 5-FU-mediated TakoTsubo cardiomyopathy.
Topics: Aged; Fluorouracil; Humans; Medical Oncology; Neoplasms; Oncologists; Takotsubo Cardiomyopathy | 2020 |
On a New Proposed Mechanism of 5-Fluorouracil-Mediated Cytotoxicity.
Topics: Cell Cycle; Cell Survival; DNA Damage; Fluorouracil; Humans; Methylation; Neoplasms; Recombinational | 2020 |
On a New Proposed Mechanism of 5-Fluorouracil-Mediated Cytotoxicity.
Topics: Cell Cycle; Cell Survival; DNA Damage; Fluorouracil; Humans; Methylation; Neoplasms; Recombinational | 2020 |
A Rat Model of Oral Mucositis Induced by Cancer Chemotherapy for Quantitative Experiments.
Topics: Animals; Antineoplastic Agents; Body Weight; Disease Models, Animal; Fluorouracil; Leukocyte Count; | 2020 |
A Rat Model of Oral Mucositis Induced by Cancer Chemotherapy for Quantitative Experiments.
Topics: Animals; Antineoplastic Agents; Body Weight; Disease Models, Animal; Fluorouracil; Leukocyte Count; | 2020 |
DPD status and fluoropyrimidines-based treatment: high activity matters too.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Dihydrouracil | 2020 |
DPD status and fluoropyrimidines-based treatment: high activity matters too.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Dihydrouracil | 2020 |
Auxiliary antitumor effects of fungal proteins from Hericium erinaceus by target on the gut microbiota.
Topics: Animals; Antineoplastic Agents; Bacteria; Basidiomycota; Dysbiosis; Fluorouracil; Fungal Proteins; G | 2020 |
Auxiliary antitumor effects of fungal proteins from Hericium erinaceus by target on the gut microbiota.
Topics: Animals; Antineoplastic Agents; Bacteria; Basidiomycota; Dysbiosis; Fluorouracil; Fungal Proteins; G | 2020 |
ROS-Responsive Chitosan Coated Magnetic Iron Oxide Nanoparticles as Potential Vehicles for Targeted Drug Delivery in Cancer Therapy.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Chitosan; Drug Carriers; Drug Delivery Systems; | 2020 |
ROS-Responsive Chitosan Coated Magnetic Iron Oxide Nanoparticles as Potential Vehicles for Targeted Drug Delivery in Cancer Therapy.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Chitosan; Drug Carriers; Drug Delivery Systems; | 2020 |
Intracellular prodrug gene therapy for cancer mediated by tumor cell suicide gene exosomes.
Topics: Animals; Antineoplastic Agents; Cell Engineering; Cell Line, Tumor; Culture Media, Conditioned; Cyto | 2021 |
Intracellular prodrug gene therapy for cancer mediated by tumor cell suicide gene exosomes.
Topics: Animals; Antineoplastic Agents; Cell Engineering; Cell Line, Tumor; Culture Media, Conditioned; Cyto | 2021 |
Inhibition of the ATR kinase enhances 5-FU sensitivity independently of nonhomologous end-joining and homologous recombination repair pathways.
Topics: Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; DNA End-Joining Repair; Drug Resistance, N | 2020 |
Inhibition of the ATR kinase enhances 5-FU sensitivity independently of nonhomologous end-joining and homologous recombination repair pathways.
Topics: Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; DNA End-Joining Repair; Drug Resistance, N | 2020 |
To perform genotyping of dihydropyrimidine dehydrogenase (DPD) before starting treatment with 5-fluorouracil or related medicines: really feasible?
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotype; Humans; | 2021 |
To perform genotyping of dihydropyrimidine dehydrogenase (DPD) before starting treatment with 5-fluorouracil or related medicines: really feasible?
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotype; Humans; | 2021 |
Leveraging TCGA gene expression data to build predictive models for cancer drug response.
Topics: Antineoplastic Agents; Area Under Curve; Cluster Analysis; Databases, Genetic; Deoxycytidine; Fluoro | 2020 |
Leveraging TCGA gene expression data to build predictive models for cancer drug response.
Topics: Antineoplastic Agents; Area Under Curve; Cluster Analysis; Databases, Genetic; Deoxycytidine; Fluoro | 2020 |
Design and synthesis of pyrazole-pyrazoline hybrids as cancer-associated selective COX-2 inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Drug Design; Fluorouracil; Hum | 2021 |
Design and synthesis of pyrazole-pyrazoline hybrids as cancer-associated selective COX-2 inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Drug Design; Fluorouracil; Hum | 2021 |
Targeted delivery of 5-fluorouracil-1-acetic acid (5-FA) to cancer cells overexpressing epithelial growth factor receptor (EGFR) using virus-like nanoparticles.
Topics: Acetic Acid; Antineoplastic Agents; Drug Carriers; Drug Delivery Systems; ErbB Receptors; Fluorourac | 2020 |
Targeted delivery of 5-fluorouracil-1-acetic acid (5-FA) to cancer cells overexpressing epithelial growth factor receptor (EGFR) using virus-like nanoparticles.
Topics: Acetic Acid; Antineoplastic Agents; Drug Carriers; Drug Delivery Systems; ErbB Receptors; Fluorourac | 2020 |
Combined chemotherapy of platinum and fluorouracil promotes T cell-mediated antitumor immunity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; CD8-Positive T- | 2021 |
Combined chemotherapy of platinum and fluorouracil promotes T cell-mediated antitumor immunity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; CD8-Positive T- | 2021 |
Pumpless, unidirectional microphysiological system for testing metabolism-dependent chemotherapeutic toxicity.
Topics: Antimetabolites, Antineoplastic; Cell Death; Drug Evaluation, Preclinical; Drug-Related Side Effects | 2021 |
Pumpless, unidirectional microphysiological system for testing metabolism-dependent chemotherapeutic toxicity.
Topics: Antimetabolites, Antineoplastic; Cell Death; Drug Evaluation, Preclinical; Drug-Related Side Effects | 2021 |
Deep Drug Penetration of Nanodrug Aggregates at Tumor Tissues by Fast Extracellular Drug Release.
Topics: Animals; Cell Line, Tumor; Drug Liberation; Fluorouracil; Mice; Mice, Nude; Micelles; Nanoparticles; | 2021 |
Deep Drug Penetration of Nanodrug Aggregates at Tumor Tissues by Fast Extracellular Drug Release.
Topics: Animals; Cell Line, Tumor; Drug Liberation; Fluorouracil; Mice; Mice, Nude; Micelles; Nanoparticles; | 2021 |
Genome-Guided Reassurance of Drug Safety in Cancer Therapy: The Paradigm of Fluorouracil.
Topics: Capecitabine; Fluorouracil; Genetic Testing; Humans; Neoplasms; Pharmaceutical Preparations | 2020 |
Genome-Guided Reassurance of Drug Safety in Cancer Therapy: The Paradigm of Fluorouracil.
Topics: Capecitabine; Fluorouracil; Genetic Testing; Humans; Neoplasms; Pharmaceutical Preparations | 2020 |
Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-κB.
Topics: Ataxia Telangiectasia Mutated Proteins; Cisplatin; CRISPR-Cas Systems; Cytidine Deaminase; DNA Repai | 2021 |
Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-κB.
Topics: Ataxia Telangiectasia Mutated Proteins; Cisplatin; CRISPR-Cas Systems; Cytidine Deaminase; DNA Repai | 2021 |
Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy.
Topics: Aged; Alleles; Antimetabolites, Antineoplastic; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Dr | 2021 |
Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy.
Topics: Aged; Alleles; Antimetabolites, Antineoplastic; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Dr | 2021 |
Application of a novel thermo-sensitive injectable hydrogel in therapy in situ for drug accurate controlled release.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; | 2020 |
Application of a novel thermo-sensitive injectable hydrogel in therapy in situ for drug accurate controlled release.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; | 2020 |
Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events.
Topics: Aged; Antimetabolites, Antineoplastic; Canada; Capecitabine; Dihydropyrimidine Dehydrogenase Deficie | 2021 |
Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events.
Topics: Aged; Antimetabolites, Antineoplastic; Canada; Capecitabine; Dihydropyrimidine Dehydrogenase Deficie | 2021 |
Cyclophilin A is a factor of antitumor defense in the early stages of tumor development.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclophilin A; Female; Fluorou | 2021 |
Cyclophilin A is a factor of antitumor defense in the early stages of tumor development.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclophilin A; Female; Fluorou | 2021 |
Near Miss or Standard of Care?
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Early Detection of Cancer; Fluo | 2020 |
Near Miss or Standard of Care?
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Early Detection of Cancer; Fluo | 2020 |
Hazardous Drug Contamination: Presence of Bathroom Contamination in an Ambulatory Cancer Center.
Topics: Antineoplastic Agents; Drug Contamination; Fluorouracil; Humans; Neoplasms; Oxaliplatin; Toilet Faci | 2021 |
Hazardous Drug Contamination: Presence of Bathroom Contamination in an Ambulatory Cancer Center.
Topics: Antineoplastic Agents; Drug Contamination; Fluorouracil; Humans; Neoplasms; Oxaliplatin; Toilet Faci | 2021 |
Association of Pharmacogenetics With Adverse Events of Fluorouracil/Capecitabine in Patients With Cancer.
Topics: Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Pharmacogenetics | 2021 |
Association of Pharmacogenetics With Adverse Events of Fluorouracil/Capecitabine in Patients With Cancer.
Topics: Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Pharmacogenetics | 2021 |
Parallel G-quadruplex Structures Increase Cellular Uptake and Cytotoxicity of 5-Fluoro-2'-deoxyuridine Oligomers in 5-Fluorouracil Resistant Cells.
Topics: Cytotoxins; Deoxyuridine; Drug Resistance, Neoplasm; Fluorouracil; G-Quadruplexes; HeLa Cells; HT29 | 2021 |
Parallel G-quadruplex Structures Increase Cellular Uptake and Cytotoxicity of 5-Fluoro-2'-deoxyuridine Oligomers in 5-Fluorouracil Resistant Cells.
Topics: Cytotoxins; Deoxyuridine; Drug Resistance, Neoplasm; Fluorouracil; G-Quadruplexes; HeLa Cells; HT29 | 2021 |
Use of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant.
Topics: Acetates; Fluorouracil; Humans; Neoplasms; Uridine | 2021 |
Use of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant.
Topics: Acetates; Fluorouracil; Humans; Neoplasms; Uridine | 2021 |
Metformin alters therapeutic effects in the BALB/c tumor therapy model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BALB 3T3 Cells; Carcinogens; Cell Survival; | 2021 |
Metformin alters therapeutic effects in the BALB/c tumor therapy model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BALB 3T3 Cells; Carcinogens; Cell Survival; | 2021 |
Design, synthesis, and molecular docking study of novel quinoline-based bis-chalcones as potential antitumor agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chalcones; Doxorubicin; Fluorouracil; HCT116 Cells; HT29 Ce | 2021 |
Design, synthesis, and molecular docking study of novel quinoline-based bis-chalcones as potential antitumor agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chalcones; Doxorubicin; Fluorouracil; HCT116 Cells; HT29 Ce | 2021 |
Force Field Parameters for Fe
Topics: Animals; Antineoplastic Agents; Computer Simulation; Dihydrouracil Dehydrogenase (NADP); Enzyme Stab | 2021 |
Force Field Parameters for Fe
Topics: Animals; Antineoplastic Agents; Computer Simulation; Dihydrouracil Dehydrogenase (NADP); Enzyme Stab | 2021 |
Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; beta-Alanine; Capecitabine; Female; Fluorouracil; Huma | 2021 |
Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; beta-Alanine; Capecitabine; Female; Fluorouracil; Huma | 2021 |
Capecitabine induced Steven-Johnson syndrome: A rare case report.
Topics: Aged; Antineoplastic Agents; Capecitabine; Fluorouracil; Humans; Male; Neoplasms; Stevens-Johnson Sy | 2022 |
Capecitabine induced Steven-Johnson syndrome: A rare case report.
Topics: Aged; Antineoplastic Agents; Capecitabine; Fluorouracil; Humans; Male; Neoplasms; Stevens-Johnson Sy | 2022 |
CETSA interaction proteomics define specific RNA-modification pathways as key components of fluorouracil-based cancer drug cytotoxicity.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Proteome; Proteomics; RNA | 2022 |
CETSA interaction proteomics define specific RNA-modification pathways as key components of fluorouracil-based cancer drug cytotoxicity.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Proteome; Proteomics; RNA | 2022 |
New In Vitro-In Silico Approach for the Prediction of In Vivo Performance of Drug Combinations.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Prolif | 2021 |
New In Vitro-In Silico Approach for the Prediction of In Vivo Performance of Drug Combinations.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Prolif | 2021 |
RNA-seq and
Topics: Animals; Cell Line; Curcumin; Disease Models, Animal; Epithelial Cells; Fluorouracil; Gene Expressio | 2021 |
RNA-seq and
Topics: Animals; Cell Line; Curcumin; Disease Models, Animal; Epithelial Cells; Fluorouracil; Gene Expressio | 2021 |
dUTPase inhibition augments replication defects of 5-Fluorouracil.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; D | 2017 |
dUTPase inhibition augments replication defects of 5-Fluorouracil.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; D | 2017 |
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; | 2017 |
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; | 2017 |
Inhibition of PI3K suppresses propagation of drug-tolerant cancer cell subpopulations enriched by 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidyl | 2017 |
Inhibition of PI3K suppresses propagation of drug-tolerant cancer cell subpopulations enriched by 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidyl | 2017 |
Extreme low dose of 5-fluorouracil reverses MDR in cancer by sensitizing cancer associated fibroblasts and down-regulating P-gp.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily | 2017 |
Extreme low dose of 5-fluorouracil reverses MDR in cancer by sensitizing cancer associated fibroblasts and down-regulating P-gp.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily | 2017 |
B
Topics: Antineoplastic Agents; Drug Delivery Systems; Fluorouracil; Fullerenes; Humans; Models, Molecular; N | 2017 |
B
Topics: Antineoplastic Agents; Drug Delivery Systems; Fluorouracil; Fullerenes; Humans; Models, Molecular; N | 2017 |
Formation and characterization of polyelectrolyte complex synthesized by chitosan and carboxylic curdlan for 5-fluorouracil delivery.
Topics: beta-Glucans; Chitosan; Drug Carriers; Fluorouracil; HeLa Cells; Humans; Nanoparticles; Neoplasms; P | 2018 |
Formation and characterization of polyelectrolyte complex synthesized by chitosan and carboxylic curdlan for 5-fluorouracil delivery.
Topics: beta-Glucans; Chitosan; Drug Carriers; Fluorouracil; HeLa Cells; Humans; Nanoparticles; Neoplasms; P | 2018 |
Modulating mitochondrial morphology enhances antitumor effect of 5-ALA-mediated photodynamic therapy both in vitro and in vivo.
Topics: Aminolevulinic Acid; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Dynamins; Fl | 2017 |
Modulating mitochondrial morphology enhances antitumor effect of 5-ALA-mediated photodynamic therapy both in vitro and in vivo.
Topics: Aminolevulinic Acid; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Dynamins; Fl | 2017 |
Novel c(RGDyK)-based conjugates of POPAM and 5-fluorouracil for integrin-targeted cancer therapy.
Topics: A549 Cells; Amino Acid Sequence; Aniline Mustard; Antineoplastic Agents; Cell Line, Tumor; Cell Prol | 2017 |
Novel c(RGDyK)-based conjugates of POPAM and 5-fluorouracil for integrin-targeted cancer therapy.
Topics: A549 Cells; Amino Acid Sequence; Aniline Mustard; Antineoplastic Agents; Cell Line, Tumor; Cell Prol | 2017 |
Active Ingredients of Hange-shashin-to, Baicalelin and 6-Gingerol, Inhibit 5-Fluorouracil-Induced Upregulation of CXCL1 in the Colon to Attenuate Diarrhea Development.
Topics: Animals; Antimetabolites, Antineoplastic; Catechols; Chemokine CXCL1; Colon; Diarrhea; Disease Model | 2017 |
Active Ingredients of Hange-shashin-to, Baicalelin and 6-Gingerol, Inhibit 5-Fluorouracil-Induced Upregulation of CXCL1 in the Colon to Attenuate Diarrhea Development.
Topics: Animals; Antimetabolites, Antineoplastic; Catechols; Chemokine CXCL1; Colon; Diarrhea; Disease Model | 2017 |
Folic acid-modified liposomal drug delivery strategy for tumor targeting of 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Dose-Response Relationshi | 2018 |
Folic acid-modified liposomal drug delivery strategy for tumor targeting of 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Dose-Response Relationshi | 2018 |
Mathematical modeling of tumor-induced immunosuppression by myeloid-derived suppressor cells: Implications for therapeutic targeting strategies.
Topics: Algorithms; Animals; Antineoplastic Agents; Arginine; Fluorouracil; Humans; Immune Tolerance; Immuni | 2018 |
Mathematical modeling of tumor-induced immunosuppression by myeloid-derived suppressor cells: Implications for therapeutic targeting strategies.
Topics: Algorithms; Animals; Antineoplastic Agents; Arginine; Fluorouracil; Humans; Immune Tolerance; Immuni | 2018 |
Probing the interaction of two chemotherapeutic drugs of oxali-palladium and 5-fluorouracil simultaneously with milk carrier protein of β-lactoglobulin.
Topics: Antineoplastic Agents; Binding Sites; Carrier Proteins; Circular Dichroism; Fluorouracil; Humans; La | 2018 |
Probing the interaction of two chemotherapeutic drugs of oxali-palladium and 5-fluorouracil simultaneously with milk carrier protein of β-lactoglobulin.
Topics: Antineoplastic Agents; Binding Sites; Carrier Proteins; Circular Dichroism; Fluorouracil; Humans; La | 2018 |
Comparative Proteomics of Dying and Surviving Cancer Cells Improves the Identification of Drug Targets and Sheds Light on Cell Life/Death Decisions.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Survival; Fluorouracil; Humans; Methotrexa | 2018 |
Comparative Proteomics of Dying and Surviving Cancer Cells Improves the Identification of Drug Targets and Sheds Light on Cell Life/Death Decisions.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Survival; Fluorouracil; Humans; Methotrexa | 2018 |
Effects of cisplatin-5-fluorouracil combination therapy on oxidative stress, DNA damage, mitochondrial apoptosis, and death receptor signalling in retinal pigment epithelium cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line; Cell Survival; Cisplatin; DNA | 2018 |
Effects of cisplatin-5-fluorouracil combination therapy on oxidative stress, DNA damage, mitochondrial apoptosis, and death receptor signalling in retinal pigment epithelium cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line; Cell Survival; Cisplatin; DNA | 2018 |
A Self-Assembled Coumarin-Anchored Dendrimer for Efficient Gene Delivery and Light-Responsive Drug Delivery.
Topics: Antineoplastic Agents; Cell Line, Tumor; Coumarins; Dendrimers; Drug Delivery Systems; Fluorouracil; | 2018 |
A Self-Assembled Coumarin-Anchored Dendrimer for Efficient Gene Delivery and Light-Responsive Drug Delivery.
Topics: Antineoplastic Agents; Cell Line, Tumor; Coumarins; Dendrimers; Drug Delivery Systems; Fluorouracil; | 2018 |
Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bloo | 2018 |
Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bloo | 2018 |
Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capeci | 2018 |
Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capeci | 2018 |
A Judgement Bias Test to Assess Affective State and Potential Therapeutics in a Rat Model of Chemotherapy-Induced Mucositis.
Topics: Affect; Analgesics, Opioid; Animals; Antineoplastic Agents; Buprenorphine; Disease Models, Animal; D | 2018 |
A Judgement Bias Test to Assess Affective State and Potential Therapeutics in a Rat Model of Chemotherapy-Induced Mucositis.
Topics: Affect; Analgesics, Opioid; Animals; Antineoplastic Agents; Buprenorphine; Disease Models, Animal; D | 2018 |
Preliminary Evidence for Enhanced Thymine Absorption: A Putative New Phenotype Associated With Fluoropyrimidine Toxicity in Cancer Patients.
Topics: Adult; Aged; Amidohydrolases; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil | 2018 |
Preliminary Evidence for Enhanced Thymine Absorption: A Putative New Phenotype Associated With Fluoropyrimidine Toxicity in Cancer Patients.
Topics: Adult; Aged; Amidohydrolases; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil | 2018 |
An NAD(P)H:Quinone Oxidoreductase 1 Responsive and Self-Immolative Prodrug of 5-Fluorouracil for Safe and Effective Cancer Therapy.
Topics: Fluorouracil; Humans; Molecular Structure; NAD; NAD(P)H Dehydrogenase (Quinone); Neoplasms; Prodrugs | 2018 |
An NAD(P)H:Quinone Oxidoreductase 1 Responsive and Self-Immolative Prodrug of 5-Fluorouracil for Safe and Effective Cancer Therapy.
Topics: Fluorouracil; Humans; Molecular Structure; NAD; NAD(P)H Dehydrogenase (Quinone); Neoplasms; Prodrugs | 2018 |
Implantable chemothermal brachytherapy seeds: A synergistic approach to brachytherapy using polymeric dual drug delivery and hyperthermia for malignant solid tumor ablation.
Topics: Alloys; Animals; Antineoplastic Agents; Bortezomib; Brachytherapy; Combined Modality Therapy; Drug C | 2018 |
Implantable chemothermal brachytherapy seeds: A synergistic approach to brachytherapy using polymeric dual drug delivery and hyperthermia for malignant solid tumor ablation.
Topics: Alloys; Animals; Antineoplastic Agents; Bortezomib; Brachytherapy; Combined Modality Therapy; Drug C | 2018 |
Novel theranostic nanoplatform for complete mice tumor elimination via MR imaging-guided acid-enhanced photothermo-/chemo-therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Copper; Female; Fluorouracil; Hydroxides; Hyperthermia, In | 2018 |
Novel theranostic nanoplatform for complete mice tumor elimination via MR imaging-guided acid-enhanced photothermo-/chemo-therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Copper; Female; Fluorouracil; Hydroxides; Hyperthermia, In | 2018 |
Determination of 5-fluorouracil and tegafur in tear fluid of patients treated with oral fluoropyrimidine anticancer agent, S-1.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chromatograph | 2018 |
Determination of 5-fluorouracil and tegafur in tear fluid of patients treated with oral fluoropyrimidine anticancer agent, S-1.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chromatograph | 2018 |
Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Febrile Neutropen | 2018 |
Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Febrile Neutropen | 2018 |
Cyclophosphamide with or without fluorouracil followed by subcutaneous or intravenous interleukin-2 use in solid tumors: A feasibility off-label experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Feasibility Studies; Female; | 2019 |
Cyclophosphamide with or without fluorouracil followed by subcutaneous or intravenous interleukin-2 use in solid tumors: A feasibility off-label experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Feasibility Studies; Female; | 2019 |
Predicting fluoropyrimidine-related toxicity: turning wish to will, the PAMM-EORTC position.
Topics: Consensus; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Dose-Resp | 2018 |
Predicting fluoropyrimidine-related toxicity: turning wish to will, the PAMM-EORTC position.
Topics: Consensus; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Dose-Resp | 2018 |
Improving the Subcutaneous Mouse Tumor Model by Effective Manipulation of Magnetic Nanoparticles-Treated Implanted Cancer Cells.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Disease Models, Animal; Fluorouracil; Ma | 2018 |
Improving the Subcutaneous Mouse Tumor Model by Effective Manipulation of Magnetic Nanoparticles-Treated Implanted Cancer Cells.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Disease Models, Animal; Fluorouracil; Ma | 2018 |
Rhizopus nigricans polysaccharide activated macrophages and suppressed tumor growth in CT26 tumor-bearing mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Synergism; Female; Fluorouracil; Fungal Polys | 2018 |
Rhizopus nigricans polysaccharide activated macrophages and suppressed tumor growth in CT26 tumor-bearing mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Synergism; Female; Fluorouracil; Fungal Polys | 2018 |
A pan-cancer study of the transcriptional regulation of uricogenesis in human tumours: pathological and pharmacological correlates.
Topics: Adenine Phosphoribosyltransferase; Databases, Factual; DNA Copy Number Variations; DNA Methylation; | 2018 |
A pan-cancer study of the transcriptional regulation of uricogenesis in human tumours: pathological and pharmacological correlates.
Topics: Adenine Phosphoribosyltransferase; Databases, Factual; DNA Copy Number Variations; DNA Methylation; | 2018 |
Effect of Grifola frondosa polysaccharide on anti-tumor activity in combination with 5-Fu in Heps-bearing mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Female; Flu | 2019 |
Effect of Grifola frondosa polysaccharide on anti-tumor activity in combination with 5-Fu in Heps-bearing mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Female; Flu | 2019 |
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2018 |
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2018 |
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2018 |
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2018 |
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2018 |
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2018 |
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2018 |
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2018 |
Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiotoxicity; Clinical Trials, Phase | 2019 |
Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiotoxicity; Clinical Trials, Phase | 2019 |
Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Capecitabine; Chemoradioth | 2018 |
Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Capecitabine; Chemoradioth | 2018 |
Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy.
Topics: Algorithms; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Computational Biology; Databases, Fa | 2018 |
Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy.
Topics: Algorithms; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Computational Biology; Databases, Fa | 2018 |
Hepatitis B Reactivation Rate Is Higher Undergoing Some Cytotoxic Chemotherapy in Patients with Solid Tumors: A Large Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; DN | 2018 |
Hepatitis B Reactivation Rate Is Higher Undergoing Some Cytotoxic Chemotherapy in Patients with Solid Tumors: A Large Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; DN | 2018 |
In Vitro Evaluation of Sulforaphane and a Natural Analog as Potent Inducers of 5-Fluorouracil Anticancer Activity.
Topics: Antineoplastic Agents; Caco-2 Cells; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2018 |
In Vitro Evaluation of Sulforaphane and a Natural Analog as Potent Inducers of 5-Fluorouracil Anticancer Activity.
Topics: Antineoplastic Agents; Caco-2 Cells; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2018 |
Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2019 |
Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2019 |
Photochemical Internalization Enhanced Nonviral Suicide Gene Therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Fluorou | 2019 |
Photochemical Internalization Enhanced Nonviral Suicide Gene Therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Fluorou | 2019 |
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Costs and Cost Analysis; Dihydrouracil | 2019 |
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Costs and Cost Analysis; Dihydrouracil | 2019 |
Therapeutic Effect of GGsTop, Selective Gamma-glutamyl Transpeptidase Inhibitor, on a Mouse Model of 5-Fluorouracil-induced Oral Mucositis.
Topics: Aminobutyrates; Animals; Disease Models, Animal; Fluorouracil; gamma-Glutamyltransferase; Humans; Mi | 2019 |
Therapeutic Effect of GGsTop, Selective Gamma-glutamyl Transpeptidase Inhibitor, on a Mouse Model of 5-Fluorouracil-induced Oral Mucositis.
Topics: Aminobutyrates; Animals; Disease Models, Animal; Fluorouracil; gamma-Glutamyltransferase; Humans; Mi | 2019 |
Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Camptothec | 2019 |
Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Camptothec | 2019 |
Therapeutic drug monitoring (TDM) of 5-fluorouracil (5-FU): new preanalytic aspects.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Drug Monitoring; Female; Fluorouracil; Humans; Imm | 2019 |
Therapeutic drug monitoring (TDM) of 5-fluorouracil (5-FU): new preanalytic aspects.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Drug Monitoring; Female; Fluorouracil; Humans; Imm | 2019 |
Supramolecular self-assembly of triazine-based small molecules: targeting the endoplasmic reticulum in cancer cells.
Topics: Chloroquine; Drug Delivery Systems; Endoplasmic Reticulum; Fluorouracil; HeLa Cells; Humans; Neoplas | 2019 |
Supramolecular self-assembly of triazine-based small molecules: targeting the endoplasmic reticulum in cancer cells.
Topics: Chloroquine; Drug Delivery Systems; Endoplasmic Reticulum; Fluorouracil; HeLa Cells; Humans; Neoplas | 2019 |
Dietary Methionine Restriction-Based Cancer Chemotherapy in Rodents.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cisplatin; Coculture Techniques; Diet; Doxorubicin; Ethionine | 2019 |
Dietary Methionine Restriction-Based Cancer Chemotherapy in Rodents.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cisplatin; Coculture Techniques; Diet; Doxorubicin; Ethionine | 2019 |
Engineered Targeted Hyaluronic Acid-Glutathione-Stabilized Gold Nanoclusters/Graphene Oxide-5-Fluorouracil as a Smart Theranostic Platform for Stimulus-Controlled Fluorescence Imaging-Assisted Synergetic Chemo/Phototherapy.
Topics: Animals; Cell Line; Cell Survival; Combined Modality Therapy; Cricetinae; Drug Carriers; Drug Libera | 2019 |
Engineered Targeted Hyaluronic Acid-Glutathione-Stabilized Gold Nanoclusters/Graphene Oxide-5-Fluorouracil as a Smart Theranostic Platform for Stimulus-Controlled Fluorescence Imaging-Assisted Synergetic Chemo/Phototherapy.
Topics: Animals; Cell Line; Cell Survival; Combined Modality Therapy; Cricetinae; Drug Carriers; Drug Libera | 2019 |
[5-FU: At last!]
Topics: Acetates; Antidotes; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Fl | 2019 |
[5-FU: At last!]
Topics: Acetates; Antidotes; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Fl | 2019 |
Magnetic bio-metal-organic framework nanocomposites decorated with folic acid conjugated chitosan as a promising biocompatible targeted theranostic system for cancer treatment.
Topics: Animals; Biocompatible Materials; Cell Death; Cell Line, Tumor; Cell Survival; Chitosan; Curcumin; D | 2019 |
Magnetic bio-metal-organic framework nanocomposites decorated with folic acid conjugated chitosan as a promising biocompatible targeted theranostic system for cancer treatment.
Topics: Animals; Biocompatible Materials; Cell Death; Cell Line, Tumor; Cell Survival; Chitosan; Curcumin; D | 2019 |
Facile Transfer of Reverse Micelles from the Organic to the Aqueous Phase for Mimicking Enzyme Catalysis and Imaging-Guided Cancer Therapy.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; A549 Cells; Antineoplastic Agents; Benzoin; Catalysis; Drug Carri | 2019 |
Facile Transfer of Reverse Micelles from the Organic to the Aqueous Phase for Mimicking Enzyme Catalysis and Imaging-Guided Cancer Therapy.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; A549 Cells; Antineoplastic Agents; Benzoin; Catalysis; Drug Carri | 2019 |
Fluoropyrimidines and DPD testing: is there truly an inexorable link?
Topics: Antineoplastic Agents; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP | 2019 |
Fluoropyrimidines and DPD testing: is there truly an inexorable link?
Topics: Antineoplastic Agents; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP | 2019 |
Targeted Transmembrane Delivery of Ca
Topics: Animals; Calcium; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Drug Carriers; F | 2019 |
Targeted Transmembrane Delivery of Ca
Topics: Animals; Calcium; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Drug Carriers; F | 2019 |
Evaluating dose of cisplatin responsible for causing nephrotoxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationsh | 2019 |
Evaluating dose of cisplatin responsible for causing nephrotoxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationsh | 2019 |
Juglone eliminates MDSCs accumulation and enhances antitumor immunity.
Topics: Animals; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Chemical and Drug Indu | 2019 |
Juglone eliminates MDSCs accumulation and enhances antitumor immunity.
Topics: Animals; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Chemical and Drug Indu | 2019 |
Prediction of Small Molecule-MicroRNA Associations by Sparse Learning and Heterogeneous Graph Inference.
Topics: Algorithms; Area Under Curve; Computational Biology; Computer Simulation; Decitabine; Estradiol; Flu | 2019 |
Prediction of Small Molecule-MicroRNA Associations by Sparse Learning and Heterogeneous Graph Inference.
Topics: Algorithms; Area Under Curve; Computational Biology; Computer Simulation; Decitabine; Estradiol; Flu | 2019 |
IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer.
Topics: Animals; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Fluorouracil; HCT116 Cells; Humans; I-ka | 2019 |
IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer.
Topics: Animals; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Fluorouracil; HCT116 Cells; Humans; I-ka | 2019 |
A simple ex vivo bioassay for 5-FU transport into healthy buccal mucosal cells.
Topics: Antimetabolites, Antineoplastic; Biological Transport, Active; Biological Variation, Population; Fem | 2019 |
A simple ex vivo bioassay for 5-FU transport into healthy buccal mucosal cells.
Topics: Antimetabolites, Antineoplastic; Biological Transport, Active; Biological Variation, Population; Fem | 2019 |
The Impact of Magnesium-Aluminum-Layered Double Hydroxide-Based Polyvinyl Alcohol Coated on Magnetite on the Preparation of Core-Shell Nanoparticles as a Drug Delivery Agent.
Topics: 3T3 Cells; Aluminum Hydroxide; Animals; Antimetabolites, Antineoplastic; Delayed-Action Preparations | 2019 |
The Impact of Magnesium-Aluminum-Layered Double Hydroxide-Based Polyvinyl Alcohol Coated on Magnetite on the Preparation of Core-Shell Nanoparticles as a Drug Delivery Agent.
Topics: 3T3 Cells; Aluminum Hydroxide; Animals; Antimetabolites, Antineoplastic; Delayed-Action Preparations | 2019 |
Retrovirus-mediated transduction of a cytosine deaminase gene preserves the stemness of mesenchymal stem cells.
Topics: Adolescent; Animals; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplast | 2013 |
Retrovirus-mediated transduction of a cytosine deaminase gene preserves the stemness of mesenchymal stem cells.
Topics: Adolescent; Animals; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplast | 2013 |
In vitro and in vivo evaluation of injectable implants for intratumoral delivery of 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Delayed-Action Preparations; Drug Delivery Systems; Female | 2014 |
In vitro and in vivo evaluation of injectable implants for intratumoral delivery of 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Delayed-Action Preparations; Drug Delivery Systems; Female | 2014 |
Multifunctional nanoparticles based on a single-molecule modification for the treatment of drug-resistant cancer.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport | 2013 |
Multifunctional nanoparticles based on a single-molecule modification for the treatment of drug-resistant cancer.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport | 2013 |
Possible role of mural cell-covered mature blood vessels in inducing drug resistance in cancer-initiating cells.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 2; ATP-Binding | 2013 |
Possible role of mural cell-covered mature blood vessels in inducing drug resistance in cancer-initiating cells.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 2; ATP-Binding | 2013 |
Preliminary evaluation of the interactions of Panax ginseng and Salvia miltiorrhiza Bunge with 5-fluorouracil on pharmacokinetics in rats and pharmacodynamics in human cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; | 2013 |
Preliminary evaluation of the interactions of Panax ginseng and Salvia miltiorrhiza Bunge with 5-fluorouracil on pharmacokinetics in rats and pharmacodynamics in human cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; | 2013 |
A facile synthesis of strong near infrared fluorescent layered double hydroxide nanovehicles with an anticancer drug for tumor optical imaging and therapy.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Membrane; Drug Carriers; Erbium; Fluorescenc | 2013 |
A facile synthesis of strong near infrared fluorescent layered double hydroxide nanovehicles with an anticancer drug for tumor optical imaging and therapy.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Membrane; Drug Carriers; Erbium; Fluorescenc | 2013 |
Chemotherapy and immunomodulation: from immunogenic chemotherapies to novel therapeutic strategies.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Death; Cyclop | 2013 |
Chemotherapy and immunomodulation: from immunogenic chemotherapies to novel therapeutic strategies.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Death; Cyclop | 2013 |
Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2013 |
Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2013 |
A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity.
Topics: Adult; Antimetabolites, Antineoplastic; Black or African American; Cohort Studies; Dihydrouracil Deh | 2013 |
A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity.
Topics: Adult; Antimetabolites, Antineoplastic; Black or African American; Cohort Studies; Dihydrouracil Deh | 2013 |
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antibodies; Antibodies, Monoclonal, Murine-Derived; Antineoplastic A | 2014 |
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antibodies; Antibodies, Monoclonal, Murine-Derived; Antineoplastic A | 2014 |
Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cytidine Deaminase; Dihydrouracil D | 2013 |
Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cytidine Deaminase; Dihydrouracil D | 2013 |
Using continuous data on tumour measurements to improve inference in phase II cancer studies.
Topics: Antineoplastic Agents; Capecitabine; Clinical Trials, Phase II as Topic; Computer Simulation; Data I | 2013 |
Using continuous data on tumour measurements to improve inference in phase II cancer studies.
Topics: Antineoplastic Agents; Capecitabine; Clinical Trials, Phase II as Topic; Computer Simulation; Data I | 2013 |
Formulation and characterization of nanoliposomal 5-fluorouracil for cancer nanotherapy.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Cell Line, Tumor; Cholesterol; Drug Delivery Systems; Fluorourac | 2014 |
Formulation and characterization of nanoliposomal 5-fluorouracil for cancer nanotherapy.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Cell Line, Tumor; Cholesterol; Drug Delivery Systems; Fluorourac | 2014 |
Survivin-3B potentiates immune escape in cancer but also inhibits the toxicity of cancer chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Proliferation; Female; | 2013 |
Survivin-3B potentiates immune escape in cancer but also inhibits the toxicity of cancer chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Proliferation; Female; | 2013 |
In vivo anti-cancer efficacy of magnetite nanocrystal--based system using locoregional hyperthermia combined with 5-fluorouracil chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ce | 2013 |
In vivo anti-cancer efficacy of magnetite nanocrystal--based system using locoregional hyperthermia combined with 5-fluorouracil chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ce | 2013 |
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
Topics: Axitinib; Blood Pressure; Clinical Trials as Topic; Combined Modality Therapy; Erythrocyte Count; Er | 2013 |
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
Topics: Axitinib; Blood Pressure; Clinical Trials as Topic; Combined Modality Therapy; Erythrocyte Count; Er | 2013 |
Controlled release of 5-fluorouracil from microporous zeolites.
Topics: Antineoplastic Agents; Caco-2 Cells; Cell Survival; Diffusion; Drug Carriers; Fluorouracil; Humans; | 2014 |
Controlled release of 5-fluorouracil from microporous zeolites.
Topics: Antineoplastic Agents; Caco-2 Cells; Cell Survival; Diffusion; Drug Carriers; Fluorouracil; Humans; | 2014 |
ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carbam | 2013 |
ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carbam | 2013 |
ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression.
Topics: Aged; ATP-Binding Cassette Transporters; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expre | 2013 |
ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression.
Topics: Aged; ATP-Binding Cassette Transporters; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expre | 2013 |
A case of 5-FU-related severe toxicity associated with the p.Y186C DPYD variant.
Topics: Antimetabolites, Antineoplastic; Black or African American; Dihydrouracil Dehydrogenase (NADP); Fema | 2014 |
A case of 5-FU-related severe toxicity associated with the p.Y186C DPYD variant.
Topics: Antimetabolites, Antineoplastic; Black or African American; Dihydrouracil Dehydrogenase (NADP); Fema | 2014 |
Response to "A case of 5-FU-related severe toxicity associated with the P.Y186C DPYD variant".
Topics: Antimetabolites, Antineoplastic; Black or African American; Dihydrouracil Dehydrogenase (NADP); Fema | 2014 |
Response to "A case of 5-FU-related severe toxicity associated with the P.Y186C DPYD variant".
Topics: Antimetabolites, Antineoplastic; Black or African American; Dihydrouracil Dehydrogenase (NADP); Fema | 2014 |
Ultrasound-activated agents comprised of 5FU-bearing nanoparticles bonded to microbubbles inhibit solid tumor growth and improve survival.
Topics: Administration, Intravenous; Animals; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug | 2014 |
Ultrasound-activated agents comprised of 5FU-bearing nanoparticles bonded to microbubbles inhibit solid tumor growth and improve survival.
Topics: Administration, Intravenous; Animals; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug | 2014 |
Enhanced antitumor and reduced toxicity effect of Schisanreae polysaccharide in 5-Fu treated Heps-bearing mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Fluoroura | 2014 |
Enhanced antitumor and reduced toxicity effect of Schisanreae polysaccharide in 5-Fu treated Heps-bearing mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Fluoroura | 2014 |
An 'in-cell trial' to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics.
Topics: Antibodies, Monoclonal; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell L | 2014 |
An 'in-cell trial' to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics.
Topics: Antibodies, Monoclonal; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell L | 2014 |
[Efficacy of AboundTM for hand-foot syndrome caused by capecitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Arginine; Butyrates; Capecitabine; Deoxycytidine; Female; Flu | 2013 |
[Efficacy of AboundTM for hand-foot syndrome caused by capecitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Arginine; Butyrates; Capecitabine; Deoxycytidine; Female; Flu | 2013 |
microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites.
Topics: Animals; Binding Sites; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NAD | 2014 |
microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites.
Topics: Animals; Binding Sites; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NAD | 2014 |
The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circad | 2014 |
The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circad | 2014 |
In vitro anti cancer activity of ethanol extract fractions of Aerva lanata L.
Topics: Acetates; Amaranthaceae; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Ch | 2013 |
In vitro anti cancer activity of ethanol extract fractions of Aerva lanata L.
Topics: Acetates; Amaranthaceae; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Ch | 2013 |
Overcoming multidrug resistance in 2D and 3D culture models by controlled drug chitosan-graft poly(caprolactone)-based nanoparticles.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Chitosan; Delayed-Action Preparations; Drug Resis | 2014 |
Overcoming multidrug resistance in 2D and 3D culture models by controlled drug chitosan-graft poly(caprolactone)-based nanoparticles.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Chitosan; Delayed-Action Preparations; Drug Resis | 2014 |
Curcumin and 5-fluorouracil-loaded, folate- and transferrin-decorated polymeric magnetic nanoformulation: a synergistic cancer therapeutic approach, accelerated by magnetic hyperthermia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line; Combined Modality Therapy; Curcumin; Drug Carr | 2014 |
Curcumin and 5-fluorouracil-loaded, folate- and transferrin-decorated polymeric magnetic nanoformulation: a synergistic cancer therapeutic approach, accelerated by magnetic hyperthermia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line; Combined Modality Therapy; Curcumin; Drug Carr | 2014 |
Niosomes from glucuronic acid-based surfactant as new carriers for cancer therapy: preparation, characterization and biological properties.
Topics: Antineoplastic Agents; Doxorubicin; Drug Carriers; Fluorouracil; Glucuronic Acid; Hemolysis; Humans; | 2014 |
Niosomes from glucuronic acid-based surfactant as new carriers for cancer therapy: preparation, characterization and biological properties.
Topics: Antineoplastic Agents; Doxorubicin; Drug Carriers; Fluorouracil; Glucuronic Acid; Hemolysis; Humans; | 2014 |
Purification of a polysaccharide from Boschniakia rossica and its synergistic antitumor effect combined with 5-Fluorouracil.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ce | 2012 |
Purification of a polysaccharide from Boschniakia rossica and its synergistic antitumor effect combined with 5-Fluorouracil.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ce | 2012 |
Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Capecitabine; Cell Cycle Checkpo | 2015 |
Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Capecitabine; Cell Cycle Checkpo | 2015 |
[Dihydropirymidine dehydrogenase (DPD)--a toxicity marker for 5-fluorouracil?].
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Dihydropyrimidine Dehydrogenase Deficiency; Dihy | 2013 |
[Dihydropirymidine dehydrogenase (DPD)--a toxicity marker for 5-fluorouracil?].
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Dihydropyrimidine Dehydrogenase Deficiency; Dihy | 2013 |
Modulating drug resistance by targeting BCRP/ABCG2 using retrovirus-mediated RNA interference.
Topics: Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Tr | 2014 |
Modulating drug resistance by targeting BCRP/ABCG2 using retrovirus-mediated RNA interference.
Topics: Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Tr | 2014 |
Design and synthesis of new cholesterol-conjugated 5-Fluorouracil: a novel potential delivery system for cancer treatment.
Topics: Animals; Cholesterol; Drug Delivery Systems; Drug Design; Fluorouracil; Humans; Lipoproteins, LDL; M | 2014 |
Design and synthesis of new cholesterol-conjugated 5-Fluorouracil: a novel potential delivery system for cancer treatment.
Topics: Animals; Cholesterol; Drug Delivery Systems; Drug Design; Fluorouracil; Humans; Lipoproteins, LDL; M | 2014 |
Development of a 5-fluorouracil-loaded PLGA microsphere delivery system by a solid-in-oil-in-hydrophilic oil (S/O/hO) novel method for the treatment of tumors.
Topics: Animals; Antimetabolites, Antineoplastic; Delayed-Action Preparations; Drug Compounding; Drug Delive | 2014 |
Development of a 5-fluorouracil-loaded PLGA microsphere delivery system by a solid-in-oil-in-hydrophilic oil (S/O/hO) novel method for the treatment of tumors.
Topics: Animals; Antimetabolites, Antineoplastic; Delayed-Action Preparations; Drug Compounding; Drug Delive | 2014 |
5-Fluorouracil toxicity and dihydropyrimidine dehydrogenase enzyme: implications for practice.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Neoplasms | 2014 |
5-Fluorouracil toxicity and dihydropyrimidine dehydrogenase enzyme: implications for practice.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Neoplasms | 2014 |
Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Female; Fluorouracil; Gastrointesti | 2015 |
Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Female; Fluorouracil; Gastrointesti | 2015 |
Effects of American ginseng on pharmacokinetics of 5-fluorouracil in rats.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Drug Interactions; Fluorouraci | 2015 |
Effects of American ginseng on pharmacokinetics of 5-fluorouracil in rats.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Drug Interactions; Fluorouraci | 2015 |
Extracts and compounds with anti-diabetic complications and anti-cancer activity from Castanea mollissina Blume (Chinese chestnut).
Topics: Aldehyde Reductase; Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Diabete | 2014 |
Extracts and compounds with anti-diabetic complications and anti-cancer activity from Castanea mollissina Blume (Chinese chestnut).
Topics: Aldehyde Reductase; Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Diabete | 2014 |
A polymeric prodrug of 5-fluorouracil-1-acetic acid using a multi-hydroxyl polyethylene glycol derivative as the drug carrier.
Topics: Acetic Acid; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Fluorouracil; Male; Mi | 2014 |
A polymeric prodrug of 5-fluorouracil-1-acetic acid using a multi-hydroxyl polyethylene glycol derivative as the drug carrier.
Topics: Acetic Acid; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Fluorouracil; Male; Mi | 2014 |
Adherence to capecitabine treatment and contributing factors among cancer patients in Malaysia.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Capecitabine; Cross-Sectional Studies; | 2014 |
Adherence to capecitabine treatment and contributing factors among cancer patients in Malaysia.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Capecitabine; Cross-Sectional Studies; | 2014 |
Advancements in the development of HIF-1α-activated protein switches for use in enzyme prodrug therapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Discovery; Escherichia coli; Fluorouracil; Humans; Hyp | 2014 |
Advancements in the development of HIF-1α-activated protein switches for use in enzyme prodrug therapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Discovery; Escherichia coli; Fluorouracil; Humans; Hyp | 2014 |
OVA12, a novel tumor antigen, promotes cancer cell growth and inhibits 5-fluorouracil-induced apoptosis.
Topics: Animals; Antigens, Neoplasm; Apoptosis; Cell Line, Tumor; Cell Proliferation; Female; Fluorouracil; | 2015 |
OVA12, a novel tumor antigen, promotes cancer cell growth and inhibits 5-fluorouracil-induced apoptosis.
Topics: Animals; Antigens, Neoplasm; Apoptosis; Cell Line, Tumor; Cell Proliferation; Female; Fluorouracil; | 2015 |
Hypersensitivity reactions to racemic calcium folinate (leucovorin) during FOLFOX and FOLFIRI chemotherapy administrations.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Hypersen | 2015 |
Hypersensitivity reactions to racemic calcium folinate (leucovorin) during FOLFOX and FOLFIRI chemotherapy administrations.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Hypersen | 2015 |
S-nitrosoglutathione accelerates recovery from 5-fluorouracil-induced oral mucositis.
Topics: Administration, Topical; Animals; Cricetinae; Disease Models, Animal; Fluorouracil; Gene Expression | 2014 |
S-nitrosoglutathione accelerates recovery from 5-fluorouracil-induced oral mucositis.
Topics: Administration, Topical; Animals; Cricetinae; Disease Models, Animal; Fluorouracil; Gene Expression | 2014 |
Fabrication of high specificity hollow mesoporous silica nanoparticles assisted by Eudragit for targeted drug delivery.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Fluorouraci | 2015 |
Fabrication of high specificity hollow mesoporous silica nanoparticles assisted by Eudragit for targeted drug delivery.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Fluorouraci | 2015 |
Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dihydrouracil Dehydrogenase (NADP | 2015 |
Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dihydrouracil Dehydrogenase (NADP | 2015 |
Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Aged; Antineoplastic Combined Chemotherapy Protoco | 2015 |
Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Aged; Antineoplastic Combined Chemotherapy Protoco | 2015 |
Implantable hydrogel embedded dark-gold nanoswitch as a theranostic probe to sense and overcome cancer multidrug resistance.
Topics: Adipose Tissue; Animals; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flu | 2015 |
Implantable hydrogel embedded dark-gold nanoswitch as a theranostic probe to sense and overcome cancer multidrug resistance.
Topics: Adipose Tissue; Animals; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flu | 2015 |
The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination.
Topics: Animals; Apoptosis; Benzophenones; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2015 |
The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination.
Topics: Animals; Apoptosis; Benzophenones; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2015 |
Nanopotentiated combination cancer therapy: Chemotherapeutic and chemosensitizer (2C approach).
Topics: Antineoplastic Agents, Phytogenic; Curcumin; Drug Delivery Systems; Drug Therapy, Combination; Flavo | 2015 |
Nanopotentiated combination cancer therapy: Chemotherapeutic and chemosensitizer (2C approach).
Topics: Antineoplastic Agents, Phytogenic; Curcumin; Drug Delivery Systems; Drug Therapy, Combination; Flavo | 2015 |
Facile synthesis of gold nanorods/hydrogels core/shell nanospheres for pH and near-infrared-light induced release of 5-fluorouracil and chemo-photothermal therapy.
Topics: Acrylamides; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Drug Carrier | 2015 |
Facile synthesis of gold nanorods/hydrogels core/shell nanospheres for pH and near-infrared-light induced release of 5-fluorouracil and chemo-photothermal therapy.
Topics: Acrylamides; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Drug Carrier | 2015 |
Human ACAP2 is a homolog of C. elegans CNT-1 that promotes apoptosis in cancer cells.
Topics: Amino Acid Sequence; Animals; Apoptosis; Caenorhabditis elegans Proteins; Caspases; Cell Line, Tumor | 2015 |
Human ACAP2 is a homolog of C. elegans CNT-1 that promotes apoptosis in cancer cells.
Topics: Amino Acid Sequence; Animals; Apoptosis; Caenorhabditis elegans Proteins; Caspases; Cell Line, Tumor | 2015 |
Local pelvic irradiation modulates Pharmacokinetics of 5-Fluorouracil in the plasma but not in the Lymphatic System.
Topics: Animals; Combined Modality Therapy; Fluorouracil; Humans; Lymphatic System; Male; Neoplasms; Pelvis; | 2015 |
Local pelvic irradiation modulates Pharmacokinetics of 5-Fluorouracil in the plasma but not in the Lymphatic System.
Topics: Animals; Combined Modality Therapy; Fluorouracil; Humans; Lymphatic System; Male; Neoplasms; Pelvis; | 2015 |
Synthesis and in vitro antiproliferative evaluation of novel hybrids from 1,3,4-thiadiazole and benzisoselenazolone.
Topics: Antineoplastic Agents; Azoles; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proli | 2015 |
Synthesis and in vitro antiproliferative evaluation of novel hybrids from 1,3,4-thiadiazole and benzisoselenazolone.
Topics: Antineoplastic Agents; Azoles; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proli | 2015 |
Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dihydrouracil Dehydroge | 2015 |
Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dihydrouracil Dehydroge | 2015 |
Targeting chemotherapy-induced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; C-Reactive Protein; CCAAT-Enhancer-Binding Protein-delta; | 2015 |
Targeting chemotherapy-induced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; C-Reactive Protein; CCAAT-Enhancer-Binding Protein-delta; | 2015 |
Oxytocin evokes a pulsatile PGE2 release from ileum mucosa and is required for repair of intestinal epithelium after injury.
Topics: Animals; Antineoplastic Agents; Calcium; Cyclooxygenase 2; Dextran Sulfate; Dinoprostone; Disease Mo | 2015 |
Oxytocin evokes a pulsatile PGE2 release from ileum mucosa and is required for repair of intestinal epithelium after injury.
Topics: Animals; Antineoplastic Agents; Calcium; Cyclooxygenase 2; Dextran Sulfate; Dinoprostone; Disease Mo | 2015 |
Delimiting Allelic Imbalance of TYMS by Allele-Specific Analysis.
Topics: 3' Untranslated Regions; 5' Untranslated Regions; Adult; Aged; Aged, 80 and over; Alleles; Allelic I | 2015 |
Delimiting Allelic Imbalance of TYMS by Allele-Specific Analysis.
Topics: 3' Untranslated Regions; 5' Untranslated Regions; Adult; Aged; Aged, 80 and over; Alleles; Allelic I | 2015 |
Novel pH sensitive ferrogels as new approach in cancer treatment: Effect of the magnetic field on swelling and drug delivery.
Topics: Drug Carriers; Fluorouracil; Gels; Hydrogen-Ion Concentration; In Vitro Techniques; Magnetics; Neopl | 2015 |
Novel pH sensitive ferrogels as new approach in cancer treatment: Effect of the magnetic field on swelling and drug delivery.
Topics: Drug Carriers; Fluorouracil; Gels; Hydrogen-Ion Concentration; In Vitro Techniques; Magnetics; Neopl | 2015 |
Influence of an elemental diet on 5-fluorouracil-induced morphological changes in the mouse salivary gland and colon.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Colon; Diarrhea; Disease Models, Anim | 2016 |
Influence of an elemental diet on 5-fluorouracil-induced morphological changes in the mouse salivary gland and colon.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Colon; Diarrhea; Disease Models, Anim | 2016 |
Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types.
Topics: Cell Line, Tumor; Cell Survival; Cytosine Deaminase; Drug Resistance, Neoplasm; Fluorouracil; Gene E | 2016 |
Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types.
Topics: Cell Line, Tumor; Cell Survival; Cytosine Deaminase; Drug Resistance, Neoplasm; Fluorouracil; Gene E | 2016 |
Improved Chemotherapeutic Activity by Morus alba Fruits through Immune Response of Toll-Like Receptor 4.
Topics: Adaptor Proteins, Vesicular Transport; Animals; Antineoplastic Agents; Antineoplastic Combined Chemo | 2015 |
Improved Chemotherapeutic Activity by Morus alba Fruits through Immune Response of Toll-Like Receptor 4.
Topics: Adaptor Proteins, Vesicular Transport; Animals; Antineoplastic Agents; Antineoplastic Combined Chemo | 2015 |
CXCL4 mediates tumor regrowth after chemotherapy by suppression of antitumor immunity.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferati | 2015 |
CXCL4 mediates tumor regrowth after chemotherapy by suppression of antitumor immunity.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferati | 2015 |
Culture at a Higher Temperature Mildly Inhibits Cancer Cell Growth but Enhances Chemotherapeutic Effects by Inhibiting Cell-Cell Collaboration.
Topics: Antineoplastic Agents; Cell Communication; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferat | 2015 |
Culture at a Higher Temperature Mildly Inhibits Cancer Cell Growth but Enhances Chemotherapeutic Effects by Inhibiting Cell-Cell Collaboration.
Topics: Antineoplastic Agents; Cell Communication; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferat | 2015 |
Structural studies of UBXN2A and mortalin interaction and the putative role of silenced UBXN2A in preventing response to chemotherapy.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Binding Sites; Cell Line, Tumor; Colonic Neoplasms; Fluo | 2016 |
Structural studies of UBXN2A and mortalin interaction and the putative role of silenced UBXN2A in preventing response to chemotherapy.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Binding Sites; Cell Line, Tumor; Colonic Neoplasms; Fluo | 2016 |
Investigation of Potentially Deleterious Alleles for Response to Cancer Treatment with 5-Fluorouracil.
Topics: Alleles; Antineoplastic Agents; Asian People; Black People; Brazil; Dihydrouracil Dehydrogenase (NAD | 2015 |
Investigation of Potentially Deleterious Alleles for Response to Cancer Treatment with 5-Fluorouracil.
Topics: Alleles; Antineoplastic Agents; Asian People; Black People; Brazil; Dihydrouracil Dehydrogenase (NAD | 2015 |
Novel Morphologic and Genetic Analysis of Cancer Cells in a 3D Microenvironment Identifies STAT3 as a Regulator of Tumor Permeability Barrier Function.
Topics: Animals; Benzoquinones; Cell Line, Tumor; Cell Membrane Permeability; Drug Resistance, Neoplasm; Flu | 2016 |
Novel Morphologic and Genetic Analysis of Cancer Cells in a 3D Microenvironment Identifies STAT3 as a Regulator of Tumor Permeability Barrier Function.
Topics: Animals; Benzoquinones; Cell Line, Tumor; Cell Membrane Permeability; Drug Resistance, Neoplasm; Flu | 2016 |
Low Noncytotoxic Concentrations of 5-Fluorouracil Have No Adverse Effects on Maturation and Function of Bone Marrow-Derived Dendritic Cells in vitro: A Potentially Safe Adjuvant for Dendritic Cell-Based Cancer Therapy.
Topics: Adjuvants, Immunologic; Animals; Antimetabolites, Antineoplastic; Bone Marrow Cells; Cancer Vaccines | 2015 |
Low Noncytotoxic Concentrations of 5-Fluorouracil Have No Adverse Effects on Maturation and Function of Bone Marrow-Derived Dendritic Cells in vitro: A Potentially Safe Adjuvant for Dendritic Cell-Based Cancer Therapy.
Topics: Adjuvants, Immunologic; Animals; Antimetabolites, Antineoplastic; Bone Marrow Cells; Cancer Vaccines | 2015 |
PRX1 knockdown potentiates vitamin K3 toxicity in cancer cells: a potential new therapeutic perspective for an old drug.
Topics: Antineoplastic Agents; Dactinomycin; Daunorubicin; Doxorubicin; Fluorouracil; Gene Knockdown Techniq | 2015 |
PRX1 knockdown potentiates vitamin K3 toxicity in cancer cells: a potential new therapeutic perspective for an old drug.
Topics: Antineoplastic Agents; Dactinomycin; Daunorubicin; Doxorubicin; Fluorouracil; Gene Knockdown Techniq | 2015 |
Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Capecitabine; Chromatography, Liquid; Clinical Tr | 2016 |
Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Capecitabine; Chromatography, Liquid; Clinical Tr | 2016 |
In Vivo Anti-Tumor Activity and Toxicological Evaluations of Perillaldehyde 8,9-Epoxide, a Derivative of Perillyl Alcohol.
Topics: Animals; Antineoplastic Agents; Female; Fluorouracil; Mice; Monoterpenes; Neoplasm Transplantation; | 2016 |
In Vivo Anti-Tumor Activity and Toxicological Evaluations of Perillaldehyde 8,9-Epoxide, a Derivative of Perillyl Alcohol.
Topics: Animals; Antineoplastic Agents; Female; Fluorouracil; Mice; Monoterpenes; Neoplasm Transplantation; | 2016 |
Effect of Polyethylene Glycol on Properties and Drug Encapsulation-Release Performance of Biodegradable/Cytocompatible Agarose-Polyethylene Glycol-Polycaprolactone Amphiphilic Co-Network Gels.
Topics: Drug Carriers; Drug Delivery Systems; Drug Liberation; Ethylene Glycols; Fluorouracil; Humans; Hydro | 2016 |
Effect of Polyethylene Glycol on Properties and Drug Encapsulation-Release Performance of Biodegradable/Cytocompatible Agarose-Polyethylene Glycol-Polycaprolactone Amphiphilic Co-Network Gels.
Topics: Drug Carriers; Drug Delivery Systems; Drug Liberation; Ethylene Glycols; Fluorouracil; Humans; Hydro | 2016 |
Moderate intensity static magnetic fields affect mitotic spindles and increase the antitumor efficacy of 5-FU and Taxol.
Topics: Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Fluorouracil; Humans; Magnetic F | 2016 |
Moderate intensity static magnetic fields affect mitotic spindles and increase the antitumor efficacy of 5-FU and Taxol.
Topics: Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Fluorouracil; Humans; Magnetic F | 2016 |
Synergistic anti-tumor activity through combinational intratumoral injection of an in-situ injectable drug depot.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ce | 2016 |
Synergistic anti-tumor activity through combinational intratumoral injection of an in-situ injectable drug depot.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ce | 2016 |
Self-assembly of a 5-fluorouracil-dipeptide hydrogel.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Dipep | 2016 |
Self-assembly of a 5-fluorouracil-dipeptide hydrogel.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Dipep | 2016 |
PKM1 is involved in resistance to anti-cancer drugs.
Topics: Antineoplastic Agents; Apoptosis; Carrier Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Flu | 2016 |
PKM1 is involved in resistance to anti-cancer drugs.
Topics: Antineoplastic Agents; Apoptosis; Carrier Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Flu | 2016 |
DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cell Line; Cell Line, Tumor; | 2016 |
DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cell Line; Cell Line, Tumor; | 2016 |
Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients.
Topics: Antineoplastic Agents; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Genot | 2016 |
Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients.
Topics: Antineoplastic Agents; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Genot | 2016 |
Mini-pillar array for hydrogel-supported 3D culture and high-content histologic analysis of human tumor spheroids.
Topics: Alginates; Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Collagen; Drug Combinat | 2016 |
Mini-pillar array for hydrogel-supported 3D culture and high-content histologic analysis of human tumor spheroids.
Topics: Alginates; Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Collagen; Drug Combinat | 2016 |
Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2016 |
Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2016 |
Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Fluorouracil; Gene Transfer Techniques; Genetic V | 2016 |
Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Fluorouracil; Gene Transfer Techniques; Genetic V | 2016 |
Current insights into the impact of dihydropyrimidine dehydrogenase deficiency in patients receiving treatment with 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2016 |
Current insights into the impact of dihydropyrimidine dehydrogenase deficiency in patients receiving treatment with 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2016 |
Platinum based radiochemotherapies: Free radical mechanisms and radiotherapy sensitizers.
Topics: Antineoplastic Agents; Carboplatin; Chemoradiotherapy; Cisplatin; DNA Adducts; DNA Damage; Drug Syne | 2016 |
Platinum based radiochemotherapies: Free radical mechanisms and radiotherapy sensitizers.
Topics: Antineoplastic Agents; Carboplatin; Chemoradiotherapy; Cisplatin; DNA Adducts; DNA Damage; Drug Syne | 2016 |
Influence of Chemotherapy on the Antioxidant Status of Human Skin.
Topics: Adult; Aged; Antineoplastic Agents; Antioxidants; Carotenoids; Docetaxel; Doxorubicin; Female; Fluor | 2016 |
Influence of Chemotherapy on the Antioxidant Status of Human Skin.
Topics: Adult; Aged; Antineoplastic Agents; Antioxidants; Carotenoids; Docetaxel; Doxorubicin; Female; Fluor | 2016 |
Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2016 |
Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2016 |
Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling.
Topics: Biomarkers, Tumor; Camptothecin; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Gene Expres | 2016 |
Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling.
Topics: Biomarkers, Tumor; Camptothecin; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Gene Expres | 2016 |
Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dih | 2016 |
Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dih | 2016 |
Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.
Topics: Acetates; Antimetabolites, Antineoplastic; Capecitabine; Drug Overdose; Female; Fluorouracil; Humans | 2017 |
Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.
Topics: Acetates; Antimetabolites, Antineoplastic; Capecitabine; Drug Overdose; Female; Fluorouracil; Humans | 2017 |
Response to 'Comment on 'The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome''.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Veno-Occ | 2016 |
Response to 'Comment on 'The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome''.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Veno-Occ | 2016 |
Comment on 'The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome'.
Topics: Fluorouracil; Hepatic Veno-Occlusive Disease; Humans; Leucovorin; Neoplasms; Organoplatinum Compound | 2016 |
Comment on 'The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome'.
Topics: Fluorouracil; Hepatic Veno-Occlusive Disease; Humans; Leucovorin; Neoplasms; Organoplatinum Compound | 2016 |
A morphometric study of the protective effect of cryotherapy on oral mucositis in cancer patients treated with 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cryotherapy; Female; Fluorouracil; Humans; Male; Middl | 2016 |
A morphometric study of the protective effect of cryotherapy on oral mucositis in cancer patients treated with 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cryotherapy; Female; Fluorouracil; Humans; Male; Middl | 2016 |
Potential Benefits of Oral Cryotherapy for Chemotherapy-Induced Mucositis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cryotherapy; Female; Fluorouracil; Humans; Ic | 2016 |
Potential Benefits of Oral Cryotherapy for Chemotherapy-Induced Mucositis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cryotherapy; Female; Fluorouracil; Humans; Ic | 2016 |
Oral cryotherapy reduced oral mucositis in patients having cancer treatments.
Topics: Cryosurgery; Cryotherapy; Fluorouracil; Humans; Neoplasms; Stomatitis; United States | 2016 |
Oral cryotherapy reduced oral mucositis in patients having cancer treatments.
Topics: Cryosurgery; Cryotherapy; Fluorouracil; Humans; Neoplasms; Stomatitis; United States | 2016 |
Design, synthesis and biological evaluation of hybrids of β-carboline and salicylic acid as potential anticancer and apoptosis inducing agents.
Topics: Antineoplastic Agents; bcl-2-Associated X Protein; Carbolines; Caspase 9; Cell Line, Tumor; Cell Sur | 2016 |
Design, synthesis and biological evaluation of hybrids of β-carboline and salicylic acid as potential anticancer and apoptosis inducing agents.
Topics: Antineoplastic Agents; bcl-2-Associated X Protein; Carbolines; Caspase 9; Cell Line, Tumor; Cell Sur | 2016 |
Capillary electrophoresis with online stacking in combination with AgNPs@MCM-41 reinforced hollow fiber solid-liquid phase microextraction for quantitative analysis of Capecitabine and its main metabolite 5-Fluorouracil in plasma samples isolated from can
Topics: Antimetabolites, Antineoplastic; Electrophoresis, Capillary; Fluorouracil; Humans; Limit of Detectio | 2017 |
Capillary electrophoresis with online stacking in combination with AgNPs@MCM-41 reinforced hollow fiber solid-liquid phase microextraction for quantitative analysis of Capecitabine and its main metabolite 5-Fluorouracil in plasma samples isolated from can
Topics: Antimetabolites, Antineoplastic; Electrophoresis, Capillary; Fluorouracil; Humans; Limit of Detectio | 2017 |
Alpha- and Beta-Cyclodextrin Inclusion Complexes with 5-Fluorouracil: Characterization and Cytotoxic Activity Evaluation.
Topics: alpha-Cyclodextrins; beta-Cyclodextrins; Caco-2 Cells; Fluorouracil; Hep G2 Cells; Humans; MCF-7 Cel | 2016 |
Alpha- and Beta-Cyclodextrin Inclusion Complexes with 5-Fluorouracil: Characterization and Cytotoxic Activity Evaluation.
Topics: alpha-Cyclodextrins; beta-Cyclodextrins; Caco-2 Cells; Fluorouracil; Hep G2 Cells; Humans; MCF-7 Cel | 2016 |
Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dih | 2017 |
Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dih | 2017 |
A rapid albumin-binding 5-fluorouracil prodrug with a prolonged circulation time and enhanced antitumor activity.
Topics: Animals; Antineoplastic Agents; Cattle; Female; Fluorouracil; Half-Life; Mice; Models, Molecular; Ne | 2017 |
A rapid albumin-binding 5-fluorouracil prodrug with a prolonged circulation time and enhanced antitumor activity.
Topics: Animals; Antineoplastic Agents; Cattle; Female; Fluorouracil; Half-Life; Mice; Models, Molecular; Ne | 2017 |
Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity.
Topics: 20-Hydroxysteroid Dehydrogenases; 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Memb | 2017 |
Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity.
Topics: 20-Hydroxysteroid Dehydrogenases; 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Memb | 2017 |
Steroidal[17,16-d]pyrimidines derived from dehydroepiandrosterone: A convenient synthesis, antiproliferation activity, structure-activity relationships, and role of heterocyclic moiety.
Topics: Antineoplastic Agents; Cell Proliferation; Dehydroepiandrosterone; Drug Screening Assays, Antitumor; | 2017 |
Steroidal[17,16-d]pyrimidines derived from dehydroepiandrosterone: A convenient synthesis, antiproliferation activity, structure-activity relationships, and role of heterocyclic moiety.
Topics: Antineoplastic Agents; Cell Proliferation; Dehydroepiandrosterone; Drug Screening Assays, Antitumor; | 2017 |
RGO/AuNR/HA-5FU nanocomposite with multi-stage release behavior and efficient antitumor activity for synergistic therapy.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Delivery Systems; Durapatite; Fluor | 2017 |
RGO/AuNR/HA-5FU nanocomposite with multi-stage release behavior and efficient antitumor activity for synergistic therapy.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Delivery Systems; Durapatite; Fluor | 2017 |
[Outpatient chemotherapy and oncology network : Onco Pays-de-la-Loire experiment].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Deoxycytidine; Fem | 2008 |
[Outpatient chemotherapy and oncology network : Onco Pays-de-la-Loire experiment].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Deoxycytidine; Fem | 2008 |
Silencing of keratinocyte growth factor receptor restores 5-fluorouracil and tamoxifen efficacy on responsive cancer cells.
Topics: Antineoplastic Agents; Base Sequence; Cell Line, Tumor; DNA Primers; Drug Resistance, Neoplasm; Fibr | 2008 |
Silencing of keratinocyte growth factor receptor restores 5-fluorouracil and tamoxifen efficacy on responsive cancer cells.
Topics: Antineoplastic Agents; Base Sequence; Cell Line, Tumor; DNA Primers; Drug Resistance, Neoplasm; Fibr | 2008 |
Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene.
Topics: Antineoplastic Agents; Area Under Curve; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil D | 2008 |
Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene.
Topics: Antineoplastic Agents; Area Under Curve; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil D | 2008 |
Altered dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil containing chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); Fem | 2008 |
Altered dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil containing chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); Fem | 2008 |
Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targeting.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Delivery Systems; | 2008 |
Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targeting.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Delivery Systems; | 2008 |
FLEX data, KRAS and ERCC1 testing in oncology.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
FLEX data, KRAS and ERCC1 testing in oncology.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Thymidylate synthase and 5-fluorouracil: a cautionary tale.
Topics: Antimetabolites, Antineoplastic; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation | 2008 |
Thymidylate synthase and 5-fluorouracil: a cautionary tale.
Topics: Antimetabolites, Antineoplastic; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation | 2008 |
Bisphosphonates activate the 5-fluorouracil/uracil phosphoribosyltransferase activity present in Saccharomyces cerevisiae cell extracts: implications for tumor treatments.
Topics: Antimetabolites, Antineoplastic; Bone Density Conservation Agents; Diphosphonates; Fluorouracil; Neo | 2008 |
Bisphosphonates activate the 5-fluorouracil/uracil phosphoribosyltransferase activity present in Saccharomyces cerevisiae cell extracts: implications for tumor treatments.
Topics: Antimetabolites, Antineoplastic; Bone Density Conservation Agents; Diphosphonates; Fluorouracil; Neo | 2008 |
An anti-transferrin receptor antibody enhanced the growth inhibitory effects of chemotherapeutic drugs on human non-hematopoietic tumor cells.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell | 2008 |
An anti-transferrin receptor antibody enhanced the growth inhibitory effects of chemotherapeutic drugs on human non-hematopoietic tumor cells.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell | 2008 |
Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); DNA Methylation; Fluorour | 2008 |
Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); DNA Methylation; Fluorour | 2008 |
Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice.
Topics: Animals; Antineoplastic Agents; Dendrimers; Drug Carriers; Female; Fluorouracil; Folic Acid; Hemolys | 2008 |
Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice.
Topics: Animals; Antineoplastic Agents; Dendrimers; Drug Carriers; Female; Fluorouracil; Folic Acid; Hemolys | 2008 |
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Leukocyte | 2009 |
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Leukocyte | 2009 |
[Feasibility of peripheral vein during FOLFOX/FOLFIRI chemotherapy through peripheral venous system].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Feasibility Studies; Fema | 2008 |
[Feasibility of peripheral vein during FOLFOX/FOLFIRI chemotherapy through peripheral venous system].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Feasibility Studies; Fema | 2008 |
Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis.
Topics: Antineoplastic Agents; Dihydrouracil Dehydrogenase (NADP); Enzyme-Linked Immunosorbent Assay; Fluoro | 2008 |
Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis.
Topics: Antineoplastic Agents; Dihydrouracil Dehydrogenase (NADP); Enzyme-Linked Immunosorbent Assay; Fluoro | 2008 |
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; History, 20th Century; Hi | 2009 |
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; History, 20th Century; Hi | 2009 |
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; History, 20th Century; Hi | 2009 |
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; History, 20th Century; Hi | 2009 |
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; History, 20th Century; Hi | 2009 |
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; History, 20th Century; Hi | 2009 |
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; History, 20th Century; Hi | 2009 |
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; History, 20th Century; Hi | 2009 |
[Report from the 44th Congress of the American Society of Clinical Oncology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms | 2008 |
[Report from the 44th Congress of the American Society of Clinical Oncology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms | 2008 |
Early tumor drug pharmacokinetics is influenced by tumor perfusion but not plasma drug exposure.
Topics: Acridines; Antineoplastic Agents; Area Under Curve; Fluorouracil; Humans; Neoplasms; Solubility | 2008 |
Early tumor drug pharmacokinetics is influenced by tumor perfusion but not plasma drug exposure.
Topics: Acridines; Antineoplastic Agents; Area Under Curve; Fluorouracil; Humans; Neoplasms; Solubility | 2008 |
Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Case-Control | 2008 |
Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Case-Control | 2008 |
Monitoring of tumor response to chemotherapy in vivo by a novel small-molecule detector of apoptosis.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkyla | 2009 |
Monitoring of tumor response to chemotherapy in vivo by a novel small-molecule detector of apoptosis.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkyla | 2009 |
Mutational inhibition of c-Myb or p300 ameliorates treatment-induced thrombocytopenia.
Topics: Animals; Antineoplastic Agents; bcl-X Protein; Bone Marrow Transplantation; Cells, Cultured; Cytopro | 2009 |
Mutational inhibition of c-Myb or p300 ameliorates treatment-induced thrombocytopenia.
Topics: Animals; Antineoplastic Agents; bcl-X Protein; Bone Marrow Transplantation; Cells, Cultured; Cytopro | 2009 |
Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Exons; Female; Flu | 2009 |
Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Exons; Female; Flu | 2009 |
Grape seed extract protects IEC-6 cells from chemotherapy-induced cytotoxicity and improves parameters of small intestinal mucositis in rats with experimentally-induced mucositis.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line; Cell Survival; Female; Fluorouracil; Humans; In | 2009 |
Grape seed extract protects IEC-6 cells from chemotherapy-induced cytotoxicity and improves parameters of small intestinal mucositis in rats with experimentally-induced mucositis.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line; Cell Survival; Female; Fluorouracil; Humans; In | 2009 |
The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells.
Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Cell Survival; DNA-Binding P | 2009 |
The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells.
Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Cell Survival; DNA-Binding P | 2009 |
Risk of venous thromboembolism with bevacizumab in cancer patients.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
Risk of venous thromboembolism with bevacizumab in cancer patients.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
Heidelberger symposium on the 50th anniversary of fluoropyrimidines.
Topics: Antineoplastic Agents; Fluorouracil; Humans; Neoplasms | 2009 |
Heidelberger symposium on the 50th anniversary of fluoropyrimidines.
Topics: Antineoplastic Agents; Fluorouracil; Humans; Neoplasms | 2009 |
Pharmacokinetics of 5-fluorouracil in elderly Japanese patients with cancer treated with S-1 (a combination of tegafur and dihydropyrimidine dehydrogenase inhibitor 5-chloro-2,4-dihydroxypyridine).
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asian People; | 2009 |
Pharmacokinetics of 5-fluorouracil in elderly Japanese patients with cancer treated with S-1 (a combination of tegafur and dihydropyrimidine dehydrogenase inhibitor 5-chloro-2,4-dihydroxypyridine).
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asian People; | 2009 |
Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Cycle; Cell Death; Cell Line, Tumor; DNA Damage; DNA | 2009 |
Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Cycle; Cell Death; Cell Line, Tumor; DNA Damage; DNA | 2009 |
XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center.
Topics: Antineoplastic Agents; Fluorouracil; Humans; Neoplasms | 2009 |
XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center.
Topics: Antineoplastic Agents; Fluorouracil; Humans; Neoplasms | 2009 |
Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Cell Cycle; | 2009 |
Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Cell Cycle; | 2009 |
Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy.
Topics: Adenine; Cell Death; Cell Line; Coculture Techniques; Deoxyadenosines; Drug Screening Assays, Antitu | 2009 |
Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy.
Topics: Adenine; Cell Death; Cell Line; Coculture Techniques; Deoxyadenosines; Drug Screening Assays, Antitu | 2009 |
Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2009 |
Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2009 |
Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2010 |
Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2010 |
Allergic reactions to oxaliplatin in a single institute in Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Hypersensitivity; Female; Fluorouracil; H | 2009 |
Allergic reactions to oxaliplatin in a single institute in Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Hypersensitivity; Female; Fluorouracil; H | 2009 |
Tumor-targeted Salmonella typhimurium overexpressing cytosine deaminase: a novel, tumor-selective therapy.
Topics: Animals; Chromosomes, Bacterial; Cloning, Molecular; Cytosine Deaminase; Escherichia coli; Female; F | 2009 |
Tumor-targeted Salmonella typhimurium overexpressing cytosine deaminase: a novel, tumor-selective therapy.
Topics: Animals; Chromosomes, Bacterial; Cloning, Molecular; Cytosine Deaminase; Escherichia coli; Female; F | 2009 |
Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Combined Modality Therapy; Disease Models, Animal; Flu | 2009 |
Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Combined Modality Therapy; Disease Models, Animal; Flu | 2009 |
Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients.
Topics: Adult; Aged; Alleles; Amidohydrolases; Antimetabolites, Antineoplastic; Base Sequence; Chi-Square Di | 2010 |
Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients.
Topics: Adult; Aged; Alleles; Amidohydrolases; Antimetabolites, Antineoplastic; Base Sequence; Chi-Square Di | 2010 |
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Count; Cell | 2010 |
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Count; Cell | 2010 |
In vivo antitumor efficacy of interleukin-21 in combination with chemotherapeutics.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell L | 2009 |
In vivo antitumor efficacy of interleukin-21 in combination with chemotherapeutics.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell L | 2009 |
Pharmacology, pharmacogenetics, and pharmacoepidemiology: three ps of individualized therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Evidence-Based Medicine; | 2009 |
Pharmacology, pharmacogenetics, and pharmacoepidemiology: three ps of individualized therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Evidence-Based Medicine; | 2009 |
Variations in the content of CD34+ cells in the peripheral blood of cancer patients receiving out-patient chemotherapy.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1999 |
Variations in the content of CD34+ cells in the peripheral blood of cancer patients receiving out-patient chemotherapy.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1999 |
Minocycline attenuates 5-fluorouracil-induced small intestinal mucositis in mouse model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Apoptosis; Cell P | 2009 |
Minocycline attenuates 5-fluorouracil-induced small intestinal mucositis in mouse model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Apoptosis; Cell P | 2009 |
The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogena | 2010 |
The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogena | 2010 |
Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.
Topics: Aged; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gen | 2010 |
Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.
Topics: Aged; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gen | 2010 |
Call for clarity in the reporting of benefit associated with anticancer therapies.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Editorial Policies; Fluorouracil; Ge | 2009 |
Call for clarity in the reporting of benefit associated with anticancer therapies.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Editorial Policies; Fluorouracil; Ge | 2009 |
JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Fluorouracil; Hist | 2009 |
JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Fluorouracil; Hist | 2009 |
Iron/ethylcellulose (core/shell) nanoplatform loaded with 5-fluorouracil for cancer targeting.
Topics: Antimetabolites, Antineoplastic; Biocompatible Materials; Cellulose; Drug Delivery Systems; Fluorour | 2010 |
Iron/ethylcellulose (core/shell) nanoplatform loaded with 5-fluorouracil for cancer targeting.
Topics: Antimetabolites, Antineoplastic; Biocompatible Materials; Cellulose; Drug Delivery Systems; Fluorour | 2010 |
Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Col | 2010 |
Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Col | 2010 |
Investigation of IVS14 + 1G > A polymorphism of DPYD gene in a group of Bosnian patients treated with 5-Fluorouracil and capecitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bosnia and Herzegovina; Dihydrouracil Dehydrogenase (N | 2010 |
Investigation of IVS14 + 1G > A polymorphism of DPYD gene in a group of Bosnian patients treated with 5-Fluorouracil and capecitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bosnia and Herzegovina; Dihydrouracil Dehydrogenase (N | 2010 |
A breast cancer prognostic signature predicts clinical outcomes in multiple tumor types.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Brea | 2010 |
A breast cancer prognostic signature predicts clinical outcomes in multiple tumor types.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Brea | 2010 |
[mRNA quantification. The next challenge in routine diagnostics].
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2010 |
[mRNA quantification. The next challenge in routine diagnostics].
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2010 |
Phase I studies of drug combinations.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2010 |
Phase I studies of drug combinations.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2010 |
Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy | 2010 |
Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy | 2010 |
Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Proto | 2010 |
Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Proto | 2010 |
Technical evaluation of a new sterile medical device to improve anticancer chemotherapy administration.
Topics: Antineoplastic Agents; Cytotoxins; Fluorouracil; Humans; Infusions, Intravenous; Neoplasms; Oncology | 2010 |
Technical evaluation of a new sterile medical device to improve anticancer chemotherapy administration.
Topics: Antineoplastic Agents; Cytotoxins; Fluorouracil; Humans; Infusions, Intravenous; Neoplasms; Oncology | 2010 |
Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy.
Topics: Animals; Biological Availability; Body Weight; Cell Survival; Cholesterol; DNA-Binding Proteins; Dru | 2011 |
Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy.
Topics: Animals; Biological Availability; Body Weight; Cell Survival; Cholesterol; DNA-Binding Proteins; Dru | 2011 |
Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography-tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity.
Topics: Antimetabolites, Antineoplastic; Biotransformation; Chromatography, High Pressure Liquid; Dihydropyr | 2011 |
Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography-tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity.
Topics: Antimetabolites, Antineoplastic; Biotransformation; Chromatography, High Pressure Liquid; Dihydropyr | 2011 |
Pharmacogenetic testing to predict serious toxicity from 5-fluorouracil (5-FU) for patients administered 5-FU-based chemotherapy for cancer.
Topics: Antimetabolites, Antineoplastic; Blue Cross Blue Shield Insurance Plans; Cohort Studies; Dihydrourac | 2010 |
Pharmacogenetic testing to predict serious toxicity from 5-fluorouracil (5-FU) for patients administered 5-FU-based chemotherapy for cancer.
Topics: Antimetabolites, Antineoplastic; Blue Cross Blue Shield Insurance Plans; Cohort Studies; Dihydrourac | 2010 |
[Application of non-steroidal anti-inflammatory drugs to enhance 5-fluorouracil efficacy in experimental systems].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase | 2010 |
[Application of non-steroidal anti-inflammatory drugs to enhance 5-fluorouracil efficacy in experimental systems].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase | 2010 |
Measurement of 5-FU plasma levels in patients with advanced cancer: correct approach to practical procedures is essential.
Topics: Area Under Curve; Female; Fluorouracil; Humans; Neoplasm Staging; Neoplasms | 2011 |
Measurement of 5-FU plasma levels in patients with advanced cancer: correct approach to practical procedures is essential.
Topics: Area Under Curve; Female; Fluorouracil; Humans; Neoplasm Staging; Neoplasms | 2011 |
Relationship between gene expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in primary cancer cells isolated from malignant ascites.
Topics: Antimetabolites, Antineoplastic; Ascites; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; | 2011 |
Relationship between gene expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in primary cancer cells isolated from malignant ascites.
Topics: Antimetabolites, Antineoplastic; Ascites; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; | 2011 |
Effect of green tea on pharmacokinetics of 5-fluorouracil in rats and pharmacodynamics in human cell lines in vitro.
Topics: Animals; Antimetabolites, Antineoplastic; Area Under Curve; Camellia sinensis; Catechin; Cell Line, | 2011 |
Effect of green tea on pharmacokinetics of 5-fluorouracil in rats and pharmacodynamics in human cell lines in vitro.
Topics: Animals; Antimetabolites, Antineoplastic; Area Under Curve; Camellia sinensis; Catechin; Cell Line, | 2011 |
Interleukin 32 promotes hematopoietic progenitor expansion and attenuates bone marrow cytotoxicity.
Topics: Animals; Apoptosis; Bone Marrow Cells; Cell Communication; Cell Growth Processes; Cell Survival; Cel | 2011 |
Interleukin 32 promotes hematopoietic progenitor expansion and attenuates bone marrow cytotoxicity.
Topics: Animals; Apoptosis; Bone Marrow Cells; Cell Communication; Cell Growth Processes; Cell Survival; Cel | 2011 |
APEX microarray panel for genotyping polymorphisms in cancer chemotherapy and estimation frequencies in a Slovak population.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Camptothecin; Drug Resistance, Neoplasm; Fluorou | 2011 |
APEX microarray panel for genotyping polymorphisms in cancer chemotherapy and estimation frequencies in a Slovak population.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Camptothecin; Drug Resistance, Neoplasm; Fluorou | 2011 |
5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases.
Topics: Aged; Antimetabolites, Antineoplastic; Brain; Dihydropyrimidine Dehydrogenase Deficiency; Electroenc | 2011 |
5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases.
Topics: Aged; Antimetabolites, Antineoplastic; Brain; Dihydropyrimidine Dehydrogenase Deficiency; Electroenc | 2011 |
Courage, collaboration, complexity and chemotherapy safety: the view from the sharp end.
Topics: Alberta; Antineoplastic Agents; Community Participation; Drug Overdose; Female; Fluorouracil; Humans | 2011 |
Courage, collaboration, complexity and chemotherapy safety: the view from the sharp end.
Topics: Alberta; Antineoplastic Agents; Community Participation; Drug Overdose; Female; Fluorouracil; Humans | 2011 |
[Therapeutic adherence to oral cancer therapy and interdisciplinary management].
Topics: Adenocarcinoma; Administration, Oral; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protoco | 2011 |
[Therapeutic adherence to oral cancer therapy and interdisciplinary management].
Topics: Adenocarcinoma; Administration, Oral; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protoco | 2011 |
Novel anticancer polymeric conjugates of activated nucleoside analogues.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cholesterol; Female; Fluorouracil; Human | 2011 |
Novel anticancer polymeric conjugates of activated nucleoside analogues.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cholesterol; Female; Fluorouracil; Human | 2011 |
A novel pH-sensitive (±)-α-tocopherol-5-fluorouracil adduct with antioxidant and anticancer properties.
Topics: Antineoplastic Agents; Antioxidants; Binding Sites; Cell Proliferation; Chemoprevention; Computer Si | 2011 |
A novel pH-sensitive (±)-α-tocopherol-5-fluorouracil adduct with antioxidant and anticancer properties.
Topics: Antineoplastic Agents; Antioxidants; Binding Sites; Cell Proliferation; Chemoprevention; Computer Si | 2011 |
Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Deoxycytidine; Drug Evalua | 2011 |
Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Deoxycytidine; Drug Evalua | 2011 |
Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Capecitabine; Deoxycytidine; Fluorouracil; | 2012 |
Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Capecitabine; Deoxycytidine; Fluorouracil; | 2012 |
Clinical and electrocardiography changes in patients treated with capecitabine.
Topics: Capecitabine; Cardiovascular Diseases; Deoxycytidine; Electrocardiography; Female; Fluorouracil; Hum | 2011 |
Clinical and electrocardiography changes in patients treated with capecitabine.
Topics: Capecitabine; Cardiovascular Diseases; Deoxycytidine; Electrocardiography; Female; Fluorouracil; Hum | 2011 |
Anticancer activity of an extract from needles and twigs of Taxus cuspidata and its synergistic effect as a cocktail with 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Drug Synergism; Fluorouraci | 2011 |
Anticancer activity of an extract from needles and twigs of Taxus cuspidata and its synergistic effect as a cocktail with 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Drug Synergism; Fluorouraci | 2011 |
Preparation and characterization of 5-fluorouracil pH-sensitive niosome and its tumor-targeted evaluation: in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Chemistry, Pharmaceutical; Cholesterol E | 2012 |
Preparation and characterization of 5-fluorouracil pH-sensitive niosome and its tumor-targeted evaluation: in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Chemistry, Pharmaceutical; Cholesterol E | 2012 |
Variability in fluorouracil exposure during continuous intravenous infusion.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Body Surface Area; Dose-Response Relationship, Dr | 2012 |
Variability in fluorouracil exposure during continuous intravenous infusion.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Body Surface Area; Dose-Response Relationship, Dr | 2012 |
Mobile health for drug dose optimisation.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Blood Glucose Self-Monitoring; Capecitabine; | 2011 |
Mobile health for drug dose optimisation.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Blood Glucose Self-Monitoring; Capecitabine; | 2011 |
Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects.
Topics: Animals; Aorta; Cell Line, Tumor; Cell Proliferation; Female; Fluorouracil; Human Umbilical Vein End | 2012 |
Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects.
Topics: Animals; Aorta; Cell Line, Tumor; Cell Proliferation; Female; Fluorouracil; Human Umbilical Vein End | 2012 |
Association and correlation of different chemotherapeutic regimens and doses with onset and severity of anemia among solid cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Association and correlation of different chemotherapeutic regimens and doses with onset and severity of anemia among solid cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bayes Theorem; Biotransformation; Dihydropyrimidine De | 2012 |
Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bayes Theorem; Biotransformation; Dihydropyrimidine De | 2012 |
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Tria | 2012 |
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Tria | 2012 |
A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL/min) and end stage renal disease on hemodialysis.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Creatinine; Deoxycytidine; D | 2012 |
A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL/min) and end stage renal disease on hemodialysis.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Creatinine; Deoxycytidine; D | 2012 |
Double-input compartmental modeling and spectral analysis for the quantification of positron emission tomography data in oncology.
Topics: Dideoxynucleosides; Fluorouracil; Humans; Kinetics; Models, Biological; Neoplasms; Positron-Emission | 2012 |
Double-input compartmental modeling and spectral analysis for the quantification of positron emission tomography data in oncology.
Topics: Dideoxynucleosides; Fluorouracil; Humans; Kinetics; Models, Biological; Neoplasms; Positron-Emission | 2012 |
Docetaxel and 5-fluorouracil induce human p53 tumor suppressor gene transcription via a short sequence at core promoter element.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport | 2012 |
Docetaxel and 5-fluorouracil induce human p53 tumor suppressor gene transcription via a short sequence at core promoter element.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport | 2012 |
Cdt1 is differentially targeted for degradation by anticancer chemotherapeutic drugs.
Topics: Antineoplastic Agents; Cell Cycle Proteins; Cisplatin; Doxorubicin; Etoposide; Fluorouracil; HeLa Ce | 2012 |
Cdt1 is differentially targeted for degradation by anticancer chemotherapeutic drugs.
Topics: Antineoplastic Agents; Cell Cycle Proteins; Cisplatin; Doxorubicin; Etoposide; Fluorouracil; HeLa Ce | 2012 |
Folate-conjugated β-cyclodextrin from click chemistry strategy and for tumor-targeted drug delivery.
Topics: Antimetabolites, Antineoplastic; beta-Cyclodextrins; Cell Line, Tumor; Click Chemistry; Drug Carrier | 2012 |
Folate-conjugated β-cyclodextrin from click chemistry strategy and for tumor-targeted drug delivery.
Topics: Antimetabolites, Antineoplastic; beta-Cyclodextrins; Cell Line, Tumor; Click Chemistry; Drug Carrier | 2012 |
Development of a novel probe sonication assisted enhanced loading of 5-FU in SPION encapsulated pectin nanocarriers for magnetic targeted drug delivery system.
Topics: Antimetabolites, Antineoplastic; Body Fluids; Cell Line, Tumor; Delayed-Action Preparations; Drug Ca | 2012 |
Development of a novel probe sonication assisted enhanced loading of 5-FU in SPION encapsulated pectin nanocarriers for magnetic targeted drug delivery system.
Topics: Antimetabolites, Antineoplastic; Body Fluids; Cell Line, Tumor; Delayed-Action Preparations; Drug Ca | 2012 |
Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camp | 2013 |
Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camp | 2013 |
Adenovirus KH901 promotes 5-FU antitumor efficacy and S phase in LoVo cells.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; bcl-2-Associated X Protein; Blotting, Western; Cell L | 2012 |
Adenovirus KH901 promotes 5-FU antitumor efficacy and S phase in LoVo cells.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; bcl-2-Associated X Protein; Blotting, Western; Cell L | 2012 |
The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells.
Topics: Adenocarcinoma; Bone Neoplasms; Breast Neoplasms; Cell Line; Cytokines; DNA Damage; DNA, Neoplasm; D | 2012 |
The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells.
Topics: Adenocarcinoma; Bone Neoplasms; Breast Neoplasms; Cell Line; Cytokines; DNA Damage; DNA, Neoplasm; D | 2012 |
Preparation and characterization of 5-fluorouracil-loaded PLLA-PEG/PEG nanoparticles by a novel supercritical CO2 technique.
Topics: Animals; Antimetabolites, Antineoplastic; Carbon Dioxide; Drug Carriers; Fluorouracil; Lactates; Mal | 2012 |
Preparation and characterization of 5-fluorouracil-loaded PLLA-PEG/PEG nanoparticles by a novel supercritical CO2 technique.
Topics: Animals; Antimetabolites, Antineoplastic; Carbon Dioxide; Drug Carriers; Fluorouracil; Lactates; Mal | 2012 |
A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bradycardia; | 2012 |
A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bradycardia; | 2012 |
Hypersensitivity reactions to oxaliplatin: clinical features and risk factors in Koreans.
Topics: Aged; Anaphylaxis; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycy | 2012 |
Hypersensitivity reactions to oxaliplatin: clinical features and risk factors in Koreans.
Topics: Aged; Anaphylaxis; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycy | 2012 |
Increasing the therapeutic index of 5-fluorouracil and 6-thioguanine by targeting loss of MTAP in tumor cells.
Topics: Adenosine; Animals; Cell Line; Cell Line, Tumor; Disease Models, Animal; Fibrosarcoma; Fluorouracil; | 2012 |
Increasing the therapeutic index of 5-fluorouracil and 6-thioguanine by targeting loss of MTAP in tumor cells.
Topics: Adenosine; Animals; Cell Line; Cell Line, Tumor; Disease Models, Animal; Fibrosarcoma; Fluorouracil; | 2012 |
5-Fluorouracil encapsulated HA/PLGA composite microspheres for cancer therapy.
Topics: Antimetabolites, Antineoplastic; Durapatite; Fluorouracil; Lactic Acid; Microscopy, Electron, Scanni | 2012 |
5-Fluorouracil encapsulated HA/PLGA composite microspheres for cancer therapy.
Topics: Antimetabolites, Antineoplastic; Durapatite; Fluorouracil; Lactic Acid; Microscopy, Electron, Scanni | 2012 |
Anticancer activities of the extract from Longkong (Lansium domesticum) young fruits.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplat | 2012 |
Anticancer activities of the extract from Longkong (Lansium domesticum) young fruits.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplat | 2012 |
Stereocontrolled facile synthesis and biological evaluation of (3'S) and (3'R)-3'-amino (and Azido)-3'-deoxy pyranonucleosides.
Topics: Antineoplastic Agents; Antiviral Agents; Azides; Cell Line, Tumor; Fluorouracil; Humans; Neoplasms; | 2012 |
Stereocontrolled facile synthesis and biological evaluation of (3'S) and (3'R)-3'-amino (and Azido)-3'-deoxy pyranonucleosides.
Topics: Antineoplastic Agents; Antiviral Agents; Azides; Cell Line, Tumor; Fluorouracil; Humans; Neoplasms; | 2012 |
A mixture of amino acids and other small molecules present in the serum suppresses the growth of murine and human tumors in vivo.
Topics: Amino Acids; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Caspase | 2013 |
A mixture of amino acids and other small molecules present in the serum suppresses the growth of murine and human tumors in vivo.
Topics: Amino Acids; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Caspase | 2013 |
Lack of communication rusts and ages stem cells.
Topics: Animals; Bone Marrow; Cell Communication; Connexin 43; DNA Damage; Fluorouracil; Gap Junctions; Hema | 2012 |
Lack of communication rusts and ages stem cells.
Topics: Animals; Bone Marrow; Cell Communication; Connexin 43; DNA Damage; Fluorouracil; Gap Junctions; Hema | 2012 |
Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen.
Topics: Algorithms; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival | 2012 |
Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen.
Topics: Algorithms; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival | 2012 |
Exposure of family members to antineoplastic drugs via excreta of treated cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Environmental Exposure; Environmental Monitori | 2013 |
Exposure of family members to antineoplastic drugs via excreta of treated cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Environmental Exposure; Environmental Monitori | 2013 |
[Predicting drug efficacy-fluorinated pyrimidines (fluorouracil, S-1 and capecitabine)].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Human | 2012 |
[Predicting drug efficacy-fluorinated pyrimidines (fluorouracil, S-1 and capecitabine)].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Human | 2012 |
[Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].
Topics: Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency | 2012 |
[Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].
Topics: Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency | 2012 |
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.
Topics: Animals; Antineoplastic Agents; bcl-2-Associated X Protein; Carrier Proteins; Caspase 1; Cathepsin B | 2013 |
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.
Topics: Animals; Antineoplastic Agents; bcl-2-Associated X Protein; Carrier Proteins; Caspase 1; Cathepsin B | 2013 |
Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Cytidine Deaminase; Deoxyc | 2013 |
Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Cytidine Deaminase; Deoxyc | 2013 |
The effect of chemotherapy on telomere dynamics: clinical results and possible mechanisms.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Case-Control Stu | 2013 |
The effect of chemotherapy on telomere dynamics: clinical results and possible mechanisms.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Case-Control Stu | 2013 |
Dual role of immunomodulation by anticancer chemotherapy.
Topics: Animals; Carrier Proteins; Caspase 1; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infl | 2013 |
Dual role of immunomodulation by anticancer chemotherapy.
Topics: Animals; Carrier Proteins; Caspase 1; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infl | 2013 |
Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity.
Topics: Acid Ceramidase; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival | 2013 |
Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity.
Topics: Acid Ceramidase; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival | 2013 |
Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy.
Topics: Adult; Aged; Contrast Media; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; N | 2012 |
Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy.
Topics: Adult; Aged; Contrast Media; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; N | 2012 |
Injectable intratumoral hydrogel as 5-fluorouracil drug depot.
Topics: Animals; Antimetabolites, Antineoplastic; Biocompatible Materials; Cell Proliferation; Female; Fluor | 2013 |
Injectable intratumoral hydrogel as 5-fluorouracil drug depot.
Topics: Animals; Antimetabolites, Antineoplastic; Biocompatible Materials; Cell Proliferation; Female; Fluor | 2013 |
Blocking the proliferation of human tumor cell lines by peptidase inhibitors from Bauhinia seeds.
Topics: Antineoplastic Agents, Phytogenic; Bauhinia; Cathepsin G; Cell Line, Tumor; Cell Movement; Cell Prol | 2013 |
Blocking the proliferation of human tumor cell lines by peptidase inhibitors from Bauhinia seeds.
Topics: Antineoplastic Agents, Phytogenic; Bauhinia; Cathepsin G; Cell Line, Tumor; Cell Movement; Cell Prol | 2013 |
Advancement towards tin-based anticancer chemotherapeutics: structural modification and computer modeling approach to drug-enzyme interactions.
Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Survival; Cisplatin; Computer Simulatio | 2012 |
Advancement towards tin-based anticancer chemotherapeutics: structural modification and computer modeling approach to drug-enzyme interactions.
Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Survival; Cisplatin; Computer Simulatio | 2012 |
A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Agents; Cell Differentiation; Cl | 2013 |
A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Agents; Cell Differentiation; Cl | 2013 |
Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Exons; Female; Flu | 2002 |
Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Exons; Female; Flu | 2002 |
High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.
Topics: Adult; Aged; Alternative Splicing; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NAD | 2002 |
High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.
Topics: Adult; Aged; Alternative Splicing; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NAD | 2002 |
Tumor treatment by sustained intratumoral release of 5-fluorouracil: effects of drug alone and in combined treatments.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cobalt Ra | 2002 |
Tumor treatment by sustained intratumoral release of 5-fluorouracil: effects of drug alone and in combined treatments.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cobalt Ra | 2002 |
Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Capecitabine; Combined Modality Therapy; Cyt | 2002 |
Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Capecitabine; Combined Modality Therapy; Cyt | 2002 |
A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Therapy, Combination; Enzym | 2003 |
A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Therapy, Combination; Enzym | 2003 |
Quantification of human Alu sequences by real-time PCR--an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants.
Topics: Alu Elements; Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Colonic Neoplasms; DNA, N | 2002 |
Quantification of human Alu sequences by real-time PCR--an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants.
Topics: Alu Elements; Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Colonic Neoplasms; DNA, N | 2002 |
Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors.
Topics: Antimetabolites, Antineoplastic; Bifidobacterium; Blotting, Western; Cloning, Molecular; Cytosine De | 2002 |
Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors.
Topics: Antimetabolites, Antineoplastic; Bifidobacterium; Blotting, Western; Cloning, Molecular; Cytosine De | 2002 |
Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Catheterization, Central Venous; Drug Interac | 2003 |
Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Catheterization, Central Venous; Drug Interac | 2003 |
A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance.
Topics: Antineoplastic Agents; Cell Division; Down-Regulation; Drug Resistance, Neoplasm; Female; Fluorourac | 2003 |
A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance.
Topics: Antineoplastic Agents; Cell Division; Down-Regulation; Drug Resistance, Neoplasm; Female; Fluorourac | 2003 |
Increased tumour extracellular pH induced by Bafilomycin A1 inhibits tumour growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Antimetabolites, Antineoplastic; Cell Division; F | 2003 |
Increased tumour extracellular pH induced by Bafilomycin A1 inhibits tumour growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Antimetabolites, Antineoplastic; Cell Division; F | 2003 |
Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity.
Topics: Aged; Angina Pectoris; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; Male; Middle A | 2003 |
Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity.
Topics: Aged; Angina Pectoris; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; Male; Middle A | 2003 |
3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Topics: Adenosine Triphosphate; Animals; Dideoxynucleosides; Drug Monitoring; Fluorine Radioisotopes; Fluoro | 2003 |
3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Topics: Adenosine Triphosphate; Animals; Dideoxynucleosides; Drug Monitoring; Fluorine Radioisotopes; Fluoro | 2003 |
Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy.
Topics: Adult; Aged; Anthracyclines; Antigens, Neoplasm; Bone Marrow Cells; Breast Neoplasms; Cell Adhesion; | 2003 |
Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy.
Topics: Adult; Aged; Anthracyclines; Antigens, Neoplasm; Bone Marrow Cells; Breast Neoplasms; Cell Adhesion; | 2003 |
Pretreatment growth environments alter the sensitivity of tumor cells to cytotoxic agents.
Topics: Agar; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antioxidants; Bleomycin; Carcinom | 2003 |
Pretreatment growth environments alter the sensitivity of tumor cells to cytotoxic agents.
Topics: Agar; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antioxidants; Bleomycin; Carcinom | 2003 |
CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Cohort Studies; Colorectal Neoplasms; CpG Islands; DNA Methyl | 2003 |
CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Cohort Studies; Colorectal Neoplasms; CpG Islands; DNA Methyl | 2003 |
Simultaneous onset of acute inflammatory response, sepsis-like symptoms and intestinal mucosal injury after cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Bacteria; Bacterial Infections; Bacterial Translocation; Digestive S | 2003 |
Simultaneous onset of acute inflammatory response, sepsis-like symptoms and intestinal mucosal injury after cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Bacteria; Bacterial Infections; Bacterial Translocation; Digestive S | 2003 |
Studies on fluorinated pyrimidines. III. The metabolism of 5-fluorouracil-2-C14 and 5-fluoroorotic-2-C14 acid in vivo.
Topics: Antineoplastic Agents; Fluorides; Fluorouracil; Humans; Neoplasms; Orotic Acid; Pyrimidines | 1958 |
Studies on fluorinated pyrimidines. III. The metabolism of 5-fluorouracil-2-C14 and 5-fluoroorotic-2-C14 acid in vivo.
Topics: Antineoplastic Agents; Fluorides; Fluorouracil; Humans; Neoplasms; Orotic Acid; Pyrimidines | 1958 |
Clinical studies with 5-fluorouracil.
Topics: Biomedical Research; Fluorouracil; Neoplasms; Uracil | 1958 |
Clinical studies with 5-fluorouracil.
Topics: Biomedical Research; Fluorouracil; Neoplasms; Uracil | 1958 |
Enzymic ribosidation and ribotidation of 5-fluorouracil by extracts of the Ehrlich-ascites tumor.
Topics: Antineoplastic Agents; Ascites; Fluorouracil; Neoplasms; Uracil | 1958 |
Enzymic ribosidation and ribotidation of 5-fluorouracil by extracts of the Ehrlich-ascites tumor.
Topics: Antineoplastic Agents; Ascites; Fluorouracil; Neoplasms; Uracil | 1958 |
Cytochemical effects of 5-fluorouracil on sensitive and resistant Ehrlich ascites tumor cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Fluorouracil; Neoplasms; Nucleic Acids; Pr | 1959 |
Cytochemical effects of 5-fluorouracil on sensitive and resistant Ehrlich ascites tumor cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Fluorouracil; Neoplasms; Nucleic Acids; Pr | 1959 |
Possible enzymic mechanism for the development of resistance against fluorouracil in ascites tumours.
Topics: Antineoplastic Agents; Ascites; Biochemical Phenomena; Fluorouracil; Neoplasms; Uracil | 1959 |
Possible enzymic mechanism for the development of resistance against fluorouracil in ascites tumours.
Topics: Antineoplastic Agents; Ascites; Biochemical Phenomena; Fluorouracil; Neoplasms; Uracil | 1959 |
Clinical experience with 5-fluorouracil (NSC-19893) in the treatment of malignant disease.
Topics: Fluorouracil; Neoplasms; Uracil | 1960 |
Clinical experience with 5-fluorouracil (NSC-19893) in the treatment of malignant disease.
Topics: Fluorouracil; Neoplasms; Uracil | 1960 |
The potentiation of radiation effects with 5-fluoro-uracil.
Topics: Aged; Carcinoma, Squamous Cell; Esophagitis; Fluorouracil; Humans; Lung; Lung Neoplasms; Male; Middl | 1960 |
The potentiation of radiation effects with 5-fluoro-uracil.
Topics: Aged; Carcinoma, Squamous Cell; Esophagitis; Fluorouracil; Humans; Lung; Lung Neoplasms; Male; Middl | 1960 |
Preliminary pharmacologic observations on the concomitant use of x-ray and 5-fluorouracil in human malignancies.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil; X-Rays | 1961 |
Preliminary pharmacologic observations on the concomitant use of x-ray and 5-fluorouracil in human malignancies.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil; X-Rays | 1961 |
[Inhibition of the development of the Rous sarcoma virus by 5-fluorouracil in tissue culture].
Topics: Fluorouracil; Neoplasms; Research Design; Rous sarcoma virus; Uracil; Viruses | 1961 |
[Inhibition of the development of the Rous sarcoma virus by 5-fluorouracil in tissue culture].
Topics: Fluorouracil; Neoplasms; Research Design; Rous sarcoma virus; Uracil; Viruses | 1961 |
One year's clinical experience with 5-fluorouracil and x-ray-a preliminary report.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil; X-Rays | 1961 |
One year's clinical experience with 5-fluorouracil and x-ray-a preliminary report.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil; X-Rays | 1961 |
Treatment of advanced neoplastic disease with 5-fluorouracil and irradiation.
Topics: Fluorouracil; Neoplasms; Uracil | 1960 |
Treatment of advanced neoplastic disease with 5-fluorouracil and irradiation.
Topics: Fluorouracil; Neoplasms; Uracil | 1960 |
The effect of 5-fluorouracil upon carcinomas of the gastrointestinal tract and related organs.
Topics: Biliary Tract; Biliary Tract Neoplasms; Digestive System Neoplasms; Fluorouracil; Gastrointestinal T | 1961 |
The effect of 5-fluorouracil upon carcinomas of the gastrointestinal tract and related organs.
Topics: Biliary Tract; Biliary Tract Neoplasms; Digestive System Neoplasms; Fluorouracil; Gastrointestinal T | 1961 |
5-Fluorouracil in clinical cancer experience with 155 patients.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil | 1960 |
5-Fluorouracil in clinical cancer experience with 155 patients.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil | 1960 |
The potentiation of radiation effects with 5-fluorouracil.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil | 1960 |
The potentiation of radiation effects with 5-fluorouracil.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil | 1960 |
The clinical effects of the continuous administration of fluorinated pyrimidines (5-fluorouracil and 5-fluoro-2'-deoxyuridine).
Topics: Deoxyuridine; Fluorouracil; Halogenation; Neoplasms; Nucleosides; Nucleotides; Pyrimidines | 1960 |
The clinical effects of the continuous administration of fluorinated pyrimidines (5-fluorouracil and 5-fluoro-2'-deoxyuridine).
Topics: Deoxyuridine; Fluorouracil; Halogenation; Neoplasms; Nucleosides; Nucleotides; Pyrimidines | 1960 |
The clinical evaluation of 5-fluorouracil and 5-fluoro-2'-deoxyuridine in solid tumors in adults: a progress report.
Topics: Antineoplastic Agents; Deoxyuridine; Fluorouracil; Neoplasms; Nucleosides; Nucleotides; Research Rep | 1960 |
The clinical evaluation of 5-fluorouracil and 5-fluoro-2'-deoxyuridine in solid tumors in adults: a progress report.
Topics: Antineoplastic Agents; Deoxyuridine; Fluorouracil; Neoplasms; Nucleosides; Nucleotides; Research Rep | 1960 |
Cancer chemotherapy with 5-fluorouracil alone and in combination with x-ray therapy.
Topics: Fluorouracil; Humans; Neoplasms; Uracil; X-Ray Therapy | 1961 |
Cancer chemotherapy with 5-fluorouracil alone and in combination with x-ray therapy.
Topics: Fluorouracil; Humans; Neoplasms; Uracil; X-Ray Therapy | 1961 |
A preliminary report on the use of 5-fluorouracil in malignant disease.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil | 1962 |
A preliminary report on the use of 5-fluorouracil in malignant disease.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil | 1962 |
Effects of 5-fluorouracil on the adrenals of normal and tumor-bearing rats.
Topics: Adrenal Glands; Animals; Cortisone; Fluorouracil; Neomycin; Neoplasms; Rats; Uracil | 1962 |
Effects of 5-fluorouracil on the adrenals of normal and tumor-bearing rats.
Topics: Adrenal Glands; Animals; Cortisone; Fluorouracil; Neomycin; Neoplasms; Rats; Uracil | 1962 |
Observations on the combined use of 5-fluorouracil and 2 Mev radiation in advanced solid tumors in man.
Topics: Antineoplastic Agents; Fluorouracil; Neomycin; Neoplasms; Radiation; Research; Uracil | 1961 |
Observations on the combined use of 5-fluorouracil and 2 Mev radiation in advanced solid tumors in man.
Topics: Antineoplastic Agents; Fluorouracil; Neomycin; Neoplasms; Radiation; Research; Uracil | 1961 |
The effects of 5-fluorouracil in patients with incurable cancer.
Topics: Fluorouracil; Humans; Neoplasms; Uracil | 1962 |
The effects of 5-fluorouracil in patients with incurable cancer.
Topics: Fluorouracil; Humans; Neoplasms; Uracil | 1962 |
Observations on the concomitant use of x-rays and 5-fluorouracil in human malignant neoplasms.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil; X-Rays | 1962 |
Observations on the concomitant use of x-rays and 5-fluorouracil in human malignant neoplasms.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil; X-Rays | 1962 |
Further observations on the concomitant use of x rays and 5-fluorouracil in neoplasms of humans.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil; X-Rays | 1962 |
Further observations on the concomitant use of x rays and 5-fluorouracil in neoplasms of humans.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil; X-Rays | 1962 |
Studies on resistance against 5-fluorouracil. II. Thymidylate synthetase from drug-resistant tumor lines.
Topics: Enzymes; Fluorouracil; Humans; Neoplasms; Thymidylate Synthase; Uracil | 1962 |
Studies on resistance against 5-fluorouracil. II. Thymidylate synthetase from drug-resistant tumor lines.
Topics: Enzymes; Fluorouracil; Humans; Neoplasms; Thymidylate Synthase; Uracil | 1962 |
Advanced neoplastic disease. Treatment with 5-fluorouracil and irradiation.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil | 1961 |
Advanced neoplastic disease. Treatment with 5-fluorouracil and irradiation.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil | 1961 |
Treatment of far-advanced cancer with 5-fluorouracil, used alone and in combination with irradiation. Incidence and duration of remission and survival-time data in 223 patients.
Topics: Antineoplastic Agents; Fluorouracil; Incidence; Neoplasms; Uracil | 1962 |
Treatment of far-advanced cancer with 5-fluorouracil, used alone and in combination with irradiation. Incidence and duration of remission and survival-time data in 223 patients.
Topics: Antineoplastic Agents; Fluorouracil; Incidence; Neoplasms; Uracil | 1962 |
The clinical excursion into 5-fluoro-uracil.
Topics: Fluorouracil; Humans; Neoplasms; Uracil | 1962 |
The clinical excursion into 5-fluoro-uracil.
Topics: Fluorouracil; Humans; Neoplasms; Uracil | 1962 |
Intra-arterial infusion of tumors with 5-fluorouracil.
Topics: Antineoplastic Agents; Fluorouracil; Infusions, Intra-Arterial; Infusions, Parenteral; Neoplasms; Ur | 1962 |
Intra-arterial infusion of tumors with 5-fluorouracil.
Topics: Antineoplastic Agents; Fluorouracil; Infusions, Intra-Arterial; Infusions, Parenteral; Neoplasms; Ur | 1962 |
Fluorouracil in the treatment of cancer.
Topics: Fluorouracil; Humans; Neoplasms | 1963 |
Fluorouracil in the treatment of cancer.
Topics: Fluorouracil; Humans; Neoplasms | 1963 |
[On nucleic acids].
Topics: DNA; Fluorouracil; Metabolism; Neoplasms; Nucleic Acids; Proteins; Purines; Pyrimidines; Radiation E | 1963 |
[On nucleic acids].
Topics: DNA; Fluorouracil; Metabolism; Neoplasms; Nucleic Acids; Proteins; Purines; Pyrimidines; Radiation E | 1963 |
Continuous intraarterial chemotherapy in advanced bladder cancer. A preliminary report.
Topics: Carcinoma; Carcinoma, Papillary; Carcinoma, Transitional Cell; Fluorouracil; Humans; Neoplasms; Urin | 1963 |
Continuous intraarterial chemotherapy in advanced bladder cancer. A preliminary report.
Topics: Carcinoma; Carcinoma, Papillary; Carcinoma, Transitional Cell; Fluorouracil; Humans; Neoplasms; Urin | 1963 |
Cancer chemotherapy by arterial infusion.
Topics: Antineoplastic Agents; Fluorouracil; Humans; Injections; Injections, Intramuscular; Leucovorin; Meth | 1963 |
Cancer chemotherapy by arterial infusion.
Topics: Antineoplastic Agents; Fluorouracil; Humans; Injections; Injections, Intramuscular; Leucovorin; Meth | 1963 |
In vitro synthesis of acidsoluble thymine compounds by human neoplastic tissues.
Topics: DNA; DNA, Neoplasm; Floxuridine; Fluorouracil; Humans; In Vitro Techniques; Neoplasms; Thymine | 1963 |
In vitro synthesis of acidsoluble thymine compounds by human neoplastic tissues.
Topics: DNA; DNA, Neoplasm; Floxuridine; Fluorouracil; Humans; In Vitro Techniques; Neoplasms; Thymine | 1963 |
Chemotherapy of malignant disease. I. Solid tumours.
Topics: Cyclophosphamide; Dactinomycin; Fluorouracil; Mechlorethamine; Methotrexate; Mitomycin; Mitomycins; | 1962 |
Chemotherapy of malignant disease. I. Solid tumours.
Topics: Cyclophosphamide; Dactinomycin; Fluorouracil; Mechlorethamine; Methotrexate; Mitomycin; Mitomycins; | 1962 |
Cancer chemotherapy by intra-arterial infusion.
Topics: Dactinomycin; Fluorouracil; Humans; Infusions, Intra-Arterial; Mechlorethamine; Methotrexate; Neopla | 1963 |
Cancer chemotherapy by intra-arterial infusion.
Topics: Dactinomycin; Fluorouracil; Humans; Infusions, Intra-Arterial; Mechlorethamine; Methotrexate; Neopla | 1963 |
Preoperative anticancer chemotherapy. Preliminary report.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Surgical Procedures, Operative; Thiotepa | 1962 |
Preoperative anticancer chemotherapy. Preliminary report.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Surgical Procedures, Operative; Thiotepa | 1962 |
An evaluation of 5-fluorouracil in malignant disease.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil | 1961 |
An evaluation of 5-fluorouracil in malignant disease.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil | 1961 |
A clinical study of 5-fluorouracil in a variety of far advanced human malignancies.
Topics: Antineoplastic Agents; Biomedical Research; Fluorouracil; Humans; Neoplasms; Uracil | 1962 |
A clinical study of 5-fluorouracil in a variety of far advanced human malignancies.
Topics: Antineoplastic Agents; Biomedical Research; Fluorouracil; Humans; Neoplasms; Uracil | 1962 |
Some observations of the effects of 5-fluorouracil in the treatment of malignant tumors.
Topics: Fluorouracil; Humans; Neoplasms; Uracil | 1962 |
Some observations of the effects of 5-fluorouracil in the treatment of malignant tumors.
Topics: Fluorouracil; Humans; Neoplasms; Uracil | 1962 |
Chemotherapy of disseminated solid tumors.
Topics: Antineoplastic Agents; Floxuridine; Fluorouracil; Humans; Neoplasms | 1962 |
Chemotherapy of disseminated solid tumors.
Topics: Antineoplastic Agents; Floxuridine; Fluorouracil; Humans; Neoplasms | 1962 |
Experience with 5-fluorouracil in a variety of solid tumors.
Topics: Fluorouracil; Humans; Neoplasms | 1962 |
Experience with 5-fluorouracil in a variety of solid tumors.
Topics: Fluorouracil; Humans; Neoplasms | 1962 |
Ineffectiveness of five compounds on spontaneous mammary tumors of mice.
Topics: Animals; Chlorprothixene; Fluorouracil; Hydrocarbons; Mammary Neoplasms, Animal; Mice; Naphthoquinon | 1963 |
Ineffectiveness of five compounds on spontaneous mammary tumors of mice.
Topics: Animals; Chlorprothixene; Fluorouracil; Hydrocarbons; Mammary Neoplasms, Animal; Mice; Naphthoquinon | 1963 |
Experience with 5-fluorouracil in metastatic cancer of the breast.
Topics: Breast; Breast Neoplasms; Fluorouracil; Humans; Neoplasms | 1962 |
Experience with 5-fluorouracil in metastatic cancer of the breast.
Topics: Breast; Breast Neoplasms; Fluorouracil; Humans; Neoplasms | 1962 |
DECREASED INTOXICATION BY FLUOROURACIL WHEN SLOWLY ADMINISTERED IN GLUCOSE.
Topics: Fluorouracil; Glucose; Infusions, Parenteral; Neoplasms; Toxicology | 1963 |
DECREASED INTOXICATION BY FLUOROURACIL WHEN SLOWLY ADMINISTERED IN GLUCOSE.
Topics: Fluorouracil; Glucose; Infusions, Parenteral; Neoplasms; Toxicology | 1963 |
REGIONAL PERFUSION CHEMOTHERAPY OF ADVANCED CANCER.
Topics: Chemotherapy, Cancer, Regional Perfusion; Dactinomycin; Fluorouracil; Hypothermia; Hypothermia, Indu | 1963 |
REGIONAL PERFUSION CHEMOTHERAPY OF ADVANCED CANCER.
Topics: Chemotherapy, Cancer, Regional Perfusion; Dactinomycin; Fluorouracil; Hypothermia; Hypothermia, Indu | 1963 |
COORDINATED SURGICAL-CHEMICAL THERAPY OF CANCER.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cyclophosphamide; DNA; DNA, Neoplasm; Fluorouracil; | 1963 |
COORDINATED SURGICAL-CHEMICAL THERAPY OF CANCER.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cyclophosphamide; DNA; DNA, Neoplasm; Fluorouracil; | 1963 |
COMBINED RADIATION AND CHEMOTHERAPY.
Topics: Chemotherapy, Cancer, Regional Perfusion; Cobalt Isotopes; Fluorouracil; Humans; Neoplasms; Radioiso | 1963 |
COMBINED RADIATION AND CHEMOTHERAPY.
Topics: Chemotherapy, Cancer, Regional Perfusion; Cobalt Isotopes; Fluorouracil; Humans; Neoplasms; Radioiso | 1963 |
CONTINUOUS INFUSION OF ADVANCED PELVIC MALIGNANCIES BY RETROGRADE FEMORAL CATHETER.
Topics: Catheters; Fluorouracil; Infusions, Parenteral; Leucovorin; Methotrexate; Neoplasms; Pelvic Neoplasm | 1963 |
CONTINUOUS INFUSION OF ADVANCED PELVIC MALIGNANCIES BY RETROGRADE FEMORAL CATHETER.
Topics: Catheters; Fluorouracil; Infusions, Parenteral; Leucovorin; Methotrexate; Neoplasms; Pelvic Neoplasm | 1963 |
TESTING SENSITIVITY TO 5-FLUOROURACIL.
Topics: Fluorouracil; Gingiva; Neoplasms; Pharmacology; Skin Tests; Toxicology | 1963 |
TESTING SENSITIVITY TO 5-FLUOROURACIL.
Topics: Fluorouracil; Gingiva; Neoplasms; Pharmacology; Skin Tests; Toxicology | 1963 |
HYPOGASTRIC ARTERY INFUSION OF 5-FLUOROURACIL IN THE TREATMENT OF ADVANCED BLADDER CANCER.
Topics: Arteries; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusions, Parenteral; Injections, Intra- | 1963 |
HYPOGASTRIC ARTERY INFUSION OF 5-FLUOROURACIL IN THE TREATMENT OF ADVANCED BLADDER CANCER.
Topics: Arteries; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusions, Parenteral; Injections, Intra- | 1963 |
STUDIES ON RESISTANCE AGAINST 5-FLUOROURACIL. IV. EVIDENCE FOR AN ALTERED URIDINE KINASE IN RESISTANT CELLS.
Topics: Chromatography; Fluorouracil; Neoplasms; Neoplasms, Experimental; Pharmacology; Phosphotransferases; | 1963 |
STUDIES ON RESISTANCE AGAINST 5-FLUOROURACIL. IV. EVIDENCE FOR AN ALTERED URIDINE KINASE IN RESISTANT CELLS.
Topics: Chromatography; Fluorouracil; Neoplasms; Neoplasms, Experimental; Pharmacology; Phosphotransferases; | 1963 |
SUMMARY OF INFORMAL DISCUSSIONS ON THE ROLE OF PYRIMIDINE ANTAGONISTS FOLLOWING PAPERS BY DR. PRUSOFF AND DR. CALABRESI.
Topics: Antimetabolites; Antineoplastic Agents; Floxuridine; Fluorouracil; Idoxuridine; Neoplasms; Nucleosid | 1963 |
SUMMARY OF INFORMAL DISCUSSIONS ON THE ROLE OF PYRIMIDINE ANTAGONISTS FOLLOWING PAPERS BY DR. PRUSOFF AND DR. CALABRESI.
Topics: Antimetabolites; Antineoplastic Agents; Floxuridine; Fluorouracil; Idoxuridine; Neoplasms; Nucleosid | 1963 |
EVALUATION OF 5-FLUOROURACIL (5-FU) IN SURGICAL PRACTICE.
Topics: Fluorouracil; Neoplasms; Radiotherapy Dosage; Toxicology | 1963 |
EVALUATION OF 5-FLUOROURACIL (5-FU) IN SURGICAL PRACTICE.
Topics: Fluorouracil; Neoplasms; Radiotherapy Dosage; Toxicology | 1963 |
CHEMOTHERAPY IN MALIGNANT LESIONS.
Topics: Fluorouracil; Gastrointestinal Neoplasms; Neoplasms; Toxicology | 1963 |
CHEMOTHERAPY IN MALIGNANT LESIONS.
Topics: Fluorouracil; Gastrointestinal Neoplasms; Neoplasms; Toxicology | 1963 |
STUDIES ON TUMOR RESISTANCE TO 5-FLUOROURACIL.
Topics: Animals; Carbon Isotopes; Carboxy-Lyases; Fluorouracil; Genetics; Lymphoma; Lymphoma, Non-Hodgkin; M | 1963 |
STUDIES ON TUMOR RESISTANCE TO 5-FLUOROURACIL.
Topics: Animals; Carbon Isotopes; Carboxy-Lyases; Fluorouracil; Genetics; Lymphoma; Lymphoma, Non-Hodgkin; M | 1963 |
METHODOLOGY OF PRELIMINARY CHEMOTHERAPEUTIC TRIALS IN PATIENTS WITH MALIGNANT SOLID TUMORS.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Colonic Neoplasms; Cyclophosp | 1963 |
METHODOLOGY OF PRELIMINARY CHEMOTHERAPEUTIC TRIALS IN PATIENTS WITH MALIGNANT SOLID TUMORS.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Colonic Neoplasms; Cyclophosp | 1963 |
[REPORT ON REGIONAL CHEMOTHERAPY IN CANCEROLOGY].
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Mannomustine; Methotr | 1963 |
[REPORT ON REGIONAL CHEMOTHERAPY IN CANCEROLOGY].
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Mannomustine; Methotr | 1963 |
[PROLONGED INTRA-ARTERIAL CHEMOTHERAPY USING AN ANTINEOPLASTIC INFUSION IN THE TREATMENT OF INOPERABLE NEOPLASIA. 1. INTRODUCTION, MATERIAL AND METHOD].
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Infusions, Parenteral | 1963 |
[PROLONGED INTRA-ARTERIAL CHEMOTHERAPY USING AN ANTINEOPLASTIC INFUSION IN THE TREATMENT OF INOPERABLE NEOPLASIA. 1. INTRODUCTION, MATERIAL AND METHOD].
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Infusions, Parenteral | 1963 |
EARLY RESULTS OF COMBINED RADIATION AND CHEMOTHERAPY IN TREATMENT OF MALIGNANT TUMORS.
Topics: Antineoplastic Agents; Colonic Neoplasms; Dactinomycin; Fluorouracil; Humans; Lung Neoplasms; Mitomy | 1963 |
EARLY RESULTS OF COMBINED RADIATION AND CHEMOTHERAPY IN TREATMENT OF MALIGNANT TUMORS.
Topics: Antineoplastic Agents; Colonic Neoplasms; Dactinomycin; Fluorouracil; Humans; Lung Neoplasms; Mitomy | 1963 |
SIDE-EFFECTS OF COMBINED RADIATION AND CHEMOTHERAPY IN THE TREATMENT OF MALIGNANT TUMORS.
Topics: Chlorambucil; Dactinomycin; Fluorouracil; Mitomycin; Mitomycins; Neoplasms; Toxicology | 1963 |
SIDE-EFFECTS OF COMBINED RADIATION AND CHEMOTHERAPY IN THE TREATMENT OF MALIGNANT TUMORS.
Topics: Chlorambucil; Dactinomycin; Fluorouracil; Mitomycin; Mitomycins; Neoplasms; Toxicology | 1963 |
RADIATION AND 5-FLUOROURACIL: A CONTROLLED CLINICAL STUDY.
Topics: Biomedical Research; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasms; Radiotherapy Dosage | 1963 |
RADIATION AND 5-FLUOROURACIL: A CONTROLLED CLINICAL STUDY.
Topics: Biomedical Research; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasms; Radiotherapy Dosage | 1963 |
5-FLUOROURACIL (NSC-19893) TREATMENT OF ADVANCED CANCER IN AMBULATORY PATIENTS.
Topics: Ampulla of Vater; Bile Duct Neoplasms; Breast Neoplasms; Colonic Neoplasms; Fluorouracil; Humans; Ne | 1963 |
5-FLUOROURACIL (NSC-19893) TREATMENT OF ADVANCED CANCER IN AMBULATORY PATIENTS.
Topics: Ampulla of Vater; Bile Duct Neoplasms; Breast Neoplasms; Colonic Neoplasms; Fluorouracil; Humans; Ne | 1963 |
DRUGS OF CURRENT USE FOR THE TREATMENT OF CANCER AND ALLIED DISEASES.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antineoplastic Agents; Aziridines; Busulfan; Colchic | 1963 |
DRUGS OF CURRENT USE FOR THE TREATMENT OF CANCER AND ALLIED DISEASES.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antineoplastic Agents; Aziridines; Busulfan; Colchic | 1963 |
[NEW METHODS OF ADMINISTRATION OF 5-FLUOROURACIL].
Topics: Fluorouracil; Humans; Neoplasms; Perfusion | 1963 |
[NEW METHODS OF ADMINISTRATION OF 5-FLUOROURACIL].
Topics: Fluorouracil; Humans; Neoplasms; Perfusion | 1963 |
CANCER CHEMOTHERAPY BY PROLONGED ARTERIAL INFUSION.
Topics: Angiography; Arm; Brachiocephalic Trunk; Brain Neoplasms; Carotid Arteries; Chemotherapy, Cancer, Re | 1964 |
CANCER CHEMOTHERAPY BY PROLONGED ARTERIAL INFUSION.
Topics: Angiography; Arm; Brachiocephalic Trunk; Brain Neoplasms; Carotid Arteries; Chemotherapy, Cancer, Re | 1964 |
INTRA-ARTERIAL INFUSION FOR HEAD AND NECK CANCER.
Topics: Antineoplastic Agents; Brain Neoplasms; Dactinomycin; Facial Neoplasms; Fluorouracil; Head and Neck | 1964 |
INTRA-ARTERIAL INFUSION FOR HEAD AND NECK CANCER.
Topics: Antineoplastic Agents; Brain Neoplasms; Dactinomycin; Facial Neoplasms; Fluorouracil; Head and Neck | 1964 |
PERCUTANEOUS VISCERAL CATHETERIZATION FOR INFUSION CANCER CHEMOTHERAPY.
Topics: Biomedical Research; Catheterization; Fluorouracil; Geriatrics; Humans; Injections, Intra-Arterial; | 1964 |
PERCUTANEOUS VISCERAL CATHETERIZATION FOR INFUSION CANCER CHEMOTHERAPY.
Topics: Biomedical Research; Catheterization; Fluorouracil; Geriatrics; Humans; Injections, Intra-Arterial; | 1964 |
PRELIMINARY OBSERVATIONS ON CARCINOMA OF THE CERVIX TREATED WITH 5-FLUOROURACIL.
Topics: Carcinoma; Female; Fluorouracil; Humans; Injections, Intravenous; Mortality; Neoplasms; Stomatitis; | 1964 |
PRELIMINARY OBSERVATIONS ON CARCINOMA OF THE CERVIX TREATED WITH 5-FLUOROURACIL.
Topics: Carcinoma; Female; Fluorouracil; Humans; Injections, Intravenous; Mortality; Neoplasms; Stomatitis; | 1964 |
CHEMOTHERAPY FOR CANCER.
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Dactinomycin; Exudates and Transuda | 1964 |
CHEMOTHERAPY FOR CANCER.
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Dactinomycin; Exudates and Transuda | 1964 |
VINCRISTINE (NSC-67574) THERAPY OF ADULT PATIENTS WITH SOLID TUMORS.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Bronchogenic; Carcinoma, Squamous | 1964 |
VINCRISTINE (NSC-67574) THERAPY OF ADULT PATIENTS WITH SOLID TUMORS.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Bronchogenic; Carcinoma, Squamous | 1964 |
CLINICOPATHOLOGIC CONFERENCE.
Topics: Black People; Bromides; Diagnosis, Differential; Drug Eruptions; Fluorouracil; Granuloma; Humans; Ke | 1964 |
CLINICOPATHOLOGIC CONFERENCE.
Topics: Black People; Bromides; Diagnosis, Differential; Drug Eruptions; Fluorouracil; Granuloma; Humans; Ke | 1964 |
[NEW ANTIBLASTIC AGENTS].
Topics: Antineoplastic Agents; Colonic Neoplasms; Ethoglucid; Fluorouracil; Neoplasm Metastasis; Neoplasms; | 1963 |
[NEW ANTIBLASTIC AGENTS].
Topics: Antineoplastic Agents; Colonic Neoplasms; Ethoglucid; Fluorouracil; Neoplasm Metastasis; Neoplasms; | 1963 |
COMPARISON OF HIGH-DOSAGE AND LOW-DOSAGE-MAINTENANCE THERAPY WITH 5-FLUOROURACIL IN SOLID TUMORS.
Topics: Diarrhea; Fluorouracil; Humans; Nausea; Neoplasms; Stomatitis; Toxicology; Vomiting | 1964 |
COMPARISON OF HIGH-DOSAGE AND LOW-DOSAGE-MAINTENANCE THERAPY WITH 5-FLUOROURACIL IN SOLID TUMORS.
Topics: Diarrhea; Fluorouracil; Humans; Nausea; Neoplasms; Stomatitis; Toxicology; Vomiting | 1964 |
SOME PROBLEMS IN THE CHEMOTHERAPY OF SOLID TUMOURS.
Topics: Breast Neoplasms; Cyclophosphamide; Fluorouracil; Humans; Mechlorethamine; Neoplasms; Thiotepa; Toxi | 1964 |
SOME PROBLEMS IN THE CHEMOTHERAPY OF SOLID TUMOURS.
Topics: Breast Neoplasms; Cyclophosphamide; Fluorouracil; Humans; Mechlorethamine; Neoplasms; Thiotepa; Toxi | 1964 |
CURRENT MANAGEMENT OF NEPHROBLASTOMA AND NEUROBLASTOMA.
Topics: Antineoplastic Agents; Child; Dactinomycin; Fluorouracil; Infant; Infant, Newborn; Kidney Neoplasms; | 1964 |
CURRENT MANAGEMENT OF NEPHROBLASTOMA AND NEUROBLASTOMA.
Topics: Antineoplastic Agents; Child; Dactinomycin; Fluorouracil; Infant; Infant, Newborn; Kidney Neoplasms; | 1964 |
UTILIZATION OF DNA AND RNA PRECURSORS AS INDICATORS OF DRUG EFFECT ON CANCER CELLS. ANL-6723.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Dactinomycin; DNA; DNA, Neoplasm; Fluorour | 1963 |
UTILIZATION OF DNA AND RNA PRECURSORS AS INDICATORS OF DRUG EFFECT ON CANCER CELLS. ANL-6723.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Dactinomycin; DNA; DNA, Neoplasm; Fluorour | 1963 |
PRESENT-DAY MANAGEMENT OF GASTRIC CANCER.
Topics: Fluorouracil; Gastrectomy; Humans; Mitomycin; Mitomycins; Mortality; Neoplasms; Stomach Neoplasms | 1964 |
PRESENT-DAY MANAGEMENT OF GASTRIC CANCER.
Topics: Fluorouracil; Gastrectomy; Humans; Mitomycin; Mitomycins; Mortality; Neoplasms; Stomach Neoplasms | 1964 |
CURRENT STATUS OF CHEMOTHERAPY OF CANCER.
Topics: Alkylating Agents; Anti-Bacterial Agents; Antineoplastic Agents; Black People; Chemotherapy, Cancer, | 1964 |
CURRENT STATUS OF CHEMOTHERAPY OF CANCER.
Topics: Alkylating Agents; Anti-Bacterial Agents; Antineoplastic Agents; Black People; Chemotherapy, Cancer, | 1964 |
[TREATMENT PROCEDURE IN ONCOLYTIC CHEMOTHERAPY WITH 5-FLUOROURACIL].
Topics: Fluorouracil; Neoplasms; Perfusion; Toxicology | 1964 |
[TREATMENT PROCEDURE IN ONCOLYTIC CHEMOTHERAPY WITH 5-FLUOROURACIL].
Topics: Fluorouracil; Neoplasms; Perfusion; Toxicology | 1964 |
EFFECTS OF IONIZING IRRADIATION AND CHEMOTHERAPEUTIC AGENTS ON HUMAN CHROMOSOMES.
Topics: Antineoplastic Agents; Biomedical Research; Chlorambucil; Choriocarcinoma; Chromosome Aberrations; C | 1964 |
EFFECTS OF IONIZING IRRADIATION AND CHEMOTHERAPEUTIC AGENTS ON HUMAN CHROMOSOMES.
Topics: Antineoplastic Agents; Biomedical Research; Chlorambucil; Choriocarcinoma; Chromosome Aberrations; C | 1964 |
CURRENT STATUS OF 5-FLUOROURACIL THERAPY IN FAR-ADVANCED NEOPLASTIC DISEASE.
Topics: Alopecia; Chlorpromazine; Diarrhea; Erythema; Fluorouracil; Leukopenia; Nausea; Neoplasms; Thrombocy | 1964 |
CURRENT STATUS OF 5-FLUOROURACIL THERAPY IN FAR-ADVANCED NEOPLASTIC DISEASE.
Topics: Alopecia; Chlorpromazine; Diarrhea; Erythema; Fluorouracil; Leukopenia; Nausea; Neoplasms; Thrombocy | 1964 |
CANCER CHEMOTHERAPY.
Topics: Adrenal Cortex Hormones; Aminopterin; Androgens; Antimetabolites; Antineoplastic Agents; Blood Plate | 1964 |
CANCER CHEMOTHERAPY.
Topics: Adrenal Cortex Hormones; Aminopterin; Androgens; Antimetabolites; Antineoplastic Agents; Blood Plate | 1964 |
CHEMOTHERAPY STUDIES WITH VIRUS-INDUCED LEUKEMIA IN MICE.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Fluorouracil; Leukemia; Leukemia, Experimental; Me | 1964 |
CHEMOTHERAPY STUDIES WITH VIRUS-INDUCED LEUKEMIA IN MICE.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Fluorouracil; Leukemia; Leukemia, Experimental; Me | 1964 |
POTENTIATION OF CHEMOTHERAPY OF EXPERIMENTAL TUMORS BY DEUTERIUM OXIDE.
Topics: Animals; Cyclophosphamide; Deuterium; Deuterium Oxide; Fluorouracil; Mercaptopurine; Mice; Neoplasms | 1964 |
POTENTIATION OF CHEMOTHERAPY OF EXPERIMENTAL TUMORS BY DEUTERIUM OXIDE.
Topics: Animals; Cyclophosphamide; Deuterium; Deuterium Oxide; Fluorouracil; Mercaptopurine; Mice; Neoplasms | 1964 |
STUDIES ON HUMAN MELANOMA CELLS IN TISSUE CULTURE. II. EFFECTS OF SEVERAL CANCER CHEMOTHERAPEUTIC AGENTS ON CYTOLOGY AND GROWTH.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Chlorambucil; Dactinomycin; Fluorouracil; Melanoma; Me | 1964 |
STUDIES ON HUMAN MELANOMA CELLS IN TISSUE CULTURE. II. EFFECTS OF SEVERAL CANCER CHEMOTHERAPEUTIC AGENTS ON CYTOLOGY AND GROWTH.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Chlorambucil; Dactinomycin; Fluorouracil; Melanoma; Me | 1964 |
SERIAL ENZYME CHANGES IN CANCER PATIENTS UNDERGOING CHEMOTHERAPY.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Clinical Enzyme Tests; Colonic Neoplasms; D-Alani | 1964 |
SERIAL ENZYME CHANGES IN CANCER PATIENTS UNDERGOING CHEMOTHERAPY.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Clinical Enzyme Tests; Colonic Neoplasms; D-Alani | 1964 |
TREATMENT OF ADVANCED CANCER WITH 5-FLUOROURACIL.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Humans; Leuko | 1964 |
TREATMENT OF ADVANCED CANCER WITH 5-FLUOROURACIL.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Humans; Leuko | 1964 |
RATIONALE FOR THE DESIGN OF FLUORINATED PYRIMIDINES.
Topics: Animals; Antimetabolites; DNA; Floxuridine; Fluorouracil; Halogenation; Ligases; Mice; Neoplasms; Ne | 1964 |
RATIONALE FOR THE DESIGN OF FLUORINATED PYRIMIDINES.
Topics: Animals; Antimetabolites; DNA; Floxuridine; Fluorouracil; Halogenation; Ligases; Mice; Neoplasms; Ne | 1964 |
COMBINED 5-FLUOROURACIL AND COBALT IRRADIATION EVALUATED BY DOUBLE BLIND TECHNIQUE.
Topics: Cobalt; Cobalt Isotopes; Double-Blind Method; Epiglottis; Fluorouracil; Humans; Neoplasms; Palatal N | 1964 |
COMBINED 5-FLUOROURACIL AND COBALT IRRADIATION EVALUATED BY DOUBLE BLIND TECHNIQUE.
Topics: Cobalt; Cobalt Isotopes; Double-Blind Method; Epiglottis; Fluorouracil; Humans; Neoplasms; Palatal N | 1964 |
THE CLINICAL EFFECTS OF THE CONTINUOUS INTRAVENOUS INFUSION OF CANCER CHEMOTHERAPEUTIC COMPOUNDS.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antineoplastic Agents; Floxuridine; Fluorouracil | 1964 |
THE CLINICAL EFFECTS OF THE CONTINUOUS INTRAVENOUS INFUSION OF CANCER CHEMOTHERAPEUTIC COMPOUNDS.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antineoplastic Agents; Floxuridine; Fluorouracil | 1964 |
ANALYSIS OF AGENTS FOR USE IN ISOLATED PERFUSION.
Topics: Chemotherapy, Cancer, Regional Perfusion; Dogs; Extremities; Fluorouracil; Mechlorethamine; Mitomyci | 1964 |
ANALYSIS OF AGENTS FOR USE IN ISOLATED PERFUSION.
Topics: Chemotherapy, Cancer, Regional Perfusion; Dogs; Extremities; Fluorouracil; Mechlorethamine; Mitomyci | 1964 |
A REPORT OF THE SYSTEMIC USE OF 5-FLUOROURACIL IN THE TREATMENT OF CHINESE CANCER PATIENTS.
Topics: Adenocarcinoma; Aged; Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; China; Fallopian Tube N | 1964 |
A REPORT OF THE SYSTEMIC USE OF 5-FLUOROURACIL IN THE TREATMENT OF CHINESE CANCER PATIENTS.
Topics: Adenocarcinoma; Aged; Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; China; Fallopian Tube N | 1964 |
INDIVIDUALIZED CHEMOTHERAPY BY IN VITRO DRUG SELECTION.
Topics: Antineoplastic Agents; Bone Neoplasms; Dactinomycin; Female; Floxuridine; Fluorouracil; Genital Neop | 1964 |
INDIVIDUALIZED CHEMOTHERAPY BY IN VITRO DRUG SELECTION.
Topics: Antineoplastic Agents; Bone Neoplasms; Dactinomycin; Female; Floxuridine; Fluorouracil; Genital Neop | 1964 |
EXPERIENCE WITH CHEMOTHERAPY OF CANCER AT THE UNIVERSITY OF PRETORIA.
Topics: Antineoplastic Agents; Aziridines; Breast Neoplasms; Cyclophosphamide; Dactinomycin; Fluorouracil; H | 1964 |
EXPERIENCE WITH CHEMOTHERAPY OF CANCER AT THE UNIVERSITY OF PRETORIA.
Topics: Antineoplastic Agents; Aziridines; Breast Neoplasms; Cyclophosphamide; Dactinomycin; Fluorouracil; H | 1964 |
CATALASE ACTIVITY IN THE EPIDERMIS OF PATIENTS WITH ADVANCED CANCER.
Topics: Antineoplastic Agents; Breast Neoplasms; Carbamates; Catalase; Clinical Enzyme Tests; Cobalt Isotope | 1964 |
CATALASE ACTIVITY IN THE EPIDERMIS OF PATIENTS WITH ADVANCED CANCER.
Topics: Antineoplastic Agents; Breast Neoplasms; Carbamates; Catalase; Clinical Enzyme Tests; Cobalt Isotope | 1964 |
COMBINED CHEMOTHERAPY AND RADIATION THERAPY IN ADVANCED MALIGNANCIES.
Topics: Carcinoma, Bronchogenic; Cyclophosphamide; Female; Fluorouracil; Head and Neck Neoplasms; Humans; La | 1964 |
COMBINED CHEMOTHERAPY AND RADIATION THERAPY IN ADVANCED MALIGNANCIES.
Topics: Carcinoma, Bronchogenic; Cyclophosphamide; Female; Fluorouracil; Head and Neck Neoplasms; Humans; La | 1964 |
PALLIATIVE MANAGEMENT OF GASTROINTESTINAL CANCER.
Topics: Adenocarcinoma; Ascites; Deglutition Disorders; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasms | 1964 |
PALLIATIVE MANAGEMENT OF GASTROINTESTINAL CANCER.
Topics: Adenocarcinoma; Ascites; Deglutition Disorders; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasms | 1964 |
NONSURGICAL TREATMENT OF PULMONARY CANCER.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Agen | 1964 |
NONSURGICAL TREATMENT OF PULMONARY CANCER.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Agen | 1964 |
CARCINOMA OF THE COLON IN ULCERATIVE COLITIS.
Topics: Aged; Aging; Cell Biology; Colitis; Colitis, Ulcerative; Colonic Neoplasms; Fluorouracil; Humans; Me | 1964 |
CARCINOMA OF THE COLON IN ULCERATIVE COLITIS.
Topics: Aged; Aging; Cell Biology; Colitis; Colitis, Ulcerative; Colonic Neoplasms; Fluorouracil; Humans; Me | 1964 |
ALKYLATING AGENTS, ANTI-METABOLITES, ALKALOIDS AND X-RAYS IN THE TREATMENT OF INOPERABLE BRONCHOGENIC CARCINOMA.
Topics: Alkaloids; Alkylating Agents; Antimetabolites; Antineoplastic Agents; Carcinoma; Carcinoma, Bronchog | 1964 |
ALKYLATING AGENTS, ANTI-METABOLITES, ALKALOIDS AND X-RAYS IN THE TREATMENT OF INOPERABLE BRONCHOGENIC CARCINOMA.
Topics: Alkaloids; Alkylating Agents; Antimetabolites; Antineoplastic Agents; Carcinoma; Carcinoma, Bronchog | 1964 |
TREATMENT OF MALIGNANT TUMOURS WITH 5-FLUOROURACIL IN 80 PATIENTS.
Topics: Biomedical Research; Breast Neoplasms; Colonic Neoplasms; Drug Therapy; Esophageal Neoplasms; Female | 1964 |
TREATMENT OF MALIGNANT TUMOURS WITH 5-FLUOROURACIL IN 80 PATIENTS.
Topics: Biomedical Research; Breast Neoplasms; Colonic Neoplasms; Drug Therapy; Esophageal Neoplasms; Female | 1964 |
[PRESENT POSSIBILITIES OF CHEMOPROPHYLAXIS, COMPLEMENTARY AND PALLIATIVE CHEMOTHERAPY IN ASSOCIATION WITH SURGERY IN THE TREATMENT OF UTERINE NEOPLASMS].
Topics: Adenocarcinoma; Antineoplastic Agents; Aziridines; Chemoprevention; Female; Fluorouracil; Humans; Mi | 1964 |
[PRESENT POSSIBILITIES OF CHEMOPROPHYLAXIS, COMPLEMENTARY AND PALLIATIVE CHEMOTHERAPY IN ASSOCIATION WITH SURGERY IN THE TREATMENT OF UTERINE NEOPLASMS].
Topics: Adenocarcinoma; Antineoplastic Agents; Aziridines; Chemoprevention; Female; Fluorouracil; Humans; Mi | 1964 |
THE ROLE OF DEOXYRIBONUCLEIC ACID IN THE SYNTHESIS OF ROUS SARCOMA VIRUS.
Topics: Animals; Avian Sarcoma Viruses; Colchicine; Dactinomycin; DNA; DNA, Neoplasm; DNA, Viral; Fluorourac | 1964 |
THE ROLE OF DEOXYRIBONUCLEIC ACID IN THE SYNTHESIS OF ROUS SARCOMA VIRUS.
Topics: Animals; Avian Sarcoma Viruses; Colchicine; Dactinomycin; DNA; DNA, Neoplasm; DNA, Viral; Fluorourac | 1964 |
RESPONSE OF PRIMARY UNKNOWN CANCERS TO TREATMENT WITH 5-FLUOROURACIL (NSC-19893).
Topics: Adolescent; Biomedical Research; Child; Cyclophosphamide; Floxuridine; Fluorouracil; Geriatrics; Neo | 1964 |
RESPONSE OF PRIMARY UNKNOWN CANCERS TO TREATMENT WITH 5-FLUOROURACIL (NSC-19893).
Topics: Adolescent; Biomedical Research; Child; Cyclophosphamide; Floxuridine; Fluorouracil; Geriatrics; Neo | 1964 |
CLINICAL STUDIES OF COMBINED CHEMOTHERAPY AND IRRADIATION IN INOPERABLE BRONCHOGENIC CARCINOMA.
Topics: Adenocarcinoma; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophosphamide; Fluo | 1964 |
CLINICAL STUDIES OF COMBINED CHEMOTHERAPY AND IRRADIATION IN INOPERABLE BRONCHOGENIC CARCINOMA.
Topics: Adenocarcinoma; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophosphamide; Fluo | 1964 |
THE PRACTITIONER AND CANCER CHEMOTHERAPY.
Topics: Anti-Bacterial Agents; Antimetabolites; Antineoplastic Agents; Cortisone; Cyclophosphamide; Fluorour | 1964 |
THE PRACTITIONER AND CANCER CHEMOTHERAPY.
Topics: Anti-Bacterial Agents; Antimetabolites; Antineoplastic Agents; Cortisone; Cyclophosphamide; Fluorour | 1964 |
TREATMENT OF BLADDER TUMORS BY DIRECT INSTILLATION OF 5-FLUOROURACIL. EXPERIMENTAL OBSERVATIONS IN DOGS.
Topics: Amines; Animals; Carcinogens; Carcinoma; Carcinoma, Transitional Cell; Dogs; Fluorouracil; Gastroent | 1964 |
TREATMENT OF BLADDER TUMORS BY DIRECT INSTILLATION OF 5-FLUOROURACIL. EXPERIMENTAL OBSERVATIONS IN DOGS.
Topics: Amines; Animals; Carcinogens; Carcinoma; Carcinoma, Transitional Cell; Dogs; Fluorouracil; Gastroent | 1964 |
THE TREATMENT OF CANCER BY ISOLATION PERFUSION.
Topics: Alkylating Agents; Anti-Bacterial Agents; Antimetabolites; Antineoplastic Agents; Chemotherapy, Canc | 1964 |
THE TREATMENT OF CANCER BY ISOLATION PERFUSION.
Topics: Alkylating Agents; Anti-Bacterial Agents; Antimetabolites; Antineoplastic Agents; Chemotherapy, Canc | 1964 |
SKIN CHANGES CAUSED BY CANCER CHEMOTHERAPY.
Topics: Alopecia; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antineoplastic Agents; Cyclophosphamid | 1964 |
SKIN CHANGES CAUSED BY CANCER CHEMOTHERAPY.
Topics: Alopecia; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antineoplastic Agents; Cyclophosphamid | 1964 |
[REGIONAL INTRA-ARTERIAL CYTOSTATIC THERAPY OF MALIGNANT TUMORS OF THE HEAD AND NECK].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Fluorouracil; Head; Head and Neck Neoplasms; Humans | 1964 |
[REGIONAL INTRA-ARTERIAL CYTOSTATIC THERAPY OF MALIGNANT TUMORS OF THE HEAD AND NECK].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Fluorouracil; Head; Head and Neck Neoplasms; Humans | 1964 |
FLUOROURACIL COLON-RECTUM ADJUVANT CHEMOTHERAPY.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Therapy; Fluorouracil; Humans; Infusions, Parenteral | 1964 |
FLUOROURACIL COLON-RECTUM ADJUVANT CHEMOTHERAPY.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Therapy; Fluorouracil; Humans; Infusions, Parenteral | 1964 |
EXPERIMENTAL CHEMOTHERAPY STUDIES. V. THE COLLATERAL SENSITIVITY TO ALKYLATING AGENTS OF SEVERAL ANTIMETABOLITE-RESISTANT ASCITES TUMORS IN MICE.
Topics: Alkylating Agents; Animals; Antimetabolites; Antineoplastic Agents; Ascites; Azaserine; Carcinoma, E | 1964 |
EXPERIMENTAL CHEMOTHERAPY STUDIES. V. THE COLLATERAL SENSITIVITY TO ALKYLATING AGENTS OF SEVERAL ANTIMETABOLITE-RESISTANT ASCITES TUMORS IN MICE.
Topics: Alkylating Agents; Animals; Antimetabolites; Antineoplastic Agents; Ascites; Azaserine; Carcinoma, E | 1964 |
HYPERBARIC OXYGEN AND 5-FLUOROURACIL IN THE TREATMENT OF EXPERIMENTAL MELANOMA.
Topics: Animals; Fluorouracil; Hyperbaric Oxygenation; Melanoma; Melanoma, Experimental; Mice; Neoplasms; Ne | 1964 |
HYPERBARIC OXYGEN AND 5-FLUOROURACIL IN THE TREATMENT OF EXPERIMENTAL MELANOMA.
Topics: Animals; Fluorouracil; Hyperbaric Oxygenation; Melanoma; Melanoma, Experimental; Mice; Neoplasms; Ne | 1964 |
TIME-DOSE RELATIONSHIP OF 5-FLUROURACIL.
Topics: Dogs; Dosage Forms; Fluorouracil; Neoplasms; Pharmacology; Research; Toxicology | 1964 |
TIME-DOSE RELATIONSHIP OF 5-FLUROURACIL.
Topics: Dogs; Dosage Forms; Fluorouracil; Neoplasms; Pharmacology; Research; Toxicology | 1964 |
OBSERVATIONS ON THE USE OF CANCER CHEMOTHERAPEUTIC AGENTS IN PATIENTS WITH MYCOSIS FUNGOIDES.
Topics: Alkylating Agents; Anti-Bacterial Agents; Antineoplastic Agents; Carbamates; Chlorambucil; Dactinomy | 1964 |
OBSERVATIONS ON THE USE OF CANCER CHEMOTHERAPEUTIC AGENTS IN PATIENTS WITH MYCOSIS FUNGOIDES.
Topics: Alkylating Agents; Anti-Bacterial Agents; Antineoplastic Agents; Carbamates; Chlorambucil; Dactinomy | 1964 |
REGRESSION OF METASTATIC HEPATOMEGALY FROM MAMMARY CARCINOMA. CYTOTOXIC COMBINATION CHEMOTHERAPY WITH 5-FU.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Hepatomegaly; Humans; L | 1964 |
REGRESSION OF METASTATIC HEPATOMEGALY FROM MAMMARY CARCINOMA. CYTOTOXIC COMBINATION CHEMOTHERAPY WITH 5-FU.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Hepatomegaly; Humans; L | 1964 |
[TREATMENT OF INOPERABLE BRONCHIAL CANCER WITH A COMBINATION OF CHEMOTHERAPY AND IRRADIATION].
Topics: Bronchial Neoplasms; Carcinoma, Bronchogenic; Cyclophosphamide; Fluorouracil; Humans; Idoxuridine; L | 1964 |
[TREATMENT OF INOPERABLE BRONCHIAL CANCER WITH A COMBINATION OF CHEMOTHERAPY AND IRRADIATION].
Topics: Bronchial Neoplasms; Carcinoma, Bronchogenic; Cyclophosphamide; Fluorouracil; Humans; Idoxuridine; L | 1964 |
COMBINATION OF SURGERY AND CHEMOTHERAPY IN THE TREATMENT OF ORAL CANCER.
Topics: DNA; DNA, Neoplasm; Drug Therapy; Fluorouracil; Humans; Methotrexate; Mouth Neoplasms; Neck Dissecti | 1964 |
COMBINATION OF SURGERY AND CHEMOTHERAPY IN THE TREATMENT OF ORAL CANCER.
Topics: DNA; DNA, Neoplasm; Drug Therapy; Fluorouracil; Humans; Methotrexate; Mouth Neoplasms; Neck Dissecti | 1964 |
CEREBELLAR ATAXIA ASSOCIATED WITH FLUORINATED PYRIMIDINE THERAPY.
Topics: Ataxia; Cerebellar Ataxia; Cerebellar Diseases; Floxuridine; Fluorouracil; Gastrointestinal Neoplasm | 1964 |
CEREBELLAR ATAXIA ASSOCIATED WITH FLUORINATED PYRIMIDINE THERAPY.
Topics: Ataxia; Cerebellar Ataxia; Cerebellar Diseases; Floxuridine; Fluorouracil; Gastrointestinal Neoplasm | 1964 |
REGIONAL INTRA-ARTERIAL INFUSION OF 5-FLUOROURACIL FOR CANCER.
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Carcinoma, Squamous Cell; Female; Fluorouracil; Glioblast | 1964 |
REGIONAL INTRA-ARTERIAL INFUSION OF 5-FLUOROURACIL FOR CANCER.
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Carcinoma, Squamous Cell; Female; Fluorouracil; Glioblast | 1964 |
A LESS TOXIC FLUOROURACIL DOSAGE SCHEDULE.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Epistaxis; Female; Floxurid | 1964 |
A LESS TOXIC FLUOROURACIL DOSAGE SCHEDULE.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Epistaxis; Female; Floxurid | 1964 |
ACUTE CEREBELLAR SYNDROME SECONDARY TO 5-FLUOROURACIL THERAPY.
Topics: Abdominal Neoplasms; Adenocarcinoma; Bone Neoplasms; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, | 1964 |
ACUTE CEREBELLAR SYNDROME SECONDARY TO 5-FLUOROURACIL THERAPY.
Topics: Abdominal Neoplasms; Adenocarcinoma; Bone Neoplasms; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, | 1964 |
CLINICAL EXPERIENCE WITH PALLIATION OF METASTATIC ADENOCARCINOMA WITH 5-FLUOROURACIL CHEMOTHERAPY.
Topics: Adenocarcinoma; Bone Neoplasms; Breast Neoplasms; Colonic Neoplasms; Dextropropoxyphene; Fluorouraci | 1964 |
CLINICAL EXPERIENCE WITH PALLIATION OF METASTATIC ADENOCARCINOMA WITH 5-FLUOROURACIL CHEMOTHERAPY.
Topics: Adenocarcinoma; Bone Neoplasms; Breast Neoplasms; Colonic Neoplasms; Dextropropoxyphene; Fluorouraci | 1964 |
STUDIES IN THE TOXICITY AND CLINICAL APPLICATION OF 5-FLUOROURACIL.
Topics: Fluorouracil; Neoplasms; Pharmacology; Toxicology | 1964 |
STUDIES IN THE TOXICITY AND CLINICAL APPLICATION OF 5-FLUOROURACIL.
Topics: Fluorouracil; Neoplasms; Pharmacology; Toxicology | 1964 |
ANTICANCER AGENTS.
Topics: Alkylating Agents; Aminopterin; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cor | 1964 |
ANTICANCER AGENTS.
Topics: Alkylating Agents; Aminopterin; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cor | 1964 |
COMBINED SPLIT-COURSE THERAPY WITH 5-FLUOROURACIL AND MEGAVOLTAGE IRRADIATION.
Topics: Colonic Neoplasms; Drug Therapy; Fluorouracil; Lung Neoplasms; Neoplasms; Radiography, Thoracic; Rad | 1964 |
COMBINED SPLIT-COURSE THERAPY WITH 5-FLUOROURACIL AND MEGAVOLTAGE IRRADIATION.
Topics: Colonic Neoplasms; Drug Therapy; Fluorouracil; Lung Neoplasms; Neoplasms; Radiography, Thoracic; Rad | 1964 |
IN VITRO CULTURE OF YOSHIDA SARCOMA CELLS: METHODS FOR DETERMINING ACQUIRED RESISTANCE TO DRUGS.
Topics: Animals; Antineoplastic Agents; Azaguanine; Culture Media; Cyclophosphamide; Dactinomycin; Drug Tole | 1964 |
IN VITRO CULTURE OF YOSHIDA SARCOMA CELLS: METHODS FOR DETERMINING ACQUIRED RESISTANCE TO DRUGS.
Topics: Animals; Antineoplastic Agents; Azaguanine; Culture Media; Cyclophosphamide; Dactinomycin; Drug Tole | 1964 |
COMBINED 5-FLUOROURACIL AND SUPERVOLTAGE RADIATION THERAPY IN THE PALLIATIVE MANAGEMENT OF ADVANCED GASTROINTESTINAL CANCER: A PILOT STUDY.
Topics: Adenocarcinoma; Biomedical Research; Cobalt Isotopes; Drug Therapy; Fluorouracil; Gastrointestinal N | 1964 |
COMBINED 5-FLUOROURACIL AND SUPERVOLTAGE RADIATION THERAPY IN THE PALLIATIVE MANAGEMENT OF ADVANCED GASTROINTESTINAL CANCER: A PILOT STUDY.
Topics: Adenocarcinoma; Biomedical Research; Cobalt Isotopes; Drug Therapy; Fluorouracil; Gastrointestinal N | 1964 |
[FRICTION RUB SOUNDS IN THE ABDOMEN].
Topics: Abdomen; Auscultation; Blood Protein Electrophoresis; Cyclophosphamide; Fluorouracil; Friction; Geri | 1964 |
[FRICTION RUB SOUNDS IN THE ABDOMEN].
Topics: Abdomen; Auscultation; Blood Protein Electrophoresis; Cyclophosphamide; Fluorouracil; Friction; Geri | 1964 |
CLOSED PELVIC PERFUSION: ISOLATION PERFUSION OF THE PELVIS WITHOUT CELIOTOMY.
Topics: Catheterization; Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Drug Therapy; Fluoroura | 1964 |
CLOSED PELVIC PERFUSION: ISOLATION PERFUSION OF THE PELVIS WITHOUT CELIOTOMY.
Topics: Catheterization; Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Drug Therapy; Fluoroura | 1964 |
PERFUSION TREATMENT OF CANCER.
Topics: Carcinoma; Carcinoma, Squamous Cell; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Fluo | 1965 |
PERFUSION TREATMENT OF CANCER.
Topics: Carcinoma; Carcinoma, Squamous Cell; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Fluo | 1965 |
THE TREATMENT OF ADVANCED CANCER WITH A COMBINATION OF 5-FLUOROURACIL, CYTOXAN, AND METHOTREXATE.
Topics: Cyclophosphamide; Drug Therapy; Fluorouracil; Humans; Methotrexate; Neoplasms; Toxicology | 1964 |
THE TREATMENT OF ADVANCED CANCER WITH A COMBINATION OF 5-FLUOROURACIL, CYTOXAN, AND METHOTREXATE.
Topics: Cyclophosphamide; Drug Therapy; Fluorouracil; Humans; Methotrexate; Neoplasms; Toxicology | 1964 |
CHEMOTHERAPY OF MALIGNANCIES OF THE GASTROINTESTINAL TRACT.
Topics: Antineoplastic Agents; Carcinoid Tumor; Colonic Neoplasms; Cyclophosphamide; Fluorouracil; Gastroint | 1965 |
CHEMOTHERAPY OF MALIGNANCIES OF THE GASTROINTESTINAL TRACT.
Topics: Antineoplastic Agents; Carcinoid Tumor; Colonic Neoplasms; Cyclophosphamide; Fluorouracil; Gastroint | 1965 |
CANCER CHEMOTHERAPY OF THE GASTROINTESTINAL TRACT WITH REFERENCE TO INTRA-ARTERIAL INFUSION AND IRRADIATION.
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cobalt Isotopes; Cyclophosphamide; | 1965 |
CANCER CHEMOTHERAPY OF THE GASTROINTESTINAL TRACT WITH REFERENCE TO INTRA-ARTERIAL INFUSION AND IRRADIATION.
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cobalt Isotopes; Cyclophosphamide; | 1965 |
PELVIC PERFUSION AND CARCINOMA OF THE RECTUM.
Topics: Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Equipment and Supplies; Fluorouracil; Humans; M | 1965 |
PELVIC PERFUSION AND CARCINOMA OF THE RECTUM.
Topics: Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Equipment and Supplies; Fluorouracil; Humans; M | 1965 |
EFFECTIVENESS AND TOXICITY OF PROLONGED INFUSIONS OF 5-FLUOROURACIL IN THE TREATMENT OF CANCER.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma; Carcinoma, Sq | 1965 |
EFFECTIVENESS AND TOXICITY OF PROLONGED INFUSIONS OF 5-FLUOROURACIL IN THE TREATMENT OF CANCER.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma; Carcinoma, Sq | 1965 |
COMBINED INTRA-ARTERIAL CHEMOTHERAPY AND RADIATION TREATMENT FOR ADVANCED CERVICAL CARCINOMA. THE MCCALL TECHNIQUE AND RESULTS.
Topics: Chemotherapy, Cancer, Regional Perfusion; Drug Therapy; Drug Therapy, Combination; Female; Fluoroura | 1965 |
COMBINED INTRA-ARTERIAL CHEMOTHERAPY AND RADIATION TREATMENT FOR ADVANCED CERVICAL CARCINOMA. THE MCCALL TECHNIQUE AND RESULTS.
Topics: Chemotherapy, Cancer, Regional Perfusion; Drug Therapy; Drug Therapy, Combination; Female; Fluoroura | 1965 |
TREATMENT OF BLADDER TUMORS BY INSTILLATION OF THIO-TEPA, ACTINOMYCIN D, OR 5-FLUOROURACIL.
Topics: Carcinoma; Carcinoma, Papillary; Dactinomycin; Drug Therapy; Fluorouracil; Humans; Neoplasms; Thiote | 1965 |
TREATMENT OF BLADDER TUMORS BY INSTILLATION OF THIO-TEPA, ACTINOMYCIN D, OR 5-FLUOROURACIL.
Topics: Carcinoma; Carcinoma, Papillary; Dactinomycin; Drug Therapy; Fluorouracil; Humans; Neoplasms; Thiote | 1965 |
THE INDICATIONS FOR 5-FLUOROURACIL IN THE TREATMENT OF BREAST CANCER.
Topics: Breast Neoplasms; Drug Therapy; Fluorouracil; Geriatrics; Humans; Neoplasm Metastasis; Neoplasms | 1965 |
THE INDICATIONS FOR 5-FLUOROURACIL IN THE TREATMENT OF BREAST CANCER.
Topics: Breast Neoplasms; Drug Therapy; Fluorouracil; Geriatrics; Humans; Neoplasm Metastasis; Neoplasms | 1965 |
SIDE REACTIONS TO THE CHEMOTHERAPY OF SOLID TUMORS.
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy; Fluorouracil; Neoplasms; Toxicology | 1965 |
SIDE REACTIONS TO THE CHEMOTHERAPY OF SOLID TUMORS.
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy; Fluorouracil; Neoplasms; Toxicology | 1965 |
A REPORT UPON ARTERIAL INFUSION WITH 5-FLUOROURACIL IN 100 PATIENTS.
Topics: Arteries; Fluorouracil; Humans; Infusions, Parenteral; Injections, Intra-Arterial; Neoplasms; Pallia | 1965 |
A REPORT UPON ARTERIAL INFUSION WITH 5-FLUOROURACIL IN 100 PATIENTS.
Topics: Arteries; Fluorouracil; Humans; Infusions, Parenteral; Injections, Intra-Arterial; Neoplasms; Pallia | 1965 |
COMPARISON OF THE EFFECTS OF CHEMOTHERAPY AND LOCAL IRRADIATION ON THE VASCULARITY OF A TRANSPLANTED MOUSE MAMMARY ADENOCARCINOMA AND A PLEOMORPHIC SARCOMA.
Topics: Adenocarcinoma; Angiography; Animals; Blood Vessels; Fluorouracil; Mammary Neoplasms, Animal; Mammar | 1965 |
COMPARISON OF THE EFFECTS OF CHEMOTHERAPY AND LOCAL IRRADIATION ON THE VASCULARITY OF A TRANSPLANTED MOUSE MAMMARY ADENOCARCINOMA AND A PLEOMORPHIC SARCOMA.
Topics: Adenocarcinoma; Angiography; Animals; Blood Vessels; Fluorouracil; Mammary Neoplasms, Animal; Mammar | 1965 |
REGIONAL ARTERIAL INFUSION OF ANTIMETABOLITES. AN ANALYSIS OF THE RESULTS OBTAINED IN 33 PATIENTS WITH MALIGNANT TUMORS OF THE HEAD AND NECK.
Topics: Antimetabolites; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; H | 1965 |
REGIONAL ARTERIAL INFUSION OF ANTIMETABOLITES. AN ANALYSIS OF THE RESULTS OBTAINED IN 33 PATIENTS WITH MALIGNANT TUMORS OF THE HEAD AND NECK.
Topics: Antimetabolites; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; H | 1965 |
[ANTI-CANCER CHEMOTHERAPY BY PROLONGED INTRA-ARTERIAL INFUSIONS].
Topics: Adrenal Cortex Hormones; Aminocaproates; Aminocaproic Acid; Anti-Bacterial Agents; Chemotherapy, Can | 1965 |
[ANTI-CANCER CHEMOTHERAPY BY PROLONGED INTRA-ARTERIAL INFUSIONS].
Topics: Adrenal Cortex Hormones; Aminocaproates; Aminocaproic Acid; Anti-Bacterial Agents; Chemotherapy, Can | 1965 |
RECTAL MUCOSAL BIOPSY IN THE EVALUATION OF CANCER CHEMOTHERAPY.
Topics: Adenocarcinoma; Biopsy; Cecal Neoplasms; Drug Therapy; Fluorouracil; Humans; Mucous Membrane; Neopla | 1965 |
RECTAL MUCOSAL BIOPSY IN THE EVALUATION OF CANCER CHEMOTHERAPY.
Topics: Adenocarcinoma; Biopsy; Cecal Neoplasms; Drug Therapy; Fluorouracil; Humans; Mucous Membrane; Neopla | 1965 |
SQUAMOUS CELL CARCINOMA OF ORAL CAVITY; INTRA-ARTERIAL INFUSION WITH FLUOROURACIL AND IDOXURIDINE.
Topics: Carcinoma; Carcinoma, Squamous Cell; Drug Therapy; Fluorouracil; Humans; Idoxuridine; Infusions, Int | 1965 |
SQUAMOUS CELL CARCINOMA OF ORAL CAVITY; INTRA-ARTERIAL INFUSION WITH FLUOROURACIL AND IDOXURIDINE.
Topics: Carcinoma; Carcinoma, Squamous Cell; Drug Therapy; Fluorouracil; Humans; Idoxuridine; Infusions, Int | 1965 |
CLOSED PELVIC PERFUSION IN ADVANCED GYNECOLOGIC CANCER.
Topics: Catheterization; Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Female; Fluorouracil; F | 1965 |
CLOSED PELVIC PERFUSION IN ADVANCED GYNECOLOGIC CANCER.
Topics: Catheterization; Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Female; Fluorouracil; F | 1965 |
TREATMENT OF MALIGNANT NEOPLASMS OF THE GASTROINTESTINAL TRACT WITH A COMBINATION OF 5-FLUOROURACIL AND RADIATION: A RANDOMIZED DOUBLE-BLIND STUDY.
Topics: Adenocarcinoma; Colonic Neoplasms; Double-Blind Method; Drug Therapy; Fluorouracil; Humans; Neoplasm | 1965 |
TREATMENT OF MALIGNANT NEOPLASMS OF THE GASTROINTESTINAL TRACT WITH A COMBINATION OF 5-FLUOROURACIL AND RADIATION: A RANDOMIZED DOUBLE-BLIND STUDY.
Topics: Adenocarcinoma; Colonic Neoplasms; Double-Blind Method; Drug Therapy; Fluorouracil; Humans; Neoplasm | 1965 |
TUMORS OF THE SKIN. IV. DOUBLE-BLIND STUDY ON EFFECTS OF LOCAL ADMINISTRATION OF ANTI-TUMOR AGENTS IN BASAL CELL CARCINOMA.
Topics: Antineoplastic Agents; Carcinoma, Basal Cell; Dactinomycin; Double-Blind Method; Drug Therapy; Fluor | 1965 |
TUMORS OF THE SKIN. IV. DOUBLE-BLIND STUDY ON EFFECTS OF LOCAL ADMINISTRATION OF ANTI-TUMOR AGENTS IN BASAL CELL CARCINOMA.
Topics: Antineoplastic Agents; Carcinoma, Basal Cell; Dactinomycin; Double-Blind Method; Drug Therapy; Fluor | 1965 |
N-ISOPROPYL-ALPHA-(2-METHYLHYDRAZINO)-P-TOLUAMIDE, HYDROCHLORIDE (NSC-77213) IN TREATMENT OF SOLID TUMORS.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Therapy; Fluorouracil; Humans; Injections, Intra-Arter | 1965 |
N-ISOPROPYL-ALPHA-(2-METHYLHYDRAZINO)-P-TOLUAMIDE, HYDROCHLORIDE (NSC-77213) IN TREATMENT OF SOLID TUMORS.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Therapy; Fluorouracil; Humans; Injections, Intra-Arter | 1965 |
PYRIMIDINE METABOLISM IN TISSUE CULTURE CELLS DERIVED FROM RAT HEPATOMAS. I. SUSPENSION CELL CULTURES DERIVED FROM THE NOVIKOFF HEPATOMA.
Topics: Animals; Carcinoma, Hepatocellular; Cell Culture Techniques; Floxuridine; Fluorouracil; Glycine; Liv | 1965 |
PYRIMIDINE METABOLISM IN TISSUE CULTURE CELLS DERIVED FROM RAT HEPATOMAS. I. SUSPENSION CELL CULTURES DERIVED FROM THE NOVIKOFF HEPATOMA.
Topics: Animals; Carcinoma, Hepatocellular; Cell Culture Techniques; Floxuridine; Fluorouracil; Glycine; Liv | 1965 |
SYSTEMIC CHEMOTHERAPY FOR CNS METASTASES OF SOLID TUMORS.
Topics: Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy; Floxuridine; Fluo | 1965 |
SYSTEMIC CHEMOTHERAPY FOR CNS METASTASES OF SOLID TUMORS.
Topics: Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy; Floxuridine; Fluo | 1965 |
[METHYLHYDRAZINE IN THE TREATMENT OF SOLID TUMORS].
Topics: Adolescent; Antineoplastic Agents; Fluorouracil; Geriatrics; Humans; Hydrazines; Methylhydrazines; N | 1965 |
[METHYLHYDRAZINE IN THE TREATMENT OF SOLID TUMORS].
Topics: Adolescent; Antineoplastic Agents; Fluorouracil; Geriatrics; Humans; Hydrazines; Methylhydrazines; N | 1965 |
[RESULTS OF COMBINED TREATMENT OF LUNG CANCER (5-FLUOROURACIL AND ROENTGENTHERAPY)].
Topics: Combined Modality Therapy; Fluorouracil; Humans; Lung Neoplasms; Neoplasms | 1965 |
[RESULTS OF COMBINED TREATMENT OF LUNG CANCER (5-FLUOROURACIL AND ROENTGENTHERAPY)].
Topics: Combined Modality Therapy; Fluorouracil; Humans; Lung Neoplasms; Neoplasms | 1965 |
DIFFERENTIAL EFFECTS OF INHIBITORS ON THE STEPS LEADING TO THE FORMATION OF SV40 TUMOR AND VIRUS ANTIGENS.
Topics: Animals; Antigens; Antigens, Viral; Antimetabolites; Chlorocebus aethiops; Complement Fixation Tests | 1965 |
DIFFERENTIAL EFFECTS OF INHIBITORS ON THE STEPS LEADING TO THE FORMATION OF SV40 TUMOR AND VIRUS ANTIGENS.
Topics: Animals; Antigens; Antigens, Viral; Antimetabolites; Chlorocebus aethiops; Complement Fixation Tests | 1965 |
[USE OF 5-FLUOROURACIL IN CLINICAL MALIGNANT TUMORS].
Topics: Fluorouracil; Neoplasms; Toxicology | 1964 |
[USE OF 5-FLUOROURACIL IN CLINICAL MALIGNANT TUMORS].
Topics: Fluorouracil; Neoplasms; Toxicology | 1964 |
CLOSED PELVIC PERFUSION: A NEW APPROACH TO THE PROBLEM OF ADVANCED GYNECOLOGIC MALIGNANCY.
Topics: Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Drug Therapy; Female; Fluorouracil; Geni | 1965 |
CLOSED PELVIC PERFUSION: A NEW APPROACH TO THE PROBLEM OF ADVANCED GYNECOLOGIC MALIGNANCY.
Topics: Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Drug Therapy; Female; Fluorouracil; Geni | 1965 |
INTRACAVITARY 5-FLUOROURACIL IN MALIGNANT EFFUSIONS.
Topics: Antimetabolites; Fluorouracil; Humans; Infusions, Parenteral; Neoplasm Metastasis; Neoplasms; Perica | 1965 |
INTRACAVITARY 5-FLUOROURACIL IN MALIGNANT EFFUSIONS.
Topics: Antimetabolites; Fluorouracil; Humans; Infusions, Parenteral; Neoplasm Metastasis; Neoplasms; Perica | 1965 |
CHEMOTHERAPY OF BREAST CANCER.
Topics: Antineoplastic Agents; Biomedical Research; Breast Neoplasms; Carcinoma, Ductal; Cyclophosphamide; F | 1965 |
CHEMOTHERAPY OF BREAST CANCER.
Topics: Antineoplastic Agents; Biomedical Research; Breast Neoplasms; Carcinoma, Ductal; Cyclophosphamide; F | 1965 |
[PRELIMINARY RESULTS OF PRIMARY BRONCHOGENIC CARCINOMAS TREATED WITH COBALT-THERAPY ASSOCIATED WITH 5-FLUORO-URACIL. (APROPOS OF 50 CASES)].
Topics: Bronchial Neoplasms; Carcinoma, Bronchogenic; Cobalt; Fluorouracil; Humans; Neoplasms; Radiotherapy, | 1965 |
[PRELIMINARY RESULTS OF PRIMARY BRONCHOGENIC CARCINOMAS TREATED WITH COBALT-THERAPY ASSOCIATED WITH 5-FLUORO-URACIL. (APROPOS OF 50 CASES)].
Topics: Bronchial Neoplasms; Carcinoma, Bronchogenic; Cobalt; Fluorouracil; Humans; Neoplasms; Radiotherapy, | 1965 |
Reduction of 5-fluorouracil toxicity in man with retention of anticancer effects by prolonged intravenous administration in 5 per cent dextrose.
Topics: Administration, Intravenous; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Glucose; | 1960 |
Reduction of 5-fluorouracil toxicity in man with retention of anticancer effects by prolonged intravenous administration in 5 per cent dextrose.
Topics: Administration, Intravenous; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Glucose; | 1960 |
Evaluation of 5-fluorouracil in the treatment of cancer.
Topics: Fluorouracil; Neoplasms; Uracil | 1960 |
Evaluation of 5-fluorouracil in the treatment of cancer.
Topics: Fluorouracil; Neoplasms; Uracil | 1960 |
Permeability of Ehrlich cells to uracil, thymine and fluorouracil.
Topics: Fluorouracil; Humans; Neoplasms; Permeability; Thymine; Uracil | 1962 |
Permeability of Ehrlich cells to uracil, thymine and fluorouracil.
Topics: Fluorouracil; Humans; Neoplasms; Permeability; Thymine; Uracil | 1962 |
The role of 5-fluorouracil in malignant disease.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil | 1961 |
The role of 5-fluorouracil in malignant disease.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil | 1961 |
Tumors of the skin. II. Keratoacanthoma; local effct of 5-fluorouracil.
Topics: Fluorouracil; Humans; Keratoacanthoma; Neoplasms; Skin; Skin Neoplasms; Uracil | 1962 |
Tumors of the skin. II. Keratoacanthoma; local effct of 5-fluorouracil.
Topics: Fluorouracil; Humans; Keratoacanthoma; Neoplasms; Skin; Skin Neoplasms; Uracil | 1962 |
Biochemical changes during treatment with 5-fluorouracil.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Phosphotransferases; Uracil | 1962 |
Biochemical changes during treatment with 5-fluorouracil.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Phosphotransferases; Uracil | 1962 |
Massive intra-aortic injections of nitrogen mustard (Dichloren), 5-fluorouracil, nitromin, and endoxan prior to roentgen irradiation for advanced tumors of the uterus.
Topics: Antineoplastic Agents; Cyclophosphamide; Female; Fluorouracil; Humans; Mechlorethamine; Neoplasms; N | 1962 |
Massive intra-aortic injections of nitrogen mustard (Dichloren), 5-fluorouracil, nitromin, and endoxan prior to roentgen irradiation for advanced tumors of the uterus.
Topics: Antineoplastic Agents; Cyclophosphamide; Female; Fluorouracil; Humans; Mechlorethamine; Neoplasms; N | 1962 |
Use of 5-fluorouracil in disseminated solid neoplasms.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil | 1962 |
Use of 5-fluorouracil in disseminated solid neoplasms.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil | 1962 |
Anti-tumor activities of decursinol angelate and decursin from Angelica gigas.
Topics: Angelica; Animals; Antineoplastic Agents, Phytogenic; Benzopyrans; Butyrates; Cell Line, Tumor; Fluo | 2003 |
Anti-tumor activities of decursinol angelate and decursin from Angelica gigas.
Topics: Angelica; Animals; Antineoplastic Agents, Phytogenic; Benzopyrans; Butyrates; Cell Line, Tumor; Fluo | 2003 |
Capecitabine in colorectal, breast, and other solid tumors: novel therapeutic approaches. Selected abstracts from ASCO 2003.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deox | 2003 |
Capecitabine in colorectal, breast, and other solid tumors: novel therapeutic approaches. Selected abstracts from ASCO 2003.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deox | 2003 |
Developing a patient pathway to deliver a new oral chemotherapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Critical Pathways; Fluorouracil; Humans; Neop | 2003 |
Developing a patient pathway to deliver a new oral chemotherapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Critical Pathways; Fluorouracil; Humans; Neop | 2003 |
[Cancer chemotherapy in the future. Discussion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Delivery Sys | 2003 |
[Cancer chemotherapy in the future. Discussion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Delivery Sys | 2003 |
Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); DNA Mutational Analysis; DNA, N | 2003 |
Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); DNA Mutational Analysis; DNA, N | 2003 |
The role of p53 in the chemotherapeutic responses to cisplatin, doxorubicin and 5-fluorouracil treatment.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cisplatin; Doxorubicin; Female; Fluorouracil; Hum | 2004 |
The role of p53 in the chemotherapeutic responses to cisplatin, doxorubicin and 5-fluorouracil treatment.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cisplatin; Doxorubicin; Female; Fluorouracil; Hum | 2004 |
Clinical trials with GDEPT: cytosine deaminase and 5-fluorocytosine.
Topics: Autoradiography; Chromatography, Thin Layer; Clinical Trials as Topic; Cytosine Deaminase; Fluoroura | 2004 |
Clinical trials with GDEPT: cytosine deaminase and 5-fluorocytosine.
Topics: Autoradiography; Chromatography, Thin Layer; Clinical Trials as Topic; Cytosine Deaminase; Fluoroura | 2004 |
Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro.
Topics: Animals; Antibodies; Cadherins; Cell Cycle; Cell Line, Tumor; Drug Resistance; Etoposide; Fluorourac | 2004 |
Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro.
Topics: Animals; Antibodies; Cadherins; Cell Cycle; Cell Line, Tumor; Drug Resistance; Etoposide; Fluorourac | 2004 |
Potential therapeutic applications of recombinant, invasive E. coli.
Topics: Adhesins, Bacterial; Animals; Antineoplastic Agents; Bacterial Proteins; Caco-2 Cells; Cell Line; De | 2004 |
Potential therapeutic applications of recombinant, invasive E. coli.
Topics: Adhesins, Bacterial; Animals; Antineoplastic Agents; Bacterial Proteins; Caco-2 Cells; Cell Line; De | 2004 |
[Management of chemotherapy induced diarrhea].
Topics: Antidiarrheals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2004 |
[Management of chemotherapy induced diarrhea].
Topics: Antidiarrheals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2004 |
The DNA double-stranded break repair protein endo-exonuclease as a therapeutic target for cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; | 2004 |
The DNA double-stranded break repair protein endo-exonuclease as a therapeutic target for cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; | 2004 |
Dihydopyrimidine dehydrogenase: a critical molecular biomarker for 5-Fluorouracil toxicity.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Human | 2004 |
Dihydopyrimidine dehydrogenase: a critical molecular biomarker for 5-Fluorouracil toxicity.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Human | 2004 |
Random mutagenesis and selection of Escherichia coli cytosine deaminase for cancer gene therapy.
Topics: Amino Acid Sequence; Amino Acid Substitution; Antimetabolites, Antineoplastic; Cytosine Deaminase; E | 2004 |
Random mutagenesis and selection of Escherichia coli cytosine deaminase for cancer gene therapy.
Topics: Amino Acid Sequence; Amino Acid Substitution; Antimetabolites, Antineoplastic; Cytosine Deaminase; E | 2004 |
Low-dose warfarin prophylaxis for catheter-associated thrombosis in cancer patients. Can it be safely associated with 5-Fluorouracil-based chemotherapy?
Topics: Anticoagulants; Antimetabolites, Antineoplastic; Catheterization, Central Venous; Catheters, Indwell | 2004 |
Low-dose warfarin prophylaxis for catheter-associated thrombosis in cancer patients. Can it be safely associated with 5-Fluorouracil-based chemotherapy?
Topics: Anticoagulants; Antimetabolites, Antineoplastic; Catheterization, Central Venous; Catheters, Indwell | 2004 |
The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies.
Topics: Animals; Antineoplastic Agents; Artificial Gene Fusion; Brain; Cytosine Deaminase; Diffusion Magneti | 2004 |
The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies.
Topics: Animals; Antineoplastic Agents; Artificial Gene Fusion; Brain; Cytosine Deaminase; Diffusion Magneti | 2004 |
Three-color labeling method for flow cytometric measurement of cytogenetic damage in rodent and human blood.
Topics: Adult; Animals; Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Antimetabolites, Antineoplast | 2004 |
Three-color labeling method for flow cytometric measurement of cytogenetic damage in rodent and human blood.
Topics: Adult; Animals; Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Antimetabolites, Antineoplast | 2004 |
Tumor-based pharmacokinetics has greater significance for anticancer drugs than does blood-based pharmacokinetics.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Drug Interactions; Fluorouracil; Humans; Neo | 2004 |
Tumor-based pharmacokinetics has greater significance for anticancer drugs than does blood-based pharmacokinetics.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Drug Interactions; Fluorouracil; Humans; Neo | 2004 |
A non-radioactive sensitive assay to measure 5-fluorouracil incorporation into DNA of solid tumors.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA; Drug Screening A | 2004 |
A non-radioactive sensitive assay to measure 5-fluorouracil incorporation into DNA of solid tumors.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA; Drug Screening A | 2004 |
Role of platelet derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity and potential role of deoxyribose-1-phosphate.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Dose-Response Relationship, Drug; Fluorouracil; H | 2004 |
Role of platelet derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity and potential role of deoxyribose-1-phosphate.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Dose-Response Relationship, Drug; Fluorouracil; H | 2004 |
Capecitabine: fixed daily dose and continuous (noncyclic) dosing schedule.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Drug Administra | 2004 |
Capecitabine: fixed daily dose and continuous (noncyclic) dosing schedule.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Drug Administra | 2004 |
Should screening for DPD deficiency be mandatory before 5-FU exposure?
Topics: Antineoplastic Agents; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP | 2004 |
Should screening for DPD deficiency be mandatory before 5-FU exposure?
Topics: Antineoplastic Agents; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP | 2004 |
Synthesis of [18F]Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers.
Topics: Animals; Capecitabine; Deoxycytidine; Fluorine Radioisotopes; Fluorouracil; Humans; Isotope Labeling | 2004 |
Synthesis of [18F]Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers.
Topics: Animals; Capecitabine; Deoxycytidine; Fluorine Radioisotopes; Fluorouracil; Humans; Isotope Labeling | 2004 |
Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth.
Topics: Animals; Apoptosis; Blotting, Western; Caspase 3; Caspases; Cell Hypoxia; Cell Line, Tumor; Cell Pro | 2004 |
Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth.
Topics: Animals; Apoptosis; Blotting, Western; Caspase 3; Caspases; Cell Hypoxia; Cell Line, Tumor; Cell Pro | 2004 |
Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy.
Topics: Blotting, Western; Cell Hypoxia; Cell Line, Tumor; Cytosine Deaminase; Enhancer Elements, Genetic; E | 2005 |
Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy.
Topics: Blotting, Western; Cell Hypoxia; Cell Line, Tumor; Cytosine Deaminase; Enhancer Elements, Genetic; E | 2005 |
The mathematical modelling of adjuvant chemotherapy scheduling: incorporating the effects of protocol rest phases and pharmacokinetics.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Cycle; Cell Survival; | 2005 |
The mathematical modelling of adjuvant chemotherapy scheduling: incorporating the effects of protocol rest phases and pharmacokinetics.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Cycle; Cell Survival; | 2005 |
NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Capillary Permeability; Cell Line, Tumor; Do | 2005 |
NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Capillary Permeability; Cell Line, Tumor; Do | 2005 |
Rapid up-regulation of cyclooxygenase-2 by 5-fluorouracil in human solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cyclooxygenase 2; Enzyme Induction; | 2005 |
Rapid up-regulation of cyclooxygenase-2 by 5-fluorouracil in human solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cyclooxygenase 2; Enzyme Induction; | 2005 |
Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibri | 2005 |
Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibri | 2005 |
Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients.
Topics: Atmospheric Pressure; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Deoxyuridin | 2005 |
Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients.
Topics: Atmospheric Pressure; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Deoxyuridin | 2005 |
Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.
Topics: Antimetabolites, Antineoplastic; Bayes Theorem; Clinical Trials, Phase I as Topic; Computer Simulati | 2005 |
Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.
Topics: Antimetabolites, Antineoplastic; Bayes Theorem; Clinical Trials, Phase I as Topic; Computer Simulati | 2005 |
Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Renal Cell; Cell Line; C | 2005 |
Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Renal Cell; Cell Line; C | 2005 |
Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; | 2005 |
Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; | 2005 |
High incidence of haemostatic interference in cancer patients treated with FOLFOX regimen and concomitant minidose of warfarin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2005 |
High incidence of haemostatic interference in cancer patients treated with FOLFOX regimen and concomitant minidose of warfarin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2005 |
Gender differences in the dihydropyrimidine dehydrogenase expression may contribute to higher toxicity in women treated with 5-fluorouracil therapy.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydro | 2005 |
Gender differences in the dihydropyrimidine dehydrogenase expression may contribute to higher toxicity in women treated with 5-fluorouracil therapy.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydro | 2005 |
Cancer cell adaptation to chemotherapy.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biopsy; Camptothecin | 2005 |
Cancer cell adaptation to chemotherapy.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biopsy; Camptothecin | 2005 |
Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer.
Topics: Adult; Anticoagulants; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Synergism; | 2005 |
Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer.
Topics: Adult; Anticoagulants; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Synergism; | 2005 |
Warfarin-5-FU interactions.
Topics: Anticoagulants; Antimetabolites, Antineoplastic; Drug Interactions; Fluorouracil; Humans; Internatio | 2006 |
Warfarin-5-FU interactions.
Topics: Anticoagulants; Antimetabolites, Antineoplastic; Drug Interactions; Fluorouracil; Humans; Internatio | 2006 |
Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients.
Topics: Adult; Aged; Aged, 80 and over; Anaphylaxis; Antineoplastic Agents; Antineoplastic Combined Chemothe | 2005 |
Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients.
Topics: Adult; Aged; Aged, 80 and over; Anaphylaxis; Antineoplastic Agents; Antineoplastic Combined Chemothe | 2005 |
Advances in radiosensitization.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Cetuxima | 2004 |
Advances in radiosensitization.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Cetuxima | 2004 |
Albumin-bound nanoparticle paclitaxel.
Topics: Albumin-Bound Paclitaxel; Albumins; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; | 2005 |
Albumin-bound nanoparticle paclitaxel.
Topics: Albumin-Bound Paclitaxel; Albumins; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; | 2005 |
Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cryotherapy; F | 2005 |
Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cryotherapy; F | 2005 |
Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Drug Resistance; Fluorouracil; | 2005 |
Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Drug Resistance; Fluorouracil; | 2005 |
Effect of cystathionine beta-synthase variant 844ins68bp and methylenetetrahydrofolate reductase A1298C polymorphisms in xenografts on 5-FU efficacy and doubling time.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Proliferation; Cystathionine beta-Synthase; | 2006 |
Effect of cystathionine beta-synthase variant 844ins68bp and methylenetetrahydrofolate reductase A1298C polymorphisms in xenografts on 5-FU efficacy and doubling time.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Proliferation; Cystathionine beta-Synthase; | 2006 |
TYMS and DPYD polymorphisms in a Turkish population.
Topics: Adult; Aged; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Genetics, Population; Humans; | 2005 |
TYMS and DPYD polymorphisms in a Turkish population.
Topics: Adult; Aged; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Genetics, Population; Humans; | 2005 |
Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
Topics: Adult; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; CpG Islands; Dihydropy | 2005 |
Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
Topics: Adult; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; CpG Islands; Dihydropy | 2005 |
A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
Topics: Adult; Aged; Anemia, Hypochromic; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Anti | 2005 |
A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
Topics: Adult; Aged; Anemia, Hypochromic; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Anti | 2005 |
Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy.
Topics: Age Factors; Animals; Antineoplastic Agents; Cognition; Cyclophosphamide; Female; Fluorouracil; Hipp | 2006 |
Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy.
Topics: Age Factors; Animals; Antineoplastic Agents; Cognition; Cyclophosphamide; Female; Fluorouracil; Hipp | 2006 |
Visualization of telomerase reverse transcriptase (hTERT) promoter activity using a trimodality fusion reporter construct.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Enzyme Activation; Fluorouracil; Gene Expres | 2006 |
Visualization of telomerase reverse transcriptase (hTERT) promoter activity using a trimodality fusion reporter construct.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Enzyme Activation; Fluorouracil; Gene Expres | 2006 |
Timing of significant adverse events is essential information during early development of new drugs.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Administration Schedule; Fluorour | 2006 |
Timing of significant adverse events is essential information during early development of new drugs.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Administration Schedule; Fluorour | 2006 |
A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antimetabolites, Antineoplastic; Blood Coagulation D | 2006 |
A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antimetabolites, Antineoplastic; Blood Coagulation D | 2006 |
Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2006 |
Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2006 |
Regulation of MDK expression in human cancer cells modulates sensitivities to various anticancer drugs: MDK overexpression confers to a multi-drug resistance.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Res | 2007 |
Regulation of MDK expression in human cancer cells modulates sensitivities to various anticancer drugs: MDK overexpression confers to a multi-drug resistance.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Res | 2007 |
Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screenin | 2006 |
Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screenin | 2006 |
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Cell Line, Tumor; Clinical | 2006 |
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Cell Line, Tumor; Clinical | 2006 |
Relation between cytokine promoter gene polymorphism and toxicity of 5-fluorouracil plus cisplatin chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cisplatin; Cytokines; Female; Fluor | 2006 |
Relation between cytokine promoter gene polymorphism and toxicity of 5-fluorouracil plus cisplatin chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cisplatin; Cytokines; Female; Fluor | 2006 |
[FOLFOX].
Topics: Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fluoroura | 2006 |
[FOLFOX].
Topics: Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fluoroura | 2006 |
A proposed clinical test for monitoring fluoropyrimidine therapy: detection and stability of thymidylate synthase ternary complexes.
Topics: Animals; Female; Fluorouracil; Folic Acid Antagonists; Humans; Methotrexate; Mice; Mice, Inbred BALB | 2006 |
A proposed clinical test for monitoring fluoropyrimidine therapy: detection and stability of thymidylate synthase ternary complexes.
Topics: Animals; Female; Fluorouracil; Folic Acid Antagonists; Humans; Methotrexate; Mice; Mice, Inbred BALB | 2006 |
[Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2006 |
[Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2006 |
Cytosine deaminase producing Clostridium may be used in detection of tumors.
Topics: Bacterial Proteins; Clostridium; Cytosine Deaminase; Flucytosine; Fluorouracil; Humans; Neoplasms | 2006 |
Cytosine deaminase producing Clostridium may be used in detection of tumors.
Topics: Bacterial Proteins; Clostridium; Cytosine Deaminase; Flucytosine; Fluorouracil; Humans; Neoplasms | 2006 |
Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.
Topics: Antineoplastic Agents; Camptothecin; cdc25 Phosphatases; Cell Cycle; Checkpoint Kinase 1; Checkpoint | 2006 |
Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.
Topics: Antineoplastic Agents; Camptothecin; cdc25 Phosphatases; Cell Cycle; Checkpoint Kinase 1; Checkpoint | 2006 |
Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; ARNTL Transcription Factors; Basic H | 2006 |
Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; ARNTL Transcription Factors; Basic H | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecit | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecit | 2006 |
Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Cohort S | 2006 |
Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Cohort S | 2006 |
The role of a drug holiday: even patients with cancer need a vacation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovo | 2006 |
The role of a drug holiday: even patients with cancer need a vacation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovo | 2006 |
A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Dihydropyrimidin | 2006 |
A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Dihydropyrimidin | 2006 |
[What happened during these 12 years since CPT-11 was launched in Japan ?].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Proto | 2006 |
[What happened during these 12 years since CPT-11 was launched in Japan ?].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Proto | 2006 |
MDMX regulation of p53 response to ribosomal stress.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Dactinomy | 2006 |
MDMX regulation of p53 response to ribosomal stress.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Dactinomy | 2006 |
Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cycloheximide; Dose-R | 2006 |
Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cycloheximide; Dose-R | 2006 |
The contribution of Gianni Bonadonna to the history of chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; | 2007 |
The contribution of Gianni Bonadonna to the history of chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; | 2007 |
Fourteen novel genetic variations and haplotype structures of the TYMS gene encoding human thymidylate synthase (TS).
Topics: 3' Untranslated Regions; 5' Untranslated Regions; Asian People; Base Sequence; DNA Mutational Analys | 2006 |
Fourteen novel genetic variations and haplotype structures of the TYMS gene encoding human thymidylate synthase (TS).
Topics: 3' Untranslated Regions; 5' Untranslated Regions; Asian People; Base Sequence; DNA Mutational Analys | 2006 |
Changes to the dihydropyrimidine dehydrogenase gene copy number influence the susceptibility of cancers to 5-FU-based drugs: Data mining of the NCI-DTP data sets and validation with human tumour xenografts.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); Drug Resistan | 2007 |
Changes to the dihydropyrimidine dehydrogenase gene copy number influence the susceptibility of cancers to 5-FU-based drugs: Data mining of the NCI-DTP data sets and validation with human tumour xenografts.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); Drug Resistan | 2007 |
Involvement of gene polymorphisms of thymidylate synthase in gene expression, protein activity and anticancer drug cytotoxicity using the NCI-60 panel.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Gene Exp | 2007 |
Involvement of gene polymorphisms of thymidylate synthase in gene expression, protein activity and anticancer drug cytotoxicity using the NCI-60 panel.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Gene Exp | 2007 |
Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated | 2007 |
Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated | 2007 |
[Our outpatient cases for home anti-cancer chemotherapy using a CV port and a portable pump system].
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2006 |
[Our outpatient cases for home anti-cancer chemotherapy using a CV port and a portable pump system].
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2006 |
Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients.
Topics: Adult; Aged; Antineoplastic Agents; Brain; Brain Edema; Capecitabine; Dementia, Vascular; Deoxycytid | 2008 |
Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients.
Topics: Adult; Aged; Antineoplastic Agents; Brain; Brain Edema; Capecitabine; Dementia, Vascular; Deoxycytid | 2008 |
A novel and efficient synthesis of [2-11C]5-fluorouracil for prognosis of cancer chemotherapy.
Topics: Antimetabolites, Antineoplastic; Carbon Radioisotopes; Fluorouracil; Neoplasms; Positron-Emission To | 2007 |
A novel and efficient synthesis of [2-11C]5-fluorouracil for prognosis of cancer chemotherapy.
Topics: Antimetabolites, Antineoplastic; Carbon Radioisotopes; Fluorouracil; Neoplasms; Positron-Emission To | 2007 |
Orotate phosphoribosyltransferase expression level in tumors is a potential determinant of the efficacy of 5-fluorouracil.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Fluorouracil; Gene Expres | 2007 |
Orotate phosphoribosyltransferase expression level in tumors is a potential determinant of the efficacy of 5-fluorouracil.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Fluorouracil; Gene Expres | 2007 |
Topical henna for capecitabine induced hand-foot syndrome.
Topics: Administration, Cutaneous; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine | 2008 |
Topical henna for capecitabine induced hand-foot syndrome.
Topics: Administration, Cutaneous; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine | 2008 |
In vivo gene regulation in Salmonella spp. by a salicylate-dependent control circuit.
Topics: 3-Phosphoshikimate 1-Carboxyvinyltransferase; Animals; Aspirin; Bacterial Proteins; beta-Galactosida | 2007 |
In vivo gene regulation in Salmonella spp. by a salicylate-dependent control circuit.
Topics: 3-Phosphoshikimate 1-Carboxyvinyltransferase; Animals; Aspirin; Bacterial Proteins; beta-Galactosida | 2007 |
Pathogens on aspirin: promising research and therapeutic applications.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bacterial Proteins; Flucytosine; Fluorour | 2007 |
Pathogens on aspirin: promising research and therapeutic applications.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bacterial Proteins; Flucytosine; Fluorour | 2007 |
Pooled analysis of diarrhea events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinic | 2008 |
Pooled analysis of diarrhea events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinic | 2008 |
Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy | 2008 |
Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy | 2008 |
A forward genetic approach for analyzing the mechanism of resistance to the anti-cancer drug, 5-fluorouracil, using Caenorhabditis elegans.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Caenorhabditis elegans; Drug Resistance, Neopla | 2008 |
A forward genetic approach for analyzing the mechanism of resistance to the anti-cancer drug, 5-fluorouracil, using Caenorhabditis elegans.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Caenorhabditis elegans; Drug Resistance, Neopla | 2008 |
Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients.
Topics: Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Asian People; China; Chromatography, Hi | 2008 |
Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients.
Topics: Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Asian People; China; Chromatography, Hi | 2008 |
Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency.
Topics: Antineoplastic Agents; Apoptosis; Calcium Channel Blockers; Cell Cycle; Cell Line, Tumor; Chromosome | 2008 |
Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency.
Topics: Antineoplastic Agents; Apoptosis; Calcium Channel Blockers; Cell Cycle; Cell Line, Tumor; Chromosome | 2008 |
Chemotherapy for the control of pain in inoperable cancer. A report of intra-arterial infusion in four patients.
Topics: Aged; Fluorouracil; Humans; Injections, Intra-Arterial; Male; Methotrexate; Middle Aged; Neoplasms; | 1967 |
Chemotherapy for the control of pain in inoperable cancer. A report of intra-arterial infusion in four patients.
Topics: Aged; Fluorouracil; Humans; Injections, Intra-Arterial; Male; Methotrexate; Middle Aged; Neoplasms; | 1967 |
[5-fluorouracil and its carcinostatic effects].
Topics: Adult; Aged; Animals; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Mice; Middle A | 1967 |
[5-fluorouracil and its carcinostatic effects].
Topics: Adult; Aged; Animals; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Mice; Middle A | 1967 |
New developments in cancer chemotherapy.
Topics: Breast Neoplasms; Female; Fluorouracil; Humans; Male; Neoplasms | 1967 |
New developments in cancer chemotherapy.
Topics: Breast Neoplasms; Female; Fluorouracil; Humans; Male; Neoplasms | 1967 |
Evaluation of beta thromboglobulin levels in cancer patients: effects of antitumor chemotherapy.
Topics: Adult; Aged; Beta-Globulins; beta-Thromboglobulin; Cyclophosphamide; Doxorubicin; Drug Therapy, Comb | 1980 |
Evaluation of beta thromboglobulin levels in cancer patients: effects of antitumor chemotherapy.
Topics: Adult; Aged; Beta-Globulins; beta-Thromboglobulin; Cyclophosphamide; Doxorubicin; Drug Therapy, Comb | 1980 |
[Chemotherapy of malignant solid tumors].
Topics: Bleomycin; Breast Neoplasms; Bronchial Neoplasms; Cyclophosphamide; Fluorouracil; Humans; Kidney Neo | 1980 |
[Chemotherapy of malignant solid tumors].
Topics: Bleomycin; Breast Neoplasms; Bronchial Neoplasms; Cyclophosphamide; Fluorouracil; Humans; Kidney Neo | 1980 |
Metabolism of 5-fluorouracil in various human normal and tumor tissues.
Topics: Adenocarcinoma; Adenosine Triphosphate; Carcinoma, Squamous Cell; Digestive System; Fluorouracil; Ga | 1981 |
Metabolism of 5-fluorouracil in various human normal and tumor tissues.
Topics: Adenocarcinoma; Adenosine Triphosphate; Carcinoma, Squamous Cell; Digestive System; Fluorouracil; Ga | 1981 |
[Growth of tumour-cell colonies from human solid tumours (author's transl)].
Topics: Carmustine; Cisplatin; Clone Cells; Doxorubicin; Drug Resistance; Fluorouracil; Humans; In Vitro Tec | 1982 |
[Growth of tumour-cell colonies from human solid tumours (author's transl)].
Topics: Carmustine; Cisplatin; Clone Cells; Doxorubicin; Drug Resistance; Fluorouracil; Humans; In Vitro Tec | 1982 |
A novel dye exclusion method for testing in vitro chemosensitivity of human tumors.
Topics: Antineoplastic Agents; Cell Line; Cell Survival; Doxorubicin; Drug Evaluation, Preclinical; Eosine Y | 1983 |
A novel dye exclusion method for testing in vitro chemosensitivity of human tumors.
Topics: Antineoplastic Agents; Cell Line; Cell Survival; Doxorubicin; Drug Evaluation, Preclinical; Eosine Y | 1983 |
Interferon potentiates cytotoxic effects of 5-fluorouracil on cell proliferation of established human cell lines originating from neoplastic tissues.
Topics: Cell Line; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; Fluorouracil; HeLa Cells; Hu | 1983 |
Interferon potentiates cytotoxic effects of 5-fluorouracil on cell proliferation of established human cell lines originating from neoplastic tissues.
Topics: Cell Line; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; Fluorouracil; HeLa Cells; Hu | 1983 |
Combined effects of 5-fluorouracil and interferon on proliferation of human neoplastic cells in culture.
Topics: Animals; Cell Line; Cell Transformation, Neoplastic; Drug Evaluation, Preclinical; Fibroblasts; Fluo | 1982 |
Combined effects of 5-fluorouracil and interferon on proliferation of human neoplastic cells in culture.
Topics: Animals; Cell Line; Cell Transformation, Neoplastic; Drug Evaluation, Preclinical; Fibroblasts; Fluo | 1982 |
[Combined effects of 5-fluorouracil and interferon on proliferation of human neoplastic cells in culture].
Topics: Cell Division; Cells, Cultured; Drug Synergism; Fluorouracil; HeLa Cells; Humans; Interferons; Neopl | 1982 |
[Combined effects of 5-fluorouracil and interferon on proliferation of human neoplastic cells in culture].
Topics: Cell Division; Cells, Cultured; Drug Synergism; Fluorouracil; HeLa Cells; Humans; Interferons; Neopl | 1982 |
Vitamins - cytotoxic drug interaction.
Topics: Animals; Antineoplastic Agents; Avitaminosis; Bleomycin; Female; Fluorouracil; Humans; Liver; Neopla | 1983 |
Vitamins - cytotoxic drug interaction.
Topics: Animals; Antineoplastic Agents; Avitaminosis; Bleomycin; Female; Fluorouracil; Humans; Liver; Neopla | 1983 |
Drug resistance in cancer.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Azacitidine; Cisplatin; Cytar | 1984 |
Drug resistance in cancer.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Azacitidine; Cisplatin; Cytar | 1984 |
Comparison of drug sensitivity among tumor cells within a tumor, between primary tumor and metastases, and between different metastases in the human tumor colony-forming assay.
Topics: Antineoplastic Agents; Bleomycin; Cell Division; Cell Survival; Cells, Cultured; Cisplatin; Doxorubi | 1984 |
Comparison of drug sensitivity among tumor cells within a tumor, between primary tumor and metastases, and between different metastases in the human tumor colony-forming assay.
Topics: Antineoplastic Agents; Bleomycin; Cell Division; Cell Survival; Cells, Cultured; Cisplatin; Doxorubi | 1984 |
[The clinical effect of hyperthermia combined with induced hypertension chemotherapy].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Pressure; Cisplatin | 1984 |
[The clinical effect of hyperthermia combined with induced hypertension chemotherapy].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Pressure; Cisplatin | 1984 |
Phase-I trial of combination therapy with continuous-infusion MMPR and continuous-infusion 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Fluorouracil; | 1984 |
Phase-I trial of combination therapy with continuous-infusion MMPR and continuous-infusion 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Fluorouracil; | 1984 |
In vitro and in vivo studies on potentiation of cytotoxic effects of anticancer drugs or cobalt 60 gamma ray by interferon on human neoplastic cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cobal | 1984 |
In vitro and in vivo studies on potentiation of cytotoxic effects of anticancer drugs or cobalt 60 gamma ray by interferon on human neoplastic cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cobal | 1984 |
Biochemical pharmacology in medical oncology.
Topics: Antineoplastic Agents; Cisplatin; Doxorubicin; Floxuridine; Fluorouracil; Humans; Infusions, Intra-A | 1981 |
Biochemical pharmacology in medical oncology.
Topics: Antineoplastic Agents; Cisplatin; Doxorubicin; Floxuridine; Fluorouracil; Humans; Infusions, Intra-A | 1981 |
5'-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow.
Topics: Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Cell Survival; Colonic Neoplasms; Floxuridine; | 1983 |
5'-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow.
Topics: Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Cell Survival; Colonic Neoplasms; Floxuridine; | 1983 |
[Pharmacological and pharmacodynamic aspects of cancer chemotherapy, with special reference to 5-fluorouracil and its derivatives].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Floxuridine; Fluorouracil; Humans | 1982 |
[Pharmacological and pharmacodynamic aspects of cancer chemotherapy, with special reference to 5-fluorouracil and its derivatives].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Floxuridine; Fluorouracil; Humans | 1982 |
Renal complications of cytotoxic therapy.
Topics: Animals; Antineoplastic Agents; Asparaginase; Cisplatin; Cyclophosphamide; Cytarabine; Dogs; Fluorou | 1983 |
Renal complications of cytotoxic therapy.
Topics: Animals; Antineoplastic Agents; Asparaginase; Cisplatin; Cyclophosphamide; Cytarabine; Dogs; Fluorou | 1983 |
Phase I study of continuous-infusion PALA and 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Asparti | 1984 |
Phase I study of continuous-infusion PALA and 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Asparti | 1984 |
[5'-Deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues].
Topics: Administration, Oral; Aged; Animals; Antineoplastic Agents; Enzyme Activation; Female; Floxuridine; | 1984 |
[5'-Deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues].
Topics: Administration, Oral; Aged; Animals; Antineoplastic Agents; Enzyme Activation; Female; Floxuridine; | 1984 |
[Non-hematologic adverse effects of cytostatic drugs].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Diarrhea; Drug Eruptions; Female; | 1984 |
[Non-hematologic adverse effects of cytostatic drugs].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Diarrhea; Drug Eruptions; Female; | 1984 |
Metabolic and distribution studies with radiolabeled 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Animals; Biotransformation; Breast Neoplasms; Carcinoma, Hepatocellular | 1982 |
Metabolic and distribution studies with radiolabeled 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Animals; Biotransformation; Breast Neoplasms; Carcinoma, Hepatocellular | 1982 |
Synthesis of 18F-6-fluoropurine and 18F-6-fluoro-9-beta-d-ribofuranosylpurine.
Topics: Fluorouracil; Isotope Labeling; Neoplasms; Purines; Radionuclide Imaging; Receptors, Cell Surface; R | 1982 |
Synthesis of 18F-6-fluoropurine and 18F-6-fluoro-9-beta-d-ribofuranosylpurine.
Topics: Fluorouracil; Isotope Labeling; Neoplasms; Purines; Radionuclide Imaging; Receptors, Cell Surface; R | 1982 |
Cancer chemotherapy via ambulatory infusion pump.
Topics: Ambulatory Care; Antineoplastic Agents; Doxorubicin; Fluorouracil; Humans; Infusions, Parenteral; Mi | 1983 |
Cancer chemotherapy via ambulatory infusion pump.
Topics: Ambulatory Care; Antineoplastic Agents; Doxorubicin; Fluorouracil; Humans; Infusions, Parenteral; Mi | 1983 |
[Cancer chemotherapy in combination with angiotensin-induced hypertension].
Topics: Angiotensin II; Animals; Blood Pressure; Carbazilquinone; Doxorubicin; Drug Therapy, Combination; Fl | 1983 |
[Cancer chemotherapy in combination with angiotensin-induced hypertension].
Topics: Angiotensin II; Animals; Blood Pressure; Carbazilquinone; Doxorubicin; Drug Therapy, Combination; Fl | 1983 |
The effects of total-body hyperthermia combined with anticancer drugs on immunity in advanced cancer patients.
Topics: Adult; Antineoplastic Agents; Complement System Proteins; Cyclophosphamide; Doxorubicin; Female; Fev | 1983 |
The effects of total-body hyperthermia combined with anticancer drugs on immunity in advanced cancer patients.
Topics: Adult; Antineoplastic Agents; Complement System Proteins; Cyclophosphamide; Doxorubicin; Female; Fev | 1983 |
[UFT concentration in various tissues from cancer patients].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1983 |
[UFT concentration in various tissues from cancer patients].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1983 |
The significance of ascorbic acid, thiamin and retinol in cancer.
Topics: Animals; Ascorbic Acid; Breast Neoplasms; Fluorouracil; Humans; Lung Neoplasms; Mice; Neoplasms; Neo | 1983 |
The significance of ascorbic acid, thiamin and retinol in cancer.
Topics: Animals; Ascorbic Acid; Breast Neoplasms; Fluorouracil; Humans; Lung Neoplasms; Mice; Neoplasms; Neo | 1983 |
[Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Pr | 1983 |
[Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Pr | 1983 |
[Cooperative phase II study of spansule tegafur (SF-SP)].
Topics: Administration, Oral; Aged; Breast Neoplasms; Capsules; Colonic Neoplasms; Delayed-Action Preparatio | 1984 |
[Cooperative phase II study of spansule tegafur (SF-SP)].
Topics: Administration, Oral; Aged; Breast Neoplasms; Capsules; Colonic Neoplasms; Delayed-Action Preparatio | 1984 |
Phase I-II studies of oral tegafur (ftorafur).
Topics: Administration, Oral; Bone Marrow; Breast Neoplasms; Colonic Neoplasms; Dose-Response Relationship, | 1983 |
Phase I-II studies of oral tegafur (ftorafur).
Topics: Administration, Oral; Bone Marrow; Breast Neoplasms; Colonic Neoplasms; Dose-Response Relationship, | 1983 |
Cytolytic activity of interferon-gamma and its synergism with 5-fluorouracil.
Topics: Antibodies, Monoclonal; Cell Line; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Drug | 1984 |
Cytolytic activity of interferon-gamma and its synergism with 5-fluorouracil.
Topics: Antibodies, Monoclonal; Cell Line; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Drug | 1984 |
[Pharmacokinetics of fluoropyrimidines].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ehrlich Tumor; Fluorouracil; Hum | 1984 |
[Pharmacokinetics of fluoropyrimidines].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ehrlich Tumor; Fluorouracil; Hum | 1984 |
[Fluorinated pyrimidines--administration methods].
Topics: Drug Administration Schedule; Fluorouracil; Humans; Infusions, Parenteral; Neoplasms; Tegafur | 1984 |
[Fluorinated pyrimidines--administration methods].
Topics: Drug Administration Schedule; Fluorouracil; Humans; Infusions, Parenteral; Neoplasms; Tegafur | 1984 |
[10 years' use of ftorafur in tumor chemotherapy at the Robert Rössle Institute. A retrospective analysis from the clinical-toxologic point of view].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Adm | 1984 |
[10 years' use of ftorafur in tumor chemotherapy at the Robert Rössle Institute. A retrospective analysis from the clinical-toxologic point of view].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Adm | 1984 |
Effects of combination chemotherapy on immunoregulatory cells in peripheral blood of solid tumor cancer patients: correlation with rebound overshoot immune function recovery.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Cell Adhesion; Drug Therapy, Combination; Fluoroura | 1981 |
Effects of combination chemotherapy on immunoregulatory cells in peripheral blood of solid tumor cancer patients: correlation with rebound overshoot immune function recovery.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Cell Adhesion; Drug Therapy, Combination; Fluoroura | 1981 |
Allopurinol modulation of fluorouracil toxicity.
Topics: Allopurinol; Drug Eruptions; Drug Therapy, Combination; Fluorouracil; Hematologic Diseases; Humans; | 1981 |
Allopurinol modulation of fluorouracil toxicity.
Topics: Allopurinol; Drug Eruptions; Drug Therapy, Combination; Fluorouracil; Hematologic Diseases; Humans; | 1981 |
Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids.
Topics: Cell Line; Cytoplasmic Granules; Drug Resistance; Fluorouracil; Humans; Neoplasms; Vinblastine | 1984 |
Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids.
Topics: Cell Line; Cytoplasmic Granules; Drug Resistance; Fluorouracil; Humans; Neoplasms; Vinblastine | 1984 |
[Mode of action of fluoropyrimidines, in relation to their clinical application].
Topics: Animals; DNA Replication; Fluorouracil; Humans; Leukemia L1210; Mice; Neoplasms; Stomach Neoplasms; | 1984 |
[Mode of action of fluoropyrimidines, in relation to their clinical application].
Topics: Animals; DNA Replication; Fluorouracil; Humans; Leukemia L1210; Mice; Neoplasms; Stomach Neoplasms; | 1984 |
The use of human cancer cell lines as a primary screening system for antineoplastic compounds.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line; Cell Survival; Colonic Neoplasms; Cytarabine; Dr | 1984 |
The use of human cancer cell lines as a primary screening system for antineoplastic compounds.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line; Cell Survival; Colonic Neoplasms; Cytarabine; Dr | 1984 |
On the immunopharmacology of cancer chemotherapeutics.
Topics: Adjuvants, Immunologic; Animals; Antibody-Producing Cells; Antineoplastic Agents; Cyclosporins; Fluo | 1984 |
On the immunopharmacology of cancer chemotherapeutics.
Topics: Adjuvants, Immunologic; Animals; Antibody-Producing Cells; Antineoplastic Agents; Cyclosporins; Fluo | 1984 |
Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Drug Therapy, Combination; Female; Fluorouracil; Leuc | 1983 |
Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Drug Therapy, Combination; Female; Fluorouracil; Leuc | 1983 |
Human muscle: a model for the study of human neoplasia.
Topics: Cell Division; Cell Line; Culture Media; Fluorouracil; Humans; Models, Biological; Muscles; Neoplasm | 1983 |
Human muscle: a model for the study of human neoplasia.
Topics: Cell Division; Cell Line; Culture Media; Fluorouracil; Humans; Models, Biological; Muscles; Neoplasm | 1983 |
Constant intraperitoneal 5-fluorouracil infusion through a totally implanted system.
Topics: Adult; Chemotherapy, Cancer, Regional Perfusion; Chromatography, High Pressure Liquid; Drug Evaluati | 1984 |
Constant intraperitoneal 5-fluorouracil infusion through a totally implanted system.
Topics: Adult; Chemotherapy, Cancer, Regional Perfusion; Chromatography, High Pressure Liquid; Drug Evaluati | 1984 |
Phase I evaluation of a biochemically designed combination: PALA, thymidine, and 5-FU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Drug Evaluation; Fluorouracil; Humans | 1984 |
Phase I evaluation of a biochemically designed combination: PALA, thymidine, and 5-FU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Drug Evaluation; Fluorouracil; Humans | 1984 |
Increased levels of thymidylate synthetase in cells exposed to 5-fluorouracil.
Topics: Cell Line; Fluorodeoxyuridylate; Fluorouracil; Humans; Kinetics; Methyltransferases; Neoplasms; Prot | 1984 |
Increased levels of thymidylate synthetase in cells exposed to 5-fluorouracil.
Topics: Cell Line; Fluorodeoxyuridylate; Fluorouracil; Humans; Kinetics; Methyltransferases; Neoplasms; Prot | 1984 |
The design of rational combination chemotherapy for cancer.
Topics: Antineoplastic Agents; Drug Interactions; Drug Therapy, Combination; Fluorouracil; Humans; Methotrex | 1984 |
The design of rational combination chemotherapy for cancer.
Topics: Antineoplastic Agents; Drug Interactions; Drug Therapy, Combination; Fluorouracil; Humans; Methotrex | 1984 |
Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil.
Topics: Adult; Aged; Biopsy; Cytosol; Female; Fluorouracil; Humans; Injections, Intravenous; Kinetics; Liver | 1984 |
Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil.
Topics: Adult; Aged; Biopsy; Cytosol; Female; Fluorouracil; Humans; Injections, Intravenous; Kinetics; Liver | 1984 |
Review of a new antimetabolic agent, 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione (FD-1).
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Delayed-Action Preparations; Dogs; Drug Evalu | 1980 |
Review of a new antimetabolic agent, 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione (FD-1).
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Delayed-Action Preparations; Dogs; Drug Evalu | 1980 |
Quantitative determination of 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione and its metabolites in visceral tissues by high-performance liquid chromatography and gas chromatography-mass fragmentography.
Topics: Animals; Chromatography, High Pressure Liquid; Fluorouracil; Gas Chromatography-Mass Spectrometry; N | 1980 |
Quantitative determination of 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione and its metabolites in visceral tissues by high-performance liquid chromatography and gas chromatography-mass fragmentography.
Topics: Animals; Chromatography, High Pressure Liquid; Fluorouracil; Gas Chromatography-Mass Spectrometry; N | 1980 |
Chemically triggered time delay activation chemotherapy for the treatment of cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; beta-Glucosidase; DNA, Neoplasm; Dose-Respon | 1980 |
Chemically triggered time delay activation chemotherapy for the treatment of cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; beta-Glucosidase; DNA, Neoplasm; Dose-Respon | 1980 |
Relationship of chemotherapy on human cancer xenografts in nude mice to clinical response in donor patient.
Topics: Adult; Animals; Cytarabine; Drug Resistance; Drug Therapy, Combination; Female; Fluorouracil; Humans | 1980 |
Relationship of chemotherapy on human cancer xenografts in nude mice to clinical response in donor patient.
Topics: Adult; Animals; Cytarabine; Drug Resistance; Drug Therapy, Combination; Female; Fluorouracil; Humans | 1980 |
A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC-148958).
Topics: Administration, Oral; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combination; | 1980 |
A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC-148958).
Topics: Administration, Oral; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combination; | 1980 |
Correlation between the level of urinary D-glucaric acid and the degree of activation of masked compound (FT-207) in cancer patients.
Topics: Adult; Aged; Biotransformation; Cytochrome P-450 Enzyme System; Esophageal Neoplasms; Female; Fluoro | 1981 |
Correlation between the level of urinary D-glucaric acid and the degree of activation of masked compound (FT-207) in cancer patients.
Topics: Adult; Aged; Biotransformation; Cytochrome P-450 Enzyme System; Esophageal Neoplasms; Female; Fluoro | 1981 |
Drug activity and therapeutic synergism in cancer treatment.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration S | 1982 |
Drug activity and therapeutic synergism in cancer treatment.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration S | 1982 |
Enteral versus parenteral nutritional support in cancer patients.
Topics: Animals; Cachexia; Enteral Nutrition; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; | 1981 |
Enteral versus parenteral nutritional support in cancer patients.
Topics: Animals; Cachexia; Enteral Nutrition; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; | 1981 |
[Clinical experiences with UFD-1].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combination | 1982 |
[Clinical experiences with UFD-1].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combination | 1982 |
[Clinical survey on cardiotoxicity of tegafur (FT-207)--compilation of a nationwide survey].
Topics: Administration, Oral; Adult; Aged; Electrocardiography; Female; Fluorouracil; Heart; Humans; Infusio | 1982 |
[Clinical survey on cardiotoxicity of tegafur (FT-207)--compilation of a nationwide survey].
Topics: Administration, Oral; Adult; Aged; Electrocardiography; Female; Fluorouracil; Heart; Humans; Infusio | 1982 |
[Clinical studies of cancer chemotherapy combined with angiotensin-II (ANG-II)].
Topics: Adult; Aged; Angiotensin II; Antibiotics, Antineoplastic; Antineoplastic Agents; Blood Pressure; Bre | 1982 |
[Clinical studies of cancer chemotherapy combined with angiotensin-II (ANG-II)].
Topics: Adult; Aged; Angiotensin II; Antibiotics, Antineoplastic; Antineoplastic Agents; Blood Pressure; Bre | 1982 |
Use of high-dose oral methotrexate sequenced at 24 hours with 5-FU: a clinical toxicity study.
Topics: Breast Neoplasms; Colonic Neoplasms; Drug Administration Schedule; Drug Therapy, Combination; Female | 1983 |
Use of high-dose oral methotrexate sequenced at 24 hours with 5-FU: a clinical toxicity study.
Topics: Breast Neoplasms; Colonic Neoplasms; Drug Administration Schedule; Drug Therapy, Combination; Female | 1983 |
[Cardiotoxicity of drugs used in the treatment of malignant neoplasms].
Topics: Antineoplastic Agents; Arrhythmias, Cardiac; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinatio | 1983 |
[Cardiotoxicity of drugs used in the treatment of malignant neoplasms].
Topics: Antineoplastic Agents; Arrhythmias, Cardiac; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinatio | 1983 |
The delivery of cancer chemotherapy by constant venous infusion. Ambulatory management of venous access and portable pump.
Topics: Ambulatory Care; Antineoplastic Agents; Catheters, Indwelling; Cisplatin; Doxorubicin; Drug Administ | 1982 |
The delivery of cancer chemotherapy by constant venous infusion. Ambulatory management of venous access and portable pump.
Topics: Ambulatory Care; Antineoplastic Agents; Catheters, Indwelling; Cisplatin; Doxorubicin; Drug Administ | 1982 |
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; | 1982 |
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; | 1982 |
Differences in chemotherapeutic susceptibility of human T-, B-, and non-T-/non-B-lymphocytes in culture.
Topics: Asparaginase; Asparagine; B-Lymphocytes; Cell Line; Cytarabine; Dose-Response Relationship, Drug; Fl | 1980 |
Differences in chemotherapeutic susceptibility of human T-, B-, and non-T-/non-B-lymphocytes in culture.
Topics: Asparaginase; Asparagine; B-Lymphocytes; Cell Line; Cytarabine; Dose-Response Relationship, Drug; Fl | 1980 |
Clinical and pharmacological studies of methotrexate-minimal leucovorin rescue plus fluorouracil.
Topics: Adult; Aged; Bone Marrow; Drug Therapy, Combination; Female; Fluorouracil; Half-Life; Humans; Kineti | 1982 |
Clinical and pharmacological studies of methotrexate-minimal leucovorin rescue plus fluorouracil.
Topics: Adult; Aged; Bone Marrow; Drug Therapy, Combination; Female; Fluorouracil; Half-Life; Humans; Kineti | 1982 |
The effect of protein depletion on bone marrow myeloid cell repopulation.
Topics: Animals; Cells, Cultured; Fluorouracil; Hematopoietic Stem Cells; In Vitro Techniques; Male; Mice; M | 1982 |
The effect of protein depletion on bone marrow myeloid cell repopulation.
Topics: Animals; Cells, Cultured; Fluorouracil; Hematopoietic Stem Cells; In Vitro Techniques; Male; Mice; M | 1982 |
Hypogonadism in male patients with metastatic cancer prior to chemotherapy.
Topics: Body Weight; Fluorouracil; Follow-Up Studies; Humans; Hypogonadism; Luteinizing Hormone; Male; Middl | 1982 |
Hypogonadism in male patients with metastatic cancer prior to chemotherapy.
Topics: Body Weight; Fluorouracil; Follow-Up Studies; Humans; Hypogonadism; Luteinizing Hormone; Male; Middl | 1982 |
A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Bone Marrow; Digestive System; Drug Evaluation; D | 1982 |
A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Bone Marrow; Digestive System; Drug Evaluation; D | 1982 |
Cardiac toxicity of 5-fluorouracil: a study on 1083 patients.
Topics: Aged; Angina Pectoris; Drug Therapy, Combination; Female; Fluorouracil; Heart; Humans; Male; Middle | 1982 |
Cardiac toxicity of 5-fluorouracil: a study on 1083 patients.
Topics: Aged; Angina Pectoris; Drug Therapy, Combination; Female; Fluorouracil; Heart; Humans; Male; Middle | 1982 |
Pharmacological data and technical feasibility of intraperitoneal 5-fluorouracil administration.
Topics: Aged; Female; Fluorouracil; Humans; Injections, Intraperitoneal; Male; Middle Aged; Neoplasms | 1982 |
Pharmacological data and technical feasibility of intraperitoneal 5-fluorouracil administration.
Topics: Aged; Female; Fluorouracil; Humans; Injections, Intraperitoneal; Male; Middle Aged; Neoplasms | 1982 |
[Protective effect of CoQ 10 administration on cardial toxicity in FAC therapy].
Topics: Adult; Aged; Breast Neoplasms; Coenzymes; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; | 1982 |
[Protective effect of CoQ 10 administration on cardial toxicity in FAC therapy].
Topics: Adult; Aged; Breast Neoplasms; Coenzymes; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; | 1982 |
[Phase II study of a new fluorinated pyrimidine, ethyl (+/-)-t-6-butoxy-5-fluoro-2, 4-dioxohexahydropyrimidine-r-5-carboxylate (TAC-278)].
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Fluo | 1982 |
[Phase II study of a new fluorinated pyrimidine, ethyl (+/-)-t-6-butoxy-5-fluoro-2, 4-dioxohexahydropyrimidine-r-5-carboxylate (TAC-278)].
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Fluo | 1982 |
[Phase I clinical study of a new fluorinated pyrimidine antineoplastic agent, TAC-278].
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Drug Tolerance; Female; Fluorouracil; Humans; K | 1982 |
[Phase I clinical study of a new fluorinated pyrimidine antineoplastic agent, TAC-278].
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Drug Tolerance; Female; Fluorouracil; Humans; K | 1982 |
[TAC-278. A new 5-FU derivative, by the oral route for its efficacy and safety in 36 patients with advanced cancers].
Topics: Adult; Aged; Blood Platelets; Drug Evaluation; Female; Fluorouracil; Humans; Intestinal Neoplasms; I | 1982 |
[TAC-278. A new 5-FU derivative, by the oral route for its efficacy and safety in 36 patients with advanced cancers].
Topics: Adult; Aged; Blood Platelets; Drug Evaluation; Female; Fluorouracil; Humans; Intestinal Neoplasms; I | 1982 |
[Toxic effects of prolonged oral administration of tegafur (FT-207)].
Topics: Administration, Oral; Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransf | 1982 |
[Toxic effects of prolonged oral administration of tegafur (FT-207)].
Topics: Administration, Oral; Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransf | 1982 |
[Phase II study of carmofur (HCFU) fine granules].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Child; Child, Preschool; Colonic N | 1982 |
[Phase II study of carmofur (HCFU) fine granules].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Child; Child, Preschool; Colonic N | 1982 |
Anaplastic malignant neoplasms: diagnosis and treatment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Dacarbazine; Dactinomycin; Doxorub | 1981 |
Anaplastic malignant neoplasms: diagnosis and treatment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Dacarbazine; Dactinomycin; Doxorub | 1981 |
Penetration of substances into tumor tissue--a methodological study on cellular spheroids.
Topics: Albumins; Biological Transport; Cell Line; Clone Cells; Fluorouracil; Glioma; Humans; Leucine; Model | 1981 |
Penetration of substances into tumor tissue--a methodological study on cellular spheroids.
Topics: Albumins; Biological Transport; Cell Line; Clone Cells; Fluorouracil; Glioma; Humans; Leucine; Model | 1981 |
5-Fluorouracil: a comparative pharmacokinetic study and preliminary results of a clinical phase I study.
Topics: Administration, Oral; Drug Evaluation; Female; Fluorouracil; Humans; Injections, Intravenous; Kineti | 1981 |
5-Fluorouracil: a comparative pharmacokinetic study and preliminary results of a clinical phase I study.
Topics: Administration, Oral; Drug Evaluation; Female; Fluorouracil; Humans; Injections, Intravenous; Kineti | 1981 |
Pharmacokinetics of 5-fluorouracil : impact of the measurement of the 5,6-dihydrofluorouracil.
Topics: Fluorouracil; Humans; Kinetics; Neoplasms | 1981 |
Pharmacokinetics of 5-fluorouracil : impact of the measurement of the 5,6-dihydrofluorouracil.
Topics: Fluorouracil; Humans; Kinetics; Neoplasms | 1981 |
Defective function of granulocytes in patients with cancer.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Femal | 1981 |
Defective function of granulocytes in patients with cancer.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Femal | 1981 |
Modulation of 5-FU action by thymidine in murine and human tumors.
Topics: Animals; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Fluorouracil; Humans; Kineti | 1981 |
Modulation of 5-FU action by thymidine in murine and human tumors.
Topics: Animals; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Fluorouracil; Humans; Kineti | 1981 |
Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a Phase I trial.
Topics: Adult; Bone Marrow; Drug Evaluation; Female; Fluorouracil; Half-Life; Humans; Infusions, Parenteral; | 1980 |
Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a Phase I trial.
Topics: Adult; Bone Marrow; Drug Evaluation; Female; Fluorouracil; Half-Life; Humans; Infusions, Parenteral; | 1980 |
Review of a new antimetabolic agent 1-hexylcarbamoyl-5-fluorouracil (HCFU).
Topics: Aged; Animals; Drug Evaluation; Drug Evaluation, Preclinical; Female; Fluorouracil; Humans; Male; Mi | 1980 |
Review of a new antimetabolic agent 1-hexylcarbamoyl-5-fluorouracil (HCFU).
Topics: Aged; Animals; Drug Evaluation; Drug Evaluation, Preclinical; Female; Fluorouracil; Humans; Male; Mi | 1980 |
Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation.
Topics: Adult; Aged; Bone Marrow; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Flu | 1980 |
Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation.
Topics: Adult; Aged; Bone Marrow; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Flu | 1980 |
Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion.
Topics: Adenocarcinoma; Administration, Oral; Bone Marrow; Fluorouracil; Humans; Infusions, Parenteral; Inje | 1980 |
Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion.
Topics: Adenocarcinoma; Administration, Oral; Bone Marrow; Fluorouracil; Humans; Infusions, Parenteral; Inje | 1980 |
18F-5-fluorouracil studies in humans and animals.
Topics: Adult; Aged; Animals; Female; Fluorine; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Radioiso | 1980 |
18F-5-fluorouracil studies in humans and animals.
Topics: Adult; Aged; Animals; Female; Fluorine; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Radioiso | 1980 |
Extravasation of chemotherapeutic agents.
Topics: Aged; Antineoplastic Agents; Doxorubicin; Female; Fluorouracil; Humans; Infusions, Parenteral; Male; | 1980 |
Extravasation of chemotherapeutic agents.
Topics: Aged; Antineoplastic Agents; Doxorubicin; Female; Fluorouracil; Humans; Infusions, Parenteral; Male; | 1980 |
Thiamin status of patients treated with drug combinations containing 5-fluorouracil.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; | 1980 |
Thiamin status of patients treated with drug combinations containing 5-fluorouracil.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; | 1980 |
Learned taste aversions in humans.
Topics: Adolescent; Adult; Aged; Avoidance Learning; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Hu | 1980 |
Learned taste aversions in humans.
Topics: Adolescent; Adult; Aged; Avoidance Learning; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Hu | 1980 |
Early clinical experience with radiation therapy of the advanced tumors following synchronization of the cell cycle with 5-fluorouracil.
Topics: Cell Cycle; Female; Fluorouracil; Humans; Male; Neoplasms | 1980 |
Early clinical experience with radiation therapy of the advanced tumors following synchronization of the cell cycle with 5-fluorouracil.
Topics: Cell Cycle; Female; Fluorouracil; Humans; Male; Neoplasms | 1980 |
Clinical pharmacologic effects of thymidine plus 5-FU.
Topics: Adult; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouraci | 1980 |
Clinical pharmacologic effects of thymidine plus 5-FU.
Topics: Adult; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouraci | 1980 |
Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bon | 1995 |
Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bon | 1995 |
Stopping a clinical trial very early based on unplanned interim analyses: a group sequential approach.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biometry | 1995 |
Stopping a clinical trial very early based on unplanned interim analyses: a group sequential approach.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biometry | 1995 |
Fluorouracil: active in ZD1694 (tomudex)-resistant cell lines with markedly elevated thymidylate synthase levels.
Topics: Drug Resistance; Fluorouracil; Humans; Neoplasms; Quinazolines; Thiophenes; Thymidylate Synthase; Tu | 1995 |
Fluorouracil: active in ZD1694 (tomudex)-resistant cell lines with markedly elevated thymidylate synthase levels.
Topics: Drug Resistance; Fluorouracil; Humans; Neoplasms; Quinazolines; Thiophenes; Thymidylate Synthase; Tu | 1995 |
Gene therapy for cancer using tumour-specific prodrug activation.
Topics: Base Sequence; Biotransformation; Breast Neoplasms; Cytosine Deaminase; DNA Primers; Female; Flucyto | 1994 |
Gene therapy for cancer using tumour-specific prodrug activation.
Topics: Base Sequence; Biotransformation; Breast Neoplasms; Cytosine Deaminase; DNA Primers; Female; Flucyto | 1994 |
[Increase of dose intensity by pharmacomodulation. General concepts and therapeutic applications].
Topics: Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; ATP Binding Cassette Transporter, Subf | 1995 |
[Increase of dose intensity by pharmacomodulation. General concepts and therapeutic applications].
Topics: Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; ATP Binding Cassette Transporter, Subf | 1995 |
Re: Enigma of fluorouracil and levamisole.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Folic Acid; Humans; Leucovorin; Levamisole; Neoplasms | 1995 |
Re: Enigma of fluorouracil and levamisole.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Folic Acid; Humans; Leucovorin; Levamisole; Neoplasms | 1995 |
Anticancer chemosensitivity changes between the original and recurrent tumors after successful chemotherapy selected according to the sensitivity assay.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; DNA, Neoplasm; Dox | 1995 |
Anticancer chemosensitivity changes between the original and recurrent tumors after successful chemotherapy selected according to the sensitivity assay.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; DNA, Neoplasm; Dox | 1995 |
Tumour pharmacokinetics?--we do need to know.
Topics: Fluorouracil; Humans; Magnetic Resonance Spectroscopy; Neoplasms | 1994 |
Tumour pharmacokinetics?--we do need to know.
Topics: Fluorouracil; Humans; Magnetic Resonance Spectroscopy; Neoplasms | 1994 |
Association of intratumoral pharmacokinetics of fluorouracil with clinical response.
Topics: Fluorouracil; Half-Life; Humans; Magnetic Resonance Spectroscopy; Neoplasms; Treatment Outcome | 1994 |
Association of intratumoral pharmacokinetics of fluorouracil with clinical response.
Topics: Fluorouracil; Half-Life; Humans; Magnetic Resonance Spectroscopy; Neoplasms; Treatment Outcome | 1994 |
Timing of peripheral blood progenitor cell (PBPC) collections during recovery from chemotherapy supported by haematopoietic growth factor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colony-Forming Units Assay; Cyclophosphamide; Doxoru | 1994 |
Timing of peripheral blood progenitor cell (PBPC) collections during recovery from chemotherapy supported by haematopoietic growth factor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colony-Forming Units Assay; Cyclophosphamide; Doxoru | 1994 |
Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Topics: Adult; Aged; Antiviral Agents; Bromodeoxyuridine; Female; Fluorouracil; Humans; Male; Middle Aged; N | 1994 |
Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Topics: Adult; Aged; Antiviral Agents; Bromodeoxyuridine; Female; Fluorouracil; Humans; Male; Middle Aged; N | 1994 |
Clinical cardiotoxicity of 5-fluorouracil.
Topics: Aged; Arrhythmias, Cardiac; Coronary Vasospasm; Electrocardiography; Female; Fluorouracil; Heart Arr | 1993 |
Clinical cardiotoxicity of 5-fluorouracil.
Topics: Aged; Arrhythmias, Cardiac; Coronary Vasospasm; Electrocardiography; Female; Fluorouracil; Heart Arr | 1993 |
Cytokine production in whole blood cell cultures of patients undergoing therapy with biological response modifiers or 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Cytokines; Enzyme-Link | 1993 |
Cytokine production in whole blood cell cultures of patients undergoing therapy with biological response modifiers or 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Cytokines; Enzyme-Link | 1993 |
Bioavailability and feasibility of subcutaneous 5-fluorouracil.
Topics: Adult; Aged; Biological Availability; Female; Fluorouracil; Humans; Injections, Subcutaneous; Kineti | 1993 |
Bioavailability and feasibility of subcutaneous 5-fluorouracil.
Topics: Adult; Aged; Biological Availability; Female; Fluorouracil; Humans; Injections, Subcutaneous; Kineti | 1993 |
Transient hyperammonemia related to chemotherapy with continuous infusion of high-dose 5-fluorouracil.
Topics: Adult; Aged; Ammonia; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases, Metabolic; Dos | 1993 |
Transient hyperammonemia related to chemotherapy with continuous infusion of high-dose 5-fluorouracil.
Topics: Adult; Aged; Ammonia; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases, Metabolic; Dos | 1993 |
Predictors of self-care: a test of Orem's model.
Topics: Activities of Daily Living; Adaptation, Psychological; Affect; Antineoplastic Combined Chemotherapy | 1993 |
Predictors of self-care: a test of Orem's model.
Topics: Activities of Daily Living; Adaptation, Psychological; Affect; Antineoplastic Combined Chemotherapy | 1993 |
[Clinical application of drug delivery system of anti-cancer drugs--the pharmacokinetics and clinical results].
Topics: Antibodies, Monoclonal; Drug Delivery Systems; Fluorouracil; Humans; Immunotoxins; Iodized Oil; Mito | 1993 |
[Clinical application of drug delivery system of anti-cancer drugs--the pharmacokinetics and clinical results].
Topics: Antibodies, Monoclonal; Drug Delivery Systems; Fluorouracil; Humans; Immunotoxins; Iodized Oil; Mito | 1993 |
5-fluorouracil permits access to a primitive subpopulation of peripheral blood stem cells.
Topics: Antineoplastic Agents; Blood Cells; Bone Marrow Diseases; Cell Cycle; Colony-Forming Units Assay; Cu | 1993 |
5-fluorouracil permits access to a primitive subpopulation of peripheral blood stem cells.
Topics: Antineoplastic Agents; Blood Cells; Bone Marrow Diseases; Cell Cycle; Colony-Forming Units Assay; Cu | 1993 |
Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Diarrhea; Drug Synergism | 1993 |
Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Diarrhea; Drug Synergism | 1993 |
Reversal of 5-fluorouracil-induced toxicity by oral administration of uridine.
Topics: Administration, Oral; Adult; Aged; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leukopen | 1993 |
Reversal of 5-fluorouracil-induced toxicity by oral administration of uridine.
Topics: Administration, Oral; Adult; Aged; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leukopen | 1993 |
5-fluorouracil by protracted subcutaneous infusion. A pilot study.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Fluorouracil; Humans; Injectio | 1995 |
5-fluorouracil by protracted subcutaneous infusion. A pilot study.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Fluorouracil; Humans; Injectio | 1995 |
Investigation of the comparative effects of 2-chlorodeoxyadenosine on tumor colony forming units in vitro.
Topics: Antineoplastic Agents; Cell Division; Cisplatin; Cladribine; Dose-Response Relationship, Drug; Doxor | 1995 |
Investigation of the comparative effects of 2-chlorodeoxyadenosine on tumor colony forming units in vitro.
Topics: Antineoplastic Agents; Cell Division; Cisplatin; Cladribine; Dose-Response Relationship, Drug; Doxor | 1995 |
[Estimation of pathways of 5-fluorouracil anabolism in human cancer cells in vitro and in vivo].
Topics: Animals; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; Lung Neoplasms; Mice; Mice, | 1996 |
[Estimation of pathways of 5-fluorouracil anabolism in human cancer cells in vitro and in vivo].
Topics: Animals; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; Lung Neoplasms; Mice; Mice, | 1996 |
The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and gemcitabine in vitro and in human tumour xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Deoxycytidine; Dipyridamole; | 1995 |
The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and gemcitabine in vitro and in human tumour xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Deoxycytidine; Dipyridamole; | 1995 |
Portable pumps in cancer chemotherapy: how to deal with marked fluctuations in 5-fluorouracil blood concentrations.
Topics: Antineoplastic Agents; Fluorouracil; Humans; Infusion Pumps; Neoplasms | 1995 |
Portable pumps in cancer chemotherapy: how to deal with marked fluctuations in 5-fluorouracil blood concentrations.
Topics: Antineoplastic Agents; Fluorouracil; Humans; Infusion Pumps; Neoplasms | 1995 |
[Cardiotoxic effect of the herec-TNF alpha preparation given intravenously to patients with advanced neoplasms].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Female; Fluoroura | 1996 |
[Cardiotoxic effect of the herec-TNF alpha preparation given intravenously to patients with advanced neoplasms].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Female; Fluoroura | 1996 |
Meta-analyses of randomised trials: when the whole is more than just the sum of the parts.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin | 1996 |
Meta-analyses of randomised trials: when the whole is more than just the sum of the parts.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin | 1996 |
The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251.
Topics: Administration, Oral; Animals; Antibiotics, Antineoplastic; Cell Line; Doxorubicin; Drug Resistance, | 1995 |
The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251.
Topics: Administration, Oral; Animals; Antibiotics, Antineoplastic; Cell Line; Doxorubicin; Drug Resistance, | 1995 |
Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia.
Topics: Antigens, Viral; Base Sequence; Cell Survival; Cytosine Deaminase; DNA-Binding Proteins; Epstein-Bar | 1996 |
Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia.
Topics: Antigens, Viral; Base Sequence; Cell Survival; Cytosine Deaminase; DNA-Binding Proteins; Epstein-Bar | 1996 |
Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bloo | 1996 |
Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bloo | 1996 |
Assessing whether to perform a confirmatory randomized clinical trial.
Topics: Adjuvants, Immunologic; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Combined M | 1996 |
Assessing whether to perform a confirmatory randomized clinical trial.
Topics: Adjuvants, Immunologic; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Combined M | 1996 |
Tumor retention of 5-fluorouracil following irradiation observed using 19F nuclear magnetic resonance spectroscopy.
Topics: Animals; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; Magnetic Resonance Spectrosc | 1996 |
Tumor retention of 5-fluorouracil following irradiation observed using 19F nuclear magnetic resonance spectroscopy.
Topics: Animals; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; Magnetic Resonance Spectrosc | 1996 |
Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues.
Topics: Animals; Antibodies, Monoclonal; Enzyme-Linked Immunosorbent Assay; Floxuridine; Fluorouracil; Human | 1996 |
Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues.
Topics: Animals; Antibodies, Monoclonal; Enzyme-Linked Immunosorbent Assay; Floxuridine; Fluorouracil; Human | 1996 |
New approaches to the management and treatment of malignant pericardial effusion.
Topics: Adult; Aged; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 1997 |
New approaches to the management and treatment of malignant pericardial effusion.
Topics: Adult; Aged; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 1997 |
High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy.
Topics: Acidosis; Ammonia; Antimetabolites, Antineoplastic; Brain Diseases; Coma; Diagnosis, Differential; E | 1997 |
High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy.
Topics: Acidosis; Ammonia; Antimetabolites, Antineoplastic; Brain Diseases; Coma; Diagnosis, Differential; E | 1997 |
AcSDKP plasma concentrations in patients with solid tumours: comparison of two chemotherapeutic regimens.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouracil; Growth Inhibi | 1997 |
AcSDKP plasma concentrations in patients with solid tumours: comparison of two chemotherapeutic regimens.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouracil; Growth Inhibi | 1997 |
[The correlation between thymidylate synthase expression and cytotoxicity of 5-fluorouracil in human cancer cell lines: study using polyclonal antibody against recombinant human thymidylate synthase].
Topics: Antibodies; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Neoplasms; Recombinant Proteins; | 1997 |
[The correlation between thymidylate synthase expression and cytotoxicity of 5-fluorouracil in human cancer cell lines: study using polyclonal antibody against recombinant human thymidylate synthase].
Topics: Antibodies; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Neoplasms; Recombinant Proteins; | 1997 |
Secondary ion mass spectrometry (SIMS) microscopy: a new tool for pharmacological studies in humans.
Topics: Antineoplastic Agents; Doxorubicin; Fluorouracil; Humans; Mass Spectrometry; Microscopy; Neoplasms | 1997 |
Secondary ion mass spectrometry (SIMS) microscopy: a new tool for pharmacological studies in humans.
Topics: Antineoplastic Agents; Doxorubicin; Fluorouracil; Humans; Mass Spectrometry; Microscopy; Neoplasms | 1997 |
Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal 5-fluorouracil efficacy: experimental data.
Topics: Antidotes; Antimetabolites, Antineoplastic; Biopsy; Drug Screening Assays, Antitumor; Drug Synergism | 1997 |
Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal 5-fluorouracil efficacy: experimental data.
Topics: Antidotes; Antimetabolites, Antineoplastic; Biopsy; Drug Screening Assays, Antitumor; Drug Synergism | 1997 |
Simultaneous determination of 5-fluorouracil and its active metabolites in serum and tissue by high-performance liquid chromatography.
Topics: Animals; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Circadian Rhythm; Dr | 1997 |
Simultaneous determination of 5-fluorouracil and its active metabolites in serum and tissue by high-performance liquid chromatography.
Topics: Animals; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Circadian Rhythm; Dr | 1997 |
Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Monitoring; Fluorouracil; Humans; Merc | 1998 |
Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Monitoring; Fluorouracil; Humans; Merc | 1998 |
Inhibition of cancer cell proliferation by disruption of interdigitated/concatenated hierarchies of metabolic control/implementation processes: a proposal.
Topics: Cell Division; Drug Therapy, Combination; Fluorouracil; Humans; Indoles; Lipoxygenase Inhibitors; Ne | 1998 |
Inhibition of cancer cell proliferation by disruption of interdigitated/concatenated hierarchies of metabolic control/implementation processes: a proposal.
Topics: Cell Division; Drug Therapy, Combination; Fluorouracil; Humans; Indoles; Lipoxygenase Inhibitors; Ne | 1998 |
Pharmacokinetics of cisplatin and combination chemotherapy of cisplatin plus 5-FU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergism; Fluorouracil; Humans; Neo | 1998 |
Pharmacokinetics of cisplatin and combination chemotherapy of cisplatin plus 5-FU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergism; Fluorouracil; Humans; Neo | 1998 |
Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Surface Area; Dih | 1998 |
Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Surface Area; Dih | 1998 |
A risk-benefit assessment of irinotecan in solid tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothe | 1998 |
A risk-benefit assessment of irinotecan in solid tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothe | 1998 |
[Liposomal forms of cytostatics in oncology].
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Drug Carriers; Fluorouracil; | 1998 |
[Liposomal forms of cytostatics in oncology].
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Drug Carriers; Fluorouracil; | 1998 |
Interaction of tomudex with radiation in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Lewis Lung; Carcinoma, Squamous Cell; Cell Surv | 1998 |
Interaction of tomudex with radiation in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Lewis Lung; Carcinoma, Squamous Cell; Cell Surv | 1998 |
Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined | 1998 |
Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined | 1998 |
A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Topics: Animals; Antimetabolites, Antineoplastic; Antiviral Agents; Arabinofuranosyluracil; Bromouracil; Cau | 1998 |
A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Topics: Animals; Antimetabolites, Antineoplastic; Antiviral Agents; Arabinofuranosyluracil; Bromouracil; Cau | 1998 |
Interferon induces thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in vivo.
Topics: Antineoplastic Agents; Blood Platelets; Clinical Trials as Topic; Colonic Neoplasms; Endothelial Gro | 1997 |
Interferon induces thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in vivo.
Topics: Antineoplastic Agents; Blood Platelets; Clinical Trials as Topic; Colonic Neoplasms; Endothelial Gro | 1997 |
Recent advances in oral fluoropyrimidine therapies. Proceedings of a meeting. Chicago, Illinois, USA. July 11, 1998.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluoroura | 1998 |
Recent advances in oral fluoropyrimidine therapies. Proceedings of a meeting. Chicago, Illinois, USA. July 11, 1998.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluoroura | 1998 |
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Topics: Animals; Capecitabine; Carboxylic Ester Hydrolases; Cytidine Deaminase; Deoxycytidine; Female; Floxu | 1998 |
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Topics: Animals; Capecitabine; Carboxylic Ester Hydrolases; Cytidine Deaminase; Deoxycytidine; Female; Floxu | 1998 |
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Topics: Animals; Capecitabine; Carboxylic Ester Hydrolases; Cytidine Deaminase; Deoxycytidine; Female; Floxu | 1998 |
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Topics: Animals; Capecitabine; Carboxylic Ester Hydrolases; Cytidine Deaminase; Deoxycytidine; Female; Floxu | 1998 |
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Topics: Animals; Capecitabine; Carboxylic Ester Hydrolases; Cytidine Deaminase; Deoxycytidine; Female; Floxu | 1998 |
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Topics: Animals; Capecitabine; Carboxylic Ester Hydrolases; Cytidine Deaminase; Deoxycytidine; Female; Floxu | 1998 |
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Topics: Animals; Capecitabine; Carboxylic Ester Hydrolases; Cytidine Deaminase; Deoxycytidine; Female; Floxu | 1998 |
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Topics: Animals; Capecitabine; Carboxylic Ester Hydrolases; Cytidine Deaminase; Deoxycytidine; Female; Floxu | 1998 |
Overwhelming 5-fluorouracil toxicity in patients whose diabetes is poorly controlled.
Topics: Aged; Antimetabolites, Antineoplastic; Diabetes Complications; Female; Fluorouracil; Humans; Hypergl | 1998 |
Overwhelming 5-fluorouracil toxicity in patients whose diabetes is poorly controlled.
Topics: Aged; Antimetabolites, Antineoplastic; Diabetes Complications; Female; Fluorouracil; Humans; Hypergl | 1998 |
Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Half- | 1998 |
Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Half- | 1998 |
[Experience of cancer home chemotherapy with cooperation between hospital and clinic].
Topics: Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; | 1998 |
[Experience of cancer home chemotherapy with cooperation between hospital and clinic].
Topics: Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; | 1998 |
Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Digestive System; Dihydrouracil Dehydrogenase (NADP); | 1999 |
Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Digestive System; Dihydrouracil Dehydrogenase (NADP); | 1999 |
[The determination of individual sensitivity to 5-fluorouracil in patients with malignant tumors in different locations].
Topics: Antimetabolites, Antineoplastic; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Inj | 1999 |
[The determination of individual sensitivity to 5-fluorouracil in patients with malignant tumors in different locations].
Topics: Antimetabolites, Antineoplastic; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Inj | 1999 |
Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bacterial Infections; Brain Diseases; Dehydration; Fem | 1999 |
Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bacterial Infections; Brain Diseases; Dehydration; Fem | 1999 |
Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Aspartic Acid; Co | 1999 |
Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Aspartic Acid; Co | 1999 |
The leucocyte nadir, a predictor of chemotherapy efficacy?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph | 1999 |
The leucocyte nadir, a predictor of chemotherapy efficacy?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph | 1999 |
Dihydropyrimidine dehydrogenase activity: prognostic partner of 5-fluorouracil?
Topics: Adult; Aged; Breast Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adv | 1999 |
Dihydropyrimidine dehydrogenase activity: prognostic partner of 5-fluorouracil?
Topics: Adult; Aged; Breast Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adv | 1999 |
Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Drug Resistance, Neoplasm; Fluo | 1999 |
Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Drug Resistance, Neoplasm; Fluo | 1999 |
A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Feces; Female; Fluor | 1999 |
A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Feces; Female; Fluor | 1999 |
An update on thymidylate synthase inhibitors.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Humans; Neoplasms; Thymidine; Thymidylate Synthase | 1999 |
An update on thymidylate synthase inhibitors.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Humans; Neoplasms; Thymidine; Thymidylate Synthase | 1999 |
[Consideration of cancer home chemotherapy with cooperation between hospital and clinic].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cooperative Behavior; Drug Administration | 1999 |
[Consideration of cancer home chemotherapy with cooperation between hospital and clinic].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cooperative Behavior; Drug Administration | 1999 |
[Ambulatory and domiciliary cancer chemotherapy with forearm implant catheter system and low-dose CDDP + 5-FU therapy].
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cat | 1999 |
[Ambulatory and domiciliary cancer chemotherapy with forearm implant catheter system and low-dose CDDP + 5-FU therapy].
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cat | 1999 |
[Current status of "low-dose cisplatin-5-FU therapy" for solid tumors (2nd report)--from a nationwide questionnaire on its adverse effects].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cispla | 2000 |
[Current status of "low-dose cisplatin-5-FU therapy" for solid tumors (2nd report)--from a nationwide questionnaire on its adverse effects].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cispla | 2000 |
Known variant DPYD alleles do not explain DPD deficiency in cancer patients.
Topics: Alleles; Antimetabolites, Antineoplastic; Cohort Studies; Dihydrouracil Dehydrogenase (NADP); Exons; | 2000 |
Known variant DPYD alleles do not explain DPD deficiency in cancer patients.
Topics: Alleles; Antimetabolites, Antineoplastic; Cohort Studies; Dihydrouracil Dehydrogenase (NADP); Exons; | 2000 |
Estimation of dihydropyrimidine dehydrogenase activity: does it have a role in cancer therapy?
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Immunohis | 2000 |
Estimation of dihydropyrimidine dehydrogenase activity: does it have a role in cancer therapy?
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Immunohis | 2000 |
Enhanced efficacy of radioimmunotherapy combined with systemic chemotherapy and local hyperthermia in xenograft model.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Body Weight; Combined Modality The | 2000 |
Enhanced efficacy of radioimmunotherapy combined with systemic chemotherapy and local hyperthermia in xenograft model.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Body Weight; Combined Modality The | 2000 |
Weekly 5-fluorouracil and interferon-alfa-2b in metastatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration | 1996 |
Weekly 5-fluorouracil and interferon-alfa-2b in metastatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration | 1996 |
[Pharmacologic markers predictive of neutropenia chemically induced by cisplatin (CDDP)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Choriocarcino | 1999 |
[Pharmacologic markers predictive of neutropenia chemically induced by cisplatin (CDDP)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Choriocarcino | 1999 |
Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues.
Topics: Animals; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Enz | 2000 |
Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues.
Topics: Animals; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Enz | 2000 |
1H decoupling for in vivo (19)F MRS studies using the time-share modulation method on a clinical 1.5 T NMR system.
Topics: Antimetabolites, Antineoplastic; Computer Simulation; Finite Element Analysis; Fluorine; Fluorouraci | 2000 |
1H decoupling for in vivo (19)F MRS studies using the time-share modulation method on a clinical 1.5 T NMR system.
Topics: Antimetabolites, Antineoplastic; Computer Simulation; Finite Element Analysis; Fluorine; Fluorouraci | 2000 |
Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cis | 2000 |
Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cis | 2000 |
Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; | 2000 |
Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; | 2000 |
[Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development].
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; | 2000 |
[Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development].
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; | 2000 |
Evaluation of drug interactions in the established FEC regimen in primary cultures of tumour cells from patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cyclophosphamide; Drug Synergism; Epi | 2000 |
Evaluation of drug interactions in the established FEC regimen in primary cultures of tumour cells from patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cyclophosphamide; Drug Synergism; Epi | 2000 |
[Oral chemotherapeutic agents: the roles in cancer chemotherapy].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Co | 1999 |
[Oral chemotherapeutic agents: the roles in cancer chemotherapy].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Co | 1999 |
Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
Topics: Adult; Aged; Alleles; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Dihydrou | 2000 |
Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
Topics: Adult; Aged; Alleles; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Dihydrou | 2000 |
Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Survival; Cispla | 2000 |
Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Survival; Cispla | 2000 |
Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bacterial Infections; Camptothecin; Cell Line; Cell Survi | 2001 |
Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bacterial Infections; Camptothecin; Cell Line; Cell Survi | 2001 |
Telomere dysfunction alters the chemotherapeutic profile of transformed cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Transformed; Cisplatin; Cyclin-Dependent Kinase Inhibitor | 2001 |
Telomere dysfunction alters the chemotherapeutic profile of transformed cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Transformed; Cisplatin; Cyclin-Dependent Kinase Inhibitor | 2001 |
Quality of life in cancer patients treated by chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2000 |
Quality of life in cancer patients treated by chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2000 |
Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Base | 2001 |
Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Base | 2001 |
[The potential of capecitabine (Xeloda) in the treatment of disseminated solid tumors].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine | 2001 |
[The potential of capecitabine (Xeloda) in the treatment of disseminated solid tumors].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine | 2001 |
Preparation and characterization of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) microspheres for the sustained release of 5-fluorouracil.
Topics: Antineoplastic Agents; Biocompatible Materials; Biodegradation, Environmental; Delayed-Action Prepar | 2001 |
Preparation and characterization of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) microspheres for the sustained release of 5-fluorouracil.
Topics: Antineoplastic Agents; Biocompatible Materials; Biodegradation, Environmental; Delayed-Action Prepar | 2001 |
Simple gas chromatographic-mass spectrometric procedure for diagnosing pyrimidine degradation defects for prevention of severe anticancer side effects.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Gas Chromatography-Mass Spectrometry; Neoplasms; Pyri | 2001 |
Simple gas chromatographic-mass spectrometric procedure for diagnosing pyrimidine degradation defects for prevention of severe anticancer side effects.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Gas Chromatography-Mass Spectrometry; Neoplasms; Pyri | 2001 |
A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Blood Proteins; Capecitabine; Deoxycytidine; Fluo | 2001 |
A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Blood Proteins; Capecitabine; Deoxycytidine; Fluo | 2001 |
Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; | 2001 |
Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; | 2001 |
Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies.
Topics: Blotting, Northern; Blotting, Western; Camptothecin; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; | 2001 |
Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies.
Topics: Blotting, Northern; Blotting, Western; Camptothecin; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; | 2001 |
Stereoselective metabolism and pharmacokinetics of tegafur.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Humans; Neoplasms; Stereoisomerism; Tegafur | 2001 |
Stereoselective metabolism and pharmacokinetics of tegafur.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Humans; Neoplasms; Stereoisomerism; Tegafur | 2001 |
Nitric oxide-mediated regulation of chemosensitivity in cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell | 2001 |
Nitric oxide-mediated regulation of chemosensitivity in cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell | 2001 |
Future treatment options with capecitabine in solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; | 2002 |
Future treatment options with capecitabine in solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; | 2002 |
Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls
Topics: Alternative Splicing; Antimetabolites, Antineoplastic; Diarrhea; Dihydrouracil Dehydrogenase (NADP); | 2002 |
Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls
Topics: Alternative Splicing; Antimetabolites, Antineoplastic; Diarrhea; Dihydrouracil Dehydrogenase (NADP); | 2002 |
Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dihydrou | 2002 |
Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dihydrou | 2002 |
Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy -- a survey of 427 patients.
Topics: Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Administration Schedul | 2002 |
Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy -- a survey of 427 patients.
Topics: Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Administration Schedul | 2002 |
On clinical biochemical pharmacology of 5-fluorouracil and anticancer pyrimidines, Marseille, July 22-23, 1978, USA-France agreement in clinical trial and treatment research (NCI-INSERM).
Topics: Animals; Antineoplastic Agents; Congresses as Topic; Fluorouracil; France; Humans; International Coo | 1979 |
On clinical biochemical pharmacology of 5-fluorouracil and anticancer pyrimidines, Marseille, July 22-23, 1978, USA-France agreement in clinical trial and treatment research (NCI-INSERM).
Topics: Animals; Antineoplastic Agents; Congresses as Topic; Fluorouracil; France; Humans; International Coo | 1979 |
Kinetically-based multiple drug treatment for advanced head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Ear Neopla | 1975 |
Kinetically-based multiple drug treatment for advanced head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Ear Neopla | 1975 |
Carcinoembryonic antigen (CEA) monitoring in the management of radiotherapeutic and chemotherapeutic patients.
Topics: Antigens, Neoplasm; Azacitidine; Carcinoembryonic Antigen; Dacarbazine; Fluorouracil; Humans; Monito | 1975 |
Carcinoembryonic antigen (CEA) monitoring in the management of radiotherapeutic and chemotherapeutic patients.
Topics: Antigens, Neoplasm; Azacitidine; Carcinoembryonic Antigen; Dacarbazine; Fluorouracil; Humans; Monito | 1975 |
Cell synchronization in solid tumors.
Topics: Animals; Bleomycin; Carcinoma, Ehrlich Tumor; Cell Division; Cricetinae; DNA, Neoplasm; Fluorouracil | 1975 |
Cell synchronization in solid tumors.
Topics: Animals; Bleomycin; Carcinoma, Ehrlich Tumor; Cell Division; Cricetinae; DNA, Neoplasm; Fluorouracil | 1975 |
Clinical pharmacology of anticancer drugs.
Topics: Animals; Antineoplastic Agents; Azacitidine; Bleomycin; Cyclophosphamide; Cytarabine; Dacarbazine; D | 1977 |
Clinical pharmacology of anticancer drugs.
Topics: Animals; Antineoplastic Agents; Azacitidine; Bleomycin; Cyclophosphamide; Cytarabine; Dacarbazine; D | 1977 |
Management of malignant pleural effusion.
Topics: Bleomycin; Fluorouracil; Gold Radioisotopes; Humans; Mechlorethamine; Methods; Neoplasms; Phosphorus | 1978 |
Management of malignant pleural effusion.
Topics: Bleomycin; Fluorouracil; Gold Radioisotopes; Humans; Mechlorethamine; Methods; Neoplasms; Phosphorus | 1978 |
[Parenteral feeding during aggressive chemotherapy of various neoplasms].
Topics: Adult; Bleomycin; Body Weight; Cachexia; Cyclophosphamide; Fluorouracil; Humans; Methotrexate; Middl | 1978 |
[Parenteral feeding during aggressive chemotherapy of various neoplasms].
Topics: Adult; Bleomycin; Body Weight; Cachexia; Cyclophosphamide; Fluorouracil; Humans; Methotrexate; Middl | 1978 |
Limitations of a portable infusion pump in ambulatory patients receiving continuous infusions of anticancer drugs.
Topics: Ambulatory Care; Antineoplastic Agents; Bleomycin; Evaluation Studies as Topic; Female; Fluorouracil | 1979 |
Limitations of a portable infusion pump in ambulatory patients receiving continuous infusions of anticancer drugs.
Topics: Ambulatory Care; Antineoplastic Agents; Bleomycin; Evaluation Studies as Topic; Female; Fluorouracil | 1979 |
The effect of combination chemotherapy on neutrophil function in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Chemotaxis, Leukocyte; Drug Administration Schedule; Drug Therap | 1979 |
The effect of combination chemotherapy on neutrophil function in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Chemotaxis, Leukocyte; Drug Administration Schedule; Drug Therap | 1979 |
[Specificity of antitumoral substances].
Topics: Antineoplastic Agents; Bleomycin; Cytarabine; DNA, Neoplasm; Fluorouracil; Neoplasms | 1979 |
[Specificity of antitumoral substances].
Topics: Antineoplastic Agents; Bleomycin; Cytarabine; DNA, Neoplasm; Fluorouracil; Neoplasms | 1979 |
Biochemical determinants of tumor sensitivity to 5-fluorouracil: ultrasensitive methods for the determination of 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthetase.
Topics: Cell Line; Deoxyuracil Nucleotides; Fluorodeoxyuridylate; Fluorouracil; Humans; Lacticaseibacillus c | 1979 |
Biochemical determinants of tumor sensitivity to 5-fluorouracil: ultrasensitive methods for the determination of 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthetase.
Topics: Cell Line; Deoxyuracil Nucleotides; Fluorodeoxyuridylate; Fluorouracil; Humans; Lacticaseibacillus c | 1979 |
[Long-term oral administration of anticancer drug (author's transl)].
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Fluorouracil; Humans; Immunoglobulins; | 1979 |
[Long-term oral administration of anticancer drug (author's transl)].
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Fluorouracil; Humans; Immunoglobulins; | 1979 |
Sensitivity tests of tumors to cytostatic agents. II. Investigation on human tumors.
Topics: Antineoplastic Agents; Autoradiography; Breast Neoplasms; Cell Count; Cell Division; Culture Techniq | 1975 |
Sensitivity tests of tumors to cytostatic agents. II. Investigation on human tumors.
Topics: Antineoplastic Agents; Autoradiography; Breast Neoplasms; Cell Count; Cell Division; Culture Techniq | 1975 |
Recent trends in chemotherapy of solid tumors.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Brain Neoplasms; Breast Neopl | 1975 |
Recent trends in chemotherapy of solid tumors.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Brain Neoplasms; Breast Neopl | 1975 |
Current status of regional arterial infusion chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Hepatocellular; Carotid Arteries; Catheterization; | 1975 |
Current status of regional arterial infusion chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Hepatocellular; Carotid Arteries; Catheterization; | 1975 |
Inhibition of collagen peptidase in HeLa cells and human tumours by compounds including drugs used in cancer therapy.
Topics: Antineoplastic Agents; Aprotinin; Collagen; Cyclophosphamide; Edetic Acid; Fluorouracil; HeLa Cells; | 1978 |
Inhibition of collagen peptidase in HeLa cells and human tumours by compounds including drugs used in cancer therapy.
Topics: Antineoplastic Agents; Aprotinin; Collagen; Cyclophosphamide; Edetic Acid; Fluorouracil; HeLa Cells; | 1978 |
In vitro incorporation of [3H]TdR in human and murine solid tumours. Influence of 5-fluorouracil and/or hyperbaric oxygen on spatial distribution of labelling.
Topics: Animals; Autoradiography; Carcinoma, Squamous Cell; Fluorouracil; Humans; Mice; Neoplasms; Neoplasms | 1979 |
In vitro incorporation of [3H]TdR in human and murine solid tumours. Influence of 5-fluorouracil and/or hyperbaric oxygen on spatial distribution of labelling.
Topics: Animals; Autoradiography; Carcinoma, Squamous Cell; Fluorouracil; Humans; Mice; Neoplasms; Neoplasms | 1979 |
Current trends and prospects in surgical adjuvant trials.
Topics: Antineoplastic Agents; Breast Neoplasms; Cisplatin; Colonic Neoplasms; Cyclophosphamide; Dianhydroga | 1978 |
Current trends and prospects in surgical adjuvant trials.
Topics: Antineoplastic Agents; Breast Neoplasms; Cisplatin; Colonic Neoplasms; Cyclophosphamide; Dianhydroga | 1978 |
Comparison of the effects of single versus multiple agent chemotherapy on lymphocytes assayed by the rosette technique.
Topics: Antineoplastic Agents; B-Lymphocytes; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; | 1978 |
Comparison of the effects of single versus multiple agent chemotherapy on lymphocytes assayed by the rosette technique.
Topics: Antineoplastic Agents; B-Lymphocytes; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; | 1978 |
Toward improved selectivity in cancer chemotherapy: the Richard and Hinda Rosenthal Foundation Award Lecture.
Topics: Animals; Antineoplastic Agents; Carboxypeptidases; Drug Resistance; Drug Therapy, Combination; Fluor | 1979 |
Toward improved selectivity in cancer chemotherapy: the Richard and Hinda Rosenthal Foundation Award Lecture.
Topics: Animals; Antineoplastic Agents; Carboxypeptidases; Drug Resistance; Drug Therapy, Combination; Fluor | 1979 |
[Therapeutic effect of ftorafur].
Topics: Adenocarcinoma; Animals; Cat Diseases; Cats; Dog Diseases; Dogs; Female; Fluorouracil; Mammary Gland | 1977 |
[Therapeutic effect of ftorafur].
Topics: Adenocarcinoma; Animals; Cat Diseases; Cats; Dog Diseases; Dogs; Female; Fluorouracil; Mammary Gland | 1977 |
[Ftorafur concentration in the blood and urine of oncological patients].
Topics: Biopharmaceutics; Biotransformation; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Flu | 1977 |
[Ftorafur concentration in the blood and urine of oncological patients].
Topics: Biopharmaceutics; Biotransformation; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Flu | 1977 |
[A combined immuno-chemotherapy with futraful and picibanil for advanced cancer (author's transl)].
Topics: Aged; Biological Products; Drug Therapy, Combination; Female; Fluorouracil; Humans; Intestinal Neopl | 1977 |
[A combined immuno-chemotherapy with futraful and picibanil for advanced cancer (author's transl)].
Topics: Aged; Biological Products; Drug Therapy, Combination; Female; Fluorouracil; Humans; Intestinal Neopl | 1977 |
Intermittent high single-dose ftorafur: phase I clinical trial with a pharmacologic-toxicity correlation.
Topics: Adult; Aged; Evaluation Studies as Topic; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms | 1977 |
Intermittent high single-dose ftorafur: phase I clinical trial with a pharmacologic-toxicity correlation.
Topics: Adult; Aged; Evaluation Studies as Topic; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms | 1977 |
[Chemoimmunotherapy with BCG and FT 207 (author's transl)].
Topics: Adult; Aged; BCG Vaccine; Erythrocyte Count; Female; Fluorouracil; Humans; Lymphocytes; Male; Middle | 1977 |
[Chemoimmunotherapy with BCG and FT 207 (author's transl)].
Topics: Adult; Aged; BCG Vaccine; Erythrocyte Count; Female; Fluorouracil; Humans; Lymphocytes; Male; Middle | 1977 |
[Effect of ftorafur and 5-fluorouracil on the chromosomes of human tumor cell cultures].
Topics: Cells, Cultured; Chromosome Deletion; Chromosomes, Human; Colonic Neoplasms; Fluorouracil; Humans; K | 1979 |
[Effect of ftorafur and 5-fluorouracil on the chromosomes of human tumor cell cultures].
Topics: Cells, Cultured; Chromosome Deletion; Chromosomes, Human; Colonic Neoplasms; Fluorouracil; Humans; K | 1979 |
5-Fluorouracil concentrations in human plasma following R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) administration.
Topics: Fluorouracil; Humans; Infusions, Parenteral; Neoplasms; Tegafur; Time Factors | 1979 |
5-Fluorouracil concentrations in human plasma following R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) administration.
Topics: Fluorouracil; Humans; Infusions, Parenteral; Neoplasms; Tegafur; Time Factors | 1979 |
Studies on mechanisms of 5-fluorouracil resistance in murine and human tumors.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Drug Resistance; Fluorodeoxyuridylate; Fluorouracil; Huma | 1979 |
Studies on mechanisms of 5-fluorouracil resistance in murine and human tumors.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Drug Resistance; Fluorodeoxyuridylate; Fluorouracil; Huma | 1979 |
Chemotherapy of common solid tumours in a general surgical unit.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Interactions; Drug Syne | 1979 |
Chemotherapy of common solid tumours in a general surgical unit.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Interactions; Drug Syne | 1979 |
Assessment of myelotoxic effects of chemotherapy from early leukopenic response: application of a mathematical model for granulopoiesis.
Topics: Antineoplastic Agents; Bone Marrow; Cell Survival; Fluorouracil; Granulocytes; Hematopoiesis; Humans | 1979 |
Assessment of myelotoxic effects of chemotherapy from early leukopenic response: application of a mathematical model for granulopoiesis.
Topics: Antineoplastic Agents; Bone Marrow; Cell Survival; Fluorouracil; Granulocytes; Hematopoiesis; Humans | 1979 |
Delayed complications following combination of radiation and chemotherapy.
Topics: Antineoplastic Agents; Fluorouracil; Humans; Neoplasms; Radiation Injuries; Radiation Tolerance; Res | 1979 |
Delayed complications following combination of radiation and chemotherapy.
Topics: Antineoplastic Agents; Fluorouracil; Humans; Neoplasms; Radiation Injuries; Radiation Tolerance; Res | 1979 |
Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients.
Topics: Administration, Oral; Adult; Aged; Drug Therapy, Combination; Female; Fluorouracil; Humans; Injectio | 1979 |
Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients.
Topics: Administration, Oral; Adult; Aged; Drug Therapy, Combination; Female; Fluorouracil; Humans; Injectio | 1979 |
Clinical studies on the combined immunochemotherapy with a streptococcal preparation (Picibanil) and other anticancer drugs.
Topics: Antineoplastic Agents; Biological Products; Carbazilquinone; Drug Therapy, Combination; Female; Fluo | 1979 |
Clinical studies on the combined immunochemotherapy with a streptococcal preparation (Picibanil) and other anticancer drugs.
Topics: Antineoplastic Agents; Biological Products; Carbazilquinone; Drug Therapy, Combination; Female; Fluo | 1979 |
Sister-chromatid exchanges and chromosal breakage in patients treated with cytostatics.
Topics: Bromodeoxyuridine; Busulfan; Chromatids; Chromosome Aberrations; Cyclophosphamide; Doxorubicin; Fluo | 1979 |
Sister-chromatid exchanges and chromosal breakage in patients treated with cytostatics.
Topics: Bromodeoxyuridine; Busulfan; Chromatids; Chromosome Aberrations; Cyclophosphamide; Doxorubicin; Fluo | 1979 |
Flame-ionization GLC assay for fluorouracil in plasma of cancer patients.
Topics: Alkylation; Flame Ionization; Fluorouracil; Humans; Methods; Neoplasms; Time Factors | 1979 |
Flame-ionization GLC assay for fluorouracil in plasma of cancer patients.
Topics: Alkylation; Flame Ionization; Fluorouracil; Humans; Methods; Neoplasms; Time Factors | 1979 |
Correlation between lymphocyte responsiveness to mitogens and results of chemo-immunotherapy in patients with advanced cancer.
Topics: Adult; Aged; Biological Products; Female; Fluorouracil; Humans; Immunotherapy; Lymphocyte Activation | 1979 |
Correlation between lymphocyte responsiveness to mitogens and results of chemo-immunotherapy in patients with advanced cancer.
Topics: Adult; Aged; Biological Products; Female; Fluorouracil; Humans; Immunotherapy; Lymphocyte Activation | 1979 |
Multidrug combination in cancer chemotherapy: MFU therapy.
Topics: Drug Therapy, Combination; Fluorouracil; Humans; Mitomycins; Neoplasms; Nitrosourea Compounds | 1979 |
Multidrug combination in cancer chemotherapy: MFU therapy.
Topics: Drug Therapy, Combination; Fluorouracil; Humans; Mitomycins; Neoplasms; Nitrosourea Compounds | 1979 |
Determination of 1-hexylcarbamoyl-5-fluorouracil and its metabolites in biomedical specimens by high-performance liquid chromatography.
Topics: Adult; Antineoplastic Agents; Chromatography, High Pressure Liquid; Female; Fluorouracil; Humans; Ma | 1979 |
Determination of 1-hexylcarbamoyl-5-fluorouracil and its metabolites in biomedical specimens by high-performance liquid chromatography.
Topics: Adult; Antineoplastic Agents; Chromatography, High Pressure Liquid; Female; Fluorouracil; Humans; Ma | 1979 |
[Mechanism of and dosage in the combination of ionizing radiation and substances in tumor therapy].
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Bromodeoxyuridine; Fluorourac | 1978 |
[Mechanism of and dosage in the combination of ionizing radiation and substances in tumor therapy].
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Bromodeoxyuridine; Fluorourac | 1978 |
Drug interactions with antineoplastic agents.
Topics: Adrenal Cortex Hormones; Animals; Antineoplastic Agents; Chloramphenicol; Cyclophosphamide; Drug Int | 1977 |
Drug interactions with antineoplastic agents.
Topics: Adrenal Cortex Hormones; Animals; Antineoplastic Agents; Chloramphenicol; Cyclophosphamide; Drug Int | 1977 |
An in vitro method to determine the sensitivity of solid malignant tumours to cytostatic agents.
Topics: Antineoplastic Agents; Cells, Cultured; DNA Replication; Fluorouracil; Humans; Methotrexate; Neoplas | 1977 |
An in vitro method to determine the sensitivity of solid malignant tumours to cytostatic agents.
Topics: Antineoplastic Agents; Cells, Cultured; DNA Replication; Fluorouracil; Humans; Methotrexate; Neoplas | 1977 |
The influence of 5-fluorouracil on cellular and humoral immunity in cancer patients.
Topics: Antibody Formation; Female; Fluorouracil; Humans; Immunity, Cellular; In Vitro Techniques; Lectins; | 1978 |
The influence of 5-fluorouracil on cellular and humoral immunity in cancer patients.
Topics: Antibody Formation; Female; Fluorouracil; Humans; Immunity, Cellular; In Vitro Techniques; Lectins; | 1978 |
Fluorouracil cardiotoxicity.
Topics: Adult; Aged; Coronary Disease; Electrocardiography; Female; Fluorouracil; Humans; Male; Middle Aged; | 1978 |
Fluorouracil cardiotoxicity.
Topics: Adult; Aged; Coronary Disease; Electrocardiography; Female; Fluorouracil; Humans; Male; Middle Aged; | 1978 |
The effect of combination chemotherapy on the reticuloendothelial system in man.
Topics: Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lomustine; Mac | 1978 |
The effect of combination chemotherapy on the reticuloendothelial system in man.
Topics: Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lomustine; Mac | 1978 |
Pharmacokinetics of fluorouracil in humans.
Topics: Adult; Aged; Female; Fluorouracil; Half-Life; Humans; Injections, Intravenous; Male; Metabolic Clear | 1978 |
Pharmacokinetics of fluorouracil in humans.
Topics: Adult; Aged; Female; Fluorouracil; Half-Life; Humans; Injections, Intravenous; Male; Metabolic Clear | 1978 |
Tuberculin and dinitrochlorobenzene (DNCB) tests in cancer patients before and after cytostatic drug therapy.
Topics: Cyclophosphamide; Dinitrochlorobenzene; Fluorouracil; Humans; Immunity, Cellular; Methotrexate; Neop | 1978 |
Tuberculin and dinitrochlorobenzene (DNCB) tests in cancer patients before and after cytostatic drug therapy.
Topics: Cyclophosphamide; Dinitrochlorobenzene; Fluorouracil; Humans; Immunity, Cellular; Methotrexate; Neop | 1978 |
Rapid determination of 1-(2-tetrahydrofuryl)-5-fluorouracil in human blood by high-pressure liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Fluorouracil; Humans; Liver Function Tests; Neoplasms | 1978 |
Rapid determination of 1-(2-tetrahydrofuryl)-5-fluorouracil in human blood by high-pressure liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Fluorouracil; Humans; Liver Function Tests; Neoplasms | 1978 |
Rationale of chemotherapeutic adjuvant treatment.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Admi | 1978 |
Rationale of chemotherapeutic adjuvant treatment.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Admi | 1978 |
[Symposium on cancer and immunity. (5) Experimental and clinical evaluation of chemoimmunotherapy for solid tumors (author's transl)].
Topics: Animals; Antineoplastic Agents; BCG Vaccine; Drug Therapy, Combination; Evaluation Studies as Topic; | 1978 |
[Symposium on cancer and immunity. (5) Experimental and clinical evaluation of chemoimmunotherapy for solid tumors (author's transl)].
Topics: Animals; Antineoplastic Agents; BCG Vaccine; Drug Therapy, Combination; Evaluation Studies as Topic; | 1978 |
Detection of mutagenic activity in human urine using mutant strains of Salmonella typhimurium.
Topics: Antineoplastic Agents; Biological Assay; Cyclophosphamide; Ethylnitrosourea; Fluorouracil; Humans; M | 1976 |
Detection of mutagenic activity in human urine using mutant strains of Salmonella typhimurium.
Topics: Antineoplastic Agents; Biological Assay; Cyclophosphamide; Ethylnitrosourea; Fluorouracil; Humans; M | 1976 |
Drugs that make cancer retreat.
Topics: Antineoplastic Agents; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Nitrogen Mustard | 1976 |
Drugs that make cancer retreat.
Topics: Antineoplastic Agents; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Nitrogen Mustard | 1976 |
Intravenous hyperalimentation as an adjunct to cancer chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Body Weight; Cachexia; Evaluation Studies as Topic; Fe | 1975 |
Intravenous hyperalimentation as an adjunct to cancer chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Body Weight; Cachexia; Evaluation Studies as Topic; Fe | 1975 |
Intravenous hyperalimentation as an adjunct to cancer chemotherapy with 5-fluorouracil.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Digestive System; Fluorouracil; Humans; Male; Neoplasms; | 1975 |
Intravenous hyperalimentation as an adjunct to cancer chemotherapy with 5-fluorouracil.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Digestive System; Fluorouracil; Humans; Male; Neoplasms; | 1975 |
Fresh explant culture of human tumours in vitro and the assessment of sensitivity to cytotoxic chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Culture Techniques; Drug Evaluation, Preclini | 1975 |
Fresh explant culture of human tumours in vitro and the assessment of sensitivity to cytotoxic chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Culture Techniques; Drug Evaluation, Preclini | 1975 |
Immunological overshoot phenomenon following cancer chemotherapy: significance in prognosis evaluation of solid tumors.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Immune | 1975 |
Immunological overshoot phenomenon following cancer chemotherapy: significance in prognosis evaluation of solid tumors.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Immune | 1975 |
Multimodal surgical adjuvant therapy for a broad spectrum of tumors in humans.?
Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neo | 1976 |
Multimodal surgical adjuvant therapy for a broad spectrum of tumors in humans.?
Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neo | 1976 |
Cancer: nutritional concepts.
Topics: Acute Disease; Drug Tolerance; Fistula; Fluorouracil; Humans; Leukemia; Neoplasms; Nutrition Disorde | 1975 |
Cancer: nutritional concepts.
Topics: Acute Disease; Drug Tolerance; Fistula; Fluorouracil; Humans; Leukemia; Neoplasms; Nutrition Disorde | 1975 |
Combination chemotherapy using cyclophosphamide, vincristine, methotrexate, 5-fluorouracil, and prednisone in solid tumors.
Topics: Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Neoplasms; Human | 1977 |
Combination chemotherapy using cyclophosphamide, vincristine, methotrexate, 5-fluorouracil, and prednisone in solid tumors.
Topics: Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Neoplasms; Human | 1977 |
Quadruple chemotherapy for advanced malignant disease.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotr | 1977 |
Quadruple chemotherapy for advanced malignant disease.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotr | 1977 |
Indication of antitumor agents by microbiologic methods.
Topics: Animals; Antineoplastic Agents; Bacteria; Biological Assay; Female; Fluorouracil; Humans; Kinetics; | 1977 |
Indication of antitumor agents by microbiologic methods.
Topics: Animals; Antineoplastic Agents; Bacteria; Biological Assay; Female; Fluorouracil; Humans; Kinetics; | 1977 |
[Experiences with cytostatic treatment of malignant tumors].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Cyclophos | 1976 |
[Experiences with cytostatic treatment of malignant tumors].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Cyclophos | 1976 |
Pharmacokinetics of the fluoropyrimidines: implications for their clinical use.
Topics: Central Nervous System; Drug Evaluation; Drug Resistance, Microbial; Female; Fluorouracil; Humans; N | 1976 |
Pharmacokinetics of the fluoropyrimidines: implications for their clinical use.
Topics: Central Nervous System; Drug Evaluation; Drug Resistance, Microbial; Female; Fluorouracil; Humans; N | 1976 |
A sensitive assay of 5-fluorouracil in plasma by gas chromatography-mass spectrometry.
Topics: Chromatography, Gas; Fluorouracil; Humans; Mass Spectrometry; Neoplasms | 1976 |
A sensitive assay of 5-fluorouracil in plasma by gas chromatography-mass spectrometry.
Topics: Chromatography, Gas; Fluorouracil; Humans; Mass Spectrometry; Neoplasms | 1976 |
[Cytostatic therapy of inoperable carcinomas].
Topics: Breast Neoplasms; Bronchial Neoplasms; Chlorambucil; Choriocarcinoma; Cyclophosphamide; Dactinomycin | 1976 |
[Cytostatic therapy of inoperable carcinomas].
Topics: Breast Neoplasms; Bronchial Neoplasms; Chlorambucil; Choriocarcinoma; Cyclophosphamide; Dactinomycin | 1976 |
[Five years treatment of advanced solid malignomas with a combination of four cytostatic drugs (author's transl)].
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Hu | 1976 |
[Five years treatment of advanced solid malignomas with a combination of four cytostatic drugs (author's transl)].
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Hu | 1976 |
Systemic chemotherapy of advanced head and neck malignancies.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Doxor | 1975 |
Systemic chemotherapy of advanced head and neck malignancies.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Doxor | 1975 |
The influence of site of metastasis on tumour growth and response to chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Female; Fluorouracil; Genital Neoplasms, Fema | 1975 |
The influence of site of metastasis on tumour growth and response to chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Female; Fluorouracil; Genital Neoplasms, Fema | 1975 |
Phase I study of ftorafur, an analog of 5-fluorouracil.
Topics: Adult; Aged; Animals; Female; Fluorouracil; Humans; Injections, Intravenous; Male; Mice; Middle Aged | 1975 |
Phase I study of ftorafur, an analog of 5-fluorouracil.
Topics: Adult; Aged; Animals; Female; Fluorouracil; Humans; Injections, Intravenous; Male; Mice; Middle Aged | 1975 |
[Clinical evaluation of Ftorafur (author's transl)].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Drug | 1975 |
[Clinical evaluation of Ftorafur (author's transl)].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Drug | 1975 |
Combination chemotherapy.
Topics: Adult; Antineoplastic Agents; Child; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Fluor | 1975 |
Combination chemotherapy.
Topics: Adult; Antineoplastic Agents; Child; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Fluor | 1975 |
Adriamycin in the treatment of cancer.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Drug Therapy, Combi | 1976 |
Adriamycin in the treatment of cancer.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Drug Therapy, Combi | 1976 |
Clinical evaluation of ftorafur (pyrimidine-deoxyribose n1-2'-furanidyl-5-fluorouracil).
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Drug Evaluation; Female; Fluorouracil; Gastrointestinal Dise | 1976 |
Clinical evaluation of ftorafur (pyrimidine-deoxyribose n1-2'-furanidyl-5-fluorouracil).
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Drug Evaluation; Female; Fluorouracil; Gastrointestinal Dise | 1976 |
[Distribution of ftorafur in the organism of experimental animals].
Topics: Animals; Brain; Fluorouracil; Furans; Kidney; Liver; Lung; Mice; Neoplasms; Spleen; Time Factors | 1976 |
[Distribution of ftorafur in the organism of experimental animals].
Topics: Animals; Brain; Fluorouracil; Furans; Kidney; Liver; Lung; Mice; Neoplasms; Spleen; Time Factors | 1976 |
Back to the future: new theories on 5-fluorouracil/interferon interactions.
Topics: Drug Interactions; Fluorouracil; Humans; Interferons; Neoplasms | 1992 |
Back to the future: new theories on 5-fluorouracil/interferon interactions.
Topics: Drug Interactions; Fluorouracil; Humans; Interferons; Neoplasms | 1992 |
Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study.
Topics: Adult; Aged; Echocardiography; Electrocardiography; Female; Fluoroacetates; Fluorouracil; Heart Dise | 1992 |
Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study.
Topics: Adult; Aged; Echocardiography; Electrocardiography; Female; Fluoroacetates; Fluorouracil; Heart Dise | 1992 |
Chemotherapy of solid tumors in private practice in Malaysia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Drug | 1992 |
Chemotherapy of solid tumors in private practice in Malaysia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Drug | 1992 |
Fatal systemic candidiasis of gastrointestinal origin: an experimental model in mice compromised by anti-cancer treatment.
Topics: Animals; Candida albicans; Candidiasis; Cecum; Chemotherapy, Adjuvant; Disease Models, Animal; Esoph | 1992 |
Fatal systemic candidiasis of gastrointestinal origin: an experimental model in mice compromised by anti-cancer treatment.
Topics: Animals; Candida albicans; Candidiasis; Cecum; Chemotherapy, Adjuvant; Disease Models, Animal; Esoph | 1992 |
[Evaluation of implantation of a cancer chemotherapeutic vascular access device: report of 91 cases].
Topics: Catheters, Indwelling; Cisplatin; Evaluation Studies as Topic; Femoral Artery; Fluorouracil; Humans; | 1992 |
[Evaluation of implantation of a cancer chemotherapeutic vascular access device: report of 91 cases].
Topics: Catheters, Indwelling; Cisplatin; Evaluation Studies as Topic; Femoral Artery; Fluorouracil; Humans; | 1992 |
[Nephrotic syndrome associated with neoplasms and malignant lymphoma].
Topics: Adult; Aged; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphoma; Male; Middle Aged; Mitomycin; | 1992 |
[Nephrotic syndrome associated with neoplasms and malignant lymphoma].
Topics: Adult; Aged; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphoma; Male; Middle Aged; Mitomycin; | 1992 |
Very high endothelin plasma levels in patients with 5-FU cardiotoxicity.
Topics: Adult; Aged; Endothelins; Female; Fluorouracil; Heart Diseases; Humans; Male; Middle Aged; Neoplasms | 1992 |
Very high endothelin plasma levels in patients with 5-FU cardiotoxicity.
Topics: Adult; Aged; Endothelins; Female; Fluorouracil; Heart Diseases; Humans; Male; Middle Aged; Neoplasms | 1992 |
Oncology drug discovery and clinical trial testing: who's listening?
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation; Fluorouracil; Folic Acid; Humans; | 1992 |
Oncology drug discovery and clinical trial testing: who's listening?
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation; Fluorouracil; Folic Acid; Humans; | 1992 |
Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug.
Topics: Acetaldehyde; Aged; Animals; Drug Contamination; Female; Fluoroacetates; Fluorouracil; Heart; Humans | 1992 |
Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug.
Topics: Acetaldehyde; Aged; Animals; Drug Contamination; Female; Fluoroacetates; Fluorouracil; Heart; Humans | 1992 |
Working conference on biomodulator and chemotherapy combination therapies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fl | 1991 |
Working conference on biomodulator and chemotherapy combination therapies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fl | 1991 |
Interferon combinations in cancer therapy.
Topics: Combined Modality Therapy; Fluorouracil; Humans; Interferons; Neoplasms | 1990 |
Interferon combinations in cancer therapy.
Topics: Combined Modality Therapy; Fluorouracil; Humans; Interferons; Neoplasms | 1990 |
Morphometric and colorimetric analyses of human tumor cell line growth and drug sensitivity in soft agar culture.
Topics: Bleomycin; Carmustine; Cell Division; Cell Line; Chlorambucil; Cisplatin; Colony-Forming Units Assay | 1991 |
Morphometric and colorimetric analyses of human tumor cell line growth and drug sensitivity in soft agar culture.
Topics: Bleomycin; Carmustine; Cell Division; Cell Line; Chlorambucil; Cisplatin; Colony-Forming Units Assay | 1991 |
[Ambulatory continuous intravenous infusion of fluorouracil: a feasible palliative form of chemotherapy].
Topics: Adult; Aged; Catheterization, Peripheral; Costs and Cost Analysis; Female; Fluorouracil; Humans; Inf | 1991 |
[Ambulatory continuous intravenous infusion of fluorouracil: a feasible palliative form of chemotherapy].
Topics: Adult; Aged; Catheterization, Peripheral; Costs and Cost Analysis; Female; Fluorouracil; Humans; Inf | 1991 |
Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction.
Topics: Actins; Base Sequence; DNA, Neoplasm; Fluorouracil; Gene Amplification; Humans; Leucovorin; Molecula | 1992 |
Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction.
Topics: Actins; Base Sequence; DNA, Neoplasm; Fluorouracil; Gene Amplification; Humans; Leucovorin; Molecula | 1992 |
Phase I study of high dose 5-fluorouracil and high dose Leucovorin with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Drug Evaluation; Female; Fluorouracil; Humans; In | 1992 |
Phase I study of high dose 5-fluorouracil and high dose Leucovorin with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Drug Evaluation; Female; Fluorouracil; Humans; In | 1992 |
Soft-laser therapy for iatrogenic mucositis in cancer patients receiving high-dose fluorouracil: a preliminary report.
Topics: Female; Fluorouracil; Humans; Iatrogenic Disease; Laser Therapy; Male; Middle Aged; Mouth Mucosa; Ne | 1992 |
Soft-laser therapy for iatrogenic mucositis in cancer patients receiving high-dose fluorouracil: a preliminary report.
Topics: Female; Fluorouracil; Humans; Iatrogenic Disease; Laser Therapy; Male; Middle Aged; Mouth Mucosa; Ne | 1992 |
[Nutritional support for cancer bearing patients].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fluorouracil; Home Nursing; Humans | 1991 |
[Nutritional support for cancer bearing patients].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fluorouracil; Home Nursing; Humans | 1991 |
Continuous infusion of chemotherapy on an outpatient basis via a totally implanted venous access port.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Eval | 1991 |
Continuous infusion of chemotherapy on an outpatient basis via a totally implanted venous access port.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Eval | 1991 |
Schedule-dependent in vitro combination effects of methotrexate and 5-fluorouracil in human tumor cell lines.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; | 1991 |
Schedule-dependent in vitro combination effects of methotrexate and 5-fluorouracil in human tumor cell lines.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; | 1991 |
[Arterial infusion chemotherapy combined with biochemical modulation in cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 1991 |
[Arterial infusion chemotherapy combined with biochemical modulation in cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 1991 |
Fluorouracil/leucovorin study update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoplasms; Surviva | 1991 |
Fluorouracil/leucovorin study update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoplasms; Surviva | 1991 |
Clinical usefulness of chemosensitivity testing using the MTT assay.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Doxorubici | 1991 |
Clinical usefulness of chemosensitivity testing using the MTT assay.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Doxorubici | 1991 |
In vitro data supporting interferon plus cytotoxic agent combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clone Cells; Doxorubicin; Drug Screening Assays, Ant | 1991 |
In vitro data supporting interferon plus cytotoxic agent combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clone Cells; Doxorubicin; Drug Screening Assays, Ant | 1991 |
Pharmacokinetics of 5-fluorouracil after short systemic infusion: plasma level at the end of the distribution phase as an indicator of the total area under the plasma concentration-time curve.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Female; Fluorouracil; Half-Life; Humans; Infusion | 1991 |
Pharmacokinetics of 5-fluorouracil after short systemic infusion: plasma level at the end of the distribution phase as an indicator of the total area under the plasma concentration-time curve.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Female; Fluorouracil; Half-Life; Humans; Infusion | 1991 |
Clinical evaluation of chemotherapy under angiotensin II-induced hypertension in patients with advanced cancer.
Topics: Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Cisplatin; Dox | 1990 |
Clinical evaluation of chemotherapy under angiotensin II-induced hypertension in patients with advanced cancer.
Topics: Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Cisplatin; Dox | 1990 |
Pharmacokinetic study of doxifluridine given by 5-day stepped-dose infusion.
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; | 1990 |
Pharmacokinetic study of doxifluridine given by 5-day stepped-dose infusion.
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; | 1990 |
New spectroscopy procedure can predict effectiveness of 5FU.
Topics: Fluorouracil; Humans; Magnetic Resonance Imaging; Neoplasms; Pilot Projects | 1990 |
New spectroscopy procedure can predict effectiveness of 5FU.
Topics: Fluorouracil; Humans; Magnetic Resonance Imaging; Neoplasms; Pilot Projects | 1990 |
Modulation of fluoropyrimidines by pretreatment with antifolates or folinic acid (leucovorin).
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Floxuridine; Fluorouracil; Humans; L | 1990 |
Modulation of fluoropyrimidines by pretreatment with antifolates or folinic acid (leucovorin).
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Floxuridine; Fluorouracil; Humans; L | 1990 |
[Activities of enzymes converting 5-fluorouracil to 5-fluorouridine-5' monophosphate and 5-fluorodeoxyuridine-5' monophosphate in subcultured cell lines and solid tumor tissues].
Topics: Fluorouracil; Humans; Neoplasms; Orotate Phosphoribosyltransferase; Pentosyltransferases; Phosphotra | 1990 |
[Activities of enzymes converting 5-fluorouracil to 5-fluorouridine-5' monophosphate and 5-fluorodeoxyuridine-5' monophosphate in subcultured cell lines and solid tumor tissues].
Topics: Fluorouracil; Humans; Neoplasms; Orotate Phosphoribosyltransferase; Pentosyltransferases; Phosphotra | 1990 |
Chemo-enzymatic synthesis of optically pure l-leucovorin, an augmentor of 5-fluorouracil cytotoxicity against cancer.
Topics: Escherichia coli; Fluorouracil; Isomerism; Leucovorin; NAD; Neoplasms; Oxidation-Reduction; Plasmids | 1990 |
Chemo-enzymatic synthesis of optically pure l-leucovorin, an augmentor of 5-fluorouracil cytotoxicity against cancer.
Topics: Escherichia coli; Fluorouracil; Isomerism; Leucovorin; NAD; Neoplasms; Oxidation-Reduction; Plasmids | 1990 |
Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorine; Fluorouracil; Half-Life; Humans; Leucovori | 1990 |
Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorine; Fluorouracil; Half-Life; Humans; Leucovori | 1990 |
Concomitant administration of 4-hydroxypyrazolopyrimidine (allopurinol) and high-dose continuous infusion 5-fluorouracil.
Topics: Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fluoroura | 1990 |
Concomitant administration of 4-hydroxypyrazolopyrimidine (allopurinol) and high-dose continuous infusion 5-fluorouracil.
Topics: Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fluoroura | 1990 |
Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dipyridamole; Drug Administration Sched | 1990 |
Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dipyridamole; Drug Administration Sched | 1990 |
Phase I study of a 120-hour continuous intravenous infusion of 5-fluorouracil in pediatric patients with recurrent solid tumors: a Pediatric Oncology Group study.
Topics: Adolescent; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Child; Dose-Res | 1990 |
Phase I study of a 120-hour continuous intravenous infusion of 5-fluorouracil in pediatric patients with recurrent solid tumors: a Pediatric Oncology Group study.
Topics: Adolescent; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Child; Dose-Res | 1990 |
Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Dose-Response R | 1990 |
Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Dose-Response R | 1990 |
Modulation of fluoropyrimidines by folates. Workshop on new frontiers in medical oncology. Erice, Italy, March 20-23, 1989. Proceedings.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Folic Acid; Humans; Neoplasms | 1990 |
Modulation of fluoropyrimidines by folates. Workshop on new frontiers in medical oncology. Erice, Italy, March 20-23, 1989. Proceedings.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Folic Acid; Humans; Neoplasms | 1990 |
Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspart | 1990 |
Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspart | 1990 |
[Chemotherapy and total body hyperthermia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Colonic Neoplasms; Combined Mo | 1985 |
[Chemotherapy and total body hyperthermia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Colonic Neoplasms; Combined Mo | 1985 |
Effect of various oxygenation conditions and fluosol-DA on cancer chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Bleomycin; Breast Neoplasms; Carbon Dioxide; Cyclophosphamide; Dose- | 1988 |
Effect of various oxygenation conditions and fluosol-DA on cancer chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Bleomycin; Breast Neoplasms; Carbon Dioxide; Cyclophosphamide; Dose- | 1988 |
[Clinical use of magnetic resonance spectroscopy and positron emission tomography in oncology].
Topics: Colorectal Neoplasms; Energy Metabolism; Fluorouracil; Humans; Liver Neoplasms; Magnetic Resonance S | 1989 |
[Clinical use of magnetic resonance spectroscopy and positron emission tomography in oncology].
Topics: Colorectal Neoplasms; Energy Metabolism; Fluorouracil; Humans; Liver Neoplasms; Magnetic Resonance S | 1989 |
A phase I clinical trial of combined fluoropyrimidines with leucovorin in a 14-day infusion. Demonstration of biochemical modulation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Admin | 1989 |
A phase I clinical trial of combined fluoropyrimidines with leucovorin in a 14-day infusion. Demonstration of biochemical modulation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Admin | 1989 |
Combined 5-fluorouracil and floxuridine administered as a 14-day infusion. A phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Catheterization, Central V | 1989 |
Combined 5-fluorouracil and floxuridine administered as a 14-day infusion. A phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Catheterization, Central V | 1989 |
Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Chro | 1989 |
Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Chro | 1989 |
[Arterial infusion method: its theory and clinical application--dosage and regimen].
Topics: Antineoplastic Agents; Bleomycin; Doxorubicin; Drug Administration Schedule; Fluorouracil; Humans; I | 1985 |
[Arterial infusion method: its theory and clinical application--dosage and regimen].
Topics: Antineoplastic Agents; Bleomycin; Doxorubicin; Drug Administration Schedule; Fluorouracil; Humans; I | 1985 |
[Continuous venous infusion in cancer chemotherapy].
Topics: Bleomycin; Bone Marrow; Breast Neoplasms; Cytarabine; Doxorubicin; Drug Administration Schedule; Flu | 1985 |
[Continuous venous infusion in cancer chemotherapy].
Topics: Bleomycin; Bone Marrow; Breast Neoplasms; Cytarabine; Doxorubicin; Drug Administration Schedule; Flu | 1985 |
[Chemotherapy by ambulatory continuous infusion using a portable pump: a feasibility trial].
Topics: Ambulatory Care; Antineoplastic Agents; Bleomycin; Bone Neoplasms; Cisplatin; Disposable Equipment; | 1985 |
[Chemotherapy by ambulatory continuous infusion using a portable pump: a feasibility trial].
Topics: Ambulatory Care; Antineoplastic Agents; Bleomycin; Bone Neoplasms; Cisplatin; Disposable Equipment; | 1985 |
The concentration of 5-phosphoribosyl 1-pyrophosphate in monolayer tumor cells and the effect of various pyrimidine antimetabolites.
Topics: Animals; Aspartic Acid; Cell Line; Cells, Cultured; Fluorouracil; Humans; Methotrexate; Neoplasms; O | 1985 |
The concentration of 5-phosphoribosyl 1-pyrophosphate in monolayer tumor cells and the effect of various pyrimidine antimetabolites.
Topics: Animals; Aspartic Acid; Cell Line; Cells, Cultured; Fluorouracil; Humans; Methotrexate; Neoplasms; O | 1985 |
[Various doses cisplatin combined with multi-drug chemotherapy of malignant solid tumors].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1989 |
[Various doses cisplatin combined with multi-drug chemotherapy of malignant solid tumors].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1989 |
Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum.
Topics: Animals; Antineoplastic Agents; Carboplatin; Cisplatin; Drug Evaluation; Fluorouracil; Humans; Mice; | 1989 |
Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum.
Topics: Animals; Antineoplastic Agents; Carboplatin; Cisplatin; Drug Evaluation; Fluorouracil; Humans; Mice; | 1989 |
[Combination chemotherapy of CPM-MTX-5-FU in non-resectable and recurrent cancer patients].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Sche | 1989 |
[Combination chemotherapy of CPM-MTX-5-FU in non-resectable and recurrent cancer patients].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Sche | 1989 |
Salivary passage of 5-fluorouracil during continuous infusion.
Topics: Aged; Chromatography, High Pressure Liquid; Fluorouracil; Humans; Hydrogen-Ion Concentration; Infusi | 1989 |
Salivary passage of 5-fluorouracil during continuous infusion.
Topics: Aged; Chromatography, High Pressure Liquid; Fluorouracil; Humans; Hydrogen-Ion Concentration; Infusi | 1989 |
[Continuous arterial infusion chemotherapy in cancer cases followed as outpatients].
Topics: Ambulatory Care; Antineoplastic Agents; Cisplatin; Fluorouracil; Humans; Infusion Pumps; Infusions, | 1989 |
[Continuous arterial infusion chemotherapy in cancer cases followed as outpatients].
Topics: Ambulatory Care; Antineoplastic Agents; Cisplatin; Fluorouracil; Humans; Infusion Pumps; Infusions, | 1989 |
Advances in folate chemotherapy: status of 5-fluorouracil/leucovorin in advanced malignancies. August 3, 1988, Cleveland, Ohio. Proceedings.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoplasms | 1989 |
Advances in folate chemotherapy: status of 5-fluorouracil/leucovorin in advanced malignancies. August 3, 1988, Cleveland, Ohio. Proceedings.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoplasms | 1989 |
Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Creatinine; Fl | 1989 |
Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Creatinine; Fl | 1989 |
Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity.
Topics: Acetylglucosaminidase; Acute Disease; Adult; Aminopeptidases; Antineoplastic Combined Chemotherapy P | 1987 |
Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity.
Topics: Acetylglucosaminidase; Acute Disease; Adult; Aminopeptidases; Antineoplastic Combined Chemotherapy P | 1987 |
Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine.
Topics: Aged; Bone Marrow; Female; Fluorouracil; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocy | 1989 |
Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine.
Topics: Aged; Bone Marrow; Female; Fluorouracil; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocy | 1989 |
Cyclophosphamide, methotrexate, and 5-fluorouracil in a three-drug admixture. Phase I trial of 14-day continuous ambulatory infusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Drug | 1989 |
Cyclophosphamide, methotrexate, and 5-fluorouracil in a three-drug admixture. Phase I trial of 14-day continuous ambulatory infusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Drug | 1989 |
DNA lesions in human neoplastic cells and cytotoxicity of 5-fluoropyrimidines.
Topics: Aphidicolin; Cell Survival; Centrifugation, Density Gradient; Diterpenes; DNA, Neoplasm; Floxuridine | 1986 |
DNA lesions in human neoplastic cells and cytotoxicity of 5-fluoropyrimidines.
Topics: Aphidicolin; Cell Survival; Centrifugation, Density Gradient; Diterpenes; DNA, Neoplasm; Floxuridine | 1986 |
Enhancement of the effects of 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Drug Synergism; Floxuridine; Fluoro | 1986 |
Enhancement of the effects of 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Drug Synergism; Floxuridine; Fluoro | 1986 |
Acute effects of various chemotherapeutic combinations on hypophyseal and pineal hormone secretions in cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; beta-Endorphin; Cisplatin; Cyclophosphamide; | 1987 |
Acute effects of various chemotherapeutic combinations on hypophyseal and pineal hormone secretions in cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; beta-Endorphin; Cisplatin; Cyclophosphamide; | 1987 |
[Conversion of 5'-deoxy-5-fluorouridine to 5-FU by pyrimidine nucleoside phosphorylases in normal and tumor tissues from rodents bearing tumors and cancer patients].
Topics: Animals; Antineoplastic Agents; Carcinoma 256, Walker; Floxuridine; Fluorouracil; Humans; Leukemia L | 1987 |
[Conversion of 5'-deoxy-5-fluorouridine to 5-FU by pyrimidine nucleoside phosphorylases in normal and tumor tissues from rodents bearing tumors and cancer patients].
Topics: Animals; Antineoplastic Agents; Carcinoma 256, Walker; Floxuridine; Fluorouracil; Humans; Leukemia L | 1987 |
Phase 1 and 2 studies of trimetrexate administered in combination with fluorouracil to patients with metastatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Fluorouracil; | 1988 |
Phase 1 and 2 studies of trimetrexate administered in combination with fluorouracil to patients with metastatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Fluorouracil; | 1988 |
[Basic study of anti-cancer agents suspended in lipiodol].
Topics: Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Doxorubicin; Fluorourac | 1986 |
[Basic study of anti-cancer agents suspended in lipiodol].
Topics: Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Doxorubicin; Fluorourac | 1986 |
[Combination of selective intra-arterial infusion of an anticancer agent via the vascular access port with RF local hyperthermia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Hyperthermia, In | 1986 |
[Combination of selective intra-arterial infusion of an anticancer agent via the vascular access port with RF local hyperthermia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Hyperthermia, In | 1986 |
[Clinical study of combination chemotherapy with cisplatin (CDDP), continuously infused 5-fluorouracil (5-Fu) and mitomycin C (MMC) (PFM therapy)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans | 1986 |
[Clinical study of combination chemotherapy with cisplatin (CDDP), continuously infused 5-fluorouracil (5-Fu) and mitomycin C (MMC) (PFM therapy)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans | 1986 |
Comparative studies on in vitro human tumor clonogenic assay (HTCA) and in vivo nude mouse-isotope assay (NM-IA).
Topics: Animals; Antineoplastic Agents; Colony-Forming Units Assay; Cyclophosphamide; Doxorubicin; Fluoroura | 1987 |
Comparative studies on in vitro human tumor clonogenic assay (HTCA) and in vivo nude mouse-isotope assay (NM-IA).
Topics: Animals; Antineoplastic Agents; Colony-Forming Units Assay; Cyclophosphamide; Doxorubicin; Fluoroura | 1987 |
Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment.
Topics: Aged; beta-Alanine; Blood Proteins; Chromatography, High Pressure Liquid; Female; Fluorides; Fluorou | 1988 |
Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment.
Topics: Aged; beta-Alanine; Blood Proteins; Chromatography, High Pressure Liquid; Female; Fluorides; Fluorou | 1988 |
[Effects of OK-432 on UFT activation].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Products; | 1988 |
[Effects of OK-432 on UFT activation].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Products; | 1988 |
Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Breast Neoplasms; Drug Eruptions; Female; Fluorouracil | 1985 |
Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Breast Neoplasms; Drug Eruptions; Female; Fluorouracil | 1985 |
[Secondary effects of adjuvant therapy].
Topics: Alopecia; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 1985 |
[Secondary effects of adjuvant therapy].
Topics: Alopecia; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 1985 |
[Sensitivity of human tumor heterografts to a spin-labelled rubomycin derivative].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Daunorubicin; Dose-Respon | 1988 |
[Sensitivity of human tumor heterografts to a spin-labelled rubomycin derivative].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Daunorubicin; Dose-Respon | 1988 |
[Biological basis for combined radio-chemotherapy in radioresistant tumors].
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Survival; Combined Modality Therapy; Fluorouracil; Glio | 1988 |
[Biological basis for combined radio-chemotherapy in radioresistant tumors].
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Survival; Combined Modality Therapy; Fluorouracil; Glio | 1988 |
[Pharmacodynamic study of the in vitro clonogenic assay--with reference to dose levels].
Topics: Animals; Colony-Forming Units Assay; Fluorouracil; Humans; In Vitro Techniques; Mice; Mice, Inbred B | 1988 |
[Pharmacodynamic study of the in vitro clonogenic assay--with reference to dose levels].
Topics: Animals; Colony-Forming Units Assay; Fluorouracil; Humans; In Vitro Techniques; Mice; Mice, Inbred B | 1988 |
Clinical applicability of current pharmacokinetic models: splanchnic elimination of 5-fluorouracil in cancer patients.
Topics: Fluorouracil; Humans; Mathematics; Metabolic Clearance Rate; Models, Biological; Neoplasms; Splanchn | 1988 |
Clinical applicability of current pharmacokinetic models: splanchnic elimination of 5-fluorouracil in cancer patients.
Topics: Fluorouracil; Humans; Mathematics; Metabolic Clearance Rate; Models, Biological; Neoplasms; Splanchn | 1988 |
Heterogeneity of the response to inducers of differentiation and to cytostatics of tumor cell populations.
Topics: Antineoplastic Agents; Cell Differentiation; Cisplatin; Cytarabine; Dacarbazine; Dimethyl Sulfoxide; | 1988 |
Heterogeneity of the response to inducers of differentiation and to cytostatics of tumor cell populations.
Topics: Antineoplastic Agents; Cell Differentiation; Cisplatin; Cytarabine; Dacarbazine; Dimethyl Sulfoxide; | 1988 |
Symposium on the expanding role of folates and fluoropyrimidines in cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoplasms | 1988 |
Symposium on the expanding role of folates and fluoropyrimidines in cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoplasms | 1988 |
The expanding role of folates and fluoropyrimidines in cancer chemotherapy. Proceedings of an international symposium. April 28-29, 1988, Buffalo, New York.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoplasms | 1988 |
The expanding role of folates and fluoropyrimidines in cancer chemotherapy. Proceedings of an international symposium. April 28-29, 1988, Buffalo, New York.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoplasms | 1988 |
Pharmacokinetic analysis of (6S)-5-formyltetrahydrofolate (1-CF), (6R)-5-formyltetrahydrofolate (d-CF) and 5-methyltetrahydrofolate (5-CH3-THF) in patients receiving constant i.v. infusion of high-dose (6R,S)-5-formyltetrahydrofolate (leucovorin).
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Evaluation; Fluor | 1988 |
Pharmacokinetic analysis of (6S)-5-formyltetrahydrofolate (1-CF), (6R)-5-formyltetrahydrofolate (d-CF) and 5-methyltetrahydrofolate (5-CH3-THF) in patients receiving constant i.v. infusion of high-dose (6R,S)-5-formyltetrahydrofolate (leucovorin).
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Evaluation; Fluor | 1988 |
Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients.
Topics: Aged; Analysis of Variance; Circadian Rhythm; Female; Fluorouracil; Humans; Infusions, Intravenous; | 1988 |
Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients.
Topics: Aged; Analysis of Variance; Circadian Rhythm; Female; Fluorouracil; Humans; Infusions, Intravenous; | 1988 |
[Clinical results and problems of total-body thermochemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Combined Modality Ther | 1988 |
[Clinical results and problems of total-body thermochemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Combined Modality Ther | 1988 |
[In vivo distribution and activation of 5-FU--with special reference to biochemical modulation of intracellular metabolism].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Fluorouracil; Humans; Neoplasms | 1988 |
[In vivo distribution and activation of 5-FU--with special reference to biochemical modulation of intracellular metabolism].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Fluorouracil; Humans; Neoplasms | 1988 |
Comparative studies between in vitro and in vivo effects of human beta-interferon on natural killer activity and its relevance to immunochemotherapy.
Topics: Cytotoxicity, Immunologic; Drug Synergism; Female; Fluorouracil; Humans; Immunotherapy; In Vitro Tec | 1988 |
Comparative studies between in vitro and in vivo effects of human beta-interferon on natural killer activity and its relevance to immunochemotherapy.
Topics: Cytotoxicity, Immunologic; Drug Synergism; Female; Fluorouracil; Humans; Immunotherapy; In Vitro Tec | 1988 |
Noninvasive spectroscopic analysis of fluoropyrimidine metabolism in cultured tumor cells.
Topics: Animals; Cells, Cultured; Fluorouracil; Humans; Leukemia, Myeloid, Acute; Magnetic Resonance Spectro | 1986 |
Noninvasive spectroscopic analysis of fluoropyrimidine metabolism in cultured tumor cells.
Topics: Animals; Cells, Cultured; Fluorouracil; Humans; Leukemia, Myeloid, Acute; Magnetic Resonance Spectro | 1986 |
Phase I trial of intraperitoneal chemotherapy with 5-fluorouracil and citrovorum factor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Evaluation; F | 1986 |
Phase I trial of intraperitoneal chemotherapy with 5-fluorouracil and citrovorum factor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Evaluation; F | 1986 |
Clinical experience with 5-fluorouracil (5-FU) and high-dose folinic acid in solid tumors.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; | 1987 |
Clinical experience with 5-fluorouracil (5-FU) and high-dose folinic acid in solid tumors.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; | 1987 |
[Studies on the pleural permeability of carmofur].
Topics: Administration, Oral; Fluorouracil; Humans; Neoplasms; Permeability; Pleural Effusion | 1987 |
[Studies on the pleural permeability of carmofur].
Topics: Administration, Oral; Fluorouracil; Humans; Neoplasms; Permeability; Pleural Effusion | 1987 |
[Implantation of a vascular access device in cancer treatment: operation or angiographic technic?].
Topics: Adult; Aged; Angiography; Catheters, Indwelling; Combined Modality Therapy; Female; Fluorouracil; He | 1987 |
[Implantation of a vascular access device in cancer treatment: operation or angiographic technic?].
Topics: Adult; Aged; Angiography; Catheters, Indwelling; Combined Modality Therapy; Female; Fluorouracil; He | 1987 |
Fluorine-19 NMR spectroscopic studies of the metabolism of 5-fluorouracil in the liver of patients undergoing chemotherapy.
Topics: Female; Fluorouracil; Humans; Liver; Magnetic Resonance Spectroscopy; Male; Neoplasms | 1987 |
Fluorine-19 NMR spectroscopic studies of the metabolism of 5-fluorouracil in the liver of patients undergoing chemotherapy.
Topics: Female; Fluorouracil; Humans; Liver; Magnetic Resonance Spectroscopy; Male; Neoplasms | 1987 |
1-Hexylcarbamoyl-5-fluorouracil is more cytostatic than 5-fluorouracil against human tumors in vitro.
Topics: Antineoplastic Agents; Cell Survival; Fluorouracil; HeLa Cells; Humans; Neoplasms; Succinate Dehydro | 1987 |
1-Hexylcarbamoyl-5-fluorouracil is more cytostatic than 5-fluorouracil against human tumors in vitro.
Topics: Antineoplastic Agents; Cell Survival; Fluorouracil; HeLa Cells; Humans; Neoplasms; Succinate Dehydro | 1987 |
[Continuous intra-arterial infusion chemotherapy by implantable catheter access connected with a continuous infusion pump].
Topics: Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Infusion Pumps; Infusions, Intra-Arterial; In | 1987 |
[Continuous intra-arterial infusion chemotherapy by implantable catheter access connected with a continuous infusion pump].
Topics: Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Infusion Pumps; Infusions, Intra-Arterial; In | 1987 |
Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity.
Topics: Aged; Body Temperature; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Paren | 1986 |
Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity.
Topics: Aged; Body Temperature; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Paren | 1986 |
[Effect of methotrexate on 5-fluorouracil metabolism and clinical studies with methotrexate and 5-fluorouracil sequential therapy].
Topics: Drug Administration Schedule; Drug Synergism; Fluorouracil; Humans; Methotrexate; Neoplasms | 1986 |
[Effect of methotrexate on 5-fluorouracil metabolism and clinical studies with methotrexate and 5-fluorouracil sequential therapy].
Topics: Drug Administration Schedule; Drug Synergism; Fluorouracil; Humans; Methotrexate; Neoplasms | 1986 |
[Drug administration in combination for management of cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Drug Administration Schedul | 1985 |
[Drug administration in combination for management of cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Drug Administration Schedul | 1985 |
Enzymes of uracil catabolism in normal and neoplastic human tissues.
Topics: Amidohydrolases; beta-Alanine; Dihydrouracil Dehydrogenase (NAD+); Fluorouracil; Humans; Kinetics; N | 1985 |
Enzymes of uracil catabolism in normal and neoplastic human tissues.
Topics: Amidohydrolases; beta-Alanine; Dihydrouracil Dehydrogenase (NAD+); Fluorouracil; Humans; Kinetics; N | 1985 |
An implantable vascular access device for superselective administration of anticancer drugs.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Hot Temperature | 1985 |
An implantable vascular access device for superselective administration of anticancer drugs.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Hot Temperature | 1985 |
A controlled trial of the effect of 4-hydroxypyrazolopyrimidine (allopurinol) on the toxicity of a single bolus dose of 5-fluorouracil.
Topics: Adult; Aged; Allopurinol; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Granu | 1985 |
A controlled trial of the effect of 4-hydroxypyrazolopyrimidine (allopurinol) on the toxicity of a single bolus dose of 5-fluorouracil.
Topics: Adult; Aged; Allopurinol; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Granu | 1985 |
Altered plasma kinetics of 5-FU at high dosage in rat and man.
Topics: Animals; Female; Fluorouracil; Half-Life; Humans; Injections, Intravenous; Kinetics; Neoplasms; Rats | 1985 |
Altered plasma kinetics of 5-FU at high dosage in rat and man.
Topics: Animals; Female; Fluorouracil; Half-Life; Humans; Injections, Intravenous; Kinetics; Neoplasms; Rats | 1985 |
Phase I and pharmacologic study of 72-hour infused 5-fluorouracil and hyperfractionated cyclical radiation.
Topics: Combined Modality Therapy; Fluorouracil; Humans; Infusions, Parenteral; Neoplasms; Radiation-Sensiti | 1985 |
Phase I and pharmacologic study of 72-hour infused 5-fluorouracil and hyperfractionated cyclical radiation.
Topics: Combined Modality Therapy; Fluorouracil; Humans; Infusions, Parenteral; Neoplasms; Radiation-Sensiti | 1985 |
[Biochemical modulation in cancer chemotherapy].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Synergism; Fluorouracil; H | 1985 |
[Biochemical modulation in cancer chemotherapy].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Synergism; Fluorouracil; H | 1985 |
[Reduction of 5-fluorouracil toxicity with allopurinol].
Topics: Administration, Oral; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; | 1985 |
[Reduction of 5-fluorouracil toxicity with allopurinol].
Topics: Administration, Oral; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; | 1985 |
Sequential infusions of methotrexate and 5-fluorouracil in advanced cancer: pharmacology, toxicity, and response.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Half-Life; Humans | 1985 |
Sequential infusions of methotrexate and 5-fluorouracil in advanced cancer: pharmacology, toxicity, and response.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Half-Life; Humans | 1985 |
Effects of combined treatments of cis-diamminedichloroplatinum(II), 5-fluorouracil, and X-rays on growth of human cancer nodules maintained in continuous organotypic culture.
Topics: Cell Survival; Cells, Cultured; Cisplatin; Combined Modality Therapy; Drug Combinations; Fluorouraci | 1985 |
Effects of combined treatments of cis-diamminedichloroplatinum(II), 5-fluorouracil, and X-rays on growth of human cancer nodules maintained in continuous organotypic culture.
Topics: Cell Survival; Cells, Cultured; Cisplatin; Combined Modality Therapy; Drug Combinations; Fluorouraci | 1985 |
5-Fluorouracil and methotrexate administered simultaneously as a continuous infusion. A phase I study.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sc | 1985 |
5-Fluorouracil and methotrexate administered simultaneously as a continuous infusion. A phase I study.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sc | 1985 |
Factorial designs for randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biometry; Carmustine; Clinical Trials as Topic; Drug | 1985 |
Factorial designs for randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biometry; Carmustine; Clinical Trials as Topic; Drug | 1985 |
Phase I and pharmacologic study of 72-hour infused 5-fluorouracil in man.
Topics: Drug Evaluation; Female; Fluorouracil; Humans; Infusions, Parenteral; Male; Nausea; Neoplasms; Neutr | 1985 |
Phase I and pharmacologic study of 72-hour infused 5-fluorouracil in man.
Topics: Drug Evaluation; Female; Fluorouracil; Humans; Infusions, Parenteral; Male; Nausea; Neoplasms; Neutr | 1985 |
Elemental diet in the management of the intestinal lesion produced by 5-fluorouracil in man.
Topics: Aged; Amino Acids; Animals; Biopsy; Diarrhea; Diet Therapy; Dietary Proteins; Female; Fluorouracil; | 1971 |
Elemental diet in the management of the intestinal lesion produced by 5-fluorouracil in man.
Topics: Aged; Amino Acids; Animals; Biopsy; Diarrhea; Diet Therapy; Dietary Proteins; Female; Fluorouracil; | 1971 |
[Chemotherapy of so-called solid tumors].
Topics: Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Drug Synergism; Fluorouracil; Humans; Immunos | 1971 |
[Chemotherapy of so-called solid tumors].
Topics: Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Drug Synergism; Fluorouracil; Humans; Immunos | 1971 |
[Chemotherapy by intra-arterial path in cancer of the "head and neck" region].
Topics: Antineoplastic Agents; Bleomycin; Facial Neoplasms; Fluorouracil; Head; Head and Neck Neoplasms; Hum | 1971 |
[Chemotherapy by intra-arterial path in cancer of the "head and neck" region].
Topics: Antineoplastic Agents; Bleomycin; Facial Neoplasms; Fluorouracil; Head; Head and Neck Neoplasms; Hum | 1971 |
Factors influencing the success of arterial infusion chemotherapy for cancer of the head and neck.
Topics: Age Factors; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell | 1972 |
Factors influencing the success of arterial infusion chemotherapy for cancer of the head and neck.
Topics: Age Factors; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell | 1972 |
[Mitomycin alone and in therapeutic association in the palliative treatment of solid tumors].
Topics: Antineoplastic Agents; Breast Neoplasms; Cobalt Isotopes; Cyclophosphamide; Drug Combinations; Femal | 1971 |
[Mitomycin alone and in therapeutic association in the palliative treatment of solid tumors].
Topics: Antineoplastic Agents; Breast Neoplasms; Cobalt Isotopes; Cyclophosphamide; Drug Combinations; Femal | 1971 |
[The use of radiosensitizing agents in radiotherapy].
Topics: Brain Neoplasms; Bromodeoxyuridine; Dactinomycin; DNA; Fluorouracil; Glycogen; Humans; Neoplasms; Ox | 1972 |
[The use of radiosensitizing agents in radiotherapy].
Topics: Brain Neoplasms; Bromodeoxyuridine; Dactinomycin; DNA; Fluorouracil; Glycogen; Humans; Neoplasms; Ox | 1972 |
Inhibition of DNA polymerases and neoplastic cells by selected SH inhibitors.
Topics: Animals; Antineoplastic Agents; Arsenicals; Benzoates; Carbon Isotopes; Carcinoma, Ehrlich Tumor; Ch | 1972 |
Inhibition of DNA polymerases and neoplastic cells by selected SH inhibitors.
Topics: Animals; Antineoplastic Agents; Arsenicals; Benzoates; Carbon Isotopes; Carcinoma, Ehrlich Tumor; Ch | 1972 |
Value of cytotoxic infusion in dyspnoea and dysphagia due to cancer.
Topics: Antineoplastic Agents; Cyclophosphamide; Deglutition Disorders; Dyspnea; Esophageal Neoplasms; Fluor | 1973 |
Value of cytotoxic infusion in dyspnoea and dysphagia due to cancer.
Topics: Antineoplastic Agents; Cyclophosphamide; Deglutition Disorders; Dyspnea; Esophageal Neoplasms; Fluor | 1973 |
Chemotherapeutic response of epithelial tumors produced by primary implantation of a nonproducer line of murine sarcoma virus-transformed BALB 3T3 cells.
Topics: Animals; Bleomycin; Cyclophosphamide; Female; Fluorouracil; Male; Methotrexate; Mice; Neoplasm Trans | 1973 |
Chemotherapeutic response of epithelial tumors produced by primary implantation of a nonproducer line of murine sarcoma virus-transformed BALB 3T3 cells.
Topics: Animals; Bleomycin; Cyclophosphamide; Female; Fluorouracil; Male; Methotrexate; Mice; Neoplasm Trans | 1973 |
[Selective tumour chemotherapy using oncobiograms (author's transl)].
Topics: Animals; Antineoplastic Agents; Bleomycin; Cricetinae; Culture Techniques; Cytarabine; Dactinomycin; | 1974 |
[Selective tumour chemotherapy using oncobiograms (author's transl)].
Topics: Animals; Antineoplastic Agents; Bleomycin; Cricetinae; Culture Techniques; Cytarabine; Dactinomycin; | 1974 |
Intra-arterial infusion chemotherapy in head and neck cancer. A clinical and experimental study.
Topics: Animals; Carotid Artery, External; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Diseas | 1973 |
Intra-arterial infusion chemotherapy in head and neck cancer. A clinical and experimental study.
Topics: Animals; Carotid Artery, External; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Diseas | 1973 |
Chemotherapy in recurrent heat and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Drug Thera | 1974 |
Chemotherapy in recurrent heat and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Drug Thera | 1974 |
Influence of cytostatics on aggregation and adenine nucleotides of platelets.
Topics: Adenine Nucleotides; Adenosine Diphosphate; Amidines; Antineoplastic Agents; Aspirin; Bleomycin; Blo | 1972 |
Influence of cytostatics on aggregation and adenine nucleotides of platelets.
Topics: Adenine Nucleotides; Adenosine Diphosphate; Amidines; Antineoplastic Agents; Aspirin; Bleomycin; Blo | 1972 |
[The effects of cytostatic agents on short-term cultures (3H-uridine incorporation) and tissue cultures (cell counts) from human tumors (author's transl)].
Topics: Antineoplastic Agents; Bleomycin; Cell Count; Cell Transformation, Neoplastic; Cells, Cultured; Cyta | 1974 |
[The effects of cytostatic agents on short-term cultures (3H-uridine incorporation) and tissue cultures (cell counts) from human tumors (author's transl)].
Topics: Antineoplastic Agents; Bleomycin; Cell Count; Cell Transformation, Neoplastic; Cells, Cultured; Cyta | 1974 |
Editorial: Drug targets in cancer chemotherapy.
Topics: Antineoplastic Agents; Dactinomycin; Doxorubicin; Enzyme Inhibitors; Fluorouracil; Isoenzymes; Metho | 1974 |
Editorial: Drug targets in cancer chemotherapy.
Topics: Antineoplastic Agents; Dactinomycin; Doxorubicin; Enzyme Inhibitors; Fluorouracil; Isoenzymes; Metho | 1974 |
[The effect of cytostatic drugs on blood platelets and lymphocytes in patients with neoplasms].
Topics: Adenine Nucleotides; Adenosine Diphosphate; Amidines; Antibiotics, Antineoplastic; Bleomycin; Blood | 1974 |
[The effect of cytostatic drugs on blood platelets and lymphocytes in patients with neoplasms].
Topics: Adenine Nucleotides; Adenosine Diphosphate; Amidines; Antibiotics, Antineoplastic; Bleomycin; Blood | 1974 |
Low-dose combination chemotherapy of disseminated human neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Fluorouracil; Humans; Neoplasms; V | 1971 |
Low-dose combination chemotherapy of disseminated human neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Fluorouracil; Humans; Neoplasms; V | 1971 |
[Study of the action of antitumor compounds on primary explants from human tumors].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Antibiotics, Antineoplastic; An | 1967 |
[Study of the action of antitumor compounds on primary explants from human tumors].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Antibiotics, Antineoplastic; An | 1967 |
Maintenance of delayed hypersensitivity reactions in patients receiving cancer chemotherapy.
Topics: Cyclophosphamide; Female; Floxuridine; Fluorouracil; Humans; Hypersensitivity, Delayed; Immunity; Ma | 1968 |
Maintenance of delayed hypersensitivity reactions in patients receiving cancer chemotherapy.
Topics: Cyclophosphamide; Female; Floxuridine; Fluorouracil; Humans; Hypersensitivity, Delayed; Immunity; Ma | 1968 |
[Palliative radiotherapy of cancer in the Karl Bremer Hospital, 1963-1968].
Topics: Black People; Cobalt Isotopes; Colonic Neoplasms; Esophageal Neoplasms; Fluorouracil; Humans; Neopla | 1969 |
[Palliative radiotherapy of cancer in the Karl Bremer Hospital, 1963-1968].
Topics: Black People; Cobalt Isotopes; Colonic Neoplasms; Esophageal Neoplasms; Fluorouracil; Humans; Neopla | 1969 |
[On the question of preclinical selection of cytostatics in the area of treatment of human tumors].
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Carcinoma 256, Walker; Cricetinae; Culture Te | 1969 |
[On the question of preclinical selection of cytostatics in the area of treatment of human tumors].
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Carcinoma 256, Walker; Cricetinae; Culture Te | 1969 |
[Therapy of advanced tumors with 5-fluoro-uracil].
Topics: Femoral Neoplasms; Fluorouracil; Humans; Injections, Intra-Arterial; Injections, Intravenous; Intest | 1969 |
[Therapy of advanced tumors with 5-fluoro-uracil].
Topics: Femoral Neoplasms; Fluorouracil; Humans; Injections, Intra-Arterial; Injections, Intravenous; Intest | 1969 |
[Treatment of inoperable tumors by continuous and prolonged arterial perfusion of an antimitotic association].
Topics: Antineoplastic Agents; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Floxuridine; Fluor | 1969 |
[Treatment of inoperable tumors by continuous and prolonged arterial perfusion of an antimitotic association].
Topics: Antineoplastic Agents; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Floxuridine; Fluor | 1969 |
[Clinical results of synchronised radiotherapy on a theoretical and experimental basis (author's transl)].
Topics: Animals; Breast Neoplasms; Dose-Response Relationship, Radiation; Drosophila melanogaster; Ear Neopl | 1973 |
[Clinical results of synchronised radiotherapy on a theoretical and experimental basis (author's transl)].
Topics: Animals; Breast Neoplasms; Dose-Response Relationship, Radiation; Drosophila melanogaster; Ear Neopl | 1973 |
Intravenous hyperalimentation in cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Body Weight; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Ne | 1974 |
Intravenous hyperalimentation in cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Body Weight; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Ne | 1974 |
[Chromosomal studies in correlation with other biologic constants in neoplasms treated by chemotherapy].
Topics: Adult; Antibody Formation; Bone Marrow; Cell Division; Chromosome Aberrations; Female; Fluorouracil; | 1974 |
[Chromosomal studies in correlation with other biologic constants in neoplasms treated by chemotherapy].
Topics: Adult; Antibody Formation; Bone Marrow; Cell Division; Chromosome Aberrations; Female; Fluorouracil; | 1974 |
Cytochemical evaluation of metabolic inhibitors in cell culture.
Topics: Animals; Cell Division; Chloramphenicol; Culture Techniques; Dactinomycin; DNA; Floxuridine; Fluorou | 1965 |
Cytochemical evaluation of metabolic inhibitors in cell culture.
Topics: Animals; Cell Division; Chloramphenicol; Culture Techniques; Dactinomycin; DNA; Floxuridine; Fluorou | 1965 |
Effect of fluoropyrimidines on delayed cutaneous hypersensitivity.
Topics: Floxuridine; Fluorouracil; Humans; Hypersensitivity, Delayed; Neoplasms; Pyrimidines; Skin Tests | 1965 |
Effect of fluoropyrimidines on delayed cutaneous hypersensitivity.
Topics: Floxuridine; Fluorouracil; Humans; Hypersensitivity, Delayed; Neoplasms; Pyrimidines; Skin Tests | 1965 |
Determinants of human tumor sensitivity to fluorinated pyrimidine chemotherapy.
Topics: DNA, Neoplasm; Floxuridine; Fluorouracil; Humans; In Vitro Techniques; Ligases; Neoplasm Metastasis; | 1967 |
Determinants of human tumor sensitivity to fluorinated pyrimidine chemotherapy.
Topics: DNA, Neoplasm; Floxuridine; Fluorouracil; Humans; In Vitro Techniques; Ligases; Neoplasm Metastasis; | 1967 |
Responses of freshly cultured tumour cells to certain selected chemotherapeutic agents.
Topics: Adenocarcinoma; Antineoplastic Agents; Chlorambucil; Colchicine; Culture Techniques; Cyclophosphamid | 1968 |
Responses of freshly cultured tumour cells to certain selected chemotherapeutic agents.
Topics: Adenocarcinoma; Antineoplastic Agents; Chlorambucil; Colchicine; Culture Techniques; Cyclophosphamid | 1968 |
The value of fluorinated pyrimidines in advanced malignancy.
Topics: Adult; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Female; Floxuridine; Fluorouracil; Humans; Leu | 1968 |
The value of fluorinated pyrimidines in advanced malignancy.
Topics: Adult; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Female; Floxuridine; Fluorouracil; Humans; Leu | 1968 |
5-Fluorouracil and derivatives in cancer chemotherapy. II. Possible in vivo formation and stabilization of 5-fluoro-2'-deoxyuridine.
Topics: Biopharmaceutics; Biotransformation; Chromatography, Thin Layer; Deoxyuridine; Dialysis; Drug Stabil | 1972 |
5-Fluorouracil and derivatives in cancer chemotherapy. II. Possible in vivo formation and stabilization of 5-fluoro-2'-deoxyuridine.
Topics: Biopharmaceutics; Biotransformation; Chromatography, Thin Layer; Deoxyuridine; Dialysis; Drug Stabil | 1972 |
Regional arterial chemotherapy for advanced carcinoma of the head and neck. A ten-year review.
Topics: Antimetabolites; Antineoplastic Agents; Carotid Arteries; Catheterization; Digestive System; Dose-Re | 1973 |
Regional arterial chemotherapy for advanced carcinoma of the head and neck. A ten-year review.
Topics: Antimetabolites; Antineoplastic Agents; Carotid Arteries; Catheterization; Digestive System; Dose-Re | 1973 |
Combination cancer chemotherapy--a clinical trial on outpatients.
Topics: Adolescent; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Methotr | 1974 |
Combination cancer chemotherapy--a clinical trial on outpatients.
Topics: Adolescent; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Methotr | 1974 |
Hypercalcemia in cancer: response to therapy.
Topics: Adenocarcinoma; Adult; Allopurinol; Antineoplastic Agents; Calcium; Cyclophosphamide; Fluorouracil; | 1974 |
Hypercalcemia in cancer: response to therapy.
Topics: Adenocarcinoma; Adult; Allopurinol; Antineoplastic Agents; Calcium; Cyclophosphamide; Fluorouracil; | 1974 |
[The effect of the clinically usual cytostatic therapy on cell-mediated immune reactions in tumor patients].
Topics: Breast Neoplasms; Bronchial Neoplasms; Cell Migration Inhibition; Cyclophosphamide; Drug Therapy, Co | 1973 |
[The effect of the clinically usual cytostatic therapy on cell-mediated immune reactions in tumor patients].
Topics: Breast Neoplasms; Bronchial Neoplasms; Cell Migration Inhibition; Cyclophosphamide; Drug Therapy, Co | 1973 |
[Comments on the treatment of solid tumors with 5-fluorouracil].
Topics: Adenocarcinoma, Scirrhous; Adult; Breast Neoplasms; Carcinoma, Hepatocellular; Female; Fluorouracil; | 1969 |
[Comments on the treatment of solid tumors with 5-fluorouracil].
Topics: Adenocarcinoma, Scirrhous; Adult; Breast Neoplasms; Carcinoma, Hepatocellular; Female; Fluorouracil; | 1969 |
[Radiotherapy following synchronization and its theoretical prerequisites].
Topics: Cell Division; DNA; Fluorouracil; Follow-Up Studies; Humans; Mitosis; Neoplasms; Time Factors | 1972 |
[Radiotherapy following synchronization and its theoretical prerequisites].
Topics: Cell Division; DNA; Fluorouracil; Follow-Up Studies; Humans; Mitosis; Neoplasms; Time Factors | 1972 |
[Combined antineoplastic agents and surgery in treatment of cancer with multiple localizations: 22 cases].
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Synergism; Female; Fluorouracil; Humans; Male; Methods | 1970 |
[Combined antineoplastic agents and surgery in treatment of cancer with multiple localizations: 22 cases].
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Synergism; Female; Fluorouracil; Humans; Male; Methods | 1970 |
[Radiotherapy following synchronisation of the cell-division rhythm].
Topics: Animals; Carcinoma; Carcinoma, Squamous Cell; Cell Division; DNA; Fluorouracil; Humans; Mice; Neopla | 1972 |
[Radiotherapy following synchronisation of the cell-division rhythm].
Topics: Animals; Carcinoma; Carcinoma, Squamous Cell; Cell Division; DNA; Fluorouracil; Humans; Mice; Neopla | 1972 |
Clinical management of advanced gastrointestinal cancer.
Topics: Adenocarcinoma; Alkylating Agents; Biliary Tract; Carcinoid Tumor; Carcinoma, Hepatocellular; Fluoro | 1973 |
Clinical management of advanced gastrointestinal cancer.
Topics: Adenocarcinoma; Alkylating Agents; Biliary Tract; Carcinoid Tumor; Carcinoma, Hepatocellular; Fluoro | 1973 |
Effects of sodium warfarin and other carcinostatic agents on malignant cells: a study of drug synergy.
Topics: Animals; Carbon Radioisotopes; Carcinoma, Bronchogenic; Carcinoma, Hepatocellular; Carcinoma, Squamo | 1974 |
Effects of sodium warfarin and other carcinostatic agents on malignant cells: a study of drug synergy.
Topics: Animals; Carbon Radioisotopes; Carcinoma, Bronchogenic; Carcinoma, Hepatocellular; Carcinoma, Squamo | 1974 |
[Clinical results after synchronised radiotherapy in 21 cases of human malignomas (author's transl)].
Topics: Adult; Aged; Facial Neoplasms; Female; Fluorouracil; Follow-Up Studies; Germany, West; Humans; Laryn | 1974 |
[Clinical results after synchronised radiotherapy in 21 cases of human malignomas (author's transl)].
Topics: Adult; Aged; Facial Neoplasms; Female; Fluorouracil; Follow-Up Studies; Germany, West; Humans; Laryn | 1974 |
[Application of morphological and histochemical methods for evaluation of cytostatic effects on organ cultures of malignant tumors].
Topics: Animals; Antineoplastic Agents; Carcinoma; Culture Techniques; Female; Fluorouracil; Histocytochemis | 1974 |
[Application of morphological and histochemical methods for evaluation of cytostatic effects on organ cultures of malignant tumors].
Topics: Animals; Antineoplastic Agents; Carcinoma; Culture Techniques; Female; Fluorouracil; Histocytochemis | 1974 |
[Characteristics of the cell mitotic cycle and the possibility of enhancing the effect of radiotherapy].
Topics: Animals; Cell Survival; Cells, Cultured; Chromosome Aberrations; Deoxyuridine; DNA, Neoplasm; Esopha | 1974 |
[Characteristics of the cell mitotic cycle and the possibility of enhancing the effect of radiotherapy].
Topics: Animals; Cell Survival; Cells, Cultured; Chromosome Aberrations; Deoxyuridine; DNA, Neoplasm; Esopha | 1974 |
Chemotherapy and immunity to cancer.
Topics: Allyl Compounds; Aniline Compounds; Animals; Antineoplastic Agents; Cyclophosphamide; Fluorouracil; | 1974 |
Chemotherapy and immunity to cancer.
Topics: Allyl Compounds; Aniline Compounds; Animals; Antineoplastic Agents; Cyclophosphamide; Fluorouracil; | 1974 |
[Treatment of solid tumors with N-1-(2'-tetrahydrofuryl)-5-fluorouracil (FT-207) alone and in combination: comparison of intravenous and oral administration].
Topics: Administration, Oral; Chromomycins; Drug Therapy, Combination; Fluorouracil; Furans; Humans; Injecti | 1974 |
[Treatment of solid tumors with N-1-(2'-tetrahydrofuryl)-5-fluorouracil (FT-207) alone and in combination: comparison of intravenous and oral administration].
Topics: Administration, Oral; Chromomycins; Drug Therapy, Combination; Fluorouracil; Furans; Humans; Injecti | 1974 |
[Indications for fluorouracil in dermatology].
Topics: DNA; DNA Replication; Drug Evaluation; Fluorouracil; Humans; Keratoacanthoma; Keratosis; Neoplasms; | 1974 |
[Indications for fluorouracil in dermatology].
Topics: DNA; DNA Replication; Drug Evaluation; Fluorouracil; Humans; Keratoacanthoma; Keratosis; Neoplasms; | 1974 |
In vitro estimate of sensitivity of individual human tumors to antitumor agents.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Arsenicals; Benzoates; Breast Neoplasms; Carbon Radi | 1974 |
In vitro estimate of sensitivity of individual human tumors to antitumor agents.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Arsenicals; Benzoates; Breast Neoplasms; Carbon Radi | 1974 |
Results in 169 patients with cancer of the head and neck treated by intra-arterial infusion therapy.
Topics: Antineoplastic Agents; Brachial Artery; Brachiocephalic Trunk; Carcinoma, Squamous Cell; Carotid Art | 1972 |
Results in 169 patients with cancer of the head and neck treated by intra-arterial infusion therapy.
Topics: Antineoplastic Agents; Brachial Artery; Brachiocephalic Trunk; Carcinoma, Squamous Cell; Carotid Art | 1972 |
Intra-arterial infusion for head and neck cancers.
Topics: Aged; Antineoplastic Agents; Brachiocephalic Trunk; Carcinoma, Squamous Cell; Carotid Arteries; Cath | 1973 |
Intra-arterial infusion for head and neck cancers.
Topics: Aged; Antineoplastic Agents; Brachiocephalic Trunk; Carcinoma, Squamous Cell; Carotid Arteries; Cath | 1973 |
The gallbladder as a conduit between the liver and intestine.
Topics: Adenocarcinoma; Adolescent; Adult; Bile Ducts; Carcinoma; Cholangiography; Common Bile Duct; Drainag | 1973 |
The gallbladder as a conduit between the liver and intestine.
Topics: Adenocarcinoma; Adolescent; Adult; Bile Ducts; Carcinoma; Cholangiography; Common Bile Duct; Drainag | 1973 |
Cancer chemotherapy. I. Methods, agents and overall results in 400 patients.
Topics: Adenocarcinoma; Amides; Androgens; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Estrogens; | 1972 |
Cancer chemotherapy. I. Methods, agents and overall results in 400 patients.
Topics: Adenocarcinoma; Amides; Androgens; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Estrogens; | 1972 |
Leukocyte chromosome abnormalities in advanced nonhematopoietic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cells, Cultured; Chromosome Aberrations; Chromosome Disorders; C | 1972 |
Leukocyte chromosome abnormalities in advanced nonhematopoietic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cells, Cultured; Chromosome Aberrations; Chromosome Disorders; C | 1972 |
[Acid-base equilibrium under cytostatic therapy].
Topics: Acid-Base Equilibrium; Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Female; Flu | 1972 |
[Acid-base equilibrium under cytostatic therapy].
Topics: Acid-Base Equilibrium; Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Female; Flu | 1972 |
In vivo determination of the fractional kill of human tumor cells by chemotherapeutic agents.
Topics: Antineoplastic Agents; Cell Survival; Cyclophosphamide; Fluorouracil; Humans; Melphalan; Multiple My | 1972 |
In vivo determination of the fractional kill of human tumor cells by chemotherapeutic agents.
Topics: Antineoplastic Agents; Cell Survival; Cyclophosphamide; Fluorouracil; Humans; Melphalan; Multiple My | 1972 |
Study on the sensitivity test of carcinostatic agents by acid phosphatase activity.
Topics: Acid Phosphatase; Adult; Aged; Animals; Antineoplastic Agents; Chromomycins; Cyclophosphamide; Femal | 1972 |
Study on the sensitivity test of carcinostatic agents by acid phosphatase activity.
Topics: Acid Phosphatase; Adult; Aged; Animals; Antineoplastic Agents; Chromomycins; Cyclophosphamide; Femal | 1972 |
[Trial and results of improved radiotherapy for cancer. 5. Radiotherapy with simultaneous administration of radio-sensitizing agents. Administration of halogenated pyrimidine].
Topics: Bromodeoxyuridine; Fluorouracil; Humans; Neoplasms; Radiation-Sensitizing Agents; Tongue Neoplasms | 1972 |
[Trial and results of improved radiotherapy for cancer. 5. Radiotherapy with simultaneous administration of radio-sensitizing agents. Administration of halogenated pyrimidine].
Topics: Bromodeoxyuridine; Fluorouracil; Humans; Neoplasms; Radiation-Sensitizing Agents; Tongue Neoplasms | 1972 |
Administration of 5-fluorouracil by hypodermoclysis.
Topics: Fluorouracil; Humans; Injections, Subcutaneous; Methods; Neoplasms | 1973 |
Administration of 5-fluorouracil by hypodermoclysis.
Topics: Fluorouracil; Humans; Injections, Subcutaneous; Methods; Neoplasms | 1973 |
Determination of therapeutic index of drugs by in vitro sensitivity tests using human host and tumor cell suspensions.
Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cells, Cultured; Deoxyuridine; DNA, Neoplasm; | 1973 |
Determination of therapeutic index of drugs by in vitro sensitivity tests using human host and tumor cell suspensions.
Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cells, Cultured; Deoxyuridine; DNA, Neoplasm; | 1973 |
Combination therapy of solid tumors using 1,3-bis(2-chloroethyl)-1-nitrosourea (NCNU), vincristine, methotrexate, and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Carmustine; Female; Fluorouracil; Gastrointes | 1973 |
Combination therapy of solid tumors using 1,3-bis(2-chloroethyl)-1-nitrosourea (NCNU), vincristine, methotrexate, and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Carmustine; Female; Fluorouracil; Gastrointes | 1973 |
Results in fifty cases of advanced squamous cell carcinoma of the head and neck treated by intravenous chemotherapy.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Combinations; Epiglottis; Female; Fluo | 1973 |
Results in fifty cases of advanced squamous cell carcinoma of the head and neck treated by intravenous chemotherapy.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Combinations; Epiglottis; Female; Fluo | 1973 |
FIVB--a new combination of drugs in the treatment of cancer.
Topics: Adenocarcinoma; Aged; Amides; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Imi | 1973 |
FIVB--a new combination of drugs in the treatment of cancer.
Topics: Adenocarcinoma; Aged; Amides; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Imi | 1973 |
[Synchronized radiotherapy in malignant tumors. Theoretical bases and clinical results].
Topics: Aged; Animals; Cell Division; Evaluation Studies as Topic; Fluorouracil; Humans; Mice; Mouth Neoplas | 1973 |
[Synchronized radiotherapy in malignant tumors. Theoretical bases and clinical results].
Topics: Aged; Animals; Cell Division; Evaluation Studies as Topic; Fluorouracil; Humans; Mice; Mouth Neoplas | 1973 |
Excessive lacrimation from fluorouracil treatment.
Topics: Fluorouracil; Humans; Neoplasms; Tears | 1973 |
Excessive lacrimation from fluorouracil treatment.
Topics: Fluorouracil; Humans; Neoplasms; Tears | 1973 |
Multiple-drug therapy for malignant solid tumors in adults.
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Humans; Leukopenia | 1973 |
Multiple-drug therapy for malignant solid tumors in adults.
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Humans; Leukopenia | 1973 |
The etiocholanolone test for prediction of the leukopenic effect of cytoxic drugs.
Topics: Adult; Antineoplastic Agents; Cell Survival; Cyclophosphamide; Depression, Chemical; Etiocholanolone | 1973 |
The etiocholanolone test for prediction of the leukopenic effect of cytoxic drugs.
Topics: Adult; Antineoplastic Agents; Cell Survival; Cyclophosphamide; Depression, Chemical; Etiocholanolone | 1973 |
[Serum complement activity of oncologic patients].
Topics: Complement System Proteins; Esophageal Neoplasms; Fluorouracil; Humans; Immunologic Deficiency Syndr | 1973 |
[Serum complement activity of oncologic patients].
Topics: Complement System Proteins; Esophageal Neoplasms; Fluorouracil; Humans; Immunologic Deficiency Syndr | 1973 |
Age cohort variation of tumor cells.
Topics: Animals; Cell Division; Disease Models, Animal; DNA, Neoplasm; Fluorouracil; Hydroxyurea; Lymphoma; | 1973 |
Age cohort variation of tumor cells.
Topics: Animals; Cell Division; Disease Models, Animal; DNA, Neoplasm; Fluorouracil; Hydroxyurea; Lymphoma; | 1973 |
[Therapy of metastasizing solid tumors with cyclophosphamide, methotrexate, vincristine and 5-fluorouracil].
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Female; Fluorouracil; Humans; Male; Methods; Methotrexate | 1973 |
[Therapy of metastasizing solid tumors with cyclophosphamide, methotrexate, vincristine and 5-fluorouracil].
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Female; Fluorouracil; Humans; Male; Methods; Methotrexate | 1973 |
Cancer chemotherapy by intra-arterial infusion with adriamycin.
Topics: Adult; Alopecia; Anemia; Doxorubicin; Electrocardiography; Female; Femoral Artery; Fluorouracil; Hea | 1973 |
Cancer chemotherapy by intra-arterial infusion with adriamycin.
Topics: Adult; Alopecia; Anemia; Doxorubicin; Electrocardiography; Female; Femoral Artery; Fluorouracil; Hea | 1973 |
Advanced cancer: New concepts of medical therapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Choriocarcinoma; Colonic Neopl | 1973 |
Advanced cancer: New concepts of medical therapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Choriocarcinoma; Colonic Neopl | 1973 |
[Combined chemotherapy with mitomycin, 5-fluorouracil, cytosine arabinoside (MFC therapy) to inoperable cases of malignant tumor (author's transl)].
Topics: Aged; Drug Therapy, Combination; Female; Fluorouracil; Humans; Middle Aged; Mitomycins; Neoplasms | 1973 |
[Combined chemotherapy with mitomycin, 5-fluorouracil, cytosine arabinoside (MFC therapy) to inoperable cases of malignant tumor (author's transl)].
Topics: Aged; Drug Therapy, Combination; Female; Fluorouracil; Humans; Middle Aged; Mitomycins; Neoplasms | 1973 |
[Combination chemotherapy using 5-fluorouracil, chromomycin A3 and prednisolone for solid tumors (author's transl)].
Topics: Aged; Chromomycins; Drug Therapy, Combination; Female; Fluorouracil; Humans; Middle Aged; Neoplasms; | 1973 |
[Combination chemotherapy using 5-fluorouracil, chromomycin A3 and prednisolone for solid tumors (author's transl)].
Topics: Aged; Chromomycins; Drug Therapy, Combination; Female; Fluorouracil; Humans; Middle Aged; Neoplasms; | 1973 |
Biological characterization of human tumours by means of organ culture and individualized cytostatic cancer treatment.
Topics: Antineoplastic Agents; Biological Assay; Biopsy; Dose-Response Relationship, Drug; Female; Fluoroura | 1973 |
Biological characterization of human tumours by means of organ culture and individualized cytostatic cancer treatment.
Topics: Antineoplastic Agents; Biological Assay; Biopsy; Dose-Response Relationship, Drug; Female; Fluoroura | 1973 |
The administration of 5-fluorouracil by mouth.
Topics: Adenocarcinoma; Administration, Oral; Aged; Female; Fluorouracil; Gastrointestinal Neoplasms; Heart | 1974 |
The administration of 5-fluorouracil by mouth.
Topics: Adenocarcinoma; Administration, Oral; Aged; Female; Fluorouracil; Gastrointestinal Neoplasms; Heart | 1974 |
The thiamine status of patients with cancer as determined by the red cell transketolase activity.
Topics: Erythrocytes; Fluorouracil; Humans; Neoplasms; Thiamine; Thiamine Pyrophosphate; Transketolase | 1974 |
The thiamine status of patients with cancer as determined by the red cell transketolase activity.
Topics: Erythrocytes; Fluorouracil; Humans; Neoplasms; Thiamine; Thiamine Pyrophosphate; Transketolase | 1974 |
[Chemotherapy of cancer. Hints for continuing medical education].
Topics: Antineoplastic Agents; Busulfan; Chlorambucil; Cyclophosphamide; Cytarabine; Daunorubicin; Education | 1974 |
[Chemotherapy of cancer. Hints for continuing medical education].
Topics: Antineoplastic Agents; Busulfan; Chlorambucil; Cyclophosphamide; Cytarabine; Daunorubicin; Education | 1974 |
[Results of 5-fluorouracil (5FU) treatment of malignant neoplasms].
Topics: Adult; Aged; Bone Marrow; Digestive System; Evaluation Studies as Topic; Female; Fluorouracil; Gastr | 1974 |
[Results of 5-fluorouracil (5FU) treatment of malignant neoplasms].
Topics: Adult; Aged; Bone Marrow; Digestive System; Evaluation Studies as Topic; Female; Fluorouracil; Gastr | 1974 |
[Progress in chemotherapy of solid tumors and malignant lymphomas (continued)].
Topics: Adult; Antineoplastic Agents; Carcinoma; Choriocarcinoma; Female; Fluorouracil; Gonadal Steroid Horm | 1967 |
[Progress in chemotherapy of solid tumors and malignant lymphomas (continued)].
Topics: Adult; Antineoplastic Agents; Carcinoma; Choriocarcinoma; Female; Fluorouracil; Gonadal Steroid Horm | 1967 |
[Effect of 5-fluorouracil on the transfer of the multiple drug resistance factor in bacteria].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Chloramphenicol; Conjugation, Genetic; Culture Media; | 1970 |
[Effect of 5-fluorouracil on the transfer of the multiple drug resistance factor in bacteria].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Chloramphenicol; Conjugation, Genetic; Culture Media; | 1970 |
[Effects of 5-FU (5-fluorouracil) in 4.3MeV Linac x-ray treatment of advanced cancer].
Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fl | 1968 |
[Effects of 5-FU (5-fluorouracil) in 4.3MeV Linac x-ray treatment of advanced cancer].
Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fl | 1968 |
[The chemotherapy of cancer].
Topics: Adult; Alkylating Agents; Antimetabolites; Antineoplastic Agents; Dactinomycin; Female; Fluorouracil | 1967 |
[The chemotherapy of cancer].
Topics: Adult; Alkylating Agents; Antimetabolites; Antineoplastic Agents; Dactinomycin; Female; Fluorouracil | 1967 |
Chemotherapy and radiation therapy together to treat cancer.
Topics: Antineoplastic Agents; Cell Division; Cyclophosphamide; DNA, Neoplasm; Female; Fluorouracil; Heparin | 1970 |
Chemotherapy and radiation therapy together to treat cancer.
Topics: Antineoplastic Agents; Cell Division; Cyclophosphamide; DNA, Neoplasm; Female; Fluorouracil; Heparin | 1970 |
Comparison of a combination of 5-fluorouracil (NSC-19893), mitomycin C (NSC-26980), triethylenethiophosphoramide (NSC-6396), and fluoxymesterone (NSC-12165) with 5-fluorouracil alone in patients with advanced cancer.
Topics: Antineoplastic Agents; Fluorouracil; Fluoxymesterone; Humans; Mitomycins; Neoplasms; Thiotepa | 1968 |
Comparison of a combination of 5-fluorouracil (NSC-19893), mitomycin C (NSC-26980), triethylenethiophosphoramide (NSC-6396), and fluoxymesterone (NSC-12165) with 5-fluorouracil alone in patients with advanced cancer.
Topics: Antineoplastic Agents; Fluorouracil; Fluoxymesterone; Humans; Mitomycins; Neoplasms; Thiotepa | 1968 |
Combined parenteral hyperalimentation and chemotherapy in the treatment of disseminated solid tumors.
Topics: Amino Acids; Analgesics; Appetite; Body Weight; Breast Neoplasms; Carcinoid Tumor; Colonic Neoplasms | 1971 |
Combined parenteral hyperalimentation and chemotherapy in the treatment of disseminated solid tumors.
Topics: Amino Acids; Analgesics; Appetite; Body Weight; Breast Neoplasms; Carcinoid Tumor; Colonic Neoplasms | 1971 |
[Chemotherapy of solid tumors].
Topics: Antineoplastic Agents; Child; Chlorambucil; Cyclophosphamide; Dactinomycin; Drug Synergism; Fluorour | 1970 |
[Chemotherapy of solid tumors].
Topics: Antineoplastic Agents; Child; Chlorambucil; Cyclophosphamide; Dactinomycin; Drug Synergism; Fluorour | 1970 |
[The clinical evaluation of cytotoxic agents based on their inhibition of tumor growth in vitro].
Topics: Cyclophosphamide; Dactinomycin; Evaluation Studies as Topic; Female; Fluorouracil; Humans; In Vitro | 1971 |
[The clinical evaluation of cytotoxic agents based on their inhibition of tumor growth in vitro].
Topics: Cyclophosphamide; Dactinomycin; Evaluation Studies as Topic; Female; Fluorouracil; Humans; In Vitro | 1971 |
The control of cancer spread by the reticuloendothelial system.
Topics: Aged; Biopsy; Cyclophosphamide; Diethylstilbestrol; Estrogens; Female; Fluorouracil; Humans; Liver; | 1972 |
The control of cancer spread by the reticuloendothelial system.
Topics: Aged; Biopsy; Cyclophosphamide; Diethylstilbestrol; Estrogens; Female; Fluorouracil; Humans; Liver; | 1972 |
5-Fluorouracil (5-Fu; NSC-19893), 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388), vincristine (NSC-67574), and 1,3-bis(2-chloroethyl)-2-nitrosourea (BCNU; NSC-409962) given concomitantly in the treatment of solid tumors in man.
Topics: Adult; Aged; Alkylating Agents; Amides; Carmustine; Drug Combinations; Female; Fluorouracil; Humans; | 1972 |
5-Fluorouracil (5-Fu; NSC-19893), 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388), vincristine (NSC-67574), and 1,3-bis(2-chloroethyl)-2-nitrosourea (BCNU; NSC-409962) given concomitantly in the treatment of solid tumors in man.
Topics: Adult; Aged; Alkylating Agents; Amides; Carmustine; Drug Combinations; Female; Fluorouracil; Humans; | 1972 |
5-fluorouracil intravenous infusion for 48 hours, repeated every two weeks.
Topics: Adult; Aged; Breast Neoplasms; Diarrhea; Evaluation Studies as Topic; Female; Fluorouracil; Gastroin | 1972 |
5-fluorouracil intravenous infusion for 48 hours, repeated every two weeks.
Topics: Adult; Aged; Breast Neoplasms; Diarrhea; Evaluation Studies as Topic; Female; Fluorouracil; Gastroin | 1972 |
Treatment of squamous cell carcinoma of the head and neck by chemotherapy.
Topics: Administration, Oral; Carcinoma, Squamous Cell; Fluorouracil; Head; Head and Neck Neoplasms; Humans; | 1972 |
Treatment of squamous cell carcinoma of the head and neck by chemotherapy.
Topics: Administration, Oral; Carcinoma, Squamous Cell; Fluorouracil; Head; Head and Neck Neoplasms; Humans; | 1972 |
Intra-arterial infusion. A seven-year study.
Topics: Carcinoma, Squamous Cell; Fluorouracil; Head; Head and Neck Neoplasms; Humans; Injections, Intra-Art | 1972 |
Intra-arterial infusion. A seven-year study.
Topics: Carcinoma, Squamous Cell; Fluorouracil; Head; Head and Neck Neoplasms; Humans; Injections, Intra-Art | 1972 |
Chemotherapy in the management of metastatic cancer of unknown primary site.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Chlorambucil; Cyclopho | 1972 |
Chemotherapy in the management of metastatic cancer of unknown primary site.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Chlorambucil; Cyclopho | 1972 |
Expectations and pitfalls of chemotherapy in a university cancer clinic.
Topics: Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Gastrointestinal Neoplasms; Hospitals, Tea | 1972 |
Expectations and pitfalls of chemotherapy in a university cancer clinic.
Topics: Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Gastrointestinal Neoplasms; Hospitals, Tea | 1972 |
Combined 5-fluorouracil and vinblastine therapy for gastrointestinal and other solid tumors.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; | 1972 |
Combined 5-fluorouracil and vinblastine therapy for gastrointestinal and other solid tumors.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; | 1972 |
Results of treatment of malignant tumors with ftorafur.
Topics: Antimetabolites; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Colonic Neoplasms; Deoxyr | 1972 |
Results of treatment of malignant tumors with ftorafur.
Topics: Antimetabolites; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Colonic Neoplasms; Deoxyr | 1972 |
5-fluorouracil and derivatives in cancer chemotherapy: determination of 5-fluorouracil in blood.
Topics: Chromatography, Gas; Dialysis; Fluorouracil; Humans; Hydrogen-Ion Concentration; Methods; Neoplasms; | 1972 |
5-fluorouracil and derivatives in cancer chemotherapy: determination of 5-fluorouracil in blood.
Topics: Chromatography, Gas; Dialysis; Fluorouracil; Humans; Hydrogen-Ion Concentration; Methods; Neoplasms; | 1972 |
[Combined application of drugs in cancer chemotherapy with special reference to the combination of mitomycin C, 5-fluorouracil, and cytosine arabinoside].
Topics: Cytarabine; Female; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Mitomycins; Neoplasm | 1972 |
[Combined application of drugs in cancer chemotherapy with special reference to the combination of mitomycin C, 5-fluorouracil, and cytosine arabinoside].
Topics: Cytarabine; Female; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Mitomycins; Neoplasm | 1972 |
The effect of operative treatment, chemotherapy, and oestrogens on the phagocytic activity of the reticuloendothelial system.
Topics: Aged; Antineoplastic Agents; Cyclophosphamide; Diethylstilbestrol; Estradiol; Fluorouracil; Half-Lif | 1972 |
The effect of operative treatment, chemotherapy, and oestrogens on the phagocytic activity of the reticuloendothelial system.
Topics: Aged; Antineoplastic Agents; Cyclophosphamide; Diethylstilbestrol; Estradiol; Fluorouracil; Half-Lif | 1972 |
Treatment of cancer with weekly intravenous 5-fluorouracil. Study by the Western Cooperative Cancer Chemotherapy Group (WCCCG).
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Gastrointestinal D | 1971 |
Treatment of cancer with weekly intravenous 5-fluorouracil. Study by the Western Cooperative Cancer Chemotherapy Group (WCCCG).
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Gastrointestinal D | 1971 |
Complete regression of metastases following chemotherapy.
Topics: Aged; Cecal Neoplasms; Colectomy; Fluorouracil; Humans; Injections, Intravenous; Lung Neoplasms; Lym | 1971 |
Complete regression of metastases following chemotherapy.
Topics: Aged; Cecal Neoplasms; Colectomy; Fluorouracil; Humans; Injections, Intravenous; Lung Neoplasms; Lym | 1971 |
The effect of 5-fluorouracil on small bowel mucosa.
Topics: Adult; Aged; Biopsy; Diarrhea; Duodenum; Female; Fluorouracil; Humans; Intestinal Mucosa; Intestine, | 1971 |
The effect of 5-fluorouracil on small bowel mucosa.
Topics: Adult; Aged; Biopsy; Diarrhea; Duodenum; Female; Fluorouracil; Humans; Intestinal Mucosa; Intestine, | 1971 |
Fluoxydin. (Preliminary report on clinical evaluation).
Topics: Antineoplastic Agents; Drug Tolerance; Fluorine; Fluorouracil; Humans; Neoplasms; Pyrimidines | 1971 |
Fluoxydin. (Preliminary report on clinical evaluation).
Topics: Antineoplastic Agents; Drug Tolerance; Fluorine; Fluorouracil; Humans; Neoplasms; Pyrimidines | 1971 |
Multiple drug therapy for disseminated malignant tumours.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Child; Cyclophosphamide; Cytarabine; Dactinomy | 1971 |
Multiple drug therapy for disseminated malignant tumours.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Child; Cyclophosphamide; Cytarabine; Dactinomy | 1971 |
In vivo prediction of drug sensitivity with cancer-seeking isotopes.
Topics: Amides; Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma 256, Walker; Cyclophosphamide; D | 1971 |
In vivo prediction of drug sensitivity with cancer-seeking isotopes.
Topics: Amides; Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma 256, Walker; Cyclophosphamide; D | 1971 |
Seventy-five cases of solid tumours treated by a modified quadruple chemotherapy regime.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Bronchial Neoplasms; Child; Cyclophosphamide; Female; Flu | 1971 |
Seventy-five cases of solid tumours treated by a modified quadruple chemotherapy regime.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Bronchial Neoplasms; Child; Cyclophosphamide; Female; Flu | 1971 |
[Various radiobiological aspects of "Synchronization therapy in the treatment of tumors"].
Topics: Animals; Fluorouracil; L Cells; Mice; Mitosis; Neoplasms; Radiation Effects | 1971 |
[Various radiobiological aspects of "Synchronization therapy in the treatment of tumors"].
Topics: Animals; Fluorouracil; L Cells; Mice; Mitosis; Neoplasms; Radiation Effects | 1971 |
Intra-arterial chemotherapy with surgery or radiotherapy in tumours of the head-neck region.
Topics: Fluorouracil; Head; Head and Neck Neoplasms; Injections, Intra-Arterial; Methotrexate; Neoplasms | 1971 |
Intra-arterial chemotherapy with surgery or radiotherapy in tumours of the head-neck region.
Topics: Fluorouracil; Head; Head and Neck Neoplasms; Injections, Intra-Arterial; Methotrexate; Neoplasms | 1971 |
Combination cancer chemotherapy by regional intra-arterial or intra-aortic infusion of 5-fluorouracil and mitomycin-C with or without irradiation.
Topics: Aorta; Cobalt Radioisotopes; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Hea | 1971 |
Combination cancer chemotherapy by regional intra-arterial or intra-aortic infusion of 5-fluorouracil and mitomycin-C with or without irradiation.
Topics: Aorta; Cobalt Radioisotopes; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Hea | 1971 |
[New antineoplastic drugs; Cosmegen and Fluoro-uracil].
Topics: Dactinomycin; Fluorouracil; Neoplasms | 1970 |
[New antineoplastic drugs; Cosmegen and Fluoro-uracil].
Topics: Dactinomycin; Fluorouracil; Neoplasms | 1970 |
Comparative sensitivity to various antimetabolites of several established cell lines derived from the buffy coat of normal humans and patients with neoplastic diseases.
Topics: Antimetabolites; Blood Cells; Cell Line; Culture Techniques; Cytarabine; Fluorouracil; Humans; Leuke | 1969 |
Comparative sensitivity to various antimetabolites of several established cell lines derived from the buffy coat of normal humans and patients with neoplastic diseases.
Topics: Antimetabolites; Blood Cells; Cell Line; Culture Techniques; Cytarabine; Fluorouracil; Humans; Leuke | 1969 |
The effect of methotrexate (amethopterin) on wound healing: an experimental study.
Topics: Animals; Cyclophosphamide; Fluorouracil; Leucovorin; Methotrexate; Neoplasms; Rats; Wound Healing | 1965 |
The effect of methotrexate (amethopterin) on wound healing: an experimental study.
Topics: Animals; Cyclophosphamide; Fluorouracil; Leucovorin; Methotrexate; Neoplasms; Rats; Wound Healing | 1965 |
A portable pump ("conjector") for regional perfusion cancer chemotherapy.
Topics: Antineoplastic Agents; Blood Cell Count; Chemotherapy, Cancer, Regional Perfusion; Female; Fluoroura | 1966 |
A portable pump ("conjector") for regional perfusion cancer chemotherapy.
Topics: Antineoplastic Agents; Blood Cell Count; Chemotherapy, Cancer, Regional Perfusion; Female; Fluoroura | 1966 |
Historic and current intra-arterial chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Catheterization; Chemotherapy, Cancer, Regional Per | 1970 |
Historic and current intra-arterial chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Catheterization; Chemotherapy, Cancer, Regional Per | 1970 |
Skin homograft survival in cancer chemotherapy patients.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Female; Fluorouracil; Humans; Immunosuppressive Agen | 1966 |
Skin homograft survival in cancer chemotherapy patients.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Female; Fluorouracil; Humans; Immunosuppressive Agen | 1966 |
Cytotoxic penetration and concentration in human malignant tumours.
Topics: Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Injections | 1969 |
Cytotoxic penetration and concentration in human malignant tumours.
Topics: Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Injections | 1969 |
Clinical trials of a new antitumor polypeptide: neocarzinostatin (NCS).
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma; Cyclophosphamide; Female; Fluorouracil; Humans; | 1969 |
Clinical trials of a new antitumor polypeptide: neocarzinostatin (NCS).
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma; Cyclophosphamide; Female; Fluorouracil; Humans; | 1969 |
[The modification of the cell division rhythm in human tumors].
Topics: Adult; Aged; Autoradiography; Biopsy; Cell Division; Depression, Chemical; DNA, Neoplasm; Ear Neopla | 1969 |
[The modification of the cell division rhythm in human tumors].
Topics: Adult; Aged; Autoradiography; Biopsy; Cell Division; Depression, Chemical; DNA, Neoplasm; Ear Neopla | 1969 |
[Studies on the understanding of problems of radiologic cytostatic combination treatment. 6. Further syncytostatic studies with 5-fluorouracil, natulan and proresid].
Topics: Amides; Animals; Antineoplastic Agents; Cyclophosphamide; Ear, External; Female; Fluorouracil; Granu | 1969 |
[Studies on the understanding of problems of radiologic cytostatic combination treatment. 6. Further syncytostatic studies with 5-fluorouracil, natulan and proresid].
Topics: Amides; Animals; Antineoplastic Agents; Cyclophosphamide; Ear, External; Female; Fluorouracil; Granu | 1969 |
The effect of 5-fluorouracil on DNA-thymine synthesis in human tumors.
Topics: Carbon Isotopes; DNA, Neoplasm; Fluorouracil; Formates; Humans; Neoplasms; Thymidine; Thymine; Triti | 1969 |
The effect of 5-fluorouracil on DNA-thymine synthesis in human tumors.
Topics: Carbon Isotopes; DNA, Neoplasm; Fluorouracil; Formates; Humans; Neoplasms; Thymidine; Thymine; Triti | 1969 |
New approaches in administration of anticancer drugs.
Topics: Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Cytarabine; Female; Fluorouracil; Humans | 1969 |
New approaches in administration of anticancer drugs.
Topics: Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Cytarabine; Female; Fluorouracil; Humans | 1969 |
Combined 5-fluoro-uracil and procarbazin in the treatment of lung metastases from different carcinomas.
Topics: Adult; Aged; Benzoates; Fluorouracil; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasms | 1969 |
Combined 5-fluoro-uracil and procarbazin in the treatment of lung metastases from different carcinomas.
Topics: Adult; Aged; Benzoates; Fluorouracil; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasms | 1969 |
Clinical evaluation of combination chemotherapy of solid tumors with five or six anticancer drugs.
Topics: Amides; Antibiotics, Antineoplastic; Antineoplastic Agents; Drug Synergism; Female; Fluorouracil; Gl | 1969 |
Clinical evaluation of combination chemotherapy of solid tumors with five or six anticancer drugs.
Topics: Amides; Antibiotics, Antineoplastic; Antineoplastic Agents; Drug Synergism; Female; Fluorouracil; Gl | 1969 |
[Mitotic index determination of in vivo synchronized human neoplastic tissue].
Topics: Autoradiography; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male; Mitosis; Neoplasms; T | 1969 |
[Mitotic index determination of in vivo synchronized human neoplastic tissue].
Topics: Autoradiography; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male; Mitosis; Neoplasms; T | 1969 |
[Synchronization of histologically normal human tissue].
Topics: Antineoplastic Agents; Autoradiography; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; DNA; DNA, N | 1969 |
[Synchronization of histologically normal human tissue].
Topics: Antineoplastic Agents; Autoradiography; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; DNA; DNA, N | 1969 |
Comparative study of monthly courses versus weekly doses of 5-fluorouracil (NSC-19893).
Topics: Adult; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplas | 1969 |
Comparative study of monthly courses versus weekly doses of 5-fluorouracil (NSC-19893).
Topics: Adult; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplas | 1969 |
[Clinical use of 5-fluorouracil in surgical field].
Topics: Adult; Aged; Animals; Breast Neoplasms; Dogs; Female; Fluorouracil; Head and Neck Neoplasms; Humans; | 1969 |
[Clinical use of 5-fluorouracil in surgical field].
Topics: Adult; Aged; Animals; Breast Neoplasms; Dogs; Female; Fluorouracil; Head and Neck Neoplasms; Humans; | 1969 |
[Association of cytotoxic agents with radiotherapy: experimental bases and initial results in solid tumors].
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Synergism; Female; Fluorouracil; Gas | 1969 |
[Association of cytotoxic agents with radiotherapy: experimental bases and initial results in solid tumors].
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Synergism; Female; Fluorouracil; Gas | 1969 |
Clinical immunologic responsiveness in malignant disease. I. Delayed hypersensitivity reaction and the effect of cytotoxic drugs.
Topics: Adolescent; Adult; Aged; Antigens; Antineoplastic Agents; Breast Neoplasms; Candida; Child; Child, P | 1970 |
Clinical immunologic responsiveness in malignant disease. I. Delayed hypersensitivity reaction and the effect of cytotoxic drugs.
Topics: Adolescent; Adult; Aged; Antigens; Antineoplastic Agents; Breast Neoplasms; Candida; Child; Child, P | 1970 |
[Changes in the hematopoietic system during treatment with 5-fluorouracil].
Topics: Fluorouracil; Humans; Leukopenia; Neoplasms; Thrombocytopenia | 1970 |
[Changes in the hematopoietic system during treatment with 5-fluorouracil].
Topics: Fluorouracil; Humans; Leukopenia; Neoplasms; Thrombocytopenia | 1970 |
Preferential attack on cancer by selected SH inhibitors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Ascites; Breast Neoplasms; Carcinoma, Ehrlich Tumor; | 1970 |
Preferential attack on cancer by selected SH inhibitors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Ascites; Breast Neoplasms; Carcinoma, Ehrlich Tumor; | 1970 |
The place of 5-fluorouracil in experimental and clinical cancer chemotherapy.
Topics: Animals; Carcinoma, Ehrlich Tumor; Fluorouracil; Humans; Mice; Neoplasms; Sarcoma 180 | 1970 |
The place of 5-fluorouracil in experimental and clinical cancer chemotherapy.
Topics: Animals; Carcinoma, Ehrlich Tumor; Fluorouracil; Humans; Mice; Neoplasms; Sarcoma 180 | 1970 |
Reticulo-endothelial activity in humans with cancer.
Topics: Cyclophosphamide; Diethylstilbestrol; Fluorouracil; Gastrointestinal Neoplasms; Humans; Iodine Isoto | 1970 |
Reticulo-endothelial activity in humans with cancer.
Topics: Cyclophosphamide; Diethylstilbestrol; Fluorouracil; Gastrointestinal Neoplasms; Humans; Iodine Isoto | 1970 |
[Clinical studies of the method of application of antineoplastic agents].
Topics: Antineoplastic Agents; Blood Cell Count; Bone Marrow Examination; Cyclophosphamide; Fluorouracil; Hu | 1970 |
[Clinical studies of the method of application of antineoplastic agents].
Topics: Antineoplastic Agents; Blood Cell Count; Bone Marrow Examination; Cyclophosphamide; Fluorouracil; Hu | 1970 |
Preferential attack on cancer following major cancer surgery.
Topics: Agar; Alkylating Agents; Antineoplastic Agents; Culture Techniques; DNA, Neoplasm; Fluorouracil; Hum | 1971 |
Preferential attack on cancer following major cancer surgery.
Topics: Agar; Alkylating Agents; Antineoplastic Agents; Culture Techniques; DNA, Neoplasm; Fluorouracil; Hum | 1971 |
Further clinical studies of combination chemotherapy using cyclophosphamide, vincristine, methotrexate and 5-flourouracil in solid tumors.
Topics: Cyclophosphamide; Fluorouracil; Humans; Methotrexate; Neoplasms; Vincristine | 1971 |
Further clinical studies of combination chemotherapy using cyclophosphamide, vincristine, methotrexate and 5-flourouracil in solid tumors.
Topics: Cyclophosphamide; Fluorouracil; Humans; Methotrexate; Neoplasms; Vincristine | 1971 |
The relation of thymidine labeling index in human tumors in vitro to the effectiveness of 5-fluorouracil chemotherapy.
Topics: Autoradiography; Fluorouracil; Humans; In Vitro Techniques; Methods; Neoplasms; Thymidine; Tritium | 1971 |
The relation of thymidine labeling index in human tumors in vitro to the effectiveness of 5-fluorouracil chemotherapy.
Topics: Autoradiography; Fluorouracil; Humans; In Vitro Techniques; Methods; Neoplasms; Thymidine; Tritium | 1971 |
[Combined cytostatic treatment of solid tumours with cyclophosphamide (Endoxan), vincristine, methylaminopterin (Methotrexate) and 5-fluorouracil].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Child; Child, Preschool; Cyclophosphami | 1971 |
[Combined cytostatic treatment of solid tumours with cyclophosphamide (Endoxan), vincristine, methylaminopterin (Methotrexate) and 5-fluorouracil].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Child; Child, Preschool; Cyclophosphami | 1971 |
[Combined chemotherapy of solid tumors].
Topics: Cyclophosphamide; Fluorouracil; Humans; Methotrexate; Neoplasms; Vincristine | 1971 |
[Combined chemotherapy of solid tumors].
Topics: Cyclophosphamide; Fluorouracil; Humans; Methotrexate; Neoplasms; Vincristine | 1971 |
[Experience with the treatment of patients with malignant tumors with 5-fluorouracil].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Duodenal Neoplasms; Female; Fluorouracil; Humans; In | 1967 |
[Experience with the treatment of patients with malignant tumors with 5-fluorouracil].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Duodenal Neoplasms; Female; Fluorouracil; Humans; In | 1967 |
Nonhormonal cancer chemotherapy and the vaginal smear.
Topics: Female; Fluorouracil; Humans; Methotrexate; Neoplasms; Vagina; Vaginal Smears | 1967 |
Nonhormonal cancer chemotherapy and the vaginal smear.
Topics: Female; Fluorouracil; Humans; Methotrexate; Neoplasms; Vagina; Vaginal Smears | 1967 |
[Surgical use of 5-FU--with special reference to changes in tumor tissues].
Topics: Adult; Aged; Colon; Colonic Neoplasms; Female; Fluorouracil; Humans; Injections, Intravenous; Male; | 1967 |
[Surgical use of 5-FU--with special reference to changes in tumor tissues].
Topics: Adult; Aged; Colon; Colonic Neoplasms; Female; Fluorouracil; Humans; Injections, Intravenous; Male; | 1967 |
[Internal cancer therapy: cooperative clinical studies. Principles, organization and first results of the Swiss chemotherapy group].
Topics: Adenocarcinoma; Androgens; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Car | 1967 |
[Internal cancer therapy: cooperative clinical studies. Principles, organization and first results of the Swiss chemotherapy group].
Topics: Adenocarcinoma; Androgens; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Car | 1967 |
Methotrexate and the platelet count.
Topics: Antineoplastic Agents; Azathioprine; Blood Cell Count; Blood Platelets; Fluorouracil; Humans; Leukop | 1968 |
Methotrexate and the platelet count.
Topics: Antineoplastic Agents; Azathioprine; Blood Cell Count; Blood Platelets; Fluorouracil; Humans; Leukop | 1968 |
Treatment of cancer with weekly intravenous 5-fluorouracil.
Topics: Adult; Aged; Breast Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Injections, | 1968 |
Treatment of cancer with weekly intravenous 5-fluorouracil.
Topics: Adult; Aged; Breast Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Injections, | 1968 |
[Clinical considerations on the use of Vinca alkaloids in an oncological radiotherapy department].
Topics: Adult; Aged; Fluorouracil; Humans; Middle Aged; Neoplasms; Vinblastine; Vincristine | 1968 |
[Clinical considerations on the use of Vinca alkaloids in an oncological radiotherapy department].
Topics: Adult; Aged; Fluorouracil; Humans; Middle Aged; Neoplasms; Vinblastine; Vincristine | 1968 |
Preliminary trials with combination therapy of cyclophosphamide (NSC-26271), vincristine (NSC-67574), and 5-fluorouracil (NSC-19893).
Topics: Cyclophosphamide; Fluorouracil; Humans; Neoplasms; Vincristine | 1968 |
Preliminary trials with combination therapy of cyclophosphamide (NSC-26271), vincristine (NSC-67574), and 5-fluorouracil (NSC-19893).
Topics: Cyclophosphamide; Fluorouracil; Humans; Neoplasms; Vincristine | 1968 |
[Clinical application of 5-fluorouracil--with special reference to the evaluation of the intravenous administration method].
Topics: Adult; Antineoplastic Agents; Female; Fluorouracil; Humans; Injections, Intravenous; Male; Methods; | 1968 |
[Clinical application of 5-fluorouracil--with special reference to the evaluation of the intravenous administration method].
Topics: Adult; Antineoplastic Agents; Female; Fluorouracil; Humans; Injections, Intravenous; Male; Methods; | 1968 |
[Intra-arterial cancer chemotherapy of the pelvis and legs].
Topics: Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Female; Fluorouracil; Humans; Injections, Int | 1969 |
[Intra-arterial cancer chemotherapy of the pelvis and legs].
Topics: Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Female; Fluorouracil; Humans; Injections, Int | 1969 |
Combined intra-arterial infusion and radiotherapy for the treatment of advanced cancer of the head and neck.
Topics: Aged; Brain Neoplasms; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorouracil; Follow-Up Studi | 1969 |
Combined intra-arterial infusion and radiotherapy for the treatment of advanced cancer of the head and neck.
Topics: Aged; Brain Neoplasms; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorouracil; Follow-Up Studi | 1969 |
[Associated chemotherapeutic treatment of epithelial tumors. Clinical results and doctrinal considerations].
Topics: Adolescent; Adult; Cyclophosphamide; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Pre | 1969 |
[Associated chemotherapeutic treatment of epithelial tumors. Clinical results and doctrinal considerations].
Topics: Adolescent; Adult; Cyclophosphamide; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Pre | 1969 |
Kinetics of proliferation of cancer cells in neoplastic effusions in man.
Topics: Adenocarcinoma; Antineoplastic Agents; Autoradiography; Cell Division; DNA, Neoplasm; Exudates and T | 1965 |
Kinetics of proliferation of cancer cells in neoplastic effusions in man.
Topics: Adenocarcinoma; Antineoplastic Agents; Autoradiography; Cell Division; DNA, Neoplasm; Exudates and T | 1965 |
[Cyclophosphamide and 5-fluoracil in the treatment of inoperable tumors].
Topics: Antineoplastic Agents; Cyclophosphamide; Fluorouracil; Humans; Neoplasms | 1966 |
[Cyclophosphamide and 5-fluoracil in the treatment of inoperable tumors].
Topics: Antineoplastic Agents; Cyclophosphamide; Fluorouracil; Humans; Neoplasms | 1966 |
Using a mathematical model in the evaluation of human tumor response to chemotherapy.
Topics: Antineoplastic Agents; Fluorouracil; Humans; Mercaptopurine; Models, Theoretical; Neoplasms; Statist | 1966 |
Using a mathematical model in the evaluation of human tumor response to chemotherapy.
Topics: Antineoplastic Agents; Fluorouracil; Humans; Mercaptopurine; Models, Theoretical; Neoplasms; Statist | 1966 |
Is toxicity really necessary? I. The question.
Topics: Alkylating Agents; Carbamates; Chlorambucil; Fluorouracil; Humans; Leukocyte Count; Mercaptopurine; | 1966 |
Is toxicity really necessary? I. The question.
Topics: Alkylating Agents; Carbamates; Chlorambucil; Fluorouracil; Humans; Leukocyte Count; Mercaptopurine; | 1966 |
Is toxicity really necessary? II. Source and analysis of data.
Topics: Alkylating Agents; Carbamates; Chlorambucil; Fluorouracil; Humans; Leukocyte Count; Leukopenia; Merc | 1966 |
Is toxicity really necessary? II. Source and analysis of data.
Topics: Alkylating Agents; Carbamates; Chlorambucil; Fluorouracil; Humans; Leukocyte Count; Leukopenia; Merc | 1966 |
Time and vehicle studies of a safe and effective method for administration of 5-fluorouracil.
Topics: Dosage Forms; Fluorouracil; Humans; Neoplasms | 1966 |
Time and vehicle studies of a safe and effective method for administration of 5-fluorouracil.
Topics: Dosage Forms; Fluorouracil; Humans; Neoplasms | 1966 |
[Slow intravenous perfusion of 5-flourouracil. Clinical results].
Topics: Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Perfusion | 1966 |
[Slow intravenous perfusion of 5-flourouracil. Clinical results].
Topics: Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Perfusion | 1966 |
Hemodialysis in cancer chemotherapy.
Topics: Animals; Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Dogs; Fluorouracil; Injections, | 1966 |
Hemodialysis in cancer chemotherapy.
Topics: Animals; Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Dogs; Fluorouracil; Injections, | 1966 |
[On the leukocytogenic action of Fleming's lysozime in subjects treated with antineoplastic chemotherapeutic agents].
Topics: Cyclophosphamide; Female; Fluorouracil; Humans; Leukocytes; Male; Muramidase; Neoplasms; Triaziquone | 1966 |
[On the leukocytogenic action of Fleming's lysozime in subjects treated with antineoplastic chemotherapeutic agents].
Topics: Cyclophosphamide; Female; Fluorouracil; Humans; Leukocytes; Male; Muramidase; Neoplasms; Triaziquone | 1966 |
5-Fluorouracil (NSC-19893) in glucose and saline: therapeutic effect and toxicity.
Topics: Fluorouracil; Glucose; Humans; Neoplasms; Sodium Chloride; Solutions | 1966 |
5-Fluorouracil (NSC-19893) in glucose and saline: therapeutic effect and toxicity.
Topics: Fluorouracil; Glucose; Humans; Neoplasms; Sodium Chloride; Solutions | 1966 |